<SEC-DOCUMENT>0000896262-21-000110.txt : 20211103
<SEC-HEADER>0000896262-21-000110.hdr.sgml : 20211103
<ACCEPTANCE-DATETIME>20211103080149
ACCESSION NUMBER:		0000896262-21-000110
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211103
DATE AS OF CHANGE:		20211103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMEDISYS INC
		CENTRAL INDEX KEY:			0000896262
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOME HEALTH CARE SERVICES [8082]
		IRS NUMBER:				113131700
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24260
		FILM NUMBER:		211373774

	BUSINESS ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816
		BUSINESS PHONE:		2252922031

	MAIL ADDRESS:	
		STREET 1:		3854 AMERICAN WAY
		STREET 2:		SUITE A
		CITY:			BATON ROUGE
		STATE:			LA
		ZIP:			70816

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANALYTICAL NURSING MANAGEMENT CORP
		DATE OF NAME CHANGE:	19940819

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M&N CAPITAL CORP
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>amed-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:9a22ea05-d9af-4e79-9afb-aec6f57a9fea,g:f821983a-9b6a-4f0b-a7a4-a1b27b9c9a2c,d:d60bf3839b914d279c418e71b98c550c--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:amed="http://www.amedisys.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amed-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl80LTEtMS0xLTA_e47603f3-d8ee-4e3a-95aa-446f82a8d487">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl82LTEtMS0xLTA_a6338b83-dacf-4027-a4cf-079c72be5fc4">2021</ix:nonNumeric><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl83LTEtMS0xLTA_dd6037ef-be76-4e2d-a362-d506edeaf12b">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl85LTEtMS0xLTA_6fddc359-df98-4b97-93fb-4623d4dbc2c9">AMEDISYS INC</ix:nonNumeric><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl8xMC0xLTEtMS0w_ba19903d-4474-4eed-a4c0-421ba2c8ff17">0000896262</ix:nonNumeric><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl8xMS0xLTEtMS0w_ceef58c0-40ad-452a-83d5-ccf168a9e7fa">--12-31</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i0d32c084839747cea67534c70d0a7a4c_D20200401-20200630" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180MC9mcmFnOmYzYjcyYTEwYTg4ODQxOGY4ZmE1MTg1OWRjYjg5ZGMyL3RhYmxlOjdjZDQ4M2M4ZjJlYzQwMTI4MjNiY2M5ODAwNzA2YWZkL3RhYmxlcmFuZ2U6N2NkNDgzYzhmMmVjNDAxMjgyM2JjYzk4MDA3MDZhZmRfNC0xLTEtMS0w_5ec5ce1a-919b-4632-9c8c-59b95f7b9330">3.0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180Ni9mcmFnOmNiNmU4YWNjMzU1YjQwZjNhNjU2ZDQxNmM1ZTIzNTRmL3RhYmxlOmVlYWUzNTdiOGVlMDQxODM4ZTQ3NTBlYTIxZWVhNTFlL3RhYmxlcmFuZ2U6ZWVhZTM1N2I4ZWUwNDE4MzhlNDc1MGVhMjFlZWE1MWVfMy0xLTEtMS0w_cc82efad-98d8-469c-9dd1-76f15fea6205">83,357</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180Ni9mcmFnOmNiNmU4YWNjMzU1YjQwZjNhNjU2ZDQxNmM1ZTIzNTRmL3RhYmxlOmVlYWUzNTdiOGVlMDQxODM4ZTQ3NTBlYTIxZWVhNTFlL3RhYmxlcmFuZ2U6ZWVhZTM1N2I4ZWUwNDE4MzhlNDc1MGVhMjFlZWE1MWVfMy0yLTEtMS0xMzA5OQ_90fd5e1b-a718-4b69-9259-1e7faa5e7cbc">124,458</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7c481a799d7f4394b4a10e4b1471316c_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181NS9mcmFnOjE4ZTFmZWJhOGQ5NTRlZWQ4OGExYzc3OTlhOTFiN2RhL3RhYmxlOmYzMjA2MDA0MjZhZTRlZTU4N2RiZGQxNGMxMDdmYjJiL3RhYmxlcmFuZ2U6ZjMyMDYwMDQyNmFlNGVlNTg3ZGJkZDE0YzEwN2ZiMmJfMi0xLTEtMS0w_a20d9398-df19-466b-b69b-563f036ecc3e">3.8</ix:nonFraction><ix:nonNumeric contextRef="id5e9300975d94331be252f45284ba279_D20210730-20210730" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182MS9mcmFnOmNkOWQ5ZmZmNjZjOTRlOTM4YWEzODliNmU4ODMwNTFmL3RleHRyZWdpb246Y2Q5ZDlmZmY2NmM5NGU5MzhhYTM4OWI2ZTg4MzA1MWZfODA5_7518b444-634e-471b-bc61-c6acfd01aca3">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</ix:nonNumeric><ix:nonNumeric contextRef="iece39510783140d686babcc73a08f895_D20210730-20210730" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182MS9mcmFnOmNkOWQ5ZmZmNjZjOTRlOTM4YWEzODliNmU4ODMwNTFmL3RleHRyZWdpb246Y2Q5ZDlmZmY2NmM5NGU5MzhhYTM4OWI2ZTg4MzA1MWZfODEw_ea5361be-d690-4115-88e9-52519ad5e3ba">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183My9mcmFnOjExOTQ4ZjlhM2MyYzQwZTBhOTI4MWQzMDlhYjY1NjFkL3RhYmxlOjEyOTVkOTYwNDRmMTQ2ZDBhNWQ1MGNhODkzMWNhN2UzL3RhYmxlcmFuZ2U6MTI5NWQ5NjA0NGYxNDZkMGE1ZDUwY2E4OTMxY2E3ZTNfMi0xLTEtMS0xMzE0Mg_10469d0a-d1c9-490f-87a1-a0489f652d7d">297,668</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183My9mcmFnOjExOTQ4ZjlhM2MyYzQwZTBhOTI4MWQzMDlhYjY1NjFkL3RhYmxlOjEyOTVkOTYwNDRmMTQ2ZDBhNWQ1MGNhODkzMWNhN2UzL3RhYmxlcmFuZ2U6MTI5NWQ5NjA0NGYxNDZkMGE1ZDUwY2E4OTMxY2E3ZTNfMi0yLTEtMS0w_dc1604fb-55aa-4657-97dc-995a6718afb0">19,955</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183My9mcmFnOjExOTQ4ZjlhM2MyYzQwZTBhOTI4MWQzMDlhYjY1NjFkL3RhYmxlOjEyOTVkOTYwNDRmMTQ2ZDBhNWQ1MGNhODkzMWNhN2UzL3RhYmxlcmFuZ2U6MTI5NWQ5NjA0NGYxNDZkMGE1ZDUwY2E4OTMxY2E3ZTNfMy0xLTEtMS0xMzEyMQ_69f8ab10-5827-4492-b1a0-21af14837a9c">1,464,339</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183My9mcmFnOjExOTQ4ZjlhM2MyYzQwZTBhOTI4MWQzMDlhYjY1NjFkL3RhYmxlOjEyOTVkOTYwNDRmMTQ2ZDBhNWQ1MGNhODkzMWNhN2UzL3RhYmxlcmFuZ2U6MTI5NWQ5NjA0NGYxNDZkMGE1ZDUwY2E4OTMxY2E3ZTNfNC0xLTEtMS0w_1499395f-1c7e-41fe-aa6a-16a8e3aa7ef8">203,756</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amed-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i07d63b1d905741c6ac588e15cfe76e29_I20211029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84de3e983eb740b1bb3c8f25d7622369_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bdd17b976b94417b0973260d8bd3e44_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd44a5fd2068444ea4c2b014fc212aba_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81046c5f2fe9466f935a9da81d4f9b05_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i481818d771fb4e8cba7ee992ef045095_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d22e47449f4dce9025ba20e4ee868e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic477a09656e142a2ba9555f6e71e57b8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89642198499249a5a508a2b794a0c774_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id633ade135bd4fa5a755576d79307e96_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8585c2e41c09481f94254dd475c515cf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i598b6bdc5e4b441ab25be4f2fd0a21ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3722136a4de449192734a30989dde10_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29f95beb109544799227cc0e3807a5a2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9586bde96dc4b55a43e520f969b3d49_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i590fcf43ae93429c90aa189d83dd278c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f981173ad3f4a55af9ec673326e4ee7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fb123a126ca4044b4d597a6f5aeb789_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b307a62c3fb444494adee8144988b0d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e4f44436f8c4b4b84c3920f226cab7a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4afb39ea542d425cbf6ec7dcdc11d968_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6701d88a3f6b429ba56daa18c8fb08cc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e60464baed4c908a5a135d54dc4b11_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b35a3a550a440cc90fa58ad012ef681_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d9a940c2864685ae466b0f8760514a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1519169737fb443a8053b131fb736562_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0981942253684fd5b4f7eb9fb411157c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696f26883f1a42e28bc3241a2c02dc1c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39f094da56c24200a601142582cdc2a0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if09d9dfbada9402c82e04fffa1792aed_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc6b318a025b416080e2e688fa3d70f4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21bb61efbc804a59b103a8fc6e57cb32_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1180b4ef96164b9a9e4962f634ba5bcb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8c58ab1289048be8261102b772d4db9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6e494dd063a4d8aa19b36fcb24fed25_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia855683296e64bf18a9ef89f356655a0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa9afb8e5e3644a59da63953d75e842c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc92f06d04394959b3242b038919464a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42b43eecaab42a78203a133cac36e19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23b5458af0924ae791b517938fa92dba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c69e51ef304378875bd8586144f797_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ff740465893462abb39658ee50a3980_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccb3f95375f5445ba8782cf65507f940_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46836dfa696048bb8468c58880596456_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5883b3c8ba45e0853c437d045de477_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a2e6cc1034448789c21e45ddc2a62a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6566df00d848434baa97e9fd857c714c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c7b322b8d954305ab4228a0e4f5fa44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69fea3aa6870434ea5666aacfdf3d1d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d9c15c2efa64925929ae6f6cfe42a0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70db5c4d7e784bac89013422e4e11011_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i884c25e331534f468450dd28f2d93e40_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67b5b45191d24afe8a6500e067394b03_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465c7064fe5e412e978bfdd7128be6a7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d80f5ecb444e898ca8530a2f8c3d9e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b85cedd162948299f5f10b84f850dd7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i53a77f5a57b04427a02592d620527871_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97413ae1e1174a779e186bf439f4b59e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3cf4cabcef48c49d533b6054864aa6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b858c3a1e442059c913a6d2f8baa16_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="care_center"><xbrli:measure>amed:care_center</xbrli:measure></xbrli:unit><xbrli:context id="i730de4ab8dd2401da027009b92ebd36a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idba324da17d44f13b400eb4dcb6541c2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4003f84c115d4f539f2b8c54b785265e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofjointventures"><xbrli:measure>amed:numberOfJointVentures</xbrli:measure></xbrli:unit><xbrli:context id="i52fadfa94bbd423aa0033f0ef19c530a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>amed:state</xbrli:measure></xbrli:unit><xbrli:context id="ib17e4cda80354daea0f730106f4a1852_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic428d287cf9a45abae8bef5f46c3c408_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d32c084839747cea67534c70d0a7a4c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:HeritageHealthcareInnovationFundLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d7cedb10ae48fba7962484bd3a479d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf8d0d878ea44b5b6acaec5036b5b3e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb137aa1ee24433e9aa27e49dc612257_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bde2eb0cbdd4167840a8abcb889fdbe_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da000a08ec142e4bdd7cf8ee0df0f47_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a28bdb10cc74d2e928cf670bd6e2574_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia97dc36d6ba44d7a91070e28414ee451_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fcfacf66b054da0b58e2e56d9bb8bfa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99b4c1b915b04539b57e1c8613186d47_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa13ecc925ce45338808db2fe46e6eae_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab6f6ff611a4bca958bd8f881a12f27_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6978f00a4d24116b989b48f99ba0ee3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1d053dcadf4783b88264c7cec8fdad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56c30a83b044cfeb8b2c3d76169a0f2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife028e28aa6e4bff87836d3a26ef8d85_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ed27e1cb4c4b0aabe4eb9cf42597d3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a812c39af934a4fbcf34dcbb6f5f869_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide539b43139c4e9f8ca2939b91054599_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9100f75ec6d34eab92f0b7a4728ebb97_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c80de9e2e4b40cdb0613e9070ad7c04_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e067416e644747bb8fa941e424d288_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icac5f9500af546a48378980936e6335e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926e999864bd48ed884e8c5a0659188d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de65d633d9d4497bd157a0af662328c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="visit"><xbrli:measure>amed:visit</xbrli:measure></xbrli:unit><xbrli:context id="i29f7d758438c4f338ef4844b1b05b695_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15da7330f86b4f90b126f6a27ee2e91c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f2cd5e0030a4da38f5733c7cc21c188_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e45fb5802548c4ad50a57ad3f3b612_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d3a5fc24c7c41c8bc0fb5a2dae8eb49_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24116e45645b4557aa94b276ff514ba4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d0d57618875495dac3ccd68edf1aea4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68531a9539f143d39b039b1ec2d6143c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i500483d4b7f14fdaa315297298d52160_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd0e7655cc84c468271b6527bfdb445_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5462f91dd84c47b0a636202d3b8d0235_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2feac305da384a94a9d62488436d6c54_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79965b0e5aa8415ab632c4462ea0fe64_I20200327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0efbe09bd23b41df8e79378709cd08ec_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d60d9ebea4d4f7d9cefaed1ef4edefa_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifffac77654ba4ad9a0ab1f64df333300_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1393629cbb174bb6b0ebfda47cfc61fd_D20200327-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-27</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e66e59d22d74d7a814e88ec0a8b967a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38909b3d265a42439d254b12034f035b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2649a54bd32e4505aaf5229062506cea_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib38d592d04ae48798a01d60bc2b8f174_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb4c638a3b064fa5b06f2b26f52f4a80_D20210501-20210501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c8f3adc1504f4eb6682e48cf1c64c4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2017c2d404c641c2a514204df4297957_I20210501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0872fc9873bd4791b48b180e25979b56_D20210701-20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f71161254f8495192bc5012d17c1d17_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0151e438657a4e998a05f867e7a0192b_I20210701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicareLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47ee2ab8e1e4361a566cb19050d7b35_D20210712-20210712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-12</xbrli:startDate><xbrli:endDate>2021-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i851747d57a65428e80bd139d35336f78_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib551a251deb645c2b167c2d979092893_I20210712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9ba162183a34d4793c4bb95198e7c46_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66672e7c81cf4388ace524f46eb99c20_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i249984fbdc5e42819c3295bf8354d6b7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e43a9f348fe4c7ea8efde6906e553bf_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5e610cd17944eaa9db443b1b7ceed2c_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5dabca3606441b0a6016647f859c142_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i580773c45c2e4d0f89d42392a8b52a23_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib322985f813e485bb88456695369faef_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c481a799d7f4394b4a10e4b1471316c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4953a1ae43744a48ab6e34e6411026e1_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i543e41010bbd4e948680534c79d49c2e_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6da567b0484902aa61fbfea5349833_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id814fe8f58334cf9978509b3eada043c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c0952e0e5814a7380170a26c64d0563_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicareLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i953170ab35da4c52b868fca5070072f4_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592180016a3f4b9e9fa58cdf3b1f3e11_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cb7f1afbee94667b22da85810bdfcbf_I20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dd94248f0054a2eb7c4d4f6a7ce8f7f_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7f579c66d14f6f8455278885e6166c_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2212b3038014b39b18d85e2bb708130_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if630985387694c3c8fc5598653fa49c5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c80c052038b44b5a18995cafc14e750_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33dd3f1accc48d0b07ae82ea62d7bf3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93f3a54943ce4dfc93af29045df66a08_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a29fce5319a41b88a21448a8d746bc1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04620e666ce242189145fc8202e974a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c79a4a01587443798a698b9d888425d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c6b3f9117ec48d3af01c13b614cdce8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b58db92e154fe68dd728641fc3400e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb868e0e199e4a7ba64d42b2fdae307d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13ec3a58ad29418ebe42554498e48e75_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf92b4555b6d40f2a59b54d48f64f091_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic64fd34ea067411b965765c227c1c4e8_I20190204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb7c45b2d9ae4729a6b676da0434e01b_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8161c5c6f5a441498e6232b1062a0706_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9248021e924452a9ca5a099d811b891_I20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96b33383638f4da69049403922d142b6_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4d439ce912f4be0af7514da8425d3c2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9ff3a8ccb9f425b8f7441a6634cf019_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8268f6431a5342b0a5dc83e81f8cf5a1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2629c6a87704cab9b7d7cc4fcb7d9d7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6347f72e46564137a77f41c6701f04b4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a006fc8ae3144b8b0f35e0576008c13_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eda14018d5440f49c3d2c8399bf7c28_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577fdd4a436a42ea80849c81a5784c4c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66aae57e36ae41648ae8623055ad5911_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i499562ee396144d1b90e4e7f1e4b3078_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35d443fe2776475199e8bf20c5bd7195_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e39d276de254f649e239423c9cc0cc7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94c391fe27d34bb598e993c5ca12ab5e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bbf202037ab4efe84eec9c86af849aa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec7d2c9ab8af421195c28b753a977a92_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31501243538e4935b989aad968b62589_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie04b2efc6fec439ca0961cd20f0f2601_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7b640016ec74b29877d9d8af659dacf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7807a03e1d27498cb0fbd254ba18a9e2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb48a5c2350401badf76407e810a916_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4384d6ba9eb047a8b55217f4beaf64b4_D20210730-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d7f3ebbc7b4cbabe8f090e4d1c2b10_D20210730-20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ebbfca679d4a7fafa5444ca24a361f_D20231001-20260730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2026-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4322d7e66634ce4885a55d252abc28d_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4039f4791f043d6a0ea7c40d6c13d2f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib057fa7e9dc74985846be7233614be6d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a8de61107114e3188c016a866d7eee9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75a1a833f08448ae97ff44f57957725d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i257940b085494340a54f2596ffb71f9c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eabd2498ce447d59434f7882ae478d0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifba8391d8e984a3593722809cdc00c21_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i778f590556a3415eb3394ae1a6c1629f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5e9300975d94331be252f45284ba279_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iece39510783140d686babcc73a08f895_D20210730-20210730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i035bf53c46a541a5826c7f2c7b06185b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd4289f9d03348eabba8b8a1ff9153aa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>amed:patient</xbrli:measure></xbrli:unit><xbrli:context id="i601ff40a9dcb4f2e8948d32afbd39a70_D20150521-20150521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-21</xbrli:startDate><xbrli:endDate>2015-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ccc1c8d24e84db4aa8381d958233b6b_D20151103-20151103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-11-03</xbrli:startDate><xbrli:endDate>2015-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie05aa041138d438c87540387474bcbd1_D20160627-20160627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-27</xbrli:startDate><xbrli:endDate>2016-06-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="beneficiary"><xbrli:measure>amed:beneficiary</xbrli:measure></xbrli:unit><xbrli:context id="i0aa37634d03d42b08a244431e4a41f5c_D20080101-20100331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2010-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i095f59a36c244843af1db7f854a0a9a2_D20110606-20110606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-06-06</xbrli:startDate><xbrli:endDate>2011-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica3afcf2ee1c43259f1a30c2e600133a_I20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>amed:claim</xbrli:measure></xbrli:unit><xbrli:context id="i564a484715c64e40a7be81c6235e4f3d_D20160118-20160118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-18</xbrli:startDate><xbrli:endDate>2016-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i802e5888cb1648439a3f47b2b44404c2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76d5dd1a4f4a464ca4fb9d384e6aa87b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic80811cd8fd747ef98eb89b834589f68_I20190110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b5d1cbe45dc44d9b98ec0e127cd824c_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i484c5a9dd6e14e23b66ed620f5079d5d_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0294eb79c2848a59000786e83e668d1_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0de238f9be246fe96998173de4a5bcb_D20170801-20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-01</xbrli:startDate><xbrli:endDate>2017-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346f707c9d6b4ac9964bf787577aea3d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ded9eda305484fa4ab5c09016ceb41_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eb22d6ba31944238874d354008337ec_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21724093a2f42c4853d771fabb00f17_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36258c9144d84085bd1b3ea4fd537b23_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief75d072b29748ba987a8030789542dd_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e7d764f4494c88b305e1e18074b41f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60712b1793c74750b58b9385fb0c31e3_I20170831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d7c2cc8b22d455a9ebb4e72d526d36c_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eaa44efaa1a467ebc42d62d7ac69a76_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segments"><xbrli:measure>amed:Segments</xbrli:measure></xbrli:unit><xbrli:context id="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id363dc674251412f912533418a9d82dd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic29a871182a54f2094160695e03ee462_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aeb28a2785549969b2fff138237082b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93729840e4134b239b4b920086a356a1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaadc0a4a924428e834767c197639f52_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9760404300fe42ccafac45094346c6e0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147869c8a406420b87176150165db51c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d5e8892fb243b4b865bd7b871d16be_D20200810-20200810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-10</xbrli:startDate><xbrli:endDate>2020-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1427f68924a44119e86ad505b770163_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f23866255254c1e86623c880ffabe48_I20201223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2381e983ae6a4cb799879628f17fd769_D20201223-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85212f2db10a46fd81194263d32551bd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icea953f101c64f9ea9eb5be5f0f999ff_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if904a87006f24f8cbd91c764ae5909fc_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i878d81e55fc54bb5a76221d8c7ce04e9_D20210802-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c67fa7efe64016ba829366460e9a3f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5985078fbcb439bbdcb8ec2bcdb0330_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28c5a54e2c3f42ef8543c32325f45fa2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7137075508bc4a80bdbc1291c467c563_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c26203c52124e6db31cba165f90a5ba_D20211018-20211018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000896262</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-18</xbrli:startDate><xbrli:endDate>2021-10-18</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id60bf3839b914d279c418e71b98c550c_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM1_b40625cd-60e5-4e6f-89cf-c81fc7f9fd0e">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6Nzk4OThjNTc1YzAzNGRjMGIyN2U1YjA1NmVhZjNkODkvdGFibGVyYW5nZTo3OTg5OGM1NzVjMDM0ZGMwYjI3ZTViMDU2ZWFmM2Q4OV8wLTAtMS0xLTA_02861bf8-72e3-4dee-a17a-1d0ae3611c98">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8xMzg_804f1bd1-af2a-4c0a-ba1f-948ad0ac18f3">September&#160;30, 2021</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6MDI5MmI5YTNkNzg3NGY1NThmYWEzYTQ2NTc5NThiNTAvdGFibGVyYW5nZTowMjkyYjlhM2Q3ODc0ZjU1OGZhYTNhNDY1Nzk1OGI1MF8wLTAtMS0xLTA_2076a288-f715-4eb4-b206-ebf724e1a545">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM2_f18f05c6-cfde-4275-9b4a-fe24877100b3">0-24260</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><img src="amed-20210930_g1.jpg" alt="amed-20210930_g1.jpg" style="height:82px;margin-bottom:5pt;vertical-align:text-bottom;width:160px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">AMEDISYS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.486%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NjBkYmNjMGZjYWUwNGIxOGJiZmFiMzUzZDZmNzk1MWIvdGFibGVyYW5nZTo2MGRiY2MwZmNhZTA0YjE4YmJmYWIzNTNkNmY3OTUxYl8xLTAtMS0xLTA_9a27ecb9-fa42-4f83-beba-92b9f5d601f4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NjBkYmNjMGZjYWUwNGIxOGJiZmFiMzUzZDZmNzk1MWIvdGFibGVyYW5nZTo2MGRiY2MwZmNhZTA0YjE4YmJmYWIzNTNkNmY3OTUxYl8xLTItMS0xLTA_8289efdd-a50a-40e6-9a24-28e2efbcdc8f">11-3131700</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM3_1653c703-e275-4d6a-a8a5-c7a853a7b6f4">3854 American Way</ix:nonNumeric>, <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjQw_b243718b-fff1-4662-8ec5-d9f3fcc1767a">Suite A</ix:nonNumeric>, <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM4_d6741299-70c7-420a-b227-899711f88f89">Baton Rouge</ix:nonNumeric>, <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM5_c13e408d-70cf-4a08-bc60-4e8c9e513e3c">LA</ix:nonNumeric> <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjQx_d7efeb32-f585-4322-aa07-e33f6fd9ce23">70816</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjMy_1c164269-74d8-4442-a138-a1292e61d6d0">225</ix:nonNumeric>) <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjQy_b244152f-236a-44be-a9d2-ed0b2adc09c9">292-2031</ix:nonNumeric> or (800)&#160;467-2662</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:36.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.611%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NGJhNTA5YWNhZTdkNGU1ZmIwY2MxYmE5NWJmYjIwYmIvdGFibGVyYW5nZTo0YmE1MDlhY2FlN2Q0ZTVmYjBjYzFiYTk1YmZiMjBiYl8xLTAtMS0xLTA_b882752d-d20d-4378-9067-22411eb05ad9">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NGJhNTA5YWNhZTdkNGU1ZmIwY2MxYmE5NWJmYjIwYmIvdGFibGVyYW5nZTo0YmE1MDlhY2FlN2Q0ZTVmYjBjYzFiYTk1YmZiMjBiYl8xLTItMS0xLTA_554ffa54-e6d8-4134-be8b-4ff781fbf980">AMED</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NGJhNTA5YWNhZTdkNGU1ZmIwY2MxYmE5NWJmYjIwYmIvdGFibGVyYW5nZTo0YmE1MDlhY2FlN2Q0ZTVmYjBjYzFiYTk1YmZiMjBiYl8xLTQtMS0xLTA_7dd8de5e-42df-4488-ae9d-98c4aef26924">The NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjMz_6fa218d6-6b0f-4de8-97c2-289083916b01">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM0_e1d7a38a-3fe8-494f-b2c6-4a277fc5d049">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in&#160;Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.582%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NTMyNWM3NTc1NGU4NDc0YjkyMzE3ZGM0YThjNjBkYmEvdGFibGVyYW5nZTo1MzI1Yzc1NzU0ZTg0NzRiOTIzMTdkYzRhOGM2MGRiYV8xLTAtMS0xLTA_8ef17eaa-43cd-473d-a120-b487411cb7e0">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NTMyNWM3NTc1NGU4NDc0YjkyMzE3ZGM0YThjNjBkYmEvdGFibGVyYW5nZTo1MzI1Yzc1NzU0ZTg0NzRiOTIzMTdkYzRhOGM2MGRiYV8zLTYtMS0xLTA_36b6ddbf-4b6b-49e2-8350-c9a14de3e9ba">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging&#160;growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NTMyNWM3NTc1NGU4NDc0YjkyMzE3ZGM0YThjNjBkYmEvdGFibGVyYW5nZTo1MzI1Yzc1NzU0ZTg0NzRiOTIzMTdkYzRhOGM2MGRiYV81LTItMS0xLTA_32dbf9e9-f307-453e-a7da-e15f2061a233">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjQz_f0dba838-c289-4764-9012-a7178921cafa">&#9744;</ix:nonNumeric>&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date, is as follows: Common stock, $0.001 par value, <ix:nonFraction unitRef="shares" contextRef="i07d63b1d905741c6ac588e15cfe76e29_I20211029" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMTk5_3527f12b-ce08-4957-a0a4-0fb523d364ad">32,602,425</ix:nonFraction> shares outstanding as of October&#160;29, 2021.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.854%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_10">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_10">1</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">;;;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_16">FINANCIAL STATEMENTS:</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_19">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2021 (UNAUDITED) AND DECEMBER&#160;31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_25">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_25">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_28">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_28">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_31">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2021 AND 2020 (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_91">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_91">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_94">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_94">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_97">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_97">47</a></span></div></td></tr><tr style="height:12pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_100">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_103">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_103">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_106">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_106">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_109">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_109">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_112">DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_112">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_115">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_115">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_118">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_118">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ITEM&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_121">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_121">50</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id60bf3839b914d279c418e71b98c550c_124">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#id60bf3839b914d279c418e71b98c550c_124">51</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL CAUTION CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">When included in this Quarterly Report on Form 10-Q, or in other documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) or in statements made by or on behalf of the Company, words like &#8220;believes,&#8221; &#8220;belief,&#8221; &#8220;expects,&#8221; &#8220;strategy,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic ("COVID-19"), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, the impact of current and proposed federal, state and local vaccine mandates, including potential staffing shortages, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protests or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events.&#160;We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.&#160;For a discussion of some of the factors discussed above as well as additional factors, see our Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the SEC on February 25, 2021, particularly, Part I, Item&#160;1A - Risk Factors therein, which are incorporated herein by reference, and Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q. Additional risk factors may also be described in reports that we file from time to time with the SEC.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our company website address is www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled &#8220;Investors&#8221; on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website. In addition, we make available on the Investor Relations subpage of our website (under the link &#8220;SEC filings&#8221;), free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as reasonably practicable after we electronically file or furnish such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct, our Corporate Governance Guidelines and the charters for the Audit, Compensation, Quality of Care, Compliance and Ethics and Nominating and Corporate Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link &#8220;Governance&#8221;). Reference to our website does not constitute incorporation by reference of the information contained on the website and should not be considered part of this document. Our electronically filed reports can also be obtained on the SEC&#8217;s internet site at http://www.sec.gov.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="id60bf3839b914d279c418e71b98c550c_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="id60bf3839b914d279c418e71b98c550c_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:73.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMy0xLTEtMS0w_a1d5375d-040e-489e-aaf7-354ef3cf5c2d">124,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMy0zLTEtMS0w_2f1489f1-cf1e-4b11-a233-efa02512c75d">81,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNC0xLTEtMS0w_37ca7d4e-c33a-465b-aa5a-706bebf8097c">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNC0zLTEtMS0w_08d9787e-f32d-42d4-9fc1-c864f4466703">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNS0xLTEtMS0w_88c1740d-07f2-4cdb-9c39-7c5c0b428a8f">274,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNS0zLTEtMS0w_04b02dbf-8557-4350-b6c7-a8b5b48bf547">255,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNi0xLTEtMS0w_241c291b-f67c-4404-bd59-b862cc7fede5">16,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNi0zLTEtMS0w_c5e2a94b-31bc-4526-95fc-a14848a1bd44">10,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNy0xLTEtMS0w_cbfbc051-b435-4a67-babd-f337fc59e426">14,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNy0zLTEtMS0w_305ccbc3-159a-41ee-b7bc-5603a035ca4e">13,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOC0xLTEtMS0w_312db629-e902-48f2-805f-eee42b398b42">432,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOC0zLTEtMS0w_0206b8de-2f11-4e27-a88f-510ace5de1f8">361,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOS0wLTEtMS0wL3RleHRyZWdpb246MTk0MzkyZDk3NDRlNDY1NWJkM2I1NWRkNzIxYmM4NzJfNjM_79a67f70-95f2-45a7-8fc8-5f5c5f6decd8">100,407</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOS0wLTEtMS0wL3RleHRyZWdpb246MTk0MzkyZDk3NDRlNDY1NWJkM2I1NWRkNzIxYmM4NzJfNzA_20b3876c-0472-4ea3-bc75-8221c299f612">95,024</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOS0xLTEtMS0w_2a957ccf-1e8b-4b88-947f-976427415511">20,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOS0zLTEtMS0w_36305121-964c-49c3-9002-31ea287ad7b3">23,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTAtMS0xLTEtMA_9af0baf2-8fe6-4152-b823-8bfc434b60de">100,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTAtMy0xLTEtMA_77a24e02-dee1-41ca-9364-a441ce1a2a99">93,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTEtMS0xLTEtMA_c1d13b66-1170-436a-aaf0-fee7bcdee380">1,188,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTEtMy0xLTEtMA_059d24e4-86d0-4e8c-a696-35280434011a">932,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjgxZTg0NGUyZDdhODRlOGE4OWNmMjM0NjQ0ODQ5ZTdjXzU4_8462995f-bdc9-46bd-a646-4d16221d01cc">20,309</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjgxZTg0NGUyZDdhODRlOGE4OWNmMjM0NjQ0ODQ5ZTdjXzY1_906b01e1-700d-41dc-adf6-a2893cd44b70">22,973</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTItMS0xLTEtMA_e3ad788a-ef42-4f42-bdb9-5fb43836fd77">118,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTItMy0xLTEtMA_d4cea2b7-2c8c-4961-8210-ceb86f76b9fb">74,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTMtMS0xLTEtMA_6f7140e1-f67b-4aa3-941b-49eba8e64c9a">10,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTMtMy0xLTEtMA_9a9aa136-cf57-4faa-8611-2d9b2c29beb4">47,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTQtMS0xLTEtMA_5061ddf3-a646-46c4-89e6-9153ac5c6d5e">68,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTQtMy0xLTEtMA_ef2c0324-8473-4cbd-bd7f-cabf8f48db85">33,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTUtMS0xLTEtMA_6e147d5d-32c1-4258-9a4a-d037271e493c">1,937,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTUtMy0xLTEtMA_45e9e635-c181-4067-ab73-87e98a3de366">1,567,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTgtMS0xLTEtMA_71c8937f-b049-4b11-bcd9-6454c3110351">41,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTgtMy0xLTEtMA_0d9da5aa-0e3c-4336-b5af-24fd8e4fb4aa">42,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTktMS0xLTEtMA_c5275d80-f9e3-4512-b808-2b9635a9de90">155,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTktMy0xLTEtMA_5517f006-8f6e-4c49-bcb2-32aeed9f1aa6">146,929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjAtMS0xLTEtMA_638bf593-73ba-4d90-8fd3-9c1b9464630c">154,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjAtMy0xLTEtMA_cebefd11-6363-4ef4-9d3b-40cc5c2a00de">166,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider relief fund advance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:ProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjEtMS0xLTEtMA_b65f374b-6a43-496c-b1fa-30b46db74bd9">58,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="amed:ProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjEtMy0xLTEtMA_7376bd9e-1fb3-4067-9fd3-1b138e9854e6">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjItMS0xLTEtMA_0c4ced75-76ea-4244-9afa-98dff735dbcd">13,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjItMy0xLTEtMA_51652276-d253-47b8-875f-4ed727546557">10,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjMtMS0xLTEtMA_c90ac32d-88c9-4a21-a80f-6c5c2434e966">31,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjMtMy0xLTEtMA_2f795ee1-a5f3-49e3-b00b-d504d63db02e">30,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjQtMS0xLTEtMA_197e1c34-e7b7-45c3-aedf-c71238b634ff">454,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjQtMy0xLTEtMA_091c551b-5fdf-49f1-acc2-071a5ec1f319">456,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjUtMS0xLTEtMA_c6a23767-9370-4262-9946-e49bfc0763de">434,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjUtMy0xLTEtMA_c8d32311-2eb3-4734-a954-ef8e32438af2">204,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjYtMS0xLTEtMA_de018951-7ee6-4653-962a-dc5957cce32c">67,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjYtMy0xLTEtMA_aab1a4c8-87ac-4e8c-923f-48d3badfcadc">61,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjctMS0xLTEtMA_0b795cda-608d-47c3-97fb-ebb5c2bf54e5">31,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjctMy0xLTEtMA_fe642c4f-c2f6-4c8b-8721-dbdb5713426c">33,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjgtMS0xLTEtMA_119cc251-75e7-4302-a95a-11ea8f1b9cb6">988,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjgtMy0xLTEtMA_2b6324cc-a436-4bba-9b79-6107ecad77ba">756,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies&#8212;Note 6</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjktMS0xLTEtMA_9d1f3048-edbc-411a-ad6f-b273190ce42e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzIx_73760820-935a-4d95-90c9-b1ebb3dfbd7e"><ix:nonFraction unitRef="usdPerShare" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzIx_ec7086dd-5afd-4fd1-93cf-798cdad9551b">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzM1_68ef7874-4482-47fd-b251-4324eea3f6d7"><ix:nonFraction unitRef="shares" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzM1_9135caea-fe7e-4cb5-997c-fec4b4fa60aa">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzU3_54a82192-ae88-4986-a5a1-f493df5f2ca1"><ix:nonFraction unitRef="shares" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzU3_a1c9c623-017f-4e27-b5d3-1070fb783155"><ix:nonFraction unitRef="shares" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzU3_a86fca1a-974b-48fc-8b7e-66475ee777ab"><ix:nonFraction unitRef="shares" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzU3_f6d836e8-6a2c-4a32-80c1-2fb46a949fba">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>ne issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMS0xLTEtMA_735fb688-6c22-4105-8e0c-10d7c88cfaab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMy0xLTEtMA_99824331-5675-45e7-948c-cbf07e48e7ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzE4_23f9b2d6-8621-4d7f-af0c-3bc3d07555e5"><ix:nonFraction unitRef="usdPerShare" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzE4_c50b74fa-9d40-44e7-9763-ad15f5294551">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzMy_2de27f43-622d-4b53-a736-3e5d6e0dd859"><ix:nonFraction unitRef="shares" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzMy_52ed13ee-127e-41da-be45-92b58528dc7f">60,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzU0_114a8f2e-ea53-4c0c-bd43-dab5e140aaf1">37,659,284</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzYx_e3ee61d5-0ca8-4cb1-bb9b-d4f8ed31a308">37,470,212</ix:nonFraction> shares issued; and <ix:nonFraction unitRef="shares" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzgz_0bee9193-b839-4748-b197-98bc3c0d0938">32,590,775</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzkw_74302751-f107-4e23-a402-6362ab56db22">32,814,278</ix:nonFraction> shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMS0xLTEtMA_6a3d9b77-c6b4-41f8-924c-a9b737d7d47c">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMy0xLTEtMA_e3e9fd7d-7806-4ea2-b038-f364a93afc22">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzMtMS0xLTEtMA_43a616b0-e87b-4407-91b7-a2b1a9b6f595">720,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzMtMy0xLTEtMA_44a27b44-fc35-46e1-b53c-76a6391d1cdc">698,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost <ix:nonFraction unitRef="shares" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjUzNDRlYzk2YzgxNTQ0YTBiMTk3YWIwNDg4ODVmZGIwXzI4_8da7383d-b9c8-4c2d-b2bc-ce9b51561bcf">5,068,509</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjUzNDRlYzk2YzgxNTQ0YTBiMTk3YWIwNDg4ODVmZGIwXzM1_81bf5d2d-08fc-4349-8a06-a5f8700d9731">4,655,934</ix:nonFraction> shares of common stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzQtMS0xLTEtMA_51ce71f3-f025-4c7e-9972-6ea381d0b746">420,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzQtMy0xLTEtMA_45849d98-92c5-4122-85b0-205e946ca4a5">319,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzYtMS0xLTEtMA_70a408ee-0258-49f7-86b7-7854345efc6a">605,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzYtMy0xLTEtMA_33007dca-8342-4e66-a362-9b5e19a74bd0">429,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Amedisys, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzctMS0xLTEtMA_ac2baa34-28e8-4785-8c12-9c63ef2c74a1">905,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzctMy0xLTEtMA_03959670-9aba-4517-b3fd-fa0d9595f55c">809,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzgtMS0xLTEtMA_33f1319b-97f4-454d-8487-a5a22dab4afe">43,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzgtMy0xLTEtMA_9e4494ee-a855-48de-a72e-e07dafeb3955">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzktMS0xLTEtMA_fae4e835-8b70-4c0b-9558-14c07d63b14b">948,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzktMy0xLTEtMA_dad23227-8f1f-4f2f-875d-20d49a9728b2">810,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNDAtMS0xLTEtMA_410c3966-2230-4f7d-9a9b-301faab856c0">1,937,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNDAtMy0xLTEtMA_dfa470f5-aba9-458d-8ed7-1651a8f72c19">1,567,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Three-Month&#160;<br/>Periods&#160;Ended&#160;September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the Nine-Month&#160;<br/>Periods&#160;Ended&#160;September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMi0xLTEtMS0w_476ae360-0151-4629-bec8-d6ae60214645">553,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMi0zLTEtMS0w_71a324ff-5a7b-4283-a26f-3ac4a878f11d">544,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMi01LTEtMS0w_4f1ed8ed-80b8-46b3-85b4-2d8384f5c762">1,654,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMi03LTEtMS0w_3698795b-6a31-4132-9968-e8952f9f022f">1,520,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMy0xLTEtMS0w_e47adcba-9f1c-4851-9cd2-db4039298158">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMy0zLTEtMS0w_45067298-7439-40cf-b4ea-4748b5339add">4,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMy01LTEtMS0w_5028a0a0-62fe-4354-9844-100667d58ea6">13,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMy03LTEtMS0w_39045973-2bbc-4948-a9b1-fb0fa9a7ff59">27,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNC0xLTEtMS0w_9399b66c-4204-4e3f-a9ea-174d225a44ec">310,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNC0zLTEtMS0w_195efcda-303a-4477-abaa-f6844a772cc9">297,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNC01LTEtMS0w_d4a295ce-db3c-4d94-b258-74b1c39c8110">916,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNC03LTEtMS0w_ffaa7343-d53b-49f7-9540-3fdfa488828b">878,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNi0xLTEtMS0w_3667808b-2fff-489d-a7bb-6964bdb3da55">119,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNi0zLTEtMS0w_9a9e4315-5127-4a37-86c4-318e509885bc">123,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNi01LTEtMS0w_ca5d73a2-46b3-49f0-aa70-33e87d4c92c4">349,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNi03LTEtMS0w_370df3c3-e5b8-490f-abe1-a66bb4b37655">330,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNy0xLTEtMS0w_299d822f-2bfc-4914-8f83-1fe0d81971f9">4,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNy0zLTEtMS0w_102feb53-d644-4cc0-b83c-567b44d9ad49">7,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNy01LTEtMS0w_a1d7dcb8-6456-44d1-a514-dd16a7d3959c">17,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNy03LTEtMS0w_ecfcb0c2-10c2-4b00-8fac-1e4b2fea97ee">19,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOC0xLTEtMS0w_ed539a8a-65db-45ce-972e-562b636c2f8b">55,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOC0zLTEtMS0w_205abc6c-afdb-43d0-92e5-2cd34840b231">49,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOC01LTEtMS0w_45fa2b71-f7c2-498b-a537-d0a1667b4acd">158,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOC03LTEtMS0w_9cff2743-e7b4-418a-bbbb-c39ebeaa6292">142,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOS0xLTEtMS0w_e2c550ec-bf46-4936-a5a5-935998187114">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOS0zLTEtMS0w_e3428cab-87a1-4277-ab0d-c15445a28510">8,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOS01LTEtMS0w_736e1bdf-fa63-4edd-98e6-7324a6d8a092">21,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOS03LTEtMS0w_4f8ee1c5-c6e9-4cdf-8112-5dc6848910e7">19,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTAtMS0xLTEtMA_c5cf7a5f-8135-4573-b205-38c6bda5a51b">496,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTAtMy0xLTEtMA_65163125-65ad-4379-b3ab-ebcf6c713458">485,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTAtNS0xLTEtMA_5f004fd9-d320-4d36-acda-bedb33e66ce5">1,464,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTAtNy0xLTEtMA_2b43f3b2-4b95-4fb1-a28f-54737da0d8f9">1,391,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTEtMS0xLTEtMA_96de18b4-831c-46fe-bdf9-b5d9af291eb3">56,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTEtMy0xLTEtMA_e802e412-cf85-4982-aafa-1edcaaec9faf">63,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTEtNS0xLTEtMA_bdcbd6bd-5e6a-42c1-87fc-abf9a2fe5daa">203,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTEtNy0xLTEtMA_f858514c-7974-4037-988c-03ca6d1a4e80">157,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTMtMS0xLTEtMA_d4cd0dc2-7a41-4050-ba6a-fab35578b3b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTMtMy0xLTEtMA_c09ce059-c27c-438c-b280-44ab69d17bae">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTMtNS0xLTEtMA_e5c556b3-bb37-4a0f-95d7-b4040b362c16">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTMtNy0xLTEtMA_bdf40b18-19e0-4689-a88d-53febc0bfc89">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTQtMS0xLTEtMA_07997ef3-6dff-4df3-b9f3-152a5e92e67e">2,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTQtMy0xLTEtMA_75e2533c-bd60-4329-a8ad-e3b8edd32cdd">2,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTQtNS0xLTEtMA_26c2ae60-c869-49fe-9ee6-2e0a876c6b87">6,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTQtNy0xLTEtMA_a26fa539-0dc3-4d1d-8f70-b5f01c5e6b07">8,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTUtMS0xLTEtMA_56641cc6-3a1e-467c-a81e-7f2b3671bec8">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTUtMy0xLTEtMA_7f94160b-d5dc-43b9-9f46-d29b231769d5">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTUtNS0xLTEtMA_889e5a0e-64a7-4ef7-97ad-eca95338d9c5">3,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTUtNy0xLTEtMA_3476cd1e-df00-4561-9803-3383e118f5bb">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) on equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTYtMS0xLTEtMA_c4581972-1778-471a-93e4-0e95076aebdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTYtMy0xLTEtMA_cc50baca-cc98-4e6f-ad0b-bb31abdf26e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTYtNS0xLTEtMA_fc11b720-9b6f-44f6-a32c-0ad5c9f5019c">31,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTYtNy0xLTEtMA_c994acaf-1bbe-4874-af13-6edd886b051b">2,980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTctMS0xLTEtMA_e2a558cb-163e-4072-9fb3-e0cbe7d3530c">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTctMy0xLTEtMA_071a1285-f5aa-4a3d-aebb-b9231b9033ac">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTctNS0xLTEtMA_63a07c75-435c-48f9-836e-1c23ef62acc3">1,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTctNy0xLTEtMA_17af0acd-bb1a-4f55-8121-f737cd8be892">662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTgtMS0xLTEtMA_425203e6-630a-4124-811a-8bfe0a8bca8a">796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTgtMy0xLTEtMA_952b1046-77a4-4175-8f8a-f3a08482ba0a">1,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTgtNS0xLTEtMA_d3af5c85-4ed2-4953-b72e-069368dd4422">29,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTgtNy0xLTEtMA_8794467a-65bb-447c-944c-e6bf6f51b25b">8,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTktMS0xLTEtMA_9235bb26-2b77-4f5b-820a-b9f77d005839">55,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTktMy0xLTEtMA_cc766ad6-65c6-4f40-82ac-9b81184d6cf6">62,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTktNS0xLTEtMA_35781f81-5b60-4c13-90fb-4f5d36e26fa6">233,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTktNy0xLTEtMA_6eec3774-65f7-4c72-8514-caebcd5f2311">148,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjAtMS0xLTEtMA_cdfc9a1a-f26c-4e0f-bd79-3a15b83f617c">10,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjAtMy0xLTEtMA_8359b8d6-a6b3-4454-8d49-f4fa44485f5c">10,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjAtNS0xLTEtMA_72bc48f3-98d5-4d5d-8884-2729fbe116b0">57,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjAtNy0xLTEtMA_db04ad7c-4b6e-4364-9ffc-4fcc1e0d9031">9,175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjEtMS0xLTEtMA_66232457-5d5f-4dd6-858d-ef4b6ccf0a68">45,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjEtMy0xLTEtMA_51eb191c-2b0c-4893-ac89-598039106b0a">72,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjEtNS0xLTEtMA_337de5a5-18c7-4ecd-a448-9ab431fef0b4">176,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjEtNy0xLTEtMA_0f6e7639-21ee-44ce-a507-19824751799a">139,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjItMS0xLTEtMA_2b83f8e3-d991-4aaf-8433-052c2f7551be">239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjItMy0xLTEtMA_b4926eb8-a7da-46da-978c-2864be0d3e9d">430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjItNS0xLTEtMA_4cd4c3e9-19cc-48b7-9993-c16a4730ba8f">1,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjItNy0xLTEtMA_961e2514-5922-417b-9fe9-3bbfff8ac5f3">1,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjMtMS0xLTEtMA_4fcb495e-f41a-4097-acd8-df6c16f5e038">45,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjMtMy0xLTEtMA_9a8549a5-fc32-4058-94d7-17f81c7efaf9">71,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjMtNS0xLTEtMA_d89e2c59-d4e8-4af2-b72f-43b43120274a">175,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjMtNy0xLTEtMA_332796c0-d263-4e71-9de5-7ce74416a9c1">138,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjUtMS0xLTEtMA_31d8ae49-8128-464c-823e-134fe8baf780">1.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjUtMy0xLTEtMA_a284a5ba-7422-444f-b6bb-878c6e326346">2.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjUtNS0xLTEtMA_2b154c9e-4580-4dcd-9db5-6e44d173f8b7">5.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjUtNy0xLTEtMA_4461c5ea-b2cc-46a1-84ae-6538d4897099">4.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjYtMS0xLTEtMA_2bcf5f61-6f58-4844-9d72-23aa5e108c70">32,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjYtMy0xLTEtMA_7e9a6e48-91a3-4667-8ae1-39e98d85c4d0">32,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjYtNS0xLTEtMA_79e4a7b4-5694-4e4d-b98c-a26a422080c2">32,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjYtNy0xLTEtMA_4625b479-d27e-435f-b7df-a5ca7810893e">32,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc. common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjgtMS0xLTEtMA_294b2ece-3be5-477e-86ca-4f4a06356241">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjgtMy0xLTEtMA_5aa86a2d-3222-4b82-811c-66969200f964">2.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjgtNS0xLTEtMA_3ad7bf36-b64f-41cd-bb77-8c0ddf17e910">5.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjgtNy0xLTEtMA_ba35f00f-06fd-42c2-b451-5e0ecec2ba7b">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjktMS0xLTEtMA_de9e7a99-ccbb-4c92-9d6b-739c0e530148">32,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjktMy0xLTEtMA_4f7fcfe7-4e13-4847-9db8-fa1f41c0f342">33,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjktNS0xLTEtMA_8034014f-3422-461a-a277-2daf1dab4ad2">33,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjktNy0xLTEtMA_72844e20-d524-4200-a422-01894b7f9108">33,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_28"></div><hr style="page-break-after:always"/><div style="min-height:4.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except common stock shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Months Ended September 30, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdd17b976b94417b0973260d8bd3e44_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0xLTEtMS0w_67bd9696-7310-47b2-8031-44f4ad15030d">875,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd44a5fd2068444ea4c2b014fc212aba_I20210630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0zLTEtMS0w_37801ac5-6ad2-49ce-986b-c8f80072e37b">37,553,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd44a5fd2068444ea4c2b014fc212aba_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy01LTEtMS0w_10055ca6-7451-416a-9a6d-c345a8e76218">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81046c5f2fe9466f935a9da81d4f9b05_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy03LTEtMS0w_99aea05a-5ea9-4e39-a04e-9ddc3554bfe9">714,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i481818d771fb4e8cba7ee992ef045095_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy05LTEtMS0w_ccb81103-2153-4b4b-989a-bb80a32040c2">400,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2d22e47449f4dce9025ba20e4ee868e_I20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0xMS0xLTEtMA_f2fd67f7-1888-414a-8e47-b3be95f44f78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic477a09656e142a2ba9555f6e71e57b8_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0xMy0xLTEtMA_c2d010cd-e7d6-4d84-abe3-55554ea8a6a7">560,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89642198499249a5a508a2b794a0c774_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0xNS0xLTEtMA_6931895b-8f71-4443-b1aa-38e4908630d7">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNC0xLTEtMS0w_37724cd0-6bea-45de-94fe-7f72f7e1aa1b">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNC0zLTEtMS0w_5d56c2f4-d5fb-4205-8e03-4e173eb626ef">5,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNC03LTEtMS0w_d0c09b2c-6756-44e0-917c-79e722f7fd29">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNS0xLTEtMS0w_c3eca259-8d48-4740-b44e-8118af192a52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNS0zLTEtMS0w_dfab1611-e098-4380-b8b7-340f7e41795a">87,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNS01LTEtMS0w_297e8eb9-e000-4b5a-8cb8-39fe6797596f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNS03LTEtMS0w_3aa64a2c-d32a-4d28-b80e-74d2bb360f34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNi0xLTEtMS0w_d471eeeb-677e-42e1-a8dc-adaf87797de7">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNi0zLTEtMS0w_4fcd6237-3383-4921-b070-bb5971b8c788">13,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNi03LTEtMS0w_b8a41928-d4bc-43de-9963-65a3798938b2">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNy0xLTEtMS0w_570cb5ef-2d5d-4313-a14f-341c659861c7">4,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNy03LTEtMS0w_93c93dae-658b-41c1-848d-10104508ed64">4,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfOC0xLTEtMS0w_399e8cdc-5dca-4f5a-83d6-16002c041172">9,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id633ade135bd4fa5a755576d79307e96_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfOC05LTEtMS0w_3928b39a-0bbc-4707-82f5-fa3719df5a38">9,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfOS0xLTEtMS0w_a179e56e-39bb-4900-9cfa-1630528465a1">10,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id633ade135bd4fa5a755576d79307e96_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfOS05LTEtMS0w_b7c37770-8065-4d67-9a6c-ba11fb627f68">10,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTAtMS0xLTEtMA_d25790e5-862c-43d1-97db-a911bd612ba7">459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8585c2e41c09481f94254dd475c515cf_D20210701-20210930" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTAtMTUtMS0xLTA_dd0d50e2-f189-4e66-8169-96276e15f729">459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMS0xLTEtMTA1NDY_0fec00ac-0f06-478a-9589-b40e903ac51d">42,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8585c2e41c09481f94254dd475c515cf_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMTUtMS0xLTEwNTQ2_492eacbd-c955-47f6-8f74-684f47924052">42,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMS0xLTEtMA_5feefb65-c15e-431f-9b61-27a1aaa1b344">45,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i598b6bdc5e4b441ab25be4f2fd0a21ff_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMTMtMS0xLTA_d4a8a46d-e1da-414f-87c2-4c6d3f38046b">45,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8585c2e41c09481f94254dd475c515cf_D20210701-20210930" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMTUtMS0xLTA_785bb076-4b00-4316-88c3-d07e9558c366">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMS0xLTEtMA_4fd17bc8-12f2-4e57-9362-851921d51ba4">948,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3722136a4de449192734a30989dde10_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMy0xLTEtMA_803987ff-fd5e-45ea-99fd-28a1ca89e378">37,659,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3722136a4de449192734a30989dde10_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItNS0xLTEtMA_66aa22d4-7d9d-4ea3-b389-f89e8e8a053d">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f95beb109544799227cc0e3807a5a2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItNy0xLTEtMA_aa675ab9-43ed-4407-ab99-b0934d43f112">720,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9586bde96dc4b55a43e520f969b3d49_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItOS0xLTEtMA_42b6612c-e626-45e3-9cd2-5196f6bd55f8">420,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590fcf43ae93429c90aa189d83dd278c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMTEtMS0xLTA_ca1ec7fb-8895-4094-92fa-21d157f60fa3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f981173ad3f4a55af9ec673326e4ee7_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMTMtMS0xLTA_259b9c8d-f6b4-4d66-b83f-d8a85a6d5667">605,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb123a126ca4044b4d597a6f5aeb789_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMTUtMS0xLTA_186d630f-0d39-42ff-b8f2-3c4e096af087">43,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Months Ended September 30, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b307a62c3fb444494adee8144988b0d_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMS0xLTEtMA_16b50366-1f6b-404a-a111-c6bda3de8fed">722,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e4f44436f8c4b4b84c3920f226cab7a_I20200630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMy0xLTEtMA_cc95afe1-b7bd-4312-a8c4-1549db95066a">36,831,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4f44436f8c4b4b84c3920f226cab7a_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctNS0xLTEtMA_aa114012-21d9-4cc1-abb2-c83e5c833c9e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afb39ea542d425cbf6ec7dcdc11d968_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctNy0xLTEtMA_cf63e34a-2fcd-4c9c-a058-6b27fc47368d">665,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6701d88a3f6b429ba56daa18c8fb08cc_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctOS0xLTEtMA_9175c727-f44b-4e08-9ee9-802f1d1f2612">257,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59e60464baed4c908a5a135d54dc4b11_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMTEtMS0xLTA_dbcb3aad-5d2f-4a3d-98e8-a674d0a156cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b35a3a550a440cc90fa58ad012ef681_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMTMtMS0xLTA_9fe02542-4cd8-4c6e-b6c0-45fec8c1e882">312,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d9a940c2864685ae466b0f8760514a_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMTUtMS0xLTA_fbd57df4-b73e-4efd-89c5-6a34fa2069e1">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTgtMS0xLTEtMA_cf4cba32-eabe-4a3d-9b28-efc2effcfb89">914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTgtMy0xLTEtMA_a5b4ccbd-8be4-4104-8304-99657d8bb8ae">5,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTgtNy0xLTEtMA_89d3414e-5207-4c14-8880-8e339f848b43">914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTktMS0xLTEtMA_31ca737c-c826-4a94-9aea-b82843ae9fc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTktMy0xLTEtMA_dc8ec901-dcae-4cb2-b811-3367918c1de5">81,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTktNS0xLTEtMA_a20a8057-d189-4ab0-9f38-fbee8f991b71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTktNy0xLTEtMA_96c87a59-9d1c-4e9c-a072-c679477224fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjAtMS0xLTEtMA_94b5ba2e-c2e9-46ea-a2ec-aa405621900a">3,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjAtMy0xLTEtMA_9ea80d8a-b58f-42b9-afa6-466310583529">538,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjAtNy0xLTEtMA_89645871-7142-497c-9678-a5babcfd2680">3,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjEtMS0xLTEtMA_5d240cb6-6a23-4043-9244-c8ab39cb61cb">7,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjEtNy0xLTEtMA_0297d885-a93c-49ef-a3d5-f98e132622ca">7,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjItMS0xLTEtMA_bc6cfa26-f8f7-4872-891b-397752babc7a">47,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjItNy0xLTEtMA_b3f59402-fb82-4b19-8586-50f0ed2eb3db">13,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0981942253684fd5b4f7eb9fb411157c_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjItOS0xLTEtMA_92c06e14-4675-4ee4-a04a-5014d474a25d">61,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjMtMS0xLTEtMA_d1436b6f-b2d3-4e92-8bc8-6c10dc8b54e4">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696f26883f1a42e28bc3241a2c02dc1c_D20200701-20200930" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjMtMTUtMS0xLTA_7a065154-f337-4774-89e8-b97fb45f964f">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjQtMS0xLTEtMA_4d7bfceb-068c-47bb-8bbe-2cd5759e23fa">72,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f094da56c24200a601142582cdc2a0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjQtMTMtMS0xLTA_44992bca-3e9a-4340-b922-3f346ddbad8e">71,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696f26883f1a42e28bc3241a2c02dc1c_D20200701-20200930" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjQtMTUtMS0xLTA_1b228e97-2d24-4c30-8667-4fbc44a3284e">430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09d9dfbada9402c82e04fffa1792aed_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMS0xLTEtMA_a0524a3e-b009-4fe6-bb25-69772ffd7f32">757,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc6b318a025b416080e2e688fa3d70f4_I20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMy0xLTEtMA_90d40cbc-3f83-49e7-bdbe-603b51052363">37,457,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6b318a025b416080e2e688fa3d70f4_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtNS0xLTEtMA_df0b3feb-7d58-4832-8e75-c517dab52cb1">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21bb61efbc804a59b103a8fc6e57cb32_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtNy0xLTEtMA_6560532b-4229-4ded-9034-7d5a5425b955">690,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1180b4ef96164b9a9e4962f634ba5bcb_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtOS0xLTEtMA_cee2a221-da90-4e6a-a43b-85e31d998ecd">318,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c58ab1289048be8261102b772d4db9_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMTEtMS0xLTA_b735d0c7-b352-4b38-b542-c447a844d41d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e494dd063a4d8aa19b36fcb24fed25_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMTMtMS0xLTA_c0c3882e-4b2c-423e-965d-6bd3123c8555">384,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia855683296e64bf18a9ef89f356655a0_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMTUtMS0xLTA_fa9c6d36-8b3c-4e0d-bf7a-b9142530f74c">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Months Ended September 30, 2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMS0xLTEtMA_aa628e81-8b72-497a-b030-204b5c880a3c">810,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa9afb8e5e3644a59da63953d75e842c_I20201231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMy0xLTEtMA_e7d40b30-2b5d-42e4-8a49-4ca93cfffa37">37,470,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa9afb8e5e3644a59da63953d75e842c_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtNS0xLTEtMA_12758dae-e402-4c8e-9932-af33185d8c24">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc92f06d04394959b3242b038919464a_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtNy0xLTEtMA_825fced1-56d3-4a9a-a868-e6a8e6aa40bf">698,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib42b43eecaab42a78203a133cac36e19_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtOS0xLTEtMA_beb4f255-26cc-45e3-84d9-25d4667df833">319,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b5458af0924ae791b517938fa92dba_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMTEtMS0xLTA_e3cc26e0-ddf8-444d-95cc-1209780b0d53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c69e51ef304378875bd8586144f797_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMTMtMS0xLTA_4c3f5260-7564-4d4b-ac44-8928f53e8c20">429,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff740465893462abb39658ee50a3980_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMTUtMS0xLTA_8f945d51-dc23-46aa-8321-f8f8940fec27">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzEtMS0xLTEtMA_0a7f562b-c6b5-473b-be25-15dce9c8bbb7">3,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzEtMy0xLTEtMA_0a031ae5-6107-492b-bcb6-0d53856c9c87">13,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzEtNy0xLTEtMA_e762eb3a-d362-4b7d-82b5-81ebbc71937e">3,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzItMS0xLTEtMA_705beae2-7c29-4e70-996e-4033d4e6db4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzItMy0xLTEtMA_ca85bfbc-c59f-4adb-aa24-e345ce6eb822">148,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzItNS0xLTEtMA_0ef9c6ec-99e6-4cfc-a613-c9c5e509c2f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzItNy0xLTEtMA_a59f43cc-68ea-4b61-8e20-339277d06b9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzMtMS0xLTEtMA_ff5b8c37-f1f5-45e5-a6b4-8ad26de32933">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzMtMy0xLTEtMA_7bf39fd1-5f6f-4710-8082-d64c4f610dd9">27,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzMtNy0xLTEtMA_fc8be5bc-ad1e-48c9-8dd0-b3fda61431b9">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzQtMS0xLTEtMA_df439227-560c-4828-a23b-623f1f4b7011">17,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzQtNy0xLTEtMA_820d5cf8-e451-45f2-bf58-e3c15e556268">17,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzUtMS0xLTEtMA_9b0ac2d4-9d82-43c4-aa44-975bf3dce030">16,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccb3f95375f5445ba8782cf65507f940_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzUtOS0xLTEtMA_9f9fc8c6-8141-4e77-9449-f5bf03e75e05">16,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares repurchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzYtMS0xLTEtMA_5346d53c-e810-43e3-822f-95d80c151456">84,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccb3f95375f5445ba8782cf65507f940_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzYtOS0xLTEtMA_0c610999-50cf-404c-ad5d-9adf2ae35c59">84,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzctMS0xLTEtMA_b455827c-4be0-48bc-acd7-69fe4eb68f55">1,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46836dfa696048bb8468c58880596456_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzctMTUtMS0xLTA_1d79f9b1-e7f2-4128-bc26-09aef0fdd3f8">1,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMS0xLTEtMTA1Njk_6d3f6c2e-b751-483f-878a-c8d78624eb5f">42,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46836dfa696048bb8468c58880596456_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMTUtMS0xLTEwNTY5_832fcaf4-fd72-4240-8876-9072c05f0bbe">42,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzgtMS0xLTEtMA_6192eb11-3cb9-43e5-8cbb-9437f2a4ccee">176,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5883b3c8ba45e0853c437d045de477_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzgtMTMtMS0xLTA_953b35ce-c74d-4624-99e4-676a6a8cb360">175,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46836dfa696048bb8468c58880596456_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzgtMTUtMS0xLTA_1bb99229-fb30-4608-91cb-e6c08ffc4f3e">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMS0xLTEtMA_8b57dc02-7135-416e-bb79-18d5eb4cc91a">948,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia3722136a4de449192734a30989dde10_I20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMy0xLTEtMA_d7ca0450-0a03-471f-babf-0039e20e63f2">37,659,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3722136a4de449192734a30989dde10_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktNS0xLTEtMA_06b8934f-9cdc-4eb8-a96b-3c5c446bb598">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f95beb109544799227cc0e3807a5a2_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktNy0xLTEtMA_f45075ee-ba82-4244-b107-20b9bfcdd3c3">720,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9586bde96dc4b55a43e520f969b3d49_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktOS0xLTEtMA_aa1e40b0-bc70-49c1-aadc-83106e90a309">420,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i590fcf43ae93429c90aa189d83dd278c_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMTEtMS0xLTA_66dda142-c950-4574-b31f-6cf994f453f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f981173ad3f4a55af9ec673326e4ee7_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMTMtMS0xLTA_c1093880-e0ee-41f2-bd68-56bc0de6f8d6">605,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fb123a126ca4044b4d597a6f5aeb789_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMTUtMS0xLTA_70081ada-7fdb-49de-bde4-b99ae2dcfb3a">43,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Months Ended September 30, 2020</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a2e6cc1034448789c21e45ddc2a62a_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMS0xLTEtMA_b4fa02f6-f2e1-48a4-b786-97723d9fffaf">641,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6566df00d848434baa97e9fd857c714c_I20191231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMy0xLTEtMA_6b25329b-e80f-4079-b434-9e2f5b498a11">36,638,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6566df00d848434baa97e9fd857c714c_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtNS0xLTEtMA_bec3f69b-9163-47d9-9099-6a3bb76cc321">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7b322b8d954305ab4228a0e4f5fa44_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtNy0xLTEtMA_ed2ac7fd-4991-49de-b342-41012e5c1234">645,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69fea3aa6870434ea5666aacfdf3d1d0_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtOS0xLTEtMA_a8808722-7190-4bf5-9373-66b4e3eaa5d6">251,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9c15c2efa64925929ae6f6cfe42a0b_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMTEtMS0xLTA_5905e300-a54e-4140-8363-1f45d475a17a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70db5c4d7e784bac89013422e4e11011_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMTMtMS0xLTA_c5a4b555-8bb1-4fa8-8c2a-c4d210b05eec">246,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i884c25e331534f468450dd28f2d93e40_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMTUtMS0xLTA_ce98f153-1ec7-4fcf-b455-1b7a5733ba59">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDUtMS0xLTEtMA_907d0bc4-105f-43ef-a4fd-61dedacacc68">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDUtMy0xLTEtMA_aa999588-a715-4e90-ac75-26b49cf364c4">16,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDUtNy0xLTEtMA_3b5ee9ae-2acd-459e-ba19-836728afd54d">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of stock &#8211; 401(k) plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDYtMS0xLTEtMA_ee753d18-3011-4a72-a302-f56bffdca8df">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDYtMy0xLTEtMA_98a03cce-0566-4730-8e24-a09d8fdb3cc5">18,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDYtNS0xLTEtMA_4209787e-f0b5-41cc-bd0c-24961d432d8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDYtNy0xLTEtMA_4b825f9a-678c-4e42-a7c7-27ab3d75fc10">3,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance/(cancellation) of non-vested stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDctMS0xLTEtMA_79db783c-61be-4a21-a8ef-e4c0d3786c60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDctMy0xLTEtMA_76d17b95-3e58-4d64-a8aa-2ff770f212a5">166,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDctNS0xLTEtMA_78fc38f3-fb4b-4ae7-bf72-2c4f4508d08b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDctNy0xLTEtMA_92913c68-c4ab-4bac-b7e6-afb8e7edb444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDgtMS0xLTEtMA_bae561a7-5fa8-43de-b616-7cd89d3818fc">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDgtMy0xLTEtMA_a5908881-5f3a-45b6-96a2-cb9587d6ed01">617,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDgtNy0xLTEtMA_ed8f0cd2-f3e4-4f83-a574-7cd5ba5f5532">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDktMS0xLTEtMA_ec000a4f-ddd9-42c6-b626-386b24f444fc">19,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDktNy0xLTEtMA_a8cb6182-602c-4016-87ee-305d19335429">19,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surrendered shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTAtMS0xLTEtMA_8f80a7f5-1dc9-42e0-beb9-7c9e8c5c17bc">54,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTAtNy0xLTEtMA_69f4228c-71b7-4c26-a92d-5a84a3cf8f4d">13,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67b5b45191d24afe8a6500e067394b03_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:SurrenderedShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTAtOS0xLTEtMA_342f4062-20d8-4928-a179-07b213b06a4a">67,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTEtMS0xLTEtMA_3c7f78e1-5bda-4f05-bf80-62af0d828cfe">672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i465c7064fe5e412e978bfdd7128be6a7_D20200101-20200930" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTEtMTUtMS0xLTA_a6779ed1-346d-4044-b8fb-719f76002ed9">672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-off of other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTItMS0xLTEtMA_372e06ef-c20a-4567-93e6-f01a78bb128b">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96d80f5ecb444e898ca8530a2f8c3d9e_D20200101-20200930" decimals="-3" name="amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTItMTEtMS0xLTA_554bf195-ff53-4e0b-8f13-afc3eebf2877">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTMtMS0xLTEtMA_1574d19d-1a99-4dfd-9a85-ac84b7baab95">139,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b85cedd162948299f5f10b84f850dd7_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTMtMTMtMS0xLTA_54ffd64d-6bd3-4fb2-a00a-ebb197510d2b">138,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i465c7064fe5e412e978bfdd7128be6a7_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTMtMTUtMS0xLTA_0e3758cb-cd57-409d-bf84-1599741182a6">1,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09d9dfbada9402c82e04fffa1792aed_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMS0xLTEtMA_d300c920-4c66-42b6-a184-19a9415247a0">757,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc6b318a025b416080e2e688fa3d70f4_I20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMy0xLTEtMA_3e770438-a1ae-4f2a-85c6-d845b8c2517e">37,457,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6b318a025b416080e2e688fa3d70f4_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtNS0xLTEtMA_9b496b26-14fb-4f5f-910a-1f2f526d9d9e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21bb61efbc804a59b103a8fc6e57cb32_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtNy0xLTEtMA_111bb4ba-068d-4c57-8a0b-33d2550338cd">690,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1180b4ef96164b9a9e4962f634ba5bcb_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtOS0xLTEtMA_93f3f306-59c4-4276-bad1-84f76a68e3b6">318,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c58ab1289048be8261102b772d4db9_I20200930" decimals="-6" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMTEtMS0xLTA_c1582629-02d1-49b5-a11e-07f197fa9145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e494dd063a4d8aa19b36fcb24fed25_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMTMtMS0xLTA_8b3c8b21-849b-4f16-a67b-c981eb5f4cd4">384,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia855683296e64bf18a9ef89f356655a0_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMTUtMS0xLTA_1ed5a30c-292a-44ca-87b2-a0f310b45cc1">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:4.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:472.50pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For&#160;the&#160;Nine-Month&#160;<br/>Periods&#160;Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMy0xLTEtMS0w_711afb36-36f5-4953-bd02-1c76008d59ff">176,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMy0zLTEtMS0w_bfd808f0-48c0-453a-862b-b9c4ab4094de">139,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNS0xLTEtMS0w_4fb8386f-ca40-431c-a185-7cba7a34e61a">21,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNS0zLTEtMS0w_1396753b-f22c-485f-a48d-b4e9125f65b5">19,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNi0xLTEtMS0w_c044dfd8-ccb4-4fa9-b234-3075e8ee79f3">17,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNi0zLTEtMS0w_ef1eb764-8a74-45e6-8a57-2f566c49ac37">19,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and impairment of operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNy0xLTEtMS0w_fb4d3a48-0090-48e7-8ef6-12a0a859d37c">30,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNy0zLTEtMS0w_4f88b7b0-faef-43f8-be76-1760587aa573">29,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on disposal of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfOC0xLTEtMS0w_ca862190-cb74-4b2d-9874-0ac0f0ca6aa7">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfOC0zLTEtMS0w_6728494d-89f7-4000-b6ef-fd1960e4b432">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfOS0xLTEtMS0w_7fdbc561-4a8c-4fcf-a15f-c6c1a9ad371d">31,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfOS0zLTEtMS0w_8441a0c5-32c8-48dc-8891-655af129f8e5">2,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTAtMS0xLTEtMA_a45c2d09-a1de-4b30-ba85-cb08a1facb01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="amed:WriteOffOfOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTAtMy0xLTEtMA_4bf2dd49-04f2-4298-bce6-6552ca18c00b">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTEtMS0xLTEtMA_14005b0a-03fe-45a4-8011-7a7a129aa29a">34,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTEtMy0xLTEtMA_503c4968-525b-4f5b-b017-9a7c2819caca">2,762</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in earnings from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTItMS0xLTEtMA_2816ef72-e50f-4faa-a1fc-29ef4480e624">3,932</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTItMy0xLTEtMA_d30f0265-c292-4867-8f5b-a3a6e2db503f">2,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred debt issuance costs/debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTMtMS0xLTEtMA_46ae4bcb-f1eb-468c-b26b-ecf3f46bd389">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTMtMy0xLTEtMA_f9a765ee-502e-4414-a315-1483fff6794d">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return on equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTQtMS0xLTEtMA_ad8ab1d3-ea8b-4fba-afdf-067bb596a282">4,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTQtMy0xLTEtMA_93ddfe5b-eeeb-4420-9cd5-1dff77991ac3">3,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of impact of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTYtMS0xLTEtMA_b6e8e15b-cb39-4dfa-8a17-278b4baf3c10">17,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTYtMy0xLTEtMA_f97c833c-2df9-4b4c-ad80-4bb6970f1d58">6,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTctMS0xLTEtMA_28d1fe2b-6b5d-41e6-b1fe-72aad273704e">6,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTctMy0xLTEtMA_9f10908f-199b-4fee-a436-a1c00afa8f45">28,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTgtMS0xLTEtMA_48c9a068-ea7e-4c3c-9f99-3ee11491967d">938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTgtMy0xLTEtMA_60f15ebb-2555-4a5b-87fc-462219ca9ff5">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTktMS0xLTEtMA_26a83a3c-cffb-4ce7-a152-5c65478fe7bf">1,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTktMy0xLTEtMA_e19a5164-db73-4cf2-b1e8-43370e924138">1,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjAtMS0xLTEtMA_aaea1be5-0d93-46f8-9dba-12c31be6f400">9,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjAtMy0xLTEtMA_8f3e2a6a-b0dd-4a9b-9ef1-b5649e1fd4db">25,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjEtMS0xLTEtMA_8d11e975-265f-448a-b19b-229fa76d5da7">1,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjEtMy0xLTEtMA_24a452c9-ec6d-4061-abd0-ef4b9cc9c82d">38,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="amed:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjItMS0xLTEtMA_ab63fe68-3449-44a5-9b28-14f8a92d84f6">27,372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="amed:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjItMy0xLTEtMA_13a0dc35-df86-428a-a501-02d7d8eb8901">25,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjMtMS0xLTEtMA_ce3648fa-b1a2-4865-b046-47419baa2c62">2,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjMtMy0xLTEtMA_7a97a7d6-d0b7-424f-8093-4b258106c0b4">2,775</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjQtMS0xLTEtMA_333c7606-1101-4184-909d-69749d875e46">183,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjQtMy0xLTEtMA_48c1e296-4423-410f-b7e6-932ff2f36288">223,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of deferred compensation plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjYtMS0xLTEtMA_60d652ad-af00-45ef-b789-35e0991612d5">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjYtMy0xLTEtMA_da46d256-89d2-4e1d-9dfb-607a22a57b49">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjctMS0xLTEtMA_7b3dac72-46a5-4f87-b698-763abb99913f">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjctMy0xLTEtMA_fa875fcb-a443-47a6-aa23-ff32b62cec9f">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjgtMS0xLTEtMA_0338de0e-b8f8-4364-9dd9-024dfec0add9">5,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjgtMy0xLTEtMA_87ff60fa-44ab-4b39-a043-70fcb98c809f">2,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in technology assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToDevelopSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjktMS0xLTEtMTE5MTA_af26e58e-d46c-4f3f-b0af-2b9860af2453">147</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToDevelopSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjktMy0xLTEtMTIzMjQ_2bbaa29f-7dc7-450d-9795-489910a139fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjktMS0xLTEtMA_04c40430-c5b8-4da5-8a24-c6a4c49ab7e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjktMy0xLTEtMA_6c6aa47b-745f-404e-a0c1-329cc76e8ec7">875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzAtMS0xLTEtMA_ff5f17f3-799d-4d47-b709-d4ce159d098e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzAtMy0xLTEtMA_7313a845-96ea-477d-8555-469374ff3451">17,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzEtMS0xLTEtMA_cf9566ef-a8d4-4382-aec0-61cc204e876a">264,872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzEtMy0xLTEtMA_741b7f7a-d70c-4b2e-a375-0436b000429e">299,723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzItMS0xLTEtMA_db4f6379-7ac6-46a3-b7fd-ad347c48cb76">269,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzItMy0xLTEtMA_a1e0f9ec-65f8-45f4-8daa-4e072b47b80b">285,543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzQtMS0xLTEtMA_a03ca270-4597-46c8-b091-7edb3acb30ab">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzQtMy0xLTEtMA_f6a88327-71b3-42cd-807c-be629841845a">6,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of stock to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzUtMS0xLTEtMA_bfc24e43-b09b-4e9d-a4dc-1a9ddcc0cd3c">3,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzUtMy0xLTEtMA_a27db780-fb7c-4287-a2eb-421d99b4814b">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares withheld to pay taxes on non-cash compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzYtMS0xLTEtMA_6153c50f-ce77-4d25-bd98-0116d96beeaa">16,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzYtMy0xLTEtMA_383eb567-dbe2-41f0-be43-1113aeaaa1af">54,172</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest distribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzctMS0xLTEtMA_0d6dc6c0-9412-490d-9669-94836b73a7ea">1,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="amed:CashDistributionToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzctMy0xLTEtMA_21c32139-2233-4295-b4fb-1435fcbd7038">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from borrowings under term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzgtMS0xLTEtMTEz_14a4c88f-6416-4905-8358-5770a925b869">290,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzgtMy0xLTEtMTEz_28a3b4a1-2e9f-437a-966c-feebbe00cd90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from borrowings under revolving line of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzgtMS0xLTEtMA_3c818ef2-a477-4c03-bef7-d7aa5bf787a2">500,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzgtMy0xLTEtMA_d9b3c020-3fc3-4950-9803-81aa99006243">432,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of borrowings under revolving line of credit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzktMS0xLTEtMA_31086bcb-bad8-4a62-8c4e-e6434837e360">551,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfShortTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzktMy0xLTEtMA_bcb2bd88-8d92-4a34-a52f-a293b163943c">357,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDAtMS0xLTEtMA_4e5cb199-a5d7-4f1e-918f-a801cbe3ba84">5,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDAtMy0xLTEtMA_154ac0b4-9ba6-4cd9-9439-2948e1f7d854">7,360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDItMS0xLTEtMTEz_82302667-355e-46a6-82ec-ae4ae2480d92">2,792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDItMy0xLTEtMTEz_449b64d9-9644-4131-85fb-393203ac7f23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of company stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDEtMS0xLTEtMA_e7e0aad2-99d1-44f5-bbde-6063afcfb5eb">84,879</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDEtMy0xLTEtMA_06e5be52-f840-4537-a1e0-80dd6b094a66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider relief fund advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="amed:FundsReceivedFromProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDItMS0xLTEtMA_bc61f26e-0a59-4b60-9894-48b747c4ccfc">1,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:FundsReceivedFromProviderReliefFundAdvance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDItMy0xLTEtMA_3ee326bc-b26b-443d-9e9b-73963518d8e4">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDMtMS0xLTEtMA_d349e6ab-fd2a-4ccd-9b6f-8f4f40b282d0">131,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDMtMy0xLTEtMA_8598cc1c-afa3-48a5-bc4c-037703b4a8e3">81,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDQtMS0xLTEtMA_70ebcd66-0ebc-463a-a4f0-c231aa860536">44,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDQtMy0xLTEtMA_f4726550-aff5-4ce9-aa14-2b377c3c8faa">18,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDUtMS0xLTEtMA_8631886a-c7b7-4cfc-ba2b-7d7557aa26c8">83,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a2e6cc1034448789c21e45ddc2a62a_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDUtMy0xLTEtMA_bbfe7167-a0d8-4c81-b90a-87e4e06b21dc">96,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDYtMS0xLTEtMA_2adadd57-0cb1-4156-ba19-cef13fbba9c4">128,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09d9dfbada9402c82e04fffa1792aed_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDYtMy0xLTEtMA_2002363f-c02d-47e3-9d39-fd098a6588b9">115,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:472.50pt"><tr><td style="width:1.0pt"></td><td style="width:357.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Cash Flow Information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDktMS0xLTEtMA_94256677-af1e-446f-8e69-ad96d652d77e">3,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDktMy0xLTEtMA_9b4c4d9d-3035-4c0a-902b-3fd65a34a13b">4,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes, net of refunds received</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTAtMS0xLTEtMA_4ccba4e7-f887-4a3a-ad3e-c816ab651195">25,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTAtMy0xLTEtMA_a9c76c15-c4c9-4d3f-af4e-e39c3a895437">30,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:CashPaidForOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTEtMS0xLTEtMA_195b7d31-3d51-4207-80f0-0fe68df167ef">29,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:CashPaidForOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTEtMy0xLTEtMA_8cc7c2d3-25fe-4080-9c9b-bb1dc9ffd7e4">28,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for finance lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:CashPaidForFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTItMS0xLTEtMA_cc0e4555-d0f9-4a68-b54e-781f870864b7">1,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="amed:CashPaidForFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTItMy0xLTEtMA_d523144e-997a-40e6-aacf-46fd04984a0a">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures of Non-Cash Activity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTQtMS0xLTEtMA_50f8746b-57c8-46f0-a1ef-c13d7ee8b21e">34,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTQtMy0xLTEtMA_018e8643-23e5-4fce-b4e1-5b644dd3d8ec">29,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for finance lease liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTUtMS0xLTEtMA_621a7f6f-8475-4a40-ad15-b202e725591a">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTUtMy0xLTEtMA_e6ab178a-37e2-4ee6-9ef5-d28b420b6d04">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions to right of use assets resulting from reductions to operating lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTYtMS0xLTEtMA_11c8fa98-47c9-466b-8401-efd2195d5261">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTYtMy0xLTEtMA_c8b35e76-7009-4c54-aebf-b4805447d0a1">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:38.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_34"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="id60bf3839b914d279c418e71b98c550c_37"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQxNg_d7cc4bca-3a4c-4a23-986f-214a6ca2af63" continuedAt="i58616ba1b9094d338d24622fcef9d363" escape="true">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ix:nonNumeric></span></div><ix:continuation id="i58616ba1b9094d338d24622fcef9d363" continuedAt="i2396c9a37e3e47fe8802b51587750e45"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately <ix:nonFraction unitRef="number" contextRef="i53a77f5a57b04427a02592d620527871_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMzIz_4de51fa5-6d96-43b9-b891-a52eff1c0222"><ix:nonFraction unitRef="number" contextRef="i97413ae1e1174a779e186bf439f4b59e_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMzIz_bea2abfd-a5ac-4d14-965b-f5b286b7f9e6">75</ix:nonFraction></ix:nonFraction>% of our net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2021 and approximately <ix:nonFraction unitRef="number" contextRef="i9f3cf4cabcef48c49d533b6054864aa6_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNDQ5_e68655ec-532e-46c6-8028-5bc3285ffd43">76</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id4b858c3a1e442059c913a6d2f8baa16_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTYzNDU2Mg_6c44e553-44b9-454c-ae13-65fa7106e435">75</ix:nonFraction>% of our net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2020, respectively. As of September&#160;30, 2021, we owned and operated <ix:nonFraction unitRef="care_center" contextRef="i730de4ab8dd2401da027009b92ebd36a_I20210930" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNTg4_85a033ed-b623-4994-bdba-5e4df3c7a66e">328</ix:nonFraction> Medicare-certified home health care centers, <ix:nonFraction unitRef="care_center" contextRef="idba324da17d44f13b400eb4dcb6541c2_I20210930" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjM2_0f0c708b-26c6-413d-8365-1100289d36dc">177</ix:nonFraction> Medicare-certified hospice care centers, <ix:nonFraction unitRef="care_center" contextRef="i4003f84c115d4f539f2b8c54b785265e_I20210930" decimals="INF" name="amed:OperatingCareCenters" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjgz_f24cf402-0056-4044-adb0-b5e6aa87a2c5">14</ix:nonFraction> personal-care care centers and <ix:nonFraction unitRef="numberofjointventures" contextRef="i52fadfa94bbd423aa0033f0ef19c530a_I20210930" decimals="INF" name="amed:NumberOfJointVentures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTYzNDU2Nw_8e71fad3-6174-4dd5-8809-3d54ab82c807">8</ix:nonFraction> high acuity care joint ventures in <ix:nonFraction unitRef="state" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNzE2_4fda84ac-5cbb-4ddc-b970-814caaa376a3">38</ix:nonFraction> states within the United States and the District of Columbia. </span></div><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQxNw_612a65d5-f4e7-47bc-b505-c02a30016bf0" continuedAt="i3848bb9eab8b4495be6dbb65b8bccfb5" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3848bb9eab8b4495be6dbb65b8bccfb5">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 25, 2021 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.</ix:continuation> Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQxOA_3c5c7260-249a-4298-b7af-3a7d179d713f" continuedAt="icbc8049d878d45f3ab325c4ed0f16594" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><ix:continuation id="icbc8049d878d45f3ab325c4ed0f16594" continuedAt="i6964f2be735f4f69bfcc68de2a81a784"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6964f2be735f4f69bfcc68de2a81a784">, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQzMg_41c41c57-c98d-4116-b3b3-8408c8a1c0ab" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i2396c9a37e3e47fe8802b51587750e45" continuedAt="i234c545b0525457090e19ae82a0046b2"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQyNA_18c0293c-6656-4403-8f6c-4a02c33aaff7" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQzNA_cddce4a5-7039-4f69-8d55-61ee00a64151" continuedAt="i4ae1bd82b5af4782a3c0055f2d52dbfc" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of <ix:nonFraction unitRef="number" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" name="amed:MinimumPercentOwnershipForControllingInterestPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNDU5NA_090f7185-4d3f-4988-ad5b-e53a98791e54">50</ix:nonFraction>%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold <ix:nonFraction unitRef="number" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" name="amed:MaximumPercentOwnershipForEquityMethodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNDg5Mw_9b7994a3-be09-4b4c-9cf7-2a8af46199bc">50</ix:nonFraction>% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $<ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNTEwNg_b520ffd0-5f77-449e-a00a-0c8d9003f77c">48.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNTExMw_b00b339a-bf8c-4fbd-ad35-79726a8bad5e">14.2</ix:nonFraction> million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of September 30, 2021, we are proportionately consolidating <ix:nonFraction unitRef="numberofjointventures" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="amed:NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTY0MTYwOQ_2af3089a-7d8e-4d07-8ade-d55766eaf8a6">seven</ix:nonFraction> of our <ix:nonFraction unitRef="numberofjointventures" contextRef="i52fadfa94bbd423aa0033f0ef19c530a_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="amed:NumberOfJointVentures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTY0MTYyNQ_95681a97-b498-4e16-8b6f-1e085c369166">eight</ix:nonFraction> joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. We account for one of our joint ventures with a health system partner under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTY0MTYzMw_4360c192-6265-44ee-82b0-e54627d593fb" continuedAt="i05ad1e4194f94657ace43ae9d0704ca4" escape="true">The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheet are as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i05ad1e4194f94657ace43ae9d0704ca4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMy0xLTEtMS0xNDI3OQ_e577e874-0dc4-4f91-ac53-ae3507d9f02c">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfNC0xLTEtMS0xNDI4Mg_6cefb603-3833-476a-82aa-d819603daa6c">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfNS0xLTEtMS0xNDI4NA_51b6de73-d368-4a14-bdaa-8cf240a83576">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfNi0xLTEtMS0xNDI4Ng_cf3fc9f8-dc0f-46e9-bdf7-700fbc7fd126">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfNy0xLTEtMS0xNDI4OA_9976deec-0d84-4f8d-9427-136b961b65b4">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfOC0xLTEtMS0xNDI5MA_568a4b6d-934c-4df6-82cc-aec90dbc1b3f">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTEtMS0xLTEtMTQyOTI_99cb5c2d-652c-4887-84f5-ccdbdd2e2d6a">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTItMS0xLTEtMTQzMDA_a2bc369c-b55f-4c78-bdb7-f99447b1778d">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTMtMS0xLTEtMTQzMDI_ecb3e1c6-05c7-4b90-90d3-6d16c43d4b89">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTQtMS0xLTEtMTQzMDQ_2b9fb5a9-fda0-443a-b12b-538e6e26c9ce">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTUtMS0xLTEtMTQzMDY_52fcc489-03f7-4356-868a-d5bf14fa5c14">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTYtMS0xLTEtMTQzMDg_7108fbcb-5d6d-4d4c-8252-0be00da40a5d">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i234c545b0525457090e19ae82a0046b2" continuedAt="i7b2c7d3de31441dc94dea47ab561c2e1"><ix:continuation id="i4ae1bd82b5af4782a3c0055f2d52dbfc" continuedAt="i16bef028dea0479ebf7f06133e0e8cad">During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $<ix:nonFraction unitRef="usd" contextRef="ic428d287cf9a45abae8bef5f46c3c408_D20210401-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNTc0Ng_31cebbbf-61b9-4256-9019-2c96c031a35b">31.1</ix:nonFraction>&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. </ix:continuation></ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b2c7d3de31441dc94dea47ab561c2e1"><ix:continuation id="i16bef028dea0479ebf7f06133e0e8cad">During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $<ix:nonFraction unitRef="usd" contextRef="i0d32c084839747cea67534c70d0a7a4c_D20200401-20200630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjA3Mg_3a8687a3-4048-431b-acea-ee5664b4a669">17.9</ix:nonFraction>&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.</ix:continuation></ix:continuation> </span></div><div id="id60bf3839b914d279c418e71b98c550c_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MzU_207ab757-b1c6-4156-9e36-731d6a378b35" continuedAt="i9c26adfd67164fbeafed845d6f6ee948" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i9c26adfd67164fbeafed845d6f6ee948" continuedAt="idd812a9c6100498690555019e4e784be"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0NDI_6db0d66d-35c8-4652-8801-4b7c585023f1" continuedAt="i6b1c3950af83451db5ede676fdf7e6ac" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately <ix:nonFraction unitRef="number" contextRef="i53a77f5a57b04427a02592d620527871_D20210701-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMzA4MQ_4de51fa5-6d96-43b9-b891-a52eff1c0222"><ix:nonFraction unitRef="number" contextRef="i97413ae1e1174a779e186bf439f4b59e_D20210101-20210930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMzA4MQ_bea2abfd-a5ac-4d14-965b-f5b286b7f9e6">75</ix:nonFraction></ix:nonFraction>% of our net service revenue for the three and nine-month periods ended September 30, 2021 and approximately <ix:nonFraction unitRef="number" contextRef="i9f3cf4cabcef48c49d533b6054864aa6_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5OTUxMTY1MTI3NQ_e68655ec-532e-46c6-8028-5bc3285ffd43">76</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id4b858c3a1e442059c913a6d2f8baa16_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5OTUxMTY1MTkyNg_c45950ca-5ca6-453f-9354-b28e29d03460">75</ix:nonFraction>% of our net service revenue for the three and nine-month periods ended September 30, 2020, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMzk5Nw_96db8ef6-303f-476e-ae7a-6b19fd56cbac">99</ix:nonFraction>% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="idd812a9c6100498690555019e4e784be" continuedAt="i6159975ddb044dda951e0b8b2cdd71ec"><ix:continuation id="i6b1c3950af83451db5ede676fdf7e6ac" continuedAt="i283788f2738a4dc38f19dd67d19aabd1"><div><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0NDM_b2c76ace-b80a-4f49-8268-a4388da88bc6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5d7cedb10ae48fba7962484bd3a479d_D20210701-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMy0xLTEtMS0w_a82c4cf6-1b70-4eda-b7fe-056a6dce3273">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf8d0d878ea44b5b6acaec5036b5b3e_D20200701-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMy0zLTEtMS0w_e0909506-c8a4-4cf0-82a9-0c4a179f3ef0">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb137aa1ee24433e9aa27e49dc612257_D20210101-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMy01LTEtMS0w_b3ced0cd-28bb-4081-9a73-fa6094d882a8">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bde2eb0cbdd4167840a8abcb889fdbe_D20200101-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMy03LTEtMS0w_3cb6b4c0-59c4-488f-bba7-181b777abb35">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7da000a08ec142e4bdd7cf8ee0df0f47_D20210701-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNC0xLTEtMS0w_2fc4f5e8-8690-4f93-b0ee-5e3d085f995e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a28bdb10cc74d2e928cf670bd6e2574_D20200701-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNC0zLTEtMS0w_7ed0227c-d7d1-4093-a692-64787b03afb7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia97dc36d6ba44d7a91070e28414ee451_D20210101-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNC01LTEtMS0w_e66f0783-6bc3-4ded-ad8d-66137b2b73d6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fcfacf66b054da0b58e2e56d9bb8bfa_D20200101-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNC03LTEtMS0w_4b32b17e-b169-4441-b24c-455faa606fcc">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99b4c1b915b04539b57e1c8613186d47_D20210701-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNS0xLTEtMS0w_16206514-0288-4641-ad1c-69741a34b1d8">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa13ecc925ce45338808db2fe46e6eae_D20200701-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNS0zLTEtMS0w_8d5dcc10-d578-4a94-bcbb-01eb200591a3">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ab6f6ff611a4bca958bd8f881a12f27_D20210101-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNS01LTEtMS0w_e287d767-8f55-4b4f-b360-237faf9892e2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6978f00a4d24116b989b48f99ba0ee3_D20200101-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNS03LTEtMS0w_26acd9dc-5500-4dc6-ade7-81101b228fea">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifa1d053dcadf4783b88264c7cec8fdad_D20210701-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNy0xLTEtMS0w_d3603e63-f616-4834-b3be-f1529e8622ef">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id56c30a83b044cfeb8b2c3d76169a0f2_D20200701-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNy0zLTEtMS0w_25b26a7d-b593-4ba2-94ff-1db027596453">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ife028e28aa6e4bff87836d3a26ef8d85_D20210101-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNy01LTEtMS0w_d436317d-c0c3-4b9f-b5c0-016d750bdc2d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67ed27e1cb4c4b0aabe4eb9cf42597d3_D20200101-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNy03LTEtMS0w_a1283bfc-71ff-49b5-99ff-0066cbbd3e61">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a812c39af934a4fbcf34dcbb6f5f869_D20210701-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOC0xLTEtMS0w_9cf56238-cf54-461a-a87a-45e44b589d05">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide539b43139c4e9f8ca2939b91054599_D20200701-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOC0zLTEtMS0w_86e46dd5-784c-4a7e-adaa-edf0dc213170">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9100f75ec6d34eab92f0b7a4728ebb97_D20210101-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOC01LTEtMS0w_ee7a8e26-1fc5-4893-96c7-7c04e883bec9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c80de9e2e4b40cdb0613e9070ad7c04_D20200101-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOC03LTEtMS0w_477b70cd-5282-4d89-8fce-aaf013e6dfa2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42e067416e644747bb8fa941e424d288_D20210701-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOS0xLTEtMS0w_c7d72a7c-674d-4cc7-89b7-dbe437a309d0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icac5f9500af546a48378980936e6335e_D20200701-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOS0zLTEtMS0w_6fd9f3a8-0e02-46e0-bc12-f567838a1fed">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i926e999864bd48ed884e8c5a0659188d_D20210101-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOS01LTEtMS0w_28be453a-d126-43a1-b422-795cf9a7288e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7de65d633d9d4497bd157a0af662328c_D20200101-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOS03LTEtMS0w_3234f584-4f59-4458-b3d6-cf7d771f2b15">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMTAtMS0xLTEtMA_ad4d5855-5d2a-41d4-8054-38806d4ddb3f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMTAtMy0xLTEtMA_97ba2603-285f-479b-9291-6501ffd4bfb9">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMTAtNS0xLTEtMA_81a1d3ef-8d9c-44f5-9fb8-936a5ebcf538">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="2" name="amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMTAtNy0xLTEtMA_49a62ed6-aa15-4c8e-bc8b-9052ecfcf013">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNDU3Nw_0a1deefd-4086-4d42-af62-2de214003398">30</ix:nonNumeric>-day periods of care rather than <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:durday" name="amed:NetServiceRevenueEpisodePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNDYxMg_4c4b563f-0ab4-4b0a-9c94-635551d65c2d">60</ix:nonNumeric>-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNDkzMQ_d959698f-3bab-48f3-83fb-c111d1a1292d">30</ix:nonNumeric>-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at <ix:nonFraction unitRef="number" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="INF" name="amed:PercentageOfTotalReimbursementOfOutlierPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNTkzNA_82abe317-af3f-486a-9c81-9f37c7c26305">10</ix:nonFraction>% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from <ix:nonFraction unitRef="visit" contextRef="i29f7d758438c4f338ef4844b1b05b695_D20210101-20210930" decimals="0" format="ixt-sec:numwordsen" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNjEyNA_37a1b2c3-a6e2-4b37-9f08-41e3a6e64b0e">two</ix:nonFraction> to <ix:nonFraction unitRef="visit" contextRef="i15da7330f86b4f90b126f6a27ee2e91c_D20210101-20210930" decimals="0" format="ixt-sec:numwordsen" name="amed:LowUtilizationPaymentAdjustmentNumberOfVisits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNjEzMA_0f4efdf5-bab8-4095-8ea0-133d7ec23332">six</ix:nonFraction> visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNjc1OA_01c5aac4-24b2-4940-95c1-3e01ff8cf851">99</ix:nonFraction>% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i6159975ddb044dda951e0b8b2cdd71ec" continuedAt="i3e978a6a26d94557a5bdbde4c6c259ec"><ix:continuation id="i283788f2738a4dc38f19dd67d19aabd1" continuedAt="i5371f804bf754d9698f131cdefe196c6"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, <ix:nonFraction unitRef="number" contextRef="i4f2cd5e0030a4da38f5733c7cc21c188_D20200101-20201231" decimals="2" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfODkyNg_1965de11-1816-4522-802a-c8305cb692bb">20</ix:nonFraction>% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfOTIwNA_c08186b0-4275-4b64-be52-d5fba3c65b61">30</ix:nonNumeric>-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from <ix:nonFraction unitRef="number" contextRef="i29f7d758438c4f338ef4844b1b05b695_D20210101-20210930" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfOTc1NA_32414765-086d-429e-a051-1cac066ecdbb">95</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i15da7330f86b4f90b126f6a27ee2e91c_D20210101-20210930" decimals="INF" name="amed:NonMedicareRevenueTermRates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfOTc2MA_e2f98dac-9274-4261-8554-c15fd4bff714">100</ix:nonFraction>% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for <ix:nonFraction unitRef="number" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5Mzg_21f16773-f372-427d-b20d-9e089c1115a3"><ix:nonFraction unitRef="number" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5Mzg_35b144b2-3de4-4085-9d43-55a8a9a7649c"><ix:nonFraction unitRef="number" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5Mzg_ec13fccf-4357-4349-945e-c10a1fe04cbf"><ix:nonFraction unitRef="number" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="2" name="amed:HospiceMedicareRevenueRateAccountedForRoutineCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5Mzg_f13e6a06-add7-4dff-b2c5-20f6e67d0195">97</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of our total Medicare hospice service revenue for the three and nine-month periods ended September&#160;30, 2021 and September 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTE5NTY_d2700dc0-faa8-4e98-b16f-d26670e9d565">99</ix:nonFraction>% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of September&#160;30, 2021, we have recorded $<ix:nonFraction unitRef="usd" contextRef="i29e45fb5802548c4ad50a57ad3f3b612_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTI3MDM_ec7e3a29-2f96-4fef-8485-aaabb5557eef">8.6</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $<ix:nonFraction unitRef="usd" contextRef="i5d3a5fc24c7c41c8bc0fb5a2dae8eb49_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTI4NDY_bfff2c09-0833-40c4-8e06-0724a8acf7c6">2.5</ix:nonFraction>&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $<ix:nonFraction unitRef="usd" contextRef="i24116e45645b4557aa94b276ff514ba4_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTI5MzY_d947252c-c67d-44dc-90f2-24f56de83d32">9.3</ix:nonFraction> million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i3e978a6a26d94557a5bdbde4c6c259ec" continuedAt="i46c64c791b73411bb713bc8b06217f1f"><ix:continuation id="i5371f804bf754d9698f131cdefe196c6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to patients who are discharged early from a health system facility to complete their inpatient stay at home. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our health insurance plan contracts provide for fixed payment rates for a <ix:nonNumeric contextRef="i9d0d57618875495dac3ccd68edf1aea4_D20210101-20210930" format="ixt-sec:durday" name="amed:NetServiceRevenueEpisodePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTY0OTI2NzQ3MTk5Mg_56b9aee2-b543-4f26-930e-4f4b1e7c9d6c">30</ix:nonNumeric>-day or <ix:nonNumeric contextRef="i68531a9539f143d39b039b1ec2d6143c_D20210101-20210930" format="ixt-sec:durday" name="amed:NetServiceRevenueEpisodePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTY0OTI2NzQ3MTk5Nw_02e4ffff-7c38-4665-9fe4-bffda87de94e">60</ix:nonNumeric>-day episode of care indexed to assigned patient diagnoses in return for our obligation to assume risk for the coordination and payment of required medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a <ix:nonNumeric contextRef="i9d0d57618875495dac3ccd68edf1aea4_D20210101-20210930" format="ixt-sec:durday" name="amed:NetServiceRevenueEpisodePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTY0OTI2NzQ3MTk3OA_56b9aee2-b543-4f26-930e-4f4b1e7c9d6c">30</ix:nonNumeric>-day or <ix:nonNumeric contextRef="i68531a9539f143d39b039b1ec2d6143c_D20210101-20210930" format="ixt-sec:durday" name="amed:NetServiceRevenueEpisodePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTY0OTI2NzQ3MTk4Ng_02e4ffff-7c38-4665-9fe4-bffda87de94e">60</ix:nonNumeric>-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, is provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the service provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our contracts with health system partners provide for reimbursement on a per diem basis at the contracted rate for each day during the remainder of an inpatient acute stay serviced at the patient&#8217;s home. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div></ix:continuation><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="amed:GovernmentGrantsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MjQ_2c5a7e86-f941-44d5-8873-f3df46c43239" continuedAt="i64e1943a09874a1e992e3108b2b34155" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i46c64c791b73411bb713bc8b06217f1f" continuedAt="if995b4a1372d4ee2b989f8eba623e78e"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i64e1943a09874a1e992e3108b2b34155">received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</ix:continuation></span></div><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0NDQ_c1ee3e4f-60ee-43fb-bc68-cefd1ea33116" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of September 30, 2021 includes $<ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:CashBalanceAssociatedWithProviderReliefFund" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTU3MjU_50d5a019-6847-47e0-93c0-9284f5821fee">58.5</ix:nonFraction>&#160;million associated with unutilized CARES Act Provider Relief Fund ("PRF") funds, which were repaid to the U.S. Department of Health and Human Services ("HHS") in October 2021. Restricted cash includes cash that is not available for ordinary business use. As of September 30, 2021, we had $<ix:nonFraction unitRef="usd" contextRef="i500483d4b7f14fdaa315297298d52160_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTYzMjc_2017a595-2276-42d0-a38b-5c7ece157e9e">3.8</ix:nonFraction>&#160;million of restricted cash that was placed into escrow accounts related to the indemnity and closing payment adjustment provisions within the purchase agreements for various acquisitions.</span></div><div style="margin-top:9pt;text-align:justify"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MzY_6b8c7f11-f156-4d3d-8453-8c9d13c62225" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOjQ5Yzg1YmRlYmEyYTRhYmZiNGFkMTZlMTFhM2Y1NmRkL3RhYmxlcmFuZ2U6NDljODViZGViYTJhNGFiZmI0YWQxNmUxMWEzZjU2ZGRfMS0zLTEtMS0w_80f0624d-0b45-4e28-ba0e-9b494c50f41b">81.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOjQ5Yzg1YmRlYmEyYTRhYmZiNGFkMTZlMTFhM2Y1NmRkL3RhYmxlcmFuZ2U6NDljODViZGViYTJhNGFiZmI0YWQxNmUxMWEzZjU2ZGRfMi0xLTEtMS0w_14baeb5b-7e9e-4f8a-b5a4-5617dfcc5571">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-5" name="us-gaap:RestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOjQ5Yzg1YmRlYmEyYTRhYmZiNGFkMTZlMTFhM2Y1NmRkL3RhYmxlcmFuZ2U6NDljODViZGViYTJhNGFiZmI0YWQxNmUxMWEzZjU2ZGRfMi0zLTEtMS0w_0ee9e6b9-d113-4102-a315-34c7f367a276">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOjQ5Yzg1YmRlYmEyYTRhYmZiNGFkMTZlMTFhM2Y1NmRkL3RhYmxlcmFuZ2U6NDljODViZGViYTJhNGFiZmI0YWQxNmUxMWEzZjU2ZGRfMy0xLTEtMS0w_e02072cc-d21b-48b9-b63d-e477b8edc714">128.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:nonNumeric><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0Mzc_d125393c-8f99-494d-9929-61aca0712da5" continuedAt="i968bc281efe64c1fb1acdbf6e2577e83" escape="true"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of September&#160;30, 2021, there is no single payor, other than Medicare, that accounts for <ix:nonFraction unitRef="number" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="INF" name="amed:PercentageOfPatientReceivablesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTcyMjU_7e6a83b5-ba85-43fa-95f1-21630757bb74">10</ix:nonFraction>% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent <ix:nonFraction unitRef="number" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTc2Nzc_9e848ad7-6ab0-4e76-87b4-a154ead3a690">65</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="2" name="amed:AccountsReceivablePortionDerivedFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTc2ODQ_b0b66872-d063-4fee-9d9f-527152f76a48">64</ix:nonFraction>% of our patient accounts receivable at September&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over <ix:nonFraction unitRef="number" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="2" name="amed:HistoricalCollectionRateFromMedicare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTc4MDc_e6e98a19-e442-49bb-ab16-6537a1733628">99</ix:nonFraction>% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for <ix:nonFraction unitRef="number" contextRef="i4f2cd5e0030a4da38f5733c7cc21c188_D20200101-20201231" decimals="2" name="amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTg0NTM_b9357892-b511-4b62-9190-05d40b1db78f">20</ix:nonFraction>% of our estimated payment for each <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" format="ixt-sec:durday" name="amed:NetServiceRevenuePeriodOfCarePaymentRateDuration" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTg0OTA_6070cca8-dec7-4304-9675-87c7281e4ca8">30</ix:nonNumeric>-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="if995b4a1372d4ee2b989f8eba623e78e" continuedAt="i255a3da6d12242bca1f021a855f568b7"><ix:continuation id="i968bc281efe64c1fb1acdbf6e2577e83"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div></ix:continuation><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0NDY_e5bcfdb4-19a3-440b-bbbc-3477322b333c" escape="true"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MzM_391ee278-8a47-458a-b2d2-ee115f66ad59" continuedAt="i82dc2908092b4482ae95c6d6005e7a9b" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="amed:FinancialInstrumentDetailsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0Mzk_23fa05c7-9e13-454e-baf4-a5f2e1a70a62" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:24.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="amed:DebtInstrumentCarryingAmountExcludingFinanceLeases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmM4ODM4MWZjY2Q0NzQzZTk4N2UxMDQxMzE0ZWZmZGJlL3RhYmxlcmFuZ2U6Yzg4MzgxZmNjZDQ3NDNlOTg3ZTEwNDEzMTRlZmZkYmVfMi0xLTEtMS0w_9eb9545a-63b5-468b-94b6-ef3d49355b8e">450.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd0e7655cc84c468271b6527bfdb445_I20210930" decimals="1" format="ixt:fixed-zero" name="us-gaap:LongTermDebtFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmM4ODM4MWZjY2Q0NzQzZTk4N2UxMDQxMzE0ZWZmZGJlL3RhYmxlcmFuZ2U6Yzg4MzgxZmNjZDQ3NDNlOTg3ZTEwNDEzMTRlZmZkYmVfMi0zLTEtMS0w_11c8cc8b-155b-4d0c-9cad-3044df0d55a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5462f91dd84c47b0a636202d3b8d0235_I20210930" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmM4ODM4MWZjY2Q0NzQzZTk4N2UxMDQxMzE0ZWZmZGJlL3RhYmxlcmFuZ2U6Yzg4MzgxZmNjZDQ3NDNlOTg3ZTEwNDEzMTRlZmZkYmVfMi01LTEtMS0w_ba5b4e72-bd0a-441f-8f58-ff4d2a64e489">468.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2feac305da384a94a9d62488436d6c54_I20210930" decimals="1" format="ixt:fixed-zero" name="us-gaap:LongTermDebtFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmM4ODM4MWZjY2Q0NzQzZTk4N2UxMDQxMzE0ZWZmZGJlL3RhYmxlcmFuZ2U6Yzg4MzgxZmNjZDQ3NDNlOTg3ZTEwNDEzMTRlZmZkYmVfMi03LTEtMS0w_a38f1ccc-86e1-4d67-87bc-2624b571c8e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i82dc2908092b4482ae95c6d6005e7a9b">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i255a3da6d12242bca1f021a855f568b7"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MTU_fbe5e08e-ad13-4067-ad8f-16c2963ee198" continuedAt="i1ee15d7cc7f54a7b88b53b6117a57fba" escape="true">Weighted-Average Shares Outstanding</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ee15d7cc7f54a7b88b53b6117a57fba">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</ix:continuation> <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MTc_2e8b511b-bf33-4035-b184-3b90a206ea1c" continuedAt="ic64c1dec44894e658b1bf98de541c3bd" escape="true">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="ic64c1dec44894e658b1bf98de541c3bd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-<br/>Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfMi0xLTEtMS0w_687c2f16-334c-483e-b6bd-126974aa4592">32,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfMi0zLTEtMS0w_d4925b98-ddff-4cb1-966b-4ddd5fe21b11">32,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfMi01LTEtMS0w_466ccb57-2dac-4be4-8099-b9dfa2f7be00">32,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfMi03LTEtMS0w_2f383e68-515e-43b8-abeb-fcac9168b0d5">32,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNC0xLTEtMS0w_38d9ca68-fc3e-42f8-b986-494179c0c942">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNC0zLTEtMS0w_2859dbd2-2dec-400d-84b6-c6e5fb203172">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNC01LTEtMS0w_3c7d6d91-5114-494c-9013-d543bbac9f88">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNC03LTEtMS0w_0283bb4e-92e6-42ec-b2b6-cd27261ffbfc">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNS0xLTEtMS0w_1373092e-cc09-427e-ab24-d7583608c88f">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNS0zLTEtMS0w_a127277d-bf5b-496c-ba47-ffe548b64d4b">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNS01LTEtMS0w_34115017-b5ae-40f6-b5e6-472d95776d0e">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="amed:NonVestedStockAndStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNS03LTEtMS0w_ddb49d96-1a95-46c4-ba53-467df1063958">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNi0xLTEtMS0w_6b666281-ac89-4199-b591-46e77950c16c">32,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNi0zLTEtMS0w_b537d469-b6fe-4837-95d2-ab4bf357735d">33,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNi01LTEtMS0w_7835bc4e-338c-4e6d-9f6f-63ff765e6743">33,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNi03LTEtMS0w_95aac90f-c257-4e95-8e94-d26237bd5ed5">33,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNy0xLTEtMS0w_93b33cc4-b7e1-4fb0-9563-bad4f7a15f0c">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNy0zLTEtMS0w_e58e827f-4493-4821-b296-0d9aa28e5e03">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNy01LTEtMS0w_02aa60b0-8eb5-45b2-a19e-bd273dfaa867">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNy03LTEtMS0w_bcb1a64c-e4d3-4bba-b468-8f4841418cfd">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:16pt;text-align:justify"><span><br/></span></div><div id="id60bf3839b914d279c418e71b98c550c_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="amed:COVID19TextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDY0Ng_9378f583-f42c-4026-8311-ebc763e665f5" continuedAt="ib58edb2ecbed4247886c41abcd6a7feb" escape="true">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")</ix:nonNumeric></span></div><ix:continuation id="ib58edb2ecbed4247886c41abcd6a7feb" continuedAt="iaf990fc567744d83b1a66bc7cd76a9c6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $<ix:nonFraction unitRef="usd" contextRef="i79965b0e5aa8415ab632c4462ea0fe64_I20200327" decimals="-9" format="ixt:num-dot-decimal" name="amed:FundingForHealthcareProvidersIncludingHospitals" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNzI5_7c64d0f9-9eb8-473e-b5d3-9f977c1ebf4e">175</ix:nonFraction>&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $<ix:nonFraction unitRef="usd" contextRef="i79965b0e5aa8415ab632c4462ea0fe64_I20200327" decimals="-9" format="ixt:num-dot-decimal" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfODU0_01687e5b-3fc7-4e27-9112-9e2fc02e3893">30</ix:nonFraction>&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $<ix:nonFraction unitRef="usd" contextRef="i0efbe09bd23b41df8e79378709cd08ec_D20200401-20200430" decimals="-6" format="ixt:num-dot-decimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMTIxNA_d862fcb3-59cc-48b0-9c57-a2470a786b2e">100</ix:nonFraction>&#160;million from the first $<ix:nonFraction unitRef="usd" contextRef="i79965b0e5aa8415ab632c4462ea0fe64_I20200327" decimals="-9" format="ixt:num-dot-decimal" name="amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMTIzMg_534c3225-f176-4269-a0e9-c6c3d734a29d">30</ix:nonFraction>&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $<ix:nonFraction unitRef="usd" contextRef="i1d60d9ebea4d4f7d9cefaed1ef4edefa_D20200401-20200430" decimals="-6" format="ixt:num-dot-decimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMTMxNw_6dae1af5-6ee3-467a-81d1-49a4629df6ae">2</ix:nonFraction>&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $<ix:nonFraction unitRef="usd" contextRef="ifffac77654ba4ad9a0ab1f64df333300_D20200401-20200430" decimals="-6" format="ixt:num-dot-decimal" name="amed:FundingReceivedFromCARESAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMTQyMg_9ab9dc45-6287-488c-aff3-2a7304c3d7d2">6</ix:nonFraction>&#160;million of PRF funds in connection with the acquisition of AseraCare. Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our condensed consolidated statements of operations. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="iaf990fc567744d83b1a66bc7cd76a9c6" continuedAt="ie4c207b8a0b2417fb721dcc71edb10ab"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not fully utilize the PRF funds received; therefore, we have recorded a liability for the amount to be repaid which totaled $<ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="amed:ProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMjY5MQ_e4010c0a-a7b3-465a-88ee-a577103da188">59</ix:nonFraction>&#160;million (including interest) at September 30, 2021 and $<ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-6" format="ixt:num-dot-decimal" name="amed:ProviderReliefFundAdvance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMjcxNQ_dd61a983-3a91-49cd-9a48-5bfc81e14dc8">60</ix:nonFraction>&#160;million at December 31, 2020 (see the Provider Relief Fund Advance account in current liabilities within our condensed consolidated balance sheets). All unutilized funds were repaid in October 2021. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDY0Nw_02dbf861-d111-4004-8ddb-f261ab01b107" continuedAt="if9b04a1305b043a1b0d36e51b0f2200c" escape="true">In summary, the total funds that we received from the CARES Act PRF have been accounted for as follows as of September 30, 2021 (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="if9b04a1305b043a1b0d36e51b0f2200c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:76.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by consolidated entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1393629cbb174bb6b0ebfda47cfc61fd_D20200327-20210630" decimals="-5" name="amed:CARESActProviderReliefFundsUtilized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMS0xLTEtMS0w_65522106-3f38-45bb-8060-9d5e0673e22f">46.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds to be repaid to the government by consolidated entities (excludes $<ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:CARESActInterestToBeRepaidToGovernment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMi0wLTEtMS0xMzA3OC90ZXh0cmVnaW9uOjMxNGRjZDljYmJjMDRjMDk4OWU4NDRmOWVlZDIxM2Q1XzEwOTk1MTE2Mjc5MDI_3166d446-2e66-4fa8-a247-f2cece4ac7a7">0.2</ix:nonFraction>&#160;million of interest to be repaid)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMi0xLTEtMS0w_495c3259-da94-4a6c-a216-8eb91b8256aa">58.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1393629cbb174bb6b0ebfda47cfc61fd_D20200327-20210630" decimals="-5" name="amed:CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMy0xLTEtMS0xMzA3Ng_082b71e1-6c01-49eb-a0a6-597d52a2bdcc">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds to be repaid to the government by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMy0xLTEtMS0w_4bc82e2e-9791-4ae5-aa85-a183707ea629">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="amed:TotalCARESActProviderReliefFundsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfNC0xLTEtMS0w_b46fd235-4f9f-4192-8e69-3bd2f71addc1">106.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. We estimate that the suspension of sequestration will increase our 2021 net service revenue by approximately $<ix:nonFraction unitRef="usd" contextRef="i8e66e59d22d74d7a814e88ec0a8b967a_D20210101-20211231" decimals="-5" format="ixt:num-dot-decimal" name="amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMzg2NA_c6327a9a-620b-4d29-88fe-150d983cc744">36</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. During 2020, we deferred approximately $<ix:nonFraction unitRef="usd" contextRef="i38909b3d265a42439d254b12034f035b_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="amed:CARESActDeferralOfEmployerShareSocialSecurityTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDIxOQ_72a88c41-ac9f-4848-918f-be4e53a24c66">55</ix:nonFraction>&#160;million of social security tax; approximately $<ix:nonFraction unitRef="usd" contextRef="i2649a54bd32e4505aaf5229062506cea_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDI2MA_a0f1a604-11f6-44b6-9e69-d5865d3dc863"><ix:nonFraction unitRef="usd" contextRef="i2649a54bd32e4505aaf5229062506cea_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDI2MA_a8a0d99d-3e89-4268-a128-9bdb8222a465">28</ix:nonFraction></ix:nonFraction>&#160;million is reflected in each of payroll and employee benefits and other long-term obligations within our condensed consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie4c207b8a0b2417fb721dcc71edb10ab">Our personal care segment did not receive funds under the CARES Act; however, it did receive funds totaling $<ix:nonFraction unitRef="usd" contextRef="ib38d592d04ae48798a01d60bc2b8f174_D20200101-20201231" decimals="-5" format="ixt:num-dot-decimal" name="amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDUwNw_8396249e-edd0-4a9a-ba5b-047830f20810">1</ix:nonFraction>&#160;million from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which were used during 2020 to cover costs related to COVID-19.</ix:continuation>  </span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="id60bf3839b914d279c418e71b98c550c_52"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMzc3Nw_1779ceb6-1b17-4c68-902b-e3458618a289" continuedAt="i9eef21cef78e44f5bd9ba000b586258e" escape="true">ACQUISITIONS</ix:nonNumeric></span></div><ix:continuation id="i9eef21cef78e44f5bd9ba000b586258e" continuedAt="i538718a5588e40d790c07e0be223dd41"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2021, we acquired the regulatory assets of a home health provider in Randolph County, North Carolina for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="icb4c638a3b064fa5b06f2b26f52f4a80_D20210501-20210501" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTM4OQ_96c28d58-e4ee-416b-90ef-745ee8cc4c1b">2.5</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i54c8f3adc1504f4eb6682e48cf1c64c4_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTU0MQ_ff9b0ca2-62c0-439c-a4ef-df13ba6eb004">2.4</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="i2017c2d404c641c2a514204df4297957_I20210501" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTU5MQ_478c2c7e-9630-43de-91d4-c9d942df6a5d">0.1</ix:nonFraction>&#160;million in connection with the acquisition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i538718a5588e40d790c07e0be223dd41" continuedAt="i2f1dd00c7c374de293800211a86a1159"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we acquired Visiting Nurse Association ("VNA"), a home health and hospice provider with locations in Nebraska and Iowa for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i0872fc9873bd4791b48b180e25979b56_D20210701-20210701" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzMjQwNA_1f1c9d88-10f7-43e8-b404-b5ce0c3f9809">20.1</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i3f71161254f8495192bc5012d17c1d17_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzNzY3NQ_9ff3dd38-3d5c-4159-be4b-c55a3de9fee6">19.4</ix:nonFraction>&#160;million and other intangibles (licenses) of $<ix:nonFraction unitRef="usd" contextRef="i0151e438657a4e998a05f867e7a0192b_I20210701" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzOTQ3Mg_59d5331b-db82-4546-8550-897e0ca74f56">0.7</ix:nonFraction>&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we acquired the regulatory assets of a home health provider in New York for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="if47ee2ab8e1e4361a566cb19050d7b35_D20210712-20210712" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzMjUyNA_f237af14-f634-4524-8dc8-9d804cbc95ba">1.5</ix:nonFraction>&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i851747d57a65428e80bd139d35336f78_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzODA2Nw_4ae0276f-24ff-4b3e-ba9f-6accb808e844">1.4</ix:nonFraction>&#160;million and other intangibles (certificate of need) of $<ix:nonFraction unitRef="usd" contextRef="ib551a251deb645c2b167c2d979092893_I20210712" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzOTMyNg_9b89dc85-9c11-49f0-854e-40b2d44a8339">0.1</ix:nonFraction>&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility ("SNF") at-home services for an estimated purchase price of $<ix:nonFraction unitRef="usd" contextRef="id9ba162183a34d4793c4bb95198e7c46_D20210801-20210801" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzMjY5OA_b20abe87-cb50-4780-9d85-7718046feb20">240.7</ix:nonFraction>&#160;million, net of cash acquired. With the addition of Contessa&#8217;s risk-based model and claims analytics capabilities, we will be able to bring the essential elements of inpatient hospital and SNF care to patients&#8217; homes, allowing us to become a risk-bearing, home-based care delivery organization, expanding well beyond traditional home health and hospice. Contessa operates as a wholly-owned division of Amedisys and is reported as a separate operating segment. Under the purchase agreement, the purchase price is subject to a net working capital adjustment, whereby the purchase price will be adjusted to the extent the actual net working capital of Contessa as of the closing differs from the required net working capital under the purchase agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i2f1dd00c7c374de293800211a86a1159" continuedAt="i7df7dca9d6bd46d99c97574f04315677"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="amed:ScheduleOfBusinessAcquisitionsContessaTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTY1Mg_5f55e618-2543-4adf-8a4a-ccee5dff80c8" continuedAt="i7d63735fe78c40bca43e047935a7daad" escape="true">Based on the Company's preliminary valuation, the total estimated consideration of $<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzODc2Nw_f7d661d6-b069-4453-be1e-eb5e8ab72d55">240.7</ix:nonFraction>&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i7d63735fe78c40bca43e047935a7daad"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMS0xLTEtMS05NDA0_ba0fa5d9-8c77-483f-942b-5a70bf48eb51">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMi0xLTEtMS05NDA0_40377829-f80e-4a82-9a65-a0752b89d524">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMy0xLTEtMS0xMzA2MQ_e25a72af-fdd1-4a41-a78c-27f3e9646166">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMy0xLTEtMS05NDA0_a465dae0-3039-4456-971c-6a005d2a8dfa">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfNC0xLTEtMS05NDA0_64bcd1f9-c47e-4ed7-965d-e19090c98b14">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfNS0xLTEtMS05NDA0_911ac05a-de22-49b6-801c-35f23aa21e2f">55.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfNi0xLTEtMS05NDA0_b384af66-10c8-4846-b6f3-24caa4fec5fe">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfNy0xLTEtMS05NDA0_6f420d3b-dd3d-459a-8bd6-b6c9837d800c">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfOC0xLTEtMS05NDA0_3944b793-285b-4f34-a409-f73baab4564d">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfOS0xLTEtMS05NDA0_f409cb37-d38e-433e-a6db-8fc005877530">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTAtMS0xLTEtOTQwNA_07acc564-3348-405f-9d5e-772d056b3703">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTEtMS0xLTEtOTQwNA_4e5ae1bb-ba8b-45ca-b02a-c879695bbd7b">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTMtMS0xLTEtMTMwNjM_1bd5bf25-eb6d-48cf-bc65-4083953594a2">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" sign="-" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTQtMS0xLTEtMTMwNjY_d10ba059-f2cc-4dd6-a4f6-fe36d62805e4">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTUtMS0xLTEtMTMwNjg_a09ceb8b-6117-4eea-a0d8-76a2ebb0a0d1">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTItMS0xLTEtOTQwNA_336fbc10-d035-4597-b4e3-5146147e3dc8">9.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTctMS0xLTEtMTMwNzA_777c8bef-ea08-4230-a36e-afc4a37a952b">42.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" sign="-" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTgtMS0xLTEtMTMwNzI_c3abc5b7-5453-4ef1-8b94-8e75fbf409ff">42.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" sign="-" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTktMS0xLTEtMTMwNzQ_31e359bc-81ec-4b33-bd81-487f28fd3e3a">51.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTMtMS0xLTEtOTQwNA_be8c028d-736f-41e8-b3da-c42fea901561">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i249984fbdc5e42819c3295bf8354d6b7_D20210101-20210930" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTQtMS0xLTEtOTQwNA_34219db9-2b46-4adb-9df0-f1d0a917dab1">230.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTUtMS0xLTEtOTQwNA_88d35dfb-fc06-4466-b4eb-45c1ae6b31b8">240.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include acquired names ($<ix:nonFraction unitRef="usd" contextRef="i7e43a9f348fe4c7ea8efde6906e553bf_I20210801" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTU4Nw_f7bc5516-99de-47e3-b57c-19e0b524c8e5">28.6</ix:nonFraction>&#160;million), technology ($<ix:nonFraction unitRef="usd" contextRef="ie5e610cd17944eaa9db443b1b7ceed2c_I20210801" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTYwMg_526288a9-ad1c-49d6-8d42-aa839e41bd45">19.9</ix:nonFraction>&#160;million) and non-compete agreements ($<ix:nonFraction unitRef="usd" contextRef="if5dabca3606441b0a6016647f859c142_I20210801" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTYxNw_96275247-ecbb-47eb-bc98-549ec33bb558">6.7</ix:nonFraction>&#160;million). The non-compete agreements will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i580773c45c2e4d0f89d42392a8b52a23_D20210801-20210801" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTYzNg_b665d2f3-5a89-4d6e-a1e7-8d173266b0dd">2.0</ix:nonNumeric> years and the technology will be amortized over a weighted-average period of <ix:nonNumeric contextRef="ib322985f813e485bb88456695369faef_D20210801-20210801" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTY0OTI2NzQ1NjAwMw_4d9cf136-0dae-4a71-a659-20800d7d684b">7.0</ix:nonNumeric> years. The preliminary fair value of noncontrolling interest was determined using a discounted cash flow analysis and an income approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contessa contributed $<ix:nonFraction unitRef="usd" contextRef="i7c481a799d7f4394b4a10e4b1471316c_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzODc4NA_6ce205bb-d59f-4bb4-8f39-67c0c8cc06d4">1.5</ix:nonFraction>&#160;million in net service revenue and an operating loss of $3.8&#160;million (inclusive of technology intangibles amortization totaling $<ix:nonFraction unitRef="usd" contextRef="i7c481a799d7f4394b4a10e4b1471316c_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:DepreciationAndAmortizationForContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTY0OTI2NzQ1NjAyMg_0e1935d9-b13b-4a67-b4b0-ca1fb23383a6">0.5</ix:nonFraction>&#160;million) during the three-month period ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with <ix:nonFraction unitRef="care_center" contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTc5OQ_3ce9d4a8-f3a3-4f6b-8132-5942f4441637">44</ix:nonFraction> locations, for an estimated purchase price of $<ix:nonFraction unitRef="usd" contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTg0OA_94b9bc04-8939-4a5f-aec7-d660f0784e3a">230.4</ix:nonFraction>&#160;million, net of cash acquired and inclusive of a $<ix:nonFraction unitRef="usd" contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601" decimals="-5" format="ixt:num-dot-decimal" name="amed:PaymentsRelatedToTaxAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTg5Mg_fadbf0d9-d8d9-485d-ae04-c3709a8ca4c2">32</ix:nonFraction>&#160;million tax asset. The closing payment for the purchase price included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close, not to exceed $<ix:nonFraction unitRef="usd" contextRef="i4953a1ae43744a48ab6e34e6411026e1_D20200601-20200601" decimals="-5" format="ixt:num-dot-decimal" name="amed:BusinessAcquisitionClosingPaymentAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjIzMw_9a341ef0-5cd6-4f3d-a5b8-f24f3b884a1a">1.0</ix:nonFraction>&#160;million. The closing payment adjustment, which was finalized in October 2020, reduced the purchase price by $<ix:nonFraction unitRef="usd" contextRef="i543e41010bbd4e948680534c79d49c2e_D20201001-20201001" decimals="-5" format="ixt:num-dot-decimal" name="amed:BusinessAcquisitionClosingPaymentAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjMzNg_d0c188c3-5200-44aa-8873-e6d723890410">0.8</ix:nonFraction>&#160;million, from $<ix:nonFraction unitRef="usd" contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjM0NQ_6c321cf3-889d-4905-8bff-c3230b1c28fd">230.4</ix:nonFraction>&#160;million&#160;to $<ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjM1MQ_e44b6799-ccb9-4519-9556-5a76df79ce7f">229.6</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i7df7dca9d6bd46d99c97574f04315677"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finalized its valuation of the assets acquired and liabilities assumed during the three-month period ended June 30, 2021. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="amed:ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMzc3OA_6800679e-5a51-4615-8f32-9be304cc5e79" continuedAt="i00c071900ab5428281d8b430fd9e444a" escape="true">The total consideration of $<ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjUxNg_f772d667-de95-49c4-bd11-dfa4dbc351c7">229.6</ix:nonFraction> million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i00c071900ab5428281d8b430fd9e444a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:74.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.763%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMS0xLTEtMS0w_28ab67b5-9277-4f56-90ec-1814c3058afb">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMi0xLTEtMS0w_6dbb75cb-1289-4466-b55d-9e4e3bca04b9">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMy0xLTEtMS0w_35f2f7f2-51a8-409a-b703-e0d149f2ec46">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfNC0xLTEtMS0w_e154a963-07f0-4412-b76a-d47a58708ef4">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfNS0xLTEtMS0w_d56a6e40-725e-47b3-92fb-ca17b0ab1d71">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfNi0xLTEtMS0w_58214624-3213-4209-85d5-b2369bf1624d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfNy0xLTEtMS0w_bc797ff3-6b90-4bf6-a7bc-ca417ef7947d">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfOC0xLTEtMS0w_175502a7-3a3c-4407-b592-2bdf4c5e3cf5">6.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfOS0xLTEtMS0w_1da9ddee-a802-40aa-9212-4091f45e3e47">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTAtMS0xLTEtMA_4b7778cc-5004-4bec-b523-362d37a462d3">11.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTEtMS0xLTEtMA_230e4407-0e4f-4a86-90a4-92be33012d5e">5.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTItMS0xLTEtMA_d25a1b49-b56f-4e19-81ca-30a49659b6fa">29.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTMtMS0xLTEtMA_1af528f6-0fdd-4c37-a5c0-09afdfb27616">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id814fe8f58334cf9978509b3eada043c_D20210101-20210630" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTQtMS0xLTEtMA_3f12d11b-4b73-4a1c-bc40-de8149d37d45">212.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTUtMS0xLTEtMA_c7d339e1-96b3-41b3-ae9c-c4a899f8d1a7">229.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses ($<ix:nonFraction unitRef="usd" contextRef="i5c0952e0e5814a7380170a26c64d0563_I20200601" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjY5MA_5f57c023-0425-4826-98b7-07961dd0d8ae">8.7</ix:nonFraction>&#160;million), certificates of need ($<ix:nonFraction unitRef="usd" contextRef="i953170ab35da4c52b868fca5070072f4_I20200601" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjcxNw_dfe77fdc-72b7-4480-a1dc-5e496b35c900">0.7</ix:nonFraction>&#160;million), acquired names ($<ix:nonFraction unitRef="usd" contextRef="i592180016a3f4b9e9fa58cdf3b1f3e11_I20200601" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjczOA_53ff05c9-d757-4f24-bd14-386ad734dfea">5.7</ix:nonFraction>&#160;million) and non-compete agreements ($<ix:nonFraction unitRef="usd" contextRef="i0cb7f1afbee94667b22da85810bdfcbf_I20200601" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjc3MA_d8e8ebf0-e779-47e5-a77d-5f6c29911419">9.2</ix:nonFraction>&#160;million). The acquired names will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i7dd94248f0054a2eb7c4d4f6a7ce8f7f_D20200601-20200601" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjg0Ng_f548c46f-45f2-4143-a05a-011876d2c248">2.0</ix:nonNumeric> years, and the non-compete agreements will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i2e7f579c66d14f6f8455278885e6166c_D20200601-20200601" format="ixt-sec:duryear" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjkzMw_53546113-d0b1-4895-986b-cad78776ec31">1.7</ix:nonNumeric> years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately <ix:nonNumeric contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601" format="ixt-sec:duryear" name="amed:GoodwillDeductibleForIncomeTaxPurposesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMzc2Mw_c1f79282-ce0b-448f-8c04-e7796ad53049">15</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_58"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNzMwNA_b7162d20-9f86-4d1e-aea6-85331abad0eb" continuedAt="ibe289b92dde8424c87ea6de5d70fe72c" escape="true">LONG-TERM OBLIGATIONS</ix:nonNumeric></span></div><ix:continuation id="ibe289b92dde8424c87ea6de5d70fe72c" continuedAt="i218fcb79d7a14c6a85837aeaf0cbe7dc"><div style="margin-top:6pt"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNzMwNg_e045031c-0625-45e0-b32e-4751fc2c8b7f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:66.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="id2212b3038014b39b18d85e2bb708130_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0zMDkvdGV4dHJlZ2lvbjozMDIxY2I3MTU4NDg0NDkyYmJlODkxNjJjZDRmNjY0Y18xMDk5NTExNjI4MDI1_cf7b705c-fb6a-4cb3-b81e-23293e9fdbf7">450.0</ix:nonFraction> million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (<ix:nonFraction unitRef="number" contextRef="if630985387694c3c8fc5598653fa49c5_I20210930" decimals="3" name="amed:DebtInstrumentInterestRateatPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0zMDkvdGV4dHJlZ2lvbjozMDIxY2I3MTU4NDg0NDkyYmJlODkxNjJjZDRmNjY0Y18xMDk5NTExNjI3OTkw_fc57362d-2cd2-4e3d-9745-c425a397fda7">1.6</ix:nonFraction>% at September 30, 2021); due <ix:nonNumeric contextRef="i9c80c052038b44b5a18995cafc14e750_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0zMDkvdGV4dHJlZ2lvbjozMDIxY2I3MTU4NDg0NDkyYmJlODkxNjJjZDRmNjY0Y18xMDk5NTExNjI4MDA3_509964da-7c83-4818-9bf6-22f6d3d4e307">July&#160;30, 2026</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2212b3038014b39b18d85e2bb708130_I20210930" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0xLTEtMS05MzQy_75231549-73c4-4fb3-b171-6b1abebf8b88">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id33dd3f1accc48d0b07ae82ea62d7bf3_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0zLTEtMS05MzQy_bca75f75-59d7-47bb-a66f-57e9112b3d60">164.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0wL3RleHRyZWdpb246YmFmYmYwOTIyNWQwNDM5ZmJiZDIxZmY2NGIwYmRkNzZfNA_8862b461-dec5-49bd-9d11-a507ead533de">550.0</ix:nonFraction> million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due <ix:nonNumeric contextRef="i4a29fce5319a41b88a21448a8d746bc1_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0wL3RleHRyZWdpb246YmFmYmYwOTIyNWQwNDM5ZmJiZDIxZmY2NGIwYmRkNzZfMTcz_c25ba678-7c58-42d1-866b-5e1838193e78">July&#160;30, 2026</ix:nonNumeric></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0xLTEtMS0w_0384cf44-9c93-419b-bcac-416caaaa47b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04620e666ce242189145fc8202e974a5_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0zLTEtMS0w_c3973e58-65d9-4b0e-812a-136aa23f7748">51.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c79a4a01587443798a698b9d888425d_I20210930" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNC0xLTEtMS0xMDM2OA_553daa93-2a10-45d3-85bd-2d60a14b8626">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6b3f9117ec48d3af01c13b614cdce8_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNC0zLTEtMS0xMDM2OA_28c6b420-5c28-416b-83e3-bfaca9f685f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b58db92e154fe68dd728641fc3400e_I20210930" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMy0xLTEtMS0w_a297d5d0-1091-4107-a0a0-61168b64c232">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb868e0e199e4a7ba64d42b2fdae307d_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMy0zLTEtMS0w_8412999f-2c7e-4584-8f92-cb6dbcb167cc">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNC0xLTEtMS0w_550e1d77-114b-4142-a658-323ee4c1e880">452.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNC0zLTEtMS0w_41c6ce66-3dd9-47af-842a-e5a4f64ba009">217.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNS0xLTEtMS0w_00ba5665-d7cf-4f41-8fb1-495d39e69801">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNS0zLTEtMS0w_87708c7a-b77e-4a69-8c57-82976125cb74">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNi0xLTEtMS0w_a5c5b924-d008-4962-a3c5-097cd4b588b1">448.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNi0zLTEtMS0w_1ccd2b60-2a84-4bf5-a205-5ec4c91160a4">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNy0xLTEtMS0w_17873ca8-121b-4772-bbe8-1b675ebdff42">13.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNy0zLTEtMS0w_7f24a33d-8ed1-4a6a-9311-f9a3514ed3b5">10.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfOC0xLTEtMS0w_3da68b2d-90a4-444f-b7a9-8999ed41ae2d">434.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfOC0zLTEtMS0w_82c936ce-e824-4cc6-ba1e-648eca3a5c27">204.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provided for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="i13ec3a58ad29418ebe42554498e48e75_I20190204" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDU1_8c72438a-8ef0-4ffe-8c71-78954ec2da65">725.0</ix:nonFraction> million, which included a $<ix:nonFraction unitRef="usd" contextRef="ibf92b4555b6d40f2a59b54d48f64f091_I20190204" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDc2_64b8cbed-d98f-40f0-8868-7e9f66241f93">550.0</ix:nonFraction> million Revolving Credit Facility and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ic64fd34ea067411b965765c227c1c4e8_I20190204" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNTkx_db8e585d-11aa-4e34-8645-69d8c56899be">175.0</ix:nonFraction> million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ibb7c45b2d9ae4729a6b676da0434e01b_I20210730" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNTQzNg_c0b755c6-75b3-4ff1-9f34-b42a6aa5b6d8">1.0</ix:nonFraction>&#160;billion, which includes a $<ix:nonFraction unitRef="usd" contextRef="i8161c5c6f5a441498e6232b1062a0706_I20210730" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNTQ1OA_dccffda6-51cc-4ec2-8d0d-837066a31abf">550.0</ix:nonFraction>&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ic9248021e924452a9ca5a099d811b891_I20210730" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNTU4OQ_00070aae-71e6-4562-b99f-2d6a94cb872c">450.0</ix:nonFraction>&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net proceeds from the $<ix:nonFraction unitRef="usd" contextRef="ic9248021e924452a9ca5a099d811b891_I20210730" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNTczMA_ccae3e62-9f5a-4b61-b3f2-244eeb154dce">450.0</ix:nonFraction>&#160;million Amended Term Loan Facility were used to fund 100% of the Contessa acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="i96b33383638f4da69049403922d142b6_D20210730-20210730" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MTA3Mg_132dea8d-4b87-4985-8bb4-75bd1f8f65a6">0.50</ix:nonFraction>% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus <ix:nonFraction unitRef="number" contextRef="i96b33383638f4da69049403922d142b6_D20210730-20210730" decimals="INF" name="amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MTE5Mg_43247ea4-2f47-4814-852c-de3f155af0db">1</ix:nonFraction>% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of September&#160;30, 2021, the Applicable Rate is <ix:nonFraction unitRef="number" contextRef="ic4d439ce912f4be0af7514da8425d3c2_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MTU5Ng_d1d0ebe5-95af-493b-8344-742624ed99e0">0.50</ix:nonFraction>% per annum for Base Rate loans and <ix:nonFraction unitRef="number" contextRef="ib9ff3a8ccb9f425b8f7441a6634cf019_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MTYzNA_41736fa8-fe1c-4a7b-94cc-6d7da18ded3d">1.50</ix:nonFraction>% per annum for Eurodollar Rate loans. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjUwMA_212913ff-d65c-4fb8-a36c-d8da0d26ea6b" continuedAt="i260decc542e0455e9e2e9b7aa49e0c45" escape="true">We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><ix:continuation id="i260decc542e0455e9e2e9b7aa49e0c45"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:10.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; <ix:nonFraction unitRef="number" contextRef="i8268f6431a5342b0a5dc83e81f8cf5a1_D20210101-20210930" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS0xLTEtMS0zMzIvdGV4dHJlZ2lvbjoyMzFiMjhhOGU3MDU0MmIzYjA2ZDlmNjg3ZGE0NmNiNV82_9d6f6a12-7968-4169-80ba-57033b48a86f">3.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2629c6a87704cab9b7d7cc4fcb7d9d7_D20210101-20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS0yLTEtMS05NDEw_0653ee31-261b-4a41-86c6-ee11ef3a54bb">0.30</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2629c6a87704cab9b7d7cc4fcb7d9d7_D20210101-20210930" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS0zLTEtMS05NDE1_b7b77713-0526-4967-911d-50a7705c298b">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6347f72e46564137a77f41c6701f04b4_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS00LTEtMS05NDE1_62bd6bc3-97ff-4676-8cb5-b96ad90061fb">2.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a006fc8ae3144b8b0f35e0576008c13_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS01LTEtMS05NDE1_9e6d04bf-0ac6-4779-bca3-c9bb18bc7bf0">1.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> <ix:nonFraction unitRef="number" contextRef="i8eda14018d5440f49c3d2c8399bf7c28_D20210101-20210930" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi0xLTEtMS0zMzIvdGV4dHJlZ2lvbjowYzAzODI4OGZjNWI0ODczYmY1YjhiN2U4NjA5MTNlOF83_583c0c4f-1e56-4c22-9f88-3812ca52e2d2">3.00</ix:nonFraction> to 1.0 but &gt; <ix:nonFraction unitRef="number" contextRef="i577fdd4a436a42ea80849c81a5784c4c_D20210101-20210930" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi0xLTEtMS0zMzIvdGV4dHJlZ2lvbjowYzAzODI4OGZjNWI0ODczYmY1YjhiN2U4NjA5MTNlOF8yMw_c2e7e9bb-b5d3-4baa-b3b5-65f60c2cd4ef">2.00</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66aae57e36ae41648ae8623055ad5911_D20210101-20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi0yLTEtMS05NDEz_790f9154-3db4-47c0-a2b2-ffad31ffea70">0.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66aae57e36ae41648ae8623055ad5911_D20210101-20210930" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi0zLTEtMS05NDE1_6fb7074b-fff9-4b41-bedf-4719c769f1c9">1.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i499562ee396144d1b90e4e7f1e4b3078_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi00LTEtMS05NDE1_5bc8db1b-413e-46e8-94ff-7514eb9ef34e">1.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35d443fe2776475199e8bf20c5bd7195_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi01LTEtMS05NDE1_06f0bcc6-b5a5-4a48-a6e7-2f03d1406da8">0.75</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="i0e39d276de254f649e239423c9cc0cc7_D20210101-20210930" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy0xLTEtMS0zMzIvdGV4dHJlZ2lvbjowMTkzNmM4OTNjYTc0OGY3YTYwODQwZGRhMzQyMTBiZl82_5f57f6a7-4d68-40f5-8017-f077632e1e84">2.00</ix:nonFraction> to 1.0 but &gt; <ix:nonFraction unitRef="number" contextRef="i94c391fe27d34bb598e993c5ca12ab5e_D20210101-20210930" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy0xLTEtMS0zMzIvdGV4dHJlZ2lvbjowMTkzNmM4OTNjYTc0OGY3YTYwODQwZGRhMzQyMTBiZl8yMg_6cd0c009-b3c8-4fbf-b874-c3f976cfd1e9">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5bbf202037ab4efe84eec9c86af849aa_D20210101-20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy0yLTEtMS05NDEz_c5dc8ab4-40f2-467e-a68f-3531279387f8">0.20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5bbf202037ab4efe84eec9c86af849aa_D20210101-20210930" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy0zLTEtMS05NDE1_06e1ddb7-7aac-4d01-84e7-25db6961ac51">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec7d2c9ab8af421195c28b753a977a92_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy00LTEtMS05NDE1_eee1b8b5-3b5b-479a-a6ba-d001af1ff52b">1.50</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i31501243538e4935b989aad968b62589_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy01LTEtMS05NDE1_8d96455a-ad28-4fad-810e-7fc1d662cc3a">0.50</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="number" contextRef="ie04b2efc6fec439ca0961cd20f0f2601_D20210101-20210930" decimals="INF" name="amed:ConsolidatedLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC0xLTEtMS0zMzIvdGV4dHJlZ2lvbjoyYTAyMDU3NGY4MTM0ZGQxOGEwNjY2OGQ3ZjBiNDU4ZF82_e9396420-debf-4194-b810-80b48230e920">0.75</ix:nonFraction> to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7b640016ec74b29877d9d8af659dacf_D20210101-20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC0yLTEtMS05NDEz_ccf549ce-a9e5-4935-b807-6429b5830ade">0.15</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7b640016ec74b29877d9d8af659dacf_D20210101-20210930" decimals="INF" name="amed:LetterOfCreditFee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC0zLTEtMS05NDE1_0570b768-b627-4c48-b0de-e548fa19f504">1.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7807a03e1d27498cb0fbd254ba18a9e2_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC00LTEtMS05NDE1_8315208b-5053-4602-b3bd-c4a99419a578">1.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fb48a5c2350401badf76407e810a916_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC01LTEtMS05NDE1_dc087be9-eaa3-4869-b832-fb0aee4f0f42">0.25</ix:nonFraction>%</span></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is <ix:nonNumeric contextRef="i4384d6ba9eb047a8b55217f4beaf64b4_D20210730-20260730" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNjMyOA_8f7e2f90-2fbd-4f60-8e9a-f0f4edc642a4">July 30, 2026</ix:nonNumeric>. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i218fcb79d7a14c6a85837aeaf0cbe7dc" continuedAt="i21644ce923c64a8793bbbd45d19af54b"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of principal in the amount of (i) <ix:nonFraction unitRef="number" contextRef="ic8d7f3ebbc7b4cbabe8f090e4d1c2b10_D20210730-20230930" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNjU0NA_c2aad78e-22d1-43a8-b5f9-7c6eb4a40878">0.625</ix:nonFraction>% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) <ix:nonFraction unitRef="number" contextRef="i22ebbfca679d4a7fafa5444ca24a361f_D20231001-20260730" decimals="INF" name="amed:DebtInstrumentPeriodicPaymentPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNjYzNA_8c09415e-686f-4694-a0b6-215df7c3f069">1.250</ix:nonFraction>% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="ie4322d7e66634ce4885a55d252abc28d_D20210730-20210730" decimals="-5" format="ixt:num-dot-decimal" name="amed:ProceedsReceivedFromLoanPartyOfSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNzI1Ng_3504f7f1-ce60-46fb-9370-c920bfdcc2e6">5</ix:nonFraction>&#160;million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement. In connection with our entry into the Second Amended Credit Agreement, we recorded $<ix:nonFraction unitRef="usd" contextRef="ie4039f4791f043d6a0ea7c40d6c13d2f_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjE5NQ_5e12c506-036c-4903-85d5-d9e87eee2977">2.8</ix:nonFraction>&#160;million in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the three-month period ended September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i96b33383638f4da69049403922d142b6_D20210730-20210730" decimals="INF" name="amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDA2OA_dd5266a6-9a80-42f1-9f23-eb67624ffa96">95</ix:nonFraction>% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than <ix:nonFraction unitRef="number" contextRef="i96b33383638f4da69049403922d142b6_D20210730-20210730" decimals="INF" name="amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDI1MQ_633763c1-918a-4b71-b23b-283e3b38a49d">70</ix:nonFraction>% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDM3OQ_8ad96c0f-93b7-4224-8786-b5eeffea77bc">550.0</ix:nonFraction> million Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="ib057fa7e9dc74985846be7233614be6d_D20210701-20210930" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDQxMg_a0861e32-92c6-4bdd-a1f1-587ad94ec884">2.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i4a29fce5319a41b88a21448a8d746bc1_D20210101-20210930" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDQxOQ_5d09ab9a-dc49-4ba3-a368-031381a89f62">1.9</ix:nonFraction>% for the three and nine-month periods ended September&#160;30, 2021, respectively, and <ix:nonFraction unitRef="number" contextRef="i8a8de61107114e3188c016a866d7eee9_D20200701-20200930" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDQ4Ng_189681ee-2cc5-416f-bc1b-c4c50998f366">1.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i75a1a833f08448ae97ff44f57957725d_D20200101-20200930" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDQ5Mw_070d2329-6138-40b2-97f1-ab338ecf38e0">2.2</ix:nonFraction>% for the three and nine-month periods ended September 30, 2020, respectively. Our weighted average interest rate for borrowings under our $<ix:nonFraction unitRef="usd" contextRef="id2212b3038014b39b18d85e2bb708130_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjQ3MQ_f0bc823d-5fd6-4fd1-a6e5-93cdd067e22e">450.0</ix:nonFraction>&#160;million Amended Term Loan Facility was <ix:nonFraction unitRef="number" contextRef="i257940b085494340a54f2596ffb71f9c_D20210701-20210930" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjQ5Mw_b36c5e41-2af0-465e-9e3c-b081dada12ae">1.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9c80c052038b44b5a18995cafc14e750_D20210101-20210930" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MzYwMw_199bbb33-850f-454e-91aa-a6de647d9719">1.5</ix:nonFraction>% for the three and nine-month periods ended September 30, 2021, respectively, and <ix:nonFraction unitRef="number" contextRef="i4eabd2498ce447d59434f7882ae478d0_D20200701-20200930" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTY0OTI2NzQ1NzM5OA_89f92641-1ccc-4510-9a40-253b9dda0e49">1.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ifba8391d8e984a3593722809cdc00c21_D20200101-20200930" decimals="3" name="us-gaap:LongTermDebtWeightedAverageInterestRateOverTime" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTY0OTI2NzQ1NzQwMg_344e7066-bf6e-4faf-8c1b-5cd0e22bfdbf">2.3</ix:nonFraction>% for the three and nine-month periods ended September 30, 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, our consolidated leverage ratio was <ix:nonFraction unitRef="number" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" name="amed:TotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDg1NQ_67a4d48c-376a-40a4-b4d7-7f55b56f158a">1.2</ix:nonFraction>, our consolidated interest coverage ratio was <ix:nonFraction unitRef="number" contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930" decimals="INF" name="amed:ConsolidatedInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDkwNA_cf927796-eaf4-41cc-a879-8e47c136ac94">27.5</ix:nonFraction> and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, our availability under our $<ix:nonFraction unitRef="usd" contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNTI4Mg_92b0ac50-4f18-4580-b45b-f72e6834434c">550.0</ix:nonFraction> million Revolving Credit Facility was $<ix:nonFraction unitRef="usd" contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNTMxNQ_1556b76c-5fe4-49fd-8c24-ca7d7a3ae716">519.9</ix:nonFraction> million as we have <ix:nonFraction unitRef="usd" contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjU4Mw_0384cf44-9c93-419b-bcac-416caaaa47b8">no</ix:nonFraction> outstanding borrowings and $<ix:nonFraction unitRef="usd" contextRef="i778f590556a3415eb3394ae1a6c1629f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNTM2Mg_1830f083-a58d-4a3a-9d53-d62466db822e">30.1</ix:nonFraction> million outstanding in letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice, which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;Contessa and Asana Joinder,&#8221; and together with the CCH Joinder and the AseraCare Joinder, the &#8220;Joinders&#8221;). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i21644ce923c64a8793bbbd45d19af54b">Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana Hospice and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana Hospice and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.</ix:continuation></span></div><div><span><br/></span></div><div id="id60bf3839b914d279c418e71b98c550c_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMTAwODA_1133db5d-7f8a-484c-8e14-81869d07445b" continuedAt="i5f8afed04c7540a994cad2434f81eeb1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i5f8afed04c7540a994cad2434f81eeb1" continuedAt="i4edcb717498748cab3a028c3a6005575"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Completed</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). As of March 31, 2021, we had recorded a total of $<ix:nonFraction unitRef="usd" contextRef="i035bf53c46a541a5826c7f2c7b06185b_I20210331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTI3_058b7d81-1220-4671-9774-2aba0b016ce3"><ix:nonFraction unitRef="usd" contextRef="idd4289f9d03348eabba8b8a1ff9153aa_I20210630" decimals="-5" format="ixt:num-dot-decimal" name="amed:ReversalOfLossContingencyAccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTI3_7ce7cb4d-fb40-4009-976b-8a2927a0d132">6.5</ix:nonFraction></ix:nonFraction> million to accrued expenses in our condensed consolidated balance sheets related to these matters. During the three-month period ended June 30, 2021, we reversed our accrual related to these matters.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding <ix:nonFraction unitRef="patient" contextRef="i601ff40a9dcb4f2e8948d32afbd39a70_D20150521-20150521" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMTI2NQ_d16fcf79-0698-4a6f-82e0-26cc93b4b267">53</ix:nonFraction> identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May&#160;21, 2015.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="i8ccc1c8d24e84db4aa8381d958233b6b_D20151103-20151103" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMjAwOA_fe92b649-f14d-453c-89ed-b805581e71e7">66</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August 31, 2015.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding <ix:nonFraction unitRef="patient" contextRef="ie05aa041138d438c87540387474bcbd1_D20160627-20160627" decimals="INF" name="amed:Numberofpatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMjYzOA_3e678422-704b-4041-8afb-60f733bff6bb">68</ix:nonFraction> identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of Inspector General (&#8220;OIG&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i4edcb717498748cab3a028c3a6005575" continuedAt="iacba16aeb6524fa49f1d6ebbac22a8b6"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of <ix:nonFraction unitRef="beneficiary" contextRef="i0aa37634d03d42b08a244431e4a41f5c_D20080101-20100331" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMzcxMA_1be1c716-955d-4414-8d49-07c8cd3b7488">30</ix:nonFraction> beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for <ix:nonFraction unitRef="beneficiary" contextRef="i095f59a36c244843af1db7f854a0a9a2_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNDE1NA_6f0dab82-e2ce-46bd-9dec-b379b63ab775">16</ix:nonFraction> beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $<ix:nonFraction unitRef="usd" contextRef="ica3afcf2ee1c43259f1a30c2e600133a_I20160118" decimals="-5" format="ixt:num-dot-decimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNDk1Nw_91afeb41-4acf-4292-9d91-a41ba8d0c503">3.7</ix:nonFraction> million with a balance owed of $<ix:nonFraction unitRef="usd" contextRef="ica3afcf2ee1c43259f1a30c2e600133a_I20160118" decimals="-5" format="ixt:num-dot-decimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNDk4Mw_86142b83-85e8-4718-a017-2f17c6bc2e16">5.6</ix:nonFraction> million, including interest, based on <ix:nonFraction unitRef="claim" contextRef="i564a484715c64e40a7be81c6235e4f3d_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTAxNg_f5e87374-19c7-41ea-a4c1-304b7b15d2c7">9</ix:nonFraction> disputed claims (originally <ix:nonFraction unitRef="beneficiary" contextRef="i095f59a36c244843af1db7f854a0a9a2_D20110606-20110606" decimals="INF" name="amed:NumberOfBeneficiaries" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTA0Nw_4fb16581-a80e-4e6b-8dc3-69268faad2b5">16</ix:nonFraction>). We filed an appeal to the Medicare Appeals Council on the remaining <ix:nonFraction unitRef="claim" contextRef="i564a484715c64e40a7be81c6235e4f3d_D20160118-20160118" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTEyMA_e973df7b-c1bd-48b5-89f8-87e2b5230c8c">9</ix:nonFraction> disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of September&#160;30, 2021, Medicare has withheld payments of $<ix:nonFraction unitRef="usd" contextRef="i802e5888cb1648439a3f47b2b44404c2_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTM2NQ_feff172d-586e-4318-acbb-6575997d723e">5.7</ix:nonFraction> million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $<ix:nonFraction unitRef="usd" contextRef="i76d5dd1a4f4a464ca4fb9d384e6aa87b_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTg3MA_2f0923e4-ffd5-4e18-a123-43db9d2b5d5b"><ix:nonFraction unitRef="usd" contextRef="ic80811cd8fd747ef98eb89b834589f68_I20190110" decimals="-5" format="ixt:num-dot-decimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTg3MA_a49d5a4e-fddd-4471-8e52-4bb8601fda07">2.8</ix:nonFraction></ix:nonFraction> million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $<ix:nonFraction unitRef="usd" contextRef="i3b5d1cbe45dc44d9b98ec0e127cd824c_I20170831" decimals="-5" format="ixt:num-dot-decimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjcxNQ_716892ca-3bea-4e8e-a718-108d16331b50">34.0</ix:nonFraction> million for the Lakeland Care Centers on a universe of <ix:nonFraction unitRef="claim" contextRef="i484c5a9dd6e14e23b66ed620f5079d5d_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjc2NQ_0bd73943-87e0-4814-bdee-9e5e59b720f1">72</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="i3b5d1cbe45dc44d9b98ec0e127cd824c_I20170831" decimals="-5" format="ixt:num-dot-decimal" name="amed:ActualClaimsPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjc5Mw_0a609bd7-fb1f-46a1-8f10-7c4697d5215b">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="i3b5d1cbe45dc44d9b98ec0e127cd824c_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjgzMA_c762134d-9e5a-4806-9f89-4cc9602acc8c">100</ix:nonFraction>% error rate and an overpayment of $<ix:nonFraction unitRef="usd" contextRef="ic0294eb79c2848a59000786e83e668d1_I20170831" decimals="-5" format="ixt:num-dot-decimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjg2Ng_3098cffe-eda7-48bf-8918-27aadd61a84c">4.8</ix:nonFraction> million for the Clearwater Care Center on a universe of <ix:nonFraction unitRef="claim" contextRef="ie0de238f9be246fe96998173de4a5bcb_D20170801-20170831" decimals="INF" name="amed:NumberOfClaimsSubmittedBySubsidiary" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjkxNw_d4b28367-4f04-4ff2-9bc0-7937ac5f653e">70</ix:nonFraction> Medicare claims totaling $<ix:nonFraction unitRef="usd" contextRef="ic0294eb79c2848a59000786e83e668d1_I20170831" decimals="-5" format="ixt:num-dot-decimal" name="amed:ActualClaimsPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjk0NQ_cc395be8-b67f-4ae0-925d-6962b8cd2fa6">0.2</ix:nonFraction> million in actual claims payments using a <ix:nonFraction unitRef="number" contextRef="ic0294eb79c2848a59000786e83e668d1_I20170831" decimals="INF" name="amed:ErrorRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjk4Mg_921f8590-bffe-4d9a-b7ad-4a574d9fed15">100</ix:nonFraction>% error rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $<ix:nonFraction unitRef="usd" contextRef="i346f707c9d6b4ac9964bf787577aea3d_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNzM0Ng_bb470950-b056-404d-808f-6e9ca7dcdb45">26.0</ix:nonFraction> million and the alleged overpayment for the Clearwater Care Center has been reduced to $<ix:nonFraction unitRef="usd" contextRef="i89ded9eda305484fa4ab5c09016ceb41_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNzQyOA_9357814f-6e94-4f82-8191-eec5ac0018c1">3.3</ix:nonFraction> million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $<ix:nonFraction unitRef="usd" contextRef="i3eb22d6ba31944238874d354008337ec_I20170831" decimals="-5" format="ixt:num-dot-decimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNzc4Nw_2de06d33-e8ee-4f6f-95e6-79b6524930c2">12.6</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $<ix:nonFraction unitRef="usd" contextRef="ie21724093a2f42c4853d771fabb00f17_I20170831" decimals="-5" format="ixt:num-dot-decimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODAyOA_b91b664c-109b-4bd9-ba54-e4f705b98c57">6.5</ix:nonFraction> million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $<ix:nonFraction unitRef="usd" contextRef="i36258c9144d84085bd1b3ea4fd537b23_I20170831" decimals="-5" format="ixt:num-dot-decimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODI3NA_6841d953-e393-48c9-85e4-238b06b21506">38.8</ix:nonFraction> million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $<ix:nonFraction unitRef="usd" contextRef="i3eb22d6ba31944238874d354008337ec_I20170831" decimals="-5" format="ixt:num-dot-decimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODQxNA_a69b5747-de40-4f3c-b691-a5d5b871b010">12.6</ix:nonFraction> million is subject to indemnification by the prior owners) to $<ix:nonFraction unitRef="usd" contextRef="ief75d072b29748ba987a8030789542dd_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:RecoveryAmountOfOverpaymentMadeToSubsidiary" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODQ3MQ_477b2c1b-5fac-4aff-8d31-c872021859ed">29.3</ix:nonFraction> million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we have an accrued liability of approximately $<ix:nonFraction unitRef="usd" contextRef="i08e7d764f4494c88b305e1e18074b41f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODY0MQ_d6cca550-61d9-4b18-a4a4-9a7a538aa990">17.4</ix:nonFraction> million related to this matter. We expect to be indemnified by the prior owners for approximately $<ix:nonFraction unitRef="usd" contextRef="i08e7d764f4494c88b305e1e18074b41f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LossContingencyReceivableNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODczNA_fd236c15-bb1b-456c-9e79-cf7f03963c7c">10.9</ix:nonFraction> million of the total $<ix:nonFraction unitRef="usd" contextRef="i60712b1793c74750b58b9385fb0c31e3_I20170831" decimals="-5" format="ixt:num-dot-decimal" name="amed:IndemnificationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODc1MA_9b27eb97-3af7-40c2-bc88-891f154cbb8f">12.6</ix:nonFraction> million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheets. The net of these two amounts, $<ix:nonFraction unitRef="usd" contextRef="i3d7c2cc8b22d455a9ebb4e72d526d36c_D20170101-20171231" decimals="-5" format="ixt:num-dot-decimal" name="amed:FloridaZpicRevenueReduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODkyOA_043cec0b-afd2-4f41-8c51-7ba1708fd37f">6.5</ix:nonFraction> million, was recorded as a reduction in net service revenue in our condensed consolidated statements of operations during 2017. As of September&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i9eaa44efaa1a467ebc42d62d7ac69a76_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTA2MQ_b495d467-0312-46d1-8eb6-090f85694140">1.5</ix:nonFraction> million of receivables have been impacted by this payment suspension.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="iacba16aeb6524fa49f1d6ebbac22a8b6"><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:HealthInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTg4Mw_f0870348-729f-424c-8a6f-76de91367e2e">1.3</ix:nonFraction> million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:WorkersCompensationInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTk4MA_39c9f8a1-0081-46ab-9962-f20f94fa6432">1.0</ix:nonFraction> million per incident and our professional liability insurance has a retention limit of $<ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="amed:ProfessionalLiabilityInsuranceRetentionLimit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMTAwNjI_88448be0-4226-4156-89df-205acf601207">0.3</ix:nonFraction> million per incident.</span></div></ix:continuation><div id="id60bf3839b914d279c418e71b98c550c_70"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RleHRyZWdpb246MTI0MWNhYWUyNzhiNGVhMzgzZmFjMzExMDY1ODkwNWZfMTM4Mg_38fcb34d-b544-45de-9dd5-1cbcd036a5f4" continuedAt="i0a5bf69b716347259ab759e28311692b" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i0a5bf69b716347259ab759e28311692b" continuedAt="iaf6e242a45fb473c8180247f29eb0654"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our <ix:nonFraction unitRef="segments" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RleHRyZWdpb246MTI0MWNhYWUyNzhiNGVhMzgzZmFjMzExMDY1ODkwNWZfODI_5f502b79-2030-4443-8fac-805fc9c272d0">four</ix:nonFraction> reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa during the three-month period ended September 30, 2021, delivers the essential elements of inpatient hospital and skilled nursing facility ("SNF") care to patients in their homes. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><ix:continuation id="iaf6e242a45fb473c8180247f29eb0654"><ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RleHRyZWdpb246MTI0MWNhYWUyNzhiNGVhMzgzZmFjMzExMDY1ODkwNWZfMTM4NQ_4ee5cb9e-5a64-47a5-b302-9dd2e1aa72b2" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:45.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi0xLTEtMS0w_a8fb46cc-86e0-413d-9ffd-724fdcfce426">338.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi0zLTEtMS0w_138aadad-ac27-4b6b-aed6-076cabfa330a">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi01LTEtMS0w_94196f77-d28e-4d52-87d7-efb9ae03c72b">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi03LTEtMS05MzAx_b234e969-aa6d-49cc-8e95-9b7723078063">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi03LTEtMS0w_ef071f22-2f92-49ff-bd85-207bfe228acd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi05LTEtMS0w_ecb13a25-a451-4cfa-94b7-fd5a6349c0cc">553.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy0xLTEtMS0w_879d4c51-31b3-4aa3-81ac-e146c9526c9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy0zLTEtMS0w_97b3e87c-30df-4576-9850-64610ea02787">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy01LTEtMS0w_7a2078fa-f327-40f0-8b37-0cd0daafddea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy03LTEtMS05MzAx_38aeaf5f-4592-4bcf-8b59-1e8398941736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy03LTEtMS0w_58a72fac-3bf5-4828-89ee-0f8ca79694e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy05LTEtMS0w_23c83f06-0e83-4e52-9fe8-b8c597ddf141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC0xLTEtMS0w_e000aaa9-c0f3-4f3a-9f32-5950d0fd84b4">190.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC0zLTEtMS0w_c53a7c78-6709-4ad8-8c89-29376c202959">107.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC01LTEtMS0w_1ca341cc-a1ec-4ad1-b98b-80b6a31746ae">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC03LTEtMS05MzAx_c864591a-86e4-4cf1-930a-979a69e467da">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC03LTEtMS0w_c09bb82a-712c-4ed5-9af3-e7e531ff6d8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC05LTEtMS0w_35e2f6c0-faa6-4068-bf11-97f48079c134">310.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS0xLTEtMS0w_b0c72e0a-f8ca-45a1-821e-8e7637ded9f5">82.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS0zLTEtMS0w_826a1de0-12ba-42f4-a6b4-5d8588740e5f">49.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS01LTEtMS0w_27acee73-97b7-4798-9e85-8235ba7b1133">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS03LTEtMS05MzAx_15ce2795-49b7-47b8-aa03-11f789bf35f9">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS03LTEtMS0w_037b4c2c-728f-48b9-aca8-b0d31f78ab1a">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS05LTEtMS0w_67f4efa5-7679-4c4e-a21b-f256de5b01cc">178.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi0xLTEtMS0w_2d58ce36-6f75-49de-8c46-8e8e274ab385">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi0zLTEtMS0w_8c3690ab-be48-4f63-9527-626437f6ea1b">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi01LTEtMS0w_36cc1fe3-8ff8-48fc-876a-feb55116d28f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi03LTEtMS05MzAx_352675f3-3c5f-4171-8e47-e769bad8014b">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi03LTEtMS0w_bbe4746c-c0d0-416b-b92b-fdbd90736760">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi05LTEtMS0w_3af52749-4cba-4eec-926a-5d6d939f82cd">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy0xLTEtMS0w_04e053f3-fba4-4e40-939f-d18265833009">273.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy0zLTEtMS0w_2439a75e-9521-48a5-92bf-f3fda30a07a0">157.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy01LTEtMS0w_67dadbcb-43e0-46f9-9cce-ecc452fa22fe">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy03LTEtMS05MzAx_23f5ff2d-98bd-4e97-a47e-31d2744f1195">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy03LTEtMS0w_72f8e19d-1e35-48a5-ac8e-5ab42c32ceb5">45.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy05LTEtMS0w_5dc9bffb-e77b-4ff6-98a5-8b2cce3b4127">496.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC0xLTEtMS0w_e2c3ba11-158c-4e9a-b40a-83c9b56e465f">65.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC0zLTEtMS0w_023aec2d-7aad-4c03-80fc-6fde1ac1d868">39.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC01LTEtMS0w_f0d9a1ff-fa8d-4274-a13b-738d623c2e1d">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC03LTEtMS05MzAx_b3d53bf8-a8c6-48ac-8a8c-b834ddbf3fa0">3.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC03LTEtMS0w_2d0b6e26-456d-4a13-a8db-d242009431d5">45.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC05LTEtMS0w_035c266d-ca5c-47ec-94ff-ba847ec91d20">56.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItMS0xLTEtMA_a89c4143-85d3-407f-89b9-39329daf2db3">326.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItMy0xLTEtMA_9c062c68-b461-432a-b6b5-ff172b05b412">199.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItNS0xLTEtMA_83b78027-f7d6-41e5-bd4e-e28b896319ec">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItNy0xLTEtOTMwMw_184c5f9e-42c7-462a-b40a-5df420caee1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItNy0xLTEtMA_ca86bc74-e160-404c-8ccc-97e0e110cc7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItOS0xLTEtMA_404d6fb1-3cce-4c19-b98d-d4477d3830fe">544.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtMS0xLTEtMA_3eb84352-0717-4061-9770-0c2384e7c9d8">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtMy0xLTEtMA_2cf16c3a-f5a8-4992-96f6-ea29b1ccf3bf">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtNS0xLTEtMA_b40abe90-7362-432c-80f3-527805a85e91">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtNy0xLTEtOTMwMw_86daa2a3-b7e2-4f16-94fe-e99b3d41f85e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtNy0xLTEtMA_0e9411f0-82ae-4596-b5fe-071c4174cdb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtOS0xLTEtMA_663b10ad-f0b3-44d1-b6a3-63f2b6338ca1">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtMS0xLTEtMA_ddf1fb24-5d70-4d26-a9c8-0b1add53804b">180.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtMy0xLTEtMA_1fb213d4-f37b-401b-8ab0-015b788bc276">104.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtNS0xLTEtMA_e910d486-1bbf-42db-9e55-b591c96b7344">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtNy0xLTEtOTMwMw_c6217e89-118c-4aed-b0d7-54f32a18950b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtNy0xLTEtMA_7ad1ee84-44b8-4dec-9d38-46221604d7e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtMS0xLTEtMA_0175c0d9-e9e5-42ad-9b77-813f09ca7ba4">78.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtMy0xLTEtMA_5134acde-ca10-45b4-8254-29889cca4f7e">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtNS0xLTEtMA_1da7dde0-6d14-4330-a9da-684a7e011b0d">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtNy0xLTEtOTMwMw_0c377a8a-c242-4c80-8a50-7b46fce480c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtNy0xLTEtMA_36aad288-fe4b-41fb-9027-85238ad76646">49.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtOS0xLTEtMA_80aa77bd-50de-4db8-8711-9895807c0404">179.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtMS0xLTEtMA_bad7b8a8-c101-4035-842f-1985d92a5e8e">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtMy0xLTEtMA_c0901067-3eef-4e8e-b745-7e402dd1bdfd">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtNS0xLTEtMA_02b2f817-f86d-4814-af37-95205c1dec24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtNy0xLTEtOTMwMw_e6fa88a1-41ac-4570-af2e-82db840708cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtNy0xLTEtMA_bb8cbe81-48b4-470c-a093-1eedc8ddaf1e">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtOS0xLTEtMA_b630179a-1cc1-4c15-b3ee-068f0b6dabad">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctMS0xLTEtMA_ab928bf4-5337-4a8f-adcd-99083571e0dc">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctMy0xLTEtMA_a53de115-4123-4730-8e51-d654c65c94e2">152.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctNS0xLTEtMA_860e46e9-2575-4a82-816b-45d57ee1a5f1">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctNy0xLTEtOTMwMw_0aa5a659-ab3f-4727-b659-872d4abba976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctNy0xLTEtMA_7a187773-d332-4b26-ad5a-815fe23febe9">56.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctOS0xLTEtMA_78aba9df-bf71-40e8-8207-6dca58b7401c">485.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtMS0xLTEtMA_6f1e3ae8-455f-48f8-80b0-cdd0749f45e0">68.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtMy0xLTEtMA_fa3d58c2-5f30-4151-b15e-b16260265f3d">48.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtNS0xLTEtMA_37184a8c-4848-41c8-be2d-e927625b7a75">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtNy0xLTEtOTMwMw_8418e71b-21d9-4103-8256-6531444e23ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtNy0xLTEtMA_03b4db38-7b9d-472a-b84f-a8a37dcd3ad0">56.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtOS0xLTEtMA_f2ed2408-88e8-41cc-94c4-c3a0b73bce52">63.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Period Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItMS0xLTEtMA_689149b2-1343-4028-903d-1f9f8dd10873">1,016.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItMy0xLTEtMA_e4fce1c1-659c-4757-9e57-2908abb65f1d">586.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItNS0xLTEtMA_3be04c2c-ed8c-4ecd-94d3-c7dc3723b37c">49.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItNy0xLTEtOTMwNQ_3b460d0c-b00c-4c25-9029-c995388e6048">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItNy0xLTEtMA_4aee35e6-cef7-4c3d-a363-cdec337fcd98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItOS0xLTEtMA_2aad3e53-e8f7-4451-b6b5-d5ef9277c58b">1,654.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtMS0xLTEtMA_cc9e4b21-27f0-4815-9389-f558cd8f0d71">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtMy0xLTEtMA_1a5734a9-65f4-446c-973b-3244e76b8ef6">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtNS0xLTEtMA_b1634ef4-34c2-4605-ada7-62f354cdda7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtNy0xLTEtOTMwNQ_212a6b39-0c63-4eae-ba03-ae771e7d3832">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtNy0xLTEtMA_beea583e-8338-4c00-a8fb-77decdc74408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtOS0xLTEtMA_e0e5b1b7-c3d9-4b19-835c-86360ee3a90c">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtMS0xLTEtMA_125679a1-19a6-491e-8e27-c4e4f6f034a2">563.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtMy0xLTEtMA_6f3c0481-2b9e-4e4f-8dab-d997de3d9125">314.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtNS0xLTEtMA_503cfd3c-5ab3-46ab-8fff-4986ca6f8072">37.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtNy0xLTEtOTMwNQ_9d2a515a-92c0-403f-b913-bc946861529b">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtNy0xLTEtMA_ba6b69fe-5c3c-4302-b372-75e0a30210ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtOS0xLTEtMA_b1096143-c6ca-4fa1-a8b0-dc367e125198">916.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtMS0xLTEtMA_adc89ee8-488e-44b9-abfc-e8a9e484731e">243.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtMy0xLTEtMA_07c7b1e4-4694-4cc6-8b54-fafb4ac3c151">144.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtNS0xLTEtMA_a0091084-3bb4-48d6-a794-33569060685a">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtNy0xLTEtOTMwNQ_75adc21c-3e11-4ab4-8447-e35d6f3b3f1d">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtNy0xLTEtMA_0a1c46db-04b2-4a48-aab6-39597218ab8f">125.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtOS0xLTEtMA_6d1784db-bde6-4195-8e27-35a731529a14">526.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtMS0xLTEtMA_c7f93e45-40c4-476f-9b1c-8cf82d4502e0">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtMy0xLTEtMA_3d496489-02cf-4931-8433-c0bdaefd9f93">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtNS0xLTEtMA_a3bddcdf-2534-48f5-9d78-3c1bc8f8ab29">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtNy0xLTEtOTMwNQ_c25ab525-51dd-438c-8014-597cdb23418c">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtNy0xLTEtMA_c3eace47-0908-4bcc-95bf-fff0d9224df7">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtOS0xLTEtMA_7032cd54-8b51-4ee6-89ad-ed11f6c86229">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctMS0xLTEtMA_cf5b2f53-94ba-4dc3-93db-f1b56645815a">810.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctMy0xLTEtMA_2df4eaf7-7210-4b8b-a7f4-1b8005f373e3">460.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctNS0xLTEtMA_0b76fa36-e319-4e50-a9cf-29dbe371d79b">46.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctNy0xLTEtOTMwNQ_1df9dcc9-b480-477a-83c2-20ec2258323d">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctNy0xLTEtMA_fb7c9492-80dc-45e0-af4e-95a1e6e31f4e">141.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtMS0xLTEtMA_40608b5e-93a8-45b9-8e3f-afaf0ac7b1d1">213.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtMy0xLTEtMA_9865a073-4140-4810-9336-12be0b859e79">132.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtNS0xLTEtMA_3fe6b376-c9fb-4bc8-9a32-94648f2008e6">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtNy0xLTEtOTMwNQ_e2ab5a6f-a44b-4b6e-89cd-1e4c3450e9d2">3.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtNy0xLTEtMA_70ee041a-3167-44dc-9310-fc1e4a844064">141.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Period Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItMS0xLTEtMA_7434320f-ef34-4157-a3f5-83ea73168a41">919.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItMy0xLTEtMA_23ce2ee7-9c58-420c-9cd7-4e87678fea6b">546.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930" decimals="-5" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItNS0xLTEtMA_3190f3ee-7087-4444-bcd3-d69dbad1292a">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItNy0xLTEtOTMwNw_30cf431d-e94f-4d02-9dbf-1f5ae6e8854e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItNy0xLTEtMA_dc83f70c-8eb8-4cf9-9784-da82e3cbab68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItOS0xLTEtMA_8d1548ad-1e66-413f-a126-4544e8bdcaad">1,520.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtMS0xLTEtMA_8d5af6f2-a89d-455d-aef1-bfa5150577f0">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtMy0xLTEtMA_bd64a939-d677-46f2-bf66-4bf67dcfe5fc">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtNS0xLTEtMA_be3f42e3-4144-4695-ac78-8744810904c7">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtNy0xLTEtOTMwNw_04cc6f6a-3639-4712-83d2-758969f4b7da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtNy0xLTEtMA_51634986-e5a8-4e29-8844-9f1d4ac3cdec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtOS0xLTEtMA_443a78da-b343-446a-bb40-5f40f4d2b690">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtMS0xLTEtMA_dcfb9777-4d38-4474-977e-8b141e19c3f1">543.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtMy0xLTEtMA_37f843d8-7e70-4b63-b444-03e7254236fe">293.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtNS0xLTEtMA_c628e41c-4e8f-4198-ac82-625667c1cebb">41.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtNy0xLTEtOTMwNw_1a96fc49-4027-452f-816b-dcbd653aabfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtNy0xLTEtMA_4aa1846e-f3cd-4f55-b844-5d65bf68866e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtOS0xLTEtMA_a76612c4-ceba-48c4-bfdc-6ea002e9a327">878.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtMS0xLTEtMA_d42c136a-8e4c-49d2-a8a5-6cb7cd710ff9">226.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtMy0xLTEtMA_ec0b9ea4-fd90-41b2-8d91-dee4960724ae">127.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtNS0xLTEtMA_f71e743b-4eb8-466d-99cd-14fe9e9fb3ea">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtNy0xLTEtOTMwNw_62938abe-4179-45da-8b24-45f08ea2a56c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtNy0xLTEtMA_159a7427-a836-4833-9ffb-81d0019b24fa">129.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtOS0xLTEtMA_7fb8cc25-93c9-4d4d-9003-a56b48b262e8">492.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtMS0xLTEtMA_2543de86-af7b-4de4-b592-fc8d4a7e770a">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtMy0xLTEtMA_4c7c9c46-324f-4f32-81f1-768221fecc56">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtNS0xLTEtMA_812a37b2-03c0-44ae-83df-be44a69a9616">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtNy0xLTEtOTMwNw_9c22a2a3-ad3c-496a-899c-e4b7af1fda51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtNy0xLTEtMA_e0499fc5-9e15-4146-9125-2a26bfb65c31">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctMS0xLTEtMA_35b3d517-3b1a-458f-8a13-b6d0fff87476">773.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctMy0xLTEtMA_57566fdc-32c0-4e61-834b-54e227896d3b">422.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctNS0xLTEtMA_5d9fd114-14af-44e6-8120-02cdeb98db35">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctNy0xLTEtOTMwNw_df0d7861-52fc-4175-9f2a-39465855a4f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930" decimals="-5" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctNy0xLTEtMA_4e0cc100-f80d-4773-8bd5-e6126c8bbc68">144.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctOS0xLTEtMA_bb32e717-1aa4-433c-99f3-0887befbddad">1,391.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtMS0xLTEtMA_f484f903-f811-486c-927f-40788cdd4cd8">164.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtMy0xLTEtMA_88940d56-69c9-483e-a847-dd95b13b44eb">132.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtNS0xLTEtMA_ed8cdce2-09b6-4784-8bf8-037ff7dd56d1">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtNy0xLTEtOTMwNw_be34f313-7ff9-4a62-ae0c-d3645fd8d672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtNy0xLTEtMA_99be5e12-35df-483d-87b4-02a73a735e80">144.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtOS0xLTEtMA_a80ea3d5-dd37-45dd-a2b9-b6b1b5870cec">157.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_88"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMEDISYS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTY0OTI2NzQ0MzQ0Nw_5a3d9aa9-1a51-4b00-bde1-b1a5686a728f" continuedAt="i6f364ac1c60b4e799bbe87588d2a6438" escape="true">CAPITAL STOCK AND SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i6f364ac1c60b4e799bbe87588d2a6438"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised <ix:nonFraction unitRef="shares" contextRef="i01d5e8892fb243b4b865bd7b871d16be_D20200810-20200810" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTUwMw_fbf69654-df16-4992-8eaf-b5eae0bd5198">500,000</ix:nonFraction> stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. In connection with the exercise, Mr. Kusserow surrendered <ix:nonFraction unitRef="shares" contextRef="i01d5e8892fb243b4b865bd7b871d16be_D20200810-20200810" decimals="INF" format="ixt:num-dot-decimal" name="amed:SurrenderedSharesInShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTUxMg_5b02246a-c557-4e87-ade5-0d57da6cb409">231,683</ix:nonFraction> shares of common stock to us to satisfy tax withholding and strike price obligations and elected to hold the net <ix:nonFraction unitRef="shares" contextRef="i01d5e8892fb243b4b865bd7b871d16be_D20200810-20200810" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTUyMQ_61f90103-6ab0-43ff-a30a-29174cd46f03">268,317</ix:nonFraction> shares issued to him. The surrendered shares are classified as treasury shares. This transaction resulted in a cash outflow of $<ix:nonFraction unitRef="usd" contextRef="ib1427f68924a44119e86ad505b770163_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTUzMA_ccc67fa0-a09b-4847-9778-6fb5438616e5">40.4</ix:nonFraction>&#160;million, reflected within financing activities in our condensed consolidated statement of cashflows, related to the remittance of tax withholding obligations on Mr. Kusserow's behalf. In addition, Mr. Kusserow's stock option exercise resulted in a $<ix:nonFraction unitRef="usd" contextRef="ib1427f68924a44119e86ad505b770163_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTU0NQ_b24218a9-b235-43c0-8cb4-4cdca64cfb10">24.0</ix:nonFraction>&#160;million income tax benefit that was recorded in our condensed consolidated statement of operations during the three-month period ended September 30, 2020. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for GAAP purposes. If the tax deduction exceeds the cumulative GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations.</span></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="id60bf3839b914d279c418e71b98c550c_76"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTU5OQ_f439f90e-f26c-4c18-8c73-db153b0e3acd" continuedAt="i06ca083f7f5341e39dafa951b0293a3f" escape="true">SHARE REPURCHASES </ix:nonNumeric></span></div><ix:continuation id="i06ca083f7f5341e39dafa951b0293a3f" continuedAt="ifc6c32cc52e145a092149f1f4ad68275"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i3f23866255254c1e86623c880ffabe48_I20201223" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTk1_4621315d-e9e8-4d21-8e63-7431cc094e9a">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="i2381e983ae6a4cb799879628f17fd769_D20201223-20211231" format="ixt:date-monthname-day-year-en" name="us-gaap:StockRepurchaseProgramExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMjM4_201dcf19-4a4d-4751-9851-87b377a2e17d">December 31, 2021</ix:nonNumeric> (the "Existing Share Repurchase Program").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Existing Share Repurchase program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased <ix:nonFraction unitRef="shares" contextRef="i85212f2db10a46fd81194263d32551bd_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfODU2_9bba8471-014b-4eb1-ad66-a25ecc23f36a">54,609</ix:nonFraction> shares of our common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i85212f2db10a46fd81194263d32551bd_D20210701-20210930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfOTE3_e94e46af-79a1-41d7-8361-c0eba348d319">197.84</ix:nonFraction> per share and a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i85212f2db10a46fd81194263d32551bd_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfOTY0_62e28308-3239-4123-8ddc-b6c2d6034ac5">11</ix:nonFraction>&#160;million during the three-month period ended September 30, 2021 and <ix:nonFraction unitRef="shares" contextRef="icea953f101c64f9ea9eb5be5f0f999ff_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTAyMQ_d7c56823-279c-478b-ab59-960fd9968f87">351,714</ix:nonFraction> shares of our common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icea953f101c64f9ea9eb5be5f0f999ff_D20210101-20210930" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTA4Mg_67a391fc-db15-4d84-bcaf-0593597e8483">241.30</ix:nonFraction> per share and a total cost of approximately $<ix:nonFraction unitRef="usd" contextRef="icea953f101c64f9ea9eb5be5f0f999ff_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTEyOQ_daef9df5-757d-42fa-9a71-4c3315e643e1">85</ix:nonFraction>&#160;million during the nine-month period ended September 30, 2021. The repurchased shares are classified as treasury shares. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="if904a87006f24f8cbd91c764ae5909fc_I20210802" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTA5OTUxMTYyOTg3OA_1579b931-8081-4164-bc9f-b0f944f54ba8">100</ix:nonFraction>&#160;million of our outstanding common stock through <ix:nonNumeric contextRef="i878d81e55fc54bb5a76221d8c7ce04e9_D20210802-20221231" format="ixt:date-monthname-day-year-en" name="us-gaap:StockRepurchaseProgramExpirationDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTA5OTUxMTYyOTkyMg_559b9368-f3c9-404b-8afa-8ca4d2c38a35">December 31, 2022</ix:nonNumeric>, to commence upon the completion of the Company's Existing Share Repurchase Program (the "New Share Repurchase Program"). </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifc6c32cc52e145a092149f1f4ad68275">Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.</ix:continuation> </span></div><div id="id60bf3839b914d279c418e71b98c550c_79"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfNTQ0_cb4029e5-19b7-43c6-bc92-1ae80c0501f4" continuedAt="i94e26670fe5d46018fa6d0fc916d385b" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i94e26670fe5d46018fa6d0fc916d385b">We have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i12c67fa7efe64016ba829366460e9a3f_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfMjA2_63b6a308-ed14-49ea-9fe4-e9f10529bdc9">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib5985078fbcb439bbdcb8ec2bcdb0330_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfMjEz_5b3e11dc-1744-42b1-a9ad-4d56704da951">4.1</ix:nonFraction>&#160;million during the three and nine-month periods ended September&#160;30, 2021, respectively, and approximately $<ix:nonFraction unitRef="usd" contextRef="i28c5a54e2c3f42ef8543c32325f45fa2_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfMjk3_255604e1-5841-4ac2-b239-22ab7667aed1">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7137075508bc4a80bdbc1291c467c563_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfMzA0_701b860a-6b46-45ca-bcd9-646df51b5ebf">2.2</ix:nonFraction>&#160;million during the three and nine-month periods ended September 30, 2020, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</ix:continuation></span></div><div id="id60bf3839b914d279c418e71b98c550c_85"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184NS9mcmFnOmFmZTk5ZjEwYWU5MTQ0M2RhMDA4MWYzMjVhZDIzMGE0L3RleHRyZWdpb246YWZlOTlmMTBhZTkxNDQzZGEwMDgxZjMyNWFkMjMwYTRfNDMzNA_09c3f5e6-dc28-4f95-bd64-9567afdf7d34" continuedAt="i5c288ea4724b4fbcaa601e8c46296a2c" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c288ea4724b4fbcaa601e8c46296a2c">On October 18, 2021, we acquired the regulatory assets of a home health provider in North Carolina for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i6c26203c52124e6db31cba165f90a5ba_D20211018-20211018" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184NS9mcmFnOmFmZTk5ZjEwYWU5MTQ0M2RhMDA4MWYzMjVhZDIzMGE0L3RleHRyZWdpb246YWZlOTlmMTBhZTkxNDQzZGEwMDgxZjMyNWFkMjMwYTRfMTA5OTUxMTYzNjgyNg_9e7b13f3-627a-4a28-8492-617ea58fb537">4.5</ix:nonFraction>&#160;million.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations and financial condition for the three and nine-month periods ended September&#160;30, 2021. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included herein, and the consolidated financial statements and notes and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 25, 2021 (the &#8220;Form 10-K&#8221;), which are incorporated herein by this reference. Historical results that appear in the condensed consolidated financial statements should not be interpreted as being indicative of future operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise provided, &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Amedisys, Inc. and our consolidated subsidiaries.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a provider of high-quality in-home healthcare and related services to the chronic, co-morbid, aging American population, with approximately 75% of our net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2021 and approximately 76% and 75% of our net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Our hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa Health ("Contessa") during the three-month period ended September 30, 2021, delivers the essential elements of inpatient hospital and skilled nursing facility ("SNF") care to patients in their homes. As of September&#160;30, 2021, we owned and operated 328 Medicare-certified home health care centers, 177 Medicare-certified hospice care centers, 14 personal-care care centers and 8 high acuity care joint ventures in 38 states within the United States and the District of Columbia. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Care Centers Summary (Includes Unconsolidated Joint Ventures)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions/Startups/Denovos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closed/Consolidated</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governmental Inquiries and Investigations and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 &#8211; Commitments and Contingencies to our condensed consolidated financial statements for a discussion of and updates regarding legal proceedings and investigations we are involved in. No assurances can be given as to the timing or outcome of these items. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Hospice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 31, 2020, the Centers for Medicare and Medicaid Services ("CMS") issued a final rule to update hospice payment rates and the wage index for fiscal year 2021, effective for services provided beginning October 1, 2020. CMS estimated hospices serving Medicare beneficiaries would see a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2.4% increase in payments. This increase was the result of a 2.4% market basket adjustment as required under the Patient Protection and Affordable Health Care Act and the Health Care and Education Reconciliation Act (collectively, "PPACA"). The rule also changed the hospice wage index by adopting the most recent Office of Management and Budget statistical area delineations with a five percent cap on wage index decreases. Finally, CMS increased the aggregate cap amount by 2.4% to $30,684. Based on our analysis of the final rule, we estimated that our impact would be in line with the 2.4% increase.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 29, 2021, CMS issued the final rule to update hospice payment rates and the wage index for fiscal year 2022, effective for services provided beginning October 1, 2021. CMS estimates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">hospices serving Medicare beneficiaries will see a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2.0% increase in payments. This increase is the result of a 2.7% market basket adjustment as required under PPACA less a 0.7% productivity adjustment. Additionally, CMS increased the aggregate cap amount by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2.0% to $31,298. The final rule also rebases the labor shares for all four levels of care, includes updates to the hospice conditions of participation ("COPs"), which make permanent certain flexibilities allowed during the COVID-19 public health emergency, and finalizes changes to the Hospice Quality Reporting Program. Based on our analysis of the final rule, we expect our impact to be in line with the 2.0% increase. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Home Health</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 29, 2020, CMS issued the Home Health Final Rule for Medicare home health providers for calendar year 2021. CMS estimated that the final rule would result in a 1.9% increase in payments to home health providers. The increase was the result of a 2.0% market basket adjustment reduced by 0.1% for the rural add-on. Based on our analysis of the final rule, we estimated that our impact would be in line with th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e 1.9% increase. Ad</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ditionally, CMS made permanent the telehealth flexibilities that were announced in the Interim Final Rule (Emergency Rule) for COVID-19 in March 2020. These flexibilities allow home health agencies to provide certain care via telehealth if it is clinically appropriate and included in the plan of care; however, these visits still do not count as visits for purposes of patient eligibility or payment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On November 2, 2021, CMS issued the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Home Health Final Rule for Medicare home health providers for calendar year 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. CMS estimates that the final rule will result in a 3.2% increase in payments to home health providers. This increase is the result of a 2.6% payment update (3.1% market basket adjustment less a 0.5% productivity adjustment) plus a 0.7% fixed-dollar loss ratio adjustment, reduced by 0.1% for the rural add-on. The proposed rule also provides for the expansion of the Home Health Value-Based Purchasing ("HHVBP") model to all 50 states beginning January 1, 2023 with calendar year 2023 being the first performance year and calendar year 2025 being the first payment year with a proposed maximum payment adjustment, up or down, of 5%. We are currently evaluating the final rule's impact on our home health operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Coronavirus Pandemic ("COVID-19")</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and financial performance continue to be impacted by COVID-19. The financial impacts of COVID-19 are discussed in further detail under "Results of Operations" below. While we currently believe that we have a reasonable view of operations, the uncertainty created by COVID-19 could alter our outlook of the pandemic's impact on our consolidated financial condition, results of operations or cash flows. The following factors could potentially impact our performance: the increase or decrease in the number of COVID-19 cases nationwide, the severity and impacts of new variants of the virus, uncertainty regarding vaccine utilization rates and efficacy, staffing shortages due to current and proposed federal, state and local vaccine mandates, the utilization of elective procedures, the return of patient confidence to enter a hospital or a doctor's office, the ability to have access to our patients in their homes and in facilities, supply chain disruption and our ability to find suitable alternative products at reasonable prices, cost normalization around personal protective equipment ("PPE") and any future or prolonged shelter-in-place orders and other federal, state and local requirements. Potential impacts of COVID-19 on our results include lower revenue; higher salary and wage expense related to quarantine pay, contract clinicians and training; and increased supply costs related to supply chain constraints, PPE and COVID-19 testing. The impacts to net service revenue may consist of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower volumes due to interruption of the operations of our referral sources, patients' unwillingness to accept services and restrictions on access to facilities for hospice services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower reimbursement due to missed visits resulting in an increase in low utilization payment adjustments ("LUPAs") and lost billing periods; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lower hospice average daily census due to a decline in our average length of stay.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the bipartisan Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was signed into legislation. The CARES Act provided for the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$175 billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare. Consistent with the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we only utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred is reflected in other operating income within our condensed consolidated statements of operations.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. We estimate that the suspension of sequestration will increase our 2021 net service revenue by approximately $36&#160;million.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payments is due on December 31, 2021 with the remaining amounts due on December 31, 2022. During 2020, we deferred approximately $55 million of social security tax; approximately $28 million is reflected in each of payroll and employee benefits and other long-term obligations within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The temporary suspension of Medicare patient coverage criteria and documentation and care requirements and the expansion of providing home health and hospice care to patients via telehealth.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability for non-physician practitioners to certify for home health, order home health services, establish and review plans of care and certify and recertify eligibility.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The well-being of our employees has been one of our top priorities during the pandemic. We have taken the following steps to support our employees: implemented paid leave during any required quarantine periods; awarded bonuses to our clinicians and caregivers who have seen patients during the pandemic; completed an early cash pay-out of employee paid-time-off; instituted work-from-home arrangements for our corporate and administrative support employees; allowed employees to temporarily suspend any 401(k) plan loan deductions and offered employees the option of making a withdrawal from their 401(k) plan for coronavirus-related distributions without incurring the additional 10% early withdrawal penalty; expanded access to telehealth services to all employees; provided access to COVID-19 self-test kits to all employees and created a COVID-19 Resource Center, available 24 hours a day, seven days a week for employees to access educational materials, safety documents, policies, clinical protocols and operational metrics. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The safety of our clinicians and patients has also been a focus, and as a result, we have made the following business changes: developed clinical protocols for COVID-19 testing, proper usage of PPE, caring for COVID-positive patients and maintaining safety measures in our care centers; researched each state's vaccination plan to develop a state by state protocol to work with local health departments and other health systems to obtain vaccine appointments for our clinical staff; implemented software enabling us to track staff that have been vaccinated; procured PPE and created a centralized distribution center for all critical PPE, allowing us to flex our supplies on a care center by care center basis, based on need and demand.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three-Month Period Ended September&#160;30, 2021 Compared to the Three-Month Period Ended September&#160;30, 2020 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">46.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(16.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to see the impact of COVID-19 in our third quarter 2021 operating results as the Delta variant resulted in an increase in clinician quarantines, testing and our hospice discharge rate. On a consolidated basis, our operating income decreased $7 million on a $9 million increase in net service revenue. The year-over-year decrease in operating income is primarily due to the acquisition of Contessa on August 1, 2021, a decrease in other operating income due to the expiration of the CARES Act PRF funds, a decline in our hospice average daily census, which is the main driver of hospice revenue, and an increase in our cost of service resulting from increases in both home health cost per visit and hospice cost of service per day which are described in more detail below. Partially offsetting these items, our results were positively impacted by rate increases, improvements in clinician utilization and discipline mix and a decrease in our other operating expenses. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results for the three-month period ended September 30, 2021 include the acquisition of Contessa on August 1, 2021, which contributed $2 million in revenue and an operating loss of $4 million, which is inclusive of less than $1 million in intangibles amortization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, for our wholly-owned subsidiaries, we utilized the CARES Act PRF funds to cover COVID-19 expenses incurred by our home health and hospice segments through June 30, 2021. Our personal care segment received funds from the Mass Home Care ASAP COVID-19 Provider Sustainability Program during 2020; we used these funds to cover COVID-19 expenses incurred in 2020 as well. We recorded income related to both of these programs in other operating income within our condensed consolidated statements of operations. We did not have any government grant funds available to offset the COVID-19 costs incurred during the three-month period ended September 30, 2021, which totaled $4 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results reflect a $1 million decrease in our other operating expenses compared to prior year. Excluding the Contessa acquisition, our other operating expenses decreased 3% due to lower incentive compensation accruals, lower employer payroll taxes associated with employee stock option exercises and lower acquisition and integration costs partially offset by a slowdown in prior year spend related to COVID-19, the addition of resources to support growth, planned wage increases and higher recruiting fees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Home Health Segment</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our home health segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (2) (6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (3):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications (6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,919&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (6)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,651&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare completed episodes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Medicare revenue per completed episode (4)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare visits per completed episode (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visiting Clinician Cost per Visit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Manager Cost per Visit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cost per Visit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.09&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total volume includes all admissions and recertifications.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Total includes acquisitions, start-ups and denovos.</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the transition to PDGM effective January 1, 2020 and the suspension of sequestration effective May 1, 2020. </span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Prior year amounts have been recast to conform to the current year calculation.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $4 million on a $13 million increase in net service revenue. Year over year increases in volumes and Medicare revenue per episode as well as improvement in our operating performance driven by improvements in clinician utilization and discipline mix were offset by a decrease in other operating income due to the expiration of the CARES Act PRF funds, an increase in our total cost per visit and an increase in our other operating expenses which are described in more detail below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $13 million (4%) on a 1% increase in volume and a 3% increase in Medicare revenue per episode. The volume growth was driven by a 1% increase in admissions and a 2% increase in recertifications. The increase in Medicare revenue per episode is the result of a 1.9% increase in reimbursement, an increase in the functional impairment of our patients and a change in the source/timing and geographic dispersion of our patients. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $3 million during the three-month period ended September 30, 2020. We incurred COVID-19 related costs totaling $2 million during the three-month period ended September 30, 2021; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, premiums paid to contract clinicians in COVID-19 high demand areas, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists of costs associated with direct clinician care in the homes of our patients as well as the cost of clinical managers who monitor the overall delivery of care. Overall, our total cost of service increased 6% primarily due to a 6% increase in our total cost per visit partially offset by a 1% decrease in total visits. The 6% increase in our total cost per visit is primarily due to planned wage increases, higher costs associated with the utilization of contractors to supplement our staffing levels, increases in new hire pay and higher health insurance costs. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $4 million primarily due to a slowdown in prior year spend related to COVID-19, planned wage increases, the addition of resources to support volume growth, increased costs associated with insurance and legal settlements and higher recruiting fees partially offset by lower incentive compensation costs. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hospice Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our hospice segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service per day</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average discharge length of stay</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily  census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total includes acquisitions, start-ups and denovos.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $9 million on a $2 million decrease in net service revenue. The year-over-year decreases are primarily due to a decline in our average daily census, an increase in our cost of service per day, a decrease in other operating income due to the expiration of the CARES Act PRF funds and an increase in our other operating expenses. These items were partially offset by the increase in reimbursement effective October 1, 2020.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue decreased $2&#160;million primarily due to a decline in our average daily census, which is the main driver of hospice revenue, partially offset by the increase in reimbursement effective October 1, 2020. Our same store average daily census was down 5% year over year primarily due to a decline in our length of stay resulting from a delay in the timing of patients coming onto service and an increase in the discharge rate of our patients. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $2 million during the three-month period ended September 30, 2020. We incurred COVID-19 related costs totaling $1 million during the three-month period ended September 30, 2021; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service increased 3% primarily due to a 9% increase in our cost of service per day partially offset by a 5% decline in our average daily census. The increase in our cost of service per day is due to planned wage increases, higher costs associated with the utilization of contractors to supplement our staffing levels, increased costs to retain employees, higher transportation costs, higher respite utilization and an increase in visits performed by our hourly hospice aides and licensed practical nurses due to COVID-19 access restrictions being eased. In addition, our hospice cost of service per day was impacted by the decline in our average daily census; a portion of the cost associated with our salaried clinicians is fixed, so our cost of service metric will increase as our average daily census declines.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $2&#160;million primarily due to a slowdown in prior year spend related to COVID-19, planned wage increases, the addition of resources to support volume growth and higher recruiting fees partially offset by lower incentive compensation costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Personal Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our personal care segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billable hours</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clients served</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shifts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per hour</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per shift</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hours per shift</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment decreased $1 million on a $3 million decrease in net service revenue. The decrease in net service revenue is due to the impact of COVID-19 and staffing shortages. The revenue impact has been partially mitigated by a reduction in costs as most of our personal care employees are paid on an hourly basis. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">High Acuity Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our high acuity care segment results of operations: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct medical loss ratio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market penetration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient satisfaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our high acuity care segment generated revenue totaling $2 million and an operating loss of $4 million. We expect improvement in our operating income as we leverage our operating structure through growth in current and future joint ventures.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide home recovery care services for high acuity patients on either a full risk or limited risk basis, each with different reimbursement arrangements. Full risk admissions are admissions for which we assume the risk for all related healthcare services during a 30-day or 60-day episodic period in exchange for a contracted bundled rate payment based upon the assigned diagnosis related group ("DRG"). Limited risk admissions are admissions for which we assume the risk for certain healthcare services during a shorter acute phase period (equivalent to an inpatient hospital stay) in exchange for a contracted per diem payment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter, we generated net service revenue of $2 million resulting from 46 full risk admissions and 188 limited risk admissions across our seven active joint ventures with health system partners. Revenue per episode was comprised of $9,191 for full risk episodes and $5,524 for limited risk episodes. The significant utilization of limited risk episodes was primarily due to the impact of heavy COVID-19 surges across certain of our joint venture markets and the resulting patient acuity which necessitated that a portion of our patients' inpatient stays occur within the inpatient hospital facilities rather than in the home.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, whether such care was provided on the day of program admission, in the patients&#8217; homes or via telehealth. Our cost of service was favorably impacted by the significant utilization of limited risk episodes, which exclude certain high-cost components of full risk episode spend such as emergency room costs and inpatient hospitalization costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses primarily consist of salaries and benefits. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care programs on a national scale. We have employees at both the local market level and at our corporate offices, including a virtual care unit that enables us to provide monitoring services and virtual patient rounding visits via telehealth.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our corporate results of operations:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate expenses consist of costs related to our executive management and corporate and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate other operating expenses decreased approximately $9 million during the three-month period ended September 30, 2021 due to lower incentive compensation costs, lower employer payroll taxes associated with employee stock option exercises, lower costs associated with insurance and legal settlements and lower acquisition and integration costs partially offset by planned wage increases and additional functional support.</span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nine-Month Period Ended September&#160;30, 2021 Compared to the Nine-Month Period Ended September&#160;30, 2020 </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consolidated</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our consolidated results of operations (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">% of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Amedisys, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, our operating income increased approximately $47 million on a revenue increase of $134 million. The year-over-year increases are primarily related to the impact of COVID-19 on prior year&#8217;s results, the acquisition of AseraCare on June 1, 2020, rate increases, the suspension of sequestration effective May 1, 2020, severance incurred in prior year related to reductions in staffing primarily within our home health segment, improvements in clinician utilization and discipline mix and the closure of our hospice U.S. Department of Justice ("DOJ") matters (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information). Partially offsetting these items, we experienced a decline in our same store hospice average daily census, which is the main driver of hospice revenue, an increase in our revenue adjustments, an increase in our cost of service resulting from increases in both our home health cost per visit and hospice cost of service per day and an increase in other operating expenses. Additionally, our results were impacted by the acquisition of Contessa on August 1, 2021, which contributed $2 million in revenue and an operating loss of $4 million, which is inclusive of less than $1 million in intangibles amortization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AseraCare acquisition, which closed on June 1, 2020, includes nine months of acquired operations in the current year compared to four months in the prior year. For the nine-month period ended September 30, 2021, this acquisition contributed $75 million in revenue and operating income of $0.1 million, which is inclusive of $1 million in acquisition and integration costs and $6 million in intangibles amortization. For the nine-month period ended September 30, 2020, the AseraCare acquisition contributed $37 million in revenue and an operating loss of $7 million, which is inclusive of $7 million in acquisition and integration costs and $3 million in intangibles amortization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, for our wholly-owned subsidiaries, we utilized the CARES Act PRF funds and Mass Home Care ASAP COVID-19 Provider Sustainability Program funds to cover COVID-19 expenses incurred through June 30, 2021. We recorded income related to both of these programs, which totaled $13 million and $28 million, to other operating income within our condensed consolidated statements of operations during the nine-month periods ended September 30, 2021 and 2020, respectively. Due to the expiration of the CARES Act PRF funds on June 30, 2021, we were not able to recognize any operating income during the three-month period ended September 30, 2021 to offset the $4 million of COVID-19 costs incurred during the quarter.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results reflect an increase in our other operating expenses compared to prior year. Our 2021 other operating expenses include two months of the acquired operations of Contessa and nine months of the acquired operations of AseraCare compared to four months in the prior year, both of which have resulted in a year over year increase totaling $11 million. Excluding the Contessa and AseraCare acquisitions, our other operating expenses increased 5% due to a slowdown in prior year spend related to COVID-19, the addition of resources to support growth, planned wage increases, higher health insurance costs, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investments related to PDGM, higher recruiting costs, increased costs associated with insurance and legal settlements,  increased information technology fees and higher acquisition and integration costs partially offset by lower incentive compensation costs, lower employer payroll taxes associated with employee stock option exercises, lower costs directly attributable to COVID-19 and higher gains on the sale of fleet vehicles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income for the nine-month period ended September 30, 2021 includes a $31 million gain related to our investment in Medalogix (see Note 1 - Nature of Operations, Consolidation and Presentation of Financial Statements to our condensed consolidated financial statements for additional information).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Home Health Segment</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our home health segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (2)(6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (3):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recertifications (6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total volume (6)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare completed episodes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Medicare revenue per completed episode (4)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare visits per completed episode (5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visiting Clinician Cost per Visit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Manager Cost per Visit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Cost per Visit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Visits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,553,423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,563,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Total volume includes all admissions and recertifications.</span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Total includes acquisitions, start-ups and denovos.</span></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode reflects the transition to PDGM effective January 1, 2020 and the suspension of sequestration effective May 1, 2020. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.</span></div><div style="padding-left:40.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Prior year amounts have been recast to conform to the current year calculation.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income increased $49 million on a $97 million increase in net service revenue. The year over year increases are primarily related to the impact of COVID-19 on prior year's results, an increase in our Medicare revenue per episode, which is described in more detail below, severance incurred in prior year related to reductions in staffing and significant improvement in our operating performance driven by improvements in our clinician utilization and discipline mix, both of which have contributed to year over year gross margin expansion. These items were partially offset by an increase in our total cost per visit, a decrease in other operating income due to the expiration of the CARES Act PRF funds and an increase in our other operating expenses.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $97 million (11%) on a 6% increase in total volume and a 5% increase in Medicare revenue per episode. The volume growth was driven by an 8% increase in admissions and a 3% increase in recertification volume. Our admissions were significantly impacted by COVID-19 in prior year. The increase in Medicare revenue per episode is the result of a 1.9% increase in reimbursement, a full year of the 2.0% benefit related to the suspension of sequestration (effective May 1, 2020), an increase in the functional impairment of our patients and a change in the source/timing and geographic dispersion of our patients. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF, which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $7 million and $18 million during the nine-month periods ended September 30, 2021 and 2020, respectively. We incurred COVID-19 related costs totaling $2 million during the three-month period ended September 30, 2021; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, bonuses paid to our clinicians, premiums paid to contract clinicians in COVID-19 high demand areas, clinician training, quarantine pay and COVID-19 testing. The COVID-19 costs incurred during the nine-month period ended September 30, 2021 totaling $9 million have been recorded to cost of service within our condensed consolidated statements of operations. Of the $18 million of COVID-19 costs incurred in the prior year, $17 million was recorded to cost of service and $1 million was recorded to other operating expenses within our condensed consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total cost of service increased 4% primarily due to a 4% increase in our total cost per visit. Our total visits were relatively flat year over year despite a 6% increase in total volume primarily due to improvements in clinician utilization, as evidenced by a decline of 1.2 visits per completed episode year over year. The 4% increase in our total cost per visit is due to planned wage increases, higher costs associated with the utilization of contractors to supplement our staffing levels, increases in new hire pay, inclement weather pay and higher health insurance costs partially offset by a decrease in COVID-19 costs and severance incurred in prior year in connection with a reduction in staffing.  </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased approximately $17 million primarily due to planned wage increases, the addition of resources to support volume growth, higher health insurance costs, higher recruiting fees, investments related to PDGM and increased costs associated with insurance and legal settlements. These increases were partially offset by lower incentive compensation accruals and lower costs directly attributable to COVID-19 in the current year.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hospice Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our hospice segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Store Growth (1):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total (2):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average daily census</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per day, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service per day</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average discharge length of stay</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)  Total includes acquisitions, start-ups and denovos.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results for the nine-month period ended September 30, 2021 include the results of the acquisition of AseraCare on June 1, 2020 (44 hospice care centers). Acquisitions are included in our condensed consolidated financial statements from their respective acquisition dates. As a result, our hospice segment operating results for 2021 and 2020 are not fully comparable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our operating income decreased $1 million on a $41&#160;million increase in net service revenue. The year over year decrease in operating income is primarily due to a decline in our same store average daily census, an increase in our revenue adjustments, an increase in our cost of service per day, a decrease in other operating income due to the expiration of the CARES Act PRF funds and an increase in our other operating expenses. These items were partially offset by changes in reimbursement, the suspension of sequestration effective May 1, 2020, the acquisition of AseraCare which resulted in increases to net service revenue and operating income totaling $38 million and $5 million, respectively, and the reversal of a $7 million accrual previously recorded in connection with settlement discussions with the DOJ; we received notice during the second quarter of 2021 that the DOJ has closed its investigation (see Note 6 - Commitments and Contingencies to our condensed consolidated financial statements for additional information).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net service revenue increased $41&#160;million. Our results include nine months of the acquired operations of AseraCare in the current year compared to four months in the prior year which resulted in an increase to net service revenue of $38 million. Additionally, revenue was positively impacted by the increase in reimbursement effective October 1, 2020 ($12 million), the suspension of sequestration effective May 1, 2020 ($4 million) and the reversal of a $7 million accrual as mentioned above. These items were partially offset by a 4% decline in our same store average daily census, which is the main driver of hospice revenue, and an increase in revenue adjustments. Our same store average daily census was down year over year primarily due to a decline in our length of stay during the fourth quarter of 2020 resulting from a delay in the timing of patients coming onto service and an increase in the discharge rate of our patients. This lower length of stay resulted in a declining census as we exited 2020 and has continued to impact our 2021 results. We are currently seeing discharge rates higher than historical averages.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Income</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating income consists of the recognition of funds received from the CARES Act PRF which were available for use through June 30, 2021. For our wholly-owned subsidiaries, we utilized the funds to cover COVID-19 related costs only and recognized income related to these costs totaling $6 million and $9 million during the nine-month periods ended September 30, 2021 and 2020, respectively. We incurred COVID-19 related costs totaling $1 million during the three-month period ended September 30, 2021; however, we were not able to recognize any income to offset these costs due to the expiration of the CARES Act PRF funds on June 30, 2021. The COVID-19 costs were associated with the purchase of PPE, bonuses paid to our clinicians, clinician training, quarantine pay and COVID-19 testing and have been recorded to cost of service within our condensed consolidated statements of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospice cost of service increased 7%. Excluding our AseraCare acquisition, our cost of service increased less than 1% due to planned wage increases, higher costs associated with the utilization of contractors to supplement our staffing levels, increased costs to retain employees, higher health insurance costs, higher transportation costs and an increase in visits performed by our hourly hospice aides and licensed practical nurses due to access restrictions being eased partially offset by a 4% decline in our same store average daily census and lower COVID-19 costs.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses increased $17&#160;million, approximately $12 million of which is related to our AseraCare acquisition. The remaining increase is due to a slowdown in prior year spend related to COVID-19, the addition of resources to support growth, planned wage increases, higher health insurance costs, increased costs associated with insurance and legal settlements and higher recruiting fees partially offset by lower incentive compensation accruals.</span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Personal Care Segment</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our personal care segment results of operations:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billable hours</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,067,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clients served</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shifts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per hour</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue per shift</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hours per shift</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income related to our personal care segment decreased $1 million on a $5 million decrease in net service revenue. The decrease in net service revenue is due to the impact of COVID-19 and staffing shortages partially offset by rate increases. The impact of COVID-19 has been partially mitigated by a reduction in costs as most of our personal care employees are paid on an hourly basis. </span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="margin-top:18pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">High Acuity Care Segment</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our high acuity care segment results of operations: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Key Statistical Data - Total:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full risk admissions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited risk admissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total admissions</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct medical loss ratio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market penetration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient satisfaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, our high acuity care segment generated revenue totaling $2 million and an operating loss of $4 million. We expect improvement in our operating income as we leverage our operating structure through growth in current and future joint ventures.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Service Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide home recovery care services for high acuity patients on either a full risk or limited risk basis, each with different reimbursement arrangements. Full risk admissions are admissions for which we assume the risk for all related healthcare services during a 30-day or 60-day episodic period in exchange for a contracted bundled rate payment based upon the assigned diagnosis related group ("DRG"). Limited risk admissions are admissions for which we assume the risk for certain healthcare services during a shorter acute phase period (equivalent to an inpatient hospital stay) in exchange for a contracted per diem payment. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated net service revenue of $2 million resulting from 46 full risk admissions and 188 limited risk admissions across our seven active joint ventures with health system partners. Revenue per episode was comprised of $9,191 for full risk episodes and $5,524 for limited risk episodes. The significant utilization of limited risk episodes was primarily due to the impact of heavy COVID-19 surges across certain of our joint venture markets and the resulting patient acuity which necessitated that a portion of our patients' inpatient stays occur within the inpatient hospital facilities rather than in the home.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Service, Excluding Depreciation and Amortization</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of service consists primarily of medical costs associated with direct clinician care provided to our patients during the applicable episode period, whether such care was provided on the day of program admission, in the patients&#8217; homes or via telehealth. Our cost of service was favorably impacted by the significant utilization of limited risk episodes, which exclude certain high-cost components of full risk episode spend such as emergency room costs and inpatient hospitalization costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses primarily consist of salaries and benefits. We have made significant investments to build the clinical, operational and technological infrastructure necessary to support the development and future growth of home recovery care programs on a national scale. We have employees at both the local market level and at our corporate offices, including a virtual care unit that enables us to provide monitoring services and virtual patient rounding visits via telehealth.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Corporate</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our corporate results of operations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(in millions):</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate other operating expenses decreased approximately $4 million during the nine-month period ended September 30, 2021. Other operating expenses associated with our AseraCare acquisition declined $5 million year over year primarily due to higher acquisition and integration costs incurred in prior year. Excluding the AseraCare acquisition, corporate other operating expenses increased $1 million year over year due to planned wage increases, additional functional support, higher health insurance costs, increased information technology fees, increased costs associated with legal settlements and higher acquisition and integration costs; these items were partially offset by lower incentive compensation costs, lower employer payroll taxes associated with employee stock option exercises and higher gains on the sale of fleet vehicles.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (amounts in millions):</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.672%"><tr><td style="width:1.0%"></td><td style="width:70.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.553%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities decreased $39.3&#160;million during the nine-month period ended September&#160;30, 2021 compared to the nine-month period ended September&#160;30, 2020 primarily due to the deferral of payroll taxes and the receipt of CARES Act PRF funds in prior year as well as an increase in days revenue outstanding in the current year partially offset by an increase in operating income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities primarily consists of acquisition activity and the purchase of property and equipment. Cash used in investing activities decreased $15.6&#160;million during the nine-month period ended September&#160;30, 2021 compared to the nine-month period ended September&#160;30, 2020 as a result of a reduction in acquisition spend.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing activities primarily consist of borrowings under our term loan and/or revolving credit facility, repayments of borrowings, the remittance of taxes associated with shares withheld on non-cash compensation, proceeds related to the exercise of stock options and the purchase of stock under either our employee stock purchase plan or our stock repurchase program. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities totaled $131.1 million during the nine-month period ended September&#160;30, 2021 primarily due to borrowings under our Second Amended Credit Agreement to fund acquisitions partially offset by the repurchase of company stock and the repayments of borrowings. Cash provided by financing activities totaled $81.5 million during the nine-month period ended September&#160;30, 2020 due to borrowings under our Amended Credit Agreement to minimize potential cash disruption related to COVID-19. Additionally, during the nine-month period ended September 30, 2020, our financing activities included the receipt of PRF funds which we did not expect to retain totaling $60.0 million partially offset by the remittance of tax withholding obligations related to non-cash compensation and stock option exercises (see Note 8 - Capital Stock and Share-Based Compensation to our condensed consolidated financial statements for additional information).</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, our principal source of liquidity is the collection of our patient accounts receivable, primarily through the Medicare program. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine-month period ended September&#160;30, 2021, we spent $5.2 million in capital expenditures as compared to $3.0 million during the nine-month period ended September&#160;30, 2020. Our capital expenditures for 2021 are expected to be approximately $6.0 million to $8.0&#160;million, excluding the impact of any future acquisitions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the nine-month period ended September 30, 2021, pursuant to our authorized stock repurchase program, we repurchased 351,714 shares of our common stock at a weighted average price of $241.30 per share and a total cost of approximately $85&#160;million. The repurchased shares are classified as treasury shares.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we had $124.4 million in cash and cash equivalents and $519.9 million in availability under our $550.0&#160;million Revolving Credit Facility. Our cash and cash equivalents include $58.5 million of unutilized CARES Act PRF funds, which were repaid to the U.S. Department of Health and Human Services ("HHS") during October 2021 and therefore, are recorded as a liability within our condensed consolidated balance sheet as of September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our operating forecasts and our debt service requirements, we believe we will have sufficient liquidity to fund our operations, capital requirements and debt service requirements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outstanding Patient Accounts Receivable</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable increased $19.5&#160;million from December&#160;31, 2020 primarily due to the elimination of requests for anticipated payment ("RAPs") effective January 1, 2021. Our cash collection as a percentage of revenue was 104% and 106% for the nine-month periods ended September&#160;30, 2021 and 2020, respectively. Our days revenue outstanding at September&#160;30, 2021 was 43.5 days, which is an increase of 3.3 days from December&#160;31, 2020 and a increase of 0.8 days from June 30, 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounts receivable includes unbilled receivables and are aged based upon our initial service date. We monitor unbilled receivables on a care center by care center basis to ensure that all efforts are made to bill claims within timely filing deadlines. Our unbilled patient accounts receivable can be impacted by acquisition activity, probe edits or regulatory changes which result in additional information or procedures needed prior to billing. The timely filing deadline for Medicare is one year from the last day of the billing period and varies by state for Medicaid-reimbursable services and among insurance companies and other private payors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following schedules detail our patient accounts receivable, by payor class, aged based upon initial date of service (amounts in millions, except days revenue outstanding):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:42.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over&#160;365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At September 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.6&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0-90</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">91-180</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">181-365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Over 365</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare patient accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other patient accounts receivable:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patient accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days revenue outstanding (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our calculation of days revenue outstanding is derived by dividing our ending patient accounts receivable at September&#160;30, 2021 and December&#160;31, 2020 by our average daily net patient service revenue for the three-month periods ended September&#160;30, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net proceeds from the $450.0&#160;million Amended Term Loan Facility were used to fund 100% of the Contessa acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.9% and 1.9% for the three and nine-month periods ended September&#160;30, 2021, respectively, and 1.8% and 2.2% for the three and nine-month periods ended September 30, 2020, respectively. Our weighted average interest rate for borrowings under our $450.0&#160;million Amended Term Loan Facility was 1.6% and 1.5% for the three and nine-month periods ended September 30, 2021, respectively, and 1.7% and 2.3% for the three and nine-month periods ended September 30, 2020, respectively.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2021, our consolidated leverage ratio was 1.2, our consolidated interest coverage ratio was 27.5 and we are in compliance with our covenants under the Second Amended Credit Agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of September&#160;30, 2021, our availability under our $550.0&#160;million Revolving Credit Facility was $519.9 million as we have no outstanding borrowings and $30.1 million outstanding in letters of credit.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 5 - Long Term Obligations to our condensed consolidated financial statements for additional details on our outstanding long-term obligations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2021 (the "Existing Share Repurchase Program").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Existing Share Repurchase program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased 54,609 shares of our common stock at a weighted average price of $197.84 per share and a total cost of approximately $11&#160;million during the three-month period ended September 30, 2021 and 351,714 shares of our common stock at a weighted average price of $241.30 per share and a total cost of approximately $85&#160;million during the nine-month period ended September 30, 2021. The repurchased shares are classified as treasury shares. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December&#160;31, 2022, to commence upon the completion of the Company's Existing Share Repurchase Program (the "New Share Repurchase Program").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Inflation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not believe inflation has significantly impacted our results of operations.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part II, Item 7 &#8211; Critical Accounting Estimates and our consolidated financial statements and related notes in Part II, Item 8 of our 2020 Annual Report on Form 10-K, for accounting policies and related estimates we believe are the most critical to understanding our condensed consolidated financial statements, financial condition and results of operations and which require complex management judgment and assumptions, or involve uncertainties. These critical accounting estimates include revenue recognition and goodwill and other intangible assets. There have not been any changes to our significant accounting policies or their application since we filed our 2020 Annual Report on Form 10-K.</span></div><div id="id60bf3839b914d279c418e71b98c550c_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from fluctuations in interest rates. Our Revolving Credit Facility carries a floating interest rate which is tied to the Eurodollar rate (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LIBOR) and the Prime Rate and therefore, our condensed consolidated statements of operations and our condensed consolidated statements of cash flows are exposed to changes in interest rates. As of September&#160;30, 2021, the total amount of outstanding debt subject to interest rate fluctuations was $450.0 million. A 1.0% interest rate change would cause interest expense to change by approximately $4.5 million annually, assuming the Company makes no principal repayments.</span></div><div id="id60bf3839b914d279c418e71b98c550c_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established disclosure controls and procedures which are designed to provide reasonable assurance of achieving their objectives and to ensure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized, disclosed and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. This information is also accumulated and communicated to our management and Board of Directors to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of this Quarterly Report on Form 10-Q, as of September&#160;30, 2021, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September&#160;30, 2021, the end of the period covered by this Quarterly Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Controls</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) that have occurred during the quarter ended September&#160;30, 2021, that have materially impacted, or are reasonably likely to materially impact, our internal control over financial reporting.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls&#8217; effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives and, based on an evaluation of our controls and procedures, our principal executive officer and our principal financial officer concluded our disclosure controls and procedures were effective at a reasonable assurance level as of September&#160;30, 2021, the end of the period covered by this Quarterly Report.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="id60bf3839b914d279c418e71b98c550c_103"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 - Commitments and Contingencies to the condensed consolidated financial statements for information concerning our legal proceedings.</span></div><div id="id60bf3839b914d279c418e71b98c550c_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div id="id60bf3839b914d279c418e71b98c550c_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the information with respect to purchases made by us of shares of our common stock during each of the months during the three-month period ended September&#160;30, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(a)&#160;Total&#160;Number<br/>of&#160;Shares&#160;(or&#160;Units)<br/>Purchased</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(b)&#160;Average&#160;Price<br/>Paid&#160;per&#160;Share&#160;(or<br/>Unit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(c)&#160;Total&#160;Number&#160;of<br/>Shares (or Units)<br/>Purchased&#160;as&#160;Part&#160;of<br/>Publicly Announced<br/>Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(d)&#160;Maximum&#160;Number&#160;(or<br/>Approximate Dollar<br/>Value) of Shares (or<br/>Units) That May Yet Be<br/>Purchased Under the<br/>Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 1, 2021&#160;to&#160;July 31,&#160;2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,925,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 1,&#160;2021&#160;to August 31,&#160;2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,120,504&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 1, 2021 to September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,120,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,374&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.87&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,609&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,120,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes shares of common stock surrendered to us by certain employees to satisfy tax withholding and/or strike price obligations in connection with the vesting of non-vested stock and exercise of stock options previously awarded to such employees under our 2008 and 2018 Omnibus Incentive Compensation Plans.</span></div><div style="padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Includes amounts remaining under our existing $100 million share repurchase program, approved by our Board of Directors on December 17, 2020 (the "Existing Share Repurchase Program"), and an additional $100 million under a new share repurchase program approved by our Board of Directors on August 2, 2021 (the "New Share Repurchase Program"), which will commence upon the completion of the Existing Share Repurchase Program. We may repurchase shares under the Existing Share Repurchase Program through December 31, 2021 and under the New Share Repurchase Program through December 31, 2022.</span></div><div id="id60bf3839b914d279c418e71b98c550c_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id60bf3839b914d279c418e71b98c550c_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="id60bf3839b914d279c418e71b98c550c_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. EXHIBITS</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits marked with the cross symbol (&#8224;) are filed and the exhibits marked with a double cross (&#8224;&#8224;) are furnished with this Form 10-Q. Any exhibits marked with the asterisk symbol (*) are management contracts or compensatory plans or arrangements filed pursuant to Item 601(b)(10)(iii) of Regulation S-K. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.249%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.375%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Document Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Report or Registration Statement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File or<br/>Registration<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>or Other<br/>Reference</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312507166703/dex31.htm">Composite of Certificate of Incorporation of the Company inclusive of all amendments through June&#160;14, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2007</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20213009xex32.htm">Composite of By-Laws of the Company inclusive of all amendments through October 20, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/896262/000119312521236286/d196437dex101.htm">Second Amendment to Amended and Restated Credit Agreement, dated as of July 30, 2021, by and among Amedisys, Inc. and Amedisys Holding, L.L.C., as the borrowers, the Guarantors party thereto, the Lenders party thereto, Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, and the other L/C Issuers party thereto (Immaterial schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission upon request.)</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Company's Current Report on Form 8-K filed on August 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0-24260</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20213009xexx311.htm">Certification of Paul B. Kusserow, Chief Executive Officer (principal executive officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20213009xexx312.htm">Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20213009xexx321.htm">Certification of Paul B. Kusserow, Chief Executive Officer (principal executive officer), pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amed-20213009xexx322.htm">Certification of Scott G. Ginn, Executive Vice President and Chief Financial Officer (principal financial officer), pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="id60bf3839b914d279c418e71b98c550c_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.912%"><tr><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.062%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDISYS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SCOTT G. GINN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Financial Officer and</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Duly Authorized Officer</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: November&#160;3, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>amed-20213009xex32.htm
<DESCRIPTION>EX-3.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8269f53f04ff49eca32a09620eabbb90_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Exhibit 3.2</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">COMPOSITE BY-LAWS</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">OF</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AMEDISYS, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Incorporated under the Laws of the State of Delaware<br>(Inclusive of Amendments Dated October 20, 2021)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE I.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">OFFICES AND RECORDS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 1.1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Delaware Office</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The principal office of the Corporation in the State of Delaware shall be located in the City of Wilmington, County of New Castle.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 1.2.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Other Offices</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Corporation may have such other offices, either within or without the State of Delaware, as the Board of Directors may designate or as the business of the Corporation may from time to time require.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 1.3.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Books and Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The books and records of the Corporation may be kept outside the State of Delaware at such place or places as may from time to time be designated by the Board of Directors.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE II.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">STOCKHOLDER MEETINGS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Annual Meeting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The annual meeting of the stockholders of the Corporation shall be held on such date and at such place and time as may be fixed by resolution of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.2.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Special Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Subject to the rights, if any, of the holders of any series of stock having a preference over the Common Stock of the Corporation as to dividends or upon liquidation (&#8220;Preferred Stock&#8221;) with respect to such series of Preferred Stock, special meetings of the stockholders may be called only by the Chairman of the Board or by the President or by the Board of Directors or a Committee thereof, or by the holders of at least 30% of all the shares entitled to vote at the proposed special meeting. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&#8217;s notice of meeting (or any supplement thereto). Notice of any special meeting shall be delivered by the Corporation pursuant to Section 2.5 of these By-Laws. The holders of the requisite percentage of voting power may request a special meeting by submitting a written notice of demand to the Secretary of the Corporation at the Corporation&#8217;s principal executive offices stating the purpose or purposes of the meeting. Such written notice of demand shall be signed by the stockholder or stockholders holding the requisite percentage of the voting power to demand a special meeting and shall also set forth the information required by Section 2.8(c) of these By-Laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.3.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Business at Annual and Special Stockholder Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">No business (including nominating persons to be elected or re-elected to the Corporation&#8217;s Board of Directors) may be transacted at an annual meeting of the Corporation&#8217;s stockholders other than business that is&#58;</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">specified in a notice of meeting (or any supplement thereto) given by or at the direction of the Corporation&#8217;s Board of Directors or an authorized committee thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.36pt">otherwise brought before the meeting by or at the direction of the Corporation&#8217;s Board of Directors or an authorized committee thereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.03pt">otherwise brought before the meeting&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(A)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.36pt">by a stockholder who was a stockholder of record at the time of giving notice provided in Section 2.8 and at the time of the meeting and who is entitled to vote at the meeting on such business (including electing or re-electing persons to the Corporation&#8217;s Board of Directors) (a &#8220;Record Holder&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.02pt">who complies with the notice procedures set forth in Section 2.8 (any such Record Holder being hereafter referred to as a &#8220;Noticing Stockholder&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For the avoidance of doubt, clause (a)(iii) of this Section 2.3 shall be the exclusive means for a stockholder to nominate persons to be elected or re-elected to the Corporation&#8217;s Board of Directors at an annual meeting of stockholders or to bring or submit other business before an annual meeting of stockholders (other than proposals properly brought pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and included in the Corporation&#8217;s notice of and proxy materials submitted in connection with such meeting). Nothing in this Section 2.3(a) shall be deemed to affect any rights of the holders of any series of Preferred Stock to elect directors under specified circumstances.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation&#8217;s notice of meeting (or any supplement thereto). Nominations of persons for election to the Board of Directors may be made at a special meeting of stockholders at which directors are to be elected or re-elected pursuant to the Corporation&#8217;s notice of meeting only&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">by or at the direction of the Corporation&#8217;s Board of Directors or an authorized committee thereof&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.36pt">provided that the Board of Directors has determined that directors are to be elected at such special meeting, by a Noticing Stockholder who complies with the notice procedures set forth in Section 2.8.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For the avoidance of doubt, clause (b)(ii) of this Section 2.3 shall be the exclusive means for a stockholder to nominate persons to be elected or re-elected to the Corporation&#8217;s Board of Directors at a special meeting of stockholders. Nothing in this Section 2.3(b) shall be deemed to affect any rights of the holders of any series of Preferred Stock to elect directors under specified circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.4.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Place of Meeting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Board of Directors, the Chairman of the Board, or President, as the case may be, may designate the place of meeting for any annual meeting or for any special meeting of the stockholders called by the Board of Directors, the Chairman of the Board or President. If no designation is so made, the place of meeting shall be the principal office of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.5.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Notice of Meeting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Written or printed notice, stating the place, day and hour of the meeting and the purpose or purposes for which the meeting is called, shall be delivered by the Corporation not less than 10 days nor more than 60 days before the date of the meeting, either personally or by mail, to each stockholder of record entitled to notice of such meeting. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail with postage thereon prepaid, addressed to the stockholder at his address as it appears on the stock transfer books of the Corporation. Such further notice shall be given as may be required by law. Meetings may be held without notice if all stockholders entitled to vote are present, or if notice is waived by those not present in accordance with Section 6.4 of these By-Laws. Any previously scheduled meeting of the stockholders may be postponed, and (unless the Certificate of Incorporation otherwise provides) any special meeting of the stockholders (other than a special meeting called at the request of holders of at least 30% of all the shares entitled to vote at the proposed special meeting) may be cancelled, by resolution of the Board of Directors upon public notice given prior to the date previously scheduled for such meeting of stockholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.6.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Quorum and Adjournment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Except as otherwise provided by law or by the Certificate of Incorporation, the holders of a majority of the voting power of the outstanding shares of the Corporation entitled to vote generally in the election of directors (the &#8220;Voting Stock&#8221;), represented in person or by proxy, shall constitute a quorum at a meeting of stockholders, except that when specified business is to be voted on separately by a class or series of stock voting as a class, the holders of a majority of the shares of such class or series shall constitute a quorum of such class or series for the transaction of such business. The Chairman of the meeting or a majority of the shares so represented may adjourn the meeting from time to time, whether or not there is such a quorum. No notice of the time and place of adjourned meetings need be given except as required by law. The stockholders present at a duly called meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.7.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Proxies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. At all meetings of stockholders, a stockholder may vote by proxy executed in writing (or in such manner prescribed by the General Corporation Law of the State of Delaware) by the stockholder, or by his duly authorized attorney in fact.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.8.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Notice of Stockholder Business to be Conducted at a Meeting of Stockholders</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In order for a Noticing Stockholder to (i) properly bring any item of business (including nominating persons to be elected or re-elected to the Corporation&#8217;s Board of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Directors) before an annual meeting of stockholders in accordance with Section 2.3(a) or (ii) nominate persons for election to the Board of Directors at a special meeting of stockholders (at which directors are to be elected or re-elected pursuant to the Corporation&#8217;s notice of meeting) in accordance with Section 2.3(b), the Noticing Stockholder must have given timely notice of that business in proper form in writing to the Secretary of the Corporation in compliance with the requirements of this Section 2.8 and such business must otherwise be a proper matter for stockholder action under relevant law. This Section 2.8 shall constitute an &#8220;advance notice provision&#8221; for annual meetings of stockholders for purposes of Rule 14a-4(c)(1) under the Exchange Act. Certain capitalized terms used in this Section 2.8 are defined in subsection (d), below.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">To be timely, a Noticing Stockholder&#8217;s notice required by these By-Laws must be delivered to the Secretary at the Corporation&#8217;s principal executive offices in proper written form&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">Annual Meeting Deadlines. In connection with business (including nominating persons to be elected or re-elected to the Corporation&#8217;s Board of Directors) to be properly brought at an annual meeting of stockholders in accordance with Section 2.3(a), not earlier than the close of business on the one hundred twentieth (120th) day and not later than the close of business on the ninetieth (90th) day prior to the first anniversary of the preceding year&#8217;s annual meeting&#59; provided, however, that in the event the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the one hundred twentieth (120th) day prior to the date of such annual meeting and not later than the close of business on the later of&#58; (A) the ninetieth (90th) day prior to the date of such annual meeting or, (B) if the first Public Announcement of the date of such annual meeting is less than one hundred (100) days prior to the date of such annual meeting, the tenth (10th) day following the day on which Public Announcement of the date of such annual meeting is first made by the Corporation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.36pt">Special Meeting Deadlines. In connection with the nomination of persons for election to the Board of Directors at a special meeting of stockholders (at which directors are to be elected or re-elected pursuant to the Corporation&#8217;s notice of meeting) in accordance with Section 2.3(b), not earlier than the close of business on the one-hundred twentieth (120th) day prior to such special meeting and not later than the close of business on the later of&#58; (A) the ninetieth (90th) day prior to such special meeting, or (B) the tenth (10th) day following the day on which Public Announcement of the date of the special meeting is first made by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In no event shall any adjournment, deferral or postponement of an annual or special meeting of stockholders, or the announcement thereof, commence a new time period for the giving of a stockholder&#8217;s notice as described above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Notwithstanding anything in Section 2.8(a) to the contrary, if the number of persons to be elected to the Corporation&#8217;s Board of Directors is increased and there is no Public Announcement by the Corporation naming all of the nominees for director or specifying the size of the increased Board of Directors at least 100 days prior to the first anniversary of the preceding year&#8217;s annual meeting, a Noticing Stockholder&#8217;s notice required by these By-Laws shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it is delivered to the Secretary at the Corporation&#8217;s principal executive offices not later than the close of business on the tenth (10th) day following the day on which the Public Announcement naming all nominees or specifying the size of the increased Board of Directors is first made by the Corporation.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">To be in proper form, whether in regard to nominating persons to be elected or re-elected to the Corporation&#8217;s Board of Directors or any other business, a Noticing Stockholder&#8217;s written notice required by these By-Laws must completely and accurately&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">Set forth, as to each Noticing Stockholder and, if a Noticing Stockholder holds for the benefit of another, the beneficial owner on whose behalf the nomination or proposal is made (any Noticing Stockholder or such beneficial owner a &#8220;Holder&#8221; and, collectively, &#8220;Holders&#8221;), the following information together with a representation as to the completeness and accuracy of the information&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(A)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.36pt">(i) the name and address of the Noticing Stockholder as they appear on the Corporation&#8217;s books and the residence address (if different from the Corporation&#8217;s books) of the Noticing Stockholder, (ii) if the Noticing Stockholder holds for the benefit of another, the name and address of such beneficial owner and (iii) the name and address of any Holder Associated Person covered by this Section 2.8(c)(i)&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.02pt">the class or series and number of shares of the Corporation that are, directly or indirectly, owned beneficially or of record by each Holder and each Holder Associated Person covered by this Section 2.8(c)(i), and the date such ownership was acquired&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.02pt">a description of any Derivative Instrument that is directly or indirectly owned beneficially by any Holder or Holder Associated Person and any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares or other securities of the Corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(D)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.36pt">any proxy, contract, arrangement, understanding, or relationship pursuant to which any Holder or Holder Associated Person has a right to vote or has granted a right to vote any securities (including the shares of common stock) of the Corporation&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(E)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.69pt">a description of any Hedging Transaction entered into by or on behalf of any Holder or Holder Associated Person&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(F)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.35pt">any rights to dividends or other distributions on the shares or other securities of the Corporation owned beneficially by any Holder or Holder Associated Person that are separated or separable from the underlying shares or other securities of the Corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(G)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.36pt">any proportionate interest in shares or other securities of the Corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership or limited liability company or other entity in which any Holder or Holder Associated Person is a general partner or, directly or indirectly, beneficially owns an interest in a general partner, is the manager, managing member or directly or indirectly beneficially owns an interest in the manager or managing member of a limited liability company or similar entity&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(H)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.36pt">any performance-related fees (other than an asset-based fee) that any Holder or Holder Associated Person is entitled to based on any increase or decrease in the value of shares or other securities of the Corporation or Derivative Instruments, if any&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(I)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">a representation that the Noticing Stockholder intends to appear in person or by proxy at the meeting to nominate the persons named or propose the business specified in the notice, together with a statement whether the Noticing Stockholder intends to deliver a proxy &#160;&#160;&#160;&#160;statement or form of proxy to holders of at least the percentage of the Corporation&#8217;s outstanding shares required to approve the nomination or the business proposed or otherwise to solicit proxies from Corporation&#8217;s stockholders in support of the nomination or the business proposed&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(J)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:23.36pt">any other information relating to the Holder and any Holder Associated Person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal or for the election of directors in a contested election pursuant to Section 14 of the Exchange Act and the rules and regulations thereunder (even if an election contest or proxy solicitation is not involved), or is otherwise required pursuant to Section 14 of the Exchange Act.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.36pt">If a Noticing Stockholder&#8217;s notice required by these By-Laws relates to any business other than the nomination of one or more persons to be elected or re-elected to the Corporation&#8217;s Board of Directors that is proposed to be brought before the meeting, the notice also must set forth&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(A)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.36pt">a brief description of the business desired to be brought before the meeting (including the specific text of any resolutions or actions proposed for consideration and if such business includes the proposal to amend the Corporation&#8217;s Certificate of Incorporation or By-Laws, the specific language of the proposed amendment) and the reasons for conducting such business at the meeting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.02pt">a description of all direct and indirect agreements, arrangements or understandings between the Holder, any Holder Associated Person and any other Person (including their names) in connection with the proposal of such business by the Holder and any material direct or indirect interest of the Holder, any Holder Associated Person or any such other Person in such business.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.03pt">If a Noticing Stockholder&#8217;s notice required by these By-Laws relates to the nomination of a person (each such person a &#8220;Nominee&#8221; and collectively, &#8220;Nominees&#8221;) to be elected or re-elected to the Corporation&#8217;s Board of Directors, the written notice, as to each Nominee, also must&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(A)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.36pt">set forth the Nominee&#8217;s name, age, business and residence address and principal occupation or employment and the class or series and number of shares of common stock or other securities of the Corporation that are directly or indirectly owned beneficially or of record by the Nominee and all such other information that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors in a contested election (even if an election contest or proxy solicitation is not involved), or is otherwise required, pursuant to Section 14 of the Exchange Act and the rules and regulations thereunder (including the Nominee&#8217;s written consent to being named in the proxy statement as a nominee, if applicable, and to serving as a director if elected)&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.02pt">set forth a description (including party names) of any agreements, arrangements or understandings (including financial transactions) between or among the Holder, any Holder Associated Person or any Nominee, on the one hand, and any other Persons (including any Holder Associated Person and any Nominee), on the other hand, in connection with the Nominee&#8217;s nomination&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.02pt">set forth a description of all direct and indirect compensation and any other material monetary agreements, arrangements or understandings during the past three years, and any other material relationships, between or among the Holder, any Holder Associated Person and their respective Affiliates and Associates, or other Persons acting in concert therewith, on the one hand, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">each Nominee, and his or her respective Affiliates and Associates, or other Persons acting in concert therewith, on the other hand.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.69pt">Any notice submitted pursuant to this Section 2.8(c) shall be updated and supplemented by the Holder in writing and delivered to the Secretary at the Corporation&#8217;s principal executive offices not later than 10 days after the record date for the meeting, if necessary, so that the information provided or required to be provided in such notice shall be true and correct as of the record date for the meeting.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">In addition to the other terms that are defined in these By-Laws, for purposes of these By-Laws, the following terms shall have the respective meanings ascribed thereto&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">&#8220;Affiliate&#8221; means a Person that directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with, another specified Person.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.36pt">&#8220;Associate&#8221; means, with respect to a specified Person&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(A)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.36pt">any corporation or organization of which that Person is an officer or partner or of which that Person is, directly or indirectly, the beneficial owner of ten percent (10%) or more of any class of equity securities&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(B)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.02pt">any trust or other estate in which that Person has a substantial beneficial interest or as to which such Person serves as trustee or in a similar fiduciary capacity&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(C)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:20.02pt">any Immediate Family Member of that Person.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.03pt">&#8220;Control&#8221; means the possession, direct or indirect, of the power to direct or cause the direction of the management policies of a person, whether through the ownership of voting securities, by contract, or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(iv)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.69pt">&#8220;Derivative Instrument&#8221; means any derivative positions including, without limitation, any option, warrant, convertible security, stock appreciation right, profits interest or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares or other securities of the Corporation or with a value derived in whole or in part from the value of any class or series of shares or other securities of the Corporation, whether or not the instrument or right shall be subject to settlement in the underlying class or series of shares or other securities of the Corporation or otherwise and any performance-related fees to which such Holder or Holder Associated Person is entitled based, directly or indirectly, on any increase or decrease in the value of shares or other securities of the Corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(v)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">&#8220;Hedging Transaction&#8221; means, any hedging or other transaction (such as borrowed or loaned shares) or series of transactions, or any other agreement, arrangement or understanding, the effect or intent of which is to increase or decrease the voting power or economic or pecuniary interest of a Holder or Holder Associated Person with respect to the Corporation&#8217;s securities, including, without limitation, a short interest in any securities (including the shares of common stock) of the Corporation (for purposes of these By-Laws a person shall be deemed to have a short interest in a security if a Holder or Holder Associated Person directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has the opportunity to profit or share in any profit derived from any decrease in the value or price of the subject security).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(vi)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.69pt">&#8220;Holder Associated Person&#8221; means, with respect to any Holder, (A) any person acting in concert with such Holder, (B) any beneficial owner of shares of stock of the Corporation owned of record or beneficially by such Holder (other than a stockholder that is a depositary) and (C) any Person, directly or indirectly, controlling, controlled by or under common control with any Holder, or any Holder Associated Person identified in clauses (A) or (B) above.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(vii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15.36pt">&#8220;Immediate Family Member&#8221; means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of a specified person, and any person (other than a tenant or employee) sharing the household of such specified person.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(viii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:12.03pt">&#8220;Person&#8221; means an individual, partnership, corporation (including a business trust), limited liability company, joint stock company, trust, unincorporated association, joint venture or other entity, or a government or any political subdivision or agency thereof.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ix)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.69pt">&#8220;Public Announcement&#8221; means disclosure by the Corporation in a press release reported by the Dow Jones News Service, Associated Press, Business Wire, PR Newswire or comparable national news service or in a document publicly filed with or furnished by the Corporation to the Securities and Exchange Commission pursuant to Section 13, 14, or 15(d) of the Exchange Act and the rules and regulations thereunder.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Only those persons who are nominated in accordance with the procedures set forth in these By-Laws shall be eligible to serve as directors. Only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in these By-Laws. Except as otherwise provided by law, the Certificate of Incorporation, or these By-Laws, the Chairman of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in compliance with the procedures set forth </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">in these By-Laws and, if any nomination or proposed business is not in compliance with these By-Laws, to declare that such nomination or proposed business is defective, in which case it shall be disregarded.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">In addition to the foregoing provisions of these By-Laws, a Holder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in these By-Laws&#59; provided, however, that any references in these By-Laws to the Exchange Act or the rules and regulations thereunder are not intended to and shall not limit the requirements applicable to nominations or proposals as to any other business to be considered pursuant to Section 2.3 or Section 2.8.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Nothing in these By-Laws shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation&#8217;s proxy statement pursuant to Rule 14a-8 under the Exchange Act. In addition, nothing in these By-Laws shall be deemed to affect any rights of the holders of any series of Preferred Stock to elect directors under specified circumstances.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.9.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Procedure for Election of Directors&#59; Required Vote</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Election of directors at all meetings of the stockholders at which directors are to be elected shall be by ballot unless the presiding officer at the meeting determines that written ballots are unnecessary, and subject to the rights of the holders of any series of Preferred Stock to elect directors under specified circumstances, a plurality of the votes cast thereat shall elect directors. Except as otherwise provided by law, the Certificate of Incorporation, or these By-Laws, in all matters other than the election of directors, the affirmative vote of the holders of a majority of the voting power represented by the shares present in person or represented by proxy at the meeting and entitled to vote on the matter shall be the act of the stockholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.10.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Inspectors of Elections&#59; Opening and Closing the Polls</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Board of Directors by resolution may appoint one or more inspectors, which inspector or inspectors may include individuals who serve the Corporation in other capacities, including, without limitation, as officers, employees, agents or representatives, to act at the meetings of stockholders and make a written report thereof. One or more persons may be designated as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate has been appointed to act or is able to act at a meeting of stockholders, the Chairman of the meeting may appoint one or more inspectors to act at the meeting. Each inspector, before discharging such inspector&#8217;s duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector&#8217;s ability. The inspectors shall have the duties prescribed by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Chairman of the meeting shall fix and announce at the meeting the date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.11.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Record Date for Action by Written Consent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which date shall not be more than 10 days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. Any stockholder of record seeking to have the stockholders authorize or take corporate action by written consent shall, by written notice to the Secretary (which written notice must set forth the information required by Section 2.8(c) of these By-Laws and include a copy of the proposed written consent), request the Board of Directors to fix a record date. The Board of Directors shall promptly, but in all events within 10 days after the date on which such a request is received, adopt a resolution fixing the record date. If no record date has been fixed by the Board of Directors within 10 days of the date on which such a request is received, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business or to any officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation&#8217;s registered office shall be by hand or by certified or registered mail, return receipt requested. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by applicable law, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the date on which the Board of Directors adopts the resolution taking such prior action.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.12.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Inspectors of Written Consent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In the event of the delivery, in the manner provided by Section 2.11, to the Corporation of the requisite written consent or consents to take corporate action and&#47;or any related revocation or revocations, the Corporation shall engage nationally recognized independent inspectors of elections for the purpose of promptly performing a ministerial review of the validity of the consents and revocations. For the purpose of permitting the inspectors to perform such review, no action by written consent without a meeting shall be effective until such date as the independent inspectors certify to the Corporation that the consents delivered to the Corporation in accordance with Section 2.11 represent at least the minimum number of votes that would be necessary to take the corporate action. Nothing contained in this paragraph shall in any way be construed to suggest or imply that the Board of Directors or any stockholder shall not be entitled to contest the validity of any consent or revocation thereof, whether before or after such certification by the independent inspectors, or to take any other action (including, without limitation, the commencement, prosecution or defense of any litigation with respect thereto, and the seeking of injunctive relief in such litigation).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 2.13.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Effectiveness of Written Consent</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Every written consent shall bear the date of signature of each stockholder who signs the consent and no written consent shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated written consent received in accordance with Section 2.11, a written consent or consents signed by a sufficient number of holders to take such action are delivered to the Corporation in the manner prescribed in Section 2.11.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE III.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">BOARD OF DIRECTORS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">General Powers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The business and affairs of the Corporation shall be managed under the direction of the Board of Directors. In addition to the powers and authorities by these By-Laws expressly conferred upon them, the Board of Directors may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Certificate of Incorporation or by these By-Laws required to be exercised or done by the stockholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.2.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Number and Tenure</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Subject to the rights of the holders of any series of Preferred Stock to elect directors under specified circumstances, the business and affairs of the Corporation shall be managed by the Board of Directors of not less than three nor more than 15 persons, the exact number thereof to be determined from time to time by resolution of the Board of Directors. Each director shall serve for a term expiring at the next annual meeting of stockholders and until his successor shall have been duly elected and qualified. Directors need not be stockholders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.3.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Chairman of the Board</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Chairman of the Board shall be chosen from among the Directors. The Chairman of the Board shall preside at all meetings of the stockholders and of the Board of Directors. The Chairman of the Board shall perform all duties incidental to his office which may be required by law and all such other duties as are properly required of him by the Board of Directors. In the event the Board has elected Co-Chairmen of the Board, each Co-Chairman shall have the authority to act as a Chairman of the Board as provided in these By-laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.4.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Lead Director</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Whenever the Chairman of the Board is an executive officer of the Corporation, the independent directors, within the meaning of then effective NASDAQ Marketplace Rules, shall appoint one of the independent directors as Lead Director of the Corporation to lead the Board in fulfilling its duties effectively, efficiently and independent of management. The Lead Director&#8217;s responsibilities will be set forth in the Company&#8217;s Corporate Governance Guidelines, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.5.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Regular Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Regular meetings of the Board of Directors shall be held without notice at such time and at such place as shall from time to time be determined by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.6.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Special Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Special meetings of the Board of Directors shall be called at the request of the Chairman of the Board or a majority of the Board of Directors then in office. The person or persons authorized to call special meetings of the Board of Directors may fix the place and time of the meetings.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.7.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Notice of Board Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Notice of any special meeting of directors shall be given to each director at the director&#8217;s business or residence in writing by hand delivery, first-class or overnight mail or courier service or by telegram or facsimile transmission, by electronic transmission or orally by telephone. If mailed by first-class mail, such notice shall be deemed adequately delivered when deposited in the United States mails so addressed, with postage thereon prepaid, at least five days before such meeting. If by telegram, overnight mail or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">courier service, such notice shall be deemed adequately delivered when the telegram is delivered to the telegraph company or the notice is delivered to the overnight mail or courier service company at least 24 hours before such meeting. If by facsimile transmission or by electronic transmission, such notice shall be deemed adequately delivered when the notice is transmitted at least 12 hours before such meeting. If by telephone or by hand delivery, the notice shall be given at least 12 hours prior to the time set for the meeting. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the Board of Directors need be specified in the notice of such meeting, except for amendments to these By-Laws, as provided under Section 8.1. A meeting may be held at any time without notice if all the directors are present or if those not present waive notice of the meeting in accordance with Section 6.4 of these By-Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.8.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Action by Consent of Board of Directors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board or committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.9.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Conference Telephone Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Members of the Board of Directors, or any committee thereof, may participate in a meeting of the Board of Directors or such committee by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at such meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.10.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Quorum</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Subject to Section 3.9, a whole number of directors equal to at least a majority of the total number of directors which the Corporation would have if there were no vacancies (&#8220;Whole Board&#8221;) shall constitute a quorum for the transaction of business, but if at any meeting of the Board of Directors there shall be less than a quorum present, a majority of the directors present may adjourn the meeting from time to time without further notice. The act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. The directors present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough directors to leave less than a quorum.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.11.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Vacancies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Subject to applicable law and the rights of the holders of any series of Preferred Stock with respect to such series of Preferred Stock, and unless the Board of Directors otherwise determines, vacancies resulting from death, resignation, retirement, disqualification, removal from office or other cause, and newly created directorships resulting from any increase in the authorized number of directors, may be filled only by the affirmative vote of a majority of the remaining directors, though less than a quorum of the Board of Directors, and directors so chosen shall hold office for a term expiring at the next annual meeting of stockholders and until such director&#8217;s successor shall have been duly elected and qualified. No decrease in the number of authorized directors constituting the Whole Board shall shorten the term of any incumbent director.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.12.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Executive and Other Committees</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Board of Directors may, by resolution adopted by a majority of the Whole Board, designate an Executive Committee to exercise, subject to and to the full extent of applicable provisions of law, all the powers of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Board in the management of the business and affairs of the Corporation when the Board is not in session and may, by resolution similarly adopted, designate one or more other committees. The Executive Committee may not, however (i) approve or adopt, or recommend to the stockholders of the Corporation, any action or matter expressly required by the General Corporation Law of the State of Delaware to be submitted to stockholders for approval, or (ii) adopt, amend or repeal any By-Law of the Corporation. The Executive Committee and each such other committee shall consist of two or more directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. Any such committee, other than the Executive Committee (the powers of which are expressly provided for herein), may to the extent permitted by law exercise such powers and shall have such responsibilities as shall be specified in the designating resolution. In the absence or disqualification of any member of such committee or committees, the member or members thereof present at any meeting and not disqualified from voting, whether or not constituting a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Each committee shall keep written minutes of its proceedings and shall report such proceedings to the Board when required.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">A majority of any committee may determine its action and fix the time and place of its meetings, unless the Board shall otherwise provide. Notice of such meetings shall be given to each member of the committee in any such manner as the committee may determine from time to time. A majority of the Whole Board shall have power at any time to fill vacancies in, to change the membership of, or to dissolve any such committee. Nothing herein shall be deemed to prevent the Board from appointing one or more committees consisting in whole or in part of persons who are not directors of the Corporation&#59; provided, however, that no such committee shall have or may exercise any authority of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.13.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Removal</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Subject to the rights of the holders of any series of Preferred Stock with respect to such series of Preferred Stock, any director, or the entire Board of Directors, may be removed from office at any time, either with or without cause, by the affirmative vote of holders of a majority of the voting power of shares of Voting Stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 3.14.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Records</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Board of Directors shall cause to be kept a record containing the minutes of the proceedings of the meetings of the Board and of the stockholders, appropriate stock books and registers and such books of records and accounts as may be necessary for the proper conduct of the business of the Corporation.</font></div><div style="margin-bottom:0.12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE IV.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">OFFICERS</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Elected Officers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The elected officers of the Corporation shall be a Chief Executive Officer, a President, a Secretary, a Treasurer, and such other officers (including, without limitation, a Chief Financial Officer) as the Board of Directors from time to time may deem proper. All officers elected by the Board of Directors shall each have such powers and duties as generally pertain to their respective offices, subject to the specific provisions of this Article IV. Such officers shall also have such powers and duties as from time to time may be conferred by the Board of Directors or by any committee thereof. The Board or any committee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">thereof may from time to time elect, or the Chief Executive Officer may appoint, such other officers (including one or more Assistant Vice Presidents, Assistant Secretaries, Assistant Treasurers, and Assistant Controllers) and such agents, as may be necessary or desirable for the conduct of the business of the Corporation. Such other officers and agents shall have such duties and shall hold their offices for such terms as shall be provided in these By-Laws or as may be prescribed by the Board or such committee or by the Chief Executive Officer, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.2.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Election and Term of Office</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The elected officers of the Corporation shall be elected annually by the Board of Directors at the regular meeting of the Board of Directors held after the annual meeting of the stockholders. If the election of officers shall not be held at such meeting, such election shall be held as soon thereafter as convenient. Each officer shall hold office until his successor shall have been duly elected and shall have been qualified or until his death, resignation or removal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.3.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Chief Executive Officer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Chief Executive Officer shall be responsible for the general management of the affairs of the Corporation and shall perform all duties incidental to this office which may be required by law and all such other duties as are properly required of this officer by the Board of Directors. The Chief Executive Officer shall make reports to the Board of Directors and the stockholders, and shall see that all orders and resolutions of the Board of Directors and of any committee thereof are carried into effect. The Chief Executive Officer may also serve as President, if so elected by the Board.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.4.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">President</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The President shall act in a general executive capacity and shall assist the Chief Executive Officer in the administration and operation of the Corporation&#8217;s business and general supervision of its policies and affairs. The President shall, in the absence of or because of the inability to act of the Chief Executive Officer, perform all duties of the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.5.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Vice-Presidents</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Each Vice President shall have such powers and shall perform such duties as shall be assigned to him by the Board of Directors or the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.6.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Chief Financial Officer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Chief Financial Officer (if any) shall be a Vice President and act in an executive financial capacity. He shall assist the Chief Executive Officer and the President in the general supervision of the Corporation&#8217;s financial policies and affairs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.7.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Treasurer</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Treasurer shall exercise general supervision over the receipt, custody and disbursement of corporate funds. The Treasurer shall cause the funds of the Corporation to be deposited in such banks as may be authorized by the Board of Directors, or in such banks as maybe designated as depositaries in the manner provided by resolution of the Board of Directors. He shall have such further powers and duties and shall be subject to such directions as may be granted or imposed upon him from time to time by the Board of Directors or the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.8.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Secretary</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Secretary shall keep or cause to be kept in one or more books provided for that purpose, the minutes of all meetings of the Board, the committees </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">of the Board and the stockholders&#59; he shall see that all notices are duly given in accordance with the provisions of these By-Laws and as required by law&#59; he shall be custodian of the records and the seal of the Corporation and affix and attest the seal to all stock certificates of the Corporation (unless the seal of the Corporation on such certificates shall be a facsimile, as hereinafter provided) and affix and attest the seal to all other documents to be executed on behalf of the Corporation under its seal&#59; and he shall see that the books, reports, statements, certificates and other documents and records required by law to be kept and filed are properly kept and filed&#59; and in general, he shall perform all the duties incident to the office of Secretary and such other duties as from time to time may be assigned to him by the Board or the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.9.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Removal</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any officer or agent may be removed at any time by the affirmative vote of a majority of the Whole Board or, except in the case of an officer or agent elected by the Board, by the Chief Executive Officer. Such removal shall be without prejudice to the contractual rights, if any, of the person so removed. No elected officer shall have any contractual rights against the Corporation for compensation by virtue of such election beyond the date of the election of his successor, his death, his resignation or his removal, whichever event shall first occur, except as otherwise provided in an employment contract or under an employee deferred compensation plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 4.10.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.02pt;text-decoration:underline">Vacancies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. A newly created elected office and a vacancy in any elected office because of death, resignation, or removal may be filled by the Board of Directors for the unexpired portion of the term at any meeting of the Board of Directors. Any vacancy in an office appointed by the Chief Executive Officer because of death, resignation, or removal may be filled by the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE V.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">STOCK CERTIFICATES AND TRANSFERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 5.1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Stock Certificates and Transfers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">The interest of each stockholder of the Corporation shall be evidenced by certificates for shares of stock in such form as the appropriate officers of the Corporation may from time to time prescribe&#59; provided that the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of the stock of the Corporation shall be represented by uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Except as otherwise expressly provided by law, the rights and obligations of the holders of uncertificated stock and the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The shares of stock represented by certificates shall be signed, countersigned and registered in such manner as the Board of Directors may by resolution prescribe, which resolutions may permit all or any of the signatures on such certificates (if any) to be by facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">The shares of the stock of the Corporation represented by certificates shall be transferred on the books of the Corporation by the holder thereof in person or by his attorney, upon surrender for cancellation of certificates for at least the same number of shares, with an assignment and power of transfer endorsed thereon or attached thereto, duly executed, with such proof of the authenticity of the signature as the Corporation or its agents may reasonably require. Upon receipt of proper transfer instructions from the registered owner of uncertificated shares, such uncertificated shares shall be canceled and issuance of new equivalent uncertificated shares or certificated shares (if authorized) shall be made to the person entitled thereto and the transaction shall be recorded upon the books of the Corporation.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Within a reasonable time after the issuance or transfer of uncertificated shares, the Corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to the General Corporation Law of the State of Delaware or, unless otherwise provided by the General Corporation Law of the State of Delaware, a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and&#47;or rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 5.2.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Lost, Stolen or Destroyed Certificates</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. No certificate for shares of stock nor uncertificated shares of stock in the Corporation shall be issued in place of any certificate alleged to have been lost, destroyed or stolen, except on production of such evidence of such loss, destruction or theft and on delivery to the Corporation of a bond of indemnity in such amount, upon such terms and secured by such surety, as the Board of Directors or any financial officer may in its or his discretion require.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE VI.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">MISCELLANEOUS PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 6.1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Fiscal Year</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The fiscal year of the Corporation shall begin on the first day of January and end on the 31st day of December of each year.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 6.2.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Dividends</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Board of Directors may from time to time declare, and the Corporation may pay, dividends on its outstanding shares in the manner and upon the terms and conditions provided by law and the Certificate of Incorporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 6.3.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Seal</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The Corporation need not have a corporate seal, but if it does the corporate seal shall have inscribed thereon the words &#8220;Corporate Seal&#8221;, the year of incorporation and around the margin thereof the words &#8220;Amedisys, Inc. &#8211; Delaware&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 6.4.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Waiver of Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Whenever any notice is required to be given to any stockholder or director of the Corporation under the provisions of the General Corporation </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Law of the State of Delaware or these By-Laws, a waiver thereof in writing, signed by the person or persons entitled to such notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice. Neither the business to be transacted at, nor the purpose of, any annual or special meeting of the stockholders or the Board of Directors or committee thereof need be specified in any waiver of notice of such meeting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 6.5.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Audits</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. The accounts, books and records of the Corporation shall be audited upon the conclusion of each fiscal year by an independent certified public accountant selected by the Board of Directors, and it shall be the duty of the Board of Directors to cause such audit to be done annually.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 6.6.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Resignations</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Any director or any officer, whether elected or appointed, may resign at any time by giving written notice of such resignation to the Chief Executive Officer, the President, or the Secretary, and such resignation shall be deemed to be effective as of the close of business on the date said notice is received by the Chief Executive Officer, the President, or the Secretary, or at such later time as is specified therein. No formal action shall be required of the Board of Directors or the stockholders to make any such resignation effective.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 6.7.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Indemnification and Insurance</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. In addition to the indemnification rights provided in the Certificate of Incorporation&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">Each person who was or is made a party or is threatened to be made a party to or is involved in any action, suit, or proceeding, whether civil, criminal, administrative or investigative (hereinafter a &#8220;proceeding&#8221;), by reason of the fact that such person or a person of whom such person is the legal representative is or was a director or officer of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans maintained or sponsored by the Corporation, whether the basis of such proceeding is alleged action in an official capacity as a director, officer, employee or agent or in any other capacity while serving as a director, officer, employee or agent, shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the General Corporation Law of the State of Delaware as the same exists or may hereafter be amended(but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against all expense, liability and loss (including attorneys fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement)reasonably incurred or suffered by such person in connection therewith, and such indemnification shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators&#59; provided, however, that except as provided in paragraph (c) of this By-Law, the Corporation shall indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person only if such proceeding (or part thereof) was authorized by the Board of Directors. The </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">right to indemnification conferred in this By-Law shall be a contract right and shall include the right to be paid by the Corporation the expenses incurred in defending any such proceeding in advance of its final disposition, such advances to be paid by the Corporation within 20 days after the receipt by the Corporation of a statement or statements from the claimant requesting such advance or advances from time to time&#59; provided, however, that if the General Corporation Law of the State of Delaware requires, the payment of such expenses incurred by a director or officer in such persons capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service to an employee benefit plan) in advance of the final disposition of a proceeding, shall be made only upon delivery to the Corporation of an undertaking by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not entitled to be indemnified under this By-Law or otherwise.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">To obtain indemnification under this By-Law, a claimant shall submit to the Corporation a written request, including therein or therewith such documentation and information as is reasonably available to the claimant and is reasonably necessary to determine whether and to what extent the claimant is entitled to indemnification. Upon written request by a claimant for indemnification pursuant to the first sentence of this paragraph (b), a determination, if required by applicable law, with respect to the claimant&#8217;s entitlement thereto shall be made as follows&#58; (i) by the Board of Directors by a majority vote of a quorum consisting of Disinterested Directors (as hereinafter defined), or (ii) if a quorum of the Board of Directors consisting of Disinterested Directors is not obtainable or, even if obtainable, such quorum of Disinterested Directors so directs, by Independent Counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the claimant, or (iii) if a quorum of Disinterested Directors so directs, by the stockholders of the Corporation. If it is so determined that the claimant is entitled to indemnification, payment to the claimant shall be made within 10 days after such determination.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">If a claim under paragraph (a) of this By-Law is not paid in full by the Corporation within 30 days after a written claim pursuant to paragraph (b) of this By-Law has been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where the required undertaking, if any is required, has been tendered to the Corporation) that the claimant has not met the standard of conduct which makes it permissible under the General Corporation Law of the State of Delaware for the Corporation to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, Independent Counselor stockholders) to have </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because such claimant has met the applicable standard of conduct set forth in the General Corporation Law of the State of Delaware, nor an actual determination by the Corporation (including its Board of Directors, Independent Counsel or stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(d)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">If a determination shall have been made pursuant to paragraph (b) of this By-Law that the claimant is entitled to indemnification, the Corporation shall be bound by such determination in any judicial proceeding commenced pursuant to paragraph (c) of this By-Law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(e)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt">The Corporation shall be precluded from asserting in any judicial proceeding commenced pursuant to paragraph (C) of this By-Law that the procedures and presumptions of this By-Law are not valid, binding and enforceable and shall stipulate in such proceeding that the Corporation is bound by all the provisions of this By-Law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(f)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.03pt">The right to indemnification and the payment of expenses incurred in defending a proceeding in advance of its final disposition conferred in this By-Law shall not be exclusive of any other right which any person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, By-Laws, agreement, vote of stockholders or Disinterested Directors or otherwise. No repeal or modification of this By-Law shall in anyway diminish or adversely affect the rights of any director, officer, employee or agent of the Corporation hereunder in respect of any occurrence or matter arising prior to any such repeal or modification.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(g)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, employee or agent of the Corporation or another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the General Corporation Law of the State of Delaware. To the extent that the Corporation maintains any policy or policies providing such insurance, each such director or officer, and each such agent or employee to which rights to indemnification have been granted as provided in paragraph (h) of this By-Law, shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage thereunder for any such director, officer, employee or agent.</font></div><div style="margin-bottom:12.8pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(h)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">The Corporation may, to the extent authorized from time to time by the Board of Directors, grant rights to indemnification, and rights to be paid by the Corporation the expenses incurred in defending any proceeding in advance of its final disposition, to any employee or agent of the Corporation to the fullest extent of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12.8pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">the provisions of this By-Law with respect to the indemnification and advancement of expenses of directors and officers of the Corporation.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">If any provision or provisions of this By-Law shall be held to be invalid, illegal or unenforceable for any reason whatsoever&#58; (1) the validity, legality and enforceability of the remaining provisions of this By-Law (including, without limitation, each portion of any paragraph of this By-Law containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in anyway be affected or impaired thereby&#59; and (2) to the fullest extent possible, the provisions of this By-Law (including, without limitation, each such portion of any paragraph of this By-Law containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(j)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">For purposes of this By-Law&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:24.69pt">&#8220;Disinterested Director&#8221; means a director of the Corporation who is not and was not a party to the matter in respect of which indemnification is sought by the claimant.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:21.36pt">&#8220;Independent Counsel&#8221; means a law firm, a member of a law firm, or an independent practitioner, that is experienced in matters of corporation law and shall include any person who, under the applicable standards of professional conduct then prevailing, would not have a conflict of interest in representing either the Corporation or the claimant in an action to determine the claimant&#8217;s rights under this By-Law.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(k)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt">Any notice, request or other communication required or permitted to be given to the Corporation under this By-Law shall be in writing and either delivered in person or sent by telecopy, telex, telegram, overnight mail or courier service, or certified or registered mail, postage prepaid, return receipt requested, to the Secretary of the Corporation and shall be effective only upon receipt by the Secretary.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE VII.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CONTRACTS, PROXIES, ETC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 7.1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Contracts</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Except as otherwise required by law, the Certificate of Incorporation or these By-Laws, any contracts or other instruments may be executed and delivered in the name and on the behalf of the Corporation by such officer or officers of the Corporation as the Board of Directors may from time to time direct. Such authority may be general or confined to specific instances as the Board may determine. The Chief Executive Officer, the President or any Vice President may execute bonds, contracts, deeds, leases and other instruments to be made or executed for or on behalf of the Corporation. Subject to any restrictions imposed by the Board of Directors or the Chief Executive Officer, the President or any Vice President of the Corporation may delegate contractual powers to others under his </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">jurisdiction, it being understood, however, that any such delegation of power shall not relieve such officer of responsibility with respect to the exercise of such delegated power.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 7.2.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Proxies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Unless otherwise provided by resolution adopted by the Board of Directors, the Chief Executive Officer, the President or any Vice President may from time to time appoint an attorney or attorneys or agent or agents of the Corporation, in the name and on behalf of the Corporation, to cast the votes which the Corporation may be entitled to cast as the holder of stock or other securities in any other corporation, any of whose stock or other securities may be held by the Corporation, at meetings of the holders of the stock or other securities of such other corporation, or to consent in writing, in the name of the Corporation as such holder, to any action by such other corporation, and may instruct the person or persons so appointed as to the manner of casting such votes or giving such consent, and may execute or cause to be executed in the name and on behalf of the Corporation and under its corporate seal or otherwise, all such written proxies or other instruments as he may deem necessary or proper in the premises.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE VIII.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">AMENDMENTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 8.1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Amendments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Except as expressly provided otherwise by the Delaware General Corporation Law, the Certificate of Incorporation of the Corporation, or other provisions of these By-Laws, these By-Laws may be altered, amended or repealed and new By-Laws adopted at any regular or special meeting of the Board of Directors by an affirmative vote of a majority of the Whole Board.</font></div><div style="margin-bottom:12pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">ARTICLE IX.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">EXCLUSIVE FORUM</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 9.1.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt;text-decoration:underline">Exclusive Forum for Internal Actions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation&#59; (ii) any action asserting a claim for breach of a fiduciary duty owed by any director, officer, employee, or agent of the Corporation to the Corporation or the Corporation&#8217;s stockholders&#59; (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, the Certificate of Incorporation or the By-Laws of the Corporation&#59; or (iv) any action asserting a claim governed by the internal affairs doctrine, in each case, subject to said court having personal jurisdiction over the indispensable parties named as defendants therein. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.02pt;text-decoration:underline">Personal Jurisdiction</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  If any action the subject matter of which is within the scope of this Section 9.1 is filed in a court other than a court located within the State of Delaware (a &#8220;Foreign Action&#8221;) in the name of any stockholder, such stockholder shall be deemed to have consented to&#58; (x) the personal jurisdiction of the state and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">federal courts located within the State of Delaware in connection with any action brought in any such court to enforce this Section 9.1 (an &#8220;Enforcement Action&#8221;), and (y) having service of process made upon such stockholder in any such Enforcement Action by service upon such stockholder's counsel in the Foreign Action as agent for such stockholder. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:22.7pt;text-decoration:underline">Notice</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.  Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECTION 9.2.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:27.02pt;text-decoration:underline">Exclusive Forum for Securities Act Claims</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 9.2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">   </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">If any action the subject matter of which is within the scope of&#160;this Section 9.2 is filed in a court other than a federal district court of the United States of America (a &#8220;foreign securities act action&#8221;) in the name of any stockholder (current, former or future), such stockholder shall be deemed to have consented to&#58; (x) the personal jurisdiction of the federal district courts of the United States of America in connection with any action brought in any such court to enforce this&#160;Section 9.2&#160;(a &#8220;Section 9.2 enforcement action&#8221;), and (y) having service of process made upon such stockholder in any such enforcement action by service upon such stockholder&#8217;s counsel in the Section 9.2 enforcement action as agent for such stockholder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>amed-20213009xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="id0e5f94464ac413fb492e54adff15e5a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Paul B. Kusserow, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2021, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;3, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.748%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Paul B. Kusserow</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul B. Kusserow</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>amed-20213009xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i10b2c23792b547bb8313bc232164ac51_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott G. Ginn, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September&#160;30, 2021, of Amedisys, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c. Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d. Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;3, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn<br>Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>amed-20213009xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i173e512557ac4edba20efa49b97caac4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September&#160;30, 2021 (the &#8220;Report&#8221;), I, Paul B. Kusserow, Chief Executive Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;3, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:32.748%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Paul B. Kusserow</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paul B. Kusserow<br>Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>amed-20213009xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3e3b29140dd14e5d8f5b9a6a16d6fa5e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Amedisys, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September&#160;30, 2021 (the &#8220;Report&#8221;), I, Scott G. Ginn, Executive Vice President and Chief Financial Officer of the Company, hereby certify to my knowledge, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:6pt;padding-left:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the periods presented in the Report.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;3, 2021 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47; Scott G. Ginn</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scott G. Ginn<br>Executive Vice President and Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>amed-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9a22ea05-d9af-4e79-9afb-aec6f57a9fea,g:f821983a-9b6a-4f0b-a7a4-a1b27b9c9a2c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amed="http://www.amedisys.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amedisys.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amed-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.amedisys.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS">
        <link:definition>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables">
        <link:definition>2302301 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
        <link:definition>2403401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2104102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2306302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>2407402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
        <link:definition>2408403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
        <link:definition>2409404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
        <link:definition>2410405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
        <link:definition>2411406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails">
        <link:definition>2412407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19">
        <link:definition>2113103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19"</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Tables" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables">
        <link:definition>2314303 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NOVELCORONAVIRUSPANDEMICCOVID19Details" roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details">
        <link:definition>2415408 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONS" roleURI="http://www.amedisys.com/role/ACQUISITIONS">
        <link:definition>2116104 - Disclosure - ACQUISITIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSTables" roleURI="http://www.amedisys.com/role/ACQUISITIONSTables">
        <link:definition>2317304 - Disclosure - ACQUISITIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails">
        <link:definition>2418409 - Disclosure - ACQUISITIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSProFormaDetails" roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails">
        <link:definition>2419410 - Disclosure - ACQUISITIONS - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONS" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS">
        <link:definition>2120105 - Disclosure - LONG-TERM OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables">
        <link:definition>2321305 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
        <link:definition>2422411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1">
        <link:definition>2422411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
        <link:definition>2423412 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
        <link:definition>2424413 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LONGTERMOBLIGATIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails">
        <link:definition>2425414 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2126106 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>2427415 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION">
        <link:definition>2128107 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables">
        <link:definition>2329306 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2430416 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
        <link:definition>2431417 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATION" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION">
        <link:definition>2132108 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompensationRelatedCostsShareBasedPaymentsTables" roleURI="http://www.amedisys.com/role/CompensationRelatedCostsShareBasedPaymentsTables">
        <link:definition>2333307 - Disclosure - Compensation Related Costs, Share Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails" roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails">
        <link:definition>2434418 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASESHAREREPURCHASE" roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE">
        <link:definition>2135109 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREREPURCHASENarrativeDetails" roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails">
        <link:definition>2436419 - Disclosure - SHARE REPURCHASE Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS">
        <link:definition>2137110 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>2438420 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENT" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT">
        <link:definition>2139111 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTTables" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTTables">
        <link:definition>2340308 - Disclosure - SUBSEQUENT EVENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTNarrativeDetails" roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails">
        <link:definition>2441421 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amed_HomeHealthAndHospiceMember" abstract="true" name="HomeHealthAndHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ActualClaimsPayment" abstract="false" name="ActualClaimsPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForCostMethodPercent" abstract="false" name="MaximumPercentOwnershipForCostMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_PayorsAxis" abstract="true" name="PayorsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_PriorCreditAgreementMember" abstract="true" name="PriorCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PromissoryNotesMember" abstract="true" name="PromissoryNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TotalLeverageRatio" abstract="false" name="TotalLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_OneHundredMillionTermLoanMember" abstract="true" name="OneHundredMillionTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PercentageOfTotalReimbursementOfOutlierPayment" abstract="false" name="PercentageOfTotalReimbursementOfOutlierPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_GovernmentGrantsPolicyTextBlock" abstract="false" name="GovernmentGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareNonEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareNonEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_OperatingCareCenters" abstract="false" name="OperatingCareCenters" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" abstract="false" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_CARESActInterestToBeRepaidToGovernment" abstract="false" name="CARESActInterestToBeRepaidToGovernment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Creditfacilitymaximumallowableconsolidatedleverageratio" abstract="false" name="Creditfacilitymaximumallowableconsolidatedleverageratio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_AsanaHospiceMember" abstract="true" name="AsanaHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsContessaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_CapYearDomain" abstract="true" name="CapYearDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PayorClassDomain" abstract="true" name="PayorClassDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FloridaZpicRevenueReduction" abstract="false" name="FloridaZpicRevenueReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HomeHealthNonMedicareEpisodicBasedMember" abstract="true" name="HomeHealthNonMedicareEpisodicBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ProviderReliefFundAdvance" abstract="false" name="ProviderReliefFundAdvance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_TotalCARESActProviderReliefFundsReceived" abstract="false" name="TotalCARESActProviderReliefFundsReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessAcquisitionWorkingCapitalAdjustment" abstract="false" name="BusinessAcquisitionWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" abstract="false" name="Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MinimumPercentOwnershipForControllingInterestPercent" abstract="false" name="MinimumPercentOwnershipForControllingInterestPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_AseraCareHospiceMember" abstract="true" name="AseraCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_InternalAuditComplianceReviewMember" abstract="true" name="InternalAuditComplianceReviewMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ParkersburgWestVirginiaMember" abstract="true" name="ParkersburgWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_VariousAcquisitionsMember" abstract="true" name="VariousAcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_COVID19DeferralOfSocialSecurityMember" abstract="true" name="COVID19DeferralOfSocialSecurityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MedalogixMember" abstract="true" name="MedalogixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_Percentageofclosingstockprice" abstract="false" name="Percentageofclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_LowUtilizationPaymentAdjustmentNumberOfVisits" abstract="false" name="LowUtilizationPaymentAdjustmentNumberOfVisits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_CertificatesOfNeedMember" abstract="true" name="CertificatesOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_COVID19TextBlock" abstract="false" name="COVID19TextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_UnfavorableMember" abstract="true" name="UnfavorableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_A2021ShareRepurchaseProgramMember" abstract="true" name="A2021ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_COVID19PPEMember" abstract="true" name="COVID19PPEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" abstract="false" name="ScheduleOfCaresActProviderReliefFundsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_AcquiredNamesMember" abstract="true" name="AcquiredNamesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" abstract="true" name="CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TwoHundredMillionRevolvingCreditFacilityMember" abstract="true" name="TwoHundredMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CashDistributionToNoncontrollingInterest" abstract="false" name="CashDistributionToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ConsolidatedLeverageRatio" abstract="false" name="ConsolidatedLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_ConsolidatedInterestCoverageRatio" abstract="false" name="ConsolidatedInterestCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_ShareRepurchaseProgramMember" abstract="true" name="ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CompassionateCareHospiceCIAMember" abstract="true" name="CompassionateCareHospiceCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PayorsDomain" abstract="true" name="PayorsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_TypeOfEquityMethodInvestmentDomain" abstract="true" name="TypeOfEquityMethodInvestmentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CompassionateCareHospiceMember" abstract="true" name="CompassionateCareHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" abstract="false" name="ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RevolvingCreditFacilityTotal" abstract="false" name="RevolvingCreditFacilityTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" abstract="false" name="MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_MedicareRevenueMember" abstract="true" name="MedicareRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CashBalanceAssociatedWithProviderReliefFund" abstract="false" name="CashBalanceAssociatedWithProviderReliefFund" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CARESActDeferralOfEmployerShareSocialSecurityTax" abstract="false" name="CARESActDeferralOfEmployerShareSocialSecurityTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HomeHealthMember" abstract="true" name="HomeHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DepreciationAndAmortizationForContinuingOperations" abstract="false" name="DepreciationAndAmortizationForContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SecondAmendmentToAmendedCreditAgreementMember" abstract="true" name="SecondAmendmentToAmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" abstract="false" name="CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures" abstract="false" name="EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" abstract="false" name="AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmedisysCIAMember" abstract="true" name="AmedisysCIAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HospiceMedicareMember" abstract="true" name="HospiceMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_HighAcuityCareMember" abstract="true" name="HighAcuityCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PeriodOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="PeriodOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RevenueAdjustmentToMedicareRevenue" abstract="false" name="RevenueAdjustmentToMedicareRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EquityImpactofRepurchaseofNoncontrollingInterest" abstract="false" name="EquityImpactofRepurchaseofNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_WorkersCompensationInsuranceRetentionLimit" abstract="false" name="WorkersCompensationInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" abstract="false" name="Revenuebypayorclassasapercentageoftotalnetservicerevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiary" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HospiceMedicareRevenueRateAccountedForRoutineCare" abstract="false" name="HospiceMedicareRevenueRateAccountedForRoutineCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" abstract="false" name="MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_IndemnificationAmount" abstract="false" name="IndemnificationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_CashPaidForOperatingLeaseLiabilities" abstract="false" name="CashPaidForOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_VisitingNurseAssociationMember" abstract="true" name="VisitingNurseAssociationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessAcquisitionClosingPaymentAdjustment" abstract="false" name="BusinessAcquisitionClosingPaymentAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" abstract="true" name="FiveHundredFiftyMillionRevolvingCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ShareRepurchaseTable" abstract="true" name="ShareRepurchaseTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_FirstThresholdOfTherapyServicesRequired" abstract="false" name="FirstThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_HomeHealthMedicareMember" abstract="true" name="HomeHealthMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_MaximumPercentOwnershipForEquityMethodPercent" abstract="false" name="MaximumPercentOwnershipForEquityMethodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_ThirdThresholdOfTherapyServicesRequired" abstract="false" name="ThirdThresholdOfTherapyServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" abstract="false" name="PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_SurrenderedShares" abstract="false" name="SurrenderedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PercentageofSharesOutstanding" abstract="false" name="PercentageofSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HistoricalCollectionRateFromMedicare" abstract="false" name="HistoricalCollectionRateFromMedicare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HospiceMember" abstract="true" name="HospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_NumberOfBeneficiaries" abstract="false" name="NumberOfBeneficiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" abstract="false" name="StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CashPaidForFinanceLeaseLiabilities" abstract="false" name="CashPaidForFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" abstract="true" name="OneHundredSeventyFiveMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" abstract="false" name="FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ProfessionalLiabilityInsuranceRetentionLimit" abstract="false" name="ProfessionalLiabilityInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PaymentsRelatedToTaxAsset" abstract="false" name="PaymentsRelatedToTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_UsDepartmentOfJusticeMember" abstract="true" name="UsDepartmentOfJusticeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_ExtrapolatedMember" abstract="true" name="ExtrapolatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" abstract="false" name="EstimatedCARESActProviderReliefFundAmountsToBeRepaid" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SurrenderedSharesInShares" abstract="false" name="SurrenderedSharesInShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" abstract="false" name="ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NewShareRepurchaseProgramMember" abstract="true" name="NewShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PayorClassAxis" abstract="true" name="PayorClassAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_SwingLineLoanMember" abstract="true" name="SwingLineLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ShareRepurchaseLineItems" abstract="true" name="ShareRepurchaseLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" abstract="false" name="RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HospiceNonMedicareMember" abstract="true" name="HospiceNonMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FundingForHealthcareProvidersIncludingHospitals" abstract="false" name="FundingForHealthcareProvidersIncludingHospitals" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NumberOfJointVentures" abstract="false" name="NumberOfJointVentures" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_EstimatedFutureCOVID19RelatedExpenses" abstract="false" name="EstimatedFutureCOVID19RelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_DebtInstrumentPeriodicPaymentPercentage" abstract="false" name="DebtInstrumentPeriodicPaymentPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_TypeofEquityMethodInvestmentAxis" abstract="true" name="TypeofEquityMethodInvestmentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_CorporateIntegrityAgreementTerm" abstract="false" name="CorporateIntegrityAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" abstract="false" name="DebtInstrumentCarryingAmountExcludingFinanceLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SecondThresholdOfServicesRequired" abstract="false" name="SecondThresholdOfServicesRequired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_FinancialInstrumentDetailsTableTextBlock" abstract="false" name="FinancialInstrumentDetailsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="amed_SafeguardZoneProgramIntegrityContractorMember" abstract="true" name="SafeguardZoneProgramIntegrityContractorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_MajorSinglePayorCustomerMember" abstract="true" name="MajorSinglePayorCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" abstract="false" name="FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" abstract="false" name="EquityImpactOfWriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" abstract="false" name="NetServiceRevenuePeriodOfCarePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_InfinityHomeCareMember" abstract="true" name="InfinityHomeCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_WriteOffOfOtherComprehensiveIncome" abstract="false" name="WriteOffOfOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LakelandFloridaMember" abstract="true" name="LakelandFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MedicareLicenseMember" abstract="true" name="MedicareLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" abstract="false" name="EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_MorgantownWestVirginiaMember" abstract="true" name="MorgantownWestVirginiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_COVID19ExpensesIncurred" abstract="false" name="COVID19ExpensesIncurred" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_FundsReceivedFromProviderReliefFundAdvance" abstract="false" name="FundsReceivedFromProviderReliefFundAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Numberofpatients" abstract="false" name="Numberofpatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_CARESActProviderReliefFundsUtilized" abstract="false" name="CARESActProviderReliefFundsUtilized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CompanysinsurancecarriersMember" abstract="true" name="CompanysinsurancecarriersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_A2019ShareRepurchaseProgramMember" abstract="true" name="A2019ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ProceedsReceivedFromLoanPartyOfSubsidiary" abstract="false" name="ProceedsReceivedFromLoanPartyOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" abstract="false" name="CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="amed_LetterOfCreditFee" abstract="false" name="LetterOfCreditFee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_AsanaHospiceAquisitionMember" abstract="true" name="AsanaHospiceAquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_CertificateOfNeedMember" abstract="true" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_AccountsReceivablePortionDerivedFromMedicare" abstract="false" name="AccountsReceivablePortionDerivedFromMedicare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_ContessaHealthMember" abstract="true" name="ContessaHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ErrorRatePercentage" abstract="false" name="ErrorRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_DebtInstrumentInterestRateatPeriodEnd" abstract="false" name="DebtInstrumentInterestRateatPeriodEnd" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" abstract="false" name="EpisodeOfCareAsEpisodicBasedRevenueDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_NumberOfClaimsSubmittedBySubsidiary" abstract="false" name="NumberOfClaimsSubmittedBySubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_NonMedicareRevenueTermRates" abstract="false" name="NonMedicareRevenueTermRates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_NonVestedStockAndStockUnits" abstract="false" name="NonVestedStockAndStockUnits" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="amed_ExecutiveStockOptionExerciseMember" abstract="true" name="ExecutiveStockOptionExerciseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PercentageOfPatientReceivablesOutstanding" abstract="false" name="PercentageOfPatientReceivablesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" abstract="false" name="DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_HeritageHealthcareInnovationFundLPMember" abstract="true" name="HeritageHealthcareInnovationFundLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_CapYearAxis" abstract="true" name="CapYearAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" abstract="true" name="CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" abstract="false" name="GoodwillDeductibleForIncomeTaxPurposesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" abstract="false" name="LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitMember" abstract="true" name="SecuritiesClassActionLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FundingReceivedFromCARESAct" abstract="false" name="FundingReceivedFromCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" abstract="false" name="EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_SecuritiesClassActionLawsuitsettlement" abstract="false" name="SecuritiesClassActionLawsuitsettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" abstract="false" name="LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" abstract="false" name="RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_HealthInsuranceRetentionLimit" abstract="false" name="HealthInsuranceRetentionLimit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" abstract="true" name="AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_FourHundredFiftyMillionTermLoanFacilityMember" abstract="true" name="FourHundredFiftyMillionTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ExistingShareRepurchaseProgramMember" abstract="true" name="ExistingShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" abstract="false" name="PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="amed_Discountedclosingstockprice" abstract="false" name="Discountedclosingstockprice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" abstract="false" name="IncreaseInEstimatedFutureCOVID19RelatedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_ReversalOfLossContingencyAccrual" abstract="false" name="ReversalOfLossContingencyAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_Businessacquisitionproformaoperatingincomeloss" abstract="false" name="Businessacquisitionproformaoperatingincomeloss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_NetServiceRevenueEpisodePaymentRateDuration" abstract="false" name="NetServiceRevenueEpisodePaymentRateDuration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" abstract="false" name="NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="amed_AdditionalFundingDistributedToHealthcareProviders" abstract="false" name="AdditionalFundingDistributedToHealthcareProviders" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="amed_PersonalCareMember" abstract="true" name="PersonalCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="amed_ClearwaterFloridaMember" abstract="true" name="ClearwaterFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>amed-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9a22ea05-d9af-4e79-9afb-aec6f57a9fea,g:f821983a-9b6a-4f0b-a7a4-a1b27b9c9a2c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20210930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_405fbaa1-f034-4894-92b5-6086571635cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5fc13db2-d1b7-4629-84f8-88a33428168c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_405fbaa1-f034-4894-92b5-6086571635cb" xlink:to="loc_us-gaap_StockholdersEquity_5fc13db2-d1b7-4629-84f8-88a33428168c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b89e82ad-8550-4e91-916b-b76c361d45ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_405fbaa1-f034-4894-92b5-6086571635cb" xlink:to="loc_us-gaap_MinorityInterest_b89e82ad-8550-4e91-916b-b76c361d45ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_58160e5b-1d40-41d4-b5e2-b825813589a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2cf65c51-4151-4295-9fb7-b721c71961b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58160e5b-1d40-41d4-b5e2-b825813589a4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2cf65c51-4151-4295-9fb7-b721c71961b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_2adfa092-e46f-4b69-8497-73294d47dc5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58160e5b-1d40-41d4-b5e2-b825813589a4" xlink:to="loc_us-gaap_RestrictedCash_2adfa092-e46f-4b69-8497-73294d47dc5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9408e182-6ed4-4d75-b0a7-f0caff1fa0bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58160e5b-1d40-41d4-b5e2-b825813589a4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9408e182-6ed4-4d75-b0a7-f0caff1fa0bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5c4c7d85-ffb5-4acc-86f2-39580fe1dd0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58160e5b-1d40-41d4-b5e2-b825813589a4" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5c4c7d85-ffb5-4acc-86f2-39580fe1dd0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_84a3ce98-4889-4f08-8ffb-b89649a887c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58160e5b-1d40-41d4-b5e2-b825813589a4" xlink:to="loc_us-gaap_OtherAssetsCurrent_84a3ce98-4889-4f08-8ffb-b89649a887c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_91918933-9a5d-4f9d-a428-d7a54f7d74bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_23793377-db33-4201-ad1f-ea890ca09bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91918933-9a5d-4f9d-a428-d7a54f7d74bf" xlink:to="loc_us-gaap_AccountsPayableCurrent_23793377-db33-4201-ad1f-ea890ca09bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9e0397f-6777-428c-a141-1cba773c3072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91918933-9a5d-4f9d-a428-d7a54f7d74bf" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9e0397f-6777-428c-a141-1cba773c3072" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_033ef89d-1ca8-4178-bcd9-d28a8df1d880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91918933-9a5d-4f9d-a428-d7a54f7d74bf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_033ef89d-1ca8-4178-bcd9-d28a8df1d880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_161c08e0-febf-48a7-90c5-cacbdfdaddfe" xlink:href="amed-20210930.xsd#amed_ProviderReliefFundAdvance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91918933-9a5d-4f9d-a428-d7a54f7d74bf" xlink:to="loc_amed_ProviderReliefFundAdvance_161c08e0-febf-48a7-90c5-cacbdfdaddfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_bd53dc96-f96a-4953-9eea-d8520d297409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91918933-9a5d-4f9d-a428-d7a54f7d74bf" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_bd53dc96-f96a-4953-9eea-d8520d297409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7759db53-e3fd-4a90-9c91-36c93f141bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_91918933-9a5d-4f9d-a428-d7a54f7d74bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7759db53-e3fd-4a90-9c91-36c93f141bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8562e64b-2c1d-46b9-a347-e01bf99e06b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ef7789bb-b867-4367-b1ff-faea31039831" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8562e64b-2c1d-46b9-a347-e01bf99e06b3" xlink:to="loc_us-gaap_LiabilitiesCurrent_ef7789bb-b867-4367-b1ff-faea31039831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d08cf3c8-c123-4622-a5b4-1dbe89369a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8562e64b-2c1d-46b9-a347-e01bf99e06b3" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d08cf3c8-c123-4622-a5b4-1dbe89369a6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_005158ab-46dc-436d-9100-d7bd1f62eaf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8562e64b-2c1d-46b9-a347-e01bf99e06b3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_005158ab-46dc-436d-9100-d7bd1f62eaf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_96fa0004-70cf-41a3-b442-910dcf1f525a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8562e64b-2c1d-46b9-a347-e01bf99e06b3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_96fa0004-70cf-41a3-b442-910dcf1f525a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_35ead80b-ee3c-45f5-990e-1c7f0859936f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2aed28af-25e1-47af-a8ce-daf4e5b121cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_35ead80b-ee3c-45f5-990e-1c7f0859936f" xlink:to="loc_us-gaap_AssetsCurrent_2aed28af-25e1-47af-a8ce-daf4e5b121cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf3d5e87-b573-45c4-86ae-eb0dd05ccc4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_35ead80b-ee3c-45f5-990e-1c7f0859936f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bf3d5e87-b573-45c4-86ae-eb0dd05ccc4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_689c2ce6-d0a4-46de-95c6-427355b07969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_35ead80b-ee3c-45f5-990e-1c7f0859936f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_689c2ce6-d0a4-46de-95c6-427355b07969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e2a079b7-c474-4718-af83-259597dca6ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_35ead80b-ee3c-45f5-990e-1c7f0859936f" xlink:to="loc_us-gaap_Goodwill_e2a079b7-c474-4718-af83-259597dca6ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c3abf768-c885-4154-ad70-6d2a3493df54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_35ead80b-ee3c-45f5-990e-1c7f0859936f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_c3abf768-c885-4154-ad70-6d2a3493df54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_fd049ebc-f742-4be4-b4d8-bc90b865ae0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_35ead80b-ee3c-45f5-990e-1c7f0859936f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_fd049ebc-f742-4be4-b4d8-bc90b865ae0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d2ea9a57-de89-4996-8e27-ac93e96b1af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_35ead80b-ee3c-45f5-990e-1c7f0859936f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d2ea9a57-de89-4996-8e27-ac93e96b1af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b1dd9c94-72f1-478c-91d9-32328cf9fd38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_211d1dd0-5209-482e-916b-292d5ee9610d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b1dd9c94-72f1-478c-91d9-32328cf9fd38" xlink:to="loc_us-gaap_Liabilities_211d1dd0-5209-482e-916b-292d5ee9610d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0901a383-2538-4dd2-88a7-7713777487be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b1dd9c94-72f1-478c-91d9-32328cf9fd38" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0901a383-2538-4dd2-88a7-7713777487be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_111bc4ae-546e-4e32-87a4-5322fe446338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_60d90686-1944-4e6e-92f7-e73080115a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_111bc4ae-546e-4e32-87a4-5322fe446338" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_60d90686-1944-4e6e-92f7-e73080115a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_c60d18d7-f18f-456d-9628-e28ae50258dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_111bc4ae-546e-4e32-87a4-5322fe446338" xlink:to="loc_us-gaap_CommonStockValueOutstanding_c60d18d7-f18f-456d-9628-e28ae50258dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7a7e4fe2-6e6c-4ac0-9b72-36bb15048472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_111bc4ae-546e-4e32-87a4-5322fe446338" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7a7e4fe2-6e6c-4ac0-9b72-36bb15048472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c1edf1f7-38ba-40fe-a338-6dec26338c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_111bc4ae-546e-4e32-87a4-5322fe446338" xlink:to="loc_us-gaap_TreasuryStockValue_c1edf1f7-38ba-40fe-a338-6dec26338c40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79b04585-c5ba-458a-b40c-71188e296be9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_111bc4ae-546e-4e32-87a4-5322fe446338" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_79b04585-c5ba-458a-b40c-71188e296be9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20210930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_50bb236f-860e-4605-a044-5f9c3fa12ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_42da8861-726a-4b59-9fd5-540fee6eff14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_50bb236f-860e-4605-a044-5f9c3fa12ba4" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_42da8861-726a-4b59-9fd5-540fee6eff14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a1cc793b-9c7d-4998-b3e8-c295778f5998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_50bb236f-860e-4605-a044-5f9c3fa12ba4" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a1cc793b-9c7d-4998-b3e8-c295778f5998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_157d8444-e437-467e-9075-2682d5baf12e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_50bb236f-860e-4605-a044-5f9c3fa12ba4" xlink:to="loc_us-gaap_CostsAndExpenses_157d8444-e437-467e-9075-2682d5baf12e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5de2c371-7139-4be2-9f61-c4648de6fffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_e18d5c75-5c46-48b5-950c-db1d16200fa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5de2c371-7139-4be2-9f61-c4648de6fffd" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_e18d5c75-5c46-48b5-950c-db1d16200fa8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4e9f100b-5938-41e0-b945-695b3a44ca73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5de2c371-7139-4be2-9f61-c4648de6fffd" xlink:to="loc_us-gaap_InterestExpense_4e9f100b-5938-41e0-b945-695b3a44ca73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3509f214-6fb4-4cbb-b874-aee22bd29349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5de2c371-7139-4be2-9f61-c4648de6fffd" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3509f214-6fb4-4cbb-b874-aee22bd29349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_d04de7d3-627e-42f3-abf0-a253e496c184" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5de2c371-7139-4be2-9f61-c4648de6fffd" xlink:to="loc_us-gaap_GainLossOnInvestments_d04de7d3-627e-42f3-abf0-a253e496c184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7c6e8cef-0322-4c4c-ad22-a33fd3938917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5de2c371-7139-4be2-9f61-c4648de6fffd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7c6e8cef-0322-4c4c-ad22-a33fd3938917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f6d5a4af-a8b4-45b6-b46d-ea93f08f4a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5df6c80d-5a9f-4c97-8294-8d10a50ff877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_f6d5a4af-a8b4-45b6-b46d-ea93f08f4a8c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5df6c80d-5a9f-4c97-8294-8d10a50ff877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22da9165-ab34-4ca4-8ab9-1b121259948f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_f6d5a4af-a8b4-45b6-b46d-ea93f08f4a8c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_22da9165-ab34-4ca4-8ab9-1b121259948f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_011ce078-1fc1-4193-b839-378c1eb56c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_636e1bfd-9178-44e2-9f98-b710cf6b1c0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_011ce078-1fc1-4193-b839-378c1eb56c7c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_636e1bfd-9178-44e2-9f98-b710cf6b1c0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_5df80db7-6275-4459-8118-1da27dd136dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_011ce078-1fc1-4193-b839-378c1eb56c7c" xlink:to="loc_us-gaap_LaborAndRelatedExpense_5df80db7-6275-4459-8118-1da27dd136dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d80d61a4-199b-4a37-9bae-8e98a02993de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_011ce078-1fc1-4193-b839-378c1eb56c7c" xlink:to="loc_us-gaap_ShareBasedCompensation_d80d61a4-199b-4a37-9bae-8e98a02993de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_0dee4266-f26b-4bda-8b9c-1ebf1b6dda4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_011ce078-1fc1-4193-b839-378c1eb56c7c" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_0dee4266-f26b-4bda-8b9c-1ebf1b6dda4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6b202b81-f6ba-4f3a-82d2-87999eb93626" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_011ce078-1fc1-4193-b839-378c1eb56c7c" xlink:to="loc_us-gaap_DepreciationAndAmortization_6b202b81-f6ba-4f3a-82d2-87999eb93626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1425a5a3-8f62-4386-8a62-159f19f3a640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4afc1b5f-3b9b-4b7f-9d0b-9e6432493c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1425a5a3-8f62-4386-8a62-159f19f3a640" xlink:to="loc_us-gaap_OperatingIncomeLoss_4afc1b5f-3b9b-4b7f-9d0b-9e6432493c05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4da5dc3e-a9b3-4d8d-ba0e-e0f88406d9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1425a5a3-8f62-4386-8a62-159f19f3a640" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4da5dc3e-a9b3-4d8d-ba0e-e0f88406d9b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0ff3ccf-370a-41aa-9466-e12cfb73c486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1e631397-f8b5-4438-ad80-0c49aed43ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a0ff3ccf-370a-41aa-9466-e12cfb73c486" xlink:to="loc_us-gaap_ProfitLoss_1e631397-f8b5-4438-ad80-0c49aed43ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a8266363-e8df-464b-8b3a-6ce2ca327f76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a0ff3ccf-370a-41aa-9466-e12cfb73c486" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a8266363-e8df-464b-8b3a-6ce2ca327f76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20210930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b653840c-af0b-45d6-adee-4f4bf0b6c143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f8517c3f-f65c-4e60-88f3-ac7dbe48b202" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b653840c-af0b-45d6-adee-4f4bf0b6c143" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f8517c3f-f65c-4e60-88f3-ac7dbe48b202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7533735c-2135-425e-a137-5c585d2e1ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b653840c-af0b-45d6-adee-4f4bf0b6c143" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7533735c-2135-425e-a137-5c585d2e1ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_85b31a00-0b3e-4999-aafc-46af7f15fcb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b653840c-af0b-45d6-adee-4f4bf0b6c143" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_85b31a00-0b3e-4999-aafc-46af7f15fcb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c5599de8-7ab9-4421-9cd1-38b2ec90af43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c5599de8-7ab9-4421-9cd1-38b2ec90af43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_a48624f3-f2c2-497c-8b12-1a3ff284ecec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_us-gaap_ProceedsFromStockPlans_a48624f3-f2c2-497c-8b12-1a3ff284ecec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7579bace-d356-49fa-81a3-ffca2d84fb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7579bace-d356-49fa-81a3-ffca2d84fb30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_81f6a014-8175-47c0-a6d2-bea297d83685" xlink:href="amed-20210930.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_81f6a014-8175-47c0-a6d2-bea297d83685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d764e3a7-1fb6-497d-a861-beef90d16d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d764e3a7-1fb6-497d-a861-beef90d16d65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_d9fa8903-44c2-4f02-bdc6-da45d37de89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_d9fa8903-44c2-4f02-bdc6-da45d37de89a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_fb1b7e1b-26a7-4474-b129-55097fce09a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_fb1b7e1b-26a7-4474-b129-55097fce09a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9c94fc3f-1e53-481a-8273-26630f682bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9c94fc3f-1e53-481a-8273-26630f682bca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e4840756-8efd-49f1-b1d2-a57f5c44902c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_e4840756-8efd-49f1-b1d2-a57f5c44902c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_55ca6004-c59a-4a3b-aff0-4f4149cca460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_55ca6004-c59a-4a3b-aff0-4f4149cca460" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_5ba69fcd-925e-453b-8b80-8d56cb5a0713" xlink:href="amed-20210930.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_209d0bf4-d651-495e-b990-3701614b344a" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_5ba69fcd-925e-453b-8b80-8d56cb5a0713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_aeb58cbe-30e5-48c3-84bc-d3b34e5664bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_ProfitLoss_aeb58cbe-30e5-48c3-84bc-d3b34e5664bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_cacca136-35bf-44e3-ba6f-06ad83200d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_cacca136-35bf-44e3-ba6f-06ad83200d0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a9321754-427c-4a0a-ad27-d155e455dd94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_ShareBasedCompensation_a9321754-427c-4a0a-ad27-d155e455dd94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_5e403250-6bf4-47cf-a91e-99a3331a671b" xlink:href="amed-20210930.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_5e403250-6bf4-47cf-a91e-99a3331a671b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_05c7b97e-217a-419c-a7dd-7d0799b9a330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_05c7b97e-217a-419c-a7dd-7d0799b9a330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_421a2dc8-8039-47cf-8b73-3951c256b987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_421a2dc8-8039-47cf-8b73-3951c256b987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_1e0a9f7a-0378-4cdb-b249-9b44749436b9" xlink:href="amed-20210930.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_1e0a9f7a-0378-4cdb-b249-9b44749436b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b89a2223-11c8-442f-a971-d5407648cc73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b89a2223-11c8-442f-a971-d5407648cc73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bfb4c27c-b46b-4e86-9696-f36640fe839a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bfb4c27c-b46b-4e86-9696-f36640fe839a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3a743228-17bc-4858-abd3-e6812732695d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_3a743228-17bc-4858-abd3-e6812732695d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_ffee626a-873f-4b2e-8d42-ca034927adc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_ffee626a-873f-4b2e-8d42-ca034927adc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3fd5a91a-459b-4c8f-bb5c-c6e72e7a6e83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3fd5a91a-459b-4c8f-bb5c-c6e72e7a6e83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0bdebe5b-90db-4b46-b471-9c56186d2c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0bdebe5b-90db-4b46-b471-9c56186d2c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ce786fc0-e2f0-46f2-a25a-8b5042c2289f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ce786fc0-e2f0-46f2-a25a-8b5042c2289f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a60391ab-443c-484b-8ef2-89639c088a92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a60391ab-443c-484b-8ef2-89639c088a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1fb0df4f-0192-4229-8bfe-96988cbe8bf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_1fb0df4f-0192-4229-8bfe-96988cbe8bf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_e4478d5d-14f8-41c7-838f-8fce203e3b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_e4478d5d-14f8-41c7-838f-8fce203e3b6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_5a5e951b-11ef-4f2f-841e-434704e0abba" xlink:href="amed-20210930.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_5a5e951b-11ef-4f2f-841e-434704e0abba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_a6536b4b-c6a6-4a99-92a3-02f4d875b5e1" xlink:href="amed-20210930.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14848c7f-90df-4def-9994-8c29cda3b243" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_a6536b4b-c6a6-4a99-92a3-02f4d875b5e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d745591-a1b5-4b6d-b926-1fe06485c750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_a368d71d-b295-44db-bfe3-3c3cf9a8f802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d745591-a1b5-4b6d-b926-1fe06485c750" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_a368d71d-b295-44db-bfe3-3c3cf9a8f802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e9fc8206-5d62-41a5-8cad-6f6e24c4494a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d745591-a1b5-4b6d-b926-1fe06485c750" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e9fc8206-5d62-41a5-8cad-6f6e24c4494a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45750a07-e29d-4b70-8670-d2bef6d6554b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d745591-a1b5-4b6d-b926-1fe06485c750" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_45750a07-e29d-4b70-8670-d2bef6d6554b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_406ef122-92d4-4252-8f7d-eeaad74c6929" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d745591-a1b5-4b6d-b926-1fe06485c750" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_406ef122-92d4-4252-8f7d-eeaad74c6929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_c166db2b-9591-41fb-87d9-4e089ca2778d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d745591-a1b5-4b6d-b926-1fe06485c750" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_c166db2b-9591-41fb-87d9-4e089ca2778d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8fb67fac-5391-4394-965b-8eaf373135c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d745591-a1b5-4b6d-b926-1fe06485c750" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8fb67fac-5391-4394-965b-8eaf373135c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_43215a50-aaf6-4dc0-aa83-4211182a652c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7d745591-a1b5-4b6d-b926-1fe06485c750" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_43215a50-aaf6-4dc0-aa83-4211182a652c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f984c09-8493-40b2-9fe1-d64bace14f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57c795f6-2f64-4648-ae15-ad7d5886f2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f984c09-8493-40b2-9fe1-d64bace14f42" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_57c795f6-2f64-4648-ae15-ad7d5886f2af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c053a14d-2d01-46a1-b2d6-cc82343105d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f984c09-8493-40b2-9fe1-d64bace14f42" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c053a14d-2d01-46a1-b2d6-cc82343105d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_ac5ca75f-68b5-4cb2-8496-9285adf021f4" xlink:href="amed-20210930.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f984c09-8493-40b2-9fe1-d64bace14f42" xlink:to="loc_amed_NonVestedStockAndStockUnits_ac5ca75f-68b5-4cb2-8496-9285adf021f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_02540a90-a816-45cf-9e4d-ef0878a4108d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a4961d5d-8e11-4457-99dd-53860cbc0329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_02540a90-a816-45cf-9e4d-ef0878a4108d" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a4961d5d-8e11-4457-99dd-53860cbc0329" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_cd672ed8-6a7b-4da0-a0f6-a02a04ddc236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_02540a90-a816-45cf-9e4d-ef0878a4108d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_cd672ed8-6a7b-4da0-a0f6-a02a04ddc236" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:calculationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_388860ad-482f-476b-8880-389a28177687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0ffa62bb-baab-4e5f-97ff-affe5c14e271" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_388860ad-482f-476b-8880-389a28177687" xlink:to="loc_us-gaap_LongTermDebtCurrent_0ffa62bb-baab-4e5f-97ff-affe5c14e271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a7f99c29-c5e1-4bef-be19-9b398626f053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_388860ad-482f-476b-8880-389a28177687" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a7f99c29-c5e1-4bef-be19-9b398626f053" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>amed-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9a22ea05-d9af-4e79-9afb-aec6f57a9fea,g:f821983a-9b6a-4f0b-a7a4-a1b27b9c9a2c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20210930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended" id="i10df9aabf69940f980d3522bb5de8162_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32727725-1665-423e-94ac-0d68d2a80203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32727725-1665-423e-94ac-0d68d2a80203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7456c7a5-7b7a-40d0-8610-cf55ed9afb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_SharesOutstanding_7456c7a5-7b7a-40d0-8610-cf55ed9afb14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0a660a4d-03c9-4272-b187-244fe3a73164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0a660a4d-03c9-4272-b187-244fe3a73164" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3fded68d-8071-4739-8b7b-7e3534321ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3fded68d-8071-4739-8b7b-7e3534321ce9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_15b1d6b7-a468-4a00-9125-59c1745c476a" xlink:href="amed-20210930.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_15b1d6b7-a468-4a00-9125-59c1745c476a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_67ee1a03-1c10-44fb-a51f-f685778bac3d" xlink:href="amed-20210930.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_67ee1a03-1c10-44fb-a51f-f685778bac3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_7a0ba1d1-a639-417a-a5f2-c2b44e866fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_7a0ba1d1-a639-417a-a5f2-c2b44e866fc8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_22f620ea-ae9d-4aca-9729-3ee476b685ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_22f620ea-ae9d-4aca-9729-3ee476b685ae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c8e24fd1-4698-4c47-9b3b-7cc60dcaea89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c8e24fd1-4698-4c47-9b3b-7cc60dcaea89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_040fe51b-7b4e-435b-9b7e-875a9d03c745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_040fe51b-7b4e-435b-9b7e-875a9d03c745" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_df14da19-1f67-494e-8e8c-8fce980e0b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_df14da19-1f67-494e-8e8c-8fce980e0b76" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_0005e377-1133-47ff-9814-3eb1911fc537" xlink:href="amed-20210930.xsd#amed_SurrenderedShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_SurrenderedShares_0005e377-1133-47ff-9814-3eb1911fc537" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_66d22424-6e31-4da1-a5fd-813a9a8fc181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_66d22424-6e31-4da1-a5fd-813a9a8fc181" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_23bf27ec-b14e-4729-8140-fa5b450a67c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_23bf27ec-b14e-4729-8140-fa5b450a67c0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_a87cdeed-d64e-479a-b45f-575b86c258d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_a87cdeed-d64e-479a-b45f-575b86c258d8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_80dbf27e-9581-4470-90da-cff2d458e112" xlink:href="amed-20210930.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_80dbf27e-9581-4470-90da-cff2d458e112" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_4dcb02f3-e7a5-443f-b98e-49db777a8938" xlink:href="amed-20210930.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_4dcb02f3-e7a5-443f-b98e-49db777a8938" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2cd18d8-60cd-42af-8804-1f1b5fe7bf69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_ProfitLoss_f2cd18d8-60cd-42af-8804-1f1b5fe7bf69" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f65acc3e-8b76-4c87-841f-c9325ccdbfee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_43572249-21b1-4cca-8c87-302af5caae52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c0c192b7-2313-40b9-b57c-7a5f60e9f926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StatementTable_c0c192b7-2313-40b9-b57c-7a5f60e9f926" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_079f679e-5e58-4e99-9bd0-c491ff377105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c0c192b7-2313-40b9-b57c-7a5f60e9f926" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_079f679e-5e58-4e99-9bd0-c491ff377105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_079f679e-5e58-4e99-9bd0-c491ff377105_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_079f679e-5e58-4e99-9bd0-c491ff377105" xlink:to="loc_us-gaap_EquityComponentDomain_079f679e-5e58-4e99-9bd0-c491ff377105_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_079f679e-5e58-4e99-9bd0-c491ff377105" xlink:to="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_864681e4-b745-4672-9c41-87eff2aee4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_CommonStockMember_864681e4-b745-4672-9c41-87eff2aee4b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4c48d602-ef63-4cd5-a601-f8999145b76c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4c48d602-ef63-4cd5-a601-f8999145b76c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_67f1a739-d499-4798-a45e-e2d8b944646e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_TreasuryStockMember_67f1a739-d499-4798-a45e-e2d8b944646e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ebe6c718-dd0e-41ce-a3a5-25bb2dd8365f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ebe6c718-dd0e-41ce-a3a5-25bb2dd8365f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0d09aa79-a812-49d2-98de-9cda1b588aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_RetainedEarningsMember_0d09aa79-a812-49d2-98de-9cda1b588aeb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_42de04d4-70e5-47be-b694-c67125ba6e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_42de04d4-70e5-47be-b694-c67125ba6e4a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_59b42c0d-1b1e-4da2-943b-2ef14e36ac2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_59b42c0d-1b1e-4da2-943b-2ef14e36ac2e" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended" id="i7895d87626954228aa34638b6e6267f0_NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d6da88d3-7f05-4d24-bb28-9ea8e9e18210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d6da88d3-7f05-4d24-bb28-9ea8e9e18210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_2dbfd685-2075-4613-af95-62595aa3fd0f" xlink:href="amed-20210930.xsd#amed_OperatingCareCenters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_OperatingCareCenters_2dbfd685-2075-4613-af95-62595aa3fd0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_b8969726-01e5-41ee-889d-b4bfc6758bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_b8969726-01e5-41ee-889d-b4bfc6758bd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_bf6561ef-54c0-42ae-9fb3-f9c6794ff992" xlink:href="amed-20210930.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_bf6561ef-54c0-42ae-9fb3-f9c6794ff992" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_f5ce274a-b112-4dd9-9dd7-da83759cd89c" xlink:href="amed-20210930.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_f5ce274a-b112-4dd9-9dd7-da83759cd89c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_68721271-eca8-45e9-8d8c-509b77450d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_68721271-eca8-45e9-8d8c-509b77450d38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_484618ff-012a-444c-a8df-5b2338d2c831" xlink:href="amed-20210930.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_484618ff-012a-444c-a8df-5b2338d2c831" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0ecc1c78-70f4-41b0-baec-345620163244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_EquityMethodInvestments_0ecc1c78-70f4-41b0-baec-345620163244" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_67b04a8e-58cf-44bc-a76f-29b318e54ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_67b04a8e-58cf-44bc-a76f-29b318e54ee8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_9174fe81-205a-4f59-8095-1ba3e224ff82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_9174fe81-205a-4f59-8095-1ba3e224ff82" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_1e0f2159-f751-426a-aaa4-2dbc7e051b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_GainLossOnInvestments_1e0f2159-f751-426a-aaa4-2dbc7e051b64" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfJointVentures_50a72ab2-e3a0-4b30-8fc2-55e26a508f85" xlink:href="amed-20210930.xsd#amed_NumberOfJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_NumberOfJointVentures_50a72ab2-e3a0-4b30-8fc2-55e26a508f85" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_d40f00b3-edb7-4e1b-b30d-06c5d52585eb" xlink:href="amed-20210930.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_d40f00b3-edb7-4e1b-b30d-06c5d52585eb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c8b02cb6-de2b-44f4-95f9-882151b21900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c8b02cb6-de2b-44f4-95f9-882151b21900" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a0ce195f-dc97-4968-83dd-21c1896b4553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a0ce195f-dc97-4968-83dd-21c1896b4553" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c0c3540a-9d5e-44ae-988f-bd2f9babf2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_OtherAssetsCurrent_c0c3540a-9d5e-44ae-988f-bd2f9babf2cc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_49eb7cb8-718b-4f34-918b-56ff83c295e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_AssetsCurrent_49eb7cb8-718b-4f34-918b-56ff83c295e9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ac16a176-089d-477d-992c-e502ec9733cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ac16a176-089d-477d-992c-e502ec9733cc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1ca99204-5aba-4fc9-be70-4888cf7a02e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_Assets_1ca99204-5aba-4fc9-be70-4888cf7a02e0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b4ed172-0fc7-4165-a053-37cc5bc7b8f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b4ed172-0fc7-4165-a053-37cc5bc7b8f0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9ca81da9-3f38-46ff-8514-cf1e084a798f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9ca81da9-3f38-46ff-8514-cf1e084a798f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e86e25d0-f8b7-4846-a291-e18e5bb843c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e86e25d0-f8b7-4846-a291-e18e5bb843c0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cca9e90c-a8eb-4208-941c-cb5bd32ad57b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_LiabilitiesCurrent_cca9e90c-a8eb-4208-941c-cb5bd32ad57b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9d97e9f1-8b85-48f7-82bd-9967f8e84515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9d97e9f1-8b85-48f7-82bd-9967f8e84515" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a69eae77-08b4-4f50-b384-20246afab174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_Liabilities_a69eae77-08b4-4f50-b384-20246afab174" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_abec17c6-7b58-47e2-87b0-0fbe27242460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_abec17c6-7b58-47e2-87b0-0fbe27242460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_abec17c6-7b58-47e2-87b0-0fbe27242460_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_abec17c6-7b58-47e2-87b0-0fbe27242460" xlink:to="loc_us-gaap_TypeOfAdoptionMember_abec17c6-7b58-47e2-87b0-0fbe27242460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_cc85882a-a7da-420d-82ec-ef53eb7f742c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_abec17c6-7b58-47e2-87b0-0fbe27242460" xlink:to="loc_us-gaap_TypeOfAdoptionMember_cc85882a-a7da-420d-82ec-ef53eb7f742c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0736bf8a-995c-4fe3-8ff4-67ae3365c0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_cc85882a-a7da-420d-82ec-ef53eb7f742c" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0736bf8a-995c-4fe3-8ff4-67ae3365c0c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bc746e63-9e06-467e-bbe0-0ca87813753f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bc746e63-9e06-467e-bbe0-0ca87813753f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bc746e63-9e06-467e-bbe0-0ca87813753f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bc746e63-9e06-467e-bbe0-0ca87813753f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_bc746e63-9e06-467e-bbe0-0ca87813753f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3d9dd6b-2071-4a35-91fb-c30e4b836f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bc746e63-9e06-467e-bbe0-0ca87813753f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3d9dd6b-2071-4a35-91fb-c30e4b836f22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f08e39f8-763a-4879-b62f-dfed7004310d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3d9dd6b-2071-4a35-91fb-c30e4b836f22" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f08e39f8-763a-4879-b62f-dfed7004310d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f8afa526-4f99-4d32-873d-8576577383ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f8afa526-4f99-4d32-873d-8576577383ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f8afa526-4f99-4d32-873d-8576577383ef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f8afa526-4f99-4d32-873d-8576577383ef" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f8afa526-4f99-4d32-873d-8576577383ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1c1624f1-dec1-4084-b4c7-d9e81edb3de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f8afa526-4f99-4d32-873d-8576577383ef" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1c1624f1-dec1-4084-b4c7-d9e81edb3de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_0f86d09f-983c-4765-b0de-6962ba21246a" xlink:href="amed-20210930.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1c1624f1-dec1-4084-b4c7-d9e81edb3de0" xlink:to="loc_amed_MedicareRevenueMember_0f86d09f-983c-4765-b0de-6962ba21246a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_89821c99-ca3a-48fb-b886-08b85bcf9552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1c1624f1-dec1-4084-b4c7-d9e81edb3de0" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_89821c99-ca3a-48fb-b886-08b85bcf9552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f9b6e1fe-0548-4ada-a56c-56f88174eaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f9b6e1fe-0548-4ada-a56c-56f88174eaa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f9b6e1fe-0548-4ada-a56c-56f88174eaa1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f9b6e1fe-0548-4ada-a56c-56f88174eaa1" xlink:to="loc_us-gaap_SegmentDomain_f9b6e1fe-0548-4ada-a56c-56f88174eaa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f9b6e1fe-0548-4ada-a56c-56f88174eaa1" xlink:to="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_1179ca86-23d2-4c36-bcf4-632cdf122fc6" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:to="loc_amed_HomeHealthMember_1179ca86-23d2-4c36-bcf4-632cdf122fc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_82e965b7-88ac-463c-8715-fd072cd43004" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:to="loc_amed_HospiceMember_82e965b7-88ac-463c-8715-fd072cd43004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_50041308-b6a0-4aef-bc58-a38f6372d445" xlink:href="amed-20210930.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:to="loc_amed_PersonalCareMember_50041308-b6a0-4aef-bc58-a38f6372d445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_dda1d2ef-5704-4153-a583-ebc37e9c3684" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:to="loc_amed_HighAcuityCareMember_dda1d2ef-5704-4153-a583-ebc37e9c3684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_97d932f4-2fdd-41cb-919d-5a77dfaabbbf" xlink:href="amed-20210930.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_97d932f4-2fdd-41cb-919d-5a77dfaabbbf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_97d932f4-2fdd-41cb-919d-5a77dfaabbbf_default" xlink:href="amed-20210930.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_97d932f4-2fdd-41cb-919d-5a77dfaabbbf" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_97d932f4-2fdd-41cb-919d-5a77dfaabbbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_1f308f14-1dc3-43ec-87aa-1bb76ad0149c" xlink:href="amed-20210930.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_97d932f4-2fdd-41cb-919d-5a77dfaabbbf" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_1f308f14-1dc3-43ec-87aa-1bb76ad0149c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember_415ada62-028a-4d43-9136-55e205545ae1" xlink:href="amed-20210930.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_1f308f14-1dc3-43ec-87aa-1bb76ad0149c" xlink:to="loc_amed_HeritageHealthcareInnovationFundLPMember_415ada62-028a-4d43-9136-55e205545ae1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_fce0863f-81c2-4c67-b706-19a7864327ba" xlink:href="amed-20210930.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_1f308f14-1dc3-43ec-87aa-1bb76ad0149c" xlink:to="loc_amed_MedalogixMember_fce0863f-81c2-4c67-b706-19a7864327ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_33e7442a-fb5e-49e9-a0d6-0d75044328dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_srt_ProductOrServiceAxis_33e7442a-fb5e-49e9-a0d6-0d75044328dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_33e7442a-fb5e-49e9-a0d6-0d75044328dd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_33e7442a-fb5e-49e9-a0d6-0d75044328dd" xlink:to="loc_srt_ProductsAndServicesDomain_33e7442a-fb5e-49e9-a0d6-0d75044328dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89811f0f-69a3-4fac-8a95-93afe30395e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_33e7442a-fb5e-49e9-a0d6-0d75044328dd" xlink:to="loc_srt_ProductsAndServicesDomain_89811f0f-69a3-4fac-8a95-93afe30395e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_4e228701-b10a-4572-b395-c6da7e84b533" xlink:href="amed-20210930.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89811f0f-69a3-4fac-8a95-93afe30395e8" xlink:to="loc_amed_MedicareRevenueMember_4e228701-b10a-4572-b395-c6da7e84b533" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6c8405f2-f8db-46f7-83fa-0f04a70d6a5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6c8405f2-f8db-46f7-83fa-0f04a70d6a5d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6c8405f2-f8db-46f7-83fa-0f04a70d6a5d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6c8405f2-f8db-46f7-83fa-0f04a70d6a5d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6c8405f2-f8db-46f7-83fa-0f04a70d6a5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_decebc2f-9348-4b84-b65b-780a70a72f5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6c8405f2-f8db-46f7-83fa-0f04a70d6a5d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_decebc2f-9348-4b84-b65b-780a70a72f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ff3bcf6d-ceb9-4459-a63b-72c78f86154b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_decebc2f-9348-4b84-b65b-780a70a72f5a" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ff3bcf6d-ceb9-4459-a63b-72c78f86154b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="i7ed028fec3614a07b33a7d06adc10ab9_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_dbef2e2d-c891-4b44-a3f8-9e952487c764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_dbef2e2d-c891-4b44-a3f8-9e952487c764" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_083c3357-4c8c-4603-974d-389fd93ec619" xlink:href="amed-20210930.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_083c3357-4c8c-4603-974d-389fd93ec619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_fc84d7ab-891c-4541-be3c-a6e740126e16" xlink:href="amed-20210930.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_fc84d7ab-891c-4541-be3c-a6e740126e16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_990ee3d7-7fef-464c-ac31-8d63a25e8c6c" xlink:href="amed-20210930.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_990ee3d7-7fef-464c-ac31-8d63a25e8c6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_7590a045-141b-4ec2-978e-0916b1698ab4" xlink:href="amed-20210930.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_7590a045-141b-4ec2-978e-0916b1698ab4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_49e8b11a-4ac8-4851-aab7-2d2581749308" xlink:href="amed-20210930.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_49e8b11a-4ac8-4851-aab7-2d2581749308" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_f925eb28-2735-42df-9b19-21a56b89e72d" xlink:href="amed-20210930.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_f925eb28-2735-42df-9b19-21a56b89e72d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_ceeb56d8-accb-45bb-9a9e-cfb9376ae68a" xlink:href="amed-20210930.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_SecondThresholdOfServicesRequired_ceeb56d8-accb-45bb-9a9e-cfb9376ae68a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_151b13ab-a039-45a5-9b9c-8dedcd1a6c26" xlink:href="amed-20210930.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_151b13ab-a039-45a5-9b9c-8dedcd1a6c26" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_515c37e6-692b-43cd-a9a6-b9f1ae1b7f24" xlink:href="amed-20210930.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_515c37e6-692b-43cd-a9a6-b9f1ae1b7f24" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_3849fe92-5f0c-4817-976a-c659b04835e6" xlink:href="amed-20210930.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_NonMedicareRevenueTermRates_3849fe92-5f0c-4817-976a-c659b04835e6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_15302a74-8b91-4b18-82bf-b1c792ab1d35" xlink:href="amed-20210930.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_15302a74-8b91-4b18-82bf-b1c792ab1d35" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1b537ffa-a564-4a23-b5ad-c244ef536fd7" xlink:href="amed-20210930.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1b537ffa-a564-4a23-b5ad-c244ef536fd7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_1ddabd1c-780e-4c06-9d5c-215dc447f627" xlink:href="amed-20210930.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_1ddabd1c-780e-4c06-9d5c-215dc447f627" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_6203af7e-7715-4b55-96e3-a59ac5b3d928" xlink:href="amed-20210930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_6203af7e-7715-4b55-96e3-a59ac5b3d928" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0757cc24-f603-43be-9f39-44b627f7403a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0757cc24-f603-43be-9f39-44b627f7403a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0757cc24-f603-43be-9f39-44b627f7403a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0757cc24-f603-43be-9f39-44b627f7403a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0757cc24-f603-43be-9f39-44b627f7403a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e2202bb-db36-4626-909e-4e957ac931f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0757cc24-f603-43be-9f39-44b627f7403a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e2202bb-db36-4626-909e-4e957ac931f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_738a4533-f0c2-4fdc-b543-0c3cbd3ba740" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e2202bb-db36-4626-909e-4e957ac931f2" xlink:to="loc_amed_CompassionateCareHospiceMember_738a4533-f0c2-4fdc-b543-0c3cbd3ba740" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_7bf587bc-19b0-4130-8c09-9e6cc736f0e0" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e2202bb-db36-4626-909e-4e957ac931f2" xlink:to="loc_amed_AseraCareHospiceMember_7bf587bc-19b0-4130-8c09-9e6cc736f0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ad28042d-fbdb-4177-a0e6-fc3e32b60eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ad28042d-fbdb-4177-a0e6-fc3e32b60eb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ad28042d-fbdb-4177-a0e6-fc3e32b60eb7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ad28042d-fbdb-4177-a0e6-fc3e32b60eb7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ad28042d-fbdb-4177-a0e6-fc3e32b60eb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fc5efd1f-8e80-4e88-a381-4fde9d4a13d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ad28042d-fbdb-4177-a0e6-fc3e32b60eb7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fc5efd1f-8e80-4e88-a381-4fde9d4a13d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_dea7853d-52cc-4d61-9f90-06e5eb0fa7f0" xlink:href="amed-20210930.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fc5efd1f-8e80-4e88-a381-4fde9d4a13d4" xlink:to="loc_amed_MedicareRevenueMember_dea7853d-52cc-4d61-9f90-06e5eb0fa7f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_a758637e-522e-4f93-8516-2b1a2f90cfac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fc5efd1f-8e80-4e88-a381-4fde9d4a13d4" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_a758637e-522e-4f93-8516-2b1a2f90cfac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dcd18365-e54f-4271-beb5-7c9e843c346f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dcd18365-e54f-4271-beb5-7c9e843c346f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcd18365-e54f-4271-beb5-7c9e843c346f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dcd18365-e54f-4271-beb5-7c9e843c346f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dcd18365-e54f-4271-beb5-7c9e843c346f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_49aadc44-c44d-4b02-a1ca-fc319cde4fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dcd18365-e54f-4271-beb5-7c9e843c346f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_49aadc44-c44d-4b02-a1ca-fc319cde4fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_d5f95fc2-0c24-473e-8568-b4aaf87a344f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_49aadc44-c44d-4b02-a1ca-fc319cde4fef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_d5f95fc2-0c24-473e-8568-b4aaf87a344f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_f18fd3c9-5199-4e34-8d9e-a1ecd627e38d" xlink:href="amed-20210930.xsd#amed_CapYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_amed_CapYearAxis_f18fd3c9-5199-4e34-8d9e-a1ecd627e38d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_f18fd3c9-5199-4e34-8d9e-a1ecd627e38d_default" xlink:href="amed-20210930.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_CapYearAxis_f18fd3c9-5199-4e34-8d9e-a1ecd627e38d" xlink:to="loc_amed_CapYearDomain_f18fd3c9-5199-4e34-8d9e-a1ecd627e38d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_54843d14-723a-4551-808b-c72c84457555" xlink:href="amed-20210930.xsd#amed_CapYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_CapYearAxis_f18fd3c9-5199-4e34-8d9e-a1ecd627e38d" xlink:to="loc_amed_CapYearDomain_54843d14-723a-4551-808b-c72c84457555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_3dd1e950-9aad-4d31-bd49-c0ed727dbb34" xlink:href="amed-20210930.xsd#amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_54843d14-723a-4551-808b-c72c84457555" xlink:to="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_3dd1e950-9aad-4d31-bd49-c0ed727dbb34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_50b0fab3-e268-4c14-a1c5-8895c7933ad2" xlink:href="amed-20210930.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_CapYearDomain_54843d14-723a-4551-808b-c72c84457555" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_50b0fab3-e268-4c14-a1c5-8895c7933ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c5e1c562-deb7-4389-b895-b25dc46788fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c5e1c562-deb7-4389-b895-b25dc46788fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c5e1c562-deb7-4389-b895-b25dc46788fc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c5e1c562-deb7-4389-b895-b25dc46788fc" xlink:to="loc_us-gaap_SegmentDomain_c5e1c562-deb7-4389-b895-b25dc46788fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c5e1c562-deb7-4389-b895-b25dc46788fc" xlink:to="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_317d3f5b-fe3b-4604-b7f2-4a2f9ce9a44d" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:to="loc_amed_HomeHealthMember_317d3f5b-fe3b-4604-b7f2-4a2f9ce9a44d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_75e1c80f-8b31-47c2-9778-135f721ac6d8" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:to="loc_amed_HospiceMember_75e1c80f-8b31-47c2-9778-135f721ac6d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_cebbf484-0fc2-44ec-8b41-77c02e17c01b" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:to="loc_amed_HighAcuityCareMember_cebbf484-0fc2-44ec-8b41-77c02e17c01b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba0db8ed-218d-4b0f-a56a-bb981b15074f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_srt_RangeAxis_ba0db8ed-218d-4b0f-a56a-bb981b15074f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba0db8ed-218d-4b0f-a56a-bb981b15074f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ba0db8ed-218d-4b0f-a56a-bb981b15074f" xlink:to="loc_srt_RangeMember_ba0db8ed-218d-4b0f-a56a-bb981b15074f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0e93d82-5921-4b44-9560-4547f7a989e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ba0db8ed-218d-4b0f-a56a-bb981b15074f" xlink:to="loc_srt_RangeMember_e0e93d82-5921-4b44-9560-4547f7a989e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff2e3752-1119-4234-8eba-8a67244757fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0e93d82-5921-4b44-9560-4547f7a989e6" xlink:to="loc_srt_MinimumMember_ff2e3752-1119-4234-8eba-8a67244757fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_df6cc427-4860-4607-986b-3b456f985213" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0e93d82-5921-4b44-9560-4547f7a989e6" xlink:to="loc_srt_MaximumMember_df6cc427-4860-4607-986b-3b456f985213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_25fd731f-5d19-4ada-ae84-74b26757e5d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_srt_ProductOrServiceAxis_25fd731f-5d19-4ada-ae84-74b26757e5d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_25fd731f-5d19-4ada-ae84-74b26757e5d5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_25fd731f-5d19-4ada-ae84-74b26757e5d5" xlink:to="loc_srt_ProductsAndServicesDomain_25fd731f-5d19-4ada-ae84-74b26757e5d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92262a06-8298-4f60-849e-40c589b294a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_25fd731f-5d19-4ada-ae84-74b26757e5d5" xlink:to="loc_srt_ProductsAndServicesDomain_92262a06-8298-4f60-849e-40c589b294a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_998c6f75-9dc4-492e-9449-7bc49bb57e97" xlink:href="amed-20210930.xsd#amed_MedicareRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_92262a06-8298-4f60-849e-40c589b294a6" xlink:to="loc_amed_MedicareRevenueMember_998c6f75-9dc4-492e-9449-7bc49bb57e97" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended" id="i5ba6bde9322c473180e5f01f60fe8401_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_e0735fd3-5217-4d92-a27c-d2d46909145d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_6bb5e96b-e954-47de-8a2b-4a7a807bd2e4" xlink:href="amed-20210930.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_e0735fd3-5217-4d92-a27c-d2d46909145d" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_6bb5e96b-e954-47de-8a2b-4a7a807bd2e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_3654dfe6-7ff6-40b3-b4e7-10b379802c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_e0735fd3-5217-4d92-a27c-d2d46909145d" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_3654dfe6-7ff6-40b3-b4e7-10b379802c25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_b33bc8d4-1be7-4dc5-9abd-2ccb4683aa3b" xlink:href="amed-20210930.xsd#amed_PayorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_3654dfe6-7ff6-40b3-b4e7-10b379802c25" xlink:to="loc_amed_PayorClassAxis_b33bc8d4-1be7-4dc5-9abd-2ccb4683aa3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_b33bc8d4-1be7-4dc5-9abd-2ccb4683aa3b_default" xlink:href="amed-20210930.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorClassAxis_b33bc8d4-1be7-4dc5-9abd-2ccb4683aa3b" xlink:to="loc_amed_PayorClassDomain_b33bc8d4-1be7-4dc5-9abd-2ccb4683aa3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:href="amed-20210930.xsd#amed_PayorClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorClassAxis_b33bc8d4-1be7-4dc5-9abd-2ccb4683aa3b" xlink:to="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_5f97d1e3-7842-47ec-84c5-c00f947a7e5d" xlink:href="amed-20210930.xsd#amed_HomeHealthMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HomeHealthMedicareMember_5f97d1e3-7842-47ec-84c5-c00f947a7e5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_599fc591-d325-40b6-881e-7f9c5895042d" xlink:href="amed-20210930.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_599fc591-d325-40b6-881e-7f9c5895042d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_cd3fb653-46c5-411f-8629-eb3d9aabd173" xlink:href="amed-20210930.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_cd3fb653-46c5-411f-8629-eb3d9aabd173" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_fe586654-0416-45e1-a691-75a8e48ed44c" xlink:href="amed-20210930.xsd#amed_HospiceMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HospiceMedicareMember_fe586654-0416-45e1-a691-75a8e48ed44c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_76a047c6-44f6-434d-b205-85d766eb98fc" xlink:href="amed-20210930.xsd#amed_HospiceNonMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HospiceNonMedicareMember_76a047c6-44f6-434d-b205-85d766eb98fc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_4d267645-05c8-441d-af47-8477fb91be0b" xlink:href="amed-20210930.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_PersonalCareMember_4d267645-05c8-441d-af47-8477fb91be0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_45aa7c59-905f-4dd8-b60b-70a373818610" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HighAcuityCareMember_45aa7c59-905f-4dd8-b60b-70a373818610" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended" id="i7dbf6ac5717742a4825a4ae9d86802af_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_879bf74f-d2e1-47dc-a54c-59fdf5f5a53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_879bf74f-d2e1-47dc-a54c-59fdf5f5a53c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_fa26444e-d457-45a3-94d1-6703b40a1403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:to="loc_us-gaap_RestrictedCash_fa26444e-d457-45a3-94d1-6703b40a1403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6ceb664-7f0f-4220-a385-6856172aed5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6ceb664-7f0f-4220-a385-6856172aed5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_47212a61-5579-491d-987c-364ecc81238d" xlink:href="amed-20210930.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_47212a61-5579-491d-987c-364ecc81238d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b468f5e-eb67-455f-bcb3-fb0b3372873a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b468f5e-eb67-455f-bcb3-fb0b3372873a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_6141dd5f-6b05-4d98-8f93-1ffaa97964cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b468f5e-eb67-455f-bcb3-fb0b3372873a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_6141dd5f-6b05-4d98-8f93-1ffaa97964cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6141dd5f-6b05-4d98-8f93-1ffaa97964cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_6141dd5f-6b05-4d98-8f93-1ffaa97964cf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6141dd5f-6b05-4d98-8f93-1ffaa97964cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_6141dd5f-6b05-4d98-8f93-1ffaa97964cf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_6f10fe82-1776-42e6-87bb-69cdcb1473e3" xlink:href="amed-20210930.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:to="loc_amed_AsanaHospiceAquisitionMember_6f10fe82-1776-42e6-87bb-69cdcb1473e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_4ddf974f-e7c7-48cf-9971-d952125d6b93" xlink:href="amed-20210930.xsd#amed_COVID19PPEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:to="loc_amed_COVID19PPEMember_4ddf974f-e7c7-48cf-9971-d952125d6b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_081b8584-ddda-428a-a0b0-9e9167509f17" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:to="loc_amed_AseraCareHospiceMember_081b8584-ddda-428a-a0b0-9e9167509f17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_470de0ed-866d-4426-8a1d-0774d5e23bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b468f5e-eb67-455f-bcb3-fb0b3372873a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_470de0ed-866d-4426-8a1d-0774d5e23bb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_470de0ed-866d-4426-8a1d-0774d5e23bb0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_470de0ed-866d-4426-8a1d-0774d5e23bb0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_470de0ed-866d-4426-8a1d-0774d5e23bb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b283883-407f-4502-8207-8586a913ae84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_470de0ed-866d-4426-8a1d-0774d5e23bb0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b283883-407f-4502-8207-8586a913ae84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_8331050b-78b6-4996-8629-3ec9cd3442db" xlink:href="amed-20210930.xsd#amed_AsanaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b283883-407f-4502-8207-8586a913ae84" xlink:to="loc_amed_AsanaHospiceMember_8331050b-78b6-4996-8629-3ec9cd3442db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember_5ae2f9e8-4f9e-43cb-8cf8-48c5021e020c" xlink:href="amed-20210930.xsd#amed_VariousAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b283883-407f-4502-8207-8586a913ae84" xlink:to="loc_amed_VariousAcquisitionsMember_5ae2f9e8-4f9e-43cb-8cf8-48c5021e020c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended" id="i72c0392d64834235b189f31fd9dd28c7_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_b185f6e8-dd1d-47dd-bea8-a4045d63708c" xlink:href="amed-20210930.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_b185f6e8-dd1d-47dd-bea8-a4045d63708c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d48b757b-4f39-4c63-8c2b-31d832bf5077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d48b757b-4f39-4c63-8c2b-31d832bf5077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_3d9db12c-0f45-46bd-9480-bdaf3420b23b" xlink:href="amed-20210930.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_3d9db12c-0f45-46bd-9480-bdaf3420b23b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:to="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1235e8a1-49d9-4c32-ad33-f90c7bd00833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1235e8a1-49d9-4c32-ad33-f90c7bd00833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1235e8a1-49d9-4c32-ad33-f90c7bd00833_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1235e8a1-49d9-4c32-ad33-f90c7bd00833" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1235e8a1-49d9-4c32-ad33-f90c7bd00833_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_70c14f60-4099-45aa-a84c-029fbdcf2ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1235e8a1-49d9-4c32-ad33-f90c7bd00833" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_70c14f60-4099-45aa-a84c-029fbdcf2ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b69800dc-2e95-4103-936e-df968d0146f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_70c14f60-4099-45aa-a84c-029fbdcf2ea2" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b69800dc-2e95-4103-936e-df968d0146f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64382a85-86df-414c-a187-a964320eaef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64382a85-86df-414c-a187-a964320eaef2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64382a85-86df-414c-a187-a964320eaef2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64382a85-86df-414c-a187-a964320eaef2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_64382a85-86df-414c-a187-a964320eaef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4157c6ec-221f-427f-9677-467bb96ad40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64382a85-86df-414c-a187-a964320eaef2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4157c6ec-221f-427f-9677-467bb96ad40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_cda14f04-fb1d-4fd1-802b-4d2e9797c70b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4157c6ec-221f-427f-9677-467bb96ad40b" xlink:to="loc_us-gaap_AccountsReceivableMember_cda14f04-fb1d-4fd1-802b-4d2e9797c70b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a446c557-2bb4-4ff8-ac08-e2d1ed713761" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:to="loc_srt_MajorCustomersAxis_a446c557-2bb4-4ff8-ac08-e2d1ed713761" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a446c557-2bb4-4ff8-ac08-e2d1ed713761_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a446c557-2bb4-4ff8-ac08-e2d1ed713761" xlink:to="loc_srt_NameOfMajorCustomerDomain_a446c557-2bb4-4ff8-ac08-e2d1ed713761_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ef6c81b4-ab56-4b67-8b3e-66261625afd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a446c557-2bb4-4ff8-ac08-e2d1ed713761" xlink:to="loc_srt_NameOfMajorCustomerDomain_ef6c81b4-ab56-4b67-8b3e-66261625afd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_deaaa530-4d8e-4b16-8d92-81794c34ee89" xlink:href="amed-20210930.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_ef6c81b4-ab56-4b67-8b3e-66261625afd5" xlink:to="loc_amed_MajorSinglePayorCustomerMember_deaaa530-4d8e-4b16-8d92-81794c34ee89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6d985f40-7976-4f2f-8ba4-752982a2b368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6d985f40-7976-4f2f-8ba4-752982a2b368" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d985f40-7976-4f2f-8ba4-752982a2b368_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6d985f40-7976-4f2f-8ba4-752982a2b368" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d985f40-7976-4f2f-8ba4-752982a2b368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86a3e98f-6338-43eb-97e4-4f3c997fd939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6d985f40-7976-4f2f-8ba4-752982a2b368" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86a3e98f-6338-43eb-97e4-4f3c997fd939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_5eb2676e-a8b0-4e86-9cab-2575b97cf8b8" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86a3e98f-6338-43eb-97e4-4f3c997fd939" xlink:to="loc_amed_CompassionateCareHospiceMember_5eb2676e-a8b0-4e86-9cab-2575b97cf8b8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended" id="ida82d0b4603d4ddbbfa4d22707173569_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7de7869c-f125-45a2-b25b-d04c6b558cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_ce3d7898-31cd-440b-a95d-19c861912842" xlink:href="amed-20210930.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7de7869c-f125-45a2-b25b-d04c6b558cd0" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_ce3d7898-31cd-440b-a95d-19c861912842" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5b80e859-b0d6-427e-95c4-8c58c4ebc177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7de7869c-f125-45a2-b25b-d04c6b558cd0" xlink:to="loc_us-gaap_LongTermDebtFairValue_5b80e859-b0d6-427e-95c4-8c58c4ebc177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f2a9f9d-3d47-4f17-b342-4a7f092e4f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7de7869c-f125-45a2-b25b-d04c6b558cd0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f2a9f9d-3d47-4f17-b342-4a7f092e4f6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92a3329d-5f77-4a2c-9e3e-86c593b06265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f2a9f9d-3d47-4f17-b342-4a7f092e4f6a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92a3329d-5f77-4a2c-9e3e-86c593b06265" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92a3329d-5f77-4a2c-9e3e-86c593b06265_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92a3329d-5f77-4a2c-9e3e-86c593b06265" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92a3329d-5f77-4a2c-9e3e-86c593b06265_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92a3329d-5f77-4a2c-9e3e-86c593b06265" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_07a72e57-4bfa-4cc4-9ef6-cda67c7cf0fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_07a72e57-4bfa-4cc4-9ef6-cda67c7cf0fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e4c4bb67-b82a-4887-ad30-c193d7cb3f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e4c4bb67-b82a-4887-ad30-c193d7cb3f81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2ca9fb3e-6b4e-41ff-976b-d41bcc87bdd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2ca9fb3e-6b4e-41ff-976b-d41bcc87bdd2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20210930.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended" id="i301cce90df6b4da9955040a4ca6b1733_NOVELCORONAVIRUSPANDEMICCOVID19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_cb2bb0e5-ba1f-4610-af2f-3df7f295f19a" xlink:href="amed-20210930.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_cb2bb0e5-ba1f-4610-af2f-3df7f295f19a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_bc2090fc-c4b9-492b-b7df-4ac52feded52" xlink:href="amed-20210930.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_bc2090fc-c4b9-492b-b7df-4ac52feded52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_24e609c6-0bd1-46a6-9779-bf0d712cdace" xlink:href="amed-20210930.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_FundingReceivedFromCARESAct_24e609c6-0bd1-46a6-9779-bf0d712cdace" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_1e61d069-f627-4711-8534-1e8681913871" xlink:href="amed-20210930.xsd#amed_ProviderReliefFundAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_ProviderReliefFundAdvance_1e61d069-f627-4711-8534-1e8681913871" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_0c7096fb-23b3-47be-97e8-ea25bb939e60" xlink:href="amed-20210930.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_0c7096fb-23b3-47be-97e8-ea25bb939e60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_edfc3315-d023-4788-8107-888e053ffd86" xlink:href="amed-20210930.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_edfc3315-d023-4788-8107-888e053ffd86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses_f1b8674e-7628-44ae-ae60-9dd87ef12b1d" xlink:href="amed-20210930.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_EstimatedFutureCOVID19RelatedExpenses_f1b8674e-7628-44ae-ae60-9dd87ef12b1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred_8e60aaa5-86a7-41f4-a9ca-389312168e29" xlink:href="amed-20210930.xsd#amed_COVID19ExpensesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_COVID19ExpensesIncurred_8e60aaa5-86a7-41f4-a9ca-389312168e29" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_fa268fa4-d0d6-4f20-88cb-015327938662" xlink:href="amed-20210930.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_fa268fa4-d0d6-4f20-88cb-015327938662" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_cf735726-e20e-40d5-a546-e6f7a31d8931" xlink:href="amed-20210930.xsd#amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_cf735726-e20e-40d5-a546-e6f7a31d8931" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_99e3d0c1-e6cc-4403-bed9-63fd3e8f59f8" xlink:href="amed-20210930.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_99e3d0c1-e6cc-4403-bed9-63fd3e8f59f8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures_3c565926-0ef1-465b-bc35-190f909d29ac" xlink:href="amed-20210930.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures_3c565926-0ef1-465b-bc35-190f909d29ac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_189d790b-f727-4eb9-93f6-9fa73e6a3011" xlink:href="amed-20210930.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_189d790b-f727-4eb9-93f6-9fa73e6a3011" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActInterestToBeRepaidToGovernment_74c03b44-bf9f-41a9-8fc0-a1591d56ca6f" xlink:href="amed-20210930.xsd#amed_CARESActInterestToBeRepaidToGovernment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_CARESActInterestToBeRepaidToGovernment_74c03b44-bf9f-41a9-8fc0-a1591d56ca6f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_f9b552fe-8be0-492f-8304-0f3468950750" xlink:href="amed-20210930.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_f9b552fe-8be0-492f-8304-0f3468950750" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_cd50c19e-835e-4fa3-9078-13be1c87aff4" xlink:href="amed-20210930.xsd#amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_cd50c19e-835e-4fa3-9078-13be1c87aff4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ff366867-403b-4850-9ba2-ecf409f3a399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ff366867-403b-4850-9ba2-ecf409f3a399" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3f62efe6-8f03-4a49-a64b-ea346450b677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3f62efe6-8f03-4a49-a64b-ea346450b677" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_b3399d93-9365-4c36-88a3-15fd6efa1a79" xlink:href="amed-20210930.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_b3399d93-9365-4c36-88a3-15fd6efa1a79" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_63e5de70-eb73-4e70-82d9-5b6d140c906d" xlink:href="amed-20210930.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_63e5de70-eb73-4e70-82d9-5b6d140c906d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_954b78df-69dd-4129-8c9f-ce87d861b001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_954b78df-69dd-4129-8c9f-ce87d861b001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_954b78df-69dd-4129-8c9f-ce87d861b001_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_954b78df-69dd-4129-8c9f-ce87d861b001" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_954b78df-69dd-4129-8c9f-ce87d861b001_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b9946e10-016d-4ae7-83f5-995cbf32957f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_954b78df-69dd-4129-8c9f-ce87d861b001" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b9946e10-016d-4ae7-83f5-995cbf32957f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_869654e1-1f04-494c-a2eb-e0077e5c81f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b9946e10-016d-4ae7-83f5-995cbf32957f" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_869654e1-1f04-494c-a2eb-e0077e5c81f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_68d0111e-c3b2-44da-9619-a7e8dcc0ccbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_68d0111e-c3b2-44da-9619-a7e8dcc0ccbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68d0111e-c3b2-44da-9619-a7e8dcc0ccbb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68d0111e-c3b2-44da-9619-a7e8dcc0ccbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_68d0111e-c3b2-44da-9619-a7e8dcc0ccbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fe5f7d3-4b8d-416d-b739-3914b6cf46f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68d0111e-c3b2-44da-9619-a7e8dcc0ccbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fe5f7d3-4b8d-416d-b739-3914b6cf46f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_bb70cf7b-d20f-4b14-8ba6-1bc9c3abbb64" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fe5f7d3-4b8d-416d-b739-3914b6cf46f1" xlink:to="loc_amed_AseraCareHospiceMember_bb70cf7b-d20f-4b14-8ba6-1bc9c3abbb64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_eec97b04-8703-4798-89bc-51c227ac2e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_eec97b04-8703-4798-89bc-51c227ac2e3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_eec97b04-8703-4798-89bc-51c227ac2e3b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_eec97b04-8703-4798-89bc-51c227ac2e3b" xlink:to="loc_us-gaap_SegmentDomain_eec97b04-8703-4798-89bc-51c227ac2e3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_eec97b04-8703-4798-89bc-51c227ac2e3b" xlink:to="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_32053290-77af-4267-a966-21801179ee06" xlink:href="amed-20210930.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:to="loc_amed_HomeHealthAndHospiceMember_32053290-77af-4267-a966-21801179ee06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_0c02cfb7-9345-4b8c-ab70-131c48e25ad0" xlink:href="amed-20210930.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:to="loc_amed_PersonalCareMember_0c02cfb7-9345-4b8c-ab70-131c48e25ad0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_3d228abb-25a4-4ac5-8198-a42b6a4e8a16" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:to="loc_amed_HomeHealthMember_3d228abb-25a4-4ac5-8198-a42b6a4e8a16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_8227de49-6996-433c-9f54-e707d56bd56a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_8227de49-6996-433c-9f54-e707d56bd56a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_8227de49-6996-433c-9f54-e707d56bd56a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_8227de49-6996-433c-9f54-e707d56bd56a" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_8227de49-6996-433c-9f54-e707d56bd56a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_c3d20a71-ceed-42dc-85ae-56f8549d6378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_8227de49-6996-433c-9f54-e707d56bd56a" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_c3d20a71-ceed-42dc-85ae-56f8549d6378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityMember_6acddc6f-3189-4dc5-aa83-d23e70cc2df9" xlink:href="amed-20210930.xsd#amed_COVID19DeferralOfSocialSecurityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_c3d20a71-ceed-42dc-85ae-56f8549d6378" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityMember_6acddc6f-3189-4dc5-aa83-d23e70cc2df9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_82218067-c3f1-49e1-97a9-cd97f3d9b5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_82218067-c3f1-49e1-97a9-cd97f3d9b5ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_82218067-c3f1-49e1-97a9-cd97f3d9b5ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_82218067-c3f1-49e1-97a9-cd97f3d9b5ca" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_82218067-c3f1-49e1-97a9-cd97f3d9b5ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_152858bf-dc05-4cfd-b354-d388bdceb6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_82218067-c3f1-49e1-97a9-cd97f3d9b5ca" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_152858bf-dc05-4cfd-b354-d388bdceb6bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_186c8370-0990-4fe2-9583-d63f3c2bf3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_152858bf-dc05-4cfd-b354-d388bdceb6bd" xlink:to="loc_us-gaap_SubsequentEventMember_186c8370-0990-4fe2-9583-d63f3c2bf3da" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended" id="i977cb2033f8c46fbb76616e27e50b79b_ACQUISITIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_471e2e8c-4ceb-4891-8ffa-45852c29b9d3" xlink:href="amed-20210930.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_PercentageofSharesOutstanding_471e2e8c-4ceb-4891-8ffa-45852c29b9d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c0f7a276-1550-4cec-a870-1eb24b12982e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c0f7a276-1550-4cec-a870-1eb24b12982e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_b510d102-7859-4a01-9b4e-a9e07e0e069f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_b510d102-7859-4a01-9b4e-a9e07e0e069f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_9a2e944a-bb1f-47c8-9555-2782d078b409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_9a2e944a-bb1f-47c8-9555-2782d078b409" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_59b77ddf-ea2f-40a6-8c6d-a6de9932ee62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_59b77ddf-ea2f-40a6-8c6d-a6de9932ee62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_6a8e2cfd-9a5d-4502-bb0f-2a80a641e029" xlink:href="amed-20210930.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_6a8e2cfd-9a5d-4502-bb0f-2a80a641e029" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1a7617d8-c57c-42a5-ac9c-c8efa510c2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1a7617d8-c57c-42a5-ac9c-c8efa510c2ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_b66360b4-e87d-47ea-b7a4-f09d04e044b8" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_b66360b4-e87d-47ea-b7a4-f09d04e044b8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_729253b0-773a-41b5-bb57-de8f18f2105b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_729253b0-773a-41b5-bb57-de8f18f2105b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_cd866a38-1a90-45a2-9f7e-623816eed88a" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_cd866a38-1a90-45a2-9f7e-623816eed88a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_19432ee0-203f-428b-b167-e907856b4673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_19432ee0-203f-428b-b167-e907856b4673" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_38ba3de0-2210-4aa0-a77b-0e84af6accc0" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_38ba3de0-2210-4aa0-a77b-0e84af6accc0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7db90f5b-4454-4758-93a2-50b477786373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7db90f5b-4454-4758-93a2-50b477786373" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a74fe651-c159-4499-9f30-04b947164253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a74fe651-c159-4499-9f30-04b947164253" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_57bf3201-80cd-49f8-9a09-342c654c1a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_57bf3201-80cd-49f8-9a09-342c654c1a47" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b0d660e1-48d7-4fc1-b9c4-917d710976f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b0d660e1-48d7-4fc1-b9c4-917d710976f5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_3691d5bc-ebac-4460-adaf-cd5c98756da9" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_3691d5bc-ebac-4460-adaf-cd5c98756da9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_c7cc672b-3557-4af1-8e24-00bf11771036" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_c7cc672b-3557-4af1-8e24-00bf11771036" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_636bb75e-5156-4239-a68d-f481e761c04f" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_636bb75e-5156-4239-a68d-f481e761c04f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d1333c7a-f550-4419-8277-34a26c6a50ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d1333c7a-f550-4419-8277-34a26c6a50ab" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_e6aa059c-fb39-4d52-9900-8f996126d052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_e6aa059c-fb39-4d52-9900-8f996126d052" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_2114948f-a170-4d0a-abed-81ffd6b7126e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_2114948f-a170-4d0a-abed-81ffd6b7126e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c5f6f138-6462-4f1a-ac33-8093901b41b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c5f6f138-6462-4f1a-ac33-8093901b41b1" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1b734833-3deb-4fcc-889b-c638e3d4a53d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1b734833-3deb-4fcc-889b-c638e3d4a53d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_853d294f-ec87-4337-b260-2d83685036ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_853d294f-ec87-4337-b260-2d83685036ea" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_66a7e20e-381a-44ab-b97a-0af961da5058" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_66a7e20e-381a-44ab-b97a-0af961da5058" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_93123daa-7792-4f7e-9507-216ba6dd169e" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_93123daa-7792-4f7e-9507-216ba6dd169e" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_74a5c91b-c9a2-4d68-8d69-c86491d2ae50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_74a5c91b-c9a2-4d68-8d69-c86491d2ae50" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_cb9cd570-22ef-4e2a-af26-d77d6c811bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_cb9cd570-22ef-4e2a-af26-d77d6c811bee" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fd4c7204-b491-4331-97f6-b5e5e9c343e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fd4c7204-b491-4331-97f6-b5e5e9c343e8" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_6a83f87a-a921-4daa-9489-3f530f408603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_6a83f87a-a921-4daa-9489-3f530f408603" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d3f6128a-1ad9-4e30-8027-efc1c0e99c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_OperatingIncomeLoss_d3f6128a-1ad9-4e30-8027-efc1c0e99c68" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_3ec78a3f-38c6-4788-a59c-a00fbd9b924a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_3ec78a3f-38c6-4788-a59c-a00fbd9b924a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_0448d791-98e1-4b73-8038-bb92d077ca55" xlink:href="amed-20210930.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_0448d791-98e1-4b73-8038-bb92d077ca55" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable_78ad0cbd-cc26-4c01-8df6-dcf6b0241f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_OffMarketLeaseUnfavorable_78ad0cbd-cc26-4c01-8df6-dcf6b0241f87" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_d81e91fa-91ca-439a-bd98-aa619ffacde0" xlink:href="amed-20210930.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_d81e91fa-91ca-439a-bd98-aa619ffacde0" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_63275c56-32e3-4535-9484-14c1d40b8a1c" xlink:href="amed-20210930.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_63275c56-32e3-4535-9484-14c1d40b8a1c" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_aea5967a-fbb4-4cc2-9a75-1aecd515cb66" xlink:href="amed-20210930.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_aea5967a-fbb4-4cc2-9a75-1aecd515cb66" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a7f56dea-6dc0-445c-94eb-3980bc222d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a7f56dea-6dc0-445c-94eb-3980bc222d71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7f56dea-6dc0-445c-94eb-3980bc222d71_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a7f56dea-6dc0-445c-94eb-3980bc222d71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a7f56dea-6dc0-445c-94eb-3980bc222d71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a7f56dea-6dc0-445c-94eb-3980bc222d71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_60d89311-4d29-4271-bf14-3d465a734915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_TradeNamesMember_60d89311-4d29-4271-bf14-3d465a734915" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_055154ab-6396-47f1-9c15-ab5957d0e428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_055154ab-6396-47f1-9c15-ab5957d0e428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_988b0194-a439-4b07-8aa0-1b7a32f84a3c" xlink:href="amed-20210930.xsd#amed_AcquiredNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_amed_AcquiredNamesMember_988b0194-a439-4b07-8aa0-1b7a32f84a3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_6cc97087-9303-4c37-8c2b-1838c829aa0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_6cc97087-9303-4c37-8c2b-1838c829aa0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_6808b2cb-70ea-4eca-9337-8618ebab8fc8" xlink:href="amed-20210930.xsd#amed_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_amed_MedicareLicenseMember_6808b2cb-70ea-4eca-9337-8618ebab8fc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_43b9b819-6058-4cb3-a9e2-110486f9ee48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_43b9b819-6058-4cb3-a9e2-110486f9ee48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_bd8cbd06-b51b-4b46-80a7-204a3382a91b" xlink:href="amed-20210930.xsd#amed_CertificatesOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_amed_CertificatesOfNeedMember_bd8cbd06-b51b-4b46-80a7-204a3382a91b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_2ab79e46-3f59-43c6-bf91-faf38625c01b" xlink:href="amed-20210930.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_amed_CertificateOfNeedMember_2ab79e46-3f59-43c6-bf91-faf38625c01b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1befb204-ee54-492e-b97a-beaef5c745f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1befb204-ee54-492e-b97a-beaef5c745f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_73405276-3af4-42be-8c74-6fc90bd4031f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_srt_StatementGeographicalAxis_73405276-3af4-42be-8c74-6fc90bd4031f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_73405276-3af4-42be-8c74-6fc90bd4031f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_73405276-3af4-42be-8c74-6fc90bd4031f" xlink:to="loc_srt_SegmentGeographicalDomain_73405276-3af4-42be-8c74-6fc90bd4031f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_73405276-3af4-42be-8c74-6fc90bd4031f" xlink:to="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_61ded15a-580f-472e-9812-b3a327e1c2c6" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_TN_61ded15a-580f-472e-9812-b3a327e1c2c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_708a278e-676b-49b9-935b-3d96935a6252" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_WA_708a278e-676b-49b9-935b-3d96935a6252" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_50c87771-4a6f-4da7-abff-8ded1dcced48" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_KY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_KY_50c87771-4a6f-4da7-abff-8ded1dcced48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_50c628ee-26e4-4fad-882e-4ef398f5756f" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_NC_50c628ee-26e4-4fad-882e-4ef398f5756f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_de6387a3-d7a0-452d-ad61-2d0fc3e12196" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_NY_de6387a3-d7a0-452d-ad61-2d0fc3e12196" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5f4bc145-a115-47b3-a695-1ffc062e9958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5f4bc145-a115-47b3-a695-1ffc062e9958" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5f4bc145-a115-47b3-a695-1ffc062e9958_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5f4bc145-a115-47b3-a695-1ffc062e9958" xlink:to="loc_us-gaap_SegmentDomain_5f4bc145-a115-47b3-a695-1ffc062e9958_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5f4bc145-a115-47b3-a695-1ffc062e9958" xlink:to="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_3ffe850b-91d9-4f19-b48e-7f9f6b0f4a77" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:to="loc_amed_HospiceMember_3ffe850b-91d9-4f19-b48e-7f9f6b0f4a77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_54a81426-7682-43c8-b0b2-f64a81c0840e" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:to="loc_amed_HomeHealthMember_54a81426-7682-43c8-b0b2-f64a81c0840e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_2fea487a-c181-4709-8fda-5bdfbc94c6ac" xlink:href="amed-20210930.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:to="loc_amed_HomeHealthAndHospiceMember_2fea487a-c181-4709-8fda-5bdfbc94c6ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_67bec74b-5b11-43ee-b119-a9cf0dd91063" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:to="loc_amed_HighAcuityCareMember_67bec74b-5b11-43ee-b119-a9cf0dd91063" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5dfe2e23-a311-4aca-a1ce-354013ebc407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5dfe2e23-a311-4aca-a1ce-354013ebc407" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5dfe2e23-a311-4aca-a1ce-354013ebc407_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5dfe2e23-a311-4aca-a1ce-354013ebc407" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5dfe2e23-a311-4aca-a1ce-354013ebc407_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5dfe2e23-a311-4aca-a1ce-354013ebc407" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VisitingNurseAssociationMember_68053867-af2c-44db-9cae-816aa642b08a" xlink:href="amed-20210930.xsd#amed_VisitingNurseAssociationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:to="loc_amed_VisitingNurseAssociationMember_68053867-af2c-44db-9cae-816aa642b08a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_760c9d8d-21fa-4ec0-a4cd-94b9eafaa4ce" xlink:href="amed-20210930.xsd#amed_ContessaHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:to="loc_amed_ContessaHealthMember_760c9d8d-21fa-4ec0-a4cd-94b9eafaa4ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_e9ae1a7e-a9a3-4e1b-8a73-84ab16fedfa1" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:to="loc_amed_AseraCareHospiceMember_e9ae1a7e-a9a3-4e1b-8a73-84ab16fedfa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_38c46430-ef83-4bf3-a4e0-011990ff42ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_38c46430-ef83-4bf3-a4e0-011990ff42ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_38c46430-ef83-4bf3-a4e0-011990ff42ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_38c46430-ef83-4bf3-a4e0-011990ff42ee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_38c46430-ef83-4bf3-a4e0-011990ff42ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_885518d0-e597-4148-9a8d-18cf710ecf0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_38c46430-ef83-4bf3-a4e0-011990ff42ee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_885518d0-e597-4148-9a8d-18cf710ecf0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_4a001548-90ff-4610-be40-e34d9e6666d0" xlink:href="amed-20210930.xsd#amed_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_885518d0-e597-4148-9a8d-18cf710ecf0d" xlink:to="loc_amed_CertificateOfNeedMember_4a001548-90ff-4610-be40-e34d9e6666d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_ab4de152-1d6b-427b-bb79-95418d371283" xlink:href="amed-20210930.xsd#amed_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_885518d0-e597-4148-9a8d-18cf710ecf0d" xlink:to="loc_amed_MedicareLicenseMember_ab4de152-1d6b-427b-bb79-95418d371283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ef46599-9f90-4359-83ba-3fc60b3b1c8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_srt_RangeAxis_3ef46599-9f90-4359-83ba-3fc60b3b1c8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3ef46599-9f90-4359-83ba-3fc60b3b1c8d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3ef46599-9f90-4359-83ba-3fc60b3b1c8d" xlink:to="loc_srt_RangeMember_3ef46599-9f90-4359-83ba-3fc60b3b1c8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3d2f0f2-b7bd-46a2-af40-3b057123f58f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3ef46599-9f90-4359-83ba-3fc60b3b1c8d" xlink:to="loc_srt_RangeMember_f3d2f0f2-b7bd-46a2-af40-3b057123f58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b81a9bf8-955c-472b-a306-845c1f5397f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f3d2f0f2-b7bd-46a2-af40-3b057123f58f" xlink:to="loc_srt_MaximumMember_b81a9bf8-955c-472b-a306-845c1f5397f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#ACQUISITIONSProFormaDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended" id="i73c898db3091444baa6dd698ce4a119a_ACQUISITIONSProFormaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_98f8b9b5-3791-4113-8d36-46e57d86d11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_98f8b9b5-3791-4113-8d36-46e57d86d11a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_1af2dd26-2ff3-42cf-8701-3d5eb1f0b1f0" xlink:href="amed-20210930.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_1af2dd26-2ff3-42cf-8701-3d5eb1f0b1f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_0cb1f816-dbc0-4678-9413-50dd2f6b4fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_0cb1f816-dbc0-4678-9413-50dd2f6b4fd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6c85abbf-abd0-4ddc-ab05-282f6f0a2fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6c85abbf-abd0-4ddc-ab05-282f6f0a2fd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_57fe3ccf-4552-40b1-b889-921b93b9498e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_57fe3ccf-4552-40b1-b889-921b93b9498e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e7583f2d-f795-40b3-9ce4-fd4cf7f95df1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e7583f2d-f795-40b3-9ce4-fd4cf7f95df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e7583f2d-f795-40b3-9ce4-fd4cf7f95df1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e7583f2d-f795-40b3-9ce4-fd4cf7f95df1" xlink:to="loc_us-gaap_SegmentDomain_e7583f2d-f795-40b3-9ce4-fd4cf7f95df1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_20bd3e22-a2f6-45cb-8122-1fb21f2ebcea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e7583f2d-f795-40b3-9ce4-fd4cf7f95df1" xlink:to="loc_us-gaap_SegmentDomain_20bd3e22-a2f6-45cb-8122-1fb21f2ebcea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_fd557982-8abe-4c25-9b0e-2bea106c89df" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_20bd3e22-a2f6-45cb-8122-1fb21f2ebcea" xlink:to="loc_amed_HospiceMember_fd557982-8abe-4c25-9b0e-2bea106c89df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_86284e9f-610e-44da-9599-d137ee4ea3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_86284e9f-610e-44da-9599-d137ee4ea3de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86284e9f-610e-44da-9599-d137ee4ea3de_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_86284e9f-610e-44da-9599-d137ee4ea3de" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86284e9f-610e-44da-9599-d137ee4ea3de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80a98efd-5b96-47c5-a9fe-0f7e59470329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_86284e9f-610e-44da-9599-d137ee4ea3de" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80a98efd-5b96-47c5-a9fe-0f7e59470329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_ffe1df53-2ffd-45a6-b0e9-59f7197a50c0" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80a98efd-5b96-47c5-a9fe-0f7e59470329" xlink:to="loc_amed_CompassionateCareHospiceMember_ffe1df53-2ffd-45a6-b0e9-59f7197a50c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_bc4a04bf-6b9b-4cc8-8619-3b69736a7369" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80a98efd-5b96-47c5-a9fe-0f7e59470329" xlink:to="loc_amed_AseraCareHospiceMember_bc4a04bf-6b9b-4cc8-8619-3b69736a7369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fd2a053d-c666-48bc-b690-ff90dd11d1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fd2a053d-c666-48bc-b690-ff90dd11d1ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fd2a053d-c666-48bc-b690-ff90dd11d1ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fd2a053d-c666-48bc-b690-ff90dd11d1ac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fd2a053d-c666-48bc-b690-ff90dd11d1ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d796337d-c510-4dd6-9e63-5412aaecad2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fd2a053d-c666-48bc-b690-ff90dd11d1ac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d796337d-c510-4dd6-9e63-5412aaecad2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_1dbfb56c-60d4-4b28-8932-3e85c45f920d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_srt_OwnershipAxis_1dbfb56c-60d4-4b28-8932-3e85c45f920d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1dbfb56c-60d4-4b28-8932-3e85c45f920d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1dbfb56c-60d4-4b28-8932-3e85c45f920d" xlink:to="loc_srt_OwnershipDomain_1dbfb56c-60d4-4b28-8932-3e85c45f920d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c208f34a-b4db-4fcb-b8bd-70255094ab5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1dbfb56c-60d4-4b28-8932-3e85c45f920d" xlink:to="loc_srt_OwnershipDomain_c208f34a-b4db-4fcb-b8bd-70255094ab5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7ae2f98e-373a-4703-941a-a125bf842a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7ae2f98e-373a-4703-941a-a125bf842a24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ae2f98e-373a-4703-941a-a125bf842a24_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ae2f98e-373a-4703-941a-a125bf842a24" xlink:to="loc_us-gaap_ClassOfStockDomain_7ae2f98e-373a-4703-941a-a125bf842a24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5f1cf74f-d23d-4a21-9459-de2915ec2362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ae2f98e-373a-4703-941a-a125bf842a24" xlink:to="loc_us-gaap_ClassOfStockDomain_5f1cf74f-d23d-4a21-9459-de2915ec2362" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended" id="i8e0926f060514027b750b48f4d4d88cf_LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_aac0376b-c02d-4147-bb8f-e92de29e5659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_aac0376b-c02d-4147-bb8f-e92de29e5659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_03e19396-7c04-4660-8bac-eef9270adda7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_03e19396-7c04-4660-8bac-eef9270adda7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_792d7cf2-2b7e-45d1-96fb-afda936c72d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_LongTermDebt_792d7cf2-2b7e-45d1-96fb-afda936c72d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_13961e9b-57dc-4642-96a6-8a0e63b0416f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_LongTermDebtCurrent_13961e9b-57dc-4642-96a6-8a0e63b0416f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_867f3a58-b707-448d-9ab4-7a902b63a567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_867f3a58-b707-448d-9ab4-7a902b63a567" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d951da85-3e73-4d16-b204-308515db2a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d951da85-3e73-4d16-b204-308515db2a83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d951da85-3e73-4d16-b204-308515db2a83_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d951da85-3e73-4d16-b204-308515db2a83" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d951da85-3e73-4d16-b204-308515db2a83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d951da85-3e73-4d16-b204-308515db2a83" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_086002d1-f44d-4b73-9176-9b8d6922d053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:to="loc_us-gaap_LoansPayableMember_086002d1-f44d-4b73-9176-9b8d6922d053" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b85103ce-ada0-4b2a-a11f-c129f0c01fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b85103ce-ada0-4b2a-a11f-c129f0c01fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_9986b957-a601-42a0-ad8f-2df393a8cf5a" xlink:href="amed-20210930.xsd#amed_PromissoryNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:to="loc_amed_PromissoryNotesMember_9986b957-a601-42a0-ad8f-2df393a8cf5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_4519c81a-0d5c-472c-bcb2-4e1bded60a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_4519c81a-0d5c-472c-bcb2-4e1bded60a3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca88bff2-be67-439c-92d2-ac6edb45b51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca88bff2-be67-439c-92d2-ac6edb45b51f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ca88bff2-be67-439c-92d2-ac6edb45b51f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca88bff2-be67-439c-92d2-ac6edb45b51f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ca88bff2-be67-439c-92d2-ac6edb45b51f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca88bff2-be67-439c-92d2-ac6edb45b51f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_1a0d5ca2-0610-4dcb-84ea-bc88c046cc18" xlink:href="amed-20210930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_1a0d5ca2-0610-4dcb-84ea-bc88c046cc18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_f9f1e951-37fe-438c-aa99-d1d4d5a59843" xlink:href="amed-20210930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_f9f1e951-37fe-438c-aa99-d1d4d5a59843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_49247e18-c182-45f1-a456-775c36aec666" xlink:href="amed-20210930.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_49247e18-c182-45f1-a456-775c36aec666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_652b611e-e859-4499-a76b-a52915801d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:to="loc_us-gaap_VariableRateAxis_652b611e-e859-4499-a76b-a52915801d8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_652b611e-e859-4499-a76b-a52915801d8e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_652b611e-e859-4499-a76b-a52915801d8e" xlink:to="loc_us-gaap_VariableRateDomain_652b611e-e859-4499-a76b-a52915801d8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_db77e8a4-a102-4301-a2af-4aa75c126250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_652b611e-e859-4499-a76b-a52915801d8e" xlink:to="loc_us-gaap_VariableRateDomain_db77e8a4-a102-4301-a2af-4aa75c126250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_0daaccb2-3518-4fd1-a8b0-85dc77e5d31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_db77e8a4-a102-4301-a2af-4aa75c126250" xlink:to="loc_us-gaap_EurodollarMember_0daaccb2-3518-4fd1-a8b0-85dc77e5d31f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i30825919dce64ec68275811454ca4bb4_LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2700859d-6cda-4289-934a-d92c9cfffec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2700859d-6cda-4289-934a-d92c9cfffec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_59ac2f33-dd24-4068-ab61-c06731b09bee" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_59ac2f33-dd24-4068-ab61-c06731b09bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_128bc9b4-a6c5-4902-942c-618ece87b8c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_128bc9b4-a6c5-4902-942c-618ece87b8c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:to="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dea9a599-042b-40f4-a460-014f5bd2681f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dea9a599-042b-40f4-a460-014f5bd2681f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dea9a599-042b-40f4-a460-014f5bd2681f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dea9a599-042b-40f4-a460-014f5bd2681f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dea9a599-042b-40f4-a460-014f5bd2681f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_45f123a1-e6cb-45fe-999a-3c9c556b91ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dea9a599-042b-40f4-a460-014f5bd2681f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_45f123a1-e6cb-45fe-999a-3c9c556b91ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_68538156-0f13-48d2-9de9-67986e435c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_45f123a1-e6cb-45fe-999a-3c9c556b91ac" xlink:to="loc_us-gaap_LoansPayableMember_68538156-0f13-48d2-9de9-67986e435c70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_72064f3d-65cf-49d5-b1b9-1cf05fbd1589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_45f123a1-e6cb-45fe-999a-3c9c556b91ac" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_72064f3d-65cf-49d5-b1b9-1cf05fbd1589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1d3c6cc5-fdcd-437f-b294-ab45aa0c8b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:to="loc_us-gaap_DebtInstrumentAxis_1d3c6cc5-fdcd-437f-b294-ab45aa0c8b76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1d3c6cc5-fdcd-437f-b294-ab45aa0c8b76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d3c6cc5-fdcd-437f-b294-ab45aa0c8b76" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1d3c6cc5-fdcd-437f-b294-ab45aa0c8b76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d3c6cc5-fdcd-437f-b294-ab45aa0c8b76" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_0971e7c6-9dd2-49b3-838c-c1b6b01627d6" xlink:href="amed-20210930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_0971e7c6-9dd2-49b3-838c-c1b6b01627d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_87e4bf22-6215-463a-b22f-0ce5630bc93f" xlink:href="amed-20210930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_87e4bf22-6215-463a-b22f-0ce5630bc93f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_ba355b01-b389-415e-94c1-65220a2a5efa" xlink:href="amed-20210930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_ba355b01-b389-415e-94c1-65220a2a5efa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_a65299d6-bd61-48db-8827-8530cd9b55f5" xlink:href="amed-20210930.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_a65299d6-bd61-48db-8827-8530cd9b55f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7b3e7c20-9bed-4f3b-a141-5fe802032d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:to="loc_us-gaap_VariableRateAxis_7b3e7c20-9bed-4f3b-a141-5fe802032d76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7b3e7c20-9bed-4f3b-a141-5fe802032d76_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7b3e7c20-9bed-4f3b-a141-5fe802032d76" xlink:to="loc_us-gaap_VariableRateDomain_7b3e7c20-9bed-4f3b-a141-5fe802032d76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_34cae70f-0558-4b78-8a1b-1ac127c8cb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7b3e7c20-9bed-4f3b-a141-5fe802032d76" xlink:to="loc_us-gaap_VariableRateDomain_34cae70f-0558-4b78-8a1b-1ac127c8cb14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_8d712ec9-e13c-4a61-9fbc-b0784bb907ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_34cae70f-0558-4b78-8a1b-1ac127c8cb14" xlink:to="loc_us-gaap_EurodollarMember_8d712ec9-e13c-4a61-9fbc-b0784bb907ab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended" id="i60e6949fbe164d2b9a1733c940edd68b_LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_4aec274b-0584-410a-b56a-d557e55faa96" xlink:href="amed-20210930.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:to="loc_amed_ConsolidatedLeverageRatio_4aec274b-0584-410a-b56a-d557e55faa96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_da5b50ad-a558-4d2e-bab0-f3888322f37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_da5b50ad-a558-4d2e-bab0-f3888322f37b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_b7944e1e-9675-489f-914e-f9a7ed4ac808" xlink:href="amed-20210930.xsd#amed_LetterOfCreditFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:to="loc_amed_LetterOfCreditFee_b7944e1e-9675-489f-914e-f9a7ed4ac808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_eeb868ad-3e22-4cc7-b46b-f5c5d386bcc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_eeb868ad-3e22-4cc7-b46b-f5c5d386bcc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6c343b1-6045-4362-a395-737b8a7dfaad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_srt_RangeAxis_e6c343b1-6045-4362-a395-737b8a7dfaad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6c343b1-6045-4362-a395-737b8a7dfaad_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e6c343b1-6045-4362-a395-737b8a7dfaad" xlink:to="loc_srt_RangeMember_e6c343b1-6045-4362-a395-737b8a7dfaad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b59bc902-24a2-4598-bc8c-e469193bd20c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e6c343b1-6045-4362-a395-737b8a7dfaad" xlink:to="loc_srt_RangeMember_b59bc902-24a2-4598-bc8c-e469193bd20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f918f0d6-88db-41eb-8860-955caef5039f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b59bc902-24a2-4598-bc8c-e469193bd20c" xlink:to="loc_srt_MinimumMember_f918f0d6-88db-41eb-8860-955caef5039f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a00ce3b-2bc5-4a13-8b43-6091ea56e0ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b59bc902-24a2-4598-bc8c-e469193bd20c" xlink:to="loc_srt_MaximumMember_2a00ce3b-2bc5-4a13-8b43-6091ea56e0ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a1f5f731-1377-4baa-b8fa-bd40dd0cfc13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_us-gaap_DebtInstrumentAxis_a1f5f731-1377-4baa-b8fa-bd40dd0cfc13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a1f5f731-1377-4baa-b8fa-bd40dd0cfc13_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a1f5f731-1377-4baa-b8fa-bd40dd0cfc13" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a1f5f731-1377-4baa-b8fa-bd40dd0cfc13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a1f5f731-1377-4baa-b8fa-bd40dd0cfc13" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_4ec23888-8d35-47dc-88c1-086b73c93347" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_4ec23888-8d35-47dc-88c1-086b73c93347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_d5f761f1-d79c-43ce-a749-12550f37c7d9" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_d5f761f1-d79c-43ce-a749-12550f37c7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_54840c84-f664-4db6-8f04-43e2ef82a65b" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_54840c84-f664-4db6-8f04-43e2ef82a65b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_273f53c0-1952-4e0e-9c88-a266c940ed1c" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_273f53c0-1952-4e0e-9c88-a266c940ed1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d64d1fed-f2db-4fbb-925a-c0e69974020b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_us-gaap_VariableRateAxis_d64d1fed-f2db-4fbb-925a-c0e69974020b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d64d1fed-f2db-4fbb-925a-c0e69974020b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_d64d1fed-f2db-4fbb-925a-c0e69974020b" xlink:to="loc_us-gaap_VariableRateDomain_d64d1fed-f2db-4fbb-925a-c0e69974020b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6f698f53-c888-44cc-9599-9e4e1d4ce850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_d64d1fed-f2db-4fbb-925a-c0e69974020b" xlink:to="loc_us-gaap_VariableRateDomain_6f698f53-c888-44cc-9599-9e4e1d4ce850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_0a6eeec1-e904-45de-b73a-ea2f3c80af73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6f698f53-c888-44cc-9599-9e4e1d4ce850" xlink:to="loc_us-gaap_EurodollarMember_0a6eeec1-e904-45de-b73a-ea2f3c80af73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_007d717d-e046-4921-aca4-7829b4a1d840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6f698f53-c888-44cc-9599-9e4e1d4ce850" xlink:to="loc_us-gaap_BaseRateMember_007d717d-e046-4921-aca4-7829b4a1d840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_b811dcd7-486a-4d55-96b2-6fec5e066806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_b811dcd7-486a-4d55-96b2-6fec5e066806" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_b811dcd7-486a-4d55-96b2-6fec5e066806_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b811dcd7-486a-4d55-96b2-6fec5e066806" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_b811dcd7-486a-4d55-96b2-6fec5e066806_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5dacb155-153a-4e09-b6f7-72dc23422def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b811dcd7-486a-4d55-96b2-6fec5e066806" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5dacb155-153a-4e09-b6f7-72dc23422def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fe2254cd-9fc9-4f9e-ba56-f817877542e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_us-gaap_CreditFacilityAxis_fe2254cd-9fc9-4f9e-ba56-f817877542e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fe2254cd-9fc9-4f9e-ba56-f817877542e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_fe2254cd-9fc9-4f9e-ba56-f817877542e8" xlink:to="loc_us-gaap_CreditFacilityDomain_fe2254cd-9fc9-4f9e-ba56-f817877542e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0f6acb3d-7382-408f-b3bd-30828af39633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_fe2254cd-9fc9-4f9e-ba56-f817877542e8" xlink:to="loc_us-gaap_CreditFacilityDomain_0f6acb3d-7382-408f-b3bd-30828af39633" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended" id="ie637972c86714b5ea12367a4be26136d_LONGTERMOBLIGATIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_d122fa19-da06-4299-90fc-81bd132f75a7" xlink:href="amed-20210930.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_d122fa19-da06-4299-90fc-81bd132f75a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_6ca84e94-b765-4a73-9933-ffc86947910a" xlink:href="amed-20210930.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_6ca84e94-b765-4a73-9933-ffc86947910a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_37949164-6de0-48c2-9213-02a9349b801e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_37949164-6de0-48c2-9213-02a9349b801e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f9fdfe0f-8262-4771-9151-427eca557a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f9fdfe0f-8262-4771-9151-427eca557a45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_260119ce-75ab-4f42-a695-a0d1901694d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_260119ce-75ab-4f42-a695-a0d1901694d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_65026ddd-6d9b-41ff-82d9-3d7b6a490bc3" xlink:href="amed-20210930.xsd#amed_TotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_TotalLeverageRatio_65026ddd-6d9b-41ff-82d9-3d7b6a490bc3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_decf39a6-b06f-4f76-a95b-d190f56c4417" xlink:href="amed-20210930.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_decf39a6-b06f-4f76-a95b-d190f56c4417" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dd64572d-da58-4150-9cb6-9ce446013c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dd64572d-da58-4150-9cb6-9ce446013c99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_d693b006-f845-4632-991d-d9ca3601f7cb" xlink:href="amed-20210930.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_RevolvingCreditFacilityTotal_d693b006-f845-4632-991d-d9ca3601f7cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_4417b914-11e7-432e-b026-6749d42b0bf1" xlink:href="amed-20210930.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_4417b914-11e7-432e-b026-6749d42b0bf1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_750fb896-ac55-486b-8fe8-29a4ef9e5be6" xlink:href="amed-20210930.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_750fb896-ac55-486b-8fe8-29a4ef9e5be6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_1a4193fe-a326-4d0a-8b6b-610d11909617" xlink:href="amed-20210930.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_1a4193fe-a326-4d0a-8b6b-610d11909617" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_4d36bdc6-2939-458f-9ccf-7ee0abfe4c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_4d36bdc6-2939-458f-9ccf-7ee0abfe4c7c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_a62f61cb-c147-46eb-8813-9d4a9040ec72" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_a62f61cb-c147-46eb-8813-9d4a9040ec72" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_e5fb4b24-be8d-4949-a7af-75426ac60be6" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_e5fb4b24-be8d-4949-a7af-75426ac60be6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0968326d-7e99-4751-9484-aed08b727454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0968326d-7e99-4751-9484-aed08b727454" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_4da0c5e1-1806-4889-89b7-1e0618992be9" xlink:href="amed-20210930.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_4da0c5e1-1806-4889-89b7-1e0618992be9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_4813fad6-6512-434b-bd76-1d8c376daf8d" xlink:href="amed-20210930.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_4813fad6-6512-434b-bd76-1d8c376daf8d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_51d1b422-b002-483c-945f-31e9f5390d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_51d1b422-b002-483c-945f-31e9f5390d9d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_cd474c01-0070-475b-b466-30c8696c04da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_cd474c01-0070-475b-b466-30c8696c04da" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d557052f-f349-4229-a6f9-3df77288b96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d557052f-f349-4229-a6f9-3df77288b96e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_ce49191f-b476-42ae-a051-bca63f839f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_ce49191f-b476-42ae-a051-bca63f839f8a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_159fc2ca-b523-4fbd-a34f-f2a1b4cc0acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_159fc2ca-b523-4fbd-a34f-f2a1b4cc0acf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_cb83bc94-8498-4891-a857-070e209338d5" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_cb83bc94-8498-4891-a857-070e209338d5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3c449ea2-fd82-4150-8046-9a6285b2944c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3c449ea2-fd82-4150-8046-9a6285b2944c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c9fd5932-6ca4-4100-a8be-b2869ed5e402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c9fd5932-6ca4-4100-a8be-b2869ed5e402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c9fd5932-6ca4-4100-a8be-b2869ed5e402_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c9fd5932-6ca4-4100-a8be-b2869ed5e402" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c9fd5932-6ca4-4100-a8be-b2869ed5e402_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a1c26254-8626-45f9-beb8-01fbd69c9433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c9fd5932-6ca4-4100-a8be-b2869ed5e402" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a1c26254-8626-45f9-beb8-01fbd69c9433" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d7b59a94-84f2-4e98-85e9-75f88e9cdfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a1c26254-8626-45f9-beb8-01fbd69c9433" xlink:to="loc_us-gaap_SubsequentEventMember_d7b59a94-84f2-4e98-85e9-75f88e9cdfe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45a5b19f-a7a6-459c-a2e8-2d3e29c1bb6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_srt_RangeAxis_45a5b19f-a7a6-459c-a2e8-2d3e29c1bb6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45a5b19f-a7a6-459c-a2e8-2d3e29c1bb6e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_45a5b19f-a7a6-459c-a2e8-2d3e29c1bb6e" xlink:to="loc_srt_RangeMember_45a5b19f-a7a6-459c-a2e8-2d3e29c1bb6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_384b208b-4672-4610-afc8-bfec513029ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_45a5b19f-a7a6-459c-a2e8-2d3e29c1bb6e" xlink:to="loc_srt_RangeMember_384b208b-4672-4610-afc8-bfec513029ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2eb6d21f-032b-46ec-83a4-452f5e9d000f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_384b208b-4672-4610-afc8-bfec513029ea" xlink:to="loc_srt_MinimumMember_2eb6d21f-032b-46ec-83a4-452f5e9d000f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3a565e40-ff85-440d-af8b-4cbba824dbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_us-gaap_VariableRateAxis_3a565e40-ff85-440d-af8b-4cbba824dbe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3a565e40-ff85-440d-af8b-4cbba824dbe0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_3a565e40-ff85-440d-af8b-4cbba824dbe0" xlink:to="loc_us-gaap_VariableRateDomain_3a565e40-ff85-440d-af8b-4cbba824dbe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_dd0ffdd9-0228-4177-8ba9-b8a549a711aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_3a565e40-ff85-440d-af8b-4cbba824dbe0" xlink:to="loc_us-gaap_VariableRateDomain_dd0ffdd9-0228-4177-8ba9-b8a549a711aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_8b8e3ae8-e3ba-4702-a37d-ce778c1a61f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_dd0ffdd9-0228-4177-8ba9-b8a549a711aa" xlink:to="loc_us-gaap_BaseRateMember_8b8e3ae8-e3ba-4702-a37d-ce778c1a61f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_93245fe1-f236-4971-bb31-81b21905b7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_dd0ffdd9-0228-4177-8ba9-b8a549a711aa" xlink:to="loc_us-gaap_EurodollarMember_93245fe1-f236-4971-bb31-81b21905b7a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_03687f85-5552-4fdf-a292-9d224887fe35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_03687f85-5552-4fdf-a292-9d224887fe35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_03687f85-5552-4fdf-a292-9d224887fe35_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_03687f85-5552-4fdf-a292-9d224887fe35" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_03687f85-5552-4fdf-a292-9d224887fe35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_03687f85-5552-4fdf-a292-9d224887fe35" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_95f95610-7c13-4d56-8324-e55dfc503b9c" xlink:href="amed-20210930.xsd#amed_SwingLineLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_amed_SwingLineLoanMember_95f95610-7c13-4d56-8324-e55dfc503b9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_8673733f-42cc-4cd6-9f47-f58bf39f8b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_us-gaap_LetterOfCreditMember_8673733f-42cc-4cd6-9f47-f58bf39f8b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_7092c943-d03e-4e8a-9f1f-4668b5167eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_us-gaap_LoansPayableMember_7092c943-d03e-4e8a-9f1f-4668b5167eda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_123a7e7f-27c6-43cf-8963-5b6a7f29b1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_123a7e7f-27c6-43cf-8963-5b6a7f29b1f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_794a0211-c41f-4f62-b013-b9ca1347131b" xlink:href="amed-20210930.xsd#amed_PriorCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_amed_PriorCreditAgreementMember_794a0211-c41f-4f62-b013-b9ca1347131b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_504549ce-04eb-45f8-baf2-baf5af4802c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_us-gaap_LineOfCreditMember_504549ce-04eb-45f8-baf2-baf5af4802c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_c271b4db-1008-4ded-bcdf-138bb7a403b5" xlink:href="amed-20210930.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_amed_AmendedCreditAgreementMember_c271b4db-1008-4ded-bcdf-138bb7a403b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_2142f712-1793-44f4-9bee-e0a89a9690d6" xlink:href="amed-20210930.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_2142f712-1793-44f4-9bee-e0a89a9690d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0439f9c9-e332-4082-a59e-9e990e3f9294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_us-gaap_DebtInstrumentAxis_0439f9c9-e332-4082-a59e-9e990e3f9294" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0439f9c9-e332-4082-a59e-9e990e3f9294_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0439f9c9-e332-4082-a59e-9e990e3f9294" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0439f9c9-e332-4082-a59e-9e990e3f9294_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0439f9c9-e332-4082-a59e-9e990e3f9294" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_c5302c13-966b-4b4d-aeaa-27cc4f4c94f5" xlink:href="amed-20210930.xsd#amed_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_AmendedCreditAgreementMember_c5302c13-966b-4b4d-aeaa-27cc4f4c94f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_f7bd3b41-a03a-449e-ac1f-89dd57dfdeab" xlink:href="amed-20210930.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_OneHundredMillionTermLoanMember_f7bd3b41-a03a-449e-ac1f-89dd57dfdeab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_e2933c37-4e78-462d-9a19-1ca3ba12641e" xlink:href="amed-20210930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_e2933c37-4e78-462d-9a19-1ca3ba12641e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_598eccd3-2318-4499-ae85-f43bbae94165" xlink:href="amed-20210930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_598eccd3-2318-4499-ae85-f43bbae94165" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_55bfaffb-d874-4918-9e0d-aa6707078df2" xlink:href="amed-20210930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_55bfaffb-d874-4918-9e0d-aa6707078df2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_a4085535-ae53-488a-8d3e-d1e8b5972b1e" xlink:href="amed-20210930.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_a4085535-ae53-488a-8d3e-d1e8b5972b1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_9e941e01-17a0-406b-afa0-b17478ef8257" xlink:href="amed-20210930.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_9e941e01-17a0-406b-afa0-b17478ef8257" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="ice0c306b4bc9479c9f6f6b2ae2614955_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_069be04a-dbdc-4e7f-8c53-812cc5bf1fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_069be04a-dbdc-4e7f-8c53-812cc5bf1fb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_1485ad1c-7a98-450e-857a-b640b46b65d5" xlink:href="amed-20210930.xsd#amed_Numberofpatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_Numberofpatients_1485ad1c-7a98-450e-857a-b640b46b65d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_ce720184-489c-40f3-a640-2b9f7d147910" xlink:href="amed-20210930.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_ce720184-489c-40f3-a640-2b9f7d147910" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4a2b685d-1d51-4b88-a06e-7048ba42755e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4a2b685d-1d51-4b88-a06e-7048ba42755e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_238897b2-a114-423a-9df6-176befac4f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_238897b2-a114-423a-9df6-176befac4f80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_817d5904-4d03-47c5-89ea-3dd718b8eafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_817d5904-4d03-47c5-89ea-3dd718b8eafd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_580f52a0-abf4-4766-9f32-a2021e26e350" xlink:href="amed-20210930.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_580f52a0-abf4-4766-9f32-a2021e26e350" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_532c52d1-c944-45fe-9c52-f058e8a8799f" xlink:href="amed-20210930.xsd#amed_NumberOfBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_NumberOfBeneficiaries_532c52d1-c944-45fe-9c52-f058e8a8799f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_5312a816-9378-4bb7-93c9-f47afd818946" xlink:href="amed-20210930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_5312a816-9378-4bb7-93c9-f47afd818946" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_000b8c63-3f65-4852-87b4-a6c693fbd0a3" xlink:href="amed-20210930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_000b8c63-3f65-4852-87b4-a6c693fbd0a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_e3bbf572-a7cb-4f44-9ec0-37e3b52e876b" xlink:href="amed-20210930.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_e3bbf572-a7cb-4f44-9ec0-37e3b52e876b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_e76757f7-f0f3-4a66-b07a-616705f0e234" xlink:href="amed-20210930.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_e76757f7-f0f3-4a66-b07a-616705f0e234" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_1d3dfa48-c873-4e49-8da0-e372561df67c" xlink:href="amed-20210930.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_1d3dfa48-c873-4e49-8da0-e372561df67c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_dba8ff3d-600c-4941-a3c9-7b839a924603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_dba8ff3d-600c-4941-a3c9-7b839a924603" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_a25871ef-c93e-41a9-913f-ceb42043f7e9" xlink:href="amed-20210930.xsd#amed_ActualClaimsPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_ActualClaimsPayment_a25871ef-c93e-41a9-913f-ceb42043f7e9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_a7098edc-6569-4ee7-9052-a432a94732b1" xlink:href="amed-20210930.xsd#amed_ErrorRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_ErrorRatePercentage_a7098edc-6569-4ee7-9052-a432a94732b1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_9f09a89b-4188-4000-9d3b-25fedcfccbe7" xlink:href="amed-20210930.xsd#amed_IndemnificationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_IndemnificationAmount_9f09a89b-4188-4000-9d3b-25fedcfccbe7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_0339f7d1-c9c3-4e61-88e7-34934511cf05" xlink:href="amed-20210930.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_FloridaZpicRevenueReduction_0339f7d1-c9c3-4e61-88e7-34934511cf05" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_19fc7b5a-66ef-4d3a-b490-cb507099d816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_19fc7b5a-66ef-4d3a-b490-cb507099d816" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_a66033e5-5b53-487c-9800-a9bd4a73bc89" xlink:href="amed-20210930.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_HealthInsuranceRetentionLimit_a66033e5-5b53-487c-9800-a9bd4a73bc89" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_bd577f7e-27b6-4a82-91d6-ab4ce4bbd1b6" xlink:href="amed-20210930.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_bd577f7e-27b6-4a82-91d6-ab4ce4bbd1b6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_46f58e47-9e0d-4214-8bd3-059adbee3aeb" xlink:href="amed-20210930.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_46f58e47-9e0d-4214-8bd3-059adbee3aeb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_5dad5fc6-e198-47d4-b128-0daa20418c89" xlink:href="amed-20210930.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_5dad5fc6-e198-47d4-b128-0daa20418c89" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_ca4f0e55-a038-498c-9f91-40dbfe10ec0a" xlink:href="amed-20210930.xsd#amed_PayorsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_amed_PayorsAxis_ca4f0e55-a038-498c-9f91-40dbfe10ec0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_ca4f0e55-a038-498c-9f91-40dbfe10ec0a_default" xlink:href="amed-20210930.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_amed_PayorsAxis_ca4f0e55-a038-498c-9f91-40dbfe10ec0a" xlink:to="loc_amed_PayorsDomain_ca4f0e55-a038-498c-9f91-40dbfe10ec0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_3134cf66-1863-42af-9ecc-b1420caa9bc0" xlink:href="amed-20210930.xsd#amed_PayorsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_amed_PayorsAxis_ca4f0e55-a038-498c-9f91-40dbfe10ec0a" xlink:to="loc_amed_PayorsDomain_3134cf66-1863-42af-9ecc-b1420caa9bc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_72297ac4-ac44-437d-a838-c35a63247e3e" xlink:href="amed-20210930.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_PayorsDomain_3134cf66-1863-42af-9ecc-b1420caa9bc0" xlink:to="loc_amed_CompanysinsurancecarriersMember_72297ac4-ac44-437d-a838-c35a63247e3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d2546ff7-6b13-4f47-aa88-0fe542a1ee19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_srt_LitigationCaseAxis_d2546ff7-6b13-4f47-aa88-0fe542a1ee19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d2546ff7-6b13-4f47-aa88-0fe542a1ee19_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d2546ff7-6b13-4f47-aa88-0fe542a1ee19" xlink:to="loc_srt_LitigationCaseTypeDomain_d2546ff7-6b13-4f47-aa88-0fe542a1ee19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d2546ff7-6b13-4f47-aa88-0fe542a1ee19" xlink:to="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_eabc15c2-aa0a-498b-8312-5f35a2986402" xlink:href="amed-20210930.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_UsDepartmentOfJusticeMember_eabc15c2-aa0a-498b-8312-5f35a2986402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_c5a32973-7937-46eb-b3ca-ce5798fefb0f" xlink:href="amed-20210930.xsd#amed_AmedisysCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_AmedisysCIAMember_c5a32973-7937-46eb-b3ca-ce5798fefb0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_9d3c1a2d-364a-4447-9266-2aa4ecea6cd2" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_9d3c1a2d-364a-4447-9266-2aa4ecea6cd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_80794153-768f-46a9-922b-2843935461ad" xlink:href="amed-20210930.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_80794153-768f-46a9-922b-2843935461ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_ef17649a-6c77-4893-a43b-ebf44388a8a5" xlink:href="amed-20210930.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_ef17649a-6c77-4893-a43b-ebf44388a8a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_4d688cb4-e4f3-4ff8-a0eb-343dd4e4c679" xlink:href="amed-20210930.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_InternalAuditComplianceReviewMember_4d688cb4-e4f3-4ff8-a0eb-343dd4e4c679" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_86be09c7-4eb1-4558-a0e3-35725b5f7ca2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_srt_StatementGeographicalAxis_86be09c7-4eb1-4558-a0e3-35725b5f7ca2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_86be09c7-4eb1-4558-a0e3-35725b5f7ca2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_86be09c7-4eb1-4558-a0e3-35725b5f7ca2" xlink:to="loc_srt_SegmentGeographicalDomain_86be09c7-4eb1-4558-a0e3-35725b5f7ca2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_86be09c7-4eb1-4558-a0e3-35725b5f7ca2" xlink:to="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_3b2cd29f-e745-4302-a910-bc790fa6cff5" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_stpr_MA_3b2cd29f-e745-4302-a910-bc790fa6cff5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_0a488a3b-e769-406a-bb88-47655eac918a" xlink:href="amed-20210930.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_amed_MorgantownWestVirginiaMember_0a488a3b-e769-406a-bb88-47655eac918a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_8244f41f-db75-488a-b165-f3e50591107f" xlink:href="amed-20210930.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_amed_ParkersburgWestVirginiaMember_8244f41f-db75-488a-b165-f3e50591107f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_984e1ef5-a408-47fb-ad66-310f9c91d7c2" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_stpr_SC_984e1ef5-a408-47fb-ad66-310f9c91d7c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_ee425fd6-ce52-408f-8e21-77c6ce42a836" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_stpr_FL_ee425fd6-ce52-408f-8e21-77c6ce42a836" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_81096611-fa8a-4224-87d9-724b4258bc54" xlink:href="amed-20210930.xsd#amed_LakelandFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_ee425fd6-ce52-408f-8e21-77c6ce42a836" xlink:to="loc_amed_LakelandFloridaMember_81096611-fa8a-4224-87d9-724b4258bc54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_b5532a06-56e0-4185-b9de-4a8ddc57ac43" xlink:href="amed-20210930.xsd#amed_ClearwaterFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_stpr_FL_ee425fd6-ce52-408f-8e21-77c6ce42a836" xlink:to="loc_amed_ClearwaterFloridaMember_b5532a06-56e0-4185-b9de-4a8ddc57ac43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b2bb5890-1ab4-484e-9a84-7d676e291686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b2bb5890-1ab4-484e-9a84-7d676e291686" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b2bb5890-1ab4-484e-9a84-7d676e291686_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b2bb5890-1ab4-484e-9a84-7d676e291686" xlink:to="loc_us-gaap_SegmentDomain_b2bb5890-1ab4-484e-9a84-7d676e291686_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0386978d-e5ba-4305-a8a4-7b6d8a0b2656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b2bb5890-1ab4-484e-9a84-7d676e291686" xlink:to="loc_us-gaap_SegmentDomain_0386978d-e5ba-4305-a8a4-7b6d8a0b2656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_b0d2609c-2737-4a09-949c-8733bdfc161a" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0386978d-e5ba-4305-a8a4-7b6d8a0b2656" xlink:to="loc_amed_HospiceMember_b0d2609c-2737-4a09-949c-8733bdfc161a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_f509727b-ba7a-4173-bbcf-c4c9db05bdc3" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0386978d-e5ba-4305-a8a4-7b6d8a0b2656" xlink:to="loc_amed_HomeHealthMember_f509727b-ba7a-4173-bbcf-c4c9db05bdc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1bc0294b-9f31-4190-9763-6cc95d3e01bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1bc0294b-9f31-4190-9763-6cc95d3e01bd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc0294b-9f31-4190-9763-6cc95d3e01bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1bc0294b-9f31-4190-9763-6cc95d3e01bd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1bc0294b-9f31-4190-9763-6cc95d3e01bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e25aded-6a05-40d2-af24-ab0b7ed4e0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1bc0294b-9f31-4190-9763-6cc95d3e01bd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e25aded-6a05-40d2-af24-ab0b7ed4e0c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_95c2789f-6f7c-4a06-ae06-a7002fa5a714" xlink:href="amed-20210930.xsd#amed_InfinityHomeCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e25aded-6a05-40d2-af24-ab0b7ed4e0c3" xlink:to="loc_amed_InfinityHomeCareMember_95c2789f-6f7c-4a06-ae06-a7002fa5a714" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6bf0ae68-833d-4afc-b755-fbc2cbfec7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6bf0ae68-833d-4afc-b755-fbc2cbfec7df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_6bf0ae68-833d-4afc-b755-fbc2cbfec7df_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6bf0ae68-833d-4afc-b755-fbc2cbfec7df" xlink:to="loc_us-gaap_LossContingencyNatureDomain_6bf0ae68-833d-4afc-b755-fbc2cbfec7df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7a5becc9-bcd5-4c77-a527-1164418a2f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6bf0ae68-833d-4afc-b755-fbc2cbfec7df" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7a5becc9-bcd5-4c77-a527-1164418a2f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_608def02-9d4f-4c48-b697-bf724a51508c" xlink:href="amed-20210930.xsd#amed_ExtrapolatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7a5becc9-bcd5-4c77-a527-1164418a2f4f" xlink:to="loc_amed_ExtrapolatedMember_608def02-9d4f-4c48-b697-bf724a51508c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_7a813bb4-e016-4c37-8606-0de172cf4d14" xlink:href="amed-20210930.xsd#amed_UnfavorableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7a5becc9-bcd5-4c77-a527-1164418a2f4f" xlink:to="loc_amed_UnfavorableMember_7a813bb4-e016-4c37-8606-0de172cf4d14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3fc4aff-bf3b-434b-8f40-4153eedb1e31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_srt_RangeAxis_d3fc4aff-bf3b-434b-8f40-4153eedb1e31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3fc4aff-bf3b-434b-8f40-4153eedb1e31_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d3fc4aff-bf3b-434b-8f40-4153eedb1e31" xlink:to="loc_srt_RangeMember_d3fc4aff-bf3b-434b-8f40-4153eedb1e31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17f80a2b-08d7-4544-a9d0-152473a4d86b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d3fc4aff-bf3b-434b-8f40-4153eedb1e31" xlink:to="loc_srt_RangeMember_17f80a2b-08d7-4544-a9d0-152473a4d86b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b912b46-2286-4539-bc69-2cdaaeefdc14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17f80a2b-08d7-4544-a9d0-152473a4d86b" xlink:to="loc_srt_MinimumMember_5b912b46-2286-4539-bc69-2cdaaeefdc14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_567c81d0-cc74-4e17-9215-a5966e69e645" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17f80a2b-08d7-4544-a9d0-152473a4d86b" xlink:to="loc_srt_MaximumMember_567c81d0-cc74-4e17-9215-a5966e69e645" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended" id="i40e5aacff5344305914a98e22c887284_SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4063c0c2-3f1b-49f2-b999-2a7ca71904d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4063c0c2-3f1b-49f2-b999-2a7ca71904d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_daa94199-f7b8-4235-a9f2-1d2fb356ffc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_daa94199-f7b8-4235-a9f2-1d2fb356ffc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_05e51d3f-218e-4e68-8e33-f7840bc18cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_05e51d3f-218e-4e68-8e33-f7840bc18cfd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a0141a7c-ad93-40b4-b665-4ef48cfb7715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a0141a7c-ad93-40b4-b665-4ef48cfb7715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d4af8c66-d80d-454b-a0e7-c7bc550abed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_DepreciationAndAmortization_d4af8c66-d80d-454b-a0e7-c7bc550abed0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e31332c2-7ea6-464f-90cc-51b7712870c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_CostsAndExpenses_e31332c2-7ea6-464f-90cc-51b7712870c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9be73b50-6a09-4cb8-9b23-952d18554b53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_OperatingIncomeLoss_9be73b50-6a09-4cb8-9b23-952d18554b53" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac7c3020-8366-43be-9f50-cd0301dc47eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac7c3020-8366-43be-9f50-cd0301dc47eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_54d4be7e-47bc-4e50-b86d-3f64dd6683fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac7c3020-8366-43be-9f50-cd0301dc47eb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_54d4be7e-47bc-4e50-b86d-3f64dd6683fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_54d4be7e-47bc-4e50-b86d-3f64dd6683fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_54d4be7e-47bc-4e50-b86d-3f64dd6683fe" xlink:to="loc_us-gaap_SegmentDomain_54d4be7e-47bc-4e50-b86d-3f64dd6683fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_54d4be7e-47bc-4e50-b86d-3f64dd6683fe" xlink:to="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_bedb94b2-bb0f-42e0-a55a-72f04426aa9c" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_amed_HomeHealthMember_bedb94b2-bb0f-42e0-a55a-72f04426aa9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_cacba914-8cdf-4469-8aa1-3d8f536384a1" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_amed_HospiceMember_cacba914-8cdf-4469-8aa1-3d8f536384a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_98d108f6-307a-41fd-966b-25e2fb7dc796" xlink:href="amed-20210930.xsd#amed_PersonalCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_amed_PersonalCareMember_98d108f6-307a-41fd-966b-25e2fb7dc796" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_7cd2a35b-8d08-4d35-b1cf-0da623ebd082" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_amed_HighAcuityCareMember_7cd2a35b-8d08-4d35-b1cf-0da623ebd082" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_bc0162a9-4ab3-4d0b-b04f-88a642973cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_us-gaap_AllOtherSegmentsMember_bc0162a9-4ab3-4d0b-b04f-88a642973cf6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails" xlink:type="extended" id="ib3d4a0b92c4e4ea18d3f946231b6756f_CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_4d7ff370-39ef-4abb-8002-9348f75cbe81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_4d7ff370-39ef-4abb-8002-9348f75cbe81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedSharesInShares_c11b16ee-d301-43d4-a4ef-b1b01bcaf3dc" xlink:href="amed-20210930.xsd#amed_SurrenderedSharesInShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_amed_SurrenderedSharesInShares_c11b16ee-d301-43d4-a4ef-b1b01bcaf3dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3bfdf280-755e-43b4-8999-8519da3afa8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3bfdf280-755e-43b4-8999-8519da3afa8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8281694c-ecfc-443f-b5cb-eac964da3ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8281694c-ecfc-443f-b5cb-eac964da3ce2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fd4e3d71-05c9-441c-9694-1271f980a178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fd4e3d71-05c9-441c-9694-1271f980a178" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc23e0a2-4ee2-4162-9f09-18c663a55708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc23e0a2-4ee2-4162-9f09-18c663a55708" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5509c2bf-2611-4425-873f-4348e4def0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc23e0a2-4ee2-4162-9f09-18c663a55708" xlink:to="loc_us-gaap_AwardTypeAxis_5509c2bf-2611-4425-873f-4348e4def0d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5509c2bf-2611-4425-873f-4348e4def0d2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5509c2bf-2611-4425-873f-4348e4def0d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5509c2bf-2611-4425-873f-4348e4def0d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c7a1937-3051-43cc-94c5-fccfea6f0d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5509c2bf-2611-4425-873f-4348e4def0d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c7a1937-3051-43cc-94c5-fccfea6f0d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_9567d9a0-ae5f-4a30-bc28-9f2c14d365d0" xlink:href="amed-20210930.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c7a1937-3051-43cc-94c5-fccfea6f0d20" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_9567d9a0-ae5f-4a30-bc28-9f2c14d365d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended" id="id1c3d989ba4644dcb7369846bbe9835a_SHAREREPURCHASENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:href="amed-20210930.xsd#amed_ShareRepurchaseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0cf9d5c5-0043-4b11-9f11-1d77709afe18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0cf9d5c5-0043-4b11-9f11-1d77709afe18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_be7f0384-8e03-4ff6-8a78-5d41c6ae77c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_be7f0384-8e03-4ff6-8a78-5d41c6ae77c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_edeef491-9908-4b61-944b-3c974908c27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_edeef491-9908-4b61-944b-3c974908c27b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_7d57d01e-6734-442d-827f-07882deb448b" xlink:href="amed-20210930.xsd#amed_PercentageofSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_amed_PercentageofSharesOutstanding_7d57d01e-6734-442d-827f-07882deb448b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79167bb7-2c9a-4ce1-9f92-29ca65312c62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79167bb7-2c9a-4ce1-9f92-29ca65312c62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_6981a46f-ba94-4726-be51-f4ae80988372" xlink:href="amed-20210930.xsd#amed_Discountedclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_amed_Discountedclosingstockprice_6981a46f-ba94-4726-be51-f4ae80988372" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_00a75ac3-07ad-40fa-a450-518c5706e45d" xlink:href="amed-20210930.xsd#amed_Percentageofclosingstockprice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_amed_Percentageofclosingstockprice_00a75ac3-07ad-40fa-a450-518c5706e45d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_540311fc-65c1-4bc8-8c4f-b767b31fd9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_540311fc-65c1-4bc8-8c4f-b767b31fd9e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_e1296c56-da1a-4947-aace-3679b2e334a7" xlink:href="amed-20210930.xsd#amed_ShareRepurchaseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_amed_ShareRepurchaseTable_e1296c56-da1a-4947-aace-3679b2e334a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_f92ee016-f4ca-4f31-82c7-c88b2192276e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_e1296c56-da1a-4947-aace-3679b2e334a7" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_f92ee016-f4ca-4f31-82c7-c88b2192276e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f92ee016-f4ca-4f31-82c7-c88b2192276e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_f92ee016-f4ca-4f31-82c7-c88b2192276e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f92ee016-f4ca-4f31-82c7-c88b2192276e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_f92ee016-f4ca-4f31-82c7-c88b2192276e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember_4662788a-717e-4359-936a-038569f91948" xlink:href="amed-20210930.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_A2019ShareRepurchaseProgramMember_4662788a-717e-4359-936a-038569f91948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_c9b518ba-6fab-48a6-b66f-1b996eac6958" xlink:href="amed-20210930.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_c9b518ba-6fab-48a6-b66f-1b996eac6958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_72d0fb03-9568-43bf-8848-73708ac1352e" xlink:href="amed-20210930.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_ShareRepurchaseProgramMember_72d0fb03-9568-43bf-8848-73708ac1352e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExistingShareRepurchaseProgramMember_7451a3a4-128b-4471-a442-60936f355e21" xlink:href="amed-20210930.xsd#amed_ExistingShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_ExistingShareRepurchaseProgramMember_7451a3a4-128b-4471-a442-60936f355e21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NewShareRepurchaseProgramMember_0af71abd-386d-4cd1-8b40-91997b36f81a" xlink:href="amed-20210930.xsd#amed_NewShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_NewShareRepurchaseProgramMember_0af71abd-386d-4cd1-8b40-91997b36f81a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fc2f00f9-64bf-4481-beb5-d004ac2ca035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_amed_ShareRepurchaseTable_e1296c56-da1a-4947-aace-3679b2e334a7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fc2f00f9-64bf-4481-beb5-d004ac2ca035" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fc2f00f9-64bf-4481-beb5-d004ac2ca035_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fc2f00f9-64bf-4481-beb5-d004ac2ca035" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fc2f00f9-64bf-4481-beb5-d004ac2ca035_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2bcbdf59-53ad-4358-80b0-6866ef610f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fc2f00f9-64bf-4481-beb5-d004ac2ca035" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2bcbdf59-53ad-4358-80b0-6866ef610f01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3e6db487-8cb9-40f1-9f4f-08d9a135c09d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2bcbdf59-53ad-4358-80b0-6866ef610f01" xlink:to="loc_us-gaap_SubsequentEventMember_3e6db487-8cb9-40f1-9f4f-08d9a135c09d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended" id="iaddb3d12fe6448848951bfe6a88263dc_RELATEDPARTYTRANSACTIONSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_55e873c1-e85b-4736-a83b-34b4273edfde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_548e7849-4728-4682-b7a6-765cce320886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_55e873c1-e85b-4736-a83b-34b4273edfde" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_548e7849-4728-4682-b7a6-765cce320886" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8d834a6d-b405-473e-bb7c-3be3d6a6ccb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_55e873c1-e85b-4736-a83b-34b4273edfde" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8d834a6d-b405-473e-bb7c-3be3d6a6ccb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a62a34c9-57e2-4b73-a931-749266776cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8d834a6d-b405-473e-bb7c-3be3d6a6ccb6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a62a34c9-57e2-4b73-a931-749266776cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a62a34c9-57e2-4b73-a931-749266776cad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a62a34c9-57e2-4b73-a931-749266776cad" xlink:to="loc_us-gaap_RelatedPartyDomain_a62a34c9-57e2-4b73-a931-749266776cad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d62793d4-60d2-4c8b-bad0-f1167bb5caaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a62a34c9-57e2-4b73-a931-749266776cad" xlink:to="loc_us-gaap_RelatedPartyDomain_d62793d4-60d2-4c8b-bad0-f1167bb5caaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_eadcdad8-7dca-4c98-a60a-4d182ac99787" xlink:href="amed-20210930.xsd#amed_MedalogixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d62793d4-60d2-4c8b-bad0-f1167bb5caaf" xlink:to="loc_amed_MedalogixMember_eadcdad8-7dca-4c98-a60a-4d182ac99787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2b8cb977-1faf-4e50-af1d-3f1aa7df23e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8d834a6d-b405-473e-bb7c-3be3d6a6ccb6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2b8cb977-1faf-4e50-af1d-3f1aa7df23e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2b8cb977-1faf-4e50-af1d-3f1aa7df23e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2b8cb977-1faf-4e50-af1d-3f1aa7df23e6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2b8cb977-1faf-4e50-af1d-3f1aa7df23e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c69277c9-4414-4ffe-a81f-ba4218bd3d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2b8cb977-1faf-4e50-af1d-3f1aa7df23e6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c69277c9-4414-4ffe-a81f-ba4218bd3d8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="simple" xlink:href="amed-20210930.xsd#SUBSEQUENTEVENTTables"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="extended" id="i529ed350489740e2956ec4fbcfa13d34_SUBSEQUENTEVENTTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ebbad669-476c-42ce-b7d3-04c26e7a3d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_ceb9f923-8003-4688-a4e2-2739f71baef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_ebbad669-476c-42ce-b7d3-04c26e7a3d03" xlink:to="loc_us-gaap_SubsequentEventTable_ceb9f923-8003-4688-a4e2-2739f71baef1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7cea266f-66bc-4f0a-bc84-3bc0ba6294a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_ceb9f923-8003-4688-a4e2-2739f71baef1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7cea266f-66bc-4f0a-bc84-3bc0ba6294a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7cea266f-66bc-4f0a-bc84-3bc0ba6294a1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7cea266f-66bc-4f0a-bc84-3bc0ba6294a1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7cea266f-66bc-4f0a-bc84-3bc0ba6294a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_485ee0e4-6f17-41b6-b8c7-c812588569d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7cea266f-66bc-4f0a-bc84-3bc0ba6294a1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_485ee0e4-6f17-41b6-b8c7-c812588569d3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended" id="i3e8a221eea7f4867ad3c6c2cc4b13225_SUBSEQUENTEVENTNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1d81219f-7b8e-43d6-bd71-d8849b891cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_56f65e9e-7c99-4e42-af73-0d20fbd05df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1d81219f-7b8e-43d6-bd71-d8849b891cd9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_56f65e9e-7c99-4e42-af73-0d20fbd05df0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1d81219f-7b8e-43d6-bd71-d8849b891cd9" xlink:to="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f40dd129-127a-40d0-b707-43d3ee04522f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f40dd129-127a-40d0-b707-43d3ee04522f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f40dd129-127a-40d0-b707-43d3ee04522f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f40dd129-127a-40d0-b707-43d3ee04522f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f40dd129-127a-40d0-b707-43d3ee04522f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e93d794a-43bd-49e0-b4e3-f951e5d406aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f40dd129-127a-40d0-b707-43d3ee04522f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e93d794a-43bd-49e0-b4e3-f951e5d406aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ba8ffdf6-c424-4b73-abf1-13e9632ec50d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e93d794a-43bd-49e0-b4e3-f951e5d406aa" xlink:to="loc_us-gaap_SubsequentEventMember_ba8ffdf6-c424-4b73-abf1-13e9632ec50d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ef6cefb2-ad29-43f6-ae96-54d61714c307" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:to="loc_srt_StatementGeographicalAxis_ef6cefb2-ad29-43f6-ae96-54d61714c307" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ef6cefb2-ad29-43f6-ae96-54d61714c307_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ef6cefb2-ad29-43f6-ae96-54d61714c307" xlink:to="loc_srt_SegmentGeographicalDomain_ef6cefb2-ad29-43f6-ae96-54d61714c307_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2e213798-41c4-428d-94c2-2e5b65186726" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ef6cefb2-ad29-43f6-ae96-54d61714c307" xlink:to="loc_srt_SegmentGeographicalDomain_2e213798-41c4-428d-94c2-2e5b65186726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_b3b6cf17-a046-4d03-9dd1-063a5e0f1658" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2e213798-41c4-428d-94c2-2e5b65186726" xlink:to="loc_stpr_NC_b3b6cf17-a046-4d03-9dd1-063a5e0f1658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6150689b-9b06-4f04-9114-fc63279b0508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6150689b-9b06-4f04-9114-fc63279b0508" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6150689b-9b06-4f04-9114-fc63279b0508_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6150689b-9b06-4f04-9114-fc63279b0508" xlink:to="loc_us-gaap_SegmentDomain_6150689b-9b06-4f04-9114-fc63279b0508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a364fad-0889-4ce7-96af-97bf6d1b12fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6150689b-9b06-4f04-9114-fc63279b0508" xlink:to="loc_us-gaap_SegmentDomain_8a364fad-0889-4ce7-96af-97bf6d1b12fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_a91283a3-7fcf-45a4-865a-0cc8051322c7" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8a364fad-0889-4ce7-96af-97bf6d1b12fa" xlink:to="loc_amed_HomeHealthMember_a91283a3-7fcf-45a4-865a-0cc8051322c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>amed-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9a22ea05-d9af-4e79-9afb-aec6f57a9fea,g:f821983a-9b6a-4f0b-a7a4-a1b27b9c9a2c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_d6dea143-7578-4018-ba32-814b43da9a90_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableNoncurrent" xlink:to="lab_us-gaap_LossContingencyReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_dfb55db4-88c7-4c8a-a8ac-7d2429ad40e8_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue period of care payment rate (days)</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Period of Care Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:href="amed-20210930.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_5305fb99-8130-48f0-8199-febe64c9fa4e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_5f7cb5ee-55b0-4fc2-8373-62ee69b98b5d_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase (decrease) In Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="amed-20210930.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b9a5cd43-ee26-4f91-9f09-e53533dc51c7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ClearwaterFloridaMember_4ae9e5c3-bc6b-4703-9272-1114cf44901f_terseLabel_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_label_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:label id="lab_amed_ClearwaterFloridaMember_documentation_en-US" xlink:label="lab_amed_ClearwaterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clearwater, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember" xlink:href="amed-20210930.xsd#amed_ClearwaterFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ClearwaterFloridaMember" xlink:to="lab_amed_ClearwaterFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_SC_dd4c4704-7754-48b0-a39d-c9da6126a65b_terseLabel_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Carolina</link:label>
    <link:label id="lab_stpr_SC_label_en-US" xlink:label="lab_stpr_SC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOUTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_SC" xlink:to="lab_stpr_SC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9ecc2cba-3ad9-4e66-85fc-2e1d7086c599_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_VisitingNurseAssociationMember_ffb3aae5-b56a-4c57-81e9-dbf6ea1ee7ff_terseLabel_en-US" xlink:label="lab_amed_VisitingNurseAssociationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visiting Nurse Association</link:label>
    <link:label id="lab_amed_VisitingNurseAssociationMember_label_en-US" xlink:label="lab_amed_VisitingNurseAssociationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visiting Nurse Association [Member]</link:label>
    <link:label id="lab_amed_VisitingNurseAssociationMember_documentation_en-US" xlink:label="lab_amed_VisitingNurseAssociationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visiting Nurse Association</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VisitingNurseAssociationMember" xlink:href="amed-20210930.xsd#amed_VisitingNurseAssociationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_VisitingNurseAssociationMember" xlink:to="lab_amed_VisitingNurseAssociationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c5ece62d-0cbb-4df6-93f8-5c980a82fc49_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8ecf71c4-7194-4ae8-a43b-a78838bdea74_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_ebf4d514-e110-42a8-86e9-0cfac9521aab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_df1820d9-7fc4-4aa1-a053-4d92e56c28fb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_0db1691a-3f9c-4104-a8fd-caaeccb42d30_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_ccf3d230-c748-43f4-b80b-baef01b24f7a_terseLabel_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health period of care using PDGM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20210930.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_PeriodOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_a8322793-19d5-471a-8474-3ae2f56c0363_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_6d43aec6-1d38-4907-8ada-e840f9c38a27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_e43efaee-1f28-4f0d-8b92-8fd6ccbae59b_terseLabel_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_label_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:label id="lab_amed_MorgantownWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_MorgantownWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Morgantown, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember" xlink:href="amed-20210930.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MorgantownWestVirginiaMember" xlink:to="lab_amed_MorgantownWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1676856c-8e93-4786-95e1-c51dfea82a12_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a232a505-46b1-44cf-8a2f-d586117825af_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_18a31b7e-f744-46f4-9af2-c52ef08319fe_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_205eed22-20c7-4b17-9bd5-3648364a30c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_e0567282-d97b-4358-abd2-62f8367ca72f_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_70a971bd-8072-46da-b18a-364d0bee5e0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExistingShareRepurchaseProgramMember_28a94c07-cbbd-47f9-baf1-c53b6fa05a40_terseLabel_en-US" xlink:label="lab_amed_ExistingShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Share Repurchase Program</link:label>
    <link:label id="lab_amed_ExistingShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_ExistingShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_ExistingShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_ExistingShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExistingShareRepurchaseProgramMember" xlink:href="amed-20210930.xsd#amed_ExistingShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExistingShareRepurchaseProgramMember" xlink:to="lab_amed_ExistingShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_32da5642-c6d6-4bdc-82a7-c57f6731a2e5_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0fb6cf91-ba95-40bd-83bd-4baf375381de_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_960840e8-c75e-4529-aa54-5caaca848910_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net of accumulated amortization of $20,309 and $22,973</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_142c007f-8405-4b9f-8981-6e2133fc84ec_terseLabel_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_label_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</link:label>
    <link:label id="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_documentation_en-US" xlink:label="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:href="amed-20210930.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:to="lab_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_2003f056-8900-4699-8cfc-019de808d940_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedLeverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio" xlink:href="amed-20210930.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedLeverageRatio" xlink:to="lab_amed_ConsolidatedLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4e533e32-59f2-4342-9984-f839a032f704_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_12929338-82ad-429b-889d-7436a253cd98_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e5bf8d45-fa1f-4f8e-a93f-f69399589635_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fc4b00dc-37cf-4896-a6c1-320d21f46e31_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_ab00a170-9afb-4a8a-874e-684c0d51154f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_4b3755c9-015e-4491-9ff0-33b9af232b9a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2d0b6328-b8c8-4670-b4ed-29acf7e1fda0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_08fcbed5-abfb-450a-a3a5-70b03917cde2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_b3099299-c10f-4711-9395-40e98ac301a7_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_292bb354-69be-4f5f-8555-014e1920e3af_terseLabel_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Single Payor</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_label_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:label id="lab_amed_MajorSinglePayorCustomerMember_documentation_en-US" xlink:label="lab_amed_MajorSinglePayorCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Single Payor Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember" xlink:href="amed-20210930.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MajorSinglePayorCustomerMember" xlink:to="lab_amed_MajorSinglePayorCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_d446846f-6bc1-4eec-8b25-7f4cdddb97e6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_80bff43a-0b92-40b1-adba-bd364089beb3_terseLabel_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum ownership percentage for controlling interest (percent)</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_label_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Percent Ownership For Controlling Interest Percent</link:label>
    <link:label id="lab_amed_MinimumPercentOwnershipForControllingInterestPercent_documentation_en-US" xlink:label="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:href="amed-20210930.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:to="lab_amed_MinimumPercentOwnershipForControllingInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_dc618e1f-75b8-4035-999c-30b18ba0a7ca_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_1a62b98e-c7bf-4761-9207-4c1e004f817e_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_65ab7a9c-9330-4916-a3ce-47b0a9c96eea_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e9b07de3-aa8f-4426-8e18-f8aa9a963fc0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8dcfa1cd-6581-4c28-8a3f-af948133d461_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies&#8212;Note 6</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_5c96fec7-1a5a-4016-8954-68e271b7e72e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_77d48c10-192c-47c4-96a1-31f7c419d14f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f2a7a4b0-d190-4549-86e2-fa3145e98651_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_0bf99a3a-ea15-4647-ad73-afb966551c18_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of company stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_1db95545-1204-4afc-84f3-4c2d2a98511f_negatedLabel_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of noncontrolling interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_label_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:label id="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Repurchase of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:href="amed-20210930.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:to="lab_amed_EquityImpactofRepurchaseofNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5c6a981a-fb5a-468c-8c4f-34c3a94134a1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_1c6bde0b-78e3-435f-8ad3-2a25208efd40_terseLabel_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_label_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Patient Receivables Outstanding</link:label>
    <link:label id="lab_amed_PercentageOfPatientReceivablesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of patient receivables outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:href="amed-20210930.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfPatientReceivablesOutstanding" xlink:to="lab_amed_PercentageOfPatientReceivablesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_8bf25091-f9ea-44fb-84d8-b6c2109cd513_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5c99648b-1807-4046-a23d-d1b88331c096_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1d161012-88ce-4c05-8701-ac91a3c0b38f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_60dd6730-0e5e-4424-90f1-cd05c5734264_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_9fc71afd-82f7-4fe7-843d-232f769787a6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_43a1076b-f8b0-4fd0-938f-07d3b485cfb3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_80599db1-5103-4f74-be20-2842ded2cbbc_terseLabel_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_label_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical Collection Rate From Medicare</link:label>
    <link:label id="lab_amed_HistoricalCollectionRateFromMedicare_documentation_en-US" xlink:label="lab_amed_HistoricalCollectionRateFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Historical collection rate from Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare" xlink:href="amed-20210930.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HistoricalCollectionRateFromMedicare" xlink:to="lab_amed_HistoricalCollectionRateFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_dfce5b18-6d90-4268-92af-a3737bacf07b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of variable rate basis</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_30ebc2b5-28b6-42d4-b435-d2e4ef7af227_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_8b2cc3be-2adf-4804-a938-a198b0f0bd13_terseLabel_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode of care as episodic-based revenue (days)</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_label_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Episode Of Care As Episodic Based Revenue Duration</link:label>
    <link:label id="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_documentation_en-US" xlink:label="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days in a home health episode of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:href="amed-20210930.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:to="lab_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4ff6331e-6420-456c-a17c-99fbe6b32331_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_92e78079-d5c1-47c9-a5ba-1bd6592dfa66_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_d4b381ad-920b-4d63-8af2-2f0a8508243e_negatedLabel_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distribution</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_label_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Distribution To Noncontrolling Interest</link:label>
    <link:label id="lab_amed_CashDistributionToNoncontrollingInterest_documentation_en-US" xlink:label="lab_amed_CashDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of dividends or other distributions to noncontrolling interest holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest" xlink:href="amed-20210930.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashDistributionToNoncontrollingInterest" xlink:to="lab_amed_CashDistributionToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_f5f56592-fd8c-40b0-b7e1-2a19ac6f90e5_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Non-Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:href="amed-20210930.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareNonEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2a8a85a1-55ed-408e-a58d-31c6269fd259_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_3f561231-d443-4d10-9377-c56f4bd160f8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_a7ea3fed-c313-4df3-a270-455728d5d7c3_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_bb825139-ba57-450a-bd45-42795bf002f1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearDomain_8957af87-af6d-47f1-adae-becc7ccaac2e_terseLabel_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_label_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:label id="lab_amed_CapYearDomain_documentation_en-US" xlink:label="lab_amed_CapYearDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain" xlink:href="amed-20210930.xsd#amed_CapYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearDomain" xlink:to="lab_amed_CapYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_df0d66d8-c36b-4436-98a1-c8ea245bae80_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_820fb7fc-cd6e-479c-9b6b-60adce66fdea_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:href="amed-20210930.xsd#amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:to="lab_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_6dc7857f-936c-4165-8681-c0ff3a4a5d2f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_c08fcae1-c08c-4381-9623-0090c6b19a00_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_5d4c60a9-edc4-46d2-a241-d116c942ff6a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_b8045b71-be9f-4d09-aec4-5b059a622bfb_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_ff5d5153-ba1d-44e2-a0c6-a378d83e50cd_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_8f16a957-42dc-4ee4-a78c-a739dbb86c74_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare revenue rate accounted for routine care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_label_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare Revenue Rate Accounted For Routine Care</link:label>
    <link:label id="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_documentation_en-US" xlink:label="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:href="amed-20210930.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:to="lab_amed_HospiceMedicareRevenueRateAccountedForRoutineCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_a1111fae-a11a-4fd5-9228-d6d8da99113f_terseLabel_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions to right of use assets resulting from reductions to operating lease liabilities</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_label_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:label id="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_documentation_en-US" xlink:label="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:href="amed-20210930.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:to="lab_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b768e1bc-f6f6-4296-aff1-50b6afaca9a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_531ed2c0-69ea-478b-ae8a-2b8a93c07558_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_8572e2ac-aa43-41e8-a4b8-f2f781baf5fe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term obligations</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_a6948f7b-0f3e-4588-bd13-fa5583c0f775_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_adb74324-c71e-446e-a462-02f9f2b75b67_terseLabel_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Hundred Fifty Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:href="amed-20210930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProviderReliefFundAdvance_811982e1-57c5-4f11-9fd2-eef5bc1cdc13_terseLabel_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_ProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_ProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable related to funds received from the government related to COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance" xlink:href="amed-20210930.xsd#amed_ProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProviderReliefFundAdvance" xlink:to="lab_amed_ProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_564f2464-9f8c-405e-841e-2fdb97eca66c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMember_61e89390-77b7-4567-98be-115bb11f12be_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_label_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMember" xlink:to="lab_amed_HomeHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_ba571a7f-f55c-4d15-8daf-113e01f8eb26_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_1f28b4bf-1d6d-47e5-bcb0-dc2d857d4b46_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for subsequent episodes of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:href="amed-20210930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_b13c4172-854e-4288-8386-7a9d4b933d8c_terseLabel_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low utilization payment adjustment, maximum number of visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_label_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Low Utilization Payment Adjustment Number Of Visits</link:label>
    <link:label id="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_documentation_en-US" xlink:label="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the visit threshold for a low utilization payment adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:href="amed-20210930.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:to="lab_amed_LowUtilizationPaymentAdjustmentNumberOfVisits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_5e666b2b-451e-4d1d-897e-07dc59fe4d76_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_123778e0-0ff0-4a7d-a70b-6c02d101f6ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of net services revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_389f89f7-a044-41c0-a23f-f11f41db45ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_0060c354-d214-40cc-997e-0a3e3267134e_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected to be Utilized</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected to be Utilized</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Funds Expected to be Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:href="amed-20210930.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_36ddf1f5-6d17-4aa2-b9ed-f6d32dd6323b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_6bdd5441-919b-4667-99ee-0f63f38a62f9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_2c02e168-7f4c-4fd7-810e-aaef476a4a4b_terseLabel_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_label_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grants [Policy Text Block]</link:label>
    <link:label id="lab_amed_GovernmentGrantsPolicyTextBlock_documentation_en-US" xlink:label="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting policy disclosure text block for government grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:href="amed-20210930.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GovernmentGrantsPolicyTextBlock" xlink:to="lab_amed_GovernmentGrantsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b93a90af-84f8-4192-993c-ca22a97b083d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_248afc46-f512-46bc-9bf8-30075b7e8c29_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_f4587c8c-6631-4a98-962a-4fa2b8c437fd_terseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InfinityHomeCareMember_1ad8fdac-58cd-4f9a-b241-a21800913f0e_terseLabel_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_label_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:label id="lab_amed_InfinityHomeCareMember_documentation_en-US" xlink:label="lab_amed_InfinityHomeCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infinity HomeCare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember" xlink:href="amed-20210930.xsd#amed_InfinityHomeCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InfinityHomeCareMember" xlink:to="lab_amed_InfinityHomeCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_f427d7bf-d3fd-4bc0-82f6-f1f6f9170568_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_af21a5cd-2507-4a08-9007-d0057e144d5b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_808f3759-053e-4384-95dd-919a081c1654_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_c4f9900f-d011-4412-8185-873507b8a550_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_3a9830a2-2e68-4e68-95a1-6a7850e7ce4e_terseLabel_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Seventy Five Million Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:href="amed-20210930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:to="lab_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_8b3bc2b3-e1c0-4c9b-ac46-bea758a6c40c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_69f5b495-5693-4171-822e-2d61cee926ed_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_5f452794-3ec4-4766-9f70-f3ba68eafa5e_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_label_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:label id="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:href="amed-20210930.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:to="lab_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_fcf7c8c9-cbe0-4875-b97c-e02c05f84654_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:href="amed-20210930.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_8cb99d88-96d1-4a62-92af-45d3b150f49d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_1714a3ac-ffc2-4894-9c32-b69ef2086e12_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b80abcfd-d701-4918-8e1b-534b058ca26e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_09cfc7fe-be58-4db0-ad36-14aa0a9406ea_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_bd8b7a37-7816-4d59-8ed3-13430d053423_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating income</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Numberofpatients_94ae4378-08f3-4076-86d5-bd9592c7c9b4_terseLabel_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_label_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_amed_Numberofpatients_documentation_en-US" xlink:label="lab_amed_Numberofpatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients" xlink:href="amed-20210930.xsd#amed_Numberofpatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Numberofpatients" xlink:to="lab_amed_Numberofpatients" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_fb884579-02f9-41be-a6c4-80009cad3072_terseLabel_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_label_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice [Member]</link:label>
    <link:label id="lab_amed_HomeHealthAndHospiceMember_documentation_en-US" xlink:label="lab_amed_HomeHealthAndHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember" xlink:href="amed-20210930.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthAndHospiceMember" xlink:to="lab_amed_HomeHealthAndHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_4accfd11-6886-4b27-84c6-ee912c1d8dd7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsMember" xlink:to="lab_us-gaap_EquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_2cd9ad57-2111-4acc-9a6a-cd20624879ac_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM OBLIGATIONS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e860d1d3-ba4a-4b37-a431-d9ce3cf525b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_79e84e8d-86fa-4269-8f7a-1cdfd3bf6b9f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_082ecee4-f049-40fd-98f8-e804db55dcc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_VariousAcquisitionsMember_67d8261e-4457-4bf6-a3cd-6432a0f3e119_terseLabel_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various acquisitions</link:label>
    <link:label id="lab_amed_VariousAcquisitionsMember_label_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various acquisitions [Member]</link:label>
    <link:label id="lab_amed_VariousAcquisitionsMember_documentation_en-US" xlink:label="lab_amed_VariousAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember" xlink:href="amed-20210930.xsd#amed_VariousAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_VariousAcquisitionsMember" xlink:to="lab_amed_VariousAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_b10b0335-ca5c-4461-9b14-be027ba3ed73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f94cc85c-8e0d-41cf-970f-6bc0a0626cc1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_56ad79ce-d3e8-4b06-a6f3-57f602e97d61_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_64570e82-6c85-4657-baec-35366438b1ec_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_6be3b9d0-b37b-42a0-b761-69ca4b0c0159_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareRevenueMember_fc662177-d1f5-4203-8957-a2c0b4c57825_terseLabel_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_label_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:label id="lab_amed_MedicareRevenueMember_documentation_en-US" xlink:label="lab_amed_MedicareRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember" xlink:href="amed-20210930.xsd#amed_MedicareRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareRevenueMember" xlink:to="lab_amed_MedicareRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_d5807297-83ae-4f9d-ac2e-af79b2323aef_terseLabel_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum additional borrowing capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:label id="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="amed-20210930.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_amed_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_81e64f00-0d4a-47d8-bcfd-152442121a5b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases [Member]</link:label>
    <link:label id="lab_us-gaap_CapitalLeaseObligationsMember_label_en-US" xlink:label="lab_us-gaap_CapitalLeaseObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Lease Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsMember" xlink:to="lab_us-gaap_CapitalLeaseObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b524e7ee-144e-444f-9cb5-3e86f8f3eca0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5e8b7b44-9933-410f-897d-d1eb53f3ca9a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_74dd4d65-94ae-4329-a4e6-9dc9c54f4f75_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_64b61014-b0e7-4afb-9e86-21889f1f2ba2_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement, net</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit settlement</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitsettlement_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge related to Securities Class Action Lawsuit settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:href="amed-20210930.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitsettlement" xlink:to="lab_amed_SecuritiesClassActionLawsuitsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_bc757602-aa02-42a9-9d32-4be1b555afc5_terseLabel_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_label_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition pro forma operating income loss</link:label>
    <link:label id="lab_amed_Businessacquisitionproformaoperatingincomeloss_documentation_en-US" xlink:label="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:href="amed-20210930.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Businessacquisitionproformaoperatingincomeloss" xlink:to="lab_amed_Businessacquisitionproformaoperatingincomeloss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_ccc9177b-f3f8-4afa-a728-2fc7422ccc79_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_6962b6f1-c593-45d7-a645-bc430840b88e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in technology assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToDevelopSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsToDevelopSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Develop Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToDevelopSoftware" xlink:to="lab_us-gaap_PaymentsToDevelopSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_90fa879a-bbc6-4956-9317-9d604db364d7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondAmendmentToAmendedCreditAgreementMember_5aaa704d-1c5d-4bfc-bd32-7ef1bf352586_terseLabel_en-US" xlink:label="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amended Credit Agreement</link:label>
    <link:label id="lab_amed_SecondAmendmentToAmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment to Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_SecondAmendmentToAmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment to Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:href="amed-20210930.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:to="lab_amed_SecondAmendmentToAmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_4fce264b-0811-472a-97f8-037c658e00a8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsDomain_d604e5ac-63a3-4550-aac7-4a64fccf3b18_terseLabel_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_label_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Domain]</link:label>
    <link:label id="lab_amed_PayorsDomain_documentation_en-US" xlink:label="lab_amed_PayorsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain" xlink:href="amed-20210930.xsd#amed_PayorsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsDomain" xlink:to="lab_amed_PayorsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TN_b8dc13c9-744a-4704-8024-9f66753186ea_terseLabel_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tennessee [Member]</link:label>
    <link:label id="lab_stpr_TN_label_en-US" xlink:label="lab_stpr_TN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TENNESSEE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TN" xlink:to="lab_stpr_TN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_f659bdc2-96a2-4dbc-b3c1-6988f24d5c1d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_35ce138f-6132-448f-8f40-9c99070a6140_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_6655ff2c-3a6e-4b8f-a7e9-0c9293f127ef_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_90b7a50f-a020-4da5-b7dc-57c054211aa5_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cares Act Provider Relief Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:href="amed-20210930.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:to="lab_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_caae4a73-78a6-4777-b39a-e468f0532a5f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_48177723-aaeb-4b23-a278-0de6d6c6430a_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestRateatPeriodEnd_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:to="lab_amed_DebtInstrumentInterestRateatPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_885e2702-8c18-4b1c-8382-da808340ebdc_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the start of episode</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Start Of Period of Care</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:href="amed-20210930.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_be43e845-df1b-4fa5-b6b4-a399e33216fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_00dc3bde-be29-4c58-bc24-27af41d417b6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_69797b55-075b-45f4-ba84-b020510bdce7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitment Fee Under Credit Facilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3fa5c8c7-62b6-47f3-bb29-f0c0f318b03f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_599e92b3-34de-4c27-8d12-2f567399c136_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedCreditAgreementMember_07ab039b-b7bb-4bfd-8198-699702362b20_terseLabel_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember" xlink:href="amed-20210930.xsd#amed_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedCreditAgreementMember" xlink:to="lab_amed_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_be260015-4c3e-439c-a080-3ce6a607709a_terseLabel_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GoodwillDeductibleForIncomeTaxPurposesPeriod</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_label_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GoodwillDeductibleForIncomeTaxPurposesPeriod</link:label>
    <link:label id="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_documentation_en-US" xlink:label="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time that goodwill is deductible for income tax purposes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:href="amed-20210930.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:to="lab_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_88b1fe7e-ca93-4abb-8742-0667a215a32f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_112fe132-179a-43b0-accc-d10516b8f0df_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_eadf3b35-63d2-41d9-bf5c-8a84ae5999ce_negatedLabel_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Write Off of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Impact of Write Off of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:href="amed-20210930.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_dbc66de5-d2aa-4d37-858a-8fc2626ef5ff_terseLabel_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_label_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:label id="lab_amed_ReversalOfLossContingencyAccrual_documentation_en-US" xlink:label="lab_amed_ReversalOfLossContingencyAccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual" xlink:href="amed-20210930.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ReversalOfLossContingencyAccrual" xlink:to="lab_amed_ReversalOfLossContingencyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53507083-dacc-4f5a-9420-f4785d803814_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_1308410e-6213-43b1-baf3-5f658f72c4f5_terseLabel_en-US" xlink:label="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Estimated Future COVID-19 Related Expenses</link:label>
    <link:label id="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_label_en-US" xlink:label="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Estimated Future COVID-19 Related Expenses</link:label>
    <link:label id="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_documentation_en-US" xlink:label="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Estimated Future COVID-19 Related Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:href="amed-20210930.xsd#amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:to="lab_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_fd193c45-58b0-4f9b-b87e-41faa7398579_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, AseraCare Hospice</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, AseraCare Hospice [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:href="amed-20210930.xsd#amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_d9d0b3e4-450f-425f-9b13-ad3ea4243b4d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d8565624-0307-4ead-8e34-56bd69fe49ba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_81007e0b-cf2c-47b5-a086-9e944bec4977_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_e0487dbe-9b03-496f-ae8e-f371113eb687_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NewShareRepurchaseProgramMember_75bbc101-db0e-49b7-9b00-e260a242a598_terseLabel_en-US" xlink:label="lab_amed_NewShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Share Repurchase Program</link:label>
    <link:label id="lab_amed_NewShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_NewShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_NewShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_NewShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NewShareRepurchaseProgramMember" xlink:href="amed-20210930.xsd#amed_NewShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NewShareRepurchaseProgramMember" xlink:to="lab_amed_NewShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_fdc02299-aa19-4766-9f7a-ff838037a537_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance/(cancellation) of non-vested stock (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_25ca51dd-9177-485b-8c49-8ad6ad6dbb41_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_baf6c339-ec8a-42d7-9e2f-4a4f0acc86c7_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d81e86a2-8552-4f49-b264-a28dee4ed816_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_6164ba5b-8132-4ec8-bffb-82f459e9f558_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_29908736-7cf4-4541-88ac-d492740b3ec1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_728d089a-18bd-4492-ad28-d86ad69800a8_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Three [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_af6a90e6-d47d-4b8b-bab0-03ac333ed729_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual, period increase (decrease)</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_48604362-853e-4042-b977-dac4c45a4240_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Member]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_4a991482-6aca-4a21-a5a3-e9788ec2e7ea_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity assumed at acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e7199bc6-922e-4826-b7ff-97fb22b624e7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_2deaf59e-0212-414b-8f1f-3d426548ac69_terseLabel_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnity receivable related to amounts withheld prior to August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_label_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:label id="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_documentation_en-US" xlink:label="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:href="amed-20210930.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:to="lab_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_264249c0-e87b-47d6-b0dd-cb68602811be_terseLabel_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Instruments</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_label_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument Details [Table Text Block]</link:label>
    <link:label id="lab_amed_FinancialInstrumentDetailsTableTextBlock_documentation_en-US" xlink:label="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial instrument details, table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:href="amed-20210930.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FinancialInstrumentDetailsTableTextBlock" xlink:to="lab_amed_FinancialInstrumentDetailsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_43c04852-7e2d-4ade-a1df-8935bdb7e77a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_9b65b3ae-1424-4712-90bc-c362fba6d8e4_terseLabel_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:label id="lab_amed_RevolvingCreditFacilityTotal_label_en-US" xlink:label="lab_amed_RevolvingCreditFacilityTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal" xlink:href="amed-20210930.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevolvingCreditFacilityTotal" xlink:to="lab_amed_RevolvingCreditFacilityTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_3366bc3a-80fb-4188-b88e-66869878cf79_terseLabel_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_label_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Hundred Million Term Loan [Member]</link:label>
    <link:label id="lab_amed_OneHundredMillionTermLoanMember_documentation_en-US" xlink:label="lab_amed_OneHundredMillionTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100 Million Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember" xlink:href="amed-20210930.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OneHundredMillionTermLoanMember" xlink:to="lab_amed_OneHundredMillionTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificateOfNeedMember_fbeb216a-3f5d-4484-941d-7c011ecc031a_terseLabel_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_label_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_amed_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember" xlink:href="amed-20210930.xsd#amed_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificateOfNeedMember" xlink:to="lab_amed_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_80cf8190-f8bd-483d-9f27-3013f6f8f31e_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Contessa</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, Contessa [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule reflecting the material business combination for Contessa, completed during the period, including background, timing, and recognized assets and liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:href="amed-20210930.xsd#amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:to="lab_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_0ef8550f-6d5f-45cc-a003-f002d7896029_terseLabel_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_label_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:label id="lab_amed_TotalCARESActProviderReliefFundsReceived_documentation_en-US" xlink:label="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total CARES Act Provider Relief Funds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:href="amed-20210930.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalCARESActProviderReliefFundsReceived" xlink:to="lab_amed_TotalCARESActProviderReliefFundsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2749b10b-fd75-414a-ad30-59dc1393ce07_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedalogixMember_b701f623-1da1-4615-b38a-96d9268bf404_terseLabel_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_label_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:label id="lab_amed_MedalogixMember_documentation_en-US" xlink:label="lab_amed_MedalogixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medalogix [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember" xlink:href="amed-20210930.xsd#amed_MedalogixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedalogixMember" xlink:to="lab_amed_MedalogixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_3526d246-1539-4c47-8b93-365c3b83079f_terseLabel_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_label_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:label id="lab_amed_InternalAuditComplianceReviewMember_documentation_en-US" xlink:label="lab_amed_InternalAuditComplianceReviewMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Audit Compliance Review [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember" xlink:href="amed-20210930.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_InternalAuditComplianceReviewMember" xlink:to="lab_amed_InternalAuditComplianceReviewMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_76645788-8a7d-4b30-a438-d061a370cda9_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_7f950f66-28cd-4cd4-9cb4-f3692d86c800_terseLabel_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable derived from Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_label_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:label id="lab_amed_AccountsReceivablePortionDerivedFromMedicare_documentation_en-US" xlink:label="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Portion Derived From Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:href="amed-20210930.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:to="lab_amed_AccountsReceivablePortionDerivedFromMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7d42e680-b891-48d2-ad03-e1be2581f619_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3f6c6171-d4ef-4539-bf62-93e11a8252fe_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_f15d811a-ef4a-4f62-94d7-4dd703ce4f8e_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_ecfee846-da36-4ebe-a324-7921bea7d2f6_terseLabel_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_label_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Claims Submitted By Subsidiary</link:label>
    <link:label id="lab_amed_NumberOfClaimsSubmittedBySubsidiary_documentation_en-US" xlink:label="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims submitted by subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:href="amed-20210930.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:to="lab_amed_NumberOfClaimsSubmittedBySubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_1781460f-23f8-490b-b557-2431f230ff55_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_6b9dd267-6010-4dba-b286-598f0594c53d_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2016 Through 2021</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Sixteen Through Two Thousand Twenty One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:href="amed-20210930.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:to="lab_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_cb7fa9a4-ed47-460a-a33b-4d9895f33163_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LakelandFloridaMember_46b230b6-6a9c-4dfa-8abb-1824fe383989_terseLabel_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_label_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:label id="lab_amed_LakelandFloridaMember_documentation_en-US" xlink:label="lab_amed_LakelandFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lakeland, Florida [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember" xlink:href="amed-20210930.xsd#amed_LakelandFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LakelandFloridaMember" xlink:to="lab_amed_LakelandFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_397b75f5-943b-4e87-877f-52bebbc1f986_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_b6abbf28-9e11-4a54-88fa-d4ec55df1985_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3606dc7a-fa73-4b01-8f7e-9d21f4dea9c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_71f433ea-2864-4c0f-9e79-4d04d45011ba_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with facilities</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8d53e65a-9ad5-4992-a909-005a351733bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3414de8c-81ea-415a-9045-499fa84ad26b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c6f6141c-121a-4caa-a2ed-491fff63f135_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_4f64f872-5541-41c5-86e2-15aa1eacc668_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_5dfd330f-70e8-4668-a3d1-4b153fa5c900_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_e8cb2fcf-c768-4690-a069-85b769cdf123_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8f743b9f-81d6-41f1-a297-09700d3f8eed_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_18f0fcd3-6d0e-43c6-9ac9-e660f638d141_terseLabel_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of operating lease right of use assets</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:href="amed-20210930.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:to="lab_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_09cf434a-de77-46a4-9bc3-2825c9cc3c35_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_3a4fa5e7-8e51-4462-8713-a3caab4bf689_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_59cdf76a-8319-4d22-a7ad-7b94262ccff9_terseLabel_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future COVID-19 related expenses</link:label>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_label_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Future COVID-19 related expenses</link:label>
    <link:label id="lab_amed_EstimatedFutureCOVID19RelatedExpenses_documentation_en-US" xlink:label="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated expenses as a result of the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:href="amed-20210930.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:to="lab_amed_EstimatedFutureCOVID19RelatedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5d02a79b-0cf0-4cd4-a2f9-6220cca83bae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_05f23e0a-a43b-4e5f-897f-8d785d12dcca_terseLabel_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_label_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:label id="lab_amed_TypeOfEquityMethodInvestmentDomain_documentation_en-US" xlink:label="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain" xlink:href="amed-20210930.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain" xlink:to="lab_amed_TypeOfEquityMethodInvestmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_62bc575d-f471-4546-93aa-7f86116edc84_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e3b75608-5c36-4fa0-b798-d349832266ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_ec9f21c0-63dc-4416-ba15-28130671ac07_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMedicareMember_dc77738e-aab5-4aa9-b998-87bb18e3bcf9_terseLabel_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_label_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember" xlink:href="amed-20210930.xsd#amed_HospiceMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMedicareMember" xlink:to="lab_amed_HospiceMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_8ff8c47b-1d81-4e6a-a07c-854cc3ecb7b7_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Working Capital Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:href="amed-20210930.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:to="lab_amed_BusinessAcquisitionWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_be51f1d8-ffae-44cc-ad6d-12ec96c80209_terseLabel_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested stock and stock units (shares)</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_label_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Vested Stock And Stock Units</link:label>
    <link:label id="lab_amed_NonVestedStockAndStockUnits_documentation_en-US" xlink:label="lab_amed_NonVestedStockAndStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non vested stock and stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits" xlink:href="amed-20210930.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonVestedStockAndStockUnits" xlink:to="lab_amed_NonVestedStockAndStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedSharesInShares_79dd8d09-ff81-4a22-bb0c-2c2aea325b83_terseLabel_en-US" xlink:label="lab_amed_SurrenderedSharesInShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares (in shares)</link:label>
    <link:label id="lab_amed_SurrenderedSharesInShares_label_en-US" xlink:label="lab_amed_SurrenderedSharesInShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares (in shares)</link:label>
    <link:label id="lab_amed_SurrenderedSharesInShares_documentation_en-US" xlink:label="lab_amed_SurrenderedSharesInShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedSharesInShares" xlink:href="amed-20210930.xsd#amed_SurrenderedSharesInShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedSharesInShares" xlink:to="lab_amed_SurrenderedSharesInShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageofSharesOutstanding_dcc26015-f21e-42c9-8553-290c8585d31b_terseLabel_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_label_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:label id="lab_amed_PercentageofSharesOutstanding_documentation_en-US" xlink:label="lab_amed_PercentageofSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding" xlink:href="amed-20210930.xsd#amed_PercentageofSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageofSharesOutstanding" xlink:to="lab_amed_PercentageofSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_92cbdbd0-9000-46ad-a44b-135b5473d3e6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_a3b91f14-6154-480f-8129-8ecb4ca64982_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_681e25bb-a81c-430e-8a5b-a1046d059398_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_7ee3094c-e57e-448b-94a1-70d1c616c372_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_80f6b31e-d173-41e7-a3de-0a966e27409a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_c993fb85-8b5c-479e-926d-cd8dc712d775_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_be582989-afea-4304-b6b5-74e261726e32_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember" xlink:href="amed-20210930.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseProgramMember" xlink:to="lab_amed_ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_58a5f968-479e-417d-8843-a9dbd4b71537_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding letters of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9d7cefb7-38a3-496f-8408-90f70185447d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_3f31f860-c2b1-42ca-8eeb-3115e4ee45a3_terseLabel_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liability</link:label>
    <link:label id="lab_amed_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="amed-20210930.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_amed_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_71eeb98a-9113-47b1-8971-848190ce52a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_59e072a7-a561-4fb6-abae-9950987f35d7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_073b7246-5e99-4f3f-9712-ae27aefe699b_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_a06f354d-ecd6-4845-8f3d-fbff16d43df9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_dd5db6da-3370-4503-9c15-5cbfc22240f1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_326f57df-a6da-4879-ade8-6ccf4fb47aae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_b2906b51-bd1d-4a8d-9c73-9415d22bd633_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Income of Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_93a404c6-6d4e-460c-bf6b-07db99232c7a_terseLabel_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated amounts due back to Medicare</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_label_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Amount Due Back To Medicare In Other Accrued Liabilities</link:label>
    <link:label id="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_documentation_en-US" xlink:label="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:href="amed-20210930.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:to="lab_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_43bcfd52-d9cb-4672-ad1f-62ad4a93b736_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PersonalCareMember_af83512e-3ed3-4537-8b44-8fb9381af372_terseLabel_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_label_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:label id="lab_amed_PersonalCareMember_documentation_en-US" xlink:label="lab_amed_PersonalCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Personal Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember" xlink:href="amed-20210930.xsd#amed_PersonalCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PersonalCareMember" xlink:to="lab_amed_PersonalCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityMember_3f2a6403-94e1-4d72-a239-7d79deca755d_terseLabel_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityMember_label_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security [Member]</link:label>
    <link:label id="lab_amed_COVID19DeferralOfSocialSecurityMember_documentation_en-US" xlink:label="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Deferral of Social Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityMember" xlink:href="amed-20210930.xsd#amed_COVID19DeferralOfSocialSecurityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19DeferralOfSocialSecurityMember" xlink:to="lab_amed_COVID19DeferralOfSocialSecurityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6ae83917-24bf-47f2-9bc7-3b5c10632738_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_11320691-3069-467f-9536-006dbacd2e3b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_60adb77b-382f-4d4d-9ae9-dae4ab5c9ebb_terseLabel_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of request for anticipated payment submitted for the initial episode of care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_label_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care</link:label>
    <link:label id="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_documentation_en-US" xlink:label="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:href="amed-20210930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:to="lab_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a79957a4-c137-4e85-995d-827837b30edc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c4fc0776-1402-4aa1-90e5-2ce51bc59b19_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_a5289f40-c6ce-4fa7-81c6-8efd96d6625b_terseLabel_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_label_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:label id="lab_amed_ParkersburgWestVirginiaMember_documentation_en-US" xlink:label="lab_amed_ParkersburgWestVirginiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parkersburg, West Virginia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember" xlink:href="amed-20210930.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ParkersburgWestVirginiaMember" xlink:to="lab_amed_ParkersburgWestVirginiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NC_0a717cf6-f11e-4434-bca8-aa61ca9a6e04_terseLabel_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:label id="lab_stpr_NC_label_en-US" xlink:label="lab_stpr_NC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NORTH CAROLINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NC" xlink:to="lab_stpr_NC" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_a90f2d72-7312-4ebd-bde3-d162e2a9536f_terseLabel_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_label_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding Received From CARES Act</link:label>
    <link:label id="lab_amed_FundingReceivedFromCARESAct_documentation_en-US" xlink:label="lab_amed_FundingReceivedFromCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct" xlink:href="amed-20210930.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingReceivedFromCARESAct" xlink:to="lab_amed_FundingReceivedFromCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0b5189b3-5a2d-4e37-ad37-63d017f17ff9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_1c92c6bd-5853-4295-8058-f93953688939_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_fa9aa7a0-23ee-4883-a773-0ea039bd937a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_97c2d103-e00b-45f9-9efa-016f40c3674d_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount of Overpayment Made To Subsidiary Including Interest</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary including interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:href="amed-20210930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_304f7982-7c5a-448a-b567-24cb35d54f84_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_6f750f19-56a3-43bd-a601-9994acb25485_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_f55f0197-8b23-4763-9ce8-9495a16e627b_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassDomain_d8bf46dc-91dd-4944-b273-92dec53643f7_terseLabel_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_label_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Domain]</link:label>
    <link:label id="lab_amed_PayorClassDomain_documentation_en-US" xlink:label="lab_amed_PayorClassDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain" xlink:href="amed-20210930.xsd#amed_PayorClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassDomain" xlink:to="lab_amed_PayorClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_30beed80-bb14-49ad-ad95-14f8eab7c631_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HighAcuityCareMember_f35e8d5c-77f3-4bcf-9aa4-4c8a6d5887a7_terseLabel_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care</link:label>
    <link:label id="lab_amed_HighAcuityCareMember_label_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care [Member]</link:label>
    <link:label id="lab_amed_HighAcuityCareMember_documentation_en-US" xlink:label="lab_amed_HighAcuityCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">High Acuity Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HighAcuityCareMember" xlink:to="lab_amed_HighAcuityCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_14e4c601-0828-46b3-b989-ecc9fad205c7_terseLabel_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:href="amed-20210930.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForOperatingLeaseLiabilities" xlink:to="lab_amed_CashPaidForOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_5f1a6e65-7a5e-4fdf-938b-2b56cc76bf41_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses:</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_da8ed13d-8a00-4ce8-94d4-330453981787_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_d43572ca-0a57-4ba6-9e6d-64a319123b4b_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3494472a-3345-4426-84e2-99154fa98876_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2c4ca358-05a3-42c5-8056-61fceeae8e38_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fba38fff-2e30-44a9-9a20-73a97ff7d169_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceMember_8adfae1c-6c9a-47b7-ac09-83dfc7808089_terseLabel_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_label_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:label id="lab_amed_HospiceMember_documentation_en-US" xlink:label="lab_amed_HospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceMember" xlink:to="lab_amed_HospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_cd87f945-1f37-4db5-a7e8-ecf5284ead57_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AcquiredNamesMember_4845c164-0d18-4061-b0ed-4746f3c331f4_terseLabel_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_label_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names [Member]</link:label>
    <link:label id="lab_amed_AcquiredNamesMember_documentation_en-US" xlink:label="lab_amed_AcquiredNamesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Names</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember" xlink:href="amed-20210930.xsd#amed_AcquiredNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AcquiredNamesMember" xlink:to="lab_amed_AcquiredNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_b90cc685-26cf-4c22-877c-10a2e546179a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_c2fa3675-f34c-495f-9455-05aa1947bf10_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in earnings from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_434da889-d9a0-436e-8adc-298542692daa_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_0028138a-30c4-4d46-9f61-6550f06321cd_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7ba39e96-7ceb-4b90-bcbb-ec5b39b3b3b2_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a959e4a2-1281-433b-ac1d-8650142f8d55_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_645997ef-e681-42e4-8b0b-bbc6986001a7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ContessaHealthMember_09f13604-0251-40c3-a1b1-90a4271cb684_terseLabel_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health</link:label>
    <link:label id="lab_amed_ContessaHealthMember_label_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health [Member]</link:label>
    <link:label id="lab_amed_ContessaHealthMember_documentation_en-US" xlink:label="lab_amed_ContessaHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contessa Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember" xlink:href="amed-20210930.xsd#amed_ContessaHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ContessaHealthMember" xlink:to="lab_amed_ContessaHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_36c468fe-9cf6-4d5c-8f12-95c058e6c3bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ActualClaimsPayment_784992c6-443c-4cfa-8d89-98023b663966_terseLabel_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual claims payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_label_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:label id="lab_amed_ActualClaimsPayment_documentation_en-US" xlink:label="lab_amed_ActualClaimsPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual Claims Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment" xlink:href="amed-20210930.xsd#amed_ActualClaimsPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ActualClaimsPayment" xlink:to="lab_amed_ActualClaimsPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_e055f945-76f9-4d1c-91fa-da64245648e2_terseLabel_en-US" xlink:label="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year 2014 Through 2021</link:label>
    <link:label id="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_label_en-US" xlink:label="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Fourteen Through Two Thousand Twenty One [Member]</link:label>
    <link:label id="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_documentation_en-US" xlink:label="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year Two Thousand Fourteen Through Two Thousand Twenty One[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:href="amed-20210930.xsd#amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:to="lab_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_db55e08f-d110-443e-985d-504a2e718a65_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld to pay taxes on non-cash compensation</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5d4a7969-0490-4d66-808c-e2ac8ac8ceff_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_b9f3926f-0544-4af8-85f1-cb32e0144c6e_terseLabel_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_label_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:label id="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_documentation_en-US" xlink:label="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds Received From Loan Party Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:href="amed-20210930.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:to="lab_amed_ProceedsReceivedFromLoanPartyOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a5e4f713-f32b-4e30-b648-58f0040141ff_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_fc943663-4122-4b65-a88f-04cc8590323f_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_cb117ccb-e9af-4ebf-9dfe-c3b8fb0d5f07_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill recorded during period</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_344b19e5-0c17-4265-bfba-7870276016d6_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Four [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_93e1dc01-7a7d-41f8-ba21-15118af23f39_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_a13f5ae3-4b93-4c1e-a466-e4f85988b5e8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return on equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_770b8ec4-9f7d-4580-8d26-0189bd973184_terseLabel_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed to Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_label_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Funding Distributed to Healthcare Providers</link:label>
    <link:label id="lab_amed_AdditionalFundingDistributedToHealthcareProviders_documentation_en-US" xlink:label="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:href="amed-20210930.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:to="lab_amed_AdditionalFundingDistributedToHealthcareProviders" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_d50d9718-ebf0-4553-8fb8-162f1132378c_terseLabel_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare revenue term rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_label_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates</link:label>
    <link:label id="lab_amed_NonMedicareRevenueTermRates_documentation_en-US" xlink:label="lab_amed_NonMedicareRevenueTermRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates" xlink:href="amed-20210930.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NonMedicareRevenueTermRates" xlink:to="lab_amed_NonMedicareRevenueTermRates" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_KY_c5352da1-31ba-4b84-b7cb-96990dd581f3_terseLabel_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:label id="lab_stpr_KY_label_en-US" xlink:label="lab_stpr_KY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KENTUCKY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_KY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_KY" xlink:to="lab_stpr_KY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_b48ebe0a-dd48-4750-a215-5a581e5c80bc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_2e24a56f-6544-46ec-9b06-5857efd6db66_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_f5104ab0-5315-4329-af9b-e4c04d4f9c1d_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, including current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorsAxis_b72cac18-e6e7-46fa-aa11-de4b188fca43_terseLabel_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_label_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:label id="lab_amed_PayorsAxis_documentation_en-US" xlink:label="lab_amed_PayorsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payors [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis" xlink:href="amed-20210930.xsd#amed_PayorsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorsAxis" xlink:to="lab_amed_PayorsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_883a7ef1-d423-4c1b-a83d-614d230205a2_terseLabel_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_label_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio</link:label>
    <link:label id="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_documentation_en-US" xlink:label="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:href="amed-20210930.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:to="lab_amed_Creditfacilitymaximumallowableconsolidatedleverageratio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PromissoryNotesMember_06f53382-99b3-45f3-83e8-4d9f54f83ab8_terseLabel_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_label_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:label id="lab_amed_PromissoryNotesMember_documentation_en-US" xlink:label="lab_amed_PromissoryNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promissory Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember" xlink:href="amed-20210930.xsd#amed_PromissoryNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PromissoryNotesMember" xlink:to="lab_amed_PromissoryNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_0f2826d5-e188-4b8f-8a1a-1003dbc8d9c6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c7237bd4-517e-4cc3-981b-7a106b6bbdd7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of service, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_72fe1e3f-93ad-4546-9bfb-c957ba022a5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_ded4b3b3-bbd2-476d-b4b3-ec1d6cd1122c_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_f68c1ce0-6167-4676-8639-46e861a0db5c_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_5ff6005c-fc21-4fca-8243-bf0b0edd752b_terseLabel_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurance retention limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurance Retention Limit</link:label>
    <link:label id="lab_amed_HealthInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_HealthInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit" xlink:href="amed-20210930.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HealthInsuranceRetentionLimit" xlink:to="lab_amed_HealthInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_d04b1279-28a3-496d-86a4-8348c82ebd34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_2d5960b7-b738-41a0-af31-ca6341c3547a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76a61566-d736-4b01-b8cd-cb19e5eaf146_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_06cebf7b-2a65-40a5-8405-eb3e7a029619_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b318eb12-6c18-48cd-ac57-fd89a9bc04c6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_7341b6fa-e488-41da-ba56-e7eff4ece5ac_terseLabel_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional liability insurance retention limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Liability Insurance Retention Limit</link:label>
    <link:label id="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:href="amed-20210930.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:to="lab_amed_ProfessionalLiabilityInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_eaa076a9-25f2-4d1f-8e0c-261e259a075a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_bb77630c-d6b7-44df-a74c-f3f37ccc06b6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_ab0b71ca-9df9-47cc-8279-824af8b73e21_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_f8bc50b0-ce38-4a83-a01a-b1d1898d777a_terseLabel_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_label_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:label id="lab_amed_DepreciationAndAmortizationForContinuingOperations_documentation_en-US" xlink:label="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization For Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:href="amed-20210930.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DepreciationAndAmortizationForContinuingOperations" xlink:to="lab_amed_DepreciationAndAmortizationForContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_32d99838-b7b3-498f-8599-03d37a02257d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_63903249-bf21-4581-9051-3d7589e6095e_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtrapolatedMember_1828f73a-d3ee-4926-a0ec-937e6a2debb8_terseLabel_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_label_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:label id="lab_amed_ExtrapolatedMember_documentation_en-US" xlink:label="lab_amed_ExtrapolatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember" xlink:href="amed-20210930.xsd#amed_ExtrapolatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtrapolatedMember" xlink:to="lab_amed_ExtrapolatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_51e2209e-72d6-41f9-8dab-98bf040111c3_terseLabel_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_ThirdThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the third threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:href="amed-20210930.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ThirdThresholdOfTherapyServicesRequired" xlink:to="lab_amed_ThirdThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_b1291991-1991-42f1-95ed-a0868b448e90_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_IndemnificationAmount_36eae637-2655-41f8-97ad-96c83a80e06d_terseLabel_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_label_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Amount</link:label>
    <link:label id="lab_amed_IndemnificationAmount_documentation_en-US" xlink:label="lab_amed_IndemnificationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount to be reimbursed if and when certain assumed liabilities are paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount" xlink:href="amed-20210930.xsd#amed_IndemnificationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_IndemnificationAmount" xlink:to="lab_amed_IndemnificationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_65981a4b-ecb9-4d80-b846-d2f187e5bb89_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthMedicareMember_7f668653-c6cb-4401-8745-f328c9b39e38_terseLabel_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_label_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:label id="lab_amed_HomeHealthMedicareMember_documentation_en-US" xlink:label="lab_amed_HomeHealthMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember" xlink:href="amed-20210930.xsd#amed_HomeHealthMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthMedicareMember" xlink:to="lab_amed_HomeHealthMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4f8f2b14-2f9d-401e-9678-43dbd0563979_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8adb12c8-52f8-44d2-9645-31e9f0fbd10c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_2dea64dd-0312-4371-b037-a9dafe17860d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_5bab4c60-0044-4700-b2e7-14c948ce624f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_c982cac4-b416-4420-9c1b-239d7683d21e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_eba6d748-e1f5-4c62-9b73-9dc0a17f58c3_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Federal Fund rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Federal Fund Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_d640427a-1f45-490a-908a-880945b9a5bd_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_2fdeaa10-389c-428b-aa74-091ade43cce4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_9db50394-8da6-479e-9452-1a4cc0e7a134_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e9484021-4aea-4616-8cf0-a2f95ce9342b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PayorClassAxis_5552a1df-bf1a-4e72-b122-4106f8dd142d_terseLabel_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_label_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:label id="lab_amed_PayorClassAxis_documentation_en-US" xlink:label="lab_amed_PayorClassAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis" xlink:href="amed-20210930.xsd#amed_PayorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PayorClassAxis" xlink:to="lab_amed_PayorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_20bdbe95-68cf-4068-97de-abb9bfa99b8e_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for equity method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Equity Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForEquityMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:href="amed-20210930.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForEquityMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_eeeed6d5-4f42-449e-bc11-446e415039ee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_541f988d-ab1e-42f6-9675-832a0b835411_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_645ed344-d8d4-4892-b02f-5f5012ce2d3f_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_d417676b-057b-46fe-b19f-14495b335dd0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HospiceNonMedicareMember_b8d9c2be-97cf-4035-b263-f1976b4b6d3a_terseLabel_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_label_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:label id="lab_amed_HospiceNonMedicareMember_documentation_en-US" xlink:label="lab_amed_HospiceNonMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hospice Non-Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember" xlink:href="amed-20210930.xsd#amed_HospiceNonMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HospiceNonMedicareMember" xlink:to="lab_amed_HospiceNonMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MedicareLicenseMember_d67732be-6f96-401e-97dc-4473497d5de2_terseLabel_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare licenses [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_label_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license [Member]</link:label>
    <link:label id="lab_amed_MedicareLicenseMember_documentation_en-US" xlink:label="lab_amed_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare license</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember" xlink:href="amed-20210930.xsd#amed_MedicareLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MedicareLicenseMember" xlink:to="lab_amed_MedicareLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_914873ab-fdc0-467d-8a96-c9e599d635a4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_16ed7df7-5191-479e-9132-d33c942f74c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_52e20347-86e7-44ca-81ca-aeffe7004ae5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceMember_2b9b68df-4f11-4186-9f99-ac1ef93763bf_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_label_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember" xlink:href="amed-20210930.xsd#amed_AsanaHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceMember" xlink:to="lab_amed_AsanaHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_09a892a4-d48b-4702-8b62-64d6d11eef96_terseLabel_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_label_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:label id="lab_amed_BusinessAcquisitionClosingPaymentAdjustment_documentation_en-US" xlink:label="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Closing Payment Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:href="amed-20210930.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:to="lab_amed_BusinessAcquisitionClosingPaymentAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_74fbbde8-c9c3-4cff-9d6b-9a805a4ab3da_terseLabel_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of total reimbursement of outlier payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_label_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Reimbursement Of Outlier Payment</link:label>
    <link:label id="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment_documentation_en-US" xlink:label="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage at which total reimbursement is capped if cost of care is unusually costly.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:href="amed-20210930.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:to="lab_amed_PercentageOfTotalReimbursementOfOutlierPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnSaleOfInvestments_391dfc24-c9cf-4107-ab33-c3dd44750094_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of Investments</link:label>
    <link:label id="lab_us-gaap_GainOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnSaleOfInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnSaleOfInvestments" xlink:to="lab_us-gaap_GainOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_f1018971-844c-4901-9cd6-98d48adfd91d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_bb8039c6-ec02-4714-9ac0-5bf0aa0c9f28_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d388e91e-9b26-450b-9a99-8b3ce95551b6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_fb8e555c-39fc-4c8e-99e4-ddd68f9f9dd6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_831b93b9-5f55-4e27-9f24-2287944a46b5_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE REPURCHASE</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_3896f49a-fd83-4166-81b6-81f6e5dd4c73_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_901006a7-e4fd-4827-9890-b03a8547f304_terseLabel_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for Healthcare Providers, Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_label_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for Healthcare Providers, Including Hospitals</link:label>
    <link:label id="lab_amed_FundingForHealthcareProvidersIncludingHospitals_documentation_en-US" xlink:label="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:href="amed-20210930.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:to="lab_amed_FundingForHealthcareProvidersIncludingHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_1c7cfb50-6534-41fa-8443-682a65386238_terseLabel_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:href="amed-20210930.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:to="lab_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_333846a2-b84b-468c-b1e0-b1e677757f0d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_2f38d841-8d3e-48f5-964d-015910112963_terseLabel_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_label_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for finance lease liabilities</link:label>
    <link:label id="lab_amed_CashPaidForFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash paid for finance lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:href="amed-20210930.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashPaidForFinanceLeaseLiabilities" xlink:to="lab_amed_CashPaidForFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_47f823b3-b9e0-425a-ac67-378c0c9d7186_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramExpirationDate_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramExpirationDate" xlink:to="lab_us-gaap_StockRepurchaseProgramExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_e73cc3eb-9efe-46d8-93e5-2e2622f2a361_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7bc9fe1e-316f-423f-8594-cbc0635521e6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ErrorRatePercentage_13aa3bee-70b1-4648-a059-25485846d669_terseLabel_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error rate (percent)</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_label_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:label id="lab_amed_ErrorRatePercentage_documentation_en-US" xlink:label="lab_amed_ErrorRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Rate Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage" xlink:href="amed-20210930.xsd#amed_ErrorRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ErrorRatePercentage" xlink:to="lab_amed_ErrorRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_bc2605be-3dba-4b21-8c74-92997d9ccf0d_terseLabel_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum days to submit final bill from the date the request for anticipated payment was paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_label_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid</link:label>
    <link:label id="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_documentation_en-US" xlink:label="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:href="amed-20210930.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:to="lab_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_85b30575-43cb-4bbe-866c-098075f13576_terseLabel_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue episode payment rate</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_label_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Service Revenue, Episode Payment Rate Duration</link:label>
    <link:label id="lab_amed_NetServiceRevenueEpisodePaymentRateDuration_documentation_en-US" xlink:label="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:href="amed-20210930.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:to="lab_amed_NetServiceRevenueEpisodePaymentRateDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_a2d2dbed-adaa-4cc9-baff-75558486c235_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c037331c-5fe2-40c3-82b4-b2356c22829f_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_d724de06-db89-4ca5-aa9d-caa7bf63073d_terseLabel_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_label_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:label id="lab_amed_SecuritiesClassActionLawsuitMember_documentation_en-US" xlink:label="lab_amed_SecuritiesClassActionLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember" xlink:href="amed-20210930.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecuritiesClassActionLawsuitMember" xlink:to="lab_amed_SecuritiesClassActionLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0bb8c2c3-6a75-46ef-b4db-39fca1d42ffd_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_a3971a9f-bbcf-44ed-bdca-4e34544e737b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_70464144-6c43-4350-88aa-3cb12fe26c73_terseLabel_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_label_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld</link:label>
    <link:label id="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_documentation_en-US" xlink:label="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of over payment made to subsidiary including interest withheld</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:href="amed-20210930.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:to="lab_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_7e2cbe0f-dd22-4270-bb7a-10acd26c152c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_65f92ff7-7db9-4ce3-a90c-bd2bdf8045b8_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PriorCreditAgreementMember_17fb25a3-9d4b-4c84-aacb-42a012385e28_terseLabel_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_label_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:label id="lab_amed_PriorCreditAgreementMember_documentation_en-US" xlink:label="lab_amed_PriorCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember" xlink:href="amed-20210930.xsd#amed_PriorCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PriorCreditAgreementMember" xlink:to="lab_amed_PriorCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_fc3b77e2-8a0e-431c-b076-ceebc7a65691_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e4ac86fe-0721-4239-bb32-848db612d78e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_e8fe03c2-9f64-4084-a336-e8c010f5c132_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_c4508ee2-5ef6-4959-8c89-39d48d56c3d7_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_115d57fb-e6d6-4d7b-a701-9c03cb54653d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e07f291b-1d1e-4fa2-b978-b30401e876da_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19ExpensesIncurred_89449de2-efef-40ed-8737-765b239adf34_terseLabel_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Expenses Incurred</link:label>
    <link:label id="lab_amed_COVID19ExpensesIncurred_label_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 Expenses Incurred</link:label>
    <link:label id="lab_amed_COVID19ExpensesIncurred_documentation_en-US" xlink:label="lab_amed_COVID19ExpensesIncurred" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses incurred as a result of the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred" xlink:href="amed-20210930.xsd#amed_COVID19ExpensesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19ExpensesIncurred" xlink:to="lab_amed_COVID19ExpensesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_cf0f4020-92a0-44e9-991f-2ccf5ca2e4dc_terseLabel_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_label_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility [Member]</link:label>
    <link:label id="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember_documentation_en-US" xlink:label="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Hundred Fifty Million Term Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:href="amed-20210930.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:to="lab_amed_FourHundredFiftyMillionTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_8ccfd024-df04-4d0a-896d-a24a1b774a48_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_d21bdff9-ce40-47b3-b15a-96ec1d0cb2ce_terseLabel_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2019ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2019ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember" xlink:href="amed-20210930.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2019ShareRepurchaseProgramMember" xlink:to="lab_amed_A2019ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_e88b0a7b-3cc9-4768-aee8-51756b162fd8_terseLabel_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_label_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:label id="lab_amed_SafeguardZoneProgramIntegrityContractorMember_documentation_en-US" xlink:label="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Safeguard Zone Program Integrity Contractor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:href="amed-20210930.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:to="lab_amed_SafeguardZoneProgramIntegrityContractorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_72b97d23-ec31-44fc-b0b2-920bc95b7664_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_1de233e8-99b8-4681-bb0b-3b8ac2f70aca_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings under revolving line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_171d1b78-a11e-4cbe-b6cb-6f458bd56019_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_FL_b70f81b9-1bc4-43c7-ae59-88bbfad94332_terseLabel_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida</link:label>
    <link:label id="lab_stpr_FL_label_en-US" xlink:label="lab_stpr_FL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLORIDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_FL" xlink:to="lab_stpr_FL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9972069e-d082-4ef2-bc32-41e326331c6c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1addfebd-960f-4233-b2e6-187657f87d32_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_19fbd85d-9d68-4279-8355-8ef55523d505_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_c4ade484-5c4b-4c7f-bf12-40ed4ba8e598_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_aba9963d-b914-4b67-a009-4dedc3f22914_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceMember_324a1210-bd77-41ce-8745-9357fa52502a_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceMember" xlink:to="lab_amed_CompassionateCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a6960630-c603-4295-b514-a7a976a7fd7c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_337c9003-ef8e-49d8-ae16-577dda4b82ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_349d7e09-116c-429e-8b7b-09324017d3a0_terseLabel_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_label_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition [Member]</link:label>
    <link:label id="lab_amed_AsanaHospiceAquisitionMember_documentation_en-US" xlink:label="lab_amed_AsanaHospiceAquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asana Hospice Aquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember" xlink:href="amed-20210930.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AsanaHospiceAquisitionMember" xlink:to="lab_amed_AsanaHospiceAquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_f2d89506-a5b3-47fa-b2ce-9b98ae4b81a6_terseLabel_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_label_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with Provider Relief Fund</link:label>
    <link:label id="lab_amed_CashBalanceAssociatedWithProviderReliefFund_documentation_en-US" xlink:label="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Balance Associated with the CARES Act Provider Relief Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:href="amed-20210930.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:to="lab_amed_CashBalanceAssociatedWithProviderReliefFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_084d2941-4600-462e-b2df-da2066d09f42_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred debt issuance costs/debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_1b81f6d9-d6f7-4db1-a7f7-588c9b67f9ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,659,284 and 37,470,212 shares issued; and 32,590,775 and 32,814,278 shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1926874-5fe5-4833-a3a1-d55967a86de1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_cb66a9c9-c71e-41c3-abb1-e227173c5116_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19TextBlock_b4b8e15f-c46d-4909-a06b-92be619fd788_terseLabel_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_amed_COVID19TextBlock_label_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Text Block]</link:label>
    <link:label id="lab_amed_COVID19TextBlock_documentation_en-US" xlink:label="lab_amed_COVID19TextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock" xlink:href="amed-20210930.xsd#amed_COVID19TextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19TextBlock" xlink:to="lab_amed_COVID19TextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_9b54512b-f188-4c87-adaa-3b7a938e9b63_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_5c2812a5-15b5-46bf-a038-303cf2342781_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable Lease Contract [Member]</link:label>
    <link:label id="lab_us-gaap_OffMarketFavorableLeaseMember_label_en-US" xlink:label="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-Market Favorable Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketFavorableLeaseMember" xlink:to="lab_us-gaap_OffMarketFavorableLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6c6f6d34-e820-44c6-828f-c813badcbca2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ed05f52f-65d8-4907-b37c-c3b83d4f103a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a6b9da35-a68e-41a5-9927-d5a28c17987f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_93b2c949-839e-4457-b60e-4f227b3b2c2a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TotalLeverageRatio_6dca445f-799e-44c2-ab33-374124e2e2ae_terseLabel_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_label_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Leverage Ratio</link:label>
    <link:label id="lab_amed_TotalLeverageRatio_documentation_en-US" xlink:label="lab_amed_TotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of debt to earnings before interest, taxes, depreciation and amortization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio" xlink:href="amed-20210930.xsd#amed_TotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TotalLeverageRatio" xlink:to="lab_amed_TotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SwingLineLoanMember_72c65ee2-826d-4702-ae43-dc60d52a9340_terseLabel_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_label_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:label id="lab_amed_SwingLineLoanMember_documentation_en-US" xlink:label="lab_amed_SwingLineLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swing Line Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember" xlink:href="amed-20210930.xsd#amed_SwingLineLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SwingLineLoanMember" xlink:to="lab_amed_SwingLineLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_41374eb7-bec2-4e90-9760-5ca9855e270c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_d37d4c83-da91-4d70-91b7-7c590fff7c5d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_9ded20f0-6f73-44a7-a434-b64dda97370e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1fb4e800-b5de-4a11-b782-940857735271_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1687e7a4-e32f-4c52-ab35-b175316a4ed9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_a786a1cd-8624-485d-af7d-e3cb636bd315_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_ddda2183-4537-456c-862f-dd777b0dea58_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_5cd98947-95e3-40c9-aa88-059e01f97e6a_terseLabel_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consolidated Entities Classified as Variable Interest Entities</link:label>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_label_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consolidated Entities Classified as Variable Interest Entities</link:label>
    <link:label id="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_documentation_en-US" xlink:label="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consolidated Entities Classified as Variable Interest Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:href="amed-20210930.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:to="lab_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_f30219f4-28ed-4b1f-8bef-058c4cda12f8_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4adcc517-943b-46da-8b94-627b95e5b063_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b09275a1-9d2c-4f83-bddd-741c42f9b10b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4af04d1f-869f-4301-9751-772aad5aff6e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_a9e3cb60-38b3-4f58-be09-102f785dfa93_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_7b0d3d53-3cd1-4600-abbb-6cffa1a34eaf_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Net of Patient Service Revenue Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmedisysCIAMember_a91d6235-7c65-474c-bf7e-c68f4a5132e3_terseLabel_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_label_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:label id="lab_amed_AmedisysCIAMember_documentation_en-US" xlink:label="lab_amed_AmedisysCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amedisys CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember" xlink:href="amed-20210930.xsd#amed_AmedisysCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmedisysCIAMember" xlink:to="lab_amed_AmedisysCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_bf66be49-fc5a-45b5-86c0-d6b693e3f840_terseLabel_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_label_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:label id="lab_amed_CompanysinsurancecarriersMember_documentation_en-US" xlink:label="lab_amed_CompanysinsurancecarriersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's insurance carriers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember" xlink:href="amed-20210930.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompanysinsurancecarriersMember" xlink:to="lab_amed_CompanysinsurancecarriersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_aaa56203-dab6-4852-90c9-248e48ecce0d_terseLabel_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_amed_A2021ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_amed_A2021ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember" xlink:href="amed-20210930.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_A2021ShareRepurchaseProgramMember" xlink:to="lab_amed_A2021ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_b63aa2ad-05de-422e-9848-d959fcd05d18_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_c5679b79-0e68-48b5-a343-e28f5bf1aa2d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_5ff69ee9-2378-4a55-a988-5339132fa718_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_3d627f4a-69b2-4c13-a392-1dd52070366f_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_label_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Periodic Payment Percentage</link:label>
    <link:label id="lab_amed_DebtInstrumentPeriodicPaymentPercentage_documentation_en-US" xlink:label="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:href="amed-20210930.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:to="lab_amed_DebtInstrumentPeriodicPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6f2c1809-c53a-489b-9d65-fd33d256776b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_65de04d4-7816-4b05-9db6-3e6a539142b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_06abf6b8-0799-487d-a1d8-737b021e3642_negatedLabel_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of other comprehensive income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_label_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Other Comprehensive Income</link:label>
    <link:label id="lab_amed_WriteOffOfOtherComprehensiveIncome_documentation_en-US" xlink:label="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Other Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:href="amed-20210930.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WriteOffOfOtherComprehensiveIncome" xlink:to="lab_amed_WriteOffOfOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9314624c-f725-491a-9266-413fcf019c8d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amedisys, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_edc46e65-7752-404b-a9e3-57a16dcbe2f6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4e4bf434-be10-4cc6-b060-4165e82379dc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_758b168a-cb3f-4173-a21d-3f3dad4c60e2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_b9960233-2ec9-4c67-a414-9daedbe82b47_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, number of care centers acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8649b847-98b7-47e0-84bd-fc65ae5757f4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_02fc371f-8568-4fea-9a28-2641d9363f34_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_19ae80b8-07af-4280-b500-aa6aa7d947ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_79ee81f6-3645-4419-9bbc-0f625029f7cf_terseLabel_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_label_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock [Table Text Block]</link:label>
    <link:label id="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_documentation_en-US" xlink:label="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:href="amed-20210930.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:to="lab_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9895ad39-6d6b-45b1-bf68-4bf26e48e40a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1a90e58d-2d6c-40d2-9f6c-ae73ea19973a_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e0d5364d-abdd-4416-8b36-dd87f356c69e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OffMarketLeaseUnfavorable_cb001dc8-79ae-4f5d-8b58-d5bb4b4c5976_terseLabel_en-US" xlink:label="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-market Lease, Unfavorable</link:label>
    <link:label id="lab_us-gaap_OffMarketLeaseUnfavorable_label_en-US" xlink:label="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Off-market Lease, Unfavorable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OffMarketLeaseUnfavorable" xlink:to="lab_us-gaap_OffMarketLeaseUnfavorable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_e96a6220-d162-4ef2-92b4-3d3d0d849776_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActInterestToBeRepaidToGovernment_2a048d7f-8e29-4746-8aaf-c96d0d5116e7_terseLabel_en-US" xlink:label="lab_amed_CARESActInterestToBeRepaidToGovernment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Interest To Be Repaid to Government</link:label>
    <link:label id="lab_amed_CARESActInterestToBeRepaidToGovernment_label_en-US" xlink:label="lab_amed_CARESActInterestToBeRepaidToGovernment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Interest To Be Repaid to Government</link:label>
    <link:label id="lab_amed_CARESActInterestToBeRepaidToGovernment_documentation_en-US" xlink:label="lab_amed_CARESActInterestToBeRepaidToGovernment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Interest To Be Repaid to Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActInterestToBeRepaidToGovernment" xlink:href="amed-20210930.xsd#amed_CARESActInterestToBeRepaidToGovernment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActInterestToBeRepaidToGovernment" xlink:to="lab_amed_CARESActInterestToBeRepaidToGovernment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_34ce665b-5dcf-4369-8b22-eabc129a20de_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_2237e821-ffdd-4aa0-a81c-f556e3a2c65c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_9aa0581e-3f19-40cc-9f8b-154fa06a8f04_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_label_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:label id="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_documentation_en-US" xlink:label="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Carrying Amount Excluding Finance Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:href="amed-20210930.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:to="lab_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_a775e0e5-8e33-4415-8298-259d663cc0ec_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7c2e0f90-e1c2-4e0e-a42c-d8dbfb70e890_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3444fe6b-3ef7-464b-b226-0f858e7ef97c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_7be1e03f-f3d6-4c9d-b4e1-1d8008240562_terseLabel_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_label_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries</link:label>
    <link:label id="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_documentation_en-US" xlink:label="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of adjusted EBITDA that guarantor subsidiaries represent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:href="amed-20210930.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:to="lab_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f9ea9dbf-ef78-422e-93cf-d144ab066cc6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation of $100,407 and $95,024</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b98ad6aa-a3ab-4d84-9d0b-0ce4c574b22a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c7e66e83-94da-4adc-8319-a9fb030ee216_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_08085cb6-dcfc-43f2-95ea-00928a35c5a6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAPITAL STOCK AND SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f1dde240-5d77-4437-8ed5-935f39823c2e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_85447e18-de83-4bd4-aa35-8118cf773bc5_terseLabel_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund, LP [Member]</link:label>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_label_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund, LP [Member]</link:label>
    <link:label id="lab_amed_HeritageHealthcareInnovationFundLPMember_documentation_en-US" xlink:label="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Healthcare Innovation Fund, LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember" xlink:href="amed-20210930.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HeritageHealthcareInnovationFundLPMember" xlink:to="lab_amed_HeritageHealthcareInnovationFundLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c240224c-0cbe-4cad-b002-4b7ea67eb5ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of impact of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExecutiveStockOptionExerciseMember_24cdda8a-e40b-4ef1-9b90-3994bf04014d_terseLabel_en-US" xlink:label="lab_amed_ExecutiveStockOptionExerciseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Stock Option Exercise [Member]</link:label>
    <link:label id="lab_amed_ExecutiveStockOptionExerciseMember_label_en-US" xlink:label="lab_amed_ExecutiveStockOptionExerciseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Stock Option Exercise [Member]</link:label>
    <link:label id="lab_amed_ExecutiveStockOptionExerciseMember_documentation_en-US" xlink:label="lab_amed_ExecutiveStockOptionExerciseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Stock Option Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember" xlink:href="amed-20210930.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExecutiveStockOptionExerciseMember" xlink:to="lab_amed_ExecutiveStockOptionExerciseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_16efafed-ee04-41bf-ba9b-19da1f5cfa70_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UnfavorableMember_21df458f-cd96-4863-a1a1-18a9e50a3b9a_terseLabel_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:label id="lab_amed_UnfavorableMember_label_en-US" xlink:label="lab_amed_UnfavorableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember" xlink:href="amed-20210930.xsd#amed_UnfavorableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UnfavorableMember" xlink:to="lab_amed_UnfavorableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_43674d8a-e1c0-4feb-88b7-0a62e3fc3c28_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement amount to be paid by company's insurance carriers</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableCurrent" xlink:to="lab_us-gaap_LossContingencyReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_9db12d60-7f60-4276-9077-5aeb0e76e5db_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4180e13b-33a9-4986-a539-c342ff05139d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_d337ece4-67dd-4d3e-b1ef-b6a9193b94f1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_693a60fb-55cc-4161-8ea9-8c77d5a6740c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CapYearAxis_215690a0-c4c4-4563-9055-59c0cb6aeffd_terseLabel_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_label_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:label id="lab_amed_CapYearAxis_documentation_en-US" xlink:label="lab_amed_CapYearAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cap Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis" xlink:href="amed-20210930.xsd#amed_CapYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CapYearAxis" xlink:to="lab_amed_CapYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_a6087342-b1af-4b27-ac54-01912c78bc2a_terseLabel_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_label_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice [Member]</link:label>
    <link:label id="lab_amed_UsDepartmentOfJusticeMember_documentation_en-US" xlink:label="lab_amed_UsDepartmentOfJusticeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Department of Justice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember" xlink:href="amed-20210930.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_UsDepartmentOfJusticeMember" xlink:to="lab_amed_UsDepartmentOfJusticeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseTable_61e34b0b-6c6f-47db-8b81-7a6337b43297_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_label_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:label id="lab_amed_ShareRepurchaseTable_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable" xlink:href="amed-20210930.xsd#amed_ShareRepurchaseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseTable" xlink:to="lab_amed_ShareRepurchaseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_be4539d6-33e8-42b8-b0ec-ea711b0a2bc5_terseLabel_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue adjustment to Medicare revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_label_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Adjustment To Medicare Revenue</link:label>
    <link:label id="lab_amed_RevenueAdjustmentToMedicareRevenue_documentation_en-US" xlink:label="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:href="amed-20210930.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RevenueAdjustmentToMedicareRevenue" xlink:to="lab_amed_RevenueAdjustmentToMedicareRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_be453ada-e737-4edd-96ad-aab8fc73a31e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b21f4e75-2bd2-46c0-aa0f-1febd6fbe873_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, other intangibles recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8d66648e-ea19-4da3-abe4-f060bd437f6f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_89358d75-867d-496d-ac4b-d072d9539cb8_terseLabel_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated interest coverage ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_label_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Interest Coverage Ratio</link:label>
    <link:label id="lab_amed_ConsolidatedInterestCoverageRatio_documentation_en-US" xlink:label="lab_amed_ConsolidatedInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio" xlink:href="amed-20210930.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ConsolidatedInterestCoverageRatio" xlink:to="lab_amed_ConsolidatedInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_be2539fa-5be6-4f48-a83c-8f86d16d0854_terseLabel_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_label_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:label id="lab_amed_HomeHealthNonMedicareEpisodicBasedMember_documentation_en-US" xlink:label="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health Non-Medicare - Episodic Based [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:href="amed-20210930.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:to="lab_amed_HomeHealthNonMedicareEpisodicBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_c418c1ac-8506-4e7f-85f0-eefb4ac0fac2_terseLabel_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida ZPIC revenue reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_label_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Zpic Revenue Reduction</link:label>
    <link:label id="lab_amed_FloridaZpicRevenueReduction_documentation_en-US" xlink:label="lab_amed_FloridaZpicRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in revenue as a result of the Florida ZPIC audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction" xlink:href="amed-20210930.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FloridaZpicRevenueReduction" xlink:to="lab_amed_FloridaZpicRevenueReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_7f88ccb7-fdaa-4ae7-a7bf-db25337556e4_terseLabel_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">200 Million Revolving Credit Facility</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_label_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember_documentation_en-US" xlink:label="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Hundred Million Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:href="amed-20210930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:to="lab_amed_TwoHundredMillionRevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AseraCareHospiceMember_247f311f-a2ae-4b5e-a9ce-11b8fa96614b_terseLabel_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_label_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice [Member]</link:label>
    <link:label id="lab_amed_AseraCareHospiceMember_documentation_en-US" xlink:label="lab_amed_AseraCareHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AseraCare Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AseraCareHospiceMember" xlink:to="lab_amed_AseraCareHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_3d4a512d-d21d-4e8d-8e61-dbc0056f4f3e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_742b82b7-c3c8-4aa6-afc4-00b8ef9dbb33_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_301dce5a-76b0-4020-8457-78938cf1e953_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan (shares)</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:href="amed-20210930.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ShareRepurchaseLineItems_1792ce60-4fa6-4b0b-a8da-5d76f45e0344_terseLabel_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_label_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase [Line Items]</link:label>
    <link:label id="lab_amed_ShareRepurchaseLineItems_documentation_en-US" xlink:label="lab_amed_ShareRepurchaseLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Share Repurchase [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems" xlink:href="amed-20210930.xsd#amed_ShareRepurchaseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ShareRepurchaseLineItems" xlink:to="lab_amed_ShareRepurchaseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_OperatingCareCenters_ee0810e4-3b77-4545-888a-5317cd36f2fd_terseLabel_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of owned and operated care centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_label_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Care Centers</link:label>
    <link:label id="lab_amed_OperatingCareCenters_documentation_en-US" xlink:label="lab_amed_OperatingCareCenters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of care centers owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters" xlink:href="amed-20210930.xsd#amed_OperatingCareCenters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_OperatingCareCenters" xlink:to="lab_amed_OperatingCareCenters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_ce663641-e749-4bcc-94d4-6eb18e202822_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_906b8116-9522-4d1f-986f-93df5748731d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, aggregate cost</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c6c0a600-3a11-4997-80b6-76ebafd060d7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - employee stock purchase plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Discountedclosingstockprice_a8289968-a3d6-4f12-90c9-c4591becc872_terseLabel_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_label_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:label id="lab_amed_Discountedclosingstockprice_documentation_en-US" xlink:label="lab_amed_Discountedclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice" xlink:href="amed-20210930.xsd#amed_Discountedclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Discountedclosingstockprice" xlink:to="lab_amed_Discountedclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9c623b97-cc03-4584-91cc-62c3ae324b2c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fcfedc5d-c127-48cb-a3b8-1ac2242a22b0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b91764f7-b27c-4650-bad3-5431bfd5b6a0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_LetterOfCreditFee_edd6b973-099d-4070-b623-0968b6dc0327_terseLabel_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_label_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Fee</link:label>
    <link:label id="lab_amed_LetterOfCreditFee_documentation_en-US" xlink:label="lab_amed_LetterOfCreditFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fee, expressed as a percentage of the letters of credit, for the letters of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee" xlink:href="amed-20210930.xsd#amed_LetterOfCreditFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_LetterOfCreditFee" xlink:to="lab_amed_LetterOfCreditFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7d36f3c6-1348-454f-95f5-a39603339b92_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_52e3d825-9840-437d-86cb-be7e4cae7147_terseLabel_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of overpayment made to subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_label_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery Amount Of Overpayment Made To Subsidiary</link:label>
    <link:label id="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_documentation_en-US" xlink:label="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery amount of the overpayment made to the subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:href="amed-20210930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:to="lab_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_062742d4-15a0-4e89-82b2-94128a1d44bb_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SurrenderedShares_92861144-7e9f-4d9c-913b-97267344aa1e_negatedLabel_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_label_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surrendered Shares</link:label>
    <link:label id="lab_amed_SurrenderedShares_documentation_en-US" xlink:label="lab_amed_SurrenderedShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares" xlink:href="amed-20210930.xsd#amed_SurrenderedShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SurrenderedShares" xlink:to="lab_amed_SurrenderedShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_5f667880-b451-4fed-8ec0-d6408fbeaee6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Name of Acquired Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="lab_us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e34dafc0-2925-444e-8816-8fd2d21d4f4b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfBeneficiaries_f9d9683b-f2c4-4765-a9c6-c5b28fa3a827_terseLabel_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_label_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries</link:label>
    <link:label id="lab_amed_NumberOfBeneficiaries_documentation_en-US" xlink:label="lab_amed_NumberOfBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beneficiaries who received services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries" xlink:href="amed-20210930.xsd#amed_NumberOfBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfBeneficiaries" xlink:to="lab_amed_NumberOfBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_3bd27e4a-06fc-4763-837b-25bd8dda0e2c_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_2b62bacb-9a07-482e-9050-fd790820b1fa_terseLabel_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_label_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:label id="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_documentation_en-US" xlink:label="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by payor class as a percentage of total net service revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:href="amed-20210930.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:to="lab_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d93b46df-35ab-4dc2-b2e5-db02027419a3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_e9d37f38-aac7-45cf-bce1-d3361c655cbf_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_6ccb07cb-7ad0-4b23-95fc-540c56637745_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_bb727d73-f051-4967-ba3c-fceadc97bdec_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_label_en-US" xlink:label="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Weighted Average Interest Rate, over Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:to="lab_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_00a3dd55-1c25-4b5a-a4d4-96bbeaf919fc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures of Non-Cash Activity:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_e673c7db-72ad-4e3a-8c7e-2bec51f41ebe_terseLabel_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_label_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:label id="lab_amed_TypeofEquityMethodInvestmentAxis_documentation_en-US" xlink:label="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Equity Method Investment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:href="amed-20210930.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis" xlink:to="lab_amed_TypeofEquityMethodInvestmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_07e8abf5-d0af-49a9-8915-5940b1684232_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_fea0a9f9-9526-43a2-bbee-7e7e74699d1b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_e5a2f957-7c01-494b-8207-6fc2e7fca8b1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9d69b064-531a-4a12-9547-80858a44e046_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_10973b82-1501-4d23-b134-9e61088b3bd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Payor Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Sources, Health Care Organization [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_ec78d838-f56b-4802-b2dc-49ebacaf14ee_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_afbf876a-d618-4329-9b99-7bed8446152b_terseLabel_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_label_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:label id="lab_amed_CompassionateCareHospiceCIAMember_documentation_en-US" xlink:label="lab_amed_CompassionateCareHospiceCIAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compassionate Care Hospice CIA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CompassionateCareHospiceCIAMember" xlink:to="lab_amed_CompassionateCareHospiceCIAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_2a1c7761-b06d-468f-baae-0a5cc5e5e523_terseLabel_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_label_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:label id="lab_amed_PaymentsRelatedToTaxAsset_documentation_en-US" xlink:label="lab_amed_PaymentsRelatedToTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to tax asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset" xlink:href="amed-20210930.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_PaymentsRelatedToTaxAsset" xlink:to="lab_amed_PaymentsRelatedToTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5ca9827a-ab5f-425e-9c60-fb70f802541d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9d8ca347-6288-40e0-92b3-a3f7011434ea_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding, basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d23dbf3-16ad-454b-9d49-9c258019b0d5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of shares outstanding - basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c304299d-b0a3-4072-bfa2-7fbbc0aad23d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_dc9d6544-133c-4f44-ac92-f3bdcbd723d1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_5413a8c1-ccbc-489d-ba23-0d3bf43482e4_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_d672320e-05f6-4d39-9773-4ea8b2be3a40_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_c7042bce-62fd-4bce-8c39-b31798618004_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock at cost (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_61560c8b-6de2-41b5-9c8a-b548218d5609_terseLabel_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate integrity agreement term (years)</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_label_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:label id="lab_amed_CorporateIntegrityAgreementTerm_documentation_en-US" xlink:label="lab_amed_CorporateIntegrityAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Integrity Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm" xlink:href="amed-20210930.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CorporateIntegrityAgreementTerm" xlink:to="lab_amed_CorporateIntegrityAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7f366f1a-c981-44f5-97e7-386ecea383b8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_c7961ac1-4051-4e43-acb6-8a318299a499_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_0cab7e0b-2d34-4c47-b6b6-f02703ba84e6_terseLabel_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional interest rate above Eurodollar rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_label_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:label id="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_documentation_en-US" xlink:label="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Additional Interest Above Eurodollar Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:to="lab_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_8ca6b354-e9f8-47d2-8437-5c5ba1dd768a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_589f0bfa-1d91-49c5-982b-a5f6864e7bea_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_280cdda1-ba7f-49dc-906c-1e8538bbaeb9_terseLabel_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock - 401(k) plan</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_label_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Four Zero One K Employer Match</link:label>
    <link:label id="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_documentation_en-US" xlink:label="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:href="amed-20210930.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:to="lab_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c878daed-fc5d-42a6-89b0-3afe1f2250b1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4926b397-0460-4f26-966e-5a902d4276d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b9ebb241-d77e-4ae7-94c0-d66154f2c6dc_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Stockholders Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_d9eb9ad4-906e-4ef3-9826-7ef8cb86e3aa_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b067886b-41cf-455d-8eb5-518691c5b0e5_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_0999d256-bbf2-403b-84bb-fc0975277f30_terseLabel_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership percentage for cost method investment (percent)</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_label_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Percent Ownership For Cost Method Percent</link:label>
    <link:label id="lab_amed_MaximumPercentOwnershipForCostMethodPercent_documentation_en-US" xlink:label="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:href="amed-20210930.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:to="lab_amed_MaximumPercentOwnershipForCostMethodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_c4086900-808f-43bb-bc33-4d25499bc82a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_19a7c686-7b94-4af1-be06-bf17324c05da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_COVID19PPEMember_1f080083-8b1c-48e9-8ed2-5f7ae3524b0b_terseLabel_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_label_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE [Member]</link:label>
    <link:label id="lab_amed_COVID19PPEMember_documentation_en-US" xlink:label="lab_amed_COVID19PPEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 PPE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember" xlink:href="amed-20210930.xsd#amed_COVID19PPEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_COVID19PPEMember" xlink:to="lab_amed_COVID19PPEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CertificatesOfNeedMember_912b9c42-8bd2-49d1-906d-9b2fd1096fff_terseLabel_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_label_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need [Member]</link:label>
    <link:label id="lab_amed_CertificatesOfNeedMember_documentation_en-US" xlink:label="lab_amed_CertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates Of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember" xlink:href="amed-20210930.xsd#amed_CertificatesOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CertificatesOfNeedMember" xlink:to="lab_amed_CertificatesOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e77f7589-4407-40a0-95fe-03731579b9eb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_b8446173-2923-47ae-bbcb-a32b8d697a67_negatedLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_9326dce9-4305-433a-ab25-f176bddd13a8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes, net of refunds received</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_98838ba3-46b4-4fc6-9e99-a26ff957f796_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0bcd4a5-718b-4341-9a81-9ae6186dd215_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bced01b0-2945-48ea-867f-0b8ab469c1ae_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_65af2dd1-3822-4946-815e-4e8a30cb6eca_terseLabel_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AociAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_c20bec5f-ac23-48ea-b38f-dac9adbb44a2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity Date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDate_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_14404590-0f0e-4c2d-b2e3-6d0fc0fde505_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c4cc3a29-87c2-46b5-ab7a-c231f2d2096b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5a9fe6a7-680c-41b1-9700-98183f12f960_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7347deca-f2ad-46f9-8848-e23a907e7332_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_2e1719ed-579d-4724-923a-be307f45dc4f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_bbbcaab6-1421-4738-ab92-8e58f5229db7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_911000c5-cc9d-444a-b7ca-f6348661e512_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Two [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_c7041b56-6003-43a4-bf91-d240c28ce091_terseLabel_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_label_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche One [Member]</link:label>
    <link:label id="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_documentation_en-US" xlink:label="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Debt Instrument, By Leverage Ratio, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:to="lab_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_b801a166-390a-4a43-9925-0e84580fa0c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of deferred compensation plan assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures_8e1821b6-1d26-4c79-83a6-71cb6d306fe9_terseLabel_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures_label_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid By Unconsolidated Joint Ventures</link:label>
    <link:label id="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures_documentation_en-US" xlink:label="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated CARES Act Provider Relief Fund Amounts to be Repaid By Unconsolidated Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures" xlink:href="amed-20210930.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures" xlink:to="lab_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_2c52f700-8c00-4e29-acd1-8f9c2ecfb329_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_NumberOfJointVentures_2f6d4425-fd8b-470c-88c5-857a8c37845b_terseLabel_en-US" xlink:label="lab_amed_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Joint Ventures</link:label>
    <link:label id="lab_amed_NumberOfJointVentures_label_en-US" xlink:label="lab_amed_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Joint Ventures</link:label>
    <link:label id="lab_amed_NumberOfJointVentures_documentation_en-US" xlink:label="lab_amed_NumberOfJointVentures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of joint ventures owned by the entity as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfJointVentures" xlink:href="amed-20210930.xsd#amed_NumberOfJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_NumberOfJointVentures" xlink:to="lab_amed_NumberOfJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_9e4563c8-e164-4c2c-9db2-2e61cda41b0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b21cf0d6-5f9c-49a5-9a96-0a9105856b3f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Street Name</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_eed2cf5b-c264-4173-a5db-49b00b55f7ce_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_738622a0-3f9a-41de-bffa-1f35c19b57c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Suite</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_83e26a5d-b653-4e1f-a96a-cf3cfd712aaa_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4989df0b-3f93-4e7e-8786-439c7f7eb98a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1bf22ecf-88ab-4fed-aad9-078161167a9d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a7e94219-512b-4485-bb54-0e14db2437a2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_5bf1c49e-14d7-4578-b90f-0c81ea9624a2_terseLabel_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_label_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity</link:label>
    <link:label id="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_documentation_en-US" xlink:label="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of equity assumed at the acquisition date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:to="lab_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_359633fc-6755-4b83-8981-a9caa6a348a2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net service revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_47825b3b-b0a3-4a38-979f-ce7c818bd263_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_8976e50d-11b2-4172-9922-620ed9a0207a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_54875b38-a32a-40b6-a5b1-e017c6776a15_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_932399b8-1664-4a37-a6c6-8ca5f0f3e5c8_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_a9fa90e1-299a-4751-9c44-553b6bd180e3_terseLabel_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers compensation insurance retention limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_label_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers Compensation Insurance Retention Limit</link:label>
    <link:label id="lab_amed_WorkersCompensationInsuranceRetentionLimit_documentation_en-US" xlink:label="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:href="amed-20210930.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_WorkersCompensationInsuranceRetentionLimit" xlink:to="lab_amed_WorkersCompensationInsuranceRetentionLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2281922b-ffa2-4e10-90d3-16afc8f0f076_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_49be41b7-8878-4147-93a9-aebcf3fe69e1_terseLabel_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_label_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Threshold Of Services Required</link:label>
    <link:label id="lab_amed_SecondThresholdOfServicesRequired_documentation_en-US" xlink:label="lab_amed_SecondThresholdOfServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the second threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired" xlink:href="amed-20210930.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_SecondThresholdOfServicesRequired" xlink:to="lab_amed_SecondThresholdOfServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a3cb81ba-d476-4ee2-9779-c1fc002a875e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_1e559b9f-9b41-4fbc-b69e-cc5746dcf11b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_7407ea84-d159-4e49-93c3-cadc09bd09d4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_5f0c4f40-c4b6-4b89-962f-14c7519248b3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_c9df6b64-f906-4d22-92fd-969e831698ed_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on equity method investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_bf596571-50c4-4ad4-8dc4-a487669e8b0f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ed7900a9-ddb7-492a-8188-7f50acec2f6c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f893e946-8c68-49a5-beed-b126b5fdbb39_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_6d4726da-872d-47da-beba-0a4fa6584a8c_terseLabel_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First threshold of therapy services required (visits)</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_label_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Threshold Of Therapy Services Required</link:label>
    <link:label id="lab_amed_FirstThresholdOfTherapyServicesRequired_documentation_en-US" xlink:label="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description containing the number of visits related to the first threshold of therapy services required.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:href="amed-20210930.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FirstThresholdOfTherapyServicesRequired" xlink:to="lab_amed_FirstThresholdOfTherapyServicesRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d27c8909-0eca-49d6-a047-569e4110d307_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_fd091e68-40a5-4075-83c1-662cdcf35af7_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a3621dd1-3529-4033-bb17-40fcd67c8b76_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_2fb591d9-19c7-4fdf-8384-9d1726de3115_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_da0d9f7f-692f-4c46-b0b5-7e93aa0ec459_terseLabel_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_OtherGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_973c0cc6-f2b5-4409-a0ac-3aef0727885d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9ed71c63-7790-4ca6-bb75-13bef8f3d389_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_f493e37e-8357-43db-a1d3-c0bd98ae1796_terseLabel_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider relief fund advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_label_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds received from Provider relief fund advance</link:label>
    <link:label id="lab_amed_FundsReceivedFromProviderReliefFundAdvance_documentation_en-US" xlink:label="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:href="amed-20210930.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:to="lab_amed_FundsReceivedFromProviderReliefFundAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c53488a8-b94d-4028-bbbf-d40ca9b6d3df_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_988e7e2f-6e6b-4f54-bdb3-3616767bd337_terseLabel_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_label_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:label id="lab_amed_CARESActProviderReliefFundsUtilized_documentation_en-US" xlink:label="lab_amed_CARESActProviderReliefFundsUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Provider Relief Funds Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized" xlink:href="amed-20210930.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActProviderReliefFundsUtilized" xlink:to="lab_amed_CARESActProviderReliefFundsUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_704525dd-b4de-45f2-a97f-8551332ab988_terseLabel_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension of Temporary Suspension of Sequestration, Revenue Impact</link:label>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_label_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension of Temporary Suspension of Sequestration, Revenue Impact</link:label>
    <link:label id="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_documentation_en-US" xlink:label="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavrius pandemic ("COVID-19").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:href="amed-20210930.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:to="lab_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_99e03536-3ff7-4d4f-b1b1-fff29086a2d7_terseLabel_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_label_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:label id="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_documentation_en-US" xlink:label="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:href="amed-20210930.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:to="lab_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_7ced4695-096d-4291-8210-ddd0c87319d2_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost 5,068,509 and 4,655,934 shares of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_Percentageofclosingstockprice_a475389a-4c26-4341-a7cb-f9ac1794673a_terseLabel_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_label_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:label id="lab_amed_Percentageofclosingstockprice_documentation_en-US" xlink:label="lab_amed_Percentageofclosingstockprice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of closing stock price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice" xlink:href="amed-20210930.xsd#amed_Percentageofclosingstockprice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_Percentageofclosingstockprice" xlink:to="lab_amed_Percentageofclosingstockprice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e211b4c-7fde-44f3-b78b-b5d05c2ef985_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_41046caf-2497-4794-8b3b-1e7233c5e5b3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_543d4fbd-1578-4e25-9682-9bc13d74a964_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_edfd66af-878f-4b42-9712-2a43612e2bc0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_5c94164e-6815-4543-9181-b9c15414c73e_terseLabel_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_label_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act Deferral of Employer Share Social Security Tax</link:label>
    <link:label id="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_documentation_en-US" xlink:label="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The deferral of the employer's share social security tax provided by the CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:href="amed-20210930.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:to="lab_amed_CARESActDeferralOfEmployerShareSocialSecurityTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cf529412-ee83-4728-87f5-a56d1ed0e130_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_49f5274f-5ce0-4cec-8bf8-30b9c568a8de_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_a3b238c5-bd04-4fd6-9d20-68bef2c5405e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>amed-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9a22ea05-d9af-4e79-9afb-aec6f57a9fea,g:f821983a-9b6a-4f0b-a7a4-a1b27b9c9a2c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amedisys.com/role/Cover" xlink:type="simple" xlink:href="amed-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_300d8a80-bb8f-4d58-9d72-29d415a10d24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_DocumentType_300d8a80-bb8f-4d58-9d72-29d415a10d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fb424b18-1a06-44e2-a0f2-43f5127233f4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_DocumentQuarterlyReport_fb424b18-1a06-44e2-a0f2-43f5127233f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f22c7f3f-e8a7-4488-92b6-c385cbfc7aeb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_DocumentPeriodEndDate_f22c7f3f-e8a7-4488-92b6-c385cbfc7aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_98a99b30-5e1b-4d98-a112-3febb0db5566" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_DocumentTransitionReport_98a99b30-5e1b-4d98-a112-3febb0db5566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_95abec57-4421-470b-9737-00501397b663" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityFileNumber_95abec57-4421-470b-9737-00501397b663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_30222d5f-560f-4344-a4e5-d620566580de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityRegistrantName_30222d5f-560f-4344-a4e5-d620566580de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a4dbcd9c-5f8b-4bc6-8b53-0d5804dd1ea9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a4dbcd9c-5f8b-4bc6-8b53-0d5804dd1ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_877517bb-0873-42d8-8fd1-6419ff3ead7f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityTaxIdentificationNumber_877517bb-0873-42d8-8fd1-6419ff3ead7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0054fbbd-c019-43f5-985b-5f32c148e224" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityAddressAddressLine1_0054fbbd-c019-43f5-985b-5f32c148e224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_5baaf052-d491-4b00-af66-afbf5a8d08fd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityAddressAddressLine2_5baaf052-d491-4b00-af66-afbf5a8d08fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_12f1ee1d-e25a-4a8b-84ef-f81dcdc2382b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityAddressCityOrTown_12f1ee1d-e25a-4a8b-84ef-f81dcdc2382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4cedce91-4a28-44a3-b783-642639320787" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityAddressStateOrProvince_4cedce91-4a28-44a3-b783-642639320787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_14455c73-7f06-4e05-9224-19170faa4fb2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityAddressPostalZipCode_14455c73-7f06-4e05-9224-19170faa4fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9b7de0ac-1a9c-4994-93a7-fc2e6eaab727" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_CityAreaCode_9b7de0ac-1a9c-4994-93a7-fc2e6eaab727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a9a85ae1-d747-41ff-a47c-0b8909e80743" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_LocalPhoneNumber_a9a85ae1-d747-41ff-a47c-0b8909e80743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ef27c9b3-450f-48d2-8bb6-b2f3c6c6dc1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_Security12bTitle_ef27c9b3-450f-48d2-8bb6-b2f3c6c6dc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c7dd2a30-aa02-454b-af37-f2b0a341feef" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_TradingSymbol_c7dd2a30-aa02-454b-af37-f2b0a341feef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a4ae897c-40a1-4a52-bced-6b72b5d9923b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_SecurityExchangeName_a4ae897c-40a1-4a52-bced-6b72b5d9923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_679e2cfa-5c9e-4fe7-8547-497d75f5ffb3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityCurrentReportingStatus_679e2cfa-5c9e-4fe7-8547-497d75f5ffb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_483169c3-18ce-4e22-817b-7acffe4e4336" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityInteractiveDataCurrent_483169c3-18ce-4e22-817b-7acffe4e4336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0c1a0e8f-681f-417d-9b36-7caa37bab8b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityFilerCategory_0c1a0e8f-681f-417d-9b36-7caa37bab8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_94c702da-b6b3-4366-8d4b-86af1d2de67d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityEmergingGrowthCompany_94c702da-b6b3-4366-8d4b-86af1d2de67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5a72e728-9976-4af7-b37d-f827e834924f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntitySmallBusiness_5a72e728-9976-4af7-b37d-f827e834924f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_34f30753-3323-46aa-8fc1-bafa46530a5c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityShellCompany_34f30753-3323-46aa-8fc1-bafa46530a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_12d25474-0879-4bc1-8f0b-1b321db6c817" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_12d25474-0879-4bc1-8f0b-1b321db6c817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_284a294c-a55a-4c9e-a3aa-68533364e3bf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_AmendmentFlag_284a294c-a55a-4c9e-a3aa-68533364e3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_23e3250c-9a88-4cb8-b13a-e672bc36e49f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_DocumentFiscalYearFocus_23e3250c-9a88-4cb8-b13a-e672bc36e49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_772d09f1-918f-46c0-bb38-4351f011279c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_DocumentFiscalPeriodFocus_772d09f1-918f-46c0-bb38-4351f011279c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4037b29e-d29c-4f64-a37b-71533c21e141" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityCentralIndexKey_4037b29e-d29c-4f64-a37b-71533c21e141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_69546549-2518-4e25-81d7-438446601e87" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_CurrentFiscalYearEndDate_69546549-2518-4e25-81d7-438446601e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_4196fd4d-2757-4d6d-b4a8-b8fe56487493" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityVoluntaryFilers_4196fd4d-2757-4d6d-b4a8-b8fe56487493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7ea3bcb7-e0ab-488d-b4ef-663492d6a699" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9274310f-d5f5-4d47-a346-c62ea9bfad39" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7ea3bcb7-e0ab-488d-b4ef-663492d6a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="amed-20210930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_040ea644-7fdb-4655-9414-015aab9a5873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_040ea644-7fdb-4655-9414-015aab9a5873" xlink:to="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_055c5591-57fb-4592-a127-ace79679b4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_055c5591-57fb-4592-a127-ace79679b4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec4c2aea-e927-4a70-ae75-c2b786d1778f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_055c5591-57fb-4592-a127-ace79679b4c6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec4c2aea-e927-4a70-ae75-c2b786d1778f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bf41ae6e-c48f-4e4d-88ea-b9bda374731e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_055c5591-57fb-4592-a127-ace79679b4c6" xlink:to="loc_us-gaap_RestrictedCash_bf41ae6e-c48f-4e4d-88ea-b9bda374731e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8bbe33cb-455a-4448-aa6d-5c84aec2b235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_055c5591-57fb-4592-a127-ace79679b4c6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8bbe33cb-455a-4448-aa6d-5c84aec2b235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_76360e79-3be9-419d-bc20-38c557b7baad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_055c5591-57fb-4592-a127-ace79679b4c6" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_76360e79-3be9-419d-bc20-38c557b7baad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_151fe901-55f8-48d2-b813-15a5af44ac0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_055c5591-57fb-4592-a127-ace79679b4c6" xlink:to="loc_us-gaap_OtherAssetsCurrent_151fe901-55f8-48d2-b813-15a5af44ac0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f0a92238-d10f-44ed-a085-9c6864a7596e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_055c5591-57fb-4592-a127-ace79679b4c6" xlink:to="loc_us-gaap_AssetsCurrent_f0a92238-d10f-44ed-a085-9c6864a7596e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_539b19af-16ac-45d6-a4be-42e4372b2235" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_539b19af-16ac-45d6-a4be-42e4372b2235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_214e0047-9270-41db-9055-750a0e9085b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_214e0047-9270-41db-9055-750a0e9085b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_135d3213-ef3b-429c-acea-0c78dd59a26c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:to="loc_us-gaap_Goodwill_135d3213-ef3b-429c-acea-0c78dd59a26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8093128b-b6fc-4e2b-a650-54f22dfabd19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8093128b-b6fc-4e2b-a650-54f22dfabd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2a72de20-688b-4032-bf9e-82f2414ea6eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2a72de20-688b-4032-bf9e-82f2414ea6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b7d009e2-5b90-4223-ac47-da8e2bf912e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b7d009e2-5b90-4223-ac47-da8e2bf912e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_293fe8d8-90ac-4b50-9025-92565bba9678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_80f99c32-a8f7-428c-9694-5236ed6ba17d" xlink:to="loc_us-gaap_Assets_293fe8d8-90ac-4b50-9025-92565bba9678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_040ea644-7fdb-4655-9414-015aab9a5873" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5944109e-4ec2-40ba-ada2-01ba0790de37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5944109e-4ec2-40ba-ada2-01ba0790de37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fe8e5b36-3acb-4f27-8511-5cf06d1379b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5944109e-4ec2-40ba-ada2-01ba0790de37" xlink:to="loc_us-gaap_AccountsPayableCurrent_fe8e5b36-3acb-4f27-8511-5cf06d1379b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_aa9057d8-f531-482e-881a-a1e04e6943c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5944109e-4ec2-40ba-ada2-01ba0790de37" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_aa9057d8-f531-482e-881a-a1e04e6943c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_81f1108b-c956-4c1f-9db2-6b782141f008" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5944109e-4ec2-40ba-ada2-01ba0790de37" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_81f1108b-c956-4c1f-9db2-6b782141f008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_7a723104-9ae5-4407-98f9-d3170cf53b9a" xlink:href="amed-20210930.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5944109e-4ec2-40ba-ada2-01ba0790de37" xlink:to="loc_amed_ProviderReliefFundAdvance_7a723104-9ae5-4407-98f9-d3170cf53b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_baa61298-eae8-4f4d-8df0-f2ecbfabb031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5944109e-4ec2-40ba-ada2-01ba0790de37" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_baa61298-eae8-4f4d-8df0-f2ecbfabb031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c1c340fa-dbab-4db6-859d-24a9ac26611a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5944109e-4ec2-40ba-ada2-01ba0790de37" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c1c340fa-dbab-4db6-859d-24a9ac26611a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d40c007e-1cf3-4626-bce7-cc8ae956af62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5944109e-4ec2-40ba-ada2-01ba0790de37" xlink:to="loc_us-gaap_LiabilitiesCurrent_d40c007e-1cf3-4626-bce7-cc8ae956af62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_16e07c94-abab-46f7-bc8a-93738a1a13bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_16e07c94-abab-46f7-bc8a-93738a1a13bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f38edb32-b00a-47c0-9708-805a08bcb4d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f38edb32-b00a-47c0-9708-805a08bcb4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6bd7e671-eb78-4d7b-98da-7ef14ccf0bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6bd7e671-eb78-4d7b-98da-7ef14ccf0bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2131470a-f744-4062-8269-ed1076ad861f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:to="loc_us-gaap_Liabilities_2131470a-f744-4062-8269-ed1076ad861f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f912e9c5-1b9f-436e-a5d7-237ea83cb59e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f912e9c5-1b9f-436e-a5d7-237ea83cb59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_b9bffeac-acfe-4398-9458-cbbdd82b42ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_b9bffeac-acfe-4398-9458-cbbdd82b42ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_75f8e1b3-691a-447b-a891-27391ad65316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_75f8e1b3-691a-447b-a891-27391ad65316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6d196a85-296d-4e0f-bf59-0fd782e4472f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6d196a85-296d-4e0f-bf59-0fd782e4472f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b0810fe8-e40e-48ff-830f-3173c3888dec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:to="loc_us-gaap_TreasuryStockValue_b0810fe8-e40e-48ff-830f-3173c3888dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2334e01-89c8-42c7-87d3-a9a4e6a1164f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2334e01-89c8-42c7-87d3-a9a4e6a1164f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_507d8d62-e01c-4ce1-80fc-ba1ed98a9c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:to="loc_us-gaap_StockholdersEquity_507d8d62-e01c-4ce1-80fc-ba1ed98a9c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ceae27c3-2c7d-4b09-b3f1-63086d663956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:to="loc_us-gaap_MinorityInterest_ceae27c3-2c7d-4b09-b3f1-63086d663956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f88d629-0c88-464e-ad1a-5c38edf30f1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10b16531-d2ab-45a6-9be0-85d2ed690d5e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8f88d629-0c88-464e-ad1a-5c38edf30f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_aaa17314-1fc2-4930-884e-50fbfb53c63e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6256f53b-a147-4419-b894-8f85fca7056f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_aaa17314-1fc2-4930-884e-50fbfb53c63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="amed-20210930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_be6aeb8a-39ff-4db5-96cb-3347b07d3bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_be6aeb8a-39ff-4db5-96cb-3347b07d3bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ed670f0c-3390-4554-a67f-f0447ce4df49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ed670f0c-3390-4554-a67f-f0447ce4df49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a33d448e-f501-43f2-a79a-c496fb4424e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a33d448e-f501-43f2-a79a-c496fb4424e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8fa7d29d-7cdf-4997-8d98-cefdb750cd86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8fa7d29d-7cdf-4997-8d98-cefdb750cd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_37ec91e1-50c8-43fd-aeb3-9080927f6a66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_PreferredStockSharesIssued_37ec91e1-50c8-43fd-aeb3-9080927f6a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0450ae75-0735-43d7-abf6-e07f5e95b07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0450ae75-0735-43d7-abf6-e07f5e95b07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8d89c455-dfc2-44bf-8959-89e91806b320" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8d89c455-dfc2-44bf-8959-89e91806b320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fc0df209-3a2b-4dd1-9023-38f687b92fc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fc0df209-3a2b-4dd1-9023-38f687b92fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_030ac41a-5c68-47a5-b0ec-374e380dcf90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_CommonStockSharesIssued_030ac41a-5c68-47a5-b0ec-374e380dcf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c676ab47-f128-406d-9fb9-87dea43cd2af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c676ab47-f128-406d-9fb9-87dea43cd2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_a40d18af-5804-4601-af45-04dc1b3165f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1aa6b374-5f46-4024-951c-ae62c7521914" xlink:to="loc_us-gaap_TreasuryStockShares_a40d18af-5804-4601-af45-04dc1b3165f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="amed-20210930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_ef361cc3-c436-4f4a-8123-1f1d3719d162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_ef361cc3-c436-4f4a-8123-1f1d3719d162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_45b59095-e9c0-43c8-9fdb-3a192752e21b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_45b59095-e9c0-43c8-9fdb-3a192752e21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_13f429df-41df-417e-8eb1-6ab1d2f5abf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_13f429df-41df-417e-8eb1-6ab1d2f5abf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02ca3d46-2960-4eed-8bde-0dbbce274ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02ca3d46-2960-4eed-8bde-0dbbce274ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_7adccde8-0be9-426b-91ac-473aea92b297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02ca3d46-2960-4eed-8bde-0dbbce274ec1" xlink:to="loc_us-gaap_LaborAndRelatedExpense_7adccde8-0be9-426b-91ac-473aea92b297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a0cd94ce-d926-4b4e-9615-731dc60d94dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02ca3d46-2960-4eed-8bde-0dbbce274ec1" xlink:to="loc_us-gaap_ShareBasedCompensation_a0cd94ce-d926-4b4e-9615-731dc60d94dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherGeneralAndAdministrativeExpense_ea3cbe31-5f69-49a8-8476-a3597ee568e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseAbstract_02ca3d46-2960-4eed-8bde-0dbbce274ec1" xlink:to="loc_us-gaap_OtherGeneralAndAdministrativeExpense_ea3cbe31-5f69-49a8-8476-a3597ee568e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_16f42963-2760-468e-bdf0-d8c25e312678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_DepreciationAndAmortization_16f42963-2760-468e-bdf0-d8c25e312678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ea73e44e-72c2-4e3b-a1ac-8cc7979e78ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_CostsAndExpenses_ea73e44e-72c2-4e3b-a1ac-8cc7979e78ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c00da9d1-335c-4c9a-9b72-b2a7ea2c56cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_OperatingIncomeLoss_c00da9d1-335c-4c9a-9b72-b2a7ea2c56cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ffce001b-82c6-4892-88b2-74cf97688928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ffce001b-82c6-4892-88b2-74cf97688928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_660e8b17-8a81-4b34-aaa0-7c9e11a25f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ffce001b-82c6-4892-88b2-74cf97688928" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_660e8b17-8a81-4b34-aaa0-7c9e11a25f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bc823a1a-415d-43fb-b35d-23831e11aaae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ffce001b-82c6-4892-88b2-74cf97688928" xlink:to="loc_us-gaap_InterestExpense_bc823a1a-415d-43fb-b35d-23831e11aaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9116aac0-1ddc-40f5-ac5e-82cdf6480fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ffce001b-82c6-4892-88b2-74cf97688928" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9116aac0-1ddc-40f5-ac5e-82cdf6480fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_59c61381-a876-44e4-9e7b-394d8e324f49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ffce001b-82c6-4892-88b2-74cf97688928" xlink:to="loc_us-gaap_GainLossOnInvestments_59c61381-a876-44e4-9e7b-394d8e324f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9585084b-1447-496c-b9c9-537c7767f244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ffce001b-82c6-4892-88b2-74cf97688928" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9585084b-1447-496c-b9c9-537c7767f244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_75d11384-463b-485f-95f0-8bf6c7297b94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ffce001b-82c6-4892-88b2-74cf97688928" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_75d11384-463b-485f-95f0-8bf6c7297b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16ba672d-9e61-45a9-a735-92466e6e65fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_16ba672d-9e61-45a9-a735-92466e6e65fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b15390d7-0d66-42ac-b145-80b05ab253f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b15390d7-0d66-42ac-b145-80b05ab253f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fbf37eba-64d6-4dd5-8f1f-14b1c182eadd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_ProfitLoss_fbf37eba-64d6-4dd5-8f1f-14b1c182eadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_990c850a-a64b-47fc-b697-42b853123db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_990c850a-a64b-47fc-b697-42b853123db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b85ef788-934f-4d72-b362-6509f878af71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_NetIncomeLoss_b85ef788-934f-4d72-b362-6509f878af71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_3ecb1d3c-186a-4100-99a3-b593c3d0378f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_3ecb1d3c-186a-4100-99a3-b593c3d0378f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_849e64b3-e421-4835-9f74-f0d0e5f08084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3ecb1d3c-186a-4100-99a3-b593c3d0378f" xlink:to="loc_us-gaap_EarningsPerShareBasic_849e64b3-e421-4835-9f74-f0d0e5f08084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8baaeabd-a4d7-45de-bfdf-154d12d71a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_3ecb1d3c-186a-4100-99a3-b593c3d0378f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8baaeabd-a4d7-45de-bfdf-154d12d71a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_c6def509-b99f-4d63-99a3-60cbd4e1278a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_393d4295-78a1-4690-b65b-0660cc8f8302" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_c6def509-b99f-4d63-99a3-60cbd4e1278a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e2da5068-3a41-4240-83b6-da302dbede60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_c6def509-b99f-4d63-99a3-60cbd4e1278a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e2da5068-3a41-4240-83b6-da302dbede60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cc52fc89-22fe-4e09-9b95-1758c94c9bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_c6def509-b99f-4d63-99a3-60cbd4e1278a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cc52fc89-22fe-4e09-9b95-1758c94c9bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="simple" xlink:href="amed-20210930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9de03d23-ec8f-4f0d-8a55-12230b68b19a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c0c192b7-2313-40b9-b57c-7a5f60e9f926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9de03d23-ec8f-4f0d-8a55-12230b68b19a" xlink:to="loc_us-gaap_StatementTable_c0c192b7-2313-40b9-b57c-7a5f60e9f926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_079f679e-5e58-4e99-9bd0-c491ff377105" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c0c192b7-2313-40b9-b57c-7a5f60e9f926" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_079f679e-5e58-4e99-9bd0-c491ff377105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_079f679e-5e58-4e99-9bd0-c491ff377105" xlink:to="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_864681e4-b745-4672-9c41-87eff2aee4b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_CommonStockMember_864681e4-b745-4672-9c41-87eff2aee4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_4c48d602-ef63-4cd5-a601-f8999145b76c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_4c48d602-ef63-4cd5-a601-f8999145b76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_67f1a739-d499-4798-a45e-e2d8b944646e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_TreasuryStockMember_67f1a739-d499-4798-a45e-e2d8b944646e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ebe6c718-dd0e-41ce-a3a5-25bb2dd8365f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ebe6c718-dd0e-41ce-a3a5-25bb2dd8365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_0d09aa79-a812-49d2-98de-9cda1b588aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_RetainedEarningsMember_0d09aa79-a812-49d2-98de-9cda1b588aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_42de04d4-70e5-47be-b694-c67125ba6e4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_NoncontrollingInterestMember_42de04d4-70e5-47be-b694-c67125ba6e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_59b42c0d-1b1e-4da2-943b-2ef14e36ac2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1eebaf74-0c56-4124-815f-e9a5b4eb3d3b" xlink:to="loc_us-gaap_AociAttributableToNoncontrollingInterestMember_59b42c0d-1b1e-4da2-943b-2ef14e36ac2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c0c192b7-2313-40b9-b57c-7a5f60e9f926" xlink:to="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32727725-1665-423e-94ac-0d68d2a80203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_32727725-1665-423e-94ac-0d68d2a80203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_7456c7a5-7b7a-40d0-8610-cf55ed9afb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_SharesOutstanding_7456c7a5-7b7a-40d0-8610-cf55ed9afb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0a660a4d-03c9-4272-b187-244fe3a73164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0a660a4d-03c9-4272-b187-244fe3a73164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3fded68d-8071-4739-8b7b-7e3534321ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3fded68d-8071-4739-8b7b-7e3534321ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_15b1d6b7-a468-4a00-9125-59c1745c476a" xlink:href="amed-20210930.xsd#amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch_15b1d6b7-a468-4a00-9125-59c1745c476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_67ee1a03-1c10-44fb-a51f-f685778bac3d" xlink:href="amed-20210930.xsd#amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch_67ee1a03-1c10-44fb-a51f-f685778bac3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_7a0ba1d1-a639-417a-a5f2-c2b44e866fc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_7a0ba1d1-a639-417a-a5f2-c2b44e866fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_22f620ea-ae9d-4aca-9729-3ee476b685ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_22f620ea-ae9d-4aca-9729-3ee476b685ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c8e24fd1-4698-4c47-9b3b-7cc60dcaea89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c8e24fd1-4698-4c47-9b3b-7cc60dcaea89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_040fe51b-7b4e-435b-9b7e-875a9d03c745" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_040fe51b-7b4e-435b-9b7e-875a9d03c745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_df14da19-1f67-494e-8e8c-8fce980e0b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_df14da19-1f67-494e-8e8c-8fce980e0b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedShares_0005e377-1133-47ff-9814-3eb1911fc537" xlink:href="amed-20210930.xsd#amed_SurrenderedShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_SurrenderedShares_0005e377-1133-47ff-9814-3eb1911fc537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_66d22424-6e31-4da1-a5fd-813a9a8fc181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_66d22424-6e31-4da1-a5fd-813a9a8fc181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_23bf27ec-b14e-4729-8140-fa5b450a67c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_23bf27ec-b14e-4729-8140-fa5b450a67c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_a87cdeed-d64e-479a-b45f-575b86c258d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_a87cdeed-d64e-479a-b45f-575b86c258d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_80dbf27e-9581-4470-90da-cff2d458e112" xlink:href="amed-20210930.xsd#amed_EquityImpactofRepurchaseofNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_EquityImpactofRepurchaseofNoncontrollingInterest_80dbf27e-9581-4470-90da-cff2d458e112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_4dcb02f3-e7a5-443f-b98e-49db777a8938" xlink:href="amed-20210930.xsd#amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome_4dcb02f3-e7a5-443f-b98e-49db777a8938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2cd18d8-60cd-42af-8804-1f1b5fe7bf69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_ProfitLoss_f2cd18d8-60cd-42af-8804-1f1b5fe7bf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f65acc3e-8b76-4c87-841f-c9325ccdbfee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f65acc3e-8b76-4c87-841f-c9325ccdbfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_43572249-21b1-4cca-8c87-302af5caae52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_15006867-42a0-4bca-a716-5b408b3d85cd" xlink:to="loc_us-gaap_SharesOutstanding_43572249-21b1-4cca-8c87-302af5caae52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="amed-20210930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_22f7e77b-8b1a-4bf2-9fc5-89c97091b8f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a3c13aca-822b-4ddf-9082-f36cd30de553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22f7e77b-8b1a-4bf2-9fc5-89c97091b8f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a3c13aca-822b-4ddf-9082-f36cd30de553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8bfe5bdc-f767-4f5e-82d5-c2d985ca6b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a3c13aca-822b-4ddf-9082-f36cd30de553" xlink:to="loc_us-gaap_ProfitLoss_8bfe5bdc-f767-4f5e-82d5-c2d985ca6b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a3c13aca-822b-4ddf-9082-f36cd30de553" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7aaf8596-0b1a-4ae4-812e-d5f884add852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7aaf8596-0b1a-4ae4-812e-d5f884add852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cfd7afcd-7b7f-41b3-8068-134717e83dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_us-gaap_ShareBasedCompensation_cfd7afcd-7b7f-41b3-8068-134717e83dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_8c16f443-bfd5-428e-8012-0074e263f4d5" xlink:href="amed-20210930.xsd#amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset_8c16f443-bfd5-428e-8012-0074e263f4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e9dc27d6-0a7f-4547-a0ea-c7505a8d2aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e9dc27d6-0a7f-4547-a0ea-c7505a8d2aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_de6014e5-4c58-4898-83cf-96bcf6124abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_de6014e5-4c58-4898-83cf-96bcf6124abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WriteOffOfOtherComprehensiveIncome_dbed134d-461f-4fa8-8192-c5e59ac1c252" xlink:href="amed-20210930.xsd#amed_WriteOffOfOtherComprehensiveIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_amed_WriteOffOfOtherComprehensiveIncome_dbed134d-461f-4fa8-8192-c5e59ac1c252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f971048c-4b0a-486b-a270-6498f52a1755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f971048c-4b0a-486b-a270-6498f52a1755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3291f79b-044b-446b-ad8e-a3b9e01f4679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3291f79b-044b-446b-ad8e-a3b9e01f4679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_814fd8a4-a22f-441c-8097-63808057ca80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_814fd8a4-a22f-441c-8097-63808057ca80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_79778957-ddd8-4b69-8dfc-0bed7e5d656b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_79778957-ddd8-4b69-8dfc-0bed7e5d656b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_427eeb1e-14a0-436b-9825-24d119ae6421" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1d9e0265-1306-454a-80bd-f15210f9917a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1d9e0265-1306-454a-80bd-f15210f9917a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d1bdb6a4-2218-47b7-9a8e-9b1f43ee06f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d1bdb6a4-2218-47b7-9a8e-9b1f43ee06f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_925b4bad-89c9-4200-9576-5177e7c789d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_925b4bad-89c9-4200-9576-5177e7c789d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5cda5614-af34-4ed9-82f4-6642924091f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5cda5614-af34-4ed9-82f4-6642924091f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8349f031-c225-4921-afca-a803e90c7b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8349f031-c225-4921-afca-a803e90c7b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0336a4f3-2e5a-461c-a066-300c43619d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0336a4f3-2e5a-461c-a066-300c43619d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_b2ff1050-497c-40dd-a3f8-8f7b80d83810" xlink:href="amed-20210930.xsd#amed_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseLiability_b2ff1050-497c-40dd-a3f8-8f7b80d83810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_b7cc7608-bf9e-45e7-ba7b-6a7b5cbeb0ac" xlink:href="amed-20210930.xsd#amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_95777f1c-9b6e-49ae-ba41-2c9102beabc5" xlink:to="loc_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_b7cc7608-bf9e-45e7-ba7b-6a7b5cbeb0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e2e5e78-af08-465c-b5e6-33365f488ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a3c13aca-822b-4ddf-9082-f36cd30de553" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e2e5e78-af08-465c-b5e6-33365f488ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22f7e77b-8b1a-4bf2-9fc5-89c97091b8f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_f29f347f-5536-4faf-a9f7-e7d425be3ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_f29f347f-5536-4faf-a9f7-e7d425be3ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_59d5661c-18c6-42d9-be25-962bc3d19bd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_59d5661c-18c6-42d9-be25-962bc3d19bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_88559116-c1c0-403b-843d-6bfa34f46871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_88559116-c1c0-403b-843d-6bfa34f46871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToDevelopSoftware_164b9eae-2abe-4b61-a173-0d750e1d141c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToDevelopSoftware"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:to="loc_us-gaap_PaymentsToDevelopSoftware_164b9eae-2abe-4b61-a173-0d750e1d141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_8f32ec6e-13ae-4355-8595-fcdd8f1179f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_8f32ec6e-13ae-4355-8595-fcdd8f1179f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_68bf5f27-70c0-477e-96ad-a64e9aac1bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_68bf5f27-70c0-477e-96ad-a64e9aac1bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ac97adb8-fb2d-4163-aabe-2b2002c11d4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ac97adb8-fb2d-4163-aabe-2b2002c11d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_921c7ea0-df41-4ac0-84b7-ba35776f9e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_be49a6ec-1e58-4640-81f1-8778a60e80d1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_921c7ea0-df41-4ac0-84b7-ba35776f9e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22f7e77b-8b1a-4bf2-9fc5-89c97091b8f6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_bac7654f-02c0-44f4-b516-b39700147bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_bac7654f-02c0-44f4-b516-b39700147bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_81e012ef-8480-45bc-854f-5447361fb67d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_ProceedsFromStockPlans_81e012ef-8480-45bc-854f-5447361fb67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8a32b0b7-c52e-4204-9fa2-f925362715fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8a32b0b7-c52e-4204-9fa2-f925362715fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashDistributionToNoncontrollingInterest_4b094096-bcab-4873-b692-e089734619ab" xlink:href="amed-20210930.xsd#amed_CashDistributionToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_amed_CashDistributionToNoncontrollingInterest_4b094096-bcab-4873-b692-e089734619ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d97da740-3afa-4a03-a3f1-783dbebf7d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d97da740-3afa-4a03-a3f1-783dbebf7d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_64392205-ed49-4479-9c71-9f7fb4d00697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_64392205-ed49-4479-9c71-9f7fb4d00697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_1e2afc68-897c-4e87-ae48-87cb9ac0f33e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_1e2afc68-897c-4e87-ae48-87cb9ac0f33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_304d98aa-36f5-4b50-b16b-1e9e0c796527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_304d98aa-36f5-4b50-b16b-1e9e0c796527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3a161c33-390c-4b36-b7db-36af6405f42e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3a161c33-390c-4b36-b7db-36af6405f42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5d0ab623-de3e-4c0d-ae2e-955c9f0134d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5d0ab623-de3e-4c0d-ae2e-955c9f0134d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundsReceivedFromProviderReliefFundAdvance_0167c865-e7fc-452c-b992-1fd7ad3885c8" xlink:href="amed-20210930.xsd#amed_FundsReceivedFromProviderReliefFundAdvance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_amed_FundsReceivedFromProviderReliefFundAdvance_0167c865-e7fc-452c-b992-1fd7ad3885c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37104727-1fbd-44e8-b761-bc7a27507c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_07fb3d7e-0ab9-43a2-8656-87d61e1181ec" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37104727-1fbd-44e8-b761-bc7a27507c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ffae09e0-d5d5-4f59-ab7a-6f93f6510d4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22f7e77b-8b1a-4bf2-9fc5-89c97091b8f6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ffae09e0-d5d5-4f59-ab7a-6f93f6510d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7db5baab-aa06-471b-b5d3-91c6deffab67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22f7e77b-8b1a-4bf2-9fc5-89c97091b8f6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7db5baab-aa06-471b-b5d3-91c6deffab67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f668014-729d-4e77-8085-8ca2ef5a7e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22f7e77b-8b1a-4bf2-9fc5-89c97091b8f6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0f668014-729d-4e77-8085-8ca2ef5a7e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3702a764-bdbe-44c6-9787-3c8b850b7b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22f7e77b-8b1a-4bf2-9fc5-89c97091b8f6" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3702a764-bdbe-44c6-9787-3c8b850b7b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_0f2a822a-26dc-4284-aca2-125abd7199f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3702a764-bdbe-44c6-9787-3c8b850b7b30" xlink:to="loc_us-gaap_InterestPaidNet_0f2a822a-26dc-4284-aca2-125abd7199f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_9cdc4593-5305-4862-98f8-67dc7fc2d657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3702a764-bdbe-44c6-9787-3c8b850b7b30" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_9cdc4593-5305-4862-98f8-67dc7fc2d657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForOperatingLeaseLiabilities_64c36727-0299-4cd6-ac1c-e0139fc1da5e" xlink:href="amed-20210930.xsd#amed_CashPaidForOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3702a764-bdbe-44c6-9787-3c8b850b7b30" xlink:to="loc_amed_CashPaidForOperatingLeaseLiabilities_64c36727-0299-4cd6-ac1c-e0139fc1da5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashPaidForFinanceLeaseLiabilities_26f98e75-69be-4388-9676-60fe01a130f0" xlink:href="amed-20210930.xsd#amed_CashPaidForFinanceLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3702a764-bdbe-44c6-9787-3c8b850b7b30" xlink:to="loc_amed_CashPaidForFinanceLeaseLiabilities_26f98e75-69be-4388-9676-60fe01a130f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_13b427c4-da36-4c6c-85c4-d273d47ddc77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_22f7e77b-8b1a-4bf2-9fc5-89c97091b8f6" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_13b427c4-da36-4c6c-85c4-d273d47ddc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5f1c2429-e327-4f4e-9d69-d9bcce12d871" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_13b427c4-da36-4c6c-85c4-d273d47ddc77" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_5f1c2429-e327-4f4e-9d69-d9bcce12d871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_b709387c-21ed-4f7a-85a9-c951e3f3bcef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_13b427c4-da36-4c6c-85c4-d273d47ddc77" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_b709387c-21ed-4f7a-85a9-c951e3f3bcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_4d9f8a87-23f4-43ac-9c10-b80e4836b10d" xlink:href="amed-20210930.xsd#amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_13b427c4-da36-4c6c-85c4-d273d47ddc77" xlink:to="loc_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations_4d9f8a87-23f4-43ac-9c10-b80e4836b10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="simple" xlink:href="amed-20210930.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b198b667-9d44-470e-a126-b03bad075ba4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_022c2aad-d641-416b-9554-48b9e736a8b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b198b667-9d44-470e-a126-b03bad075ba4" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_022c2aad-d641-416b-9554-48b9e736a8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" xlink:type="simple" xlink:href="amed-20210930.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f69c9166-ed90-4372-b93b-7b23b3fe5987" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_a3555819-7043-4a07-9d58-4a593d789116" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f69c9166-ed90-4372-b93b-7b23b3fe5987" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_a3555819-7043-4a07-9d58-4a593d789116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33002e4a-dcab-4ac7-ae51-60336878ffe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33002e4a-dcab-4ac7-ae51-60336878ffe7" xlink:to="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_abec17c6-7b58-47e2-87b0-0fbe27242460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_abec17c6-7b58-47e2-87b0-0fbe27242460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_cc85882a-a7da-420d-82ec-ef53eb7f742c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_abec17c6-7b58-47e2-87b0-0fbe27242460" xlink:to="loc_us-gaap_TypeOfAdoptionMember_cc85882a-a7da-420d-82ec-ef53eb7f742c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0736bf8a-995c-4fe3-8ff4-67ae3365c0c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_cc85882a-a7da-420d-82ec-ef53eb7f742c" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0736bf8a-995c-4fe3-8ff4-67ae3365c0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bc746e63-9e06-467e-bbe0-0ca87813753f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bc746e63-9e06-467e-bbe0-0ca87813753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3d9dd6b-2071-4a35-91fb-c30e4b836f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_bc746e63-9e06-467e-bbe0-0ca87813753f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3d9dd6b-2071-4a35-91fb-c30e4b836f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_f08e39f8-763a-4879-b62f-dfed7004310d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_e3d9dd6b-2071-4a35-91fb-c30e4b836f22" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_f08e39f8-763a-4879-b62f-dfed7004310d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_f8afa526-4f99-4d32-873d-8576577383ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_f8afa526-4f99-4d32-873d-8576577383ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1c1624f1-dec1-4084-b4c7-d9e81edb3de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_f8afa526-4f99-4d32-873d-8576577383ef" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1c1624f1-dec1-4084-b4c7-d9e81edb3de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_0f86d09f-983c-4765-b0de-6962ba21246a" xlink:href="amed-20210930.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1c1624f1-dec1-4084-b4c7-d9e81edb3de0" xlink:to="loc_amed_MedicareRevenueMember_0f86d09f-983c-4765-b0de-6962ba21246a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_89821c99-ca3a-48fb-b886-08b85bcf9552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_1c1624f1-dec1-4084-b4c7-d9e81edb3de0" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_89821c99-ca3a-48fb-b886-08b85bcf9552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f9b6e1fe-0548-4ada-a56c-56f88174eaa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f9b6e1fe-0548-4ada-a56c-56f88174eaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f9b6e1fe-0548-4ada-a56c-56f88174eaa1" xlink:to="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_1179ca86-23d2-4c36-bcf4-632cdf122fc6" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:to="loc_amed_HomeHealthMember_1179ca86-23d2-4c36-bcf4-632cdf122fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_82e965b7-88ac-463c-8715-fd072cd43004" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:to="loc_amed_HospiceMember_82e965b7-88ac-463c-8715-fd072cd43004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_50041308-b6a0-4aef-bc58-a38f6372d445" xlink:href="amed-20210930.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:to="loc_amed_PersonalCareMember_50041308-b6a0-4aef-bc58-a38f6372d445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_dda1d2ef-5704-4153-a583-ebc37e9c3684" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1fe2ced6-d441-4233-8620-7cb94f239884" xlink:to="loc_amed_HighAcuityCareMember_dda1d2ef-5704-4153-a583-ebc37e9c3684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeofEquityMethodInvestmentAxis_97d932f4-2fdd-41cb-919d-5a77dfaabbbf" xlink:href="amed-20210930.xsd#amed_TypeofEquityMethodInvestmentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_amed_TypeofEquityMethodInvestmentAxis_97d932f4-2fdd-41cb-919d-5a77dfaabbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TypeOfEquityMethodInvestmentDomain_1f308f14-1dc3-43ec-87aa-1bb76ad0149c" xlink:href="amed-20210930.xsd#amed_TypeOfEquityMethodInvestmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeofEquityMethodInvestmentAxis_97d932f4-2fdd-41cb-919d-5a77dfaabbbf" xlink:to="loc_amed_TypeOfEquityMethodInvestmentDomain_1f308f14-1dc3-43ec-87aa-1bb76ad0149c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HeritageHealthcareInnovationFundLPMember_415ada62-028a-4d43-9136-55e205545ae1" xlink:href="amed-20210930.xsd#amed_HeritageHealthcareInnovationFundLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_1f308f14-1dc3-43ec-87aa-1bb76ad0149c" xlink:to="loc_amed_HeritageHealthcareInnovationFundLPMember_415ada62-028a-4d43-9136-55e205545ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_fce0863f-81c2-4c67-b706-19a7864327ba" xlink:href="amed-20210930.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_TypeOfEquityMethodInvestmentDomain_1f308f14-1dc3-43ec-87aa-1bb76ad0149c" xlink:to="loc_amed_MedalogixMember_fce0863f-81c2-4c67-b706-19a7864327ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_33e7442a-fb5e-49e9-a0d6-0d75044328dd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_srt_ProductOrServiceAxis_33e7442a-fb5e-49e9-a0d6-0d75044328dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89811f0f-69a3-4fac-8a95-93afe30395e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_33e7442a-fb5e-49e9-a0d6-0d75044328dd" xlink:to="loc_srt_ProductsAndServicesDomain_89811f0f-69a3-4fac-8a95-93afe30395e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_4e228701-b10a-4572-b395-c6da7e84b533" xlink:href="amed-20210930.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89811f0f-69a3-4fac-8a95-93afe30395e8" xlink:to="loc_amed_MedicareRevenueMember_4e228701-b10a-4572-b395-c6da7e84b533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6c8405f2-f8db-46f7-83fa-0f04a70d6a5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6c8405f2-f8db-46f7-83fa-0f04a70d6a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_decebc2f-9348-4b84-b65b-780a70a72f5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6c8405f2-f8db-46f7-83fa-0f04a70d6a5d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_decebc2f-9348-4b84-b65b-780a70a72f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ff3bcf6d-ceb9-4459-a63b-72c78f86154b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_decebc2f-9348-4b84-b65b-780a70a72f5a" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ff3bcf6d-ceb9-4459-a63b-72c78f86154b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_528d716c-a147-4e6b-b940-58a7e5c99d46" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d6da88d3-7f05-4d24-bb28-9ea8e9e18210" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d6da88d3-7f05-4d24-bb28-9ea8e9e18210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OperatingCareCenters_2dbfd685-2075-4613-af95-62595aa3fd0f" xlink:href="amed-20210930.xsd#amed_OperatingCareCenters"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_OperatingCareCenters_2dbfd685-2075-4613-af95-62595aa3fd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_b8969726-01e5-41ee-889d-b4bfc6758bd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_b8969726-01e5-41ee-889d-b4bfc6758bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_bf6561ef-54c0-42ae-9fb3-f9c6794ff992" xlink:href="amed-20210930.xsd#amed_MinimumPercentOwnershipForControllingInterestPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_MinimumPercentOwnershipForControllingInterestPercent_bf6561ef-54c0-42ae-9fb3-f9c6794ff992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_f5ce274a-b112-4dd9-9dd7-da83759cd89c" xlink:href="amed-20210930.xsd#amed_MaximumPercentOwnershipForEquityMethodPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_MaximumPercentOwnershipForEquityMethodPercent_f5ce274a-b112-4dd9-9dd7-da83759cd89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_68721271-eca8-45e9-8d8c-509b77450d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_68721271-eca8-45e9-8d8c-509b77450d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumPercentOwnershipForCostMethodPercent_484618ff-012a-444c-a8df-5b2338d2c831" xlink:href="amed-20210930.xsd#amed_MaximumPercentOwnershipForCostMethodPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_MaximumPercentOwnershipForCostMethodPercent_484618ff-012a-444c-a8df-5b2338d2c831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_0ecc1c78-70f4-41b0-baec-345620163244" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_EquityMethodInvestments_0ecc1c78-70f4-41b0-baec-345620163244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_67b04a8e-58cf-44bc-a76f-29b318e54ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_67b04a8e-58cf-44bc-a76f-29b318e54ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_9174fe81-205a-4f59-8095-1ba3e224ff82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainOnSaleOfInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_9174fe81-205a-4f59-8095-1ba3e224ff82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_1e0f2159-f751-426a-aaa4-2dbc7e051b64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_GainLossOnInvestments_1e0f2159-f751-426a-aaa4-2dbc7e051b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfJointVentures_50a72ab2-e3a0-4b30-8fc2-55e26a508f85" xlink:href="amed-20210930.xsd#amed_NumberOfJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_NumberOfJointVentures_50a72ab2-e3a0-4b30-8fc2-55e26a508f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_d40f00b3-edb7-4e1b-b30d-06c5d52585eb" xlink:href="amed-20210930.xsd#amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities_d40f00b3-edb7-4e1b-b30d-06c5d52585eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c8b02cb6-de2b-44f4-95f9-882151b21900" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c8b02cb6-de2b-44f4-95f9-882151b21900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a0ce195f-dc97-4968-83dd-21c1896b4553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a0ce195f-dc97-4968-83dd-21c1896b4553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c0c3540a-9d5e-44ae-988f-bd2f9babf2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_OtherAssetsCurrent_c0c3540a-9d5e-44ae-988f-bd2f9babf2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_49eb7cb8-718b-4f34-918b-56ff83c295e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_AssetsCurrent_49eb7cb8-718b-4f34-918b-56ff83c295e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ac16a176-089d-477d-992c-e502ec9733cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ac16a176-089d-477d-992c-e502ec9733cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1ca99204-5aba-4fc9-be70-4888cf7a02e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_Assets_1ca99204-5aba-4fc9-be70-4888cf7a02e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b4ed172-0fc7-4165-a053-37cc5bc7b8f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9b4ed172-0fc7-4165-a053-37cc5bc7b8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9ca81da9-3f38-46ff-8514-cf1e084a798f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9ca81da9-3f38-46ff-8514-cf1e084a798f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e86e25d0-f8b7-4846-a291-e18e5bb843c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_e86e25d0-f8b7-4846-a291-e18e5bb843c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cca9e90c-a8eb-4208-941c-cb5bd32ad57b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_LiabilitiesCurrent_cca9e90c-a8eb-4208-941c-cb5bd32ad57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9d97e9f1-8b85-48f7-82bd-9967f8e84515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9d97e9f1-8b85-48f7-82bd-9967f8e84515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a69eae77-08b4-4f50-b384-20246afab174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_98b5335c-0706-47ef-ab61-dd40aac7159e" xlink:to="loc_us-gaap_Liabilities_a69eae77-08b4-4f50-b384-20246afab174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d00909dd-6c3b-4411-bd89-5cf98daa452f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4849bf6a-fd02-467a-885b-b27048f50fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d00909dd-6c3b-4411-bd89-5cf98daa452f" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4849bf6a-fd02-467a-885b-b27048f50fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28718f64-6385-4917-ae04-0dad0088e9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_28718f64-6385-4917-ae04-0dad0088e9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2965f8ce-1323-44a7-8d9a-96fd72d54e57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2965f8ce-1323-44a7-8d9a-96fd72d54e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ac8bd3de-af9d-4273-aa23-f48fabc62397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_UseOfEstimates_ac8bd3de-af9d-4273-aa23-f48fabc62397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_c1584d81-df6c-42b0-bd09-2e8a665486a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_c1584d81-df6c-42b0-bd09-2e8a665486a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_0924b3b6-51ca-4b95-a2da-3c9f484692cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_0924b3b6-51ca-4b95-a2da-3c9f484692cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_56d6da56-c166-494c-848b-80a2991aa041" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_56d6da56-c166-494c-848b-80a2991aa041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GovernmentGrantsPolicyTextBlock_94a4b31d-c9ef-47ee-b86c-19cc344f67c7" xlink:href="amed-20210930.xsd#amed_GovernmentGrantsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_amed_GovernmentGrantsPolicyTextBlock_94a4b31d-c9ef-47ee-b86c-19cc344f67c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_85e50ccd-715a-4898-9081-fd99f8318eca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_85e50ccd-715a-4898-9081-fd99f8318eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_0ff08ccf-9e21-41cb-8fd7-372bae37e766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_0ff08ccf-9e21-41cb-8fd7-372bae37e766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_6432908a-d942-430f-9423-f80da2a48c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_6432908a-d942-430f-9423-f80da2a48c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_c2e72f66-d33f-4561-b39d-86c51d749e0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_c2e72f66-d33f-4561-b39d-86c51d749e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2e3f0ea9-ee69-4cbc-840e-33fd8a0439e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aff16e04-579a-4b49-a412-40f7c6ff21be" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2e3f0ea9-ee69-4cbc-840e-33fd8a0439e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d3c0f12a-6f90-427b-bf51-28415f260bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_ee11eab1-4625-4d76-ad7b-eeffe603d0d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3c0f12a-6f90-427b-bf51-28415f260bed" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock_ee11eab1-4625-4d76-ad7b-eeffe603d0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_4ea3ab78-f4a3-4315-8df4-b38c70aa0e56" xlink:href="amed-20210930.xsd#amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3c0f12a-6f90-427b-bf51-28415f260bed" xlink:to="loc_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock_4ea3ab78-f4a3-4315-8df4-b38c70aa0e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FinancialInstrumentDetailsTableTextBlock_088833c9-ef94-46d8-8a21-97f4e2916682" xlink:href="amed-20210930.xsd#amed_FinancialInstrumentDetailsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3c0f12a-6f90-427b-bf51-28415f260bed" xlink:to="loc_amed_FinancialInstrumentDetailsTableTextBlock_088833c9-ef94-46d8-8a21-97f4e2916682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1126ede1-3354-4145-bb21-11c2e821de26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3c0f12a-6f90-427b-bf51-28415f260bed" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1126ede1-3354-4145-bb21-11c2e821de26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2486ee78-89b3-43ac-9586-8b213e9461b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2486ee78-89b3-43ac-9586-8b213e9461b6" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0757cc24-f603-43be-9f39-44b627f7403a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0757cc24-f603-43be-9f39-44b627f7403a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e2202bb-db36-4626-909e-4e957ac931f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0757cc24-f603-43be-9f39-44b627f7403a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e2202bb-db36-4626-909e-4e957ac931f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_738a4533-f0c2-4fdc-b543-0c3cbd3ba740" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e2202bb-db36-4626-909e-4e957ac931f2" xlink:to="loc_amed_CompassionateCareHospiceMember_738a4533-f0c2-4fdc-b543-0c3cbd3ba740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_7bf587bc-19b0-4130-8c09-9e6cc736f0e0" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e2202bb-db36-4626-909e-4e957ac931f2" xlink:to="loc_amed_AseraCareHospiceMember_7bf587bc-19b0-4130-8c09-9e6cc736f0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ad28042d-fbdb-4177-a0e6-fc3e32b60eb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ad28042d-fbdb-4177-a0e6-fc3e32b60eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fc5efd1f-8e80-4e88-a381-4fde9d4a13d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ad28042d-fbdb-4177-a0e6-fc3e32b60eb7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fc5efd1f-8e80-4e88-a381-4fde9d4a13d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_dea7853d-52cc-4d61-9f90-06e5eb0fa7f0" xlink:href="amed-20210930.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fc5efd1f-8e80-4e88-a381-4fde9d4a13d4" xlink:to="loc_amed_MedicareRevenueMember_dea7853d-52cc-4d61-9f90-06e5eb0fa7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_a758637e-522e-4f93-8516-2b1a2f90cfac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_fc5efd1f-8e80-4e88-a381-4fde9d4a13d4" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_a758637e-522e-4f93-8516-2b1a2f90cfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dcd18365-e54f-4271-beb5-7c9e843c346f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dcd18365-e54f-4271-beb5-7c9e843c346f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_49aadc44-c44d-4b02-a1ca-fc319cde4fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dcd18365-e54f-4271-beb5-7c9e843c346f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_49aadc44-c44d-4b02-a1ca-fc319cde4fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_d5f95fc2-0c24-473e-8568-b4aaf87a344f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_49aadc44-c44d-4b02-a1ca-fc319cde4fef" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_d5f95fc2-0c24-473e-8568-b4aaf87a344f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearAxis_f18fd3c9-5199-4e34-8d9e-a1ecd627e38d" xlink:href="amed-20210930.xsd#amed_CapYearAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_amed_CapYearAxis_f18fd3c9-5199-4e34-8d9e-a1ecd627e38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearDomain_54843d14-723a-4551-808b-c72c84457555" xlink:href="amed-20210930.xsd#amed_CapYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearAxis_f18fd3c9-5199-4e34-8d9e-a1ecd627e38d" xlink:to="loc_amed_CapYearDomain_54843d14-723a-4551-808b-c72c84457555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_3dd1e950-9aad-4d31-bd49-c0ed727dbb34" xlink:href="amed-20210930.xsd#amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_54843d14-723a-4551-808b-c72c84457555" xlink:to="loc_amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember_3dd1e950-9aad-4d31-bd49-c0ed727dbb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_50b0fab3-e268-4c14-a1c5-8895c7933ad2" xlink:href="amed-20210930.xsd#amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_CapYearDomain_54843d14-723a-4551-808b-c72c84457555" xlink:to="loc_amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember_50b0fab3-e268-4c14-a1c5-8895c7933ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c5e1c562-deb7-4389-b895-b25dc46788fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c5e1c562-deb7-4389-b895-b25dc46788fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c5e1c562-deb7-4389-b895-b25dc46788fc" xlink:to="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_317d3f5b-fe3b-4604-b7f2-4a2f9ce9a44d" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:to="loc_amed_HomeHealthMember_317d3f5b-fe3b-4604-b7f2-4a2f9ce9a44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_75e1c80f-8b31-47c2-9778-135f721ac6d8" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:to="loc_amed_HospiceMember_75e1c80f-8b31-47c2-9778-135f721ac6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_cebbf484-0fc2-44ec-8b41-77c02e17c01b" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ae067478-48a4-4deb-a54f-5d3750eefa70" xlink:to="loc_amed_HighAcuityCareMember_cebbf484-0fc2-44ec-8b41-77c02e17c01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba0db8ed-218d-4b0f-a56a-bb981b15074f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_srt_RangeAxis_ba0db8ed-218d-4b0f-a56a-bb981b15074f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0e93d82-5921-4b44-9560-4547f7a989e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ba0db8ed-218d-4b0f-a56a-bb981b15074f" xlink:to="loc_srt_RangeMember_e0e93d82-5921-4b44-9560-4547f7a989e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ff2e3752-1119-4234-8eba-8a67244757fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0e93d82-5921-4b44-9560-4547f7a989e6" xlink:to="loc_srt_MinimumMember_ff2e3752-1119-4234-8eba-8a67244757fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_df6cc427-4860-4607-986b-3b456f985213" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0e93d82-5921-4b44-9560-4547f7a989e6" xlink:to="loc_srt_MaximumMember_df6cc427-4860-4607-986b-3b456f985213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_25fd731f-5d19-4ada-ae84-74b26757e5d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_srt_ProductOrServiceAxis_25fd731f-5d19-4ada-ae84-74b26757e5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92262a06-8298-4f60-849e-40c589b294a6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_25fd731f-5d19-4ada-ae84-74b26757e5d5" xlink:to="loc_srt_ProductsAndServicesDomain_92262a06-8298-4f60-849e-40c589b294a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareRevenueMember_998c6f75-9dc4-492e-9449-7bc49bb57e97" xlink:href="amed-20210930.xsd#amed_MedicareRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_92262a06-8298-4f60-849e-40c589b294a6" xlink:to="loc_amed_MedicareRevenueMember_998c6f75-9dc4-492e-9449-7bc49bb57e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_3d0428c3-36e9-4a09-b2f2-fcf42d9f82c1" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_dbef2e2d-c891-4b44-a3f8-9e952487c764" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_dbef2e2d-c891-4b44-a3f8-9e952487c764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_083c3357-4c8c-4603-974d-389fd93ec619" xlink:href="amed-20210930.xsd#amed_EpisodeOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_EpisodeOfCareAsEpisodicBasedRevenueDuration_083c3357-4c8c-4603-974d-389fd93ec619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_fc84d7ab-891c-4541-be3c-a6e740126e16" xlink:href="amed-20210930.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_fc84d7ab-891c-4541-be3c-a6e740126e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_990ee3d7-7fef-464c-ac31-8d63a25e8c6c" xlink:href="amed-20210930.xsd#amed_PeriodOfCareAsEpisodicBasedRevenueDuration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_PeriodOfCareAsEpisodicBasedRevenueDuration_990ee3d7-7fef-464c-ac31-8d63a25e8c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_7590a045-141b-4ec2-978e-0916b1698ab4" xlink:href="amed-20210930.xsd#amed_PercentageOfTotalReimbursementOfOutlierPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_PercentageOfTotalReimbursementOfOutlierPayment_7590a045-141b-4ec2-978e-0916b1698ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_49e8b11a-4ac8-4851-aab7-2d2581749308" xlink:href="amed-20210930.xsd#amed_LowUtilizationPaymentAdjustmentNumberOfVisits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_LowUtilizationPaymentAdjustmentNumberOfVisits_49e8b11a-4ac8-4851-aab7-2d2581749308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FirstThresholdOfTherapyServicesRequired_f925eb28-2735-42df-9b19-21a56b89e72d" xlink:href="amed-20210930.xsd#amed_FirstThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_FirstThresholdOfTherapyServicesRequired_f925eb28-2735-42df-9b19-21a56b89e72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondThresholdOfServicesRequired_ceeb56d8-accb-45bb-9a9e-cfb9376ae68a" xlink:href="amed-20210930.xsd#amed_SecondThresholdOfServicesRequired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_SecondThresholdOfServicesRequired_ceeb56d8-accb-45bb-9a9e-cfb9376ae68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ThirdThresholdOfTherapyServicesRequired_151b13ab-a039-45a5-9b9c-8dedcd1a6c26" xlink:href="amed-20210930.xsd#amed_ThirdThresholdOfTherapyServicesRequired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_ThirdThresholdOfTherapyServicesRequired_151b13ab-a039-45a5-9b9c-8dedcd1a6c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_515c37e6-692b-43cd-a9a6-b9f1ae1b7f24" xlink:href="amed-20210930.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_515c37e6-692b-43cd-a9a6-b9f1ae1b7f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonMedicareRevenueTermRates_3849fe92-5f0c-4817-976a-c659b04835e6" xlink:href="amed-20210930.xsd#amed_NonMedicareRevenueTermRates"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_NonMedicareRevenueTermRates_3849fe92-5f0c-4817-976a-c659b04835e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_15302a74-8b91-4b18-82bf-b1c792ab1d35" xlink:href="amed-20210930.xsd#amed_HospiceMedicareRevenueRateAccountedForRoutineCare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_HospiceMedicareRevenueRateAccountedForRoutineCare_15302a74-8b91-4b18-82bf-b1c792ab1d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1b537ffa-a564-4a23-b5ad-c244ef536fd7" xlink:href="amed-20210930.xsd#amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities_1b537ffa-a564-4a23-b5ad-c244ef536fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_1ddabd1c-780e-4c06-9d5c-215dc447f627" xlink:href="amed-20210930.xsd#amed_NetServiceRevenueEpisodePaymentRateDuration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_NetServiceRevenueEpisodePaymentRateDuration_1ddabd1c-780e-4c06-9d5c-215dc447f627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_6203af7e-7715-4b55-96e3-a59ac5b3d928" xlink:href="amed-20210930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_64339cba-8e08-4b13-be0e-1af548ff40ec" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_6203af7e-7715-4b55-96e3-a59ac5b3d928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_dea2f92f-93af-4387-949e-c66c239ee803" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_3654dfe6-7ff6-40b3-b4e7-10b379802c25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_dea2f92f-93af-4387-949e-c66c239ee803" xlink:to="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_3654dfe6-7ff6-40b3-b4e7-10b379802c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassAxis_b33bc8d4-1be7-4dc5-9abd-2ccb4683aa3b" xlink:href="amed-20210930.xsd#amed_PayorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_3654dfe6-7ff6-40b3-b4e7-10b379802c25" xlink:to="loc_amed_PayorClassAxis_b33bc8d4-1be7-4dc5-9abd-2ccb4683aa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:href="amed-20210930.xsd#amed_PayorClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassAxis_b33bc8d4-1be7-4dc5-9abd-2ccb4683aa3b" xlink:to="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMedicareMember_5f97d1e3-7842-47ec-84c5-c00f947a7e5d" xlink:href="amed-20210930.xsd#amed_HomeHealthMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HomeHealthMedicareMember_5f97d1e3-7842-47ec-84c5-c00f947a7e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_599fc591-d325-40b6-881e-7f9c5895042d" xlink:href="amed-20210930.xsd#amed_HomeHealthNonMedicareEpisodicBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HomeHealthNonMedicareEpisodicBasedMember_599fc591-d325-40b6-881e-7f9c5895042d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_cd3fb653-46c5-411f-8629-eb3d9aabd173" xlink:href="amed-20210930.xsd#amed_HomeHealthNonMedicareNonEpisodicBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HomeHealthNonMedicareNonEpisodicBasedMember_cd3fb653-46c5-411f-8629-eb3d9aabd173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMedicareMember_fe586654-0416-45e1-a691-75a8e48ed44c" xlink:href="amed-20210930.xsd#amed_HospiceMedicareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HospiceMedicareMember_fe586654-0416-45e1-a691-75a8e48ed44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceNonMedicareMember_76a047c6-44f6-434d-b205-85d766eb98fc" xlink:href="amed-20210930.xsd#amed_HospiceNonMedicareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HospiceNonMedicareMember_76a047c6-44f6-434d-b205-85d766eb98fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_4d267645-05c8-441d-af47-8477fb91be0b" xlink:href="amed-20210930.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_PersonalCareMember_4d267645-05c8-441d-af47-8477fb91be0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_45aa7c59-905f-4dd8-b60b-70a373818610" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorClassDomain_82e6fdcb-f877-40a9-8535-65fefd7c4f2c" xlink:to="loc_amed_HighAcuityCareMember_45aa7c59-905f-4dd8-b60b-70a373818610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_e0735fd3-5217-4d92-a27c-d2d46909145d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable_3654dfe6-7ff6-40b3-b4e7-10b379802c25" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_e0735fd3-5217-4d92-a27c-d2d46909145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_6bb5e96b-e954-47de-8a2b-4a7a807bd2e4" xlink:href="amed-20210930.xsd#amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_e0735fd3-5217-4d92-a27c-d2d46909145d" xlink:to="loc_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue_6bb5e96b-e954-47de-8a2b-4a7a807bd2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3b6cc297-6000-45f0-b31e-a864b2388814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b468f5e-eb67-455f-bcb3-fb0b3372873a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3b6cc297-6000-45f0-b31e-a864b2388814" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b468f5e-eb67-455f-bcb3-fb0b3372873a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_6141dd5f-6b05-4d98-8f93-1ffaa97964cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b468f5e-eb67-455f-bcb3-fb0b3372873a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_6141dd5f-6b05-4d98-8f93-1ffaa97964cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_6141dd5f-6b05-4d98-8f93-1ffaa97964cf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceAquisitionMember_6f10fe82-1776-42e6-87bb-69cdcb1473e3" xlink:href="amed-20210930.xsd#amed_AsanaHospiceAquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:to="loc_amed_AsanaHospiceAquisitionMember_6f10fe82-1776-42e6-87bb-69cdcb1473e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19PPEMember_4ddf974f-e7c7-48cf-9971-d952125d6b93" xlink:href="amed-20210930.xsd#amed_COVID19PPEMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:to="loc_amed_COVID19PPEMember_4ddf974f-e7c7-48cf-9971-d952125d6b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_081b8584-ddda-428a-a0b0-9e9167509f17" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_59e38422-6055-4973-9ecc-994b3826840e" xlink:to="loc_amed_AseraCareHospiceMember_081b8584-ddda-428a-a0b0-9e9167509f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_470de0ed-866d-4426-8a1d-0774d5e23bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b468f5e-eb67-455f-bcb3-fb0b3372873a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_470de0ed-866d-4426-8a1d-0774d5e23bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b283883-407f-4502-8207-8586a913ae84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_470de0ed-866d-4426-8a1d-0774d5e23bb0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b283883-407f-4502-8207-8586a913ae84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AsanaHospiceMember_8331050b-78b6-4996-8629-3ec9cd3442db" xlink:href="amed-20210930.xsd#amed_AsanaHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b283883-407f-4502-8207-8586a913ae84" xlink:to="loc_amed_AsanaHospiceMember_8331050b-78b6-4996-8629-3ec9cd3442db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VariousAcquisitionsMember_5ae2f9e8-4f9e-43cb-8cf8-48c5021e020c" xlink:href="amed-20210930.xsd#amed_VariousAcquisitionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8b283883-407f-4502-8207-8586a913ae84" xlink:to="loc_amed_VariousAcquisitionsMember_5ae2f9e8-4f9e-43cb-8cf8-48c5021e020c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b468f5e-eb67-455f-bcb3-fb0b3372873a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_879bf74f-d2e1-47dc-a54c-59fdf5f5a53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_879bf74f-d2e1-47dc-a54c-59fdf5f5a53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_fa26444e-d457-45a3-94d1-6703b40a1403" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:to="loc_us-gaap_RestrictedCash_fa26444e-d457-45a3-94d1-6703b40a1403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6ceb664-7f0f-4220-a385-6856172aed5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a6ceb664-7f0f-4220-a385-6856172aed5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CashBalanceAssociatedWithProviderReliefFund_47212a61-5579-491d-987c-364ecc81238d" xlink:href="amed-20210930.xsd#amed_CashBalanceAssociatedWithProviderReliefFund"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_d26b8744-7232-4454-9380-050652628cd1" xlink:to="loc_amed_CashBalanceAssociatedWithProviderReliefFund_47212a61-5579-491d-987c-364ecc81238d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5b8367b4-09c5-48a6-b7a4-6924986f26ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b8367b4-09c5-48a6-b7a4-6924986f26ee" xlink:to="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1235e8a1-49d9-4c32-ad33-f90c7bd00833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1235e8a1-49d9-4c32-ad33-f90c7bd00833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_70c14f60-4099-45aa-a84c-029fbdcf2ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1235e8a1-49d9-4c32-ad33-f90c7bd00833" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_70c14f60-4099-45aa-a84c-029fbdcf2ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b69800dc-2e95-4103-936e-df968d0146f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_70c14f60-4099-45aa-a84c-029fbdcf2ea2" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b69800dc-2e95-4103-936e-df968d0146f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64382a85-86df-414c-a187-a964320eaef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64382a85-86df-414c-a187-a964320eaef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4157c6ec-221f-427f-9677-467bb96ad40b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_64382a85-86df-414c-a187-a964320eaef2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4157c6ec-221f-427f-9677-467bb96ad40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_cda14f04-fb1d-4fd1-802b-4d2e9797c70b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_4157c6ec-221f-427f-9677-467bb96ad40b" xlink:to="loc_us-gaap_AccountsReceivableMember_cda14f04-fb1d-4fd1-802b-4d2e9797c70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a446c557-2bb4-4ff8-ac08-e2d1ed713761" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:to="loc_srt_MajorCustomersAxis_a446c557-2bb4-4ff8-ac08-e2d1ed713761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ef6c81b4-ab56-4b67-8b3e-66261625afd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a446c557-2bb4-4ff8-ac08-e2d1ed713761" xlink:to="loc_srt_NameOfMajorCustomerDomain_ef6c81b4-ab56-4b67-8b3e-66261625afd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MajorSinglePayorCustomerMember_deaaa530-4d8e-4b16-8d92-81794c34ee89" xlink:href="amed-20210930.xsd#amed_MajorSinglePayorCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_ef6c81b4-ab56-4b67-8b3e-66261625afd5" xlink:to="loc_amed_MajorSinglePayorCustomerMember_deaaa530-4d8e-4b16-8d92-81794c34ee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6d985f40-7976-4f2f-8ba4-752982a2b368" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6d985f40-7976-4f2f-8ba4-752982a2b368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86a3e98f-6338-43eb-97e4-4f3c997fd939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6d985f40-7976-4f2f-8ba4-752982a2b368" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86a3e98f-6338-43eb-97e4-4f3c997fd939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_5eb2676e-a8b0-4e86-9cab-2575b97cf8b8" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86a3e98f-6338-43eb-97e4-4f3c997fd939" xlink:to="loc_amed_CompassionateCareHospiceMember_5eb2676e-a8b0-4e86-9cab-2575b97cf8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_979a1fd9-b519-45b7-a1b8-b98ece72a4d1" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AccountsReceivablePortionDerivedFromMedicare_b185f6e8-dd1d-47dd-bea8-a4045d63708c" xlink:href="amed-20210930.xsd#amed_AccountsReceivablePortionDerivedFromMedicare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:to="loc_amed_AccountsReceivablePortionDerivedFromMedicare_b185f6e8-dd1d-47dd-bea8-a4045d63708c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d48b757b-4f39-4c63-8c2b-31d832bf5077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d48b757b-4f39-4c63-8c2b-31d832bf5077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_3d9db12c-0f45-46bd-9480-bdaf3420b23b" xlink:href="amed-20210930.xsd#amed_NetServiceRevenuePeriodOfCarePaymentRateDuration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_5b20d1c3-ce47-4d71-857f-473a84c2d1de" xlink:to="loc_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration_3d9db12c-0f45-46bd-9480-bdaf3420b23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfPatientReceivablesOutstanding_bd6a037d-25ac-4cca-9b6f-e719f411ecd6" xlink:href="amed-20210930.xsd#amed_PercentageOfPatientReceivablesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b8367b4-09c5-48a6-b7a4-6924986f26ee" xlink:to="loc_amed_PercentageOfPatientReceivablesOutstanding_bd6a037d-25ac-4cca-9b6f-e719f411ecd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HistoricalCollectionRateFromMedicare_53941cef-6428-4c16-90e6-cfb25b2afed8" xlink:href="amed-20210930.xsd#amed_HistoricalCollectionRateFromMedicare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b8367b4-09c5-48a6-b7a4-6924986f26ee" xlink:to="loc_amed_HistoricalCollectionRateFromMedicare_53941cef-6428-4c16-90e6-cfb25b2afed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevenueAdjustmentToMedicareRevenue_ed847c21-d526-4364-b5ed-d18cfe5ea427" xlink:href="amed-20210930.xsd#amed_RevenueAdjustmentToMedicareRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b8367b4-09c5-48a6-b7a4-6924986f26ee" xlink:to="loc_amed_RevenueAdjustmentToMedicareRevenue_ed847c21-d526-4364-b5ed-d18cfe5ea427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_4ae48a7a-fe1f-433c-958e-7fbcfc87755f" xlink:href="amed-20210930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b8367b4-09c5-48a6-b7a4-6924986f26ee" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare_4ae48a7a-fe1f-433c-958e-7fbcfc87755f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_95767a06-21f7-4c1d-a542-5c126b7abae2" xlink:href="amed-20210930.xsd#amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b8367b4-09c5-48a6-b7a4-6924986f26ee" xlink:to="loc_amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare_95767a06-21f7-4c1d-a542-5c126b7abae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_4b176ac0-4a99-463b-af75-3a2b7189738f" xlink:href="amed-20210930.xsd#amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b8367b4-09c5-48a6-b7a4-6924986f26ee" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare_4b176ac0-4a99-463b-af75-3a2b7189738f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_97ad6edf-757e-4ae1-a1fa-982e911dfe4c" xlink:href="amed-20210930.xsd#amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b8367b4-09c5-48a6-b7a4-6924986f26ee" xlink:to="loc_amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid_97ad6edf-757e-4ae1-a1fa-982e911dfe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ff6d3ef2-f381-49ff-b651-3a3f8e89f13f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f2a9f9d-3d47-4f17-b342-4a7f092e4f6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ff6d3ef2-f381-49ff-b651-3a3f8e89f13f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f2a9f9d-3d47-4f17-b342-4a7f092e4f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92a3329d-5f77-4a2c-9e3e-86c593b06265" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f2a9f9d-3d47-4f17-b342-4a7f092e4f6a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92a3329d-5f77-4a2c-9e3e-86c593b06265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92a3329d-5f77-4a2c-9e3e-86c593b06265" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_07a72e57-4bfa-4cc4-9ef6-cda67c7cf0fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_07a72e57-4bfa-4cc4-9ef6-cda67c7cf0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e4c4bb67-b82a-4887-ad30-c193d7cb3f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e4c4bb67-b82a-4887-ad30-c193d7cb3f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2ca9fb3e-6b4e-41ff-976b-d41bcc87bdd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fcc43c87-bb2c-46d5-a9e1-267819a80911" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2ca9fb3e-6b4e-41ff-976b-d41bcc87bdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7de7869c-f125-45a2-b25b-d04c6b558cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7f2a9f9d-3d47-4f17-b342-4a7f092e4f6a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7de7869c-f125-45a2-b25b-d04c6b558cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_ce3d7898-31cd-440b-a95d-19c861912842" xlink:href="amed-20210930.xsd#amed_DebtInstrumentCarryingAmountExcludingFinanceLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7de7869c-f125-45a2-b25b-d04c6b558cd0" xlink:to="loc_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases_ce3d7898-31cd-440b-a95d-19c861912842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_5b80e859-b0d6-427e-95c4-8c58c4ebc177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7de7869c-f125-45a2-b25b-d04c6b558cd0" xlink:to="loc_us-gaap_LongTermDebtFairValue_5b80e859-b0d6-427e-95c4-8c58c4ebc177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cf2d3f64-f136-488a-831d-4be58a91f3df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4971e55e-d8b3-4fb7-927f-fe81d22ea2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf2d3f64-f136-488a-831d-4be58a91f3df" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4971e55e-d8b3-4fb7-927f-fe81d22ea2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_aea97696-b5a3-4177-8597-e0d3a51f55dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf2d3f64-f136-488a-831d-4be58a91f3df" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_aea97696-b5a3-4177-8597-e0d3a51f55dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_54247c7c-586b-4a03-80dc-90a60d59f402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_aea97696-b5a3-4177-8597-e0d3a51f55dd" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_54247c7c-586b-4a03-80dc-90a60d59f402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NonVestedStockAndStockUnits_96f143a7-dc20-4f51-8bfd-c6dad2e8f98e" xlink:href="amed-20210930.xsd#amed_NonVestedStockAndStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_aea97696-b5a3-4177-8597-e0d3a51f55dd" xlink:to="loc_amed_NonVestedStockAndStockUnits_96f143a7-dc20-4f51-8bfd-c6dad2e8f98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d767d1e-ff3a-466e-99ef-43f294c61a93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf2d3f64-f136-488a-831d-4be58a91f3df" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6d767d1e-ff3a-466e-99ef-43f294c61a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_42060fe0-283b-4505-9a61-0c1e3d0868c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf2d3f64-f136-488a-831d-4be58a91f3df" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_42060fe0-283b-4505-9a61-0c1e3d0868c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="simple" xlink:href="amed-20210930.xsd#NOVELCORONAVIRUSPANDEMICCOVID19"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_c65ec838-e097-4af0-a126-16a5bd2d8fff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19TextBlock_61a0e613-c2c2-411e-82cc-cc44491536ce" xlink:href="amed-20210930.xsd#amed_COVID19TextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_c65ec838-e097-4af0-a126-16a5bd2d8fff" xlink:to="loc_amed_COVID19TextBlock_61a0e613-c2c2-411e-82cc-cc44491536ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="simple" xlink:href="amed-20210930.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Tables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_7f078ae0-f362-4748-9219-fbb389916dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_b2d4cdd5-43e5-41c8-ad39-d671b5d48615" xlink:href="amed-20210930.xsd#amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_7f078ae0-f362-4748-9219-fbb389916dc4" xlink:to="loc_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock_b2d4cdd5-43e5-41c8-ad39-d671b5d48615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="simple" xlink:href="amed-20210930.xsd#NOVELCORONAVIRUSPANDEMICCOVID19Details"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_c040ce1f-b3b9-47bd-8aaf-460484e17312" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_c040ce1f-b3b9-47bd-8aaf-460484e17312" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_954b78df-69dd-4129-8c9f-ce87d861b001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_954b78df-69dd-4129-8c9f-ce87d861b001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b9946e10-016d-4ae7-83f5-995cbf32957f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_954b78df-69dd-4129-8c9f-ce87d861b001" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b9946e10-016d-4ae7-83f5-995cbf32957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_869654e1-1f04-494c-a2eb-e0077e5c81f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_b9946e10-016d-4ae7-83f5-995cbf32957f" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_869654e1-1f04-494c-a2eb-e0077e5c81f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_68d0111e-c3b2-44da-9619-a7e8dcc0ccbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_68d0111e-c3b2-44da-9619-a7e8dcc0ccbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fe5f7d3-4b8d-416d-b739-3914b6cf46f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_68d0111e-c3b2-44da-9619-a7e8dcc0ccbb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fe5f7d3-4b8d-416d-b739-3914b6cf46f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_bb70cf7b-d20f-4b14-8ba6-1bc9c3abbb64" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6fe5f7d3-4b8d-416d-b739-3914b6cf46f1" xlink:to="loc_amed_AseraCareHospiceMember_bb70cf7b-d20f-4b14-8ba6-1bc9c3abbb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_eec97b04-8703-4798-89bc-51c227ac2e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_eec97b04-8703-4798-89bc-51c227ac2e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_eec97b04-8703-4798-89bc-51c227ac2e3b" xlink:to="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_32053290-77af-4267-a966-21801179ee06" xlink:href="amed-20210930.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:to="loc_amed_HomeHealthAndHospiceMember_32053290-77af-4267-a966-21801179ee06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_0c02cfb7-9345-4b8c-ab70-131c48e25ad0" xlink:href="amed-20210930.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:to="loc_amed_PersonalCareMember_0c02cfb7-9345-4b8c-ab70-131c48e25ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_3d228abb-25a4-4ac5-8198-a42b6a4e8a16" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_722fd0b1-f80a-4c61-80cb-f5c909e46ddf" xlink:to="loc_amed_HomeHealthMember_3d228abb-25a4-4ac5-8198-a42b6a4e8a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_8227de49-6996-433c-9f54-e707d56bd56a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_8227de49-6996-433c-9f54-e707d56bd56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_c3d20a71-ceed-42dc-85ae-56f8549d6378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_8227de49-6996-433c-9f54-e707d56bd56a" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_c3d20a71-ceed-42dc-85ae-56f8549d6378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19DeferralOfSocialSecurityMember_6acddc6f-3189-4dc5-aa83-d23e70cc2df9" xlink:href="amed-20210930.xsd#amed_COVID19DeferralOfSocialSecurityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_c3d20a71-ceed-42dc-85ae-56f8549d6378" xlink:to="loc_amed_COVID19DeferralOfSocialSecurityMember_6acddc6f-3189-4dc5-aa83-d23e70cc2df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_82218067-c3f1-49e1-97a9-cd97f3d9b5ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_82218067-c3f1-49e1-97a9-cd97f3d9b5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_152858bf-dc05-4cfd-b354-d388bdceb6bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_82218067-c3f1-49e1-97a9-cd97f3d9b5ca" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_152858bf-dc05-4cfd-b354-d388bdceb6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_186c8370-0990-4fe2-9583-d63f3c2bf3da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_152858bf-dc05-4cfd-b354-d388bdceb6bd" xlink:to="loc_us-gaap_SubsequentEventMember_186c8370-0990-4fe2-9583-d63f3c2bf3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_1fbdeec0-698b-4228-98d5-af98eb9299f4" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingForHealthcareProvidersIncludingHospitals_cb2bb0e5-ba1f-4610-af2f-3df7f295f19a" xlink:href="amed-20210930.xsd#amed_FundingForHealthcareProvidersIncludingHospitals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_FundingForHealthcareProvidersIncludingHospitals_cb2bb0e5-ba1f-4610-af2f-3df7f295f19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_bc2090fc-c4b9-492b-b7df-4ac52feded52" xlink:href="amed-20210930.xsd#amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements_bc2090fc-c4b9-492b-b7df-4ac52feded52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromCARESAct_24e609c6-0bd1-46a6-9779-bf0d712cdace" xlink:href="amed-20210930.xsd#amed_FundingReceivedFromCARESAct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_FundingReceivedFromCARESAct_24e609c6-0bd1-46a6-9779-bf0d712cdace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProviderReliefFundAdvance_1e61d069-f627-4711-8534-1e8681913871" xlink:href="amed-20210930.xsd#amed_ProviderReliefFundAdvance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_ProviderReliefFundAdvance_1e61d069-f627-4711-8534-1e8681913871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AdditionalFundingDistributedToHealthcareProviders_0c7096fb-23b3-47be-97e8-ea25bb939e60" xlink:href="amed-20210930.xsd#amed_AdditionalFundingDistributedToHealthcareProviders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_AdditionalFundingDistributedToHealthcareProviders_0c7096fb-23b3-47be-97e8-ea25bb939e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_edfc3315-d023-4788-8107-888e053ffd86" xlink:href="amed-20210930.xsd#amed_CARESActDeferralOfEmployerShareSocialSecurityTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_CARESActDeferralOfEmployerShareSocialSecurityTax_edfc3315-d023-4788-8107-888e053ffd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedFutureCOVID19RelatedExpenses_f1b8674e-7628-44ae-ae60-9dd87ef12b1d" xlink:href="amed-20210930.xsd#amed_EstimatedFutureCOVID19RelatedExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_EstimatedFutureCOVID19RelatedExpenses_f1b8674e-7628-44ae-ae60-9dd87ef12b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_COVID19ExpensesIncurred_8e60aaa5-86a7-41f4-a9ca-389312168e29" xlink:href="amed-20210930.xsd#amed_COVID19ExpensesIncurred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_COVID19ExpensesIncurred_8e60aaa5-86a7-41f4-a9ca-389312168e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilized_fa268fa4-d0d6-4f20-88cb-015327938662" xlink:href="amed-20210930.xsd#amed_CARESActProviderReliefFundsUtilized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_CARESActProviderReliefFundsUtilized_fa268fa4-d0d6-4f20-88cb-015327938662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_cf735726-e20e-40d5-a546-e6f7a31d8931" xlink:href="amed-20210930.xsd#amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures_cf735726-e20e-40d5-a546-e6f7a31d8931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_99e3d0c1-e6cc-4403-bed9-63fd3e8f59f8" xlink:href="amed-20210930.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid_99e3d0c1-e6cc-4403-bed9-63fd3e8f59f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures_3c565926-0ef1-465b-bc35-190f909d29ac" xlink:href="amed-20210930.xsd#amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures_3c565926-0ef1-465b-bc35-190f909d29ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalCARESActProviderReliefFundsReceived_189d790b-f727-4eb9-93f6-9fa73e6a3011" xlink:href="amed-20210930.xsd#amed_TotalCARESActProviderReliefFundsReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_TotalCARESActProviderReliefFundsReceived_189d790b-f727-4eb9-93f6-9fa73e6a3011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CARESActInterestToBeRepaidToGovernment_74c03b44-bf9f-41a9-8fc0-a1591d56ca6f" xlink:href="amed-20210930.xsd#amed_CARESActInterestToBeRepaidToGovernment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_CARESActInterestToBeRepaidToGovernment_74c03b44-bf9f-41a9-8fc0-a1591d56ca6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_f9b552fe-8be0-492f-8304-0f3468950750" xlink:href="amed-20210930.xsd#amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram_f9b552fe-8be0-492f-8304-0f3468950750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_cd50c19e-835e-4fa3-9078-13be1c87aff4" xlink:href="amed-20210930.xsd#amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses_cd50c19e-835e-4fa3-9078-13be1c87aff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ff366867-403b-4850-9ba2-ecf409f3a399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ff366867-403b-4850-9ba2-ecf409f3a399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3f62efe6-8f03-4a49-a64b-ea346450b677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3f62efe6-8f03-4a49-a64b-ea346450b677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_b3399d93-9365-4c36-88a3-15fd6efa1a79" xlink:href="amed-20210930.xsd#amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact_b3399d93-9365-4c36-88a3-15fd6efa1a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_63e5de70-eb73-4e70-82d9-5b6d140c906d" xlink:href="amed-20210930.xsd#amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_dd2355a5-1331-4f4a-821f-65eef120616e" xlink:to="loc_amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized_63e5de70-eb73-4e70-82d9-5b6d140c906d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="simple" xlink:href="amed-20210930.xsd#ACQUISITIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_cab49152-d86a-4425-adeb-fbfa036a2565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_347e9c1c-e869-43a5-97fd-5ba6d8269de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_cab49152-d86a-4425-adeb-fbfa036a2565" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_347e9c1c-e869-43a5-97fd-5ba6d8269de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="simple" xlink:href="amed-20210930.xsd#ACQUISITIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3e9ee65a-2d5b-47bb-b4d7-57cedb183072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_c3f34343-ab9b-4d75-be75-8060d90e602a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3e9ee65a-2d5b-47bb-b4d7-57cedb183072" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_c3f34343-ab9b-4d75-be75-8060d90e602a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_dc24eb7e-ce7d-4e43-abab-efc1f2557823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3e9ee65a-2d5b-47bb-b4d7-57cedb183072" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_dc24eb7e-ce7d-4e43-abab-efc1f2557823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_d2f90705-43b7-4129-a3bf-52e137934df8" xlink:href="amed-20210930.xsd#amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3e9ee65a-2d5b-47bb-b4d7-57cedb183072" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock_d2f90705-43b7-4129-a3bf-52e137934df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_e311e3ee-6eb6-43da-88e2-2500e9c3ad56" xlink:href="amed-20210930.xsd#amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3e9ee65a-2d5b-47bb-b4d7-57cedb183072" xlink:to="loc_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock_e311e3ee-6eb6-43da-88e2-2500e9c3ad56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#ACQUISITIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8162fe17-f4c0-46ae-81f5-79799ae4152e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8162fe17-f4c0-46ae-81f5-79799ae4152e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a7f56dea-6dc0-445c-94eb-3980bc222d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a7f56dea-6dc0-445c-94eb-3980bc222d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a7f56dea-6dc0-445c-94eb-3980bc222d71" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_60d89311-4d29-4271-bf14-3d465a734915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_TradeNamesMember_60d89311-4d29-4271-bf14-3d465a734915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_055154ab-6396-47f1-9c15-ab5957d0e428" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_055154ab-6396-47f1-9c15-ab5957d0e428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AcquiredNamesMember_988b0194-a439-4b07-8aa0-1b7a32f84a3c" xlink:href="amed-20210930.xsd#amed_AcquiredNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_amed_AcquiredNamesMember_988b0194-a439-4b07-8aa0-1b7a32f84a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketFavorableLeaseMember_6cc97087-9303-4c37-8c2b-1838c829aa0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketFavorableLeaseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_OffMarketFavorableLeaseMember_6cc97087-9303-4c37-8c2b-1838c829aa0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_6808b2cb-70ea-4eca-9337-8618ebab8fc8" xlink:href="amed-20210930.xsd#amed_MedicareLicenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_amed_MedicareLicenseMember_6808b2cb-70ea-4eca-9337-8618ebab8fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_43b9b819-6058-4cb3-a9e2-110486f9ee48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_BusinessAcquisitionNameOfAcquiredEntity_43b9b819-6058-4cb3-a9e2-110486f9ee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificatesOfNeedMember_bd8cbd06-b51b-4b46-80a7-204a3382a91b" xlink:href="amed-20210930.xsd#amed_CertificatesOfNeedMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_amed_CertificatesOfNeedMember_bd8cbd06-b51b-4b46-80a7-204a3382a91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_2ab79e46-3f59-43c6-bf91-faf38625c01b" xlink:href="amed-20210930.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_amed_CertificateOfNeedMember_2ab79e46-3f59-43c6-bf91-faf38625c01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1befb204-ee54-492e-b97a-beaef5c745f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b5bca28-6f37-4f1f-8c42-d5d964579c03" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_1befb204-ee54-492e-b97a-beaef5c745f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_73405276-3af4-42be-8c74-6fc90bd4031f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_srt_StatementGeographicalAxis_73405276-3af4-42be-8c74-6fc90bd4031f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_73405276-3af4-42be-8c74-6fc90bd4031f" xlink:to="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TN_61ded15a-580f-472e-9812-b3a327e1c2c6" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_TN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_TN_61ded15a-580f-472e-9812-b3a327e1c2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_708a278e-676b-49b9-935b-3d96935a6252" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_WA_708a278e-676b-49b9-935b-3d96935a6252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_KY_50c87771-4a6f-4da7-abff-8ded1dcced48" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_KY"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_KY_50c87771-4a6f-4da7-abff-8ded1dcced48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_50c628ee-26e4-4fad-882e-4ef398f5756f" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_NC_50c628ee-26e4-4fad-882e-4ef398f5756f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_de6387a3-d7a0-452d-ad61-2d0fc3e12196" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NY"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e38464a5-db81-43a1-a50b-935390390196" xlink:to="loc_stpr_NY_de6387a3-d7a0-452d-ad61-2d0fc3e12196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5f4bc145-a115-47b3-a695-1ffc062e9958" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5f4bc145-a115-47b3-a695-1ffc062e9958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5f4bc145-a115-47b3-a695-1ffc062e9958" xlink:to="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_3ffe850b-91d9-4f19-b48e-7f9f6b0f4a77" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:to="loc_amed_HospiceMember_3ffe850b-91d9-4f19-b48e-7f9f6b0f4a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_54a81426-7682-43c8-b0b2-f64a81c0840e" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:to="loc_amed_HomeHealthMember_54a81426-7682-43c8-b0b2-f64a81c0840e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthAndHospiceMember_2fea487a-c181-4709-8fda-5bdfbc94c6ac" xlink:href="amed-20210930.xsd#amed_HomeHealthAndHospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:to="loc_amed_HomeHealthAndHospiceMember_2fea487a-c181-4709-8fda-5bdfbc94c6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_67bec74b-5b11-43ee-b119-a9cf0dd91063" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b4c1f1b1-55d3-4173-bc08-1e8b9c5b7dd3" xlink:to="loc_amed_HighAcuityCareMember_67bec74b-5b11-43ee-b119-a9cf0dd91063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5dfe2e23-a311-4aca-a1ce-354013ebc407" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5dfe2e23-a311-4aca-a1ce-354013ebc407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5dfe2e23-a311-4aca-a1ce-354013ebc407" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_VisitingNurseAssociationMember_68053867-af2c-44db-9cae-816aa642b08a" xlink:href="amed-20210930.xsd#amed_VisitingNurseAssociationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:to="loc_amed_VisitingNurseAssociationMember_68053867-af2c-44db-9cae-816aa642b08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ContessaHealthMember_760c9d8d-21fa-4ec0-a4cd-94b9eafaa4ce" xlink:href="amed-20210930.xsd#amed_ContessaHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:to="loc_amed_ContessaHealthMember_760c9d8d-21fa-4ec0-a4cd-94b9eafaa4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_e9ae1a7e-a9a3-4e1b-8a73-84ab16fedfa1" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_de329346-d28a-45f9-8985-75173d990423" xlink:to="loc_amed_AseraCareHospiceMember_e9ae1a7e-a9a3-4e1b-8a73-84ab16fedfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_38c46430-ef83-4bf3-a4e0-011990ff42ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_38c46430-ef83-4bf3-a4e0-011990ff42ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_885518d0-e597-4148-9a8d-18cf710ecf0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_38c46430-ef83-4bf3-a4e0-011990ff42ee" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_885518d0-e597-4148-9a8d-18cf710ecf0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CertificateOfNeedMember_4a001548-90ff-4610-be40-e34d9e6666d0" xlink:href="amed-20210930.xsd#amed_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_885518d0-e597-4148-9a8d-18cf710ecf0d" xlink:to="loc_amed_CertificateOfNeedMember_4a001548-90ff-4610-be40-e34d9e6666d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedicareLicenseMember_ab4de152-1d6b-427b-bb79-95418d371283" xlink:href="amed-20210930.xsd#amed_MedicareLicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_885518d0-e597-4148-9a8d-18cf710ecf0d" xlink:to="loc_amed_MedicareLicenseMember_ab4de152-1d6b-427b-bb79-95418d371283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3ef46599-9f90-4359-83ba-3fc60b3b1c8d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_srt_RangeAxis_3ef46599-9f90-4359-83ba-3fc60b3b1c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3d2f0f2-b7bd-46a2-af40-3b057123f58f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3ef46599-9f90-4359-83ba-3fc60b3b1c8d" xlink:to="loc_srt_RangeMember_f3d2f0f2-b7bd-46a2-af40-3b057123f58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b81a9bf8-955c-472b-a306-845c1f5397f8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f3d2f0f2-b7bd-46a2-af40-3b057123f58f" xlink:to="loc_srt_MaximumMember_b81a9bf8-955c-472b-a306-845c1f5397f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_10b2a44a-94f6-46c1-a6de-efbc04684f08" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_471e2e8c-4ceb-4891-8ffa-45852c29b9d3" xlink:href="amed-20210930.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_PercentageofSharesOutstanding_471e2e8c-4ceb-4891-8ffa-45852c29b9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c0f7a276-1550-4cec-a870-1eb24b12982e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c0f7a276-1550-4cec-a870-1eb24b12982e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_b510d102-7859-4a01-9b4e-a9e07e0e069f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_b510d102-7859-4a01-9b4e-a9e07e0e069f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_9a2e944a-bb1f-47c8-9555-2782d078b409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_9a2e944a-bb1f-47c8-9555-2782d078b409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_59b77ddf-ea2f-40a6-8c6d-a6de9932ee62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_59b77ddf-ea2f-40a6-8c6d-a6de9932ee62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PaymentsRelatedToTaxAsset_6a8e2cfd-9a5d-4502-bb0f-2a80a641e029" xlink:href="amed-20210930.xsd#amed_PaymentsRelatedToTaxAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_PaymentsRelatedToTaxAsset_6a8e2cfd-9a5d-4502-bb0f-2a80a641e029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1a7617d8-c57c-42a5-ac9c-c8efa510c2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1a7617d8-c57c-42a5-ac9c-c8efa510c2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_b66360b4-e87d-47ea-b7a4-f09d04e044b8" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense_b66360b4-e87d-47ea-b7a4-f09d04e044b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_729253b0-773a-41b5-bb57-de8f18f2105b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_729253b0-773a-41b5-bb57-de8f18f2105b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_cd866a38-1a90-45a2-9f7e-623816eed88a" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset_cd866a38-1a90-45a2-9f7e-623816eed88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_19432ee0-203f-428b-b167-e907856b4673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_19432ee0-203f-428b-b167-e907856b4673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_38ba3de0-2210-4aa0-a77b-0e84af6accc0" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets_38ba3de0-2210-4aa0-a77b-0e84af6accc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7db90f5b-4454-4758-93a2-50b477786373" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_7db90f5b-4454-4758-93a2-50b477786373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a74fe651-c159-4499-9f30-04b947164253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_a74fe651-c159-4499-9f30-04b947164253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_57bf3201-80cd-49f8-9a09-342c654c1a47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_57bf3201-80cd-49f8-9a09-342c654c1a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b0d660e1-48d7-4fc1-b9c4-917d710976f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b0d660e1-48d7-4fc1-b9c4-917d710976f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_3691d5bc-ebac-4460-adaf-cd5c98756da9" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits_3691d5bc-ebac-4460-adaf-cd5c98756da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_c7cc672b-3557-4af1-8e24-00bf11771036" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_c7cc672b-3557-4af1-8e24-00bf11771036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_636bb75e-5156-4239-a68d-f481e761c04f" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities_636bb75e-5156-4239-a68d-f481e761c04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d1333c7a-f550-4419-8277-34a26c6a50ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_d1333c7a-f550-4419-8277-34a26c6a50ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_e6aa059c-fb39-4d52-9900-8f996126d052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt_e6aa059c-fb39-4d52-9900-8f996126d052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_2114948f-a170-4d0a-abed-81ffd6b7126e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_2114948f-a170-4d0a-abed-81ffd6b7126e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c5f6f138-6462-4f1a-ac33-8093901b41b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_c5f6f138-6462-4f1a-ac33-8093901b41b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1b734833-3deb-4fcc-889b-c638e3d4a53d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_1b734833-3deb-4fcc-889b-c638e3d4a53d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_853d294f-ec87-4337-b260-2d83685036ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_853d294f-ec87-4337-b260-2d83685036ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_66a7e20e-381a-44ab-b97a-0af961da5058" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity_66a7e20e-381a-44ab-b97a-0af961da5058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_93123daa-7792-4f7e-9507-216ba6dd169e" xlink:href="amed-20210930.xsd#amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity_93123daa-7792-4f7e-9507-216ba6dd169e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_74a5c91b-c9a2-4d68-8d69-c86491d2ae50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_74a5c91b-c9a2-4d68-8d69-c86491d2ae50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_cb9cd570-22ef-4e2a-af26-d77d6c811bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_cb9cd570-22ef-4e2a-af26-d77d6c811bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fd4c7204-b491-4331-97f6-b5e5e9c343e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_fd4c7204-b491-4331-97f6-b5e5e9c343e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_6a83f87a-a921-4daa-9489-3f530f408603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_6a83f87a-a921-4daa-9489-3f530f408603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d3f6128a-1ad9-4e30-8027-efc1c0e99c68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_OperatingIncomeLoss_d3f6128a-1ad9-4e30-8027-efc1c0e99c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_3ec78a3f-38c6-4788-a59c-a00fbd9b924a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_3ec78a3f-38c6-4788-a59c-a00fbd9b924a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_0448d791-98e1-4b73-8038-bb92d077ca55" xlink:href="amed-20210930.xsd#amed_BusinessAcquisitionWorkingCapitalAdjustment"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessAcquisitionWorkingCapitalAdjustment_0448d791-98e1-4b73-8038-bb92d077ca55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OffMarketLeaseUnfavorable_78ad0cbd-cc26-4c01-8df6-dcf6b0241f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OffMarketLeaseUnfavorable"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_us-gaap_OffMarketLeaseUnfavorable_78ad0cbd-cc26-4c01-8df6-dcf6b0241f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_d81e91fa-91ca-439a-bd98-aa619ffacde0" xlink:href="amed-20210930.xsd#amed_BusinessAcquisitionClosingPaymentAdjustment"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_BusinessAcquisitionClosingPaymentAdjustment_d81e91fa-91ca-439a-bd98-aa619ffacde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DepreciationAndAmortizationForContinuingOperations_63275c56-32e3-4535-9484-14c1d40b8a1c" xlink:href="amed-20210930.xsd#amed_DepreciationAndAmortizationForContinuingOperations"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_DepreciationAndAmortizationForContinuingOperations_63275c56-32e3-4535-9484-14c1d40b8a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_aea5967a-fbb4-4cc2-9a75-1aecd515cb66" xlink:href="amed-20210930.xsd#amed_GoodwillDeductibleForIncomeTaxPurposesPeriod"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_50cab673-b349-4ed5-8627-c6e1106bcf83" xlink:to="loc_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod_aea5967a-fbb4-4cc2-9a75-1aecd515cb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#ACQUISITIONSProFormaDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/ACQUISITIONSProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_36f8f7ef-fe05-4ed8-ba59-a18ef7146c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_36f8f7ef-fe05-4ed8-ba59-a18ef7146c87" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e7583f2d-f795-40b3-9ce4-fd4cf7f95df1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e7583f2d-f795-40b3-9ce4-fd4cf7f95df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_20bd3e22-a2f6-45cb-8122-1fb21f2ebcea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e7583f2d-f795-40b3-9ce4-fd4cf7f95df1" xlink:to="loc_us-gaap_SegmentDomain_20bd3e22-a2f6-45cb-8122-1fb21f2ebcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_fd557982-8abe-4c25-9b0e-2bea106c89df" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_20bd3e22-a2f6-45cb-8122-1fb21f2ebcea" xlink:to="loc_amed_HospiceMember_fd557982-8abe-4c25-9b0e-2bea106c89df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_86284e9f-610e-44da-9599-d137ee4ea3de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_86284e9f-610e-44da-9599-d137ee4ea3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80a98efd-5b96-47c5-a9fe-0f7e59470329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_86284e9f-610e-44da-9599-d137ee4ea3de" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80a98efd-5b96-47c5-a9fe-0f7e59470329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceMember_ffe1df53-2ffd-45a6-b0e9-59f7197a50c0" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80a98efd-5b96-47c5-a9fe-0f7e59470329" xlink:to="loc_amed_CompassionateCareHospiceMember_ffe1df53-2ffd-45a6-b0e9-59f7197a50c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AseraCareHospiceMember_bc4a04bf-6b9b-4cc8-8619-3b69736a7369" xlink:href="amed-20210930.xsd#amed_AseraCareHospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_80a98efd-5b96-47c5-a9fe-0f7e59470329" xlink:to="loc_amed_AseraCareHospiceMember_bc4a04bf-6b9b-4cc8-8619-3b69736a7369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fd2a053d-c666-48bc-b690-ff90dd11d1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fd2a053d-c666-48bc-b690-ff90dd11d1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d796337d-c510-4dd6-9e63-5412aaecad2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fd2a053d-c666-48bc-b690-ff90dd11d1ac" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d796337d-c510-4dd6-9e63-5412aaecad2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_1dbfb56c-60d4-4b28-8932-3e85c45f920d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_srt_OwnershipAxis_1dbfb56c-60d4-4b28-8932-3e85c45f920d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c208f34a-b4db-4fcb-b8bd-70255094ab5a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1dbfb56c-60d4-4b28-8932-3e85c45f920d" xlink:to="loc_srt_OwnershipDomain_c208f34a-b4db-4fcb-b8bd-70255094ab5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7ae2f98e-373a-4703-941a-a125bf842a24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7ae2f98e-373a-4703-941a-a125bf842a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5f1cf74f-d23d-4a21-9459-de2915ec2362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ae2f98e-373a-4703-941a-a125bf842a24" xlink:to="loc_us-gaap_ClassOfStockDomain_5f1cf74f-d23d-4a21-9459-de2915ec2362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a32aa81f-d3f4-4a13-b45b-97ac59dedb65" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_98f8b9b5-3791-4113-8d36-46e57d86d11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_98f8b9b5-3791-4113-8d36-46e57d86d11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Businessacquisitionproformaoperatingincomeloss_1af2dd26-2ff3-42cf-8701-3d5eb1f0b1f0" xlink:href="amed-20210930.xsd#amed_Businessacquisitionproformaoperatingincomeloss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_amed_Businessacquisitionproformaoperatingincomeloss_1af2dd26-2ff3-42cf-8701-3d5eb1f0b1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_0cb1f816-dbc0-4678-9413-50dd2f6b4fd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_0cb1f816-dbc0-4678-9413-50dd2f6b4fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6c85abbf-abd0-4ddc-ab05-282f6f0a2fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_6c85abbf-abd0-4ddc-ab05-282f6f0a2fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_57fe3ccf-4552-40b1-b889-921b93b9498e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_25322803-4232-48da-81f6-ba36ce270f8d" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted_57fe3ccf-4552-40b1-b889-921b93b9498e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ef8f0505-4f5c-4890-adb0-29c8b3538446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e183f912-be87-4b6d-9c9a-aaf07f715bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ef8f0505-4f5c-4890-adb0-29c8b3538446" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e183f912-be87-4b6d-9c9a-aaf07f715bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_603ce162-d783-4ece-aebd-c5770aeca101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_dd811db0-f833-4235-a0f4-a2f7379d059d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_603ce162-d783-4ece-aebd-c5770aeca101" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_dd811db0-f833-4235-a0f4-a2f7379d059d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_dd0147f6-b9a2-488d-911b-499609d5f464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_603ce162-d783-4ece-aebd-c5770aeca101" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_dd0147f6-b9a2-488d-911b-499609d5f464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c0b89f28-2a80-4cda-bcae-980919295c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c0b89f28-2a80-4cda-bcae-980919295c5c" xlink:to="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d951da85-3e73-4d16-b204-308515db2a83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d951da85-3e73-4d16-b204-308515db2a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d951da85-3e73-4d16-b204-308515db2a83" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_086002d1-f44d-4b73-9176-9b8d6922d053" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:to="loc_us-gaap_LoansPayableMember_086002d1-f44d-4b73-9176-9b8d6922d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_b85103ce-ada0-4b2a-a11f-c129f0c01fa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_b85103ce-ada0-4b2a-a11f-c129f0c01fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PromissoryNotesMember_9986b957-a601-42a0-ad8f-2df393a8cf5a" xlink:href="amed-20210930.xsd#amed_PromissoryNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:to="loc_amed_PromissoryNotesMember_9986b957-a601-42a0-ad8f-2df393a8cf5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLeaseObligationsMember_4519c81a-0d5c-472c-bcb2-4e1bded60a3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLeaseObligationsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_15be2ffb-988b-4ede-91dd-0ef33b477bc5" xlink:to="loc_us-gaap_CapitalLeaseObligationsMember_4519c81a-0d5c-472c-bcb2-4e1bded60a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ca88bff2-be67-439c-92d2-ac6edb45b51f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:to="loc_us-gaap_DebtInstrumentAxis_ca88bff2-be67-439c-92d2-ac6edb45b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ca88bff2-be67-439c-92d2-ac6edb45b51f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_1a0d5ca2-0610-4dcb-84ea-bc88c046cc18" xlink:href="amed-20210930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_1a0d5ca2-0610-4dcb-84ea-bc88c046cc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_f9f1e951-37fe-438c-aa99-d1d4d5a59843" xlink:href="amed-20210930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_f9f1e951-37fe-438c-aa99-d1d4d5a59843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_49247e18-c182-45f1-a456-775c36aec666" xlink:href="amed-20210930.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2a0c79d7-d729-4449-a68d-9a4e02205814" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_49247e18-c182-45f1-a456-775c36aec666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_652b611e-e859-4499-a76b-a52915801d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:to="loc_us-gaap_VariableRateAxis_652b611e-e859-4499-a76b-a52915801d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_db77e8a4-a102-4301-a2af-4aa75c126250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_652b611e-e859-4499-a76b-a52915801d8e" xlink:to="loc_us-gaap_VariableRateDomain_db77e8a4-a102-4301-a2af-4aa75c126250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_0daaccb2-3518-4fd1-a8b0-85dc77e5d31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_db77e8a4-a102-4301-a2af-4aa75c126250" xlink:to="loc_us-gaap_EurodollarMember_0daaccb2-3518-4fd1-a8b0-85dc77e5d31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9028d2c1-4880-4752-89c0-0f8ff7d57156" xlink:to="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_aac0376b-c02d-4147-bb8f-e92de29e5659" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_aac0376b-c02d-4147-bb8f-e92de29e5659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_03e19396-7c04-4660-8bac-eef9270adda7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_03e19396-7c04-4660-8bac-eef9270adda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_792d7cf2-2b7e-45d1-96fb-afda936c72d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_LongTermDebt_792d7cf2-2b7e-45d1-96fb-afda936c72d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_13961e9b-57dc-4642-96a6-8a0e63b0416f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_LongTermDebtCurrent_13961e9b-57dc-4642-96a6-8a0e63b0416f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_867f3a58-b707-448d-9ab4-7a902b63a567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_bdff1146-48ae-4222-acbc-ecfe7472ee40" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_867f3a58-b707-448d-9ab4-7a902b63a567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_62e7e5a3-9b29-43a8-88c1-93357bdf4263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_62e7e5a3-9b29-43a8-88c1-93357bdf4263" xlink:to="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_dea9a599-042b-40f4-a460-014f5bd2681f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_dea9a599-042b-40f4-a460-014f5bd2681f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_45f123a1-e6cb-45fe-999a-3c9c556b91ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_dea9a599-042b-40f4-a460-014f5bd2681f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_45f123a1-e6cb-45fe-999a-3c9c556b91ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_68538156-0f13-48d2-9de9-67986e435c70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_45f123a1-e6cb-45fe-999a-3c9c556b91ac" xlink:to="loc_us-gaap_LoansPayableMember_68538156-0f13-48d2-9de9-67986e435c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_72064f3d-65cf-49d5-b1b9-1cf05fbd1589" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_45f123a1-e6cb-45fe-999a-3c9c556b91ac" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_72064f3d-65cf-49d5-b1b9-1cf05fbd1589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1d3c6cc5-fdcd-437f-b294-ab45aa0c8b76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:to="loc_us-gaap_DebtInstrumentAxis_1d3c6cc5-fdcd-437f-b294-ab45aa0c8b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1d3c6cc5-fdcd-437f-b294-ab45aa0c8b76" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_0971e7c6-9dd2-49b3-838c-c1b6b01627d6" xlink:href="amed-20210930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_0971e7c6-9dd2-49b3-838c-c1b6b01627d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_87e4bf22-6215-463a-b22f-0ce5630bc93f" xlink:href="amed-20210930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_87e4bf22-6215-463a-b22f-0ce5630bc93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_ba355b01-b389-415e-94c1-65220a2a5efa" xlink:href="amed-20210930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_ba355b01-b389-415e-94c1-65220a2a5efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_a65299d6-bd61-48db-8827-8530cd9b55f5" xlink:href="amed-20210930.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5547ae0-2449-4358-be83-b459837c5934" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_a65299d6-bd61-48db-8827-8530cd9b55f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7b3e7c20-9bed-4f3b-a141-5fe802032d76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:to="loc_us-gaap_VariableRateAxis_7b3e7c20-9bed-4f3b-a141-5fe802032d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_34cae70f-0558-4b78-8a1b-1ac127c8cb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7b3e7c20-9bed-4f3b-a141-5fe802032d76" xlink:to="loc_us-gaap_VariableRateDomain_34cae70f-0558-4b78-8a1b-1ac127c8cb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_8d712ec9-e13c-4a61-9fbc-b0784bb907ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_34cae70f-0558-4b78-8a1b-1ac127c8cb14" xlink:to="loc_us-gaap_EurodollarMember_8d712ec9-e13c-4a61-9fbc-b0784bb907ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_667fc490-e4b7-48ee-a203-04bcbd20e46c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2700859d-6cda-4289-934a-d92c9cfffec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2700859d-6cda-4289-934a-d92c9cfffec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_59ac2f33-dd24-4068-ab61-c06731b09bee" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_59ac2f33-dd24-4068-ab61-c06731b09bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_128bc9b4-a6c5-4902-942c-618ece87b8c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0cb60d9d-bba3-4a1e-b7a9-2494abdcfcc3" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_128bc9b4-a6c5-4902-942c-618ece87b8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2584a682-2525-461d-949e-69084c0b375b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2584a682-2525-461d-949e-69084c0b375b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e6c343b1-6045-4362-a395-737b8a7dfaad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_srt_RangeAxis_e6c343b1-6045-4362-a395-737b8a7dfaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b59bc902-24a2-4598-bc8c-e469193bd20c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e6c343b1-6045-4362-a395-737b8a7dfaad" xlink:to="loc_srt_RangeMember_b59bc902-24a2-4598-bc8c-e469193bd20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f918f0d6-88db-41eb-8860-955caef5039f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b59bc902-24a2-4598-bc8c-e469193bd20c" xlink:to="loc_srt_MinimumMember_f918f0d6-88db-41eb-8860-955caef5039f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2a00ce3b-2bc5-4a13-8b43-6091ea56e0ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b59bc902-24a2-4598-bc8c-e469193bd20c" xlink:to="loc_srt_MaximumMember_2a00ce3b-2bc5-4a13-8b43-6091ea56e0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a1f5f731-1377-4baa-b8fa-bd40dd0cfc13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_us-gaap_DebtInstrumentAxis_a1f5f731-1377-4baa-b8fa-bd40dd0cfc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a1f5f731-1377-4baa-b8fa-bd40dd0cfc13" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_4ec23888-8d35-47dc-88c1-086b73c93347" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember_4ec23888-8d35-47dc-88c1-086b73c93347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_d5f761f1-d79c-43ce-a749-12550f37c7d9" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember_d5f761f1-d79c-43ce-a749-12550f37c7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_54840c84-f664-4db6-8f04-43e2ef82a65b" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember_54840c84-f664-4db6-8f04-43e2ef82a65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_273f53c0-1952-4e0e-9c88-a266c940ed1c" xlink:href="amed-20210930.xsd#amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a862c150-611c-4f3b-a3de-7970b23c06d0" xlink:to="loc_amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember_273f53c0-1952-4e0e-9c88-a266c940ed1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_d64d1fed-f2db-4fbb-925a-c0e69974020b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_us-gaap_VariableRateAxis_d64d1fed-f2db-4fbb-925a-c0e69974020b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6f698f53-c888-44cc-9599-9e4e1d4ce850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_d64d1fed-f2db-4fbb-925a-c0e69974020b" xlink:to="loc_us-gaap_VariableRateDomain_6f698f53-c888-44cc-9599-9e4e1d4ce850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_0a6eeec1-e904-45de-b73a-ea2f3c80af73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6f698f53-c888-44cc-9599-9e4e1d4ce850" xlink:to="loc_us-gaap_EurodollarMember_0a6eeec1-e904-45de-b73a-ea2f3c80af73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_007d717d-e046-4921-aca4-7829b4a1d840" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6f698f53-c888-44cc-9599-9e4e1d4ce850" xlink:to="loc_us-gaap_BaseRateMember_007d717d-e046-4921-aca4-7829b4a1d840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_b811dcd7-486a-4d55-96b2-6fec5e066806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_b811dcd7-486a-4d55-96b2-6fec5e066806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5dacb155-153a-4e09-b6f7-72dc23422def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_b811dcd7-486a-4d55-96b2-6fec5e066806" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5dacb155-153a-4e09-b6f7-72dc23422def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fe2254cd-9fc9-4f9e-ba56-f817877542e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_us-gaap_CreditFacilityAxis_fe2254cd-9fc9-4f9e-ba56-f817877542e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_0f6acb3d-7382-408f-b3bd-30828af39633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_fe2254cd-9fc9-4f9e-ba56-f817877542e8" xlink:to="loc_us-gaap_CreditFacilityDomain_0f6acb3d-7382-408f-b3bd-30828af39633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_39447c71-a898-4779-bf5e-25197f0efd58" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedLeverageRatio_4aec274b-0584-410a-b56a-d557e55faa96" xlink:href="amed-20210930.xsd#amed_ConsolidatedLeverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:to="loc_amed_ConsolidatedLeverageRatio_4aec274b-0584-410a-b56a-d557e55faa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_da5b50ad-a558-4d2e-bab0-f3888322f37b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_da5b50ad-a558-4d2e-bab0-f3888322f37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LetterOfCreditFee_b7944e1e-9675-489f-914e-f9a7ed4ac808" xlink:href="amed-20210930.xsd#amed_LetterOfCreditFee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:to="loc_amed_LetterOfCreditFee_b7944e1e-9675-489f-914e-f9a7ed4ac808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_eeb868ad-3e22-4cc7-b46b-f5c5d386bcc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_0dbc666c-99a8-4e62-bd32-da1bc3be5881" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_eeb868ad-3e22-4cc7-b46b-f5c5d386bcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#LONGTERMOBLIGATIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8ca6d539-7d22-4014-bd48-54eea327b071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8ca6d539-7d22-4014-bd48-54eea327b071" xlink:to="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_c9fd5932-6ca4-4100-a8be-b2869ed5e402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_c9fd5932-6ca4-4100-a8be-b2869ed5e402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a1c26254-8626-45f9-beb8-01fbd69c9433" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_c9fd5932-6ca4-4100-a8be-b2869ed5e402" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a1c26254-8626-45f9-beb8-01fbd69c9433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d7b59a94-84f2-4e98-85e9-75f88e9cdfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a1c26254-8626-45f9-beb8-01fbd69c9433" xlink:to="loc_us-gaap_SubsequentEventMember_d7b59a94-84f2-4e98-85e9-75f88e9cdfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_45a5b19f-a7a6-459c-a2e8-2d3e29c1bb6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_srt_RangeAxis_45a5b19f-a7a6-459c-a2e8-2d3e29c1bb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_384b208b-4672-4610-afc8-bfec513029ea" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_45a5b19f-a7a6-459c-a2e8-2d3e29c1bb6e" xlink:to="loc_srt_RangeMember_384b208b-4672-4610-afc8-bfec513029ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2eb6d21f-032b-46ec-83a4-452f5e9d000f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_384b208b-4672-4610-afc8-bfec513029ea" xlink:to="loc_srt_MinimumMember_2eb6d21f-032b-46ec-83a4-452f5e9d000f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_3a565e40-ff85-440d-af8b-4cbba824dbe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_us-gaap_VariableRateAxis_3a565e40-ff85-440d-af8b-4cbba824dbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_dd0ffdd9-0228-4177-8ba9-b8a549a711aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_3a565e40-ff85-440d-af8b-4cbba824dbe0" xlink:to="loc_us-gaap_VariableRateDomain_dd0ffdd9-0228-4177-8ba9-b8a549a711aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_8b8e3ae8-e3ba-4702-a37d-ce778c1a61f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_dd0ffdd9-0228-4177-8ba9-b8a549a711aa" xlink:to="loc_us-gaap_BaseRateMember_8b8e3ae8-e3ba-4702-a37d-ce778c1a61f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_93245fe1-f236-4971-bb31-81b21905b7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_dd0ffdd9-0228-4177-8ba9-b8a549a711aa" xlink:to="loc_us-gaap_EurodollarMember_93245fe1-f236-4971-bb31-81b21905b7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_03687f85-5552-4fdf-a292-9d224887fe35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_03687f85-5552-4fdf-a292-9d224887fe35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_03687f85-5552-4fdf-a292-9d224887fe35" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SwingLineLoanMember_95f95610-7c13-4d56-8324-e55dfc503b9c" xlink:href="amed-20210930.xsd#amed_SwingLineLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_amed_SwingLineLoanMember_95f95610-7c13-4d56-8324-e55dfc503b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_8673733f-42cc-4cd6-9f47-f58bf39f8b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_us-gaap_LetterOfCreditMember_8673733f-42cc-4cd6-9f47-f58bf39f8b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_7092c943-d03e-4e8a-9f1f-4668b5167eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_us-gaap_LoansPayableMember_7092c943-d03e-4e8a-9f1f-4668b5167eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_123a7e7f-27c6-43cf-8963-5b6a7f29b1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_123a7e7f-27c6-43cf-8963-5b6a7f29b1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PriorCreditAgreementMember_794a0211-c41f-4f62-b013-b9ca1347131b" xlink:href="amed-20210930.xsd#amed_PriorCreditAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_amed_PriorCreditAgreementMember_794a0211-c41f-4f62-b013-b9ca1347131b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_504549ce-04eb-45f8-baf2-baf5af4802c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_us-gaap_LineOfCreditMember_504549ce-04eb-45f8-baf2-baf5af4802c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_c271b4db-1008-4ded-bcdf-138bb7a403b5" xlink:href="amed-20210930.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_amed_AmendedCreditAgreementMember_c271b4db-1008-4ded-bcdf-138bb7a403b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_2142f712-1793-44f4-9bee-e0a89a9690d6" xlink:href="amed-20210930.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_32a6007b-0275-4da4-8db7-f8b9ac1e99f8" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_2142f712-1793-44f4-9bee-e0a89a9690d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0439f9c9-e332-4082-a59e-9e990e3f9294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_us-gaap_DebtInstrumentAxis_0439f9c9-e332-4082-a59e-9e990e3f9294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0439f9c9-e332-4082-a59e-9e990e3f9294" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmendedCreditAgreementMember_c5302c13-966b-4b4d-aeaa-27cc4f4c94f5" xlink:href="amed-20210930.xsd#amed_AmendedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_AmendedCreditAgreementMember_c5302c13-966b-4b4d-aeaa-27cc4f4c94f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredMillionTermLoanMember_f7bd3b41-a03a-449e-ac1f-89dd57dfdeab" xlink:href="amed-20210930.xsd#amed_OneHundredMillionTermLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_OneHundredMillionTermLoanMember_f7bd3b41-a03a-449e-ac1f-89dd57dfdeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_e2933c37-4e78-462d-9a19-1ca3ba12641e" xlink:href="amed-20210930.xsd#amed_TwoHundredMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_TwoHundredMillionRevolvingCreditFacilityMember_e2933c37-4e78-462d-9a19-1ca3ba12641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_598eccd3-2318-4499-ae85-f43bbae94165" xlink:href="amed-20210930.xsd#amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember_598eccd3-2318-4499-ae85-f43bbae94165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_55bfaffb-d874-4918-9e0d-aa6707078df2" xlink:href="amed-20210930.xsd#amed_OneHundredSeventyFiveMillionTermLoanFacilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_OneHundredSeventyFiveMillionTermLoanFacilityMember_55bfaffb-d874-4918-9e0d-aa6707078df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_a4085535-ae53-488a-8d3e-d1e8b5972b1e" xlink:href="amed-20210930.xsd#amed_FourHundredFiftyMillionTermLoanFacilityMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_FourHundredFiftyMillionTermLoanFacilityMember_a4085535-ae53-488a-8d3e-d1e8b5972b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_9e941e01-17a0-406b-afa0-b17478ef8257" xlink:href="amed-20210930.xsd#amed_SecondAmendmentToAmendedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0389ecf1-0b6e-4d7f-894e-9274570299b1" xlink:to="loc_amed_SecondAmendmentToAmendedCreditAgreementMember_9e941e01-17a0-406b-afa0-b17478ef8257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78b09ad4-cfaa-472c-9f3f-428b6cec5d93" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentPeriodicPaymentPercentage_d122fa19-da06-4299-90fc-81bd132f75a7" xlink:href="amed-20210930.xsd#amed_DebtInstrumentPeriodicPaymentPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_DebtInstrumentPeriodicPaymentPercentage_d122fa19-da06-4299-90fc-81bd132f75a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_6ca84e94-b765-4a73-9933-ffc86947910a" xlink:href="amed-20210930.xsd#amed_ProceedsReceivedFromLoanPartyOfSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_ProceedsReceivedFromLoanPartyOfSubsidiary_6ca84e94-b765-4a73-9933-ffc86947910a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_37949164-6de0-48c2-9213-02a9349b801e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_37949164-6de0-48c2-9213-02a9349b801e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_f9fdfe0f-8262-4771-9151-427eca557a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_f9fdfe0f-8262-4771-9151-427eca557a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_260119ce-75ab-4f42-a695-a0d1901694d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtWeightedAverageInterestRateOverTime"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime_260119ce-75ab-4f42-a695-a0d1901694d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_TotalLeverageRatio_65026ddd-6d9b-41ff-82d9-3d7b6a490bc3" xlink:href="amed-20210930.xsd#amed_TotalLeverageRatio"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_TotalLeverageRatio_65026ddd-6d9b-41ff-82d9-3d7b6a490bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ConsolidatedInterestCoverageRatio_decf39a6-b06f-4f76-a95b-d190f56c4417" xlink:href="amed-20210930.xsd#amed_ConsolidatedInterestCoverageRatio"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_ConsolidatedInterestCoverageRatio_decf39a6-b06f-4f76-a95b-d190f56c4417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dd64572d-da58-4150-9cb6-9ce446013c99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_dd64572d-da58-4150-9cb6-9ce446013c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RevolvingCreditFacilityTotal_d693b006-f845-4632-991d-d9ca3601f7cb" xlink:href="amed-20210930.xsd#amed_RevolvingCreditFacilityTotal"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_RevolvingCreditFacilityTotal_d693b006-f845-4632-991d-d9ca3601f7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_4417b914-11e7-432e-b026-6749d42b0bf1" xlink:href="amed-20210930.xsd#amed_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_LineOfCreditFacilityAdditionalBorrowingCapacity_4417b914-11e7-432e-b026-6749d42b0bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_750fb896-ac55-486b-8fe8-29a4ef9e5be6" xlink:href="amed-20210930.xsd#amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple_750fb896-ac55-486b-8fe8-29a4ef9e5be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_1a4193fe-a326-4d0a-8b6b-610d11909617" xlink:href="amed-20210930.xsd#amed_Creditfacilitymaximumallowableconsolidatedleverageratio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_Creditfacilitymaximumallowableconsolidatedleverageratio_1a4193fe-a326-4d0a-8b6b-610d11909617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_4d36bdc6-2939-458f-9ccf-7ee0abfe4c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_4d36bdc6-2939-458f-9ccf-7ee0abfe4c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_a62f61cb-c147-46eb-8813-9d4a9040ec72" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate_a62f61cb-c147-46eb-8813-9d4a9040ec72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_e5fb4b24-be8d-4949-a7af-75426ac60be6" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate_e5fb4b24-be8d-4949-a7af-75426ac60be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0968326d-7e99-4751-9484-aed08b727454" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0968326d-7e99-4751-9484-aed08b727454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_4da0c5e1-1806-4889-89b7-1e0618992be9" xlink:href="amed-20210930.xsd#amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries_4da0c5e1-1806-4889-89b7-1e0618992be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_4813fad6-6512-434b-bd76-1d8c376daf8d" xlink:href="amed-20210930.xsd#amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries_4813fad6-6512-434b-bd76-1d8c376daf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_51d1b422-b002-483c-945f-31e9f5390d9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross_51d1b422-b002-483c-945f-31e9f5390d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_cd474c01-0070-475b-b466-30c8696c04da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_cd474c01-0070-475b-b466-30c8696c04da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d557052f-f349-4229-a6f9-3df77288b96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d557052f-f349-4229-a6f9-3df77288b96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_ce49191f-b476-42ae-a051-bca63f839f8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_ce49191f-b476-42ae-a051-bca63f839f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_159fc2ca-b523-4fbd-a34f-f2a1b4cc0acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_159fc2ca-b523-4fbd-a34f-f2a1b4cc0acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_DebtInstrumentInterestRateatPeriodEnd_cb83bc94-8498-4891-a857-070e209338d5" xlink:href="amed-20210930.xsd#amed_DebtInstrumentInterestRateatPeriodEnd"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_amed_DebtInstrumentInterestRateatPeriodEnd_cb83bc94-8498-4891-a857-070e209338d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3c449ea2-fd82-4150-8046-9a6285b2944c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba13daa5-a269-419b-8bc0-f6ce5d42c737" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3c449ea2-fd82-4150-8046-9a6285b2944c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="amed-20210930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6e703e97-496b-4b74-a37f-f1435f755862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5ed31e8b-d971-40c3-824e-6dcb9b1f955e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6e703e97-496b-4b74-a37f-f1435f755862" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5ed31e8b-d971-40c3-824e-6dcb9b1f955e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fb0a6da8-698f-4d10-8e23-c4ef72e025dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fb0a6da8-698f-4d10-8e23-c4ef72e025dc" xlink:to="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsAxis_ca4f0e55-a038-498c-9f91-40dbfe10ec0a" xlink:href="amed-20210930.xsd#amed_PayorsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_amed_PayorsAxis_ca4f0e55-a038-498c-9f91-40dbfe10ec0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PayorsDomain_3134cf66-1863-42af-9ecc-b1420caa9bc0" xlink:href="amed-20210930.xsd#amed_PayorsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsAxis_ca4f0e55-a038-498c-9f91-40dbfe10ec0a" xlink:to="loc_amed_PayorsDomain_3134cf66-1863-42af-9ecc-b1420caa9bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompanysinsurancecarriersMember_72297ac4-ac44-437d-a838-c35a63247e3e" xlink:href="amed-20210930.xsd#amed_CompanysinsurancecarriersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_PayorsDomain_3134cf66-1863-42af-9ecc-b1420caa9bc0" xlink:to="loc_amed_CompanysinsurancecarriersMember_72297ac4-ac44-437d-a838-c35a63247e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d2546ff7-6b13-4f47-aa88-0fe542a1ee19" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_srt_LitigationCaseAxis_d2546ff7-6b13-4f47-aa88-0fe542a1ee19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d2546ff7-6b13-4f47-aa88-0fe542a1ee19" xlink:to="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UsDepartmentOfJusticeMember_eabc15c2-aa0a-498b-8312-5f35a2986402" xlink:href="amed-20210930.xsd#amed_UsDepartmentOfJusticeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_UsDepartmentOfJusticeMember_eabc15c2-aa0a-498b-8312-5f35a2986402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_AmedisysCIAMember_c5a32973-7937-46eb-b3ca-ce5798fefb0f" xlink:href="amed-20210930.xsd#amed_AmedisysCIAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_AmedisysCIAMember_c5a32973-7937-46eb-b3ca-ce5798fefb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CompassionateCareHospiceCIAMember_9d3c1a2d-364a-4447-9266-2aa4ecea6cd2" xlink:href="amed-20210930.xsd#amed_CompassionateCareHospiceCIAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_CompassionateCareHospiceCIAMember_9d3c1a2d-364a-4447-9266-2aa4ecea6cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitMember_80794153-768f-46a9-922b-2843935461ad" xlink:href="amed-20210930.xsd#amed_SecuritiesClassActionLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_SecuritiesClassActionLawsuitMember_80794153-768f-46a9-922b-2843935461ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SafeguardZoneProgramIntegrityContractorMember_ef17649a-6c77-4893-a43b-ebf44388a8a5" xlink:href="amed-20210930.xsd#amed_SafeguardZoneProgramIntegrityContractorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_SafeguardZoneProgramIntegrityContractorMember_ef17649a-6c77-4893-a43b-ebf44388a8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InternalAuditComplianceReviewMember_4d688cb4-e4f3-4ff8-a0eb-343dd4e4c679" xlink:href="amed-20210930.xsd#amed_InternalAuditComplianceReviewMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_9ea4f041-2ce0-4a5e-9814-59794d3c56e8" xlink:to="loc_amed_InternalAuditComplianceReviewMember_4d688cb4-e4f3-4ff8-a0eb-343dd4e4c679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_86be09c7-4eb1-4558-a0e3-35725b5f7ca2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_srt_StatementGeographicalAxis_86be09c7-4eb1-4558-a0e3-35725b5f7ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_86be09c7-4eb1-4558-a0e3-35725b5f7ca2" xlink:to="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_3b2cd29f-e745-4302-a910-bc790fa6cff5" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_MA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_stpr_MA_3b2cd29f-e745-4302-a910-bc790fa6cff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MorgantownWestVirginiaMember_0a488a3b-e769-406a-bb88-47655eac918a" xlink:href="amed-20210930.xsd#amed_MorgantownWestVirginiaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_amed_MorgantownWestVirginiaMember_0a488a3b-e769-406a-bb88-47655eac918a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ParkersburgWestVirginiaMember_8244f41f-db75-488a-b165-f3e50591107f" xlink:href="amed-20210930.xsd#amed_ParkersburgWestVirginiaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_amed_ParkersburgWestVirginiaMember_8244f41f-db75-488a-b165-f3e50591107f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_SC_984e1ef5-a408-47fb-ad66-310f9c91d7c2" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_SC"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_stpr_SC_984e1ef5-a408-47fb-ad66-310f9c91d7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_FL_ee425fd6-ce52-408f-8e21-77c6ce42a836" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_FL"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1de7f90c-e9b2-4dbf-8231-80508f19a3e4" xlink:to="loc_stpr_FL_ee425fd6-ce52-408f-8e21-77c6ce42a836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LakelandFloridaMember_81096611-fa8a-4224-87d9-724b4258bc54" xlink:href="amed-20210930.xsd#amed_LakelandFloridaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_ee425fd6-ce52-408f-8e21-77c6ce42a836" xlink:to="loc_amed_LakelandFloridaMember_81096611-fa8a-4224-87d9-724b4258bc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ClearwaterFloridaMember_b5532a06-56e0-4185-b9de-4a8ddc57ac43" xlink:href="amed-20210930.xsd#amed_ClearwaterFloridaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_stpr_FL_ee425fd6-ce52-408f-8e21-77c6ce42a836" xlink:to="loc_amed_ClearwaterFloridaMember_b5532a06-56e0-4185-b9de-4a8ddc57ac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b2bb5890-1ab4-484e-9a84-7d676e291686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b2bb5890-1ab4-484e-9a84-7d676e291686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0386978d-e5ba-4305-a8a4-7b6d8a0b2656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b2bb5890-1ab4-484e-9a84-7d676e291686" xlink:to="loc_us-gaap_SegmentDomain_0386978d-e5ba-4305-a8a4-7b6d8a0b2656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_b0d2609c-2737-4a09-949c-8733bdfc161a" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0386978d-e5ba-4305-a8a4-7b6d8a0b2656" xlink:to="loc_amed_HospiceMember_b0d2609c-2737-4a09-949c-8733bdfc161a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_f509727b-ba7a-4173-bbcf-c4c9db05bdc3" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0386978d-e5ba-4305-a8a4-7b6d8a0b2656" xlink:to="loc_amed_HomeHealthMember_f509727b-ba7a-4173-bbcf-c4c9db05bdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1bc0294b-9f31-4190-9763-6cc95d3e01bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1bc0294b-9f31-4190-9763-6cc95d3e01bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e25aded-6a05-40d2-af24-ab0b7ed4e0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1bc0294b-9f31-4190-9763-6cc95d3e01bd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e25aded-6a05-40d2-af24-ab0b7ed4e0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_InfinityHomeCareMember_95c2789f-6f7c-4a06-ae06-a7002fa5a714" xlink:href="amed-20210930.xsd#amed_InfinityHomeCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4e25aded-6a05-40d2-af24-ab0b7ed4e0c3" xlink:to="loc_amed_InfinityHomeCareMember_95c2789f-6f7c-4a06-ae06-a7002fa5a714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6bf0ae68-833d-4afc-b755-fbc2cbfec7df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6bf0ae68-833d-4afc-b755-fbc2cbfec7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7a5becc9-bcd5-4c77-a527-1164418a2f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_6bf0ae68-833d-4afc-b755-fbc2cbfec7df" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7a5becc9-bcd5-4c77-a527-1164418a2f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExtrapolatedMember_608def02-9d4f-4c48-b697-bf724a51508c" xlink:href="amed-20210930.xsd#amed_ExtrapolatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7a5becc9-bcd5-4c77-a527-1164418a2f4f" xlink:to="loc_amed_ExtrapolatedMember_608def02-9d4f-4c48-b697-bf724a51508c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_UnfavorableMember_7a813bb4-e016-4c37-8606-0de172cf4d14" xlink:href="amed-20210930.xsd#amed_UnfavorableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7a5becc9-bcd5-4c77-a527-1164418a2f4f" xlink:to="loc_amed_UnfavorableMember_7a813bb4-e016-4c37-8606-0de172cf4d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3fc4aff-bf3b-434b-8f40-4153eedb1e31" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_srt_RangeAxis_d3fc4aff-bf3b-434b-8f40-4153eedb1e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17f80a2b-08d7-4544-a9d0-152473a4d86b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d3fc4aff-bf3b-434b-8f40-4153eedb1e31" xlink:to="loc_srt_RangeMember_17f80a2b-08d7-4544-a9d0-152473a4d86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b912b46-2286-4539-bc69-2cdaaeefdc14" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17f80a2b-08d7-4544-a9d0-152473a4d86b" xlink:to="loc_srt_MinimumMember_5b912b46-2286-4539-bc69-2cdaaeefdc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_567c81d0-cc74-4e17-9215-a5966e69e645" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17f80a2b-08d7-4544-a9d0-152473a4d86b" xlink:to="loc_srt_MaximumMember_567c81d0-cc74-4e17-9215-a5966e69e645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3b9f283f-bd4a-4df0-95d2-5b5db83ece8d" xlink:to="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_069be04a-dbdc-4e7f-8c53-812cc5bf1fb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_069be04a-dbdc-4e7f-8c53-812cc5bf1fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Numberofpatients_1485ad1c-7a98-450e-857a-b640b46b65d5" xlink:href="amed-20210930.xsd#amed_Numberofpatients"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_Numberofpatients_1485ad1c-7a98-450e-857a-b640b46b65d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_CorporateIntegrityAgreementTerm_ce720184-489c-40f3-a640-2b9f7d147910" xlink:href="amed-20210930.xsd#amed_CorporateIntegrityAgreementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_CorporateIntegrityAgreementTerm_ce720184-489c-40f3-a640-2b9f7d147910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4a2b685d-1d51-4b88-a06e-7048ba42755e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4a2b685d-1d51-4b88-a06e-7048ba42755e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_238897b2-a114-423a-9df6-176befac4f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_238897b2-a114-423a-9df6-176befac4f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableCurrent_817d5904-4d03-47c5-89ea-3dd718b8eafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_LossContingencyReceivableCurrent_817d5904-4d03-47c5-89ea-3dd718b8eafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SecuritiesClassActionLawsuitsettlement_580f52a0-abf4-4766-9f32-a2021e26e350" xlink:href="amed-20210930.xsd#amed_SecuritiesClassActionLawsuitsettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_SecuritiesClassActionLawsuitsettlement_580f52a0-abf4-4766-9f32-a2021e26e350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfBeneficiaries_532c52d1-c944-45fe-9c52-f058e8a8799f" xlink:href="amed-20210930.xsd#amed_NumberOfBeneficiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_NumberOfBeneficiaries_532c52d1-c944-45fe-9c52-f058e8a8799f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_5312a816-9378-4bb7-93c9-f47afd818946" xlink:href="amed-20210930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiary"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary_5312a816-9378-4bb7-93c9-f47afd818946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_000b8c63-3f65-4852-87b4-a6c693fbd0a3" xlink:href="amed-20210930.xsd#amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest_000b8c63-3f65-4852-87b4-a6c693fbd0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NumberOfClaimsSubmittedBySubsidiary_e3bbf572-a7cb-4f44-9ec0-37e3b52e876b" xlink:href="amed-20210930.xsd#amed_NumberOfClaimsSubmittedBySubsidiary"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_NumberOfClaimsSubmittedBySubsidiary_e3bbf572-a7cb-4f44-9ec0-37e3b52e876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_e76757f7-f0f3-4a66-b07a-616705f0e234" xlink:href="amed-20210930.xsd#amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld_e76757f7-f0f3-4a66-b07a-616705f0e234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_1d3dfa48-c873-4e49-8da0-e372561df67c" xlink:href="amed-20210930.xsd#amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009_1d3dfa48-c873-4e49-8da0-e372561df67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableNoncurrent_dba8ff3d-600c-4941-a3c9-7b839a924603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyReceivableNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_LossContingencyReceivableNoncurrent_dba8ff3d-600c-4941-a3c9-7b839a924603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ActualClaimsPayment_a25871ef-c93e-41a9-913f-ceb42043f7e9" xlink:href="amed-20210930.xsd#amed_ActualClaimsPayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_ActualClaimsPayment_a25871ef-c93e-41a9-913f-ceb42043f7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ErrorRatePercentage_a7098edc-6569-4ee7-9052-a432a94732b1" xlink:href="amed-20210930.xsd#amed_ErrorRatePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_ErrorRatePercentage_a7098edc-6569-4ee7-9052-a432a94732b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_IndemnificationAmount_9f09a89b-4188-4000-9d3b-25fedcfccbe7" xlink:href="amed-20210930.xsd#amed_IndemnificationAmount"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_IndemnificationAmount_9f09a89b-4188-4000-9d3b-25fedcfccbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_FloridaZpicRevenueReduction_0339f7d1-c9c3-4e61-88e7-34934511cf05" xlink:href="amed-20210930.xsd#amed_FloridaZpicRevenueReduction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_FloridaZpicRevenueReduction_0339f7d1-c9c3-4e61-88e7-34934511cf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_19fc7b5a-66ef-4d3a-b490-cb507099d816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_19fc7b5a-66ef-4d3a-b490-cb507099d816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HealthInsuranceRetentionLimit_a66033e5-5b53-487c-9800-a9bd4a73bc89" xlink:href="amed-20210930.xsd#amed_HealthInsuranceRetentionLimit"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_HealthInsuranceRetentionLimit_a66033e5-5b53-487c-9800-a9bd4a73bc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_WorkersCompensationInsuranceRetentionLimit_bd577f7e-27b6-4a82-91d6-ab4ce4bbd1b6" xlink:href="amed-20210930.xsd#amed_WorkersCompensationInsuranceRetentionLimit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_WorkersCompensationInsuranceRetentionLimit_bd577f7e-27b6-4a82-91d6-ab4ce4bbd1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_46f58e47-9e0d-4214-8bd3-059adbee3aeb" xlink:href="amed-20210930.xsd#amed_ProfessionalLiabilityInsuranceRetentionLimit"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_ProfessionalLiabilityInsuranceRetentionLimit_46f58e47-9e0d-4214-8bd3-059adbee3aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ReversalOfLossContingencyAccrual_5dad5fc6-e198-47d4-b128-0daa20418c89" xlink:href="amed-20210930.xsd#amed_ReversalOfLossContingencyAccrual"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_e686a2a6-e157-4066-a002-59d1be804236" xlink:to="loc_amed_ReversalOfLossContingencyAccrual_5dad5fc6-e198-47d4-b128-0daa20418c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="amed-20210930.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_aece3798-3dcd-487d-b093-9c063c6c9091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_a7a925ff-6eda-4d35-a1fc-8eb4e4bee8b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_aece3798-3dcd-487d-b093-9c063c6c9091" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_a7a925ff-6eda-4d35-a1fc-8eb4e4bee8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="amed-20210930.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_0473c388-c4d7-4851-8be8-4ec6c717d1ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_bffa5045-879f-4b9f-9cc9-221b84deb75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0473c388-c4d7-4851-8be8-4ec6c717d1ef" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_bffa5045-879f-4b9f-9cc9-221b84deb75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cbb22ee2-a0b4-4ae2-abc8-3d99a781a14c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b6f5bd0b-cea5-46d9-9ffe-c7ee633c6326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbb22ee2-a0b4-4ae2-abc8-3d99a781a14c" xlink:to="loc_us-gaap_NumberOfReportableSegments_b6f5bd0b-cea5-46d9-9ffe-c7ee633c6326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_59f77025-7342-407f-bfb9-2f319a1ad81d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac7c3020-8366-43be-9f50-cd0301dc47eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_59f77025-7342-407f-bfb9-2f319a1ad81d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac7c3020-8366-43be-9f50-cd0301dc47eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_54d4be7e-47bc-4e50-b86d-3f64dd6683fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac7c3020-8366-43be-9f50-cd0301dc47eb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_54d4be7e-47bc-4e50-b86d-3f64dd6683fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_54d4be7e-47bc-4e50-b86d-3f64dd6683fe" xlink:to="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_bedb94b2-bb0f-42e0-a55a-72f04426aa9c" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_amed_HomeHealthMember_bedb94b2-bb0f-42e0-a55a-72f04426aa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HospiceMember_cacba914-8cdf-4469-8aa1-3d8f536384a1" xlink:href="amed-20210930.xsd#amed_HospiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_amed_HospiceMember_cacba914-8cdf-4469-8aa1-3d8f536384a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PersonalCareMember_98d108f6-307a-41fd-966b-25e2fb7dc796" xlink:href="amed-20210930.xsd#amed_PersonalCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_amed_PersonalCareMember_98d108f6-307a-41fd-966b-25e2fb7dc796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HighAcuityCareMember_7cd2a35b-8d08-4d35-b1cf-0da623ebd082" xlink:href="amed-20210930.xsd#amed_HighAcuityCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_amed_HighAcuityCareMember_7cd2a35b-8d08-4d35-b1cf-0da623ebd082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_bc0162a9-4ab3-4d0b-b04f-88a642973cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6ac03cfa-a4d5-4a4b-b78a-8506228fdb67" xlink:to="loc_us-gaap_AllOtherSegmentsMember_bc0162a9-4ab3-4d0b-b04f-88a642973cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ac7c3020-8366-43be-9f50-cd0301dc47eb" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4063c0c2-3f1b-49f2-b999-2a7ca71904d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions_4063c0c2-3f1b-49f2-b999-2a7ca71904d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_daa94199-f7b8-4235-a9f2-1d2fb356ffc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_daa94199-f7b8-4235-a9f2-1d2fb356ffc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_05e51d3f-218e-4e68-8e33-f7840bc18cfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_05e51d3f-218e-4e68-8e33-f7840bc18cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a0141a7c-ad93-40b4-b665-4ef48cfb7715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a0141a7c-ad93-40b4-b665-4ef48cfb7715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d4af8c66-d80d-454b-a0e7-c7bc550abed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_DepreciationAndAmortization_d4af8c66-d80d-454b-a0e7-c7bc550abed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e31332c2-7ea6-464f-90cc-51b7712870c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_CostsAndExpenses_e31332c2-7ea6-464f-90cc-51b7712870c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9be73b50-6a09-4cb8-9b23-952d18554b53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7d314b81-8885-42d2-8d29-06e8531492bb" xlink:to="loc_us-gaap_OperatingIncomeLoss_9be73b50-6a09-4cb8-9b23-952d18554b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="amed-20210930.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc308fcf-0360-43d6-9911-5b62d607cd0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9ad5499a-d784-4065-86b8-10093c098f1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc308fcf-0360-43d6-9911-5b62d607cd0d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9ad5499a-d784-4065-86b8-10093c098f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CompensationRelatedCostsShareBasedPaymentsTables" xlink:type="simple" xlink:href="amed-20210930.xsd#CompensationRelatedCostsShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CompensationRelatedCostsShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bb612c2b-9743-45c9-8113-98eb85c97143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_267885ea-6906-47d0-9e91-15c2ec3ea956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc23e0a2-4ee2-4162-9f09-18c663a55708" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_267885ea-6906-47d0-9e91-15c2ec3ea956" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc23e0a2-4ee2-4162-9f09-18c663a55708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5509c2bf-2611-4425-873f-4348e4def0d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc23e0a2-4ee2-4162-9f09-18c663a55708" xlink:to="loc_us-gaap_AwardTypeAxis_5509c2bf-2611-4425-873f-4348e4def0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c7a1937-3051-43cc-94c5-fccfea6f0d20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5509c2bf-2611-4425-873f-4348e4def0d2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c7a1937-3051-43cc-94c5-fccfea6f0d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExecutiveStockOptionExerciseMember_9567d9a0-ae5f-4a30-bc28-9f2c14d365d0" xlink:href="amed-20210930.xsd#amed_ExecutiveStockOptionExerciseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c7a1937-3051-43cc-94c5-fccfea6f0d20" xlink:to="loc_amed_ExecutiveStockOptionExerciseMember_9567d9a0-ae5f-4a30-bc28-9f2c14d365d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc23e0a2-4ee2-4162-9f09-18c663a55708" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_4d7ff370-39ef-4abb-8002-9348f75cbe81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_4d7ff370-39ef-4abb-8002-9348f75cbe81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_SurrenderedSharesInShares_c11b16ee-d301-43d4-a4ef-b1b01bcaf3dc" xlink:href="amed-20210930.xsd#amed_SurrenderedSharesInShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_amed_SurrenderedSharesInShares_c11b16ee-d301-43d4-a4ef-b1b01bcaf3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3bfdf280-755e-43b4-8999-8519da3afa8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_3bfdf280-755e-43b4-8999-8519da3afa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8281694c-ecfc-443f-b5cb-eac964da3ce2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8281694c-ecfc-443f-b5cb-eac964da3ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fd4e3d71-05c9-441c-9694-1271f980a178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d6e5f7e0-657f-43c6-b419-23219a503f22" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fd4e3d71-05c9-441c-9694-1271f980a178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="simple" xlink:href="amed-20210930.xsd#SHAREREPURCHASESHAREREPURCHASE"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5b6c7200-7c64-4226-b6f7-85b5535b7683" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_6c7c0493-11f6-41bc-9df7-a455d303ab52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b6c7200-7c64-4226-b6f7-85b5535b7683" xlink:to="loc_us-gaap_TreasuryStockTextBlock_6c7c0493-11f6-41bc-9df7-a455d303ab52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SHAREREPURCHASENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ee24c803-5404-4798-ba7a-b7f3d5df6df6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseTable_e1296c56-da1a-4947-aace-3679b2e334a7" xlink:href="amed-20210930.xsd#amed_ShareRepurchaseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ee24c803-5404-4798-ba7a-b7f3d5df6df6" xlink:to="loc_amed_ShareRepurchaseTable_e1296c56-da1a-4947-aace-3679b2e334a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_f92ee016-f4ca-4f31-82c7-c88b2192276e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_e1296c56-da1a-4947-aace-3679b2e334a7" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_f92ee016-f4ca-4f31-82c7-c88b2192276e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_f92ee016-f4ca-4f31-82c7-c88b2192276e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2019ShareRepurchaseProgramMember_4662788a-717e-4359-936a-038569f91948" xlink:href="amed-20210930.xsd#amed_A2019ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_A2019ShareRepurchaseProgramMember_4662788a-717e-4359-936a-038569f91948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_A2021ShareRepurchaseProgramMember_c9b518ba-6fab-48a6-b66f-1b996eac6958" xlink:href="amed-20210930.xsd#amed_A2021ShareRepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_A2021ShareRepurchaseProgramMember_c9b518ba-6fab-48a6-b66f-1b996eac6958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseProgramMember_72d0fb03-9568-43bf-8848-73708ac1352e" xlink:href="amed-20210930.xsd#amed_ShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_ShareRepurchaseProgramMember_72d0fb03-9568-43bf-8848-73708ac1352e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ExistingShareRepurchaseProgramMember_7451a3a4-128b-4471-a442-60936f355e21" xlink:href="amed-20210930.xsd#amed_ExistingShareRepurchaseProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_ExistingShareRepurchaseProgramMember_7451a3a4-128b-4471-a442-60936f355e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_NewShareRepurchaseProgramMember_0af71abd-386d-4cd1-8b40-91997b36f81a" xlink:href="amed-20210930.xsd#amed_NewShareRepurchaseProgramMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_ed247070-ee76-4a4c-ae08-8e1a6c89fb49" xlink:to="loc_amed_NewShareRepurchaseProgramMember_0af71abd-386d-4cd1-8b40-91997b36f81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fc2f00f9-64bf-4481-beb5-d004ac2ca035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_e1296c56-da1a-4947-aace-3679b2e334a7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fc2f00f9-64bf-4481-beb5-d004ac2ca035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2bcbdf59-53ad-4358-80b0-6866ef610f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fc2f00f9-64bf-4481-beb5-d004ac2ca035" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2bcbdf59-53ad-4358-80b0-6866ef610f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3e6db487-8cb9-40f1-9f4f-08d9a135c09d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2bcbdf59-53ad-4358-80b0-6866ef610f01" xlink:to="loc_us-gaap_SubsequentEventMember_3e6db487-8cb9-40f1-9f4f-08d9a135c09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:href="amed-20210930.xsd#amed_ShareRepurchaseLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseTable_e1296c56-da1a-4947-aace-3679b2e334a7" xlink:to="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0cf9d5c5-0043-4b11-9f11-1d77709afe18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0cf9d5c5-0043-4b11-9f11-1d77709afe18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramExpirationDate_be7f0384-8e03-4ff6-8a78-5d41c6ae77c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramExpirationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_StockRepurchaseProgramExpirationDate_be7f0384-8e03-4ff6-8a78-5d41c6ae77c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_edeef491-9908-4b61-944b-3c974908c27b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_edeef491-9908-4b61-944b-3c974908c27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_PercentageofSharesOutstanding_7d57d01e-6734-442d-827f-07882deb448b" xlink:href="amed-20210930.xsd#amed_PercentageofSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_amed_PercentageofSharesOutstanding_7d57d01e-6734-442d-827f-07882deb448b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79167bb7-2c9a-4ce1-9f92-29ca65312c62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_79167bb7-2c9a-4ce1-9f92-29ca65312c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Discountedclosingstockprice_6981a46f-ba94-4726-be51-f4ae80988372" xlink:href="amed-20210930.xsd#amed_Discountedclosingstockprice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_amed_Discountedclosingstockprice_6981a46f-ba94-4726-be51-f4ae80988372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_Percentageofclosingstockprice_00a75ac3-07ad-40fa-a450-518c5706e45d" xlink:href="amed-20210930.xsd#amed_Percentageofclosingstockprice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_amed_Percentageofclosingstockprice_00a75ac3-07ad-40fa-a450-518c5706e45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_540311fc-65c1-4bc8-8c4f-b767b31fd9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amed_ShareRepurchaseLineItems_e29829a3-cb7b-48da-867c-14a89f067a03" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_540311fc-65c1-4bc8-8c4f-b767b31fd9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="amed-20210930.xsd#RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_716a33f9-28cf-4ed1-afe0-e18be312e4dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_16fc5533-f0ed-4b2e-a047-21397122424d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_716a33f9-28cf-4ed1-afe0-e18be312e4dc" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_16fc5533-f0ed-4b2e-a047-21397122424d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1f3c3af8-d8f0-48a2-9051-07c8be7d20ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8d834a6d-b405-473e-bb7c-3be3d6a6ccb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1f3c3af8-d8f0-48a2-9051-07c8be7d20ab" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8d834a6d-b405-473e-bb7c-3be3d6a6ccb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a62a34c9-57e2-4b73-a931-749266776cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8d834a6d-b405-473e-bb7c-3be3d6a6ccb6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a62a34c9-57e2-4b73-a931-749266776cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d62793d4-60d2-4c8b-bad0-f1167bb5caaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_a62a34c9-57e2-4b73-a931-749266776cad" xlink:to="loc_us-gaap_RelatedPartyDomain_d62793d4-60d2-4c8b-bad0-f1167bb5caaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_MedalogixMember_eadcdad8-7dca-4c98-a60a-4d182ac99787" xlink:href="amed-20210930.xsd#amed_MedalogixMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d62793d4-60d2-4c8b-bad0-f1167bb5caaf" xlink:to="loc_amed_MedalogixMember_eadcdad8-7dca-4c98-a60a-4d182ac99787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2b8cb977-1faf-4e50-af1d-3f1aa7df23e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8d834a6d-b405-473e-bb7c-3be3d6a6ccb6" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2b8cb977-1faf-4e50-af1d-3f1aa7df23e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c69277c9-4414-4ffe-a81f-ba4218bd3d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2b8cb977-1faf-4e50-af1d-3f1aa7df23e6" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c69277c9-4414-4ffe-a81f-ba4218bd3d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_55e873c1-e85b-4736-a83b-34b4273edfde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8d834a6d-b405-473e-bb7c-3be3d6a6ccb6" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_55e873c1-e85b-4736-a83b-34b4273edfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_548e7849-4728-4682-b7a6-765cce320886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_55e873c1-e85b-4736-a83b-34b4273edfde" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_548e7849-4728-4682-b7a6-765cce320886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="simple" xlink:href="amed-20210930.xsd#SUBSEQUENTEVENT"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_8c06db16-ced0-4810-8042-296b8b82ebe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_980944b1-9dc5-4e8f-8275-ef7525325ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_8c06db16-ced0-4810-8042-296b8b82ebe0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_980944b1-9dc5-4e8f-8275-ef7525325ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="simple" xlink:href="amed-20210930.xsd#SUBSEQUENTEVENTTables"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ce168e24-64fa-4d8c-b065-0c29fd00f7ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_ceb9f923-8003-4688-a4e2-2739f71baef1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ce168e24-64fa-4d8c-b065-0c29fd00f7ae" xlink:to="loc_us-gaap_SubsequentEventTable_ceb9f923-8003-4688-a4e2-2739f71baef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7cea266f-66bc-4f0a-bc84-3bc0ba6294a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ceb9f923-8003-4688-a4e2-2739f71baef1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7cea266f-66bc-4f0a-bc84-3bc0ba6294a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_485ee0e4-6f17-41b6-b8c7-c812588569d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7cea266f-66bc-4f0a-bc84-3bc0ba6294a1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_485ee0e4-6f17-41b6-b8c7-c812588569d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_ebbad669-476c-42ce-b7d3-04c26e7a3d03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_ceb9f923-8003-4688-a4e2-2739f71baef1" xlink:to="loc_us-gaap_SubsequentEventLineItems_ebbad669-476c-42ce-b7d3-04c26e7a3d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="simple" xlink:href="amed-20210930.xsd#SUBSEQUENTEVENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9efe9f8b-b627-4aa0-b1e7-80111e3db3a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9efe9f8b-b627-4aa0-b1e7-80111e3db3a1" xlink:to="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f40dd129-127a-40d0-b707-43d3ee04522f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f40dd129-127a-40d0-b707-43d3ee04522f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e93d794a-43bd-49e0-b4e3-f951e5d406aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f40dd129-127a-40d0-b707-43d3ee04522f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e93d794a-43bd-49e0-b4e3-f951e5d406aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ba8ffdf6-c424-4b73-abf1-13e9632ec50d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e93d794a-43bd-49e0-b4e3-f951e5d406aa" xlink:to="loc_us-gaap_SubsequentEventMember_ba8ffdf6-c424-4b73-abf1-13e9632ec50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ef6cefb2-ad29-43f6-ae96-54d61714c307" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:to="loc_srt_StatementGeographicalAxis_ef6cefb2-ad29-43f6-ae96-54d61714c307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2e213798-41c4-428d-94c2-2e5b65186726" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ef6cefb2-ad29-43f6-ae96-54d61714c307" xlink:to="loc_srt_SegmentGeographicalDomain_2e213798-41c4-428d-94c2-2e5b65186726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NC_b3b6cf17-a046-4d03-9dd1-063a5e0f1658" xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_NC"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2e213798-41c4-428d-94c2-2e5b65186726" xlink:to="loc_stpr_NC_b3b6cf17-a046-4d03-9dd1-063a5e0f1658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_6150689b-9b06-4f04-9114-fc63279b0508" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_6150689b-9b06-4f04-9114-fc63279b0508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8a364fad-0889-4ce7-96af-97bf6d1b12fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_6150689b-9b06-4f04-9114-fc63279b0508" xlink:to="loc_us-gaap_SegmentDomain_8a364fad-0889-4ce7-96af-97bf6d1b12fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amed_HomeHealthMember_a91283a3-7fcf-45a4-865a-0cc8051322c7" xlink:href="amed-20210930.xsd#amed_HomeHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8a364fad-0889-4ce7-96af-97bf6d1b12fa" xlink:to="loc_amed_HomeHealthMember_a91283a3-7fcf-45a4-865a-0cc8051322c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1d81219f-7b8e-43d6-bd71-d8849b891cd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_5365541b-4668-43e7-ac97-6313909319c8" xlink:to="loc_us-gaap_SubsequentEventLineItems_1d81219f-7b8e-43d6-bd71-d8849b891cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_56f65e9e-7c99-4e42-af73-0d20fbd05df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1d81219f-7b8e-43d6-bd71-d8849b891cd9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_56f65e9e-7c99-4e42-af73-0d20fbd05df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>amed-20210930_g1.jpg
<TEXT>
begin 644 amed-20210930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1"@17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $ME96=A;BY+
M=VER86YT     >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?PGXM36(Q:7Q5+Y1P>@E'J/?U'^1U%>G&2DKH[XR4E=!1115%!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 !(4$DX Y)/:O,/&'BHZM.;*Q<BRC/+#_ );$=_IZ
M?G6OX[\2>4C:19/\[#_2'!Z#^[^/?V^M>?5PXBK]A''6J?904445QG*%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #HY'AE62)F1T
M.593@@^M>J^$_$Z:Y:^3<D+?1+\XZ>8/[P_K7E%3V5Y/I]Y%=6KE)8FRI_I]
M*UI5'3?D:TZC@SW*BL[0]8AUO2X[N'Y6^[(F?N-W%:->HFFKH]!--704444Q
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** ,3Q;JO]D^'IG1L33?NHO4$]3^ R:\AKK?B%J7V
MK6TLT.4M4Y_WVY/Z8_6N2KS,1/FG;L<%:7-+T"BBBL# **** "BBB@ HHHH
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M'J1=U<****H84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(4444 %%=KX9\&Z?K.AQWEU-<I(S,"(V4#@X[J:U_P#A7&D?\_-[_P!]I_\
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MH^I.*]S1!'&J+PJ@ ?2NS"K5LZ\.M6QU%%%=QUA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3\/?^1F;_KW;^8KEJZ?P#+'#XD9I76-?(898X'45I2^-&E/XT>I457^WV?\
MS]0?]_!1]OL_^?J#_OX*]6Z/1NBQ138Y$E3?$ZNOJIR*=3&%%127=O$Y26>)
M&'56< TS[?9_\_4'_?P4KH5T-U3_ ) ]Y_UP?_T$UXA7M&IWUHVDW86ZA),#
M@ 2#GY37B]<.*W1R8C=!1117(<H4444 %/BED@F66%VCD0Y5E."#3** -/\
MX236?^@I=?\ ?TT?\))K/_04NO\ OZ:S**KFEW*YI=RW>:I?:@BK>W<LZJ<J
M)&SBJE%;GA'2?[6\00JZY@@_>R^X'0?B<?K0DYRL"3D['H_AC3/[*\/6UNPQ
M*R^9)_O-SC\.GX5K445ZZ22LCTTK*R"BBBF,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRWQSHO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5%%>FE961Z.P4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)8L&%KY[C^*<[_TZ?I6]16D:4([(T5."V0B(L:!(U"J. JC %+116IH%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\2/^0':_]?(_]!:O-J\W$?Q#@K_&%>R>&/\ D5]/_P"N(KQNO9/#'_(KZ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4?E^-;QQ$)>1K&M"1UM%-CD2:-9(G61&&593D$?6G5N;!1110 4444 %%%%
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M/T7_ !_*HG4C#<B4XPW.[JO+J%E <37<$?\ ORJ/ZUX[?ZYJ>I,3>7LL@/\
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M ,L;W3XY,K<?D*TE\.:,GW=,M?QC!KH6%GU9NL/+J>,45[0WA_2'^]IMJ?\
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MSB-_G'JIX/Z5C2GR33,J<N629[5134=9(U>,AE8 J1W%.KUCT@HHHH ****
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MU*/,MT85H<T;]3S.I+>XDM;J.>%MLD;!E([$5'17G' >X:=>IJ.FV]W%]V9
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M\,?\BOI__7$5XW7LGAC_ )%?3_\ KB*Z\+\3.C#_ !,U:***[SM"BBB@#/\
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MFHEQMC*QA4W<GJ?RS^=<44G))G)%)NS/4[*SBT^QAM;==L<*A5_Q^M3US/\
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MTUU._P#'&K6&I^'+<V%W'/BY4E5/S ;6ZCJ*X"BBHJ3<W=D3DYN["O6_!/\
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MGI;,\*&[MQTDB'('NO4?J*\ZI0E#5:HX:E%QU6QSM6;+4;S3I-]C<RP'OL;
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ML9T'5HV'Z4GL!X:S%F+,<DG)/K2445XQY)V_PUM5>]O;IAS&BQK_ ,"))_\
M017H5<!\-)E$VH0D_,RQN![#<#_,5W]>GA_X:/0H_ @HHHK<V"BBB@ HHHH
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MV=%X%_Y&VV_W'_\ 037J]>4>!?\ D;;;_<?_ -!->KUWX;X#LP_P!11172=
M4444 %%%% !1110!X_XN_P"1KOO]_P#H*QJV?%W_ "-=]_O_ -!6-7D5/C9Y
MD_B9O>"?^1PLO^!_^@-7K=>2>"?^1PLO^!_^@-7K==N%^#YG7A_@"BBBNHZ
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M10^,[2BBBO3.\**** "BBD9U12SL%4=23@"@!:*BM[JWNT9[6>.95;:6C<,
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M<QJGQ!T^U!334:\D_O'Y4'Y\G\OQJ)3C'=DRG&.[.KFFCMX6EGD6.-!EG8X
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M#Q_Q=_R-=]_O_P!!6-6SXN_Y&N^_ZZ?T%8U>14^-GF3^)F]X)_Y'"R_X'_Z
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M@**T=;G6&6XE'*PKRBGW_O?R^M=F!@8%=M'#N_-,ZJ5%WO(****[3K"BBB@
MHHHH **** "F2Q1SQF.:-9$/577(/X4^B@# O/!6AW9+?9/(8]X6*_IT_2LN
M7X;6+?ZB^N$_WPK?X5V=%9NE![HS=.#Z'"'X9KNXU4X]/L__ -E4T7PUM P\
M[4)G'<(@7_&NUHJ?84^PO8P[&!9^"M#L\'[*;AA_%.V[].GZ5N10Q01B."-(
MT'144 #\!3Z*TC&,=D6HI;(****HHCGMX;J%HKF))HVZI(H93^!JI_86D?\
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MB7>3+IT2D]X\I_Z#BM>BDXI[B:3W.2N/AUI4F3!-<PGTW!A^HS^M4F^&<?\
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M6D8QCLC112V044450PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KSKXBZIYU]#IT;96 ;Y!_M'I^0_G7H
M%U<QV=I+<S'$<2%V/L!7B5[=R7]]-=3??F<N?;/:N7$SM'E[G/7E:-B"GP0O
M<7$<,*[I)&"*/4DX%,KK/A_I7VO66O9%S':C*Y'5ST_+D_E7#"/-)(XXQYI6
M/0],L4TS3(+.+I$@4GU/<_G5JBBO72LK'J+30****8!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ''_$/5/L^F1Z?&V)+D[GQV0?XG^5>;5W'B7PUKNLZ[/<I;H81A(LRK
M]T?CZY/XUE?\()KW_/M'_P!_E_QKSJL9SFW8X:BG*5['.5[!X4TO^RO#T$3+
MB60>;+]3V_ 8'X5Q^C^!=275[=]2A1;9&W/^\#9QVP/6O2:UP]-Q;E)&E"FU
MJPHHHKL.H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>amed-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amed="http://www.amedisys.com/20210930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="amed-20210930.xsd" xlink:type="simple"/>
    <context id="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i07d63b1d905741c6ac588e15cfe76e29_I20211029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-10-29</instant>
        </period>
    </context>
    <context id="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i84de3e983eb740b1bb3c8f25d7622369_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4041053d2da749d8975f3208c6832b54_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9bdd17b976b94417b0973260d8bd3e44_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icd44a5fd2068444ea4c2b014fc212aba_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i81046c5f2fe9466f935a9da81d4f9b05_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i481818d771fb4e8cba7ee992ef045095_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if2d22e47449f4dce9025ba20e4ee868e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic477a09656e142a2ba9555f6e71e57b8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i89642198499249a5a508a2b794a0c774_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id633ade135bd4fa5a755576d79307e96_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8585c2e41c09481f94254dd475c515cf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i598b6bdc5e4b441ab25be4f2fd0a21ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia3722136a4de449192734a30989dde10_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i29f95beb109544799227cc0e3807a5a2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if9586bde96dc4b55a43e520f969b3d49_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i590fcf43ae93429c90aa189d83dd278c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2f981173ad3f4a55af9ec673326e4ee7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2fb123a126ca4044b4d597a6f5aeb789_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3b307a62c3fb444494adee8144988b0d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5e4f44436f8c4b4b84c3920f226cab7a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i4afb39ea542d425cbf6ec7dcdc11d968_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6701d88a3f6b429ba56daa18c8fb08cc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i59e60464baed4c908a5a135d54dc4b11_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9b35a3a550a440cc90fa58ad012ef681_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i17d9a940c2864685ae466b0f8760514a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1519169737fb443a8053b131fb736562_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0981942253684fd5b4f7eb9fb411157c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i696f26883f1a42e28bc3241a2c02dc1c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i39f094da56c24200a601142582cdc2a0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if09d9dfbada9402c82e04fffa1792aed_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifc6b318a025b416080e2e688fa3d70f4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i21bb61efbc804a59b103a8fc6e57cb32_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1180b4ef96164b9a9e4962f634ba5bcb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie8c58ab1289048be8261102b772d4db9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia6e494dd063a4d8aa19b36fcb24fed25_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia855683296e64bf18a9ef89f356655a0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifa9afb8e5e3644a59da63953d75e842c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibc92f06d04394959b3242b038919464a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib42b43eecaab42a78203a133cac36e19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23b5458af0924ae791b517938fa92dba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84c69e51ef304378875bd8586144f797_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ff740465893462abb39658ee50a3980_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iccb3f95375f5445ba8782cf65507f940_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i46836dfa696048bb8468c58880596456_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2a5883b3c8ba45e0853c437d045de477_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic8a2e6cc1034448789c21e45ddc2a62a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6566df00d848434baa97e9fd857c714c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4c7b322b8d954305ab4228a0e4f5fa44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69fea3aa6870434ea5666aacfdf3d1d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6d9c15c2efa64925929ae6f6cfe42a0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i70db5c4d7e784bac89013422e4e11011_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i884c25e331534f468450dd28f2d93e40_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i67b5b45191d24afe8a6500e067394b03_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i465c7064fe5e412e978bfdd7128be6a7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i96d80f5ecb444e898ca8530a2f8c3d9e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b85cedd162948299f5f10b84f850dd7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i53a77f5a57b04427a02592d620527871_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i97413ae1e1174a779e186bf439f4b59e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f3cf4cabcef48c49d533b6054864aa6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4b858c3a1e442059c913a6d2f8baa16_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">amed:MedicareRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i730de4ab8dd2401da027009b92ebd36a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idba324da17d44f13b400eb4dcb6541c2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4003f84c115d4f539f2b8c54b785265e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i52fadfa94bbd423aa0033f0ef19c530a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib17e4cda80354daea0f730106f4a1852_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic428d287cf9a45abae8bef5f46c3c408_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0d32c084839747cea67534c70d0a7a4c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:TypeofEquityMethodInvestmentAxis">amed:HeritageHealthcareInnovationFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id5d7cedb10ae48fba7962484bd3a479d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6cf8d0d878ea44b5b6acaec5036b5b3e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb137aa1ee24433e9aa27e49dc612257_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6bde2eb0cbdd4167840a8abcb889fdbe_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7da000a08ec142e4bdd7cf8ee0df0f47_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a28bdb10cc74d2e928cf670bd6e2574_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia97dc36d6ba44d7a91070e28414ee451_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7fcfacf66b054da0b58e2e56d9bb8bfa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99b4c1b915b04539b57e1c8613186d47_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifa13ecc925ce45338808db2fe46e6eae_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8ab6f6ff611a4bca958bd8f881a12f27_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if6978f00a4d24116b989b48f99ba0ee3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HomeHealthNonMedicareNonEpisodicBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifa1d053dcadf4783b88264c7cec8fdad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id56c30a83b044cfeb8b2c3d76169a0f2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ife028e28aa6e4bff87836d3a26ef8d85_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67ed27e1cb4c4b0aabe4eb9cf42597d3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3a812c39af934a4fbcf34dcbb6f5f869_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide539b43139c4e9f8ca2939b91054599_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9100f75ec6d34eab92f0b7a4728ebb97_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6c80de9e2e4b40cdb0613e9070ad7c04_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:HospiceNonMedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i42e067416e644747bb8fa941e424d288_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icac5f9500af546a48378980936e6335e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i926e999864bd48ed884e8c5a0659188d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7de65d633d9d4497bd157a0af662328c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:PayorClassAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i29f7d758438c4f338ef4844b1b05b695_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i15da7330f86b4f90b126f6a27ee2e91c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4f2cd5e0030a4da38f5733c7cc21c188_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29e45fb5802548c4ad50a57ad3f3b612_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5d3a5fc24c7c41c8bc0fb5a2dae8eb49_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i24116e45645b4557aa94b276ff514ba4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="amed:CapYearAxis">amed:CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d0d57618875495dac3ccd68edf1aea4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i68531a9539f143d39b039b1ec2d6143c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i500483d4b7f14fdaa315297298d52160_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VariousAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iffd0e7655cc84c468271b6527bfdb445_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5462f91dd84c47b0a636202d3b8d0235_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2feac305da384a94a9d62488436d6c54_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i79965b0e5aa8415ab632c4462ea0fe64_I20200327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <instant>2020-03-27</instant>
        </period>
    </context>
    <context id="i0efbe09bd23b41df8e79378709cd08ec_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i1d60d9ebea4d4f7d9cefaed1ef4edefa_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ifffac77654ba4ad9a0ab1f64df333300_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i1393629cbb174bb6b0ebfda47cfc61fd_D20200327-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8e66e59d22d74d7a814e88ec0a8b967a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38909b3d265a42439d254b12034f035b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2649a54bd32e4505aaf5229062506cea_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">amed:COVID19DeferralOfSocialSecurityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib38d592d04ae48798a01d60bc2b8f174_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb4c638a3b064fa5b06f2b26f52f4a80_D20210501-20210501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="i54c8f3adc1504f4eb6682e48cf1c64c4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2017c2d404c641c2a514204df4297957_I20210501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-01</instant>
        </period>
    </context>
    <context id="i0872fc9873bd4791b48b180e25979b56_D20210701-20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="i3f71161254f8495192bc5012d17c1d17_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0151e438657a4e998a05f867e7a0192b_I20210701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:VisitingNurseAssociationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicareLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthAndHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="if47ee2ab8e1e4361a566cb19050d7b35_D20210712-20210712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-12</startDate>
            <endDate>2021-07-12</endDate>
        </period>
    </context>
    <context id="i851747d57a65428e80bd139d35336f78_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib551a251deb645c2b167c2d979092893_I20210712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificateOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-12</instant>
        </period>
    </context>
    <context id="id9ba162183a34d4793c4bb95198e7c46_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="i66672e7c81cf4388ace524f46eb99c20_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i249984fbdc5e42819c3295bf8354d6b7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7e43a9f348fe4c7ea8efde6906e553bf_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="ie5e610cd17944eaa9db443b1b7ceed2c_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="if5dabca3606441b0a6016647f859c142_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="i580773c45c2e4d0f89d42392a8b52a23_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="ib322985f813e485bb88456695369faef_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="i7c481a799d7f4394b4a10e4b1471316c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:ContessaHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i4953a1ae43744a48ab6e34e6411026e1_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i543e41010bbd4e948680534c79d49c2e_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i3d6da567b0484902aa61fbfea5349833_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id814fe8f58334cf9978509b3eada043c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5c0952e0e5814a7380170a26c64d0563_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:MedicareLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i953170ab35da4c52b868fca5070072f4_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:CertificatesOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i592180016a3f4b9e9fa58cdf3b1f3e11_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i0cb7f1afbee94667b22da85810bdfcbf_I20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i7dd94248f0054a2eb7c4d4f6a7ce8f7f_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">amed:AcquiredNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i2e7f579c66d14f6f8455278885e6166c_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:AseraCareHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="id2212b3038014b39b18d85e2bb708130_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if630985387694c3c8fc5598653fa49c5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9c80c052038b44b5a18995cafc14e750_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id33dd3f1accc48d0b07ae82ea62d7bf3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93f3a54943ce4dfc93af29045df66a08_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4a29fce5319a41b88a21448a8d746bc1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i04620e666ce242189145fc8202e974a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c79a4a01587443798a698b9d888425d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i8c6b3f9117ec48d3af01c13b614cdce8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:PromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86b58db92e154fe68dd728641fc3400e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ieb868e0e199e4a7ba64d42b2fdae307d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CapitalLeaseObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13ec3a58ad29418ebe42554498e48e75_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="ibf92b4555b6d40f2a59b54d48f64f091_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="ic64fd34ea067411b965765c227c1c4e8_I20190204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:OneHundredSeventyFiveMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-04</instant>
        </period>
    </context>
    <context id="ibb7c45b2d9ae4729a6b676da0434e01b_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i8161c5c6f5a441498e6232b1062a0706_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="ic9248021e924452a9ca5a099d811b891_I20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="i96b33383638f4da69049403922d142b6_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="ic4d439ce912f4be0af7514da8425d3c2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib9ff3a8ccb9f425b8f7441a6634cf019_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8268f6431a5342b0a5dc83e81f8cf5a1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id2629c6a87704cab9b7d7cc4fcb7d9d7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6347f72e46564137a77f41c6701f04b4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a006fc8ae3144b8b0f35e0576008c13_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8eda14018d5440f49c3d2c8399bf7c28_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i577fdd4a436a42ea80849c81a5784c4c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i66aae57e36ae41648ae8623055ad5911_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i499562ee396144d1b90e4e7f1e4b3078_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i35d443fe2776475199e8bf20c5bd7195_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0e39d276de254f649e239423c9cc0cc7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94c391fe27d34bb598e993c5ca12ab5e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5bbf202037ab4efe84eec9c86af849aa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec7d2c9ab8af421195c28b753a977a92_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i31501243538e4935b989aad968b62589_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie04b2efc6fec439ca0961cd20f0f2601_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7b640016ec74b29877d9d8af659dacf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7807a03e1d27498cb0fbd254ba18a9e2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5fb48a5c2350401badf76407e810a916_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:AmendedDebtInstrumentByLeverageRatioTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4384d6ba9eb047a8b55217f4beaf64b4_D20210730-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="ic8d7f3ebbc7b4cbabe8f090e4d1c2b10_D20210730-20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i22ebbfca679d4a7fafa5444ca24a361f_D20231001-20260730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2026-07-30</endDate>
        </period>
    </context>
    <context id="ie4322d7e66634ce4885a55d252abc28d_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="ie4039f4791f043d6a0ea7c40d6c13d2f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib057fa7e9dc74985846be7233614be6d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8a8de61107114e3188c016a866d7eee9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i75a1a833f08448ae97ff44f57957725d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i257940b085494340a54f2596ffb71f9c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4eabd2498ce447d59434f7882ae478d0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifba8391d8e984a3593722809cdc00c21_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FourHundredFiftyMillionTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i778f590556a3415eb3394ae1a6c1629f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:FiveHundredFiftyMillionRevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id5e9300975d94331be252f45284ba279_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="iece39510783140d686babcc73a08f895_D20210730-20210730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">amed:SecondAmendmentToAmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <context id="i035bf53c46a541a5826c7f2c7b06185b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idd4289f9d03348eabba8b8a1ff9153aa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i601ff40a9dcb4f2e8948d32afbd39a70_D20150521-20150521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-21</startDate>
            <endDate>2015-05-21</endDate>
        </period>
    </context>
    <context id="i8ccc1c8d24e84db4aa8381d958233b6b_D20151103-20151103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:MorgantownWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-03</startDate>
            <endDate>2015-11-03</endDate>
        </period>
    </context>
    <context id="ie05aa041138d438c87540387474bcbd1_D20160627-20160627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:UsDepartmentOfJusticeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ParkersburgWestVirginiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-27</startDate>
            <endDate>2016-06-27</endDate>
        </period>
    </context>
    <context id="i0aa37634d03d42b08a244431e4a41f5c_D20080101-20100331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="i095f59a36c244843af1db7f854a0a9a2_D20110606-20110606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:ExtrapolatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-06-06</startDate>
            <endDate>2011-06-06</endDate>
        </period>
    </context>
    <context id="ica3afcf2ee1c43259f1a30c2e600133a_I20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-18</instant>
        </period>
    </context>
    <context id="i564a484715c64e40a7be81c6235e4f3d_D20160118-20160118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-18</startDate>
            <endDate>2016-01-18</endDate>
        </period>
    </context>
    <context id="i802e5888cb1648439a3f47b2b44404c2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">amed:UnfavorableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i76d5dd1a4f4a464ca4fb9d384e6aa87b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic80811cd8fd747ef98eb89b834589f68_I20190110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:SC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-10</instant>
        </period>
    </context>
    <context id="i3b5d1cbe45dc44d9b98ec0e127cd824c_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i484c5a9dd6e14e23b66ed620f5079d5d_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="ic0294eb79c2848a59000786e83e668d1_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ie0de238f9be246fe96998173de4a5bcb_D20170801-20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="i346f707c9d6b4ac9964bf787577aea3d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:LakelandFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i89ded9eda305484fa4ab5c09016ceb41_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">amed:ClearwaterFloridaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3eb22d6ba31944238874d354008337ec_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ie21724093a2f42c4853d771fabb00f17_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i36258c9144d84085bd1b3ea4fd537b23_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="ief75d072b29748ba987a8030789542dd_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i08e7d764f4494c88b305e1e18074b41f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i60712b1793c74750b58b9385fb0c31e3_I20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="i3d7c2cc8b22d455a9ebb4e72d526d36c_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i9eaa44efaa1a467ebc42d62d7ac69a76_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">amed:SafeguardZoneProgramIntegrityContractorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">amed:InfinityHomeCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id363dc674251412f912533418a9d82dd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic29a871182a54f2094160695e03ee462_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6aeb28a2785549969b2fff138237082b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93729840e4134b239b4b920086a356a1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idaadc0a4a924428e834767c197639f52_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9760404300fe42ccafac45094346c6e0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i147869c8a406420b87176150165db51c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:PersonalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HighAcuityCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i01d5e8892fb243b4b865bd7b871d16be_D20200810-20200810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-10</startDate>
            <endDate>2020-08-10</endDate>
        </period>
    </context>
    <context id="ib1427f68924a44119e86ad505b770163_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">amed:ExecutiveStockOptionExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f23866255254c1e86623c880ffabe48_I20201223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="i2381e983ae6a4cb799879628f17fd769_D20201223-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85212f2db10a46fd81194263d32551bd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icea953f101c64f9ea9eb5be5f0f999ff_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:ExistingShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if904a87006f24f8cbd91c764ae5909fc_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="i878d81e55fc54bb5a76221d8c7ce04e9_D20210802-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">amed:NewShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i12c67fa7efe64016ba829366460e9a3f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib5985078fbcb439bbdcb8ec2bcdb0330_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i28c5a54e2c3f42ef8543c32325f45fa2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7137075508bc4a80bdbc1291c467c563_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">amed:MedalogixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6c26203c52124e6db31cba165f90a5ba_D20211018-20211018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000896262</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">amed:HomeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-18</startDate>
            <endDate>2021-10-18</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="care_center">
        <measure>amed:care_center</measure>
    </unit>
    <unit id="numberofjointventures">
        <measure>amed:numberOfJointVentures</measure>
    </unit>
    <unit id="state">
        <measure>amed:state</measure>
    </unit>
    <unit id="visit">
        <measure>amed:visit</measure>
    </unit>
    <unit id="patient">
        <measure>amed:patient</measure>
    </unit>
    <unit id="beneficiary">
        <measure>amed:beneficiary</measure>
    </unit>
    <unit id="claim">
        <measure>amed:claim</measure>
    </unit>
    <unit id="segments">
        <measure>amed:Segments</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl80LTEtMS0xLTA_e47603f3-d8ee-4e3a-95aa-446f82a8d487">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl82LTEtMS0xLTA_a6338b83-dacf-4027-a4cf-079c72be5fc4">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl83LTEtMS0xLTA_dd6037ef-be76-4e2d-a362-d506edeaf12b">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl85LTEtMS0xLTA_6fddc359-df98-4b97-93fb-4623d4dbc2c9">AMEDISYS INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl8xMC0xLTEtMS0w_ba19903d-4474-4eed-a4c0-421ba2c8ff17">0000896262</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180L2ZyYWc6NjMwMWRhMmM5NWU3NGJkZTkwNWY1ZjI3YjRjZGRmYTAvdGFibGU6OGM4ZGIyOGY5OTQzNDJmOGIzMjAyMzQ3ZTc0YWQxZjYvdGFibGVyYW5nZTo4YzhkYjI4Zjk5NDM0MmY4YjMyMDIzNDdlNzRhZDFmNl8xMS0xLTEtMS0w_ceef58c0-40ad-452a-83d5-ccf168a9e7fa">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:GainLossOnInvestments
      contextRef="i0d32c084839747cea67534c70d0a7a4c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180MC9mcmFnOmYzYjcyYTEwYTg4ODQxOGY4ZmE1MTg1OWRjYjg5ZGMyL3RhYmxlOjdjZDQ4M2M4ZjJlYzQwMTI4MjNiY2M5ODAwNzA2YWZkL3RhYmxlcmFuZ2U6N2NkNDgzYzhmMmVjNDAxMjgyM2JjYzk4MDA3MDZhZmRfNC0xLTEtMS0w_5ec5ce1a-919b-4632-9c8c-59b95f7b9330"
      unitRef="usd">3000000.0</us-gaap:GainLossOnInvestments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180Ni9mcmFnOmNiNmU4YWNjMzU1YjQwZjNhNjU2ZDQxNmM1ZTIzNTRmL3RhYmxlOmVlYWUzNTdiOGVlMDQxODM4ZTQ3NTBlYTIxZWVhNTFlL3RhYmxlcmFuZ2U6ZWVhZTM1N2I4ZWUwNDE4MzhlNDc1MGVhMjFlZWE1MWVfMy0xLTEtMS0w_cc82efad-98d8-469c-9dd1-76f15fea6205"
      unitRef="usd">83357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180Ni9mcmFnOmNiNmU4YWNjMzU1YjQwZjNhNjU2ZDQxNmM1ZTIzNTRmL3RhYmxlOmVlYWUzNTdiOGVlMDQxODM4ZTQ3NTBlYTIxZWVhNTFlL3RhYmxlcmFuZ2U6ZWVhZTM1N2I4ZWUwNDE4MzhlNDc1MGVhMjFlZWE1MWVfMy0yLTEtMS0xMzA5OQ_90fd5e1b-a718-4b69-9259-1e7faa5e7cbc"
      unitRef="usd">124458000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7c481a799d7f4394b4a10e4b1471316c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181NS9mcmFnOjE4ZTFmZWJhOGQ5NTRlZWQ4OGExYzc3OTlhOTFiN2RhL3RhYmxlOmYzMjA2MDA0MjZhZTRlZTU4N2RiZGQxNGMxMDdmYjJiL3RhYmxlcmFuZ2U6ZjMyMDYwMDQyNmFlNGVlNTg3ZGJkZDE0YzEwN2ZiMmJfMi0xLTEtMS0w_a20d9398-df19-466b-b69b-563f036ecc3e"
      unitRef="usd">-3800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="id5e9300975d94331be252f45284ba279_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182MS9mcmFnOmNkOWQ5ZmZmNjZjOTRlOTM4YWEzODliNmU4ODMwNTFmL3RleHRyZWdpb246Y2Q5ZDlmZmY2NmM5NGU5MzhhYTM4OWI2ZTg4MzA1MWZfODA5_7518b444-634e-471b-bc61-c6acfd01aca3">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="iece39510783140d686babcc73a08f895_D20210730-20210730"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182MS9mcmFnOmNkOWQ5ZmZmNjZjOTRlOTM4YWEzODliNmU4ODMwNTFmL3RleHRyZWdpb246Y2Q5ZDlmZmY2NmM5NGU5MzhhYTM4OWI2ZTg4MzA1MWZfODEw_ea5361be-d690-4115-88e9-52519ad5e3ba">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183My9mcmFnOjExOTQ4ZjlhM2MyYzQwZTBhOTI4MWQzMDlhYjY1NjFkL3RhYmxlOjEyOTVkOTYwNDRmMTQ2ZDBhNWQ1MGNhODkzMWNhN2UzL3RhYmxlcmFuZ2U6MTI5NWQ5NjA0NGYxNDZkMGE1ZDUwY2E4OTMxY2E3ZTNfMi0xLTEtMS0xMzE0Mg_10469d0a-d1c9-490f-87a1-a0489f652d7d"
      unitRef="usd">297668000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183My9mcmFnOjExOTQ4ZjlhM2MyYzQwZTBhOTI4MWQzMDlhYjY1NjFkL3RhYmxlOjEyOTVkOTYwNDRmMTQ2ZDBhNWQ1MGNhODkzMWNhN2UzL3RhYmxlcmFuZ2U6MTI5NWQ5NjA0NGYxNDZkMGE1ZDUwY2E4OTMxY2E3ZTNfMi0yLTEtMS0w_dc1604fb-55aa-4657-97dc-995a6718afb0"
      unitRef="usd">19955000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183My9mcmFnOjExOTQ4ZjlhM2MyYzQwZTBhOTI4MWQzMDlhYjY1NjFkL3RhYmxlOjEyOTVkOTYwNDRmMTQ2ZDBhNWQ1MGNhODkzMWNhN2UzL3RhYmxlcmFuZ2U6MTI5NWQ5NjA0NGYxNDZkMGE1ZDUwY2E4OTMxY2E3ZTNfMy0xLTEtMS0xMzEyMQ_69f8ab10-5827-4492-b1a0-21af14837a9c"
      unitRef="usd">1464339000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183My9mcmFnOjExOTQ4ZjlhM2MyYzQwZTBhOTI4MWQzMDlhYjY1NjFkL3RhYmxlOjEyOTVkOTYwNDRmMTQ2ZDBhNWQ1MGNhODkzMWNhN2UzL3RhYmxlcmFuZ2U6MTI5NWQ5NjA0NGYxNDZkMGE1ZDUwY2E4OTMxY2E3ZTNfNC0xLTEtMS0w_1499395f-1c7e-41fe-aa6a-16a8e3aa7ef8"
      unitRef="usd">203756000</us-gaap:OperatingIncomeLoss>
    <dei:DocumentType
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM1_b40625cd-60e5-4e6f-89cf-c81fc7f9fd0e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6Nzk4OThjNTc1YzAzNGRjMGIyN2U1YjA1NmVhZjNkODkvdGFibGVyYW5nZTo3OTg5OGM1NzVjMDM0ZGMwYjI3ZTViMDU2ZWFmM2Q4OV8wLTAtMS0xLTA_02861bf8-72e3-4dee-a17a-1d0ae3611c98">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8xMzg_804f1bd1-af2a-4c0a-ba1f-948ad0ac18f3">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6MDI5MmI5YTNkNzg3NGY1NThmYWEzYTQ2NTc5NThiNTAvdGFibGVyYW5nZTowMjkyYjlhM2Q3ODc0ZjU1OGZhYTNhNDY1Nzk1OGI1MF8wLTAtMS0xLTA_2076a288-f715-4eb4-b206-ebf724e1a545">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM2_f18f05c6-cfde-4275-9b4a-fe24877100b3">0-24260</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NjBkYmNjMGZjYWUwNGIxOGJiZmFiMzUzZDZmNzk1MWIvdGFibGVyYW5nZTo2MGRiY2MwZmNhZTA0YjE4YmJmYWIzNTNkNmY3OTUxYl8xLTAtMS0xLTA_9a27ecb9-fa42-4f83-beba-92b9f5d601f4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NjBkYmNjMGZjYWUwNGIxOGJiZmFiMzUzZDZmNzk1MWIvdGFibGVyYW5nZTo2MGRiY2MwZmNhZTA0YjE4YmJmYWIzNTNkNmY3OTUxYl8xLTItMS0xLTA_8289efdd-a50a-40e6-9a24-28e2efbcdc8f">11-3131700</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM3_1653c703-e275-4d6a-a8a5-c7a853a7b6f4">3854 American Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjQw_b243718b-fff1-4662-8ec5-d9f3fcc1767a">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM4_d6741299-70c7-420a-b227-899711f88f89">Baton Rouge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM5_c13e408d-70cf-4a08-bc60-4e8c9e513e3c">LA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjQx_d7efeb32-f585-4322-aa07-e33f6fd9ce23">70816</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjMy_1c164269-74d8-4442-a138-a1292e61d6d0">225</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjQy_b244152f-236a-44be-a9d2-ed0b2adc09c9">292-2031</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NGJhNTA5YWNhZTdkNGU1ZmIwY2MxYmE5NWJmYjIwYmIvdGFibGVyYW5nZTo0YmE1MDlhY2FlN2Q0ZTVmYjBjYzFiYTk1YmZiMjBiYl8xLTAtMS0xLTA_b882752d-d20d-4378-9067-22411eb05ad9">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NGJhNTA5YWNhZTdkNGU1ZmIwY2MxYmE5NWJmYjIwYmIvdGFibGVyYW5nZTo0YmE1MDlhY2FlN2Q0ZTVmYjBjYzFiYTk1YmZiMjBiYl8xLTItMS0xLTA_554ffa54-e6d8-4134-be8b-4ff781fbf980">AMED</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NGJhNTA5YWNhZTdkNGU1ZmIwY2MxYmE5NWJmYjIwYmIvdGFibGVyYW5nZTo0YmE1MDlhY2FlN2Q0ZTVmYjBjYzFiYTk1YmZiMjBiYl8xLTQtMS0xLTA_7dd8de5e-42df-4488-ae9d-98c4aef26924">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjMz_6fa218d6-6b0f-4de8-97c2-289083916b01">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjM0_e1d7a38a-3fe8-494f-b2c6-4a277fc5d049">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NTMyNWM3NTc1NGU4NDc0YjkyMzE3ZGM0YThjNjBkYmEvdGFibGVyYW5nZTo1MzI1Yzc1NzU0ZTg0NzRiOTIzMTdkYzRhOGM2MGRiYV8xLTAtMS0xLTA_8ef17eaa-43cd-473d-a120-b487411cb7e0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NTMyNWM3NTc1NGU4NDc0YjkyMzE3ZGM0YThjNjBkYmEvdGFibGVyYW5nZTo1MzI1Yzc1NzU0ZTg0NzRiOTIzMTdkYzRhOGM2MGRiYV8zLTYtMS0xLTA_36b6ddbf-4b6b-49e2-8350-c9a14de3e9ba">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGFibGU6NTMyNWM3NTc1NGU4NDc0YjkyMzE3ZGM0YThjNjBkYmEvdGFibGVyYW5nZTo1MzI1Yzc1NzU0ZTg0NzRiOTIzMTdkYzRhOGM2MGRiYV81LTItMS0xLTA_32dbf9e9-f307-453e-a7da-e15f2061a233">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMjQz_f0dba838-c289-4764-9012-a7178921cafa">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i07d63b1d905741c6ac588e15cfe76e29_I20211029"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xL2ZyYWc6OWRkMWUyMTJjZmM1NGY3ZDhjNzg0ZmZjZDQ5OTVhYTgvdGV4dHJlZ2lvbjo5ZGQxZTIxMmNmYzU0ZjdkOGM3ODRmZmNkNDk5NWFhOF8yMTk5_3527f12b-ce08-4957-a0a4-0fb523d364ad"
      unitRef="shares">32602425</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMy0xLTEtMS0w_a1d5375d-040e-489e-aaf7-354ef3cf5c2d"
      unitRef="usd">124458000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMy0zLTEtMS0w_2f1489f1-cf1e-4b11-a233-efa02512c75d"
      unitRef="usd">81808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNC0xLTEtMS0w_37ca7d4e-c33a-465b-aa5a-706bebf8097c"
      unitRef="usd">3750000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNC0zLTEtMS0w_08d9787e-f32d-42d4-9fc1-c864f4466703"
      unitRef="usd">1549000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNS0xLTEtMS0w_88c1740d-07f2-4cdb-9c39-7c5c0b428a8f"
      unitRef="usd">274570000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNS0zLTEtMS0w_04b02dbf-8557-4350-b6c7-a8b5b48bf547"
      unitRef="usd">255145000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNi0xLTEtMS0w_241c291b-f67c-4404-bd59-b862cc7fede5"
      unitRef="usd">16080000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNi0zLTEtMS0w_c5e2a94b-31bc-4526-95fc-a14848a1bd44"
      unitRef="usd">10217000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNy0xLTEtMS0w_cbfbc051-b435-4a67-babd-f337fc59e426"
      unitRef="usd">14024000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNy0zLTEtMS0w_305ccbc3-159a-41ee-b7bc-5603a035ca4e"
      unitRef="usd">13265000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOC0xLTEtMS0w_312db629-e902-48f2-805f-eee42b398b42"
      unitRef="usd">432882000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOC0zLTEtMS0w_0206b8de-2f11-4e27-a88f-510ace5de1f8"
      unitRef="usd">361984000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOS0wLTEtMS0wL3RleHRyZWdpb246MTk0MzkyZDk3NDRlNDY1NWJkM2I1NWRkNzIxYmM4NzJfNjM_79a67f70-95f2-45a7-8fc8-5f5c5f6decd8"
      unitRef="usd">100407000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOS0wLTEtMS0wL3RleHRyZWdpb246MTk0MzkyZDk3NDRlNDY1NWJkM2I1NWRkNzIxYmM4NzJfNzA_20b3876c-0472-4ea3-bc75-8221c299f612"
      unitRef="usd">95024000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOS0xLTEtMS0w_2a957ccf-1e8b-4b88-947f-976427415511"
      unitRef="usd">20381000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfOS0zLTEtMS0w_36305121-964c-49c3-9002-31ea287ad7b3"
      unitRef="usd">23719000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTAtMS0xLTEtMA_9af0baf2-8fe6-4152-b823-8bfc434b60de"
      unitRef="usd">100028000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTAtMy0xLTEtMA_77a24e02-dee1-41ca-9364-a441ce1a2a99"
      unitRef="usd">93440000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTEtMS0xLTEtMA_c1d13b66-1170-436a-aaf0-fee7bcdee380"
      unitRef="usd">1188054000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTEtMy0xLTEtMA_059d24e4-86d0-4e8c-a696-35280434011a"
      unitRef="usd">932685000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjgxZTg0NGUyZDdhODRlOGE4OWNmMjM0NjQ0ODQ5ZTdjXzU4_8462995f-bdc9-46bd-a646-4d16221d01cc"
      unitRef="usd">20309000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTItMC0xLTEtMC90ZXh0cmVnaW9uOjgxZTg0NGUyZDdhODRlOGE4OWNmMjM0NjQ0ODQ5ZTdjXzY1_906b01e1-700d-41dc-adf6-a2893cd44b70"
      unitRef="usd">22973000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTItMS0xLTEtMA_e3ad788a-ef42-4f42-bdb9-5fb43836fd77"
      unitRef="usd">118084000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTItMy0xLTEtMA_d4cea2b7-2c8c-4961-8210-ceb86f76b9fb"
      unitRef="usd">74183000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTMtMS0xLTEtMA_6f7140e1-f67b-4aa3-941b-49eba8e64c9a"
      unitRef="usd">10111000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTMtMy0xLTEtMA_9a9aa136-cf57-4faa-8611-2d9b2c29beb4"
      unitRef="usd">47987000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTQtMS0xLTEtMA_5061ddf3-a646-46c4-89e6-9153ac5c6d5e"
      unitRef="usd">68105000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTQtMy0xLTEtMA_ef2c0324-8473-4cbd-bd7f-cabf8f48db85"
      unitRef="usd">33200000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTUtMS0xLTEtMA_6e147d5d-32c1-4258-9a4a-d037271e493c"
      unitRef="usd">1937645000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTUtMy0xLTEtMA_45e9e635-c181-4067-ab73-87e98a3de366"
      unitRef="usd">1567198000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTgtMS0xLTEtMA_71c8937f-b049-4b11-bcd9-6454c3110351"
      unitRef="usd">41649000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTgtMy0xLTEtMA_0d9da5aa-0e3c-4336-b5af-24fd8e4fb4aa"
      unitRef="usd">42674000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTktMS0xLTEtMA_c5275d80-f9e3-4512-b808-2b9635a9de90"
      unitRef="usd">155123000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMTktMy0xLTEtMA_5517f006-8f6e-4c49-bcb2-32aeed9f1aa6"
      unitRef="usd">146929000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjAtMS0xLTEtMA_638bf593-73ba-4d90-8fd3-9c1b9464630c"
      unitRef="usd">154264000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjAtMy0xLTEtMA_cebefd11-6363-4ef4-9d3b-40cc5c2a00de"
      unitRef="usd">166192000</us-gaap:AccruedLiabilitiesCurrent>
    <amed:ProviderReliefFundAdvance
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjEtMS0xLTEtMA_b65f374b-6a43-496c-b1fa-30b46db74bd9"
      unitRef="usd">58535000</amed:ProviderReliefFundAdvance>
    <amed:ProviderReliefFundAdvance
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjEtMy0xLTEtMA_7376bd9e-1fb3-4067-9fd3-1b138e9854e6"
      unitRef="usd">60000000</amed:ProviderReliefFundAdvance>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjItMS0xLTEtMA_0c4ced75-76ea-4244-9afa-98dff735dbcd"
      unitRef="usd">13225000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjItMy0xLTEtMA_51652276-d253-47b8-875f-4ed727546557"
      unitRef="usd">10496000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjMtMS0xLTEtMA_c90ac32d-88c9-4a21-a80f-6c5c2434e966"
      unitRef="usd">31553000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjMtMy0xLTEtMA_2f795ee1-a5f3-49e3-b00b-d504d63db02e"
      unitRef="usd">30046000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjQtMS0xLTEtMA_197e1c34-e7b7-45c3-aedf-c71238b634ff"
      unitRef="usd">454349000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjQtMy0xLTEtMA_091c551b-5fdf-49f1-acc2-071a5ec1f319"
      unitRef="usd">456337000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjUtMS0xLTEtMA_c6a23767-9370-4262-9946-e49bfc0763de"
      unitRef="usd">434781000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjUtMy0xLTEtMA_c8d32311-2eb3-4734-a954-ef8e32438af2"
      unitRef="usd">204511000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjYtMS0xLTEtMA_de018951-7ee6-4653-962a-dc5957cce32c"
      unitRef="usd">67723000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjYtMy0xLTEtMA_aab1a4c8-87ac-4e8c-923f-48d3badfcadc"
      unitRef="usd">61987000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjctMS0xLTEtMA_0b795cda-608d-47c3-97fb-ebb5c2bf54e5"
      unitRef="usd">31991000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjctMy0xLTEtMA_fe642c4f-c2f6-4c8b-8721-dbdb5713426c"
      unitRef="usd">33622000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjgtMS0xLTEtMA_119cc251-75e7-4302-a95a-11ea8f1b9cb6"
      unitRef="usd">988844000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjgtMy0xLTEtMA_2b6324cc-a436-4bba-9b79-6107ecad77ba"
      unitRef="usd">756457000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMjktMS0xLTEtMA_9d1f3048-edbc-411a-ad6f-b273190ce42e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzIx_73760820-935a-4d95-90c9-b1ebb3dfbd7e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzIx_ec7086dd-5afd-4fd1-93cf-798cdad9551b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzM1_68ef7874-4482-47fd-b251-4324eea3f6d7"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzM1_9135caea-fe7e-4cb5-997c-fec4b4fa60aa"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzU3_54a82192-ae88-4986-a5a1-f493df5f2ca1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzU3_a1c9c623-017f-4e27-b5d3-1070fb783155"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzU3_a86fca1a-974b-48fc-8b7e-66475ee777ab"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmVjZTkxOTcwNmFmNDQyOTI5MTNiOTE4YjJiM2M3ODE0XzU3_f6d836e8-6a2c-4a32-80c1-2fb46a949fba"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMS0xLTEtMA_735fb688-6c22-4105-8e0c-10d7c88cfaab"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzEtMy0xLTEtMA_99824331-5675-45e7-948c-cbf07e48e7ca"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzE4_23f9b2d6-8621-4d7f-af0c-3bc3d07555e5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzE4_c50b74fa-9d40-44e7-9763-ad15f5294551"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzMy_2de27f43-622d-4b53-a736-3e5d6e0dd859"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzMy_52ed13ee-127e-41da-be45-92b58528dc7f"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzU0_114a8f2e-ea53-4c0c-bd43-dab5e140aaf1"
      unitRef="shares">37659284</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzYx_e3ee61d5-0ca8-4cb1-bb9b-d4f8ed31a308"
      unitRef="shares">37470212</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzgz_0bee9193-b839-4748-b197-98bc3c0d0938"
      unitRef="shares">32590775</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjYyMDAwMTg0YjQwYTU4ZmY0MzI1OWY2YmNlMzhjXzkw_74302751-f107-4e23-a402-6362ab56db22"
      unitRef="shares">32814278</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMS0xLTEtMA_6a3d9b77-c6b4-41f8-924c-a9b737d7d47c"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzItMy0xLTEtMA_e3e9fd7d-7806-4ea2-b038-f364a93afc22"
      unitRef="usd">38000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzMtMS0xLTEtMA_43a616b0-e87b-4407-91b7-a2b1a9b6f595"
      unitRef="usd">720875000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzMtMy0xLTEtMA_44a27b44-fc35-46e1-b53c-76a6391d1cdc"
      unitRef="usd">698287000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:TreasuryStockShares
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjUzNDRlYzk2YzgxNTQ0YTBiMTk3YWIwNDg4ODVmZGIwXzI4_8da7383d-b9c8-4c2d-b2bc-ce9b51561bcf"
      unitRef="shares">5068509</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzQtMC0xLTEtMC90ZXh0cmVnaW9uOjUzNDRlYzk2YzgxNTQ0YTBiMTk3YWIwNDg4ODVmZGIwXzM1_81bf5d2d-08fc-4349-8a06-a5f8700d9731"
      unitRef="shares">4655934</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzQtMS0xLTEtMA_51ce71f3-f025-4c7e-9972-6ea381d0b746"
      unitRef="usd">420665000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzQtMy0xLTEtMA_45849d98-92c5-4122-85b0-205e946ca4a5"
      unitRef="usd">319092000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzYtMS0xLTEtMA_70a408ee-0258-49f7-86b7-7854345efc6a"
      unitRef="usd">605016000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzYtMy0xLTEtMA_33007dca-8342-4e66-a362-9b5e19a74bd0"
      unitRef="usd">429991000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzctMS0xLTEtMA_ac2baa34-28e8-4785-8c12-9c63ef2c74a1"
      unitRef="usd">905264000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzctMy0xLTEtMA_03959670-9aba-4517-b3fd-fa0d9595f55c"
      unitRef="usd">809224000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzgtMS0xLTEtMA_33f1319b-97f4-454d-8487-a5a22dab4afe"
      unitRef="usd">43537000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzgtMy0xLTEtMA_9e4494ee-a855-48de-a72e-e07dafeb3955"
      unitRef="usd">1517000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzktMS0xLTEtMA_fae4e835-8b70-4c0b-9558-14c07d63b14b"
      unitRef="usd">948801000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfMzktMy0xLTEtMA_dad23227-8f1f-4f2f-875d-20d49a9728b2"
      unitRef="usd">810741000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNDAtMS0xLTEtMA_410c3966-2230-4f7d-9a9b-301faab856c0"
      unitRef="usd">1937645000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18xOS9mcmFnOmE2Njg0ZDU2ZGNhYjQxYTJhODI0MjgzMTUxNGYwMjJmL3RhYmxlOjFkZWZmZDMxOGI3MTQ2ODZhYTM5M2Q1OTM2Y2Y3YTNjL3RhYmxlcmFuZ2U6MWRlZmZkMzE4YjcxNDY4NmFhMzkzZDU5MzZjZjdhM2NfNDAtMy0xLTEtMA_dfa470f5-aba9-458d-8ed7-1651a8f72c19"
      unitRef="usd">1567198000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMi0xLTEtMS0w_476ae360-0151-4629-bec8-d6ae60214645"
      unitRef="usd">553485000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMi0zLTEtMS0w_71a324ff-5a7b-4283-a26f-3ac4a878f11d"
      unitRef="usd">544070000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMi01LTEtMS0w_4f1ed8ed-80b8-46b3-85b4-2d8384f5c762"
      unitRef="usd">1654795000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMi03LTEtMS0w_3698795b-6a31-4132-9968-e8952f9f022f"
      unitRef="usd">1520814000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMy0xLTEtMS0w_e47adcba-9f1c-4851-9cd2-db4039298158"
      unitRef="usd">-4000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMy0zLTEtMS0w_45067298-7439-40cf-b4ea-4748b5339add"
      unitRef="usd">4812000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMy01LTEtMS0w_5028a0a0-62fe-4354-9844-100667d58ea6"
      unitRef="usd">13300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMy03LTEtMS0w_39045973-2bbc-4948-a9b1-fb0fa9a7ff59"
      unitRef="usd">27592000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNC0xLTEtMS0w_9399b66c-4204-4e3f-a9ea-174d225a44ec"
      unitRef="usd">310294000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNC0zLTEtMS0w_195efcda-303a-4477-abaa-f6844a772cc9"
      unitRef="usd">297668000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNC01LTEtMS0w_d4a295ce-db3c-4d94-b258-74b1c39c8110"
      unitRef="usd">916188000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNC03LTEtMS0w_ffaa7343-d53b-49f7-9540-3fdfa488828b"
      unitRef="usd">878633000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNi0xLTEtMS0w_3667808b-2fff-489d-a7bb-6964bdb3da55"
      unitRef="usd">119373000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNi0zLTEtMS0w_9a9e4315-5127-4a37-86c4-318e509885bc"
      unitRef="usd">123146000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNi01LTEtMS0w_ca5d73a2-46b3-49f0-aa70-33e87d4c92c4"
      unitRef="usd">349533000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNi03LTEtMS0w_370df3c3-e5b8-490f-abe1-a66bb4b37655"
      unitRef="usd">330329000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNy0xLTEtMS0w_299d822f-2bfc-4914-8f83-1fe0d81971f9"
      unitRef="usd">4397000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNy0zLTEtMS0w_102feb53-d644-4cc0-b83c-567b44d9ad49"
      unitRef="usd">7124000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNy01LTEtMS0w_a1d7dcb8-6456-44d1-a514-dd16a7d3959c"
      unitRef="usd">17860000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfNy03LTEtMS0w_ecfcb0c2-10c2-4b00-8fac-1e4b2fea97ee"
      unitRef="usd">19758000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOC0xLTEtMS0w_ed539a8a-65db-45ce-972e-562b636c2f8b"
      unitRef="usd">55158000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOC0zLTEtMS0w_205abc6c-afdb-43d0-92e5-2cd34840b231"
      unitRef="usd">49348000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOC01LTEtMS0w_45fa2b71-f7c2-498b-a537-d0a1667b4acd"
      unitRef="usd">158995000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOC03LTEtMS0w_9cff2743-e7b4-418a-bbbb-c39ebeaa6292"
      unitRef="usd">142616000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOS0xLTEtMS0w_e2c550ec-bf46-4936-a5a5-935998187114"
      unitRef="usd">7487000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOS0zLTEtMS0w_e3428cab-87a1-4277-ab0d-c15445a28510"
      unitRef="usd">8283000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOS01LTEtMS0w_736e1bdf-fa63-4edd-98e6-7324a6d8a092"
      unitRef="usd">21763000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfOS03LTEtMS0w_4f8ee1c5-c6e9-4cdf-8112-5dc6848910e7"
      unitRef="usd">19955000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTAtMS0xLTEtMA_c5cf7a5f-8135-4573-b205-38c6bda5a51b"
      unitRef="usd">496709000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTAtMy0xLTEtMA_65163125-65ad-4379-b3ab-ebcf6c713458"
      unitRef="usd">485569000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTAtNS0xLTEtMA_5f004fd9-d320-4d36-acda-bedb33e66ce5"
      unitRef="usd">1464339000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTAtNy0xLTEtMA_2b43f3b2-4b95-4fb1-a28f-54737da0d8f9"
      unitRef="usd">1391291000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTEtMS0xLTEtMA_96de18b4-831c-46fe-bdf9-b5d9af291eb3"
      unitRef="usd">56772000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTEtMy0xLTEtMA_e802e412-cf85-4982-aafa-1edcaaec9faf"
      unitRef="usd">63313000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTEtNS0xLTEtMA_bdcbd6bd-5e6a-42c1-87fc-abf9a2fe5daa"
      unitRef="usd">203756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTEtNy0xLTEtMA_f858514c-7974-4037-988c-03ca6d1a4e80"
      unitRef="usd">157115000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTMtMS0xLTEtMA_d4cd0dc2-7a41-4050-ba6a-fab35578b3b7"
      unitRef="usd">0</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTMtMy0xLTEtMA_c09ce059-c27c-438c-b280-44ab69d17bae"
      unitRef="usd">31000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTMtNS0xLTEtMA_e5c556b3-bb37-4a0f-95d7-b4040b362c16"
      unitRef="usd">49000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTMtNy0xLTEtMA_bdf40b18-19e0-4689-a88d-53febc0bfc89"
      unitRef="usd">258000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTQtMS0xLTEtMA_07997ef3-6dff-4df3-b9f3-152a5e92e67e"
      unitRef="usd">2730000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTQtMy0xLTEtMA_75e2533c-bd60-4329-a8ad-e3b8edd32cdd"
      unitRef="usd">2692000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTQtNS0xLTEtMA_26c2ae60-c869-49fe-9ee6-2e0a876c6b87"
      unitRef="usd">6734000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTQtNy0xLTEtMA_a26fa539-0dc3-4d1d-8f70-b5f01c5e6b07"
      unitRef="usd">8675000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTUtMS0xLTEtMA_56641cc6-3a1e-467c-a81e-7f2b3671bec8"
      unitRef="usd">1444000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTUtMy0xLTEtMA_7f94160b-d5dc-43b9-9f46-d29b231769d5"
      unitRef="usd">1435000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTUtNS0xLTEtMA_889e5a0e-64a7-4ef7-97ad-eca95338d9c5"
      unitRef="usd">3932000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTUtNy0xLTEtMA_3476cd1e-df00-4561-9803-3383e118f5bb"
      unitRef="usd">2399000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTYtMS0xLTEtMA_c4581972-1778-471a-93e4-0e95076aebdc"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTYtMy0xLTEtMA_cc50baca-cc98-4e6f-ad0b-bb31abdf26e0"
      unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTYtNS0xLTEtMA_fc11b720-9b6f-44f6-a32c-0ad5c9f5019c"
      unitRef="usd">31092000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTYtNy0xLTEtMA_c994acaf-1bbe-4874-af13-6edd886b051b"
      unitRef="usd">-2980000</us-gaap:GainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTctMS0xLTEtMA_e2a558cb-163e-4072-9fb3-e0cbe7d3530c"
      unitRef="usd">490000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTctMy0xLTEtMA_071a1285-f5aa-4a3d-aebb-b9231b9033ac"
      unitRef="usd">122000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTctNS0xLTEtMA_63a07c75-435c-48f9-836e-1c23ef62acc3"
      unitRef="usd">1253000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTctNy0xLTEtMA_17af0acd-bb1a-4f55-8121-f737cd8be892"
      unitRef="usd">662000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTgtMS0xLTEtMA_425203e6-630a-4124-811a-8bfe0a8bca8a"
      unitRef="usd">-796000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTgtMy0xLTEtMA_952b1046-77a4-4175-8f8a-f3a08482ba0a"
      unitRef="usd">-1104000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTgtNS0xLTEtMA_d3af5c85-4ed2-4953-b72e-069368dd4422"
      unitRef="usd">29592000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTgtNy0xLTEtMA_8794467a-65bb-447c-944c-e6bf6f51b25b"
      unitRef="usd">-8336000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTktMS0xLTEtMA_9235bb26-2b77-4f5b-820a-b9f77d005839"
      unitRef="usd">55976000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTktMy0xLTEtMA_cc766ad6-65c6-4f40-82ac-9b81184d6cf6"
      unitRef="usd">62209000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTktNS0xLTEtMA_35781f81-5b60-4c13-90fb-4f5d36e26fa6"
      unitRef="usd">233348000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMTktNy0xLTEtMA_6eec3774-65f7-4c72-8514-caebcd5f2311"
      unitRef="usd">148779000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjAtMS0xLTEtMA_cdfc9a1a-f26c-4e0f-bd79-3a15b83f617c"
      unitRef="usd">10731000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjAtMy0xLTEtMA_8359b8d6-a6b3-4454-8d49-f4fa44485f5c"
      unitRef="usd">-10202000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjAtNS0xLTEtMA_72bc48f3-98d5-4d5d-8884-2729fbe116b0"
      unitRef="usd">57192000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjAtNy0xLTEtMA_db04ad7c-4b6e-4364-9ffc-4fcc1e0d9031"
      unitRef="usd">9175000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjEtMS0xLTEtMA_66232457-5d5f-4dd6-858d-ef4b6ccf0a68"
      unitRef="usd">45245000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjEtMy0xLTEtMA_51eb191c-2b0c-4893-ac89-598039106b0a"
      unitRef="usd">72411000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjEtNS0xLTEtMA_337de5a5-18c7-4ecd-a448-9ab431fef0b4"
      unitRef="usd">176156000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjEtNy0xLTEtMA_0f6e7639-21ee-44ce-a507-19824751799a"
      unitRef="usd">139604000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjItMS0xLTEtMA_2b83f8e3-d991-4aaf-8433-052c2f7551be"
      unitRef="usd">239000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjItMy0xLTEtMA_b4926eb8-a7da-46da-978c-2864be0d3e9d"
      unitRef="usd">430000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjItNS0xLTEtMA_4cd4c3e9-19cc-48b7-9993-c16a4730ba8f"
      unitRef="usd">1131000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjItNy0xLTEtMA_961e2514-5922-417b-9fe9-3bbfff8ac5f3"
      unitRef="usd">1147000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjMtMS0xLTEtMA_4fcb495e-f41a-4097-acd8-df6c16f5e038"
      unitRef="usd">45006000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjMtMy0xLTEtMA_9a8549a5-fc32-4058-94d7-17f81c7efaf9"
      unitRef="usd">71981000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjMtNS0xLTEtMA_d89e2c59-d4e8-4af2-b72f-43b43120274a"
      unitRef="usd">175025000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjMtNy0xLTEtMA_332796c0-d263-4e71-9de5-7ce74416a9c1"
      unitRef="usd">138457000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjUtMS0xLTEtMA_31d8ae49-8128-464c-823e-134fe8baf780"
      unitRef="usdPerShare">1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjUtMy0xLTEtMA_a284a5ba-7422-444f-b6bb-878c6e326346"
      unitRef="usdPerShare">2.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjUtNS0xLTEtMA_2b154c9e-4580-4dcd-9db5-6e44d173f8b7"
      unitRef="usdPerShare">5.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjUtNy0xLTEtMA_4461c5ea-b2cc-46a1-84ae-6538d4897099"
      unitRef="usdPerShare">4.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjYtMS0xLTEtMA_2bcf5f61-6f58-4844-9d72-23aa5e108c70"
      unitRef="shares">32607000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjYtMy0xLTEtMA_7e9a6e48-91a3-4667-8ae1-39e98d85c4d0"
      unitRef="shares">32662000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjYtNS0xLTEtMA_79e4a7b4-5694-4e4d-b98c-a26a422080c2"
      unitRef="shares">32658000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjYtNy0xLTEtMA_4625b479-d27e-435f-b7df-a5ca7810893e"
      unitRef="shares">32469000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjgtMS0xLTEtMA_294b2ece-3be5-477e-86ca-4f4a06356241"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjgtMy0xLTEtMA_5aa86a2d-3222-4b82-811c-66969200f964"
      unitRef="usdPerShare">2.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjgtNS0xLTEtMA_3ad7bf36-b64f-41cd-bb77-8c0ddf17e910"
      unitRef="usdPerShare">5.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjgtNy0xLTEtMA_ba35f00f-06fd-42c2-b451-5e0ecec2ba7b"
      unitRef="usdPerShare">4.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjktMS0xLTEtMA_de9e7a99-ccbb-4c92-9d6b-739c0e530148"
      unitRef="shares">32899000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjktMy0xLTEtMA_4f7fcfe7-4e13-4847-9db8-fa1f41c0f342"
      unitRef="shares">33260000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjktNS0xLTEtMA_8034014f-3422-461a-a277-2daf1dab4ad2"
      unitRef="shares">33021000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yNS9mcmFnOjYyNTE3M2VlZGEwMDQ0MGY5NDU0NjY2ZWUwYWI5MzJhL3RhYmxlOmRkNzc2NTc3MmNkNjQxOGNhN2RhNWViNDAwNGRiYmI1L3RhYmxlcmFuZ2U6ZGQ3NzY1NzcyY2Q2NDE4Y2E3ZGE1ZWI0MDA0ZGJiYjVfMjktNy0xLTEtMA_72844e20-d524-4200-a422-01894b7f9108"
      unitRef="shares">33267000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9bdd17b976b94417b0973260d8bd3e44_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0xLTEtMS0w_67bd9696-7310-47b2-8031-44f4ad15030d"
      unitRef="usd">875887000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="icd44a5fd2068444ea4c2b014fc212aba_I20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0zLTEtMS0w_37801ac5-6ad2-49ce-986b-c8f80072e37b"
      unitRef="shares">37553355</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icd44a5fd2068444ea4c2b014fc212aba_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy01LTEtMS0w_10055ca6-7451-416a-9a6d-c345a8e76218"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81046c5f2fe9466f935a9da81d4f9b05_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy03LTEtMS0w_99aea05a-5ea9-4e39-a04e-9ddc3554bfe9"
      unitRef="usd">714334000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i481818d771fb4e8cba7ee992ef045095_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy05LTEtMS0w_ccb81103-2153-4b4b-989a-bb80a32040c2"
      unitRef="usd">-400110000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2d22e47449f4dce9025ba20e4ee868e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0xMS0xLTEtMA_f2fd67f7-1888-414a-8e47-b3be95f44f78"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic477a09656e142a2ba9555f6e71e57b8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0xMy0xLTEtMA_c2d010cd-e7d6-4d84-abe3-55554ea8a6a7"
      unitRef="usd">560010000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i89642198499249a5a508a2b794a0c774_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMy0xNS0xLTEtMA_6931895b-8f71-4443-b1aa-38e4908630d7"
      unitRef="usd">1615000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNC0xLTEtMS0w_37724cd0-6bea-45de-94fe-7f72f7e1aa1b"
      unitRef="usd">1061000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNC0zLTEtMS0w_5d56c2f4-d5fb-4205-8e03-4e173eb626ef"
      unitRef="shares">5095</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNC03LTEtMS0w_d0c09b2c-6756-44e0-917c-79e722f7fd29"
      unitRef="usd">1061000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNS0xLTEtMS0w_c3eca259-8d48-4740-b44e-8118af192a52"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNS0zLTEtMS0w_dfab1611-e098-4380-b8b7-340f7e41795a"
      unitRef="shares">87460</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNS01LTEtMS0w_297e8eb9-e000-4b5a-8cb8-39fe6797596f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNS03LTEtMS0w_3aa64a2c-d32a-4d28-b80e-74d2bb360f34"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNi0xLTEtMS0w_d471eeeb-677e-42e1-a8dc-adaf87797de7"
      unitRef="usd">1083000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie4a7c5a049cf4a178fe8757886f02c7c_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNi0zLTEtMS0w_4fcd6237-3383-4921-b070-bb5971b8c788"
      unitRef="shares">13374</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNi03LTEtMS0w_b8a41928-d4bc-43de-9963-65a3798938b2"
      unitRef="usd">1083000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNy0xLTEtMS0w_570cb5ef-2d5d-4313-a14f-341c659861c7"
      unitRef="usd">4397000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibbe765a1cebf4bcf815356d176675673_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNy03LTEtMS0w_93c93dae-658b-41c1-848d-10104508ed64"
      unitRef="usd">4397000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfOC0xLTEtMS0w_399e8cdc-5dca-4f5a-83d6-16002c041172"
      unitRef="usd">9750000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="id633ade135bd4fa5a755576d79307e96_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfOC05LTEtMS0w_3928b39a-0bbc-4707-82f5-fa3719df5a38"
      unitRef="usd">9750000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfOS0xLTEtMS0w_a179e56e-39bb-4900-9cfa-1630528465a1"
      unitRef="usd">10805000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="id633ade135bd4fa5a755576d79307e96_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfOS05LTEtMS0w_b7c37770-8065-4d67-9a6c-ba11fb627f68"
      unitRef="usd">10805000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTAtMS0xLTEtMA_d25790e5-862c-43d1-97db-a911bd612ba7"
      unitRef="usd">459000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8585c2e41c09481f94254dd475c515cf_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTAtMTUtMS0xLTA_dd0d50e2-f189-4e66-8169-96276e15f729"
      unitRef="usd">459000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMS0xLTEtMTA1NDY_0fec00ac-0f06-478a-9589-b40e903ac51d"
      unitRef="usd">42142000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i8585c2e41c09481f94254dd475c515cf_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMTUtMS0xLTEwNTQ2_492eacbd-c955-47f6-8f74-684f47924052"
      unitRef="usd">42142000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:ProfitLoss
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMS0xLTEtMA_5feefb65-c15e-431f-9b61-27a1aaa1b344"
      unitRef="usd">45245000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i598b6bdc5e4b441ab25be4f2fd0a21ff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMTMtMS0xLTA_d4a8a46d-e1da-414f-87c2-4c6d3f38046b"
      unitRef="usd">45006000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8585c2e41c09481f94254dd475c515cf_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTEtMTUtMS0xLTA_785bb076-4b00-4316-88c3-d07e9558c366"
      unitRef="usd">239000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMS0xLTEtMA_4fd17bc8-12f2-4e57-9362-851921d51ba4"
      unitRef="usd">948801000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ia3722136a4de449192734a30989dde10_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMy0xLTEtMA_803987ff-fd5e-45ea-99fd-28a1ca89e378"
      unitRef="shares">37659284</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3722136a4de449192734a30989dde10_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItNS0xLTEtMA_66aa22d4-7d9d-4ea3-b389-f89e8e8a053d"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29f95beb109544799227cc0e3807a5a2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItNy0xLTEtMA_aa675ab9-43ed-4407-ab99-b0934d43f112"
      unitRef="usd">720875000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9586bde96dc4b55a43e520f969b3d49_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItOS0xLTEtMA_42b6612c-e626-45e3-9cd2-5196f6bd55f8"
      unitRef="usd">-420665000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i590fcf43ae93429c90aa189d83dd278c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMTEtMS0xLTA_ca1ec7fb-8895-4094-92fa-21d157f60fa3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f981173ad3f4a55af9ec673326e4ee7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMTMtMS0xLTA_259b9c8d-f6b4-4d66-b83f-d8a85a6d5667"
      unitRef="usd">605016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2fb123a126ca4044b4d597a6f5aeb789_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTItMTUtMS0xLTA_186d630f-0d39-42ff-b8f2-3c4e096af087"
      unitRef="usd">43537000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b307a62c3fb444494adee8144988b0d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMS0xLTEtMA_16b50366-1f6b-404a-a111-c6bda3de8fed"
      unitRef="usd">722259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i5e4f44436f8c4b4b84c3920f226cab7a_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMy0xLTEtMA_cc95afe1-b7bd-4312-a8c4-1549db95066a"
      unitRef="shares">36831298</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e4f44436f8c4b4b84c3920f226cab7a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctNS0xLTEtMA_aa114012-21d9-4cc1-abb2-c83e5c833c9e"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4afb39ea542d425cbf6ec7dcdc11d968_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctNy0xLTEtMA_cf63e34a-2fcd-4c9c-a058-6b27fc47368d"
      unitRef="usd">665580000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6701d88a3f6b429ba56daa18c8fb08cc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctOS0xLTEtMA_9175c727-f44b-4e08-9ee9-802f1d1f2612"
      unitRef="usd">-257625000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59e60464baed4c908a5a135d54dc4b11_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMTEtMS0xLTA_dbcb3aad-5d2f-4a3d-98e8-a674d0a156cb"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b35a3a550a440cc90fa58ad012ef681_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMTMtMS0xLTA_9fe02542-4cd8-4c6e-b6c0-45fec8c1e882"
      unitRef="usd">312859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17d9a940c2864685ae466b0f8760514a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTctMTUtMS0xLTA_fbd57df4-b73e-4efd-89c5-6a34fa2069e1"
      unitRef="usd">1408000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTgtMS0xLTEtMA_cf4cba32-eabe-4a3d-9b28-efc2effcfb89"
      unitRef="usd">914000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTgtMy0xLTEtMA_a5b4ccbd-8be4-4104-8304-99657d8bb8ae"
      unitRef="shares">5414</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTgtNy0xLTEtMA_89d3414e-5207-4c14-8880-8e339f848b43"
      unitRef="usd">914000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTktMS0xLTEtMA_31ca737c-c826-4a94-9aea-b82843ae9fc5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTktMy0xLTEtMA_dc8ec901-dcae-4cb2-b811-3367918c1de5"
      unitRef="shares">81767</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTktNS0xLTEtMA_a20a8057-d189-4ab0-9f38-fbee8f991b71"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMTktNy0xLTEtMA_96c87a59-9d1c-4e9c-a072-c679477224fe"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjAtMS0xLTEtMA_94b5ba2e-c2e9-46ea-a2ec-aa405621900a"
      unitRef="usd">3123000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie9b20752558b422ca7d079b9c4d304a3_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjAtMy0xLTEtMA_9ea80d8a-b58f-42b9-afa6-466310583529"
      unitRef="shares">538965</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjAtNy0xLTEtMA_89645871-7142-497c-9678-a5babcfd2680"
      unitRef="usd">3123000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjEtMS0xLTEtMA_5d240cb6-6a23-4043-9244-c8ab39cb61cb"
      unitRef="usd">7124000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjEtNy0xLTEtMA_0297d885-a93c-49ef-a3d5-f98e132622ca"
      unitRef="usd">7124000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjItMS0xLTEtMA_bc6cfa26-f8f7-4872-891b-397752babc7a"
      unitRef="usd">47788000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i1519169737fb443a8053b131fb736562_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjItNy0xLTEtMA_b3f59402-fb82-4b19-8586-50f0ed2eb3db"
      unitRef="usd">-13358000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i0981942253684fd5b4f7eb9fb411157c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjItOS0xLTEtMA_92c06e14-4675-4ee4-a04a-5014d474a25d"
      unitRef="usd">61146000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjMtMS0xLTEtMA_d1436b6f-b2d3-4e92-8bc8-6c10dc8b54e4"
      unitRef="usd">300000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i696f26883f1a42e28bc3241a2c02dc1c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjMtMTUtMS0xLTA_7a065154-f337-4774-89e8-b97fb45f964f"
      unitRef="usd">300000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjQtMS0xLTEtMA_4d7bfceb-068c-47bb-8bbe-2cd5759e23fa"
      unitRef="usd">72411000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i39f094da56c24200a601142582cdc2a0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjQtMTMtMS0xLTA_44992bca-3e9a-4340-b922-3f346ddbad8e"
      unitRef="usd">71981000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i696f26883f1a42e28bc3241a2c02dc1c_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjQtMTUtMS0xLTA_1b228e97-2d24-4c30-8667-4fbc44a3284e"
      unitRef="usd">430000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if09d9dfbada9402c82e04fffa1792aed_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMS0xLTEtMA_a0524a3e-b009-4fe6-bb25-69772ffd7f32"
      unitRef="usd">757743000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ifc6b318a025b416080e2e688fa3d70f4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMy0xLTEtMA_90d40cbc-3f83-49e7-bdbe-603b51052363"
      unitRef="shares">37457444</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc6b318a025b416080e2e688fa3d70f4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtNS0xLTEtMA_df0b3feb-7d58-4832-8e75-c517dab52cb1"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21bb61efbc804a59b103a8fc6e57cb32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtNy0xLTEtMA_6560532b-4229-4ded-9034-7d5a5425b955"
      unitRef="usd">690099000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1180b4ef96164b9a9e4962f634ba5bcb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtOS0xLTEtMA_cee2a221-da90-4e6a-a43b-85e31d998ecd"
      unitRef="usd">-318771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8c58ab1289048be8261102b772d4db9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMTEtMS0xLTA_b735d0c7-b352-4b38-b542-c447a844d41d"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6e494dd063a4d8aa19b36fcb24fed25_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMTMtMS0xLTA_c0c3882e-4b2c-423e-965d-6bd3123c8555"
      unitRef="usd">384840000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia855683296e64bf18a9ef89f356655a0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMjUtMTUtMS0xLTA_fa9c6d36-8b3c-4e0d-bf7a-b9142530f74c"
      unitRef="usd">1538000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMS0xLTEtMA_aa628e81-8b72-497a-b030-204b5c880a3c"
      unitRef="usd">810741000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ifa9afb8e5e3644a59da63953d75e842c_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMy0xLTEtMA_e7d40b30-2b5d-42e4-8a49-4ca93cfffa37"
      unitRef="shares">37470212</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa9afb8e5e3644a59da63953d75e842c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtNS0xLTEtMA_12758dae-e402-4c8e-9932-af33185d8c24"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc92f06d04394959b3242b038919464a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtNy0xLTEtMA_825fced1-56d3-4a9a-a868-e6a8e6aa40bf"
      unitRef="usd">698287000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib42b43eecaab42a78203a133cac36e19_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtOS0xLTEtMA_beb4f255-26cc-45e3-84d9-25d4667df833"
      unitRef="usd">-319092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i23b5458af0924ae791b517938fa92dba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMTEtMS0xLTA_e3cc26e0-ddf8-444d-95cc-1209780b0d53"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i84c69e51ef304378875bd8586144f797_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMTMtMS0xLTA_4c3f5260-7564-4d4b-ac44-8928f53e8c20"
      unitRef="usd">429991000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ff740465893462abb39658ee50a3980_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzAtMTUtMS0xLTA_8f945d51-dc23-46aa-8321-f8f8940fec27"
      unitRef="usd">1517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzEtMS0xLTEtMA_0a7f562b-c6b5-473b-be25-15dce9c8bbb7"
      unitRef="usd">3022000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzEtMy0xLTEtMA_0a031ae5-6107-492b-bcb6-0d53856c9c87"
      unitRef="shares">13357</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzEtNy0xLTEtMA_e762eb3a-d362-4b7d-82b5-81ebbc71937e"
      unitRef="usd">3022000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzItMS0xLTEtMA_705beae2-7c29-4e70-996e-4033d4e6db4e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzItMy0xLTEtMA_ca85bfbc-c59f-4adb-aa24-e345ce6eb822"
      unitRef="shares">148529</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzItNS0xLTEtMA_0ef9c6ec-99e6-4cfc-a613-c9c5e509c2f3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzItNy0xLTEtMA_a59f43cc-68ea-4b61-8e20-339277d06b9b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzMtMS0xLTEtMA_ff5b8c37-f1f5-45e5-a6b4-8ad26de32933"
      unitRef="usd">1706000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie8d7be353fd044cd96d17e0abab87984_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzMtMy0xLTEtMA_7bf39fd1-5f6f-4710-8082-d64c4f610dd9"
      unitRef="shares">27186</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzMtNy0xLTEtMA_fc8be5bc-ad1e-48c9-8dd0-b3fda61431b9"
      unitRef="usd">1706000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzQtMS0xLTEtMA_df439227-560c-4828-a23b-623f1f4b7011"
      unitRef="usd">17860000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaccdc636a1ec4920a0e81af33a06830f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzQtNy0xLTEtMA_820d5cf8-e451-45f2-bf58-e3c15e556268"
      unitRef="usd">17860000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzUtMS0xLTEtMA_9b0ac2d4-9d82-43c4-aa44-975bf3dce030"
      unitRef="usd">16694000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="iccb3f95375f5445ba8782cf65507f940_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzUtOS0xLTEtMA_9f9fc8c6-8141-4e77-9449-f5bf03e75e05"
      unitRef="usd">16694000</amed:SurrenderedShares>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzYtMS0xLTEtMA_5346d53c-e810-43e3-822f-95d80c151456"
      unitRef="usd">84879000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="iccb3f95375f5445ba8782cf65507f940_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzYtOS0xLTEtMA_0c610999-50cf-404c-ad5d-9adf2ae35c59"
      unitRef="usd">84879000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzctMS0xLTEtMA_b455827c-4be0-48bc-acd7-69fe4eb68f55"
      unitRef="usd">1253000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i46836dfa696048bb8468c58880596456_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzctMTUtMS0xLTA_1d79f9b1-e7f2-4128-bc26-09aef0fdd3f8"
      unitRef="usd">1253000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMS0xLTEtMTA1Njk_6d3f6c2e-b751-483f-878a-c8d78624eb5f"
      unitRef="usd">42142000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i46836dfa696048bb8468c58880596456_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMTUtMS0xLTEwNTY5_832fcaf4-fd72-4240-8876-9072c05f0bbe"
      unitRef="usd">42142000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:ProfitLoss
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzgtMS0xLTEtMA_6192eb11-3cb9-43e5-8cbb-9437f2a4ccee"
      unitRef="usd">176156000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2a5883b3c8ba45e0853c437d045de477_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzgtMTMtMS0xLTA_953b35ce-c74d-4624-99e4-676a6a8cb360"
      unitRef="usd">175025000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i46836dfa696048bb8468c58880596456_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzgtMTUtMS0xLTA_1bb99229-fb30-4608-91cb-e6c08ffc4f3e"
      unitRef="usd">1131000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMS0xLTEtMA_8b57dc02-7135-416e-bb79-18d5eb4cc91a"
      unitRef="usd">948801000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ia3722136a4de449192734a30989dde10_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMy0xLTEtMA_d7ca0450-0a03-471f-babf-0039e20e63f2"
      unitRef="shares">37659284</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3722136a4de449192734a30989dde10_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktNS0xLTEtMA_06b8934f-9cdc-4eb8-a96b-3c5c446bb598"
      unitRef="usd">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29f95beb109544799227cc0e3807a5a2_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktNy0xLTEtMA_f45075ee-ba82-4244-b107-20b9bfcdd3c3"
      unitRef="usd">720875000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9586bde96dc4b55a43e520f969b3d49_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktOS0xLTEtMA_aa1e40b0-bc70-49c1-aadc-83106e90a309"
      unitRef="usd">-420665000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i590fcf43ae93429c90aa189d83dd278c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMTEtMS0xLTA_66dda142-c950-4574-b31f-6cf994f453f8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f981173ad3f4a55af9ec673326e4ee7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMTMtMS0xLTA_c1093880-e0ee-41f2-bd68-56bc0de6f8d6"
      unitRef="usd">605016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2fb123a126ca4044b4d597a6f5aeb789_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfMzktMTUtMS0xLTA_70081ada-7fdb-49de-bde4-b99ae2dcfb3a"
      unitRef="usd">43537000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8a2e6cc1034448789c21e45ddc2a62a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMS0xLTEtMA_b4fa02f6-f2e1-48a4-b786-97723d9fffaf"
      unitRef="usd">641513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i6566df00d848434baa97e9fd857c714c_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMy0xLTEtMA_6b25329b-e80f-4079-b434-9e2f5b498a11"
      unitRef="shares">36638021</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6566df00d848434baa97e9fd857c714c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtNS0xLTEtMA_bec3f69b-9163-47d9-9099-6a3bb76cc321"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c7b322b8d954305ab4228a0e4f5fa44_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtNy0xLTEtMA_ed2ac7fd-4991-49de-b342-41012e5c1234"
      unitRef="usd">645256000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69fea3aa6870434ea5666aacfdf3d1d0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtOS0xLTEtMA_a8808722-7190-4bf5-9373-66b4e3eaa5d6"
      unitRef="usd">-251241000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d9c15c2efa64925929ae6f6cfe42a0b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMTEtMS0xLTA_5905e300-a54e-4140-8363-1f45d475a17a"
      unitRef="usd">15000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i70db5c4d7e784bac89013422e4e11011_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMTMtMS0xLTA_c5a4b555-8bb1-4fa8-8c2a-c4d210b05eec"
      unitRef="usd">246383000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i884c25e331534f468450dd28f2d93e40_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDQtMTUtMS0xLTA_ce98f153-1ec7-4fcf-b455-1b7a5733ba59"
      unitRef="usd">1063000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDUtMS0xLTEtMA_907d0bc4-105f-43ef-a4fd-61dedacacc68"
      unitRef="usd">2600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDUtMy0xLTEtMA_aa999588-a715-4e90-ac75-26b49cf364c4"
      unitRef="shares">16772</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDUtNy0xLTEtMA_3b5ee9ae-2acd-459e-ba19-836728afd54d"
      unitRef="usd">2600000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDYtMS0xLTEtMA_ee753d18-3011-4a72-a302-f56bffdca8df"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch
      contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDYtMy0xLTEtMA_98a03cce-0566-4730-8e24-a09d8fdb3cc5"
      unitRef="shares">18312</amed:StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDYtNS0xLTEtMA_4209787e-f0b5-41cc-bd0c-24961d432d8a"
      unitRef="usd">0</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch
      contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDYtNy0xLTEtMA_4b825f9a-678c-4e42-a7c7-27ab3d75fc10"
      unitRef="usd">3057000</amed:StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDctMS0xLTEtMA_79db783c-61be-4a21-a8ef-e4c0d3786c60"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDctMy0xLTEtMA_76d17b95-3e58-4d64-a8aa-2ff770f212a5"
      unitRef="shares">166651</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDctNS0xLTEtMA_78fc38f3-fb4b-4ae7-bf72-2c4f4508d08b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDctNy0xLTEtMA_92913c68-c4ab-4bac-b7e6-afb8e7edb444"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDgtMS0xLTEtMA_bae561a7-5fa8-43de-b616-7cd89d3818fc"
      unitRef="usd">6070000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iee5b59c093504cc190747f3bd3c1ae1a_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDgtMy0xLTEtMA_a5908881-5f3a-45b6-96a2-cb9587d6ed01"
      unitRef="shares">617688</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDgtNy0xLTEtMA_ed8f0cd2-f3e4-4f83-a574-7cd5ba5f5532"
      unitRef="usd">6070000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDktMS0xLTEtMA_ec000a4f-ddd9-42c6-b626-386b24f444fc"
      unitRef="usd">19758000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNDktNy0xLTEtMA_a8cb6182-602c-4016-87ee-305d19335429"
      unitRef="usd">19758000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <amed:SurrenderedShares
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTAtMS0xLTEtMA_8f80a7f5-1dc9-42e0-beb9-7c9e8c5c17bc"
      unitRef="usd">54172000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i1665f1653ce246cdbb2b39af27a60e5e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTAtNy0xLTEtMA_69f4228c-71b7-4c26-a92d-5a84a3cf8f4d"
      unitRef="usd">-13358000</amed:SurrenderedShares>
    <amed:SurrenderedShares
      contextRef="i67b5b45191d24afe8a6500e067394b03_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTAtOS0xLTEtMA_342f4062-20d8-4928-a179-07b213b06a4a"
      unitRef="usd">67530000</amed:SurrenderedShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTEtMS0xLTEtMA_3c7f78e1-5bda-4f05-bf80-62af0d828cfe"
      unitRef="usd">672000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i465c7064fe5e412e978bfdd7128be6a7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTEtMTUtMS0xLTA_a6779ed1-346d-4044-b8fb-719f76002ed9"
      unitRef="usd">672000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTItMS0xLTEtMA_372e06ef-c20a-4567-93e6-f01a78bb128b"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome
      contextRef="i96d80f5ecb444e898ca8530a2f8c3d9e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTItMTEtMS0xLTA_554bf195-ff53-4e0b-8f13-afc3eebf2877"
      unitRef="usd">15000</amed:EquityImpactOfWriteOffOfOtherComprehensiveIncome>
    <us-gaap:ProfitLoss
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTMtMS0xLTEtMA_1574d19d-1a99-4dfd-9a85-ac84b7baab95"
      unitRef="usd">139604000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4b85cedd162948299f5f10b84f850dd7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTMtMTMtMS0xLTA_54ffd64d-6bd3-4fb2-a00a-ebb197510d2b"
      unitRef="usd">138457000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i465c7064fe5e412e978bfdd7128be6a7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTMtMTUtMS0xLTA_0e3758cb-cd57-409d-bf84-1599741182a6"
      unitRef="usd">1147000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if09d9dfbada9402c82e04fffa1792aed_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMS0xLTEtMA_d300c920-4c66-42b6-a184-19a9415247a0"
      unitRef="usd">757743000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ifc6b318a025b416080e2e688fa3d70f4_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMy0xLTEtMA_3e770438-a1ae-4f2a-85c6-d845b8c2517e"
      unitRef="shares">37457444</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifc6b318a025b416080e2e688fa3d70f4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtNS0xLTEtMA_9b496b26-14fb-4f5f-910a-1f2f526d9d9e"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21bb61efbc804a59b103a8fc6e57cb32_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtNy0xLTEtMA_111bb4ba-068d-4c57-8a0b-33d2550338cd"
      unitRef="usd">690099000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1180b4ef96164b9a9e4962f634ba5bcb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtOS0xLTEtMA_93f3f306-59c4-4276-bad1-84f76a68e3b6"
      unitRef="usd">-318771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8c58ab1289048be8261102b772d4db9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMTEtMS0xLTA_c1582629-02d1-49b5-a11e-07f197fa9145"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6e494dd063a4d8aa19b36fcb24fed25_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMTMtMS0xLTA_8b3c8b21-849b-4f16-a67b-c981eb5f4cd4"
      unitRef="usd">384840000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia855683296e64bf18a9ef89f356655a0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18yOC9mcmFnOjAwODI2MGRlYWE2YjRhYWU5YWZjNTQ1YzAzNDY5ZjA0L3RhYmxlOmE5MTZhYTFhMTFmNjRhMzU5ZjgwM2FiMDk3YTEzMWI4L3RhYmxlcmFuZ2U6YTkxNmFhMWExMWY2NGEzNTlmODAzYWIwOTdhMTMxYjhfNTQtMTUtMS0xLTA_1ed5a30c-292a-44ca-87b2-a0f310b45cc1"
      unitRef="usd">1538000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMy0xLTEtMS0w_711afb36-36f5-4953-bd02-1c76008d59ff"
      unitRef="usd">176156000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMy0zLTEtMS0w_bfd808f0-48c0-453a-862b-b9c4ab4094de"
      unitRef="usd">139604000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNS0xLTEtMS0w_4fb8386f-ca40-431c-a185-7cba7a34e61a"
      unitRef="usd">21763000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNS0zLTEtMS0w_1396753b-f22c-485f-a48d-b4e9125f65b5"
      unitRef="usd">19955000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNi0xLTEtMS0w_c044dfd8-ccb4-4fa9-b234-3075e8ee79f3"
      unitRef="usd">17860000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNi0zLTEtMS0w_ef1eb764-8a74-45e6-8a57-2f566c49ac37"
      unitRef="usd">19758000</us-gaap:ShareBasedCompensation>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNy0xLTEtMS0w_fb4d3a48-0090-48e7-8ef6-12a0a859d37c"
      unitRef="usd">30181000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNy0zLTEtMS0w_4f88b7b0-faef-43f8-be76-1760587aa573"
      unitRef="usd">29149000</amed:AmortizationandImpairmentofOperatingLeaseRightOfUseAsset>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfOC0xLTEtMS0w_ca862190-cb74-4b2d-9874-0ac0f0ca6aa7"
      unitRef="usd">64000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfOC0zLTEtMS0w_6728494d-89f7-4000-b6ef-fd1960e4b432"
      unitRef="usd">77000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfOS0xLTEtMS0w_7fdbc561-4a8c-4fcf-a15f-c6c1a9ad371d"
      unitRef="usd">31092000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfOS0zLTEtMS0w_8441a0c5-32c8-48dc-8891-655af129f8e5"
      unitRef="usd">-2980000</us-gaap:GainLossOnSaleOfInvestments>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTAtMS0xLTEtMA_a45c2d09-a1de-4b30-ba85-cb08a1facb01"
      unitRef="usd">0</amed:WriteOffOfOtherComprehensiveIncome>
    <amed:WriteOffOfOtherComprehensiveIncome
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTAtMy0xLTEtMA_4bf2dd49-04f2-4298-bce6-6552ca18c00b"
      unitRef="usd">15000</amed:WriteOffOfOtherComprehensiveIncome>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTEtMS0xLTEtMA_14005b0a-03fe-45a4-8011-7a7a129aa29a"
      unitRef="usd">34729000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTEtMy0xLTEtMA_503c4968-525b-4f5b-b017-9a7c2819caca"
      unitRef="usd">-2762000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTItMS0xLTEtMA_2816ef72-e50f-4faa-a1fc-29ef4480e624"
      unitRef="usd">3932000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTItMy0xLTEtMA_d30f0265-c292-4867-8f5b-a3a6e2db503f"
      unitRef="usd">2399000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTMtMS0xLTEtMA_46ae4bcb-f1eb-468c-b26b-ecf3f46bd389"
      unitRef="usd">669000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTMtMy0xLTEtMA_f9a765ee-502e-4414-a315-1483fff6794d"
      unitRef="usd">653000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTQtMS0xLTEtMA_ad8ab1d3-ea8b-4fba-afdf-067bb596a282"
      unitRef="usd">4268000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTQtMy0xLTEtMA_93ddfe5b-eeeb-4420-9cd5-1dff77991ac3"
      unitRef="usd">3919000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTYtMS0xLTEtMA_b6e8e15b-cb39-4dfa-8a17-278b4baf3c10"
      unitRef="usd">17638000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTYtMy0xLTEtMA_f97c833c-2df9-4b4c-ad80-4bb6970f1d58"
      unitRef="usd">-6486000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTctMS0xLTEtMA_28d1fe2b-6b5d-41e6-b1fe-72aad273704e"
      unitRef="usd">6219000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTctMy0xLTEtMA_9f10908f-199b-4fee-a436-a1c00afa8f45"
      unitRef="usd">28217000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTgtMS0xLTEtMA_48c9a068-ea7e-4c3c-9f99-3ee11491967d"
      unitRef="usd">938000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTgtMy0xLTEtMA_60f15ebb-2555-4a5b-87fc-462219ca9ff5"
      unitRef="usd">91000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTktMS0xLTEtMA_26a83a3c-cffb-4ce7-a152-5c65478fe7bf"
      unitRef="usd">-1192000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMTktMy0xLTEtMA_e19a5164-db73-4cf2-b1e8-43370e924138"
      unitRef="usd">-1627000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjAtMS0xLTEtMA_aaea1be5-0d93-46f8-9dba-12c31be6f400"
      unitRef="usd">-9363000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjAtMy0xLTEtMA_8f3e2a6a-b0dd-4a9b-9ef1-b5649e1fd4db"
      unitRef="usd">25594000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjEtMS0xLTEtMA_8d11e975-265f-448a-b19b-229fa76d5da7"
      unitRef="usd">-1785000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjEtMy0xLTEtMA_24a452c9-ec6d-4061-abd0-ef4b9cc9c82d"
      unitRef="usd">38481000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjItMS0xLTEtMA_ab63fe68-3449-44a5-9b28-14f8a92d84f6"
      unitRef="usd">-27372000</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjItMy0xLTEtMA_13a0dc35-df86-428a-a501-02d7d8eb8901"
      unitRef="usd">-25576000</amed:IncreaseDecreaseInOperatingLeaseLiability>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjMtMS0xLTEtMA_ce3648fa-b1a2-4865-b046-47419baa2c62"
      unitRef="usd">-2304000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjMtMy0xLTEtMA_7a97a7d6-d0b7-424f-8093-4b258106c0b4"
      unitRef="usd">-2775000</amed:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjQtMS0xLTEtMA_333c7606-1101-4184-909d-69749d875e46"
      unitRef="usd">183727000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjQtMy0xLTEtMA_48c1e296-4423-410f-b7e6-932ff2f36288"
      unitRef="usd">223040000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjYtMS0xLTEtMA_60d652ad-af00-45ef-b789-35e0991612d5"
      unitRef="usd">126000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjYtMy0xLTEtMA_da46d256-89d2-4e1d-9dfb-607a22a57b49"
      unitRef="usd">94000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjctMS0xLTEtMA_7b3dac72-46a5-4f87-b698-763abb99913f"
      unitRef="usd">140000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjctMy0xLTEtMA_fa875fcb-a443-47a6-aa23-ff32b62cec9f"
      unitRef="usd">80000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjgtMS0xLTEtMA_0338de0e-b8f8-4364-9dd9-024dfec0add9"
      unitRef="usd">5187000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjgtMy0xLTEtMA_87ff60fa-44ab-4b39-a043-70fcb98c809f"
      unitRef="usd">2995000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjktMS0xLTEtMTE5MTA_af26e58e-d46c-4f3f-b0af-2b9860af2453"
      unitRef="usd">147000</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToDevelopSoftware
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjktMy0xLTEtMTIzMjQ_2bbaa29f-7dc7-450d-9795-489910a139fa"
      unitRef="usd">0</us-gaap:PaymentsToDevelopSoftware>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjktMS0xLTEtMA_04c40430-c5b8-4da5-8a24-c6a4c49ab7e1"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMjktMy0xLTEtMA_6c6aa47b-745f-404e-a0c1-329cc76e8ec7"
      unitRef="usd">875000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzAtMS0xLTEtMA_ff5f17f3-799d-4d47-b709-d4ce159d098e"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzAtMy0xLTEtMA_7313a845-96ea-477d-8555-469374ff3451"
      unitRef="usd">17876000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzEtMS0xLTEtMA_cf9566ef-a8d4-4382-aec0-61cc204e876a"
      unitRef="usd">264872000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzEtMy0xLTEtMA_741b7f7a-d70c-4b2e-a375-0436b000429e"
      unitRef="usd">299723000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzItMS0xLTEtMA_db4f6379-7ac6-46a3-b7fd-ad347c48cb76"
      unitRef="usd">-269940000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzItMy0xLTEtMA_a1e0f9ec-65f8-45f4-8daa-4e072b47b80b"
      unitRef="usd">-285543000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzQtMS0xLTEtMA_a03ca270-4597-46c8-b091-7edb3acb30ab"
      unitRef="usd">1706000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzQtMy0xLTEtMA_f6a88327-71b3-42cd-807c-be629841845a"
      unitRef="usd">6070000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzUtMS0xLTEtMA_bfc24e43-b09b-4e9d-a4dc-1a9ddcc0cd3c"
      unitRef="usd">3022000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzUtMy0xLTEtMA_a27db780-fb7c-4287-a2eb-421d99b4814b"
      unitRef="usd">2600000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzYtMS0xLTEtMA_6153c50f-ce77-4d25-bd98-0116d96beeaa"
      unitRef="usd">16694000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzYtMy0xLTEtMA_383eb567-dbe2-41f0-be43-1113aeaaa1af"
      unitRef="usd">54172000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzctMS0xLTEtMA_0d6dc6c0-9412-490d-9669-94836b73a7ea"
      unitRef="usd">1253000</amed:CashDistributionToNoncontrollingInterest>
    <amed:CashDistributionToNoncontrollingInterest
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzctMy0xLTEtMA_21c32139-2233-4295-b4fb-1435fcbd7038"
      unitRef="usd">672000</amed:CashDistributionToNoncontrollingInterest>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzgtMS0xLTEtMTEz_14a4c88f-6416-4905-8358-5770a925b869"
      unitRef="usd">290312000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzgtMy0xLTEtMTEz_28a3b4a1-2e9f-437a-966c-feebbe00cd90"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzgtMS0xLTEtMA_3c818ef2-a477-4c03-bef7-d7aa5bf787a2"
      unitRef="usd">500700000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzgtMy0xLTEtMA_d9b3c020-3fc3-4950-9803-81aa99006243"
      unitRef="usd">432000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzktMS0xLTEtMA_31086bcb-bad8-4a62-8c4e-e6434837e360"
      unitRef="usd">551700000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfMzktMy0xLTEtMA_bcb2bd88-8d92-4a34-a52f-a293b163943c"
      unitRef="usd">357000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDAtMS0xLTEtMA_4e5cb199-a5d7-4f1e-918f-a801cbe3ba84"
      unitRef="usd">5893000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDAtMy0xLTEtMA_154ac0b4-9ba6-4cd9-9439-2948e1f7d854"
      unitRef="usd">7360000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDItMS0xLTEtMTEz_82302667-355e-46a6-82ec-ae4ae2480d92"
      unitRef="usd">2792000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDItMy0xLTEtMTEz_449b64d9-9644-4131-85fb-393203ac7f23"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDEtMS0xLTEtMA_e7e0aad2-99d1-44f5-bbde-6063afcfb5eb"
      unitRef="usd">84879000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDEtMy0xLTEtMA_06e5be52-f840-4537-a1e0-80dd6b094a66"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDItMS0xLTEtMA_bc61f26e-0a59-4b60-9894-48b747c4ccfc"
      unitRef="usd">-1465000</amed:FundsReceivedFromProviderReliefFundAdvance>
    <amed:FundsReceivedFromProviderReliefFundAdvance
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDItMy0xLTEtMA_3ee326bc-b26b-443d-9e9b-73963518d8e4"
      unitRef="usd">60000000</amed:FundsReceivedFromProviderReliefFundAdvance>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDMtMS0xLTEtMA_d349e6ab-fd2a-4ccd-9b6f-8f4f40b282d0"
      unitRef="usd">131064000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDMtMy0xLTEtMA_8598cc1c-afa3-48a5-bc4c-037703b4a8e3"
      unitRef="usd">81466000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDQtMS0xLTEtMA_70ebcd66-0ebc-463a-a4f0-c231aa860536"
      unitRef="usd">44851000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDQtMy0xLTEtMA_f4726550-aff5-4ce9-aa14-2b377c3c8faa"
      unitRef="usd">18963000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDUtMS0xLTEtMA_8631886a-c7b7-4cfc-ba2b-7d7557aa26c8"
      unitRef="usd">83357000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic8a2e6cc1034448789c21e45ddc2a62a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDUtMy0xLTEtMA_bbfe7167-a0d8-4c81-b90a-87e4e06b21dc"
      unitRef="usd">96490000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDYtMS0xLTEtMA_2adadd57-0cb1-4156-ba19-cef13fbba9c4"
      unitRef="usd">128208000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if09d9dfbada9402c82e04fffa1792aed_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDYtMy0xLTEtMA_2002363f-c02d-47e3-9d39-fd098a6588b9"
      unitRef="usd">115453000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDktMS0xLTEtMA_94256677-af1e-446f-8e69-ad96d652d77e"
      unitRef="usd">3479000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNDktMy0xLTEtMA_9b4c4d9d-3035-4c0a-902b-3fd65a34a13b"
      unitRef="usd">4902000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTAtMS0xLTEtMA_4ccba4e7-f887-4a3a-ad3e-c816ab651195"
      unitRef="usd">25482000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTAtMy0xLTEtMA_a9c76c15-c4c9-4d3f-af4e-e39c3a895437"
      unitRef="usd">30290000</us-gaap:IncomeTaxesPaidNet>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTEtMS0xLTEtMA_195b7d31-3d51-4207-80f0-0fe68df167ef"
      unitRef="usd">29676000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForOperatingLeaseLiabilities
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTEtMy0xLTEtMA_8cc7c2d3-25fe-4080-9c9b-bb1dc9ffd7e4"
      unitRef="usd">28351000</amed:CashPaidForOperatingLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTItMS0xLTEtMA_cc0e4555-d0f9-4a68-b54e-781f870864b7"
      unitRef="usd">1509000</amed:CashPaidForFinanceLeaseLiabilities>
    <amed:CashPaidForFinanceLeaseLiabilities
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTItMy0xLTEtMA_d523144e-997a-40e6-aacf-46fd04984a0a"
      unitRef="usd">1483000</amed:CashPaidForFinanceLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTQtMS0xLTEtMA_50f8746b-57c8-46f0-a1ef-c13d7ee8b21e"
      unitRef="usd">34881000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTQtMy0xLTEtMA_018e8643-23e5-4fce-b4e1-5b644dd3d8ec"
      unitRef="usd">29876000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTUtMS0xLTEtMA_621a7f6f-8475-4a40-ad15-b202e725591a"
      unitRef="usd">814000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTUtMy0xLTEtMA_e6ab178a-37e2-4ee6-9ef5-d28b420b6d04"
      unitRef="usd">822000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTYtMS0xLTEtMA_11c8fa98-47c9-466b-8401-efd2195d5261"
      unitRef="usd">1183000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zMS9mcmFnOmIxNDcxNDQ5MTFmODQ2M2M4YzE5ZDhhM2I3NGMwODQ2L3RhYmxlOjFmZTNiZDlmYTc2MjQ3MDk4MWU3MmIyNDMxNTVhYTkyL3RhYmxlcmFuZ2U6MWZlM2JkOWZhNzYyNDcwOTgxZTcyYjI0MzE1NWFhOTJfNTYtMy0xLTEtMA_c8b35e76-7009-4c54-aebf-b4805447d0a1"
      unitRef="usd">767000</amed:LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQxNg_d7cc4bca-3a4c-4a23-986f-214a6ca2af63">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#x201c;Amedisys,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately 75% of our net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2021 and approximately 76% and 75% of our net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2020, respectively. As of September&#160;30, 2021, we owned and operated 328 Medicare-certified home health care centers, 177 Medicare-certified hospice care centers, 14 personal-care care centers and 8 high acuity care joint ventures in 38 states within the United States and the District of Columbia. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 25, 2021 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $48.3 million and $14.2 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of September 30, 2021, we are proportionately consolidating seven of our eight joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. We account for one of our joint ventures with a health system partner under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#x2019; assets and liabilities included in our condensed consolidated balance sheet are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i53a77f5a57b04427a02592d620527871_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMzIz_4de51fa5-6d96-43b9-b891-a52eff1c0222"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i97413ae1e1174a779e186bf439f4b59e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMzIz_bea2abfd-a5ac-4d14-965b-f5b286b7f9e6"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9f3cf4cabcef48c49d533b6054864aa6_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNDQ5_e68655ec-532e-46c6-8028-5bc3285ffd43"
      unitRef="number">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id4b858c3a1e442059c913a6d2f8baa16_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTYzNDU2Mg_6c44e553-44b9-454c-ae13-65fa7106e435"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <amed:OperatingCareCenters
      contextRef="i730de4ab8dd2401da027009b92ebd36a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNTg4_85a033ed-b623-4994-bdba-5e4df3c7a66e"
      unitRef="care_center">328</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="idba324da17d44f13b400eb4dcb6541c2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjM2_0f0c708b-26c6-413d-8365-1100289d36dc"
      unitRef="care_center">177</amed:OperatingCareCenters>
    <amed:OperatingCareCenters
      contextRef="i4003f84c115d4f539f2b8c54b785265e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjgz_f24cf402-0056-4044-adb0-b5e6aa87a2c5"
      unitRef="care_center">14</amed:OperatingCareCenters>
    <amed:NumberOfJointVentures
      contextRef="i52fadfa94bbd423aa0033f0ef19c530a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTYzNDU2Nw_8e71fad3-6174-4dd5-8809-3d54ab82c807"
      unitRef="numberofjointventures">8</amed:NumberOfJointVentures>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNzE2_4fda84ac-5cbb-4ddc-b970-814caaa376a3"
      unitRef="state">38</us-gaap:NumberOfStatesInWhichEntityOperates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQxNw_612a65d5-f4e7-47bc-b505-c02a30016bf0">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.&lt;/span&gt;&lt;/div&gt;This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on February 25, 2021 (the &#x201c;Form 10-K&#x201d;), which includes information and disclosures not included herein.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQxOA_3c5c7260-249a-4298-b7af-3a7d179d713f">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQzMg_41c41c57-c98d-4116-b3b3-8408c8a1c0ab">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQyNA_18c0293c-6656-4403-8f6c-4a02c33aaff7">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjQzNA_cddce4a5-7039-4f69-8d55-61ee00a64151">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $48.3 million and $14.2 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of September 30, 2021, we are proportionately consolidating seven of our eight joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. We account for one of our joint ventures with a health system partner under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#x2019; assets and liabilities included in our condensed consolidated balance sheet are as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.</us-gaap:EquityMethodInvestmentsPolicy>
    <amed:MinimumPercentOwnershipForControllingInterestPercent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNDU5NA_090f7185-4d3f-4988-ad5b-e53a98791e54"
      unitRef="number">0.50</amed:MinimumPercentOwnershipForControllingInterestPercent>
    <amed:MaximumPercentOwnershipForEquityMethodPercent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNDg5Mw_9b7994a3-be09-4b4c-9cf7-2a8af46199bc"
      unitRef="number">0.50</amed:MaximumPercentOwnershipForEquityMethodPercent>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNTEwNg_b520ffd0-5f77-449e-a00a-0c8d9003f77c"
      unitRef="usd">48300000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNTExMw_b00b339a-bf8c-4fbd-ad35-79726a8bad5e"
      unitRef="usd">14200000</us-gaap:EquityMethodInvestmentAggregateCost>
    <amed:NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTY0MTYwOQ_2af3089a-7d8e-4d07-8ade-d55766eaf8a6"
      unitRef="numberofjointventures">7</amed:NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities>
    <amed:NumberOfJointVentures
      contextRef="i52fadfa94bbd423aa0033f0ef19c530a_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTY0MTYyNQ_95681a97-b498-4e16-8b6f-1e085c369166"
      unitRef="numberofjointventures">8</amed:NumberOfJointVentures>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfMTA5OTUxMTY0MTYzMw_4360c192-6265-44ee-82b0-e54627d593fb">The carrying amount of the VIEs&#x2019; assets and liabilities included in our condensed consolidated balance sheet are as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMy0xLTEtMS0xNDI3OQ_e577e874-0dc4-4f91-ac53-ae3507d9f02c"
      unitRef="usd">3700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfNC0xLTEtMS0xNDI4Mg_6cefb603-3833-476a-82aa-d819603daa6c"
      unitRef="usd">2500000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfNS0xLTEtMS0xNDI4NA_51b6de73-d368-4a14-bdaa-8cf240a83576"
      unitRef="usd">100000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfNi0xLTEtMS0xNDI4Ng_cf3fc9f8-dc0f-46e9-bdf7-700fbc7fd126"
      unitRef="usd">6300000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfNy0xLTEtMS0xNDI4OA_9976deec-0d84-4f8d-9427-136b961b65b4"
      unitRef="usd">100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfOC0xLTEtMS0xNDI5MA_568a4b6d-934c-4df6-82cc-aec90dbc1b3f"
      unitRef="usd">6400000</us-gaap:Assets>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTEtMS0xLTEtMTQyOTI_99cb5c2d-652c-4887-84f5-ccdbdd2e2d6a"
      unitRef="usd">300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTItMS0xLTEtMTQzMDA_a2bc369c-b55f-4c78-bdb7-f99447b1778d"
      unitRef="usd">3300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTMtMS0xLTEtMTQzMDI_ecb3e1c6-05c7-4b90-90d3-6d16c43d4b89"
      unitRef="usd">800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTQtMS0xLTEtMTQzMDQ_2b9fb5a9-fda0-443a-b12b-538e6e26c9ce"
      unitRef="usd">4400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTUtMS0xLTEtMTQzMDY_52fcc489-03f7-4356-868a-d5bf14fa5c14"
      unitRef="usd">100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib17e4cda80354daea0f730106f4a1852_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RhYmxlOjlhZjc0ZmNlZjk1MjQ4NzQ4YmFkMDkyMDA2ZjE1NjA5L3RhYmxlcmFuZ2U6OWFmNzRmY2VmOTUyNDg3NDhiYWQwOTIwMDZmMTU2MDlfMTYtMS0xLTEtMTQzMDg_7108fbcb-5d6d-4d4c-8252-0be00da40a5d"
      unitRef="usd">4500000</us-gaap:Liabilities>
    <us-gaap:GainLossOnInvestments
      contextRef="ic428d287cf9a45abae8bef5f46c3c408_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNTc0Ng_31cebbbf-61b9-4256-9019-2c96c031a35b"
      unitRef="usd">31100000</us-gaap:GainLossOnInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i0d32c084839747cea67534c70d0a7a4c_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY18zNy9mcmFnOmQ5ZjJhNjBhMmIzNjRlMGRiMzBiYmRjMWU0ZmY4ZDc4L3RleHRyZWdpb246ZDlmMmE2MGEyYjM2NGUwZGIzMGJiZGMxZTRmZjhkNzhfNjA3Mg_3a8687a3-4048-431b-acea-ee5664b4a669"
      unitRef="usd">17900000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MzU_207ab757-b1c6-4156-9e36-731d6a378b35">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of our net service revenue for the three and nine-month periods ended September 30, 2021 and approximately 76% and 75% of our net service revenue for the three and nine-month periods ended September 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine-Month Periods &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 20% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and nine-month periods ended September&#160;30, 2021 and September 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. As of September&#160;30, 2021, we have recorded $8.6 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $2.5&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;High Acuity Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;High Acuity Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to patients who are discharged early from a health system facility to complete their inpatient stay at home. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our health insurance plan contracts provide for fixed payment rates for a 30-day or 60-day episode of care indexed to assigned patient diagnoses in return for our obligation to assume risk for the coordination and payment of required medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#x2019; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, is provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the service provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our contracts with health system partners provide for reimbursement on a per diem basis at the contracted rate for each day during the remainder of an inpatient acute stay serviced at the patient&#x2019;s home. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of September 30, 2021 includes $58.5&#160;million associated with unutilized CARES Act Provider Relief Fund ("PRF") funds, which were repaid to the U.S. Department of Health and Human Services ("HHS") in October 2021. Restricted cash includes cash that is not available for ordinary business use. As of September 30, 2021, we had $3.8&#160;million of restricted cash that was placed into escrow accounts related to the indemnity and closing payment adjustment provisions within the purchase agreements for various acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of September&#160;30, 2021, there is no single payor, other than Medicare, that accounts for 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent 65% and 64% of our patient accounts receivable at September&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine-&lt;br/&gt;Month Periods&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0NDI_6db0d66d-35c8-4652-8801-4b7c585023f1">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of our net service revenue for the three and nine-month periods ended September 30, 2021 and approximately 76% and 75% of our net service revenue for the three and nine-month periods ended September 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine-Month Periods &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Home Health Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#x2019;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#x201c;LUPA&#x201d;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 20% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Episodic-based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-episodic based Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hospice Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and nine-month periods ended September&#160;30, 2021 and September 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#x201c;SIA&#x201d;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the following year. As of September&#160;30, 2021, we have recorded $8.6 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $2.5&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Hospice Non-Medicare Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Personal Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Personal Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;High Acuity Care Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;High Acuity Care Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to patients who are discharged early from a health system facility to complete their inpatient stay at home. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our health insurance plan contracts provide for fixed payment rates for a 30-day or 60-day episode of care indexed to assigned patient diagnoses in return for our obligation to assume risk for the coordination and payment of required medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#x2019; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, is provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the service provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our contracts with health system partners provide for reimbursement on a per diem basis at the contracted rate for each day during the remainder of an inpatient acute stay serviced at the patient&#x2019;s home. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i53a77f5a57b04427a02592d620527871_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMzA4MQ_4de51fa5-6d96-43b9-b891-a52eff1c0222"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i97413ae1e1174a779e186bf439f4b59e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMzA4MQ_bea2abfd-a5ac-4d14-965b-f5b286b7f9e6"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9f3cf4cabcef48c49d533b6054864aa6_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5OTUxMTY1MTI3NQ_e68655ec-532e-46c6-8028-5bc3285ffd43"
      unitRef="number">0.76</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id4b858c3a1e442059c913a6d2f8baa16_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5OTUxMTY1MTkyNg_c45950ca-5ca6-453f-9354-b28e29d03460"
      unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMzk5Nw_96db8ef6-303f-476e-ae7a-6b19fd56cbac"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0NDM_b2c76ace-b80a-4f49-8268-a4388da88bc6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by payor class as a percentage of total net service revenue is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Periods Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine-Month Periods &lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Home Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Hospice:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Non-Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Personal Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="id5d7cedb10ae48fba7962484bd3a479d_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMy0xLTEtMS0w_a82c4cf6-1b70-4eda-b7fe-056a6dce3273"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i6cf8d0d878ea44b5b6acaec5036b5b3e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMy0zLTEtMS0w_e0909506-c8a4-4cf0-82a9-0c4a179f3ef0"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ieb137aa1ee24433e9aa27e49dc612257_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMy01LTEtMS0w_b3ced0cd-28bb-4081-9a73-fa6094d882a8"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i6bde2eb0cbdd4167840a8abcb889fdbe_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMy03LTEtMS0w_3cb6b4c0-59c4-488f-bba7-181b777abb35"
      unitRef="number">0.41</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i7da000a08ec142e4bdd7cf8ee0df0f47_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNC0xLTEtMS0w_2fc4f5e8-8690-4f93-b0ee-5e3d085f995e"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i5a28bdb10cc74d2e928cf670bd6e2574_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNC0zLTEtMS0w_7ed0227c-d7d1-4093-a692-64787b03afb7"
      unitRef="number">0.07</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ia97dc36d6ba44d7a91070e28414ee451_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNC01LTEtMS0w_e66f0783-6bc3-4ded-ad8d-66137b2b73d6"
      unitRef="number">0.08</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i7fcfacf66b054da0b58e2e56d9bb8bfa_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNC03LTEtMS0w_4b32b17e-b169-4441-b24c-455faa606fcc"
      unitRef="number">0.06</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i99b4c1b915b04539b57e1c8613186d47_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNS0xLTEtMS0w_16206514-0288-4641-ad1c-69741a34b1d8"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ifa13ecc925ce45338808db2fe46e6eae_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNS0zLTEtMS0w_8d5dcc10-d578-4a94-bcbb-01eb200591a3"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i8ab6f6ff611a4bca958bd8f881a12f27_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNS01LTEtMS0w_e287d767-8f55-4b4f-b360-237faf9892e2"
      unitRef="number">0.12</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="if6978f00a4d24116b989b48f99ba0ee3_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNS03LTEtMS0w_26acd9dc-5500-4dc6-ade7-81101b228fea"
      unitRef="number">0.13</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ifa1d053dcadf4783b88264c7cec8fdad_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNy0xLTEtMS0w_d3603e63-f616-4834-b3be-f1529e8622ef"
      unitRef="number">0.34</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="id56c30a83b044cfeb8b2c3d76169a0f2_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNy0zLTEtMS0w_25b26a7d-b593-4ba2-94ff-1db027596453"
      unitRef="number">0.35</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ife028e28aa6e4bff87836d3a26ef8d85_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNy01LTEtMS0w_d436317d-c0c3-4b9f-b5c0-016d750bdc2d"
      unitRef="number">0.34</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i67ed27e1cb4c4b0aabe4eb9cf42597d3_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfNy03LTEtMS0w_a1283bfc-71ff-49b5-99ff-0066cbbd3e61"
      unitRef="number">0.34</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i3a812c39af934a4fbcf34dcbb6f5f869_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOC0xLTEtMS0w_9cf56238-cf54-461a-a87a-45e44b589d05"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ide539b43139c4e9f8ca2939b91054599_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOC0zLTEtMS0w_86e46dd5-784c-4a7e-adaa-edf0dc213170"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i9100f75ec6d34eab92f0b7a4728ebb97_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOC01LTEtMS0w_ee7a8e26-1fc5-4893-96c7-7c04e883bec9"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i6c80de9e2e4b40cdb0613e9070ad7c04_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOC03LTEtMS0w_477b70cd-5282-4d89-8fce-aaf013e6dfa2"
      unitRef="number">0.02</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i42e067416e644747bb8fa941e424d288_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOS0xLTEtMS0w_c7d72a7c-674d-4cc7-89b7-dbe437a309d0"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="icac5f9500af546a48378980936e6335e_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOS0zLTEtMS0w_6fd9f3a8-0e02-46e0-bc12-f567838a1fed"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i926e999864bd48ed884e8c5a0659188d_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOS01LTEtMS0w_28be453a-d126-43a1-b422-795cf9a7288e"
      unitRef="number">0.03</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i7de65d633d9d4497bd157a0af662328c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfOS03LTEtMS0w_3234f584-4f59-4458-b3d6-cf7d771f2b15"
      unitRef="number">0.04</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMTAtMS0xLTEtMA_ad4d5855-5d2a-41d4-8054-38806d4ddb3f"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMTAtMy0xLTEtMA_97ba2603-285f-479b-9291-6501ffd4bfb9"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMTAtNS0xLTEtMA_81a1d3ef-8d9c-44f5-9fb8-936a5ebcf538"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmFiYzhiZTAyYmZlZDRhOTVhNjIwMzNhNTVhMmVjNWNjL3RhYmxlcmFuZ2U6YWJjOGJlMDJiZmVkNGE5NWE2MjAzM2E1NWEyZWM1Y2NfMTAtNy0xLTEtMA_49a62ed6-aa15-4c8e-bc8b-9052ecfcf013"
      unitRef="number">1</amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNDU3Nw_0a1deefd-4086-4d42-af62-2de214003398">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNDYxMg_4c4b563f-0ab4-4b0a-9c94-635551d65c2d">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNDkzMQ_d959698f-3bab-48f3-83fb-c111d1a1292d">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:PercentageOfTotalReimbursementOfOutlierPayment
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNTkzNA_82abe317-af3f-486a-9c81-9f37c7c26305"
      unitRef="number">0.10</amed:PercentageOfTotalReimbursementOfOutlierPayment>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i29f7d758438c4f338ef4844b1b05b695_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNjEyNA_37a1b2c3-a6e2-4b37-9f08-41e3a6e64b0e"
      unitRef="visit">2</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:LowUtilizationPaymentAdjustmentNumberOfVisits
      contextRef="i15da7330f86b4f90b126f6a27ee2e91c_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNjEzMA_0f4efdf5-bab8-4095-8ea0-133d7ec23332"
      unitRef="visit">6</amed:LowUtilizationPaymentAdjustmentNumberOfVisits>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfNjc1OA_01c5aac4-24b2-4940-95c1-3e01ff8cf851"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
      contextRef="i4f2cd5e0030a4da38f5733c7cc21c188_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfODkyNg_1965de11-1816-4522-802a-c8305cb692bb"
      unitRef="number">0.20</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfOTIwNA_c08186b0-4275-4b64-be52-d5fba3c65b61">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <amed:NonMedicareRevenueTermRates
      contextRef="i29f7d758438c4f338ef4844b1b05b695_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfOTc1NA_32414765-086d-429e-a051-1cac066ecdbb"
      unitRef="number">0.95</amed:NonMedicareRevenueTermRates>
    <amed:NonMedicareRevenueTermRates
      contextRef="i15da7330f86b4f90b126f6a27ee2e91c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfOTc2MA_e2f98dac-9274-4261-8554-c15fd4bff714"
      unitRef="number">1</amed:NonMedicareRevenueTermRates>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5Mzg_21f16773-f372-427d-b20d-9e089c1115a3"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5Mzg_35b144b2-3de4-4085-9d43-55a8a9a7649c"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5Mzg_ec13fccf-4357-4349-945e-c10a1fe04cbf"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HospiceMedicareRevenueRateAccountedForRoutineCare
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTA5Mzg_f13e6a06-add7-4dff-b2c5-20f6e67d0195"
      unitRef="number">0.97</amed:HospiceMedicareRevenueRateAccountedForRoutineCare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTE5NTY_d2700dc0-faa8-4e98-b16f-d26670e9d565"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i29e45fb5802548c4ad50a57ad3f3b612_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTI3MDM_ec7e3a29-2f96-4fef-8485-aaabb5557eef"
      unitRef="usd">8600000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i5d3a5fc24c7c41c8bc0fb5a2dae8eb49_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTI4NDY_bfff2c09-0833-40c4-8e06-0724a8acf7c6"
      unitRef="usd">2500000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities
      contextRef="i24116e45645b4557aa94b276ff514ba4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTI5MzY_d947252c-c67d-44dc-90f2-24f56de83d32"
      unitRef="usd">9300000</amed:EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i9d0d57618875495dac3ccd68edf1aea4_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTY0OTI2NzQ3MTk5Mg_56b9aee2-b543-4f26-930e-4f4b1e7c9d6c">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i68531a9539f143d39b039b1ec2d6143c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTY0OTI2NzQ3MTk5Nw_02e4ffff-7c38-4665-9fe4-bffda87de94e">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i9d0d57618875495dac3ccd68edf1aea4_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTY0OTI2NzQ3MTk3OA_56b9aee2-b543-4f26-930e-4f4b1e7c9d6c">P30D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:NetServiceRevenueEpisodePaymentRateDuration
      contextRef="i68531a9539f143d39b039b1ec2d6143c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTY0OTI2NzQ3MTk4Ng_02e4ffff-7c38-4665-9fe4-bffda87de94e">P60D</amed:NetServiceRevenueEpisodePaymentRateDuration>
    <amed:GovernmentGrantsPolicyTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MjQ_2c5a7e86-f941-44d5-8873-f3df46c43239">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Government Grants and Disclosure of Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be &lt;/span&gt;&lt;/div&gt;received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</amed:GovernmentGrantsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0NDQ_c1ee3e4f-60ee-43fb-bc68-cefd1ea33116">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of September 30, 2021 includes $58.5&#160;million associated with unutilized CARES Act Provider Relief Fund ("PRF") funds, which were repaid to the U.S. Department of Health and Human Services ("HHS") in October 2021. Restricted cash includes cash that is not available for ordinary business use. As of September 30, 2021, we had $3.8&#160;million of restricted cash that was placed into escrow accounts related to the indemnity and closing payment adjustment provisions within the purchase agreements for various acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <amed:CashBalanceAssociatedWithProviderReliefFund
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTU3MjU_50d5a019-6847-47e0-93c0-9284f5821fee"
      unitRef="usd">58500000</amed:CashBalanceAssociatedWithProviderReliefFund>
    <us-gaap:RestrictedCash
      contextRef="i500483d4b7f14fdaa315297298d52160_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTYzMjc_2017a595-2276-42d0-a38b-5c7ece157e9e"
      unitRef="usd">3800000</us-gaap:RestrictedCash>
    <amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MzY_6b8c7f11-f156-4d3d-8453-8c9d13c62225">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOjQ5Yzg1YmRlYmEyYTRhYmZiNGFkMTZlMTFhM2Y1NmRkL3RhYmxlcmFuZ2U6NDljODViZGViYTJhNGFiZmI0YWQxNmUxMWEzZjU2ZGRfMS0zLTEtMS0w_80f0624d-0b45-4e28-ba0e-9b494c50f41b"
      unitRef="usd">81800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOjQ5Yzg1YmRlYmEyYTRhYmZiNGFkMTZlMTFhM2Y1NmRkL3RhYmxlcmFuZ2U6NDljODViZGViYTJhNGFiZmI0YWQxNmUxMWEzZjU2ZGRfMi0xLTEtMS0w_14baeb5b-7e9e-4f8a-b5a4-5617dfcc5571"
      unitRef="usd">3800000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOjQ5Yzg1YmRlYmEyYTRhYmZiNGFkMTZlMTFhM2Y1NmRkL3RhYmxlcmFuZ2U6NDljODViZGViYTJhNGFiZmI0YWQxNmUxMWEzZjU2ZGRfMi0zLTEtMS0w_0ee9e6b9-d113-4102-a315-34c7f367a276"
      unitRef="usd">1500000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOjQ5Yzg1YmRlYmEyYTRhYmZiNGFkMTZlMTFhM2Y1NmRkL3RhYmxlcmFuZ2U6NDljODViZGViYTJhNGFiZmI0YWQxNmUxMWEzZjU2ZGRfMy0xLTEtMS0w_e02072cc-d21b-48b9-b63d-e477b8edc714"
      unitRef="usd">128200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0Mzc_d125393c-8f99-494d-9929-61aca0712da5">&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Patient Accounts Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of September&#160;30, 2021, there is no single payor, other than Medicare, that accounts for 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent 65% and 64% of our patient accounts receivable at September&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Home Health&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Hospice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#x2019;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <amed:PercentageOfPatientReceivablesOutstanding
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTcyMjU_7e6a83b5-ba85-43fa-95f1-21630757bb74"
      unitRef="number">0.10</amed:PercentageOfPatientReceivablesOutstanding>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTc2Nzc_9e848ad7-6ab0-4e76-87b4-a154ead3a690"
      unitRef="number">0.65</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:AccountsReceivablePortionDerivedFromMedicare
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTc2ODQ_b0b66872-d063-4fee-9d9f-527152f76a48"
      unitRef="number">0.64</amed:AccountsReceivablePortionDerivedFromMedicare>
    <amed:HistoricalCollectionRateFromMedicare
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTc4MDc_e6e98a19-e442-49bb-ab16-6537a1733628"
      unitRef="number">0.99</amed:HistoricalCollectionRateFromMedicare>
    <amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare
      contextRef="i4f2cd5e0030a4da38f5733c7cc21c188_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTg0NTM_b9357892-b511-4b62-9190-05d40b1db78f"
      unitRef="number">0.20</amed:RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare>
    <amed:NetServiceRevenuePeriodOfCarePaymentRateDuration
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMTg0OTA_6070cca8-dec7-4304-9675-87c7281e4ca8">P30D</amed:NetServiceRevenuePeriodOfCarePaymentRateDuration>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0NDY_e5bcfdb4-19a3-440b-bbbc-3477322b333c">&lt;div style="margin-top:16pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MzM_391ee278-8a47-458a-b2d2-ee115f66ad59">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1 &#x2013; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2 &#x2013; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <amed:FinancialInstrumentDetailsTableTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0Mzk_23fa05c7-9e13-454e-baf4-a5f2e1a70a62">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Financial Instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Value as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&#160;in&#160;Active&lt;br/&gt;Markets for Identical&lt;br/&gt;Items&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</amed:FinancialInstrumentDetailsTableTextBlock>
    <amed:DebtInstrumentCarryingAmountExcludingFinanceLeases
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmM4ODM4MWZjY2Q0NzQzZTk4N2UxMDQxMzE0ZWZmZGJlL3RhYmxlcmFuZ2U6Yzg4MzgxZmNjZDQ3NDNlOTg3ZTEwNDEzMTRlZmZkYmVfMi0xLTEtMS0w_9eb9545a-63b5-468b-94b6-ef3d49355b8e"
      unitRef="usd">450800000</amed:DebtInstrumentCarryingAmountExcludingFinanceLeases>
    <us-gaap:LongTermDebtFairValue
      contextRef="iffd0e7655cc84c468271b6527bfdb445_I20210930"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmM4ODM4MWZjY2Q0NzQzZTk4N2UxMDQxMzE0ZWZmZGJlL3RhYmxlcmFuZ2U6Yzg4MzgxZmNjZDQ3NDNlOTg3ZTEwNDEzMTRlZmZkYmVfMi0zLTEtMS0w_11c8cc8b-155b-4d0c-9cad-3044df0d55a0"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i5462f91dd84c47b0a636202d3b8d0235_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmM4ODM4MWZjY2Q0NzQzZTk4N2UxMDQxMzE0ZWZmZGJlL3RhYmxlcmFuZ2U6Yzg4MzgxZmNjZDQ3NDNlOTg3ZTEwNDEzMTRlZmZkYmVfMi01LTEtMS0w_ba5b4e72-bd0a-441f-8f58-ff4d2a64e489"
      unitRef="usd">468500000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i2feac305da384a94a9d62488436d6c54_I20210930"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmM4ODM4MWZjY2Q0NzQzZTk4N2UxMDQxMzE0ZWZmZGJlL3RhYmxlcmFuZ2U6Yzg4MzgxZmNjZDQ3NDNlOTg3ZTEwNDEzMTRlZmZkYmVfMi03LTEtMS0w_a38f1ccc-86e1-4d67-87bc-2624b571c8e1"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MTU_fbe5e08e-ad13-4067-ad8f-16c2963ee198">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RleHRyZWdpb246ZDQwY2EwZTMwZjFmNGFkMGE1ZDgyMDMxMjk0NTQ5NTdfMjI0MTc_2e8b511b-bf33-4035-b184-3b90a206ea1c">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-&lt;br/&gt;Month Periods&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine-&lt;br/&gt;Month Periods&lt;br/&gt;Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested stock and stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average number of shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfMi0xLTEtMS0w_687c2f16-334c-483e-b6bd-126974aa4592"
      unitRef="shares">32607000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfMi0zLTEtMS0w_d4925b98-ddff-4cb1-966b-4ddd5fe21b11"
      unitRef="shares">32662000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfMi01LTEtMS0w_466ccb57-2dac-4be4-8099-b9dfa2f7be00"
      unitRef="shares">32658000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfMi03LTEtMS0w_2f383e68-515e-43b8-abeb-fcac9168b0d5"
      unitRef="shares">32469000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNC0xLTEtMS0w_38d9ca68-fc3e-42f8-b986-494179c0c942"
      unitRef="shares">113000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNC0zLTEtMS0w_2859dbd2-2dec-400d-84b6-c6e5fb203172"
      unitRef="shares">336000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNC01LTEtMS0w_3c7d6d91-5114-494c-9013-d543bbac9f88"
      unitRef="shares">135000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNC03LTEtMS0w_0283bb4e-92e6-42ec-b2b6-cd27261ffbfc"
      unitRef="shares">506000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <amed:NonVestedStockAndStockUnits
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNS0xLTEtMS0w_1373092e-cc09-427e-ab24-d7583608c88f"
      unitRef="shares">179000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNS0zLTEtMS0w_a127277d-bf5b-496c-ba47-ffe548b64d4b"
      unitRef="shares">262000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNS01LTEtMS0w_34115017-b5ae-40f6-b5e6-472d95776d0e"
      unitRef="shares">228000</amed:NonVestedStockAndStockUnits>
    <amed:NonVestedStockAndStockUnits
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNS03LTEtMS0w_ddb49d96-1a95-46c4-ba53-467df1063958"
      unitRef="shares">292000</amed:NonVestedStockAndStockUnits>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNi0xLTEtMS0w_6b666281-ac89-4199-b591-46e77950c16c"
      unitRef="shares">32899000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNi0zLTEtMS0w_b537d469-b6fe-4837-95d2-ab4bf357735d"
      unitRef="shares">33260000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNi01LTEtMS0w_7835bc4e-338c-4e6d-9f6f-63ff765e6743"
      unitRef="shares">33021000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNi03LTEtMS0w_95aac90f-c257-4e95-8e94-d26237bd5ed5"
      unitRef="shares">33267000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNy0xLTEtMS0w_93b33cc4-b7e1-4fb0-9563-bad4f7a15f0c"
      unitRef="shares">141000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNy0zLTEtMS0w_e58e827f-4493-4821-b296-0d9aa28e5e03"
      unitRef="shares">36000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNy01LTEtMS0w_02aa60b0-8eb5-45b2-a19e-bd273dfaa867"
      unitRef="shares">82000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180My9mcmFnOmQ0MGNhMGUzMGYxZjRhZDBhNWQ4MjAzMTI5NDU0OTU3L3RhYmxlOmJiYzAyMjI2ZDkzYzQyM2FhZTBjOGUyZDY2NjQ2NDI2L3RhYmxlcmFuZ2U6YmJjMDIyMjZkOTNjNDIzYWFlMGM4ZTJkNjY2NDY0MjZfNy03LTEtMS0w_bcb1a64c-e4d3-4bba-b468-8f4841418cfd"
      unitRef="shares">31000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <amed:COVID19TextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDY0Ng_9378f583-f42c-4026-8311-ebc763e665f5">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare. Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not fully utilize the PRF funds received; therefore, we have recorded a liability for the amount to be repaid which totaled $59&#160;million (including interest) at September 30, 2021 and $60&#160;million at December 31, 2020 (see the Provider Relief Fund Advance account in current liabilities within our condensed consolidated balance sheets). All unutilized funds were repaid in October 2021. In summary, the total funds that we received from the CARES Act PRF have been accounted for as follows as of September 30, 2021 (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by consolidated entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds to be repaid to the government by consolidated entities (excludes $0.2&#160;million of interest to be repaid)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds to be repaid to the government by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. We estimate that the suspension of sequestration will increase our 2021 net service revenue by approximately $36&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. During 2020, we deferred approximately $55&#160;million of social security tax; approximately $28&#160;million is reflected in each of payroll and employee benefits and other long-term obligations within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;Our personal care segment did not receive funds under the CARES Act; however, it did receive funds totaling $1&#160;million from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which were used during 2020 to cover costs related to COVID-19.</amed:COVID19TextBlock>
    <amed:FundingForHealthcareProvidersIncludingHospitals
      contextRef="i79965b0e5aa8415ab632c4462ea0fe64_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNzI5_7c64d0f9-9eb8-473e-b5d3-9f977c1ebf4e"
      unitRef="usd">175000000000</amed:FundingForHealthcareProvidersIncludingHospitals>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i79965b0e5aa8415ab632c4462ea0fe64_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfODU0_01687e5b-3fc7-4e27-9112-9e2fc02e3893"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="i0efbe09bd23b41df8e79378709cd08ec_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMTIxNA_d862fcb3-59cc-48b0-9c57-a2470a786b2e"
      unitRef="usd">100000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
      contextRef="i79965b0e5aa8415ab632c4462ea0fe64_I20200327"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMTIzMg_534c3225-f176-4269-a0e9-c6c3d734a29d"
      unitRef="usd">30000000000</amed:FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements>
    <amed:FundingReceivedFromCARESAct
      contextRef="i1d60d9ebea4d4f7d9cefaed1ef4edefa_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMTMxNw_6dae1af5-6ee3-467a-81d1-49a4629df6ae"
      unitRef="usd">2000000</amed:FundingReceivedFromCARESAct>
    <amed:FundingReceivedFromCARESAct
      contextRef="ifffac77654ba4ad9a0ab1f64df333300_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMTQyMg_9ab9dc45-6287-488c-aff3-2a7304c3d7d2"
      unitRef="usd">6000000</amed:FundingReceivedFromCARESAct>
    <amed:ProviderReliefFundAdvance
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMjY5MQ_e4010c0a-a7b3-465a-88ee-a577103da188"
      unitRef="usd">59000000</amed:ProviderReliefFundAdvance>
    <amed:ProviderReliefFundAdvance
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMjcxNQ_dd61a983-3a91-49cd-9a48-5bfc81e14dc8"
      unitRef="usd">60000000</amed:ProviderReliefFundAdvance>
    <amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDY0Nw_02dbf861-d111-4004-8ddb-f261ab01b107">In summary, the total funds that we received from the CARES Act PRF have been accounted for as follows as of September 30, 2021 (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by consolidated entities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds to be repaid to the government by consolidated entities (excludes $0.2&#160;million of interest to be repaid)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds utilized through June 30, 2021 by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funds to be repaid to the government by unconsolidated joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock>
    <amed:CARESActProviderReliefFundsUtilized
      contextRef="i1393629cbb174bb6b0ebfda47cfc61fd_D20200327-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMS0xLTEtMS0w_65522106-3f38-45bb-8060-9d5e0673e22f"
      unitRef="usd">46600000</amed:CARESActProviderReliefFundsUtilized>
    <amed:CARESActInterestToBeRepaidToGovernment
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMi0wLTEtMS0xMzA3OC90ZXh0cmVnaW9uOjMxNGRjZDljYmJjMDRjMDk4OWU4NDRmOWVlZDIxM2Q1XzEwOTk1MTE2Mjc5MDI_3166d446-2e66-4fa8-a247-f2cece4ac7a7"
      unitRef="usd">200000</amed:CARESActInterestToBeRepaidToGovernment>
    <amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaid
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMi0xLTEtMS0w_495c3259-da94-4a6c-a216-8eb91b8256aa"
      unitRef="usd">58300000</amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaid>
    <amed:CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures
      contextRef="i1393629cbb174bb6b0ebfda47cfc61fd_D20200327-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMy0xLTEtMS0xMzA3Ng_082b71e1-6c01-49eb-a0a6-597d52a2bdcc"
      unitRef="usd">1300000</amed:CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures>
    <amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfMy0xLTEtMS0w_4bc82e2e-9791-4ae5-aa85-a183707ea629"
      unitRef="usd">600000</amed:EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures>
    <amed:TotalCARESActProviderReliefFundsReceived
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RhYmxlOjE5ZjVhNDA5Zjg1ZjRhYjg5NDkxNzNiNDZmMjI4OTcxL3RhYmxlcmFuZ2U6MTlmNWE0MDlmODVmNGFiODk0OTE3M2I0NmYyMjg5NzFfNC0xLTEtMS0w_b46fd235-4f9f-4192-8e69-3bd2f71addc1"
      unitRef="usd">106800000</amed:TotalCARESActProviderReliefFundsReceived>
    <amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
      contextRef="i8e66e59d22d74d7a814e88ec0a8b967a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfMzg2NA_c6327a9a-620b-4d29-88fe-150d983cc744"
      unitRef="usd">36000000</amed:ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact>
    <amed:CARESActDeferralOfEmployerShareSocialSecurityTax
      contextRef="i38909b3d265a42439d254b12034f035b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDIxOQ_72a88c41-ac9f-4848-918f-be4e53a24c66"
      unitRef="usd">55000000</amed:CARESActDeferralOfEmployerShareSocialSecurityTax>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2649a54bd32e4505aaf5229062506cea_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDI2MA_a0f1a604-11f6-44b6-9e69-d5865d3dc863"
      unitRef="usd">28000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2649a54bd32e4505aaf5229062506cea_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDI2MA_a8a0d99d-3e89-4268-a128-9bdb8222a465"
      unitRef="usd">28000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram
      contextRef="ib38d592d04ae48798a01d60bc2b8f174_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY180OS9mcmFnOjU1M2E2MGU4Y2Y1MjQ4NDM4NDBkZmViNWYzYjE3NjYxL3RleHRyZWdpb246NTUzYTYwZThjZjUyNDg0Mzg0MGRmZWI1ZjNiMTc2NjFfNDUwNw_8396249e-edd0-4a9a-ba5b-047830f20810"
      unitRef="usd">1000000</amed:FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMzc3Nw_1779ceb6-1b17-4c68-902b-e3458618a289">ACQUISITIONS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#x2019;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 1, 2021, we acquired the regulatory assets of a home health provider in Randolph County, North Carolina for a purchase price of $2.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $2.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2021, we acquired Visiting Nurse Association ("VNA"), a home health and hospice provider with locations in Nebraska and Iowa for a purchase price of $20.1&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $19.4&#160;million and other intangibles (licenses) of $0.7&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 12, 2021, we acquired the regulatory assets of a home health provider in New York for a purchase price of $1.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $1.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility ("SNF") at-home services for an estimated purchase price of $240.7&#160;million, net of cash acquired. With the addition of Contessa&#x2019;s risk-based model and claims analytics capabilities, we will be able to bring the essential elements of inpatient hospital and SNF care to patients&#x2019; homes, allowing us to become a risk-bearing, home-based care delivery organization, expanding well beyond traditional home health and hospice. Contessa operates as a wholly-owned division of Amedisys and is reported as a separate operating segment. Under the purchase agreement, the purchase price is subject to a net working capital adjustment, whereby the purchase price will be adjusted to the extent the actual net working capital of Contessa as of the closing differs from the required net working capital under the purchase agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $240.7&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities and equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired include acquired names ($28.6&#160;million), technology ($19.9&#160;million) and non-compete agreements ($6.7&#160;million). The non-compete agreements will be amortized over a weighted-average period of 2.0 years and the technology will be amortized over a weighted-average period of 7.0 years. The preliminary fair value of noncontrolling interest was determined using a discounted cash flow analysis and an income approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contessa contributed $1.5&#160;million in net service revenue and an operating loss of $3.8&#160;million (inclusive of technology intangibles amortization totaling $0.5&#160;million) during the three-month period ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with 44 locations, for an estimated purchase price of $230.4&#160;million, net of cash acquired and inclusive of a $32&#160;million tax asset. The closing payment for the purchase price included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close, not to exceed $1.0&#160;million. The closing payment adjustment, which was finalized in October 2020, reduced the purchase price by $0.8&#160;million, from $230.4&#160;million&#160;to $229.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company finalized its valuation of the assets acquired and liabilities assumed during the three-month period ended June 30, 2021. The total consideration of $229.6 million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired include licenses ($8.7&#160;million), certificates of need ($0.7&#160;million), acquired names ($5.7&#160;million) and non-compete agreements ($9.2&#160;million). The acquired names will be amortized over a weighted-average period of 2.0 years, and the non-compete agreements will be amortized over a weighted-average period of 1.7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="icb4c638a3b064fa5b06f2b26f52f4a80_D20210501-20210501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTM4OQ_96c28d58-e4ee-416b-90ef-745ee8cc4c1b"
      unitRef="usd">2500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i54c8f3adc1504f4eb6682e48cf1c64c4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTU0MQ_ff9b0ca2-62c0-439c-a4ef-df13ba6eb004"
      unitRef="usd">2400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i2017c2d404c641c2a514204df4297957_I20210501"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTU5MQ_478c2c7e-9630-43de-91d4-c9d942df6a5d"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i0872fc9873bd4791b48b180e25979b56_D20210701-20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzMjQwNA_1f1c9d88-10f7-43e8-b404-b5ce0c3f9809"
      unitRef="usd">20100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3f71161254f8495192bc5012d17c1d17_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzNzY3NQ_9ff3dd38-3d5c-4159-be4b-c55a3de9fee6"
      unitRef="usd">19400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i0151e438657a4e998a05f867e7a0192b_I20210701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzOTQ3Mg_59d5331b-db82-4546-8550-897e0ca74f56"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if47ee2ab8e1e4361a566cb19050d7b35_D20210712-20210712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzMjUyNA_f237af14-f634-4524-8dc8-9d804cbc95ba"
      unitRef="usd">1500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i851747d57a65428e80bd139d35336f78_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzODA2Nw_4ae0276f-24ff-4b3e-ba9f-6accb808e844"
      unitRef="usd">1400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ib551a251deb645c2b167c2d979092893_I20210712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzOTMyNg_9b89dc85-9c11-49f0-854e-40b2d44a8339"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id9ba162183a34d4793c4bb95198e7c46_D20210801-20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzMjY5OA_b20abe87-cb50-4780-9d85-7718046feb20"
      unitRef="usd">240700000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amed:ScheduleOfBusinessAcquisitionsContessaTableTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTY1Mg_5f55e618-2543-4adf-8a4a-ccee5dff80c8">Based on the Company's preliminary valuation, the total estimated consideration of $240.7&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities and equity assumed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfBusinessAcquisitionsContessaTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzODc2Nw_f7d661d6-b069-4453-be1e-eb5e8ab72d55"
      unitRef="usd">240700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMS0xLTEtMS05NDA0_ba0fa5d9-8c77-483f-942b-5a70bf48eb51"
      unitRef="usd">1500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMi0xLTEtMS05NDA0_40377829-f80e-4a82-9a65-a0752b89d524"
      unitRef="usd">300000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMy0xLTEtMS0xMzA2MQ_e25a72af-fdd1-4a41-a78c-27f3e9646166"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMy0xLTEtMS05NDA0_a465dae0-3039-4456-971c-6a005d2a8dfa"
      unitRef="usd">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfNC0xLTEtMS05NDA0_64bcd1f9-c47e-4ed7-965d-e19090c98b14"
      unitRef="usd">800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfNS0xLTEtMS05NDA0_911ac05a-de22-49b6-801c-35f23aa21e2f"
      unitRef="usd">55200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfNi0xLTEtMS05NDA0_b384af66-10c8-4846-b6f3-24caa4fec5fe"
      unitRef="usd">3300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfNy0xLTEtMS05NDA0_6f420d3b-dd3d-459a-8bd6-b6c9837d800c"
      unitRef="usd">61500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfOC0xLTEtMS05NDA0_3944b793-285b-4f34-a409-f73baab4564d"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfOS0xLTEtMS05NDA0_f409cb37-d38e-433e-a6db-8fc005877530"
      unitRef="usd">600000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTAtMS0xLTEtOTQwNA_07acc564-3348-405f-9d5e-772d056b3703"
      unitRef="usd">3400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTEtMS0xLTEtOTQwNA_4e5ae1bb-ba8b-45ca-b02a-c879695bbd7b"
      unitRef="usd">800000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTMtMS0xLTEtMTMwNjM_1bd5bf25-eb6d-48cf-bc65-4083953594a2"
      unitRef="usd">3100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTQtMS0xLTEtMTMwNjY_d10ba059-f2cc-4dd6-a4f6-fe36d62805e4"
      unitRef="usd">-900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTUtMS0xLTEtMTMwNjg_a09ceb8b-6117-4eea-a0d8-76a2ebb0a0d1"
      unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTItMS0xLTEtOTQwNA_336fbc10-d035-4597-b4e3-5146147e3dc8"
      unitRef="usd">9100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTctMS0xLTEtMTMwNzA_777c8bef-ea08-4230-a36e-afc4a37a952b"
      unitRef="usd">42100000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTgtMS0xLTEtMTMwNzI_c3abc5b7-5453-4ef1-8b94-8e75fbf409ff"
      unitRef="usd">-42100000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTktMS0xLTEtMTMwNzQ_31e359bc-81ec-4b33-bd81-487f28fd3e3a"
      unitRef="usd">-51200000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTMtMS0xLTEtOTQwNA_be8c028d-736f-41e8-b3da-c42fea901561"
      unitRef="usd">10300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i249984fbdc5e42819c3295bf8354d6b7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTQtMS0xLTEtOTQwNA_34219db9-2b46-4adb-9df0-f1d0a917dab1"
      unitRef="usd">230400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i66672e7c81cf4388ace524f46eb99c20_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOjAxODhiMWExMmI1MTRlODU5ZjY4YmUwYzY5YzlhYmZiL3RhYmxlcmFuZ2U6MDE4OGIxYTEyYjUxNGU4NTlmNjhiZTBjNjljOWFiZmJfMTUtMS0xLTEtOTQwNA_88d35dfb-fc06-4466-b4eb-45c1ae6b31b8"
      unitRef="usd">240700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i7e43a9f348fe4c7ea8efde6906e553bf_I20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTU4Nw_f7bc5516-99de-47e3-b57c-19e0b524c8e5"
      unitRef="usd">28600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ie5e610cd17944eaa9db443b1b7ceed2c_I20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTYwMg_526288a9-ad1c-49d6-8d42-aa839e41bd45"
      unitRef="usd">19900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="if5dabca3606441b0a6016647f859c142_I20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTYxNw_96275247-ecbb-47eb-bc98-549ec33bb558"
      unitRef="usd">6700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i580773c45c2e4d0f89d42392a8b52a23_D20210801-20210801"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTY0MTYzNg_b665d2f3-5a89-4d6e-a1e7-8d173266b0dd">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib322985f813e485bb88456695369faef_D20210801-20210801"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTY0OTI2NzQ1NjAwMw_4d9cf136-0dae-4a71-a659-20800d7d684b">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i7c481a799d7f4394b4a10e4b1471316c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTA5OTUxMTYzODc4NA_6ce205bb-d59f-4bb4-8f39-67c0c8cc06d4"
      unitRef="usd">1500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <amed:DepreciationAndAmortizationForContinuingOperations
      contextRef="i7c481a799d7f4394b4a10e4b1471316c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTY0OTI2NzQ1NjAyMg_0e1935d9-b13b-4a67-b4b0-ca1fb23383a6"
      unitRef="usd">500000</amed:DepreciationAndAmortizationForContinuingOperations>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTc5OQ_3ce9d4a8-f3a3-4f6b-8132-5942f4441637"
      unitRef="care_center">44</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTg0OA_94b9bc04-8939-4a5f-aec7-d660f0784e3a"
      unitRef="usd">230400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <amed:PaymentsRelatedToTaxAsset
      contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMTg5Mg_fadbf0d9-d8d9-485d-ae04-c3709a8ca4c2"
      unitRef="usd">32000000</amed:PaymentsRelatedToTaxAsset>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="i4953a1ae43744a48ab6e34e6411026e1_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjIzMw_9a341ef0-5cd6-4f3d-a5b8-f24f3b884a1a"
      unitRef="usd">1000000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <amed:BusinessAcquisitionClosingPaymentAdjustment
      contextRef="i543e41010bbd4e948680534c79d49c2e_D20201001-20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjMzNg_d0c188c3-5200-44aa-8873-e6d723890410"
      unitRef="usd">800000</amed:BusinessAcquisitionClosingPaymentAdjustment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjM0NQ_6c321cf3-889d-4905-8bff-c3230b1c28fd"
      unitRef="usd">230400000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjM1MQ_e44b6799-ccb9-4519-9556-5a76df79ce7f"
      unitRef="usd">229600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <amed:ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMzc3OA_6800679e-5a51-4615-8f32-9be304cc5e79">The total consideration of $229.6 million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.037%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net identifiable assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</amed:ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjUxNg_f772d667-de95-49c4-bd11-dfa4dbc351c7"
      unitRef="usd">229600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMS0xLTEtMS0w_28ab67b5-9277-4f56-90ec-1814c3058afb"
      unitRef="usd">15300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMi0xLTEtMS0w_6dbb75cb-1289-4466-b55d-9e4e3bca04b9"
      unitRef="usd">700000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMy0xLTEtMS0w_35f2f7f2-51a8-409a-b703-e0d149f2ec46"
      unitRef="usd">600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfNC0xLTEtMS0w_e154a963-07f0-4412-b76a-d47a58708ef4"
      unitRef="usd">5900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfNS0xLTEtMS0w_d56a6e40-725e-47b3-92fb-ca17b0ab1d71"
      unitRef="usd">24300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfNi0xLTEtMS0w_58214624-3213-4209-85d5-b2369bf1624d"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfNy0xLTEtMS0w_bc797ff3-6b90-4bf6-a7bc-ca417ef7947d"
      unitRef="usd">46900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfOC0xLTEtMS0w_175502a7-3a3c-4407-b592-2bdf4c5e3cf5"
      unitRef="usd">6300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfOS0xLTEtMS0w_1da9ddee-a802-40aa-9212-4091f45e3e47"
      unitRef="usd">5900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTAtMS0xLTEtMA_4b7778cc-5004-4bec-b523-362d37a462d3"
      unitRef="usd">11900000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses>
    <amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTEtMS0xLTEtMA_230e4407-0e4f-4a86-90a4-92be33012d5e"
      unitRef="usd">5400000</amed:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTItMS0xLTEtMA_d25a1b49-b56f-4e19-81ca-30a49659b6fa"
      unitRef="usd">29500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTMtMS0xLTEtMA_1af528f6-0fdd-4c37-a5c0-09afdfb27616"
      unitRef="usd">17400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id814fe8f58334cf9978509b3eada043c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTQtMS0xLTEtMA_3f12d11b-4b73-4a1c-bc40-de8149d37d45"
      unitRef="usd">212200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i3d6da567b0484902aa61fbfea5349833_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RhYmxlOmNjMzI3NjViZWUyZDRjYWRiMTcyYWNlMDcwYWJjNDk4L3RhYmxlcmFuZ2U6Y2MzMjc2NWJlZTJkNGNhZGIxNzJhY2UwNzBhYmM0OThfMTUtMS0xLTEtMA_c7d339e1-96b3-41b3-ae9c-c4a899f8d1a7"
      unitRef="usd">229600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i5c0952e0e5814a7380170a26c64d0563_I20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjY5MA_5f57c023-0425-4826-98b7-07961dd0d8ae"
      unitRef="usd">8700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i953170ab35da4c52b868fca5070072f4_I20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjcxNw_dfe77fdc-72b7-4480-a1dc-5e496b35c900"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i592180016a3f4b9e9fa58cdf3b1f3e11_I20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjczOA_53ff05c9-d757-4f24-bd14-386ad734dfea"
      unitRef="usd">5700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i0cb7f1afbee94667b22da85810bdfcbf_I20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjc3MA_d8e8ebf0-e779-47e5-a77d-5f6c29911419"
      unitRef="usd">9200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7dd94248f0054a2eb7c4d4f6a7ce8f7f_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjg0Ng_f548c46f-45f2-4143-a05a-011876d2c248">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i2e7f579c66d14f6f8455278885e6166c_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMjkzMw_53546113-d0b1-4895-986b-cad78776ec31">P1Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <amed:GoodwillDeductibleForIncomeTaxPurposesPeriod
      contextRef="i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181Mi9mcmFnOjE2YjJiZjI1YTQyYzRhMGI5NGZjNTcxODI3NWM5ZmM3L3RleHRyZWdpb246MTZiMmJmMjVhNDJjNGEwYjk0ZmM1NzE4Mjc1YzlmYzdfMzc2Mw_c1f79282-ce0b-448f-8c04-e7796ad53049">P15Y</amed:GoodwillDeductibleForIncomeTaxPurposesPeriod>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNzMwNA_b7162d20-9f86-4d1e-aea6-85331abad0eb">LONG-TERM OBLIGATIONS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.6% at September 30, 2021); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;First Amendment to Amended and Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provided for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which included a $550.0 million Revolving Credit Facility and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Second Amendment to Amended and Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net proceeds from the $450.0&#160;million Amended Term Loan Facility were used to fund 100% of the Contessa acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#x201c;Base Rate&#x201d; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The &#x201c;Eurodollar Rate&#x201d; means the quoted rate per annum equal to the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). The &#x201c;Applicable Rate&#x201d; is based on the consolidated leverage ratio and is presented in the table below. As of September&#160;30, 2021, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;gt; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3.00 to 1.0 but &amp;gt; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5&#160;million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement. In connection with our entry into the Second Amended Credit Agreement, we recorded $2.8&#160;million in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the three-month period ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.9% and 1.9% for the three and nine-month periods ended September&#160;30, 2021, respectively, and 1.8% and 2.2% for the three and nine-month periods ended September 30, 2020, respectively. Our weighted average interest rate for borrowings under our $450.0&#160;million Amended Term Loan Facility was 1.6% and 1.5% for the three and nine-month periods ended September 30, 2021, respectively, and 1.7% and 2.3% for the three and nine-month periods ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, our consolidated leverage ratio was 1.2, our consolidated interest coverage ratio was 27.5 and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, our availability under our $550.0 million Revolving Credit Facility was $519.9 million as we have no outstanding borrowings and $30.1 million outstanding in letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joinder Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#x201c;CCH Joinder&#x201d;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Security Agreement&#x201d;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#x201c;Amended and Restated Pledge Agreement&#x201d;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice, which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#x201c;Contessa and Asana Joinder,&#x201d; and together with the CCH Joinder and the AseraCare Joinder, the &#x201c;Joinders&#x201d;). &lt;/span&gt;&lt;/div&gt;Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana Hospice and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana Hospice and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNzMwNg_e045031c-0625-45e0-b32e-4751fc2c8b7f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consists of the following for the periods indicated (amounts in millions):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.6% at September 30, 2021); due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due July&#160;30, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Promissory notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id2212b3038014b39b18d85e2bb708130_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0zMDkvdGV4dHJlZ2lvbjozMDIxY2I3MTU4NDg0NDkyYmJlODkxNjJjZDRmNjY0Y18xMDk5NTExNjI4MDI1_cf7b705c-fb6a-4cb3-b81e-23293e9fdbf7"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestRateatPeriodEnd
      contextRef="if630985387694c3c8fc5598653fa49c5_I20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0zMDkvdGV4dHJlZ2lvbjozMDIxY2I3MTU4NDg0NDkyYmJlODkxNjJjZDRmNjY0Y18xMDk5NTExNjI3OTkw_fc57362d-2cd2-4e3d-9745-c425a397fda7"
      unitRef="number">0.016</amed:DebtInstrumentInterestRateatPeriodEnd>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i9c80c052038b44b5a18995cafc14e750_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0zMDkvdGV4dHJlZ2lvbjozMDIxY2I3MTU4NDg0NDkyYmJlODkxNjJjZDRmNjY0Y18xMDk5NTExNjI4MDA3_509964da-7c83-4818-9bf6-22f6d3d4e307">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id2212b3038014b39b18d85e2bb708130_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0xLTEtMS05MzQy_75231549-73c4-4fb3-b171-6b1abebf8b88"
      unitRef="usd">450000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id33dd3f1accc48d0b07ae82ea62d7bf3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0zLTEtMS05MzQy_bca75f75-59d7-47bb-a66f-57e9112b3d60"
      unitRef="usd">164100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0wL3RleHRyZWdpb246YmFmYmYwOTIyNWQwNDM5ZmJiZDIxZmY2NGIwYmRkNzZfNA_8862b461-dec5-49bd-9d11-a507ead533de"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i4a29fce5319a41b88a21448a8d746bc1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0wLTEtMS0wL3RleHRyZWdpb246YmFmYmYwOTIyNWQwNDM5ZmJiZDIxZmY2NGIwYmRkNzZfMTcz_c25ba678-7c58-42d1-866b-5e1838193e78">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0xLTEtMS0w_0384cf44-9c93-419b-bcac-416caaaa47b8"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i04620e666ce242189145fc8202e974a5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMi0zLTEtMS0w_c3973e58-65d9-4b0e-812a-136aa23f7748"
      unitRef="usd">51000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1c79a4a01587443798a698b9d888425d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNC0xLTEtMS0xMDM2OA_553daa93-2a10-45d3-85bd-2d60a14b8626"
      unitRef="usd">800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8c6b3f9117ec48d3af01c13b614cdce8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNC0zLTEtMS0xMDM2OA_28c6b420-5c28-416b-83e3-bfaca9f685f5"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i86b58db92e154fe68dd728641fc3400e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMy0xLTEtMS0w_a297d5d0-1091-4107-a0a0-61168b64c232"
      unitRef="usd">2000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieb868e0e199e4a7ba64d42b2fdae307d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfMy0zLTEtMS0w_8412999f-2c7e-4584-8f92-cb6dbcb167cc"
      unitRef="usd">2600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNC0xLTEtMS0w_550e1d77-114b-4142-a658-323ee4c1e880"
      unitRef="usd">452800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNC0zLTEtMS0w_41c6ce66-3dd9-47af-842a-e5a4f64ba009"
      unitRef="usd">217700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNS0xLTEtMS0w_00ba5665-d7cf-4f41-8fb1-495d39e69801"
      unitRef="usd">4800000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNS0zLTEtMS0w_87708c7a-b77e-4a69-8c57-82976125cb74"
      unitRef="usd">2700000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNi0xLTEtMS0w_a5c5b924-d008-4962-a3c5-097cd4b588b1"
      unitRef="usd">448000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNi0zLTEtMS0w_1ccd2b60-2a84-4bf5-a205-5ec4c91160a4"
      unitRef="usd">215000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNy0xLTEtMS0w_17873ca8-121b-4772-bbe8-1b675ebdff42"
      unitRef="usd">13200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfNy0zLTEtMS0w_7f24a33d-8ed1-4a6a-9311-f9a3514ed3b5"
      unitRef="usd">10500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfOC0xLTEtMS0w_3da68b2d-90a4-444f-b7a9-8999ed41ae2d"
      unitRef="usd">434800000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i84de3e983eb740b1bb3c8f25d7622369_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjYzM2QwMmE3MjgyYzQ3NjZhMjA0MmNjM2JjYWVkODdkL3RhYmxlcmFuZ2U6NjMzZDAyYTcyODJjNDc2NmEyMDQyY2MzYmNhZWQ4N2RfOC0zLTEtMS0w_82c936ce-e824-4cc6-ba1e-648eca3a5c27"
      unitRef="usd">204500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i13ec3a58ad29418ebe42554498e48e75_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDU1_8c72438a-8ef0-4ffe-8c71-78954ec2da65"
      unitRef="usd">725000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibf92b4555b6d40f2a59b54d48f64f091_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDc2_64b8cbed-d98f-40f0-8868-7e9f66241f93"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic64fd34ea067411b965765c227c1c4e8_I20190204"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNTkx_db8e585d-11aa-4e34-8645-69d8c56899be"
      unitRef="usd">175000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ibb7c45b2d9ae4729a6b676da0434e01b_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNTQzNg_c0b755c6-75b3-4ff1-9f34-b42a6aa5b6d8"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8161c5c6f5a441498e6232b1062a0706_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNTQ1OA_dccffda6-51cc-4ec2-8d0d-837066a31abf"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic9248021e924452a9ca5a099d811b891_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNTU4OQ_00070aae-71e6-4562-b99f-2d6a94cb872c"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic9248021e924452a9ca5a099d811b891_I20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNTczMA_ccae3e62-9f5a-4b61-b3f2-244eeb154dce"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate
      contextRef="i96b33383638f4da69049403922d142b6_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MTA3Mg_132dea8d-4b87-4985-8bb4-75bd1f8f65a6"
      unitRef="number">0.0050</amed:DebtInstrumentInterestAdditionalInterestAboveFederalFundRate>
    <amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate
      contextRef="i96b33383638f4da69049403922d142b6_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MTE5Mg_43247ea4-2f47-4814-852c-de3f155af0db"
      unitRef="number">0.01</amed:DebtInstrumentInterestAdditionalInterestAboveEurodollarRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ic4d439ce912f4be0af7514da8425d3c2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MTU5Ng_d1d0ebe5-95af-493b-8344-742624ed99e0"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib9ff3a8ccb9f425b8f7441a6634cf019_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MTYzNA_41736fa8-fe1c-4a7b-94cc-6d7da18ded3d"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjUwMA_212913ff-d65c-4fb8-a36c-d8da0d26ea6b">We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.151%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pricing Tier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Commitment Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Letter of Credit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Base Rate Loans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&amp;gt; 3.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 3.00 to 1.0 but &amp;gt; 2.00 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;III&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 2.00 to 1.0 but &amp;gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.50%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&amp;lt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; 0.75 to 1.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.15%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <amed:ConsolidatedLeverageRatio
      contextRef="i8268f6431a5342b0a5dc83e81f8cf5a1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS0xLTEtMS0zMzIvdGV4dHJlZ2lvbjoyMzFiMjhhOGU3MDU0MmIzYjA2ZDlmNjg3ZGE0NmNiNV82_9d6f6a12-7968-4169-80ba-57033b48a86f"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="id2629c6a87704cab9b7d7cc4fcb7d9d7_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS0yLTEtMS05NDEw_0653ee31-261b-4a41-86c6-ee11ef3a54bb"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="id2629c6a87704cab9b7d7cc4fcb7d9d7_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS0zLTEtMS05NDE1_b7b77713-0526-4967-911d-50a7705c298b"
      unitRef="number">0.0175</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6347f72e46564137a77f41c6701f04b4_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS00LTEtMS05NDE1_62bd6bc3-97ff-4676-8cb5-b96ad90061fb"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7a006fc8ae3144b8b0f35e0576008c13_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMS01LTEtMS05NDE1_9e6d04bf-0ac6-4779-bca3-c9bb18bc7bf0"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="i8eda14018d5440f49c3d2c8399bf7c28_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi0xLTEtMS0zMzIvdGV4dHJlZ2lvbjowYzAzODI4OGZjNWI0ODczYmY1YjhiN2U4NjA5MTNlOF83_583c0c4f-1e56-4c22-9f88-3812ca52e2d2"
      unitRef="number">3.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i577fdd4a436a42ea80849c81a5784c4c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi0xLTEtMS0zMzIvdGV4dHJlZ2lvbjowYzAzODI4OGZjNWI0ODczYmY1YjhiN2U4NjA5MTNlOF8yMw_c2e7e9bb-b5d3-4baa-b3b5-65f60c2cd4ef"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i66aae57e36ae41648ae8623055ad5911_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi0yLTEtMS05NDEz_790f9154-3db4-47c0-a2b2-ffad31ffea70"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i66aae57e36ae41648ae8623055ad5911_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi0zLTEtMS05NDE1_6fb7074b-fff9-4b41-bedf-4719c769f1c9"
      unitRef="number">0.0150</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i499562ee396144d1b90e4e7f1e4b3078_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi00LTEtMS05NDE1_5bc8db1b-413e-46e8-94ff-7514eb9ef34e"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i35d443fe2776475199e8bf20c5bd7195_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMi01LTEtMS05NDE1_06f0bcc6-b5a5-4a48-a6e7-2f03d1406da8"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="i0e39d276de254f649e239423c9cc0cc7_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy0xLTEtMS0zMzIvdGV4dHJlZ2lvbjowMTkzNmM4OTNjYTc0OGY3YTYwODQwZGRhMzQyMTBiZl82_5f57f6a7-4d68-40f5-8017-f077632e1e84"
      unitRef="number">2.00</amed:ConsolidatedLeverageRatio>
    <amed:ConsolidatedLeverageRatio
      contextRef="i94c391fe27d34bb598e993c5ca12ab5e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy0xLTEtMS0zMzIvdGV4dHJlZ2lvbjowMTkzNmM4OTNjYTc0OGY3YTYwODQwZGRhMzQyMTBiZl8yMg_6cd0c009-b3c8-4fbf-b874-c3f976cfd1e9"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i5bbf202037ab4efe84eec9c86af849aa_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy0yLTEtMS05NDEz_c5dc8ab4-40f2-467e-a68f-3531279387f8"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="i5bbf202037ab4efe84eec9c86af849aa_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy0zLTEtMS05NDE1_06e1ddb7-7aac-4d01-84e7-25db6961ac51"
      unitRef="number">0.0125</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iec7d2c9ab8af421195c28b753a977a92_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy00LTEtMS05NDE1_eee1b8b5-3b5b-479a-a6ba-d001af1ff52b"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i31501243538e4935b989aad968b62589_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfMy01LTEtMS05NDE1_8d96455a-ad28-4fad-810e-7fc1d662cc3a"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <amed:ConsolidatedLeverageRatio
      contextRef="ie04b2efc6fec439ca0961cd20f0f2601_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC0xLTEtMS0zMzIvdGV4dHJlZ2lvbjoyYTAyMDU3NGY4MTM0ZGQxOGEwNjY2OGQ3ZjBiNDU4ZF82_e9396420-debf-4194-b810-80b48230e920"
      unitRef="number">0.75</amed:ConsolidatedLeverageRatio>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ia7b640016ec74b29877d9d8af659dacf_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC0yLTEtMS05NDEz_ccf549ce-a9e5-4935-b807-6429b5830ade"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <amed:LetterOfCreditFee
      contextRef="ia7b640016ec74b29877d9d8af659dacf_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC0zLTEtMS05NDE1_0570b768-b627-4c48-b0de-e548fa19f504"
      unitRef="number">0.0100</amed:LetterOfCreditFee>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7807a03e1d27498cb0fbd254ba18a9e2_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC00LTEtMS05NDE1_8315208b-5053-4602-b3bd-c4a99419a578"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5fb48a5c2350401badf76407e810a916_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RhYmxlOjU0ODc1ZjhmMmY2MTRiMDlhMWRkMzAwNzI1ZjQ1NzE1L3RhYmxlcmFuZ2U6NTQ4NzVmOGYyZjYxNGIwOWExZGQzMDA3MjVmNDU3MTVfNC01LTEtMS05NDE1_dc087be9-eaa3-4869-b832-fb0aee4f0f42"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="i4384d6ba9eb047a8b55217f4beaf64b4_D20210730-20260730"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNjMyOA_8f7e2f90-2fbd-4f60-8e9a-f0f4edc642a4">2026-07-30</us-gaap:DebtInstrumentMaturityDate>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="ic8d7f3ebbc7b4cbabe8f090e4d1c2b10_D20210730-20230930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNjU0NA_c2aad78e-22d1-43a8-b5f9-7c6eb4a40878"
      unitRef="number">0.00625</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:DebtInstrumentPeriodicPaymentPercentage
      contextRef="i22ebbfca679d4a7fafa5444ca24a361f_D20231001-20260730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNjYzNA_8c09415e-686f-4694-a0b6-215df7c3f069"
      unitRef="number">0.01250</amed:DebtInstrumentPeriodicPaymentPercentage>
    <amed:ProceedsReceivedFromLoanPartyOfSubsidiary
      contextRef="ie4322d7e66634ce4885a55d252abc28d_D20210730-20210730"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTYzNzI1Ng_3504f7f1-ce60-46fb-9370-c920bfdcc2e6"
      unitRef="usd">5000000</amed:ProceedsReceivedFromLoanPartyOfSubsidiary>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ie4039f4791f043d6a0ea7c40d6c13d2f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjE5NQ_5e12c506-036c-4903-85d5-d9e87eee2977"
      unitRef="usd">2800000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries
      contextRef="i96b33383638f4da69049403922d142b6_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDA2OA_dd5266a6-9a80-42f1-9f23-eb67624ffa96"
      unitRef="number">0.95</amed:PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries>
    <amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries
      contextRef="i96b33383638f4da69049403922d142b6_D20210730-20210730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDI1MQ_633763c1-918a-4b71-b23b-283e3b38a49d"
      unitRef="number">0.70</amed:PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDM3OQ_8ad96c0f-93b7-4224-8786-b5eeffea77bc"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ib057fa7e9dc74985846be7233614be6d_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDQxMg_a0861e32-92c6-4bdd-a1f1-587ad94ec884"
      unitRef="number">0.029</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i4a29fce5319a41b88a21448a8d746bc1_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDQxOQ_5d09ab9a-dc49-4ba3-a368-031381a89f62"
      unitRef="number">0.019</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i8a8de61107114e3188c016a866d7eee9_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDQ4Ng_189681ee-2cc5-416f-bc1b-c4c50998f366"
      unitRef="number">0.018</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i75a1a833f08448ae97ff44f57957725d_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDQ5Mw_070d2329-6138-40b2-97f1-ab338ecf38e0"
      unitRef="number">0.022</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id2212b3038014b39b18d85e2bb708130_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjQ3MQ_f0bc823d-5fd6-4fd1-a6e5-93cdd067e22e"
      unitRef="usd">450000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i257940b085494340a54f2596ffb71f9c_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjQ5Mw_b36c5e41-2af0-465e-9e3c-b081dada12ae"
      unitRef="number">0.016</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i9c80c052038b44b5a18995cafc14e750_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MzYwMw_199bbb33-850f-454e-91aa-a6de647d9719"
      unitRef="number">0.015</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="i4eabd2498ce447d59434f7882ae478d0_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTY0OTI2NzQ1NzM5OA_89f92641-1ccc-4510-9a40-253b9dda0e49"
      unitRef="number">0.017</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <us-gaap:LongTermDebtWeightedAverageInterestRateOverTime
      contextRef="ifba8391d8e984a3593722809cdc00c21_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTY0OTI2NzQ1NzQwMg_344e7066-bf6e-4faf-8c1b-5cd0e22bfdbf"
      unitRef="number">0.023</us-gaap:LongTermDebtWeightedAverageInterestRateOverTime>
    <amed:TotalLeverageRatio
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDg1NQ_67a4d48c-376a-40a4-b4d7-7f55b56f158a"
      unitRef="number">1.2</amed:TotalLeverageRatio>
    <amed:ConsolidatedInterestCoverageRatio
      contextRef="ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNDkwNA_cf927796-eaf4-41cc-a879-8e47c136ac94"
      unitRef="number">27.5</amed:ConsolidatedInterestCoverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNTI4Mg_92b0ac50-4f18-4580-b45b-f72e6834434c"
      unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNTMxNQ_1556b76c-5fe4-49fd-8c24-ca7d7a3ae716"
      unitRef="usd">519900000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i93f3a54943ce4dfc93af29045df66a08_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfMTA5OTUxMTY0MjU4Mw_0384cf44-9c93-419b-bcac-416caaaa47b8"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i778f590556a3415eb3394ae1a6c1629f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY181OC9mcmFnOjBlZGFiNTZiNmJmNTRlNmNiMjUyMzRmZWYwY2FlMmM4L3RleHRyZWdpb246MGVkYWI1NmI2YmY1NGU2Y2IyNTIzNGZlZjBjYWUyYzhfNTM2Mg_1830f083-a58d-4a3a-9d53-d62466db822e"
      unitRef="usd">30100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMTAwODA_1133db5d-7f8a-484c-8e14-81869d07445b">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees related to all legal matters are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings - Completed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). As of March 31, 2021, we had recorded a total of $6.5 million to accrued expenses in our condensed consolidated balance sheets related to these matters. During the three-month period ended June 30, 2021, we reversed our accrual related to these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding 53 identified hospice patients to the United States Attorney&#x2019;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May&#160;21, 2015.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#x2019;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August 31, 2015.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#x2019;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Third Party Audits - Ongoing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#x201c;RACs&#x201d;), Zone Program Integrity Contractors (&#x201c;ZPICs&#x201d;), Uniform Program Integrity Contractors (&#x201c;UPICs&#x201d;), Program Safeguard Contractors (&#x201c;PSCs&#x201d;), Medicaid Integrity Contractors (&#x201c;MICs&#x201d;), Supplemental Medical Review Contractors (&#x201c;SMRCs&#x201d;) and the Office of Inspector General (&#x201c;OIG&#x201d;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#x201c;Review Period&#x201d;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#x2019;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#x201c;MAC&#x201d;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of September&#160;30, 2021, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#x201c;SafeGuard&#x201d;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center has been reduced to $3.3 million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $12.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $6.5 million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $38.8 million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $12.6 million is subject to indemnification by the prior owners) to $29.3 million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021, we have an accrued liability of approximately $17.4 million related to this matter. We expect to be indemnified by the prior owners for approximately $10.9 million of the total $12.6 million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheets. The net of these two amounts, $6.5 million, was recorded as a reduction in net service revenue in our condensed consolidated statements of operations during 2017. As of September&#160;30, 2021, $1.5 million of receivables have been impacted by this payment suspension.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are obligated for certain costs associated with our insurance programs, including employee health, workers&#x2019; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#x2019; compensation insurance has a retention limit of $1.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i035bf53c46a541a5826c7f2c7b06185b_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTI3_058b7d81-1220-4671-9774-2aba0b016ce3"
      unitRef="usd">6500000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <amed:ReversalOfLossContingencyAccrual
      contextRef="idd4289f9d03348eabba8b8a1ff9153aa_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTI3_7ce7cb4d-fb40-4009-976b-8a2927a0d132"
      unitRef="usd">6500000</amed:ReversalOfLossContingencyAccrual>
    <amed:Numberofpatients
      contextRef="i601ff40a9dcb4f2e8948d32afbd39a70_D20150521-20150521"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMTI2NQ_d16fcf79-0698-4a6f-82e0-26cc93b4b267"
      unitRef="patient">53</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="i8ccc1c8d24e84db4aa8381d958233b6b_D20151103-20151103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMjAwOA_fe92b649-f14d-453c-89ed-b805581e71e7"
      unitRef="patient">66</amed:Numberofpatients>
    <amed:Numberofpatients
      contextRef="ie05aa041138d438c87540387474bcbd1_D20160627-20160627"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMjYzOA_3e678422-704b-4041-8afb-60f733bff6bb"
      unitRef="patient">68</amed:Numberofpatients>
    <amed:NumberOfBeneficiaries
      contextRef="i0aa37634d03d42b08a244431e4a41f5c_D20080101-20100331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMzcxMA_1be1c716-955d-4414-8d49-07c8cd3b7488"
      unitRef="beneficiary">30</amed:NumberOfBeneficiaries>
    <amed:NumberOfBeneficiaries
      contextRef="i095f59a36c244843af1db7f854a0a9a2_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNDE1NA_6f0dab82-e2ce-46bd-9dec-b379b63ab775"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ica3afcf2ee1c43259f1a30c2e600133a_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNDk1Nw_91afeb41-4acf-4292-9d91-a41ba8d0c503"
      unitRef="usd">3700000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest
      contextRef="ica3afcf2ee1c43259f1a30c2e600133a_I20160118"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNDk4Mw_86142b83-85e8-4718-a017-2f17c6bc2e16"
      unitRef="usd">5600000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i564a484715c64e40a7be81c6235e4f3d_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTAxNg_f5e87374-19c7-41ea-a4c1-304b7b15d2c7"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:NumberOfBeneficiaries
      contextRef="i095f59a36c244843af1db7f854a0a9a2_D20110606-20110606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTA0Nw_4fb16581-a80e-4e6b-8dc3-69268faad2b5"
      unitRef="beneficiary">16</amed:NumberOfBeneficiaries>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i564a484715c64e40a7be81c6235e4f3d_D20160118-20160118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTEyMA_e973df7b-c1bd-48b5-89f8-87e2b5230c8c"
      unitRef="claim">9</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld
      contextRef="i802e5888cb1648439a3f47b2b44404c2_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTM2NQ_feff172d-586e-4318-acbb-6575997d723e"
      unitRef="usd">5700000</amed:Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i76d5dd1a4f4a464ca4fb9d384e6aa87b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTg3MA_2f0923e4-ffd5-4e18-a123-43db9d2b5d5b"
      unitRef="usd">2800000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:IndemnificationAmount
      contextRef="ic80811cd8fd747ef98eb89b834589f68_I20190110"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNTg3MA_a49d5a4e-fddd-4471-8e52-4bb8601fda07"
      unitRef="usd">2800000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i3b5d1cbe45dc44d9b98ec0e127cd824c_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjcxNQ_716892ca-3bea-4e8e-a718-108d16331b50"
      unitRef="usd">34000000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="i484c5a9dd6e14e23b66ed620f5079d5d_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjc2NQ_0bd73943-87e0-4814-bdee-9e5e59b720f1"
      unitRef="claim">72</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="i3b5d1cbe45dc44d9b98ec0e127cd824c_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjc5Mw_0a609bd7-fb1f-46a1-8f10-7c4697d5215b"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="i3b5d1cbe45dc44d9b98ec0e127cd824c_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjgzMA_c762134d-9e5a-4806-9f89-4cc9602acc8c"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ic0294eb79c2848a59000786e83e668d1_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjg2Ng_3098cffe-eda7-48bf-8918-27aadd61a84c"
      unitRef="usd">4800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:NumberOfClaimsSubmittedBySubsidiary
      contextRef="ie0de238f9be246fe96998173de4a5bcb_D20170801-20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjkxNw_d4b28367-4f04-4ff2-9bc0-7937ac5f653e"
      unitRef="claim">70</amed:NumberOfClaimsSubmittedBySubsidiary>
    <amed:ActualClaimsPayment
      contextRef="ic0294eb79c2848a59000786e83e668d1_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjk0NQ_cc395be8-b67f-4ae0-925d-6962b8cd2fa6"
      unitRef="usd">200000</amed:ActualClaimsPayment>
    <amed:ErrorRatePercentage
      contextRef="ic0294eb79c2848a59000786e83e668d1_I20170831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNjk4Mg_921f8590-bffe-4d9a-b7ad-4a574d9fed15"
      unitRef="number">1</amed:ErrorRatePercentage>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i346f707c9d6b4ac9964bf787577aea3d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNzM0Ng_bb470950-b056-404d-808f-6e9ca7dcdb45"
      unitRef="usd">26000000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i89ded9eda305484fa4ab5c09016ceb41_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNzQyOA_9357814f-6e94-4f82-8191-eec5ac0018c1"
      unitRef="usd">3300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="i3eb22d6ba31944238874d354008337ec_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfNzc4Nw_2de06d33-e8ee-4f6f-95e6-79b6524930c2"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ie21724093a2f42c4853d771fabb00f17_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODAyOA_b91b664c-109b-4bd9-ba54-e4f705b98c57"
      unitRef="usd">6500000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="i36258c9144d84085bd1b3ea4fd537b23_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODI3NA_6841d953-e393-48c9-85e4-238b06b21506"
      unitRef="usd">38800000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <amed:IndemnificationAmount
      contextRef="i3eb22d6ba31944238874d354008337ec_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODQxNA_a69b5747-de40-4f3c-b691-a5d5b871b010"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:RecoveryAmountOfOverpaymentMadeToSubsidiary
      contextRef="ief75d072b29748ba987a8030789542dd_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODQ3MQ_477b2c1b-5fac-4aff-8d31-c872021859ed"
      unitRef="usd">29300000</amed:RecoveryAmountOfOverpaymentMadeToSubsidiary>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i08e7d764f4494c88b305e1e18074b41f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODY0MQ_d6cca550-61d9-4b18-a4a4-9a7a538aa990"
      unitRef="usd">17400000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyReceivableNoncurrent
      contextRef="i08e7d764f4494c88b305e1e18074b41f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODczNA_fd236c15-bb1b-456c-9e79-cf7f03963c7c"
      unitRef="usd">10900000</us-gaap:LossContingencyReceivableNoncurrent>
    <amed:IndemnificationAmount
      contextRef="i60712b1793c74750b58b9385fb0c31e3_I20170831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODc1MA_9b27eb97-3af7-40c2-bc88-891f154cbb8f"
      unitRef="usd">12600000</amed:IndemnificationAmount>
    <amed:FloridaZpicRevenueReduction
      contextRef="i3d7c2cc8b22d455a9ebb4e72d526d36c_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfODkyOA_043cec0b-afd2-4f41-8c51-7ba1708fd37f"
      unitRef="usd">6500000</amed:FloridaZpicRevenueReduction>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9eaa44efaa1a467ebc42d62d7ac69a76_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTA2MQ_b495d467-0312-46d1-8eb6-090f85694140"
      unitRef="usd">1500000</us-gaap:AccountsReceivableNetCurrent>
    <amed:HealthInsuranceRetentionLimit
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTg4Mw_f0870348-729f-424c-8a6f-76de91367e2e"
      unitRef="usd">1300000</amed:HealthInsuranceRetentionLimit>
    <amed:WorkersCompensationInsuranceRetentionLimit
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfOTk4MA_39c9f8a1-0081-46ab-9962-f20f94fa6432"
      unitRef="usd">1000000</amed:WorkersCompensationInsuranceRetentionLimit>
    <amed:ProfessionalLiabilityInsuranceRetentionLimit
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY182NC9mcmFnOjY5MTdiMzhlZWE1YjRjMTE4ZjcwNDBiNzhiMzJhMGQzL3RleHRyZWdpb246NjkxN2IzOGVlYTViNGMxMThmNzA0MGI3OGIzMmEwZDNfMTAwNjI_88448be0-4226-4156-89df-205acf601207"
      unitRef="usd">300000</amed:ProfessionalLiabilityInsuranceRetentionLimit>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RleHRyZWdpb246MTI0MWNhYWUyNzhiNGVhMzgzZmFjMzExMDY1ODkwNWZfMTM4Mg_38fcb34d-b544-45de-9dd5-1cbcd036a5f4">SEGMENT INFORMATION&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa during the three-month period ended September 30, 2021, delivers the essential elements of inpatient hospital and skilled nursing facility ("SNF") care to patients in their homes. The &#x201c;other&#x201d; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#x2019;s chief operating decision maker and therefore are not disclosed below (amounts in millions).&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine-Month Period Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine-Month Period Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RleHRyZWdpb246MTI0MWNhYWUyNzhiNGVhMzgzZmFjMzExMDY1ODkwNWZfODI_5f502b79-2030-4443-8fac-805fc9c272d0"
      unitRef="segments">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RleHRyZWdpb246MTI0MWNhYWUyNzhiNGVhMzgzZmFjMzExMDY1ODkwNWZfMTM4NQ_4ee5cb9e-5a64-47a5-b302-9dd2e1aa72b2">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.116%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three-Month Period Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine-Month Period Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,654.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;460.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,464.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine-Month Period Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Home&lt;br/&gt;Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Personal&lt;br/&gt;Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;High Acuity Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net service revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;919.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;546.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of service, excluding depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,391.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi0xLTEtMS0w_a8fb46cc-86e0-413d-9ffd-724fdcfce426"
      unitRef="usd">338600000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi0zLTEtMS0w_138aadad-ac27-4b6b-aed6-076cabfa330a"
      unitRef="usd">197500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi01LTEtMS0w_94196f77-d28e-4d52-87d7-efb9ae03c72b"
      unitRef="usd">15900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi03LTEtMS05MzAx_b234e969-aa6d-49cc-8e95-9b7723078063"
      unitRef="usd">1500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi03LTEtMS0w_ef071f22-2f92-49ff-bd85-207bfe228acd"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMi05LTEtMS0w_ecb13a25-a451-4cfa-94b7-fd5a6349c0cc"
      unitRef="usd">553500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy0xLTEtMS0w_879d4c51-31b3-4aa3-81ac-e146c9526c9d"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy0zLTEtMS0w_97b3e87c-30df-4576-9850-64610ea02787"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy01LTEtMS0w_7a2078fa-f327-40f0-8b37-0cd0daafddea"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy03LTEtMS05MzAx_38aeaf5f-4592-4bcf-8b59-1e8398941736"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy03LTEtMS0w_58a72fac-3bf5-4828-89ee-0f8ca79694e4"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMy05LTEtMS0w_23c83f06-0e83-4e52-9fe8-b8c597ddf141"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC0xLTEtMS0w_e000aaa9-c0f3-4f3a-9f32-5950d0fd84b4"
      unitRef="usd">190100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC0zLTEtMS0w_c53a7c78-6709-4ad8-8c89-29376c202959"
      unitRef="usd">107600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC01LTEtMS0w_1ca341cc-a1ec-4ad1-b98b-80b6a31746ae"
      unitRef="usd">11700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC03LTEtMS05MzAx_c864591a-86e4-4cf1-930a-979a69e467da"
      unitRef="usd">900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC03LTEtMS0w_c09bb82a-712c-4ed5-9af3-e7e531ff6d8c"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNC05LTEtMS0w_35e2f6c0-faa6-4068-bf11-97f48079c134"
      unitRef="usd">310300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS0xLTEtMS0w_b0c72e0a-f8ca-45a1-821e-8e7637ded9f5"
      unitRef="usd">82400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS0zLTEtMS0w_826a1de0-12ba-42f4-a6b4-5d8588740e5f"
      unitRef="usd">49500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS01LTEtMS0w_27acee73-97b7-4798-9e85-8235ba7b1133"
      unitRef="usd">2600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS03LTEtMS05MzAx_15ce2795-49b7-47b8-aa03-11f789bf35f9"
      unitRef="usd">3900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS03LTEtMS0w_037b4c2c-728f-48b9-aca8-b0d31f78ab1a"
      unitRef="usd">40500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNS05LTEtMS0w_67f4efa5-7679-4c4e-a21b-f256de5b01cc"
      unitRef="usd">178900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi0xLTEtMS0w_2d58ce36-6f75-49de-8c46-8e8e274ab385"
      unitRef="usd">1100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi0zLTEtMS0w_8c3690ab-be48-4f63-9527-626437f6ea1b"
      unitRef="usd">700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi01LTEtMS0w_36cc1fe3-8ff8-48fc-876a-feb55116d28f"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi03LTEtMS05MzAx_352675f3-3c5f-4171-8e47-e769bad8014b"
      unitRef="usd">500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi03LTEtMS0w_bbe4746c-c0d0-416b-b92b-fdbd90736760"
      unitRef="usd">5100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNi05LTEtMS0w_3af52749-4cba-4eec-926a-5d6d939f82cd"
      unitRef="usd">7500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy0xLTEtMS0w_04e053f3-fba4-4e40-939f-d18265833009"
      unitRef="usd">273600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy0zLTEtMS0w_2439a75e-9521-48a5-92bf-f3fda30a07a0"
      unitRef="usd">157800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy01LTEtMS0w_67dadbcb-43e0-46f9-9cce-ecc452fa22fe"
      unitRef="usd">14400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy03LTEtMS05MzAx_23f5ff2d-98bd-4e97-a47e-31d2744f1195"
      unitRef="usd">5300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy03LTEtMS0w_72f8e19d-1e35-48a5-ac8e-5ab42c32ceb5"
      unitRef="usd">45600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfNy05LTEtMS0w_5dc9bffb-e77b-4ff6-98a5-8b2cce3b4127"
      unitRef="usd">496700000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i38f95aad66a34089aba1df18a61dd6e6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC0xLTEtMS0w_e2c3ba11-158c-4e9a-b40a-83c9b56e465f"
      unitRef="usd">65000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id363dc674251412f912533418a9d82dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC0zLTEtMS0w_023aec2d-7aad-4c03-80fc-6fde1ac1d868"
      unitRef="usd">39700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia6bb1fcfa3a64a1f865be4939d2216ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC01LTEtMS0w_f0d9a1ff-fa8d-4274-a13b-738d623c2e1d"
      unitRef="usd">1500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1dd2995298074b5fba83f79712da0a5f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC03LTEtMS05MzAx_b3d53bf8-a8c6-48ac-8a8c-b834ddbf3fa0"
      unitRef="usd">-3800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic29a871182a54f2094160695e03ee462_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC03LTEtMS0w_2d0b6e26-456d-4a13-a8db-d242009431d5"
      unitRef="usd">-45600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4041053d2da749d8975f3208c6832b54_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfOC05LTEtMS0w_035c266d-ca5c-47ec-94ff-ba847ec91d20"
      unitRef="usd">56800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItMS0xLTEtMA_a89c4143-85d3-407f-89b9-39329daf2db3"
      unitRef="usd">326000000.0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItMy0xLTEtMA_9c062c68-b461-432a-b6b5-ff172b05b412"
      unitRef="usd">199700000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItNS0xLTEtMA_83b78027-f7d6-41e5-bd4e-e28b896319ec"
      unitRef="usd">18400000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItNy0xLTEtOTMwMw_184c5f9e-42c7-462a-b40a-5df420caee1b"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItNy0xLTEtMA_ca86bc74-e160-404c-8ccc-97e0e110cc7c"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTItOS0xLTEtMA_404d6fb1-3cce-4c19-b98d-d4477d3830fe"
      unitRef="usd">544100000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtMS0xLTEtMA_3eb84352-0717-4061-9770-0c2384e7c9d8"
      unitRef="usd">2600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtMy0xLTEtMA_2cf16c3a-f5a8-4992-96f6-ea29b1ccf3bf"
      unitRef="usd">1700000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtNS0xLTEtMA_b40abe90-7362-432c-80f3-527805a85e91"
      unitRef="usd">500000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtNy0xLTEtOTMwMw_86daa2a3-b7e2-4f16-94fe-e99b3d41f85e"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtNy0xLTEtMA_0e9411f0-82ae-4596-b5fe-071c4174cdb4"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTMtOS0xLTEtMA_663b10ad-f0b3-44d1-b6a3-63f2b6338ca1"
      unitRef="usd">4800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtMS0xLTEtMA_ddf1fb24-5d70-4d26-a9c8-0b1add53804b"
      unitRef="usd">180000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtMy0xLTEtMA_1fb213d4-f37b-401b-8ab0-015b788bc276"
      unitRef="usd">104100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtNS0xLTEtMA_e910d486-1bbf-42db-9e55-b591c96b7344"
      unitRef="usd">13500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtNy0xLTEtOTMwMw_c6217e89-118c-4aed-b0d7-54f32a18950b"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTQtNy0xLTEtMA_7ad1ee84-44b8-4dec-9d38-46221604d7e5"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtMS0xLTEtMA_0175c0d9-e9e5-42ad-9b77-813f09ca7ba4"
      unitRef="usd">78800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtMy0xLTEtMA_5134acde-ca10-45b4-8254-29889cca4f7e"
      unitRef="usd">47800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtNS0xLTEtMA_1da7dde0-6d14-4330-a9da-684a7e011b0d"
      unitRef="usd">3200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtNy0xLTEtOTMwMw_0c377a8a-c242-4c80-8a50-7b46fce480c9"
      unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtNy0xLTEtMA_36aad288-fe4b-41fb-9027-85238ad76646"
      unitRef="usd">49900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTUtOS0xLTEtMA_80aa77bd-50de-4db8-8711-9895807c0404"
      unitRef="usd">179700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtMS0xLTEtMA_bad7b8a8-c101-4035-842f-1985d92a5e8e"
      unitRef="usd">1000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtMy0xLTEtMA_c0901067-3eef-4e8e-b745-7e402dd1bdfd"
      unitRef="usd">600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtNS0xLTEtMA_02b2f817-f86d-4814-af37-95205c1dec24"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtNy0xLTEtOTMwMw_e6fa88a1-41ac-4570-af2e-82db840708cf"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtNy0xLTEtMA_bb8cbe81-48b4-470c-a093-1eedc8ddaf1e"
      unitRef="usd">6700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTYtOS0xLTEtMA_b630179a-1cc1-4c15-b3ee-068f0b6dabad"
      unitRef="usd">8300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctMS0xLTEtMA_ab928bf4-5337-4a8f-adcd-99083571e0dc"
      unitRef="usd">259800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctMy0xLTEtMA_a53de115-4123-4730-8e51-d654c65c94e2"
      unitRef="usd">152500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctNS0xLTEtMA_860e46e9-2575-4a82-816b-45d57ee1a5f1"
      unitRef="usd">16700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctNy0xLTEtOTMwMw_0aa5a659-ab3f-4727-b659-872d4abba976"
      unitRef="usd">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctNy0xLTEtMA_7a187773-d332-4b26-ad5a-815fe23febe9"
      unitRef="usd">56600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTctOS0xLTEtMA_78aba9df-bf71-40e8-8207-6dca58b7401c"
      unitRef="usd">485600000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6aeb28a2785549969b2fff138237082b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtMS0xLTEtMA_6f1e3ae8-455f-48f8-80b0-cdd0749f45e0"
      unitRef="usd">68800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id9a49a1b7b764adab34b8755af8ebf4a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtMy0xLTEtMA_fa3d58c2-5f30-4151-b15e-b16260265f3d"
      unitRef="usd">48900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i93729840e4134b239b4b920086a356a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtNS0xLTEtMA_37184a8c-4848-41c8-be2d-e927625b7a75"
      unitRef="usd">2200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idaadc0a4a924428e834767c197639f52_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtNy0xLTEtOTMwMw_8418e71b-21d9-4103-8256-6531444e23ea"
      unitRef="usd">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib46b23a4f4804593a381b0e42d2f206d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtNy0xLTEtMA_03b4db38-7b9d-472a-b84f-a8a37dcd3ad0"
      unitRef="usd">-56600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8e185a6b86ec42aca4c3e10f57baf0b8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMTgtOS0xLTEtMA_f2ed2408-88e8-41cc-94c4-c3a0b73bce52"
      unitRef="usd">63300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItMS0xLTEtMA_689149b2-1343-4028-903d-1f9f8dd10873"
      unitRef="usd">1016500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItMy0xLTEtMA_e4fce1c1-659c-4757-9e57-2908abb65f1d"
      unitRef="usd">586900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItNS0xLTEtMA_3be04c2c-ed8c-4ecd-94d3-c7dc3723b37c"
      unitRef="usd">49900000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItNy0xLTEtOTMwNQ_3b460d0c-b00c-4c25-9029-c995388e6048"
      unitRef="usd">1500000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItNy0xLTEtMA_4aee35e6-cef7-4c3d-a363-cdec337fcd98"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjItOS0xLTEtMA_2aad3e53-e8f7-4451-b6b5-d5ef9277c58b"
      unitRef="usd">1654800000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtMS0xLTEtMA_cc9e4b21-27f0-4815-9389-f558cd8f0d71"
      unitRef="usd">7300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtMy0xLTEtMA_1a5734a9-65f4-446c-973b-3244e76b8ef6"
      unitRef="usd">6000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtNS0xLTEtMA_b1634ef4-34c2-4605-ada7-62f354cdda7d"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtNy0xLTEtOTMwNQ_212a6b39-0c63-4eae-ba03-ae771e7d3832"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtNy0xLTEtMA_beea583e-8338-4c00-a8fb-77decdc74408"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjMtOS0xLTEtMA_e0e5b1b7-c3d9-4b19-835c-86360ee3a90c"
      unitRef="usd">13300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtMS0xLTEtMA_125679a1-19a6-491e-8e27-c4e4f6f034a2"
      unitRef="usd">563500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtMy0xLTEtMA_6f3c0481-2b9e-4e4f-8dab-d997de3d9125"
      unitRef="usd">314400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtNS0xLTEtMA_503cfd3c-5ab3-46ab-8fff-4986ca6f8072"
      unitRef="usd">37400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtNy0xLTEtOTMwNQ_9d2a515a-92c0-403f-b913-bc946861529b"
      unitRef="usd">900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtNy0xLTEtMA_ba6b69fe-5c3c-4302-b372-75e0a30210ac"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjQtOS0xLTEtMA_b1096143-c6ca-4fa1-a8b0-dc367e125198"
      unitRef="usd">916200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtMS0xLTEtMA_adc89ee8-488e-44b9-abfc-e8a9e484731e"
      unitRef="usd">243800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtMy0xLTEtMA_07c7b1e4-4694-4cc6-8b54-fafb4ac3c151"
      unitRef="usd">144400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtNS0xLTEtMA_a0091084-3bb4-48d6-a794-33569060685a"
      unitRef="usd">8800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtNy0xLTEtOTMwNQ_75adc21c-3e11-4ab4-8447-e35d6f3b3f1d"
      unitRef="usd">3900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtNy0xLTEtMA_0a1c46db-04b2-4a48-aab6-39597218ab8f"
      unitRef="usd">125500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjUtOS0xLTEtMA_6d1784db-bde6-4195-8e27-35a731529a14"
      unitRef="usd">526400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtMS0xLTEtMA_c7f93e45-40c4-476f-9b1c-8cf82d4502e0"
      unitRef="usd">3300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtMy0xLTEtMA_3d496489-02cf-4931-8433-c0bdaefd9f93"
      unitRef="usd">2000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtNS0xLTEtMA_a3bddcdf-2534-48f5-9d78-3c1bc8f8ab29"
      unitRef="usd">200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtNy0xLTEtOTMwNQ_c25ab525-51dd-438c-8014-597cdb23418c"
      unitRef="usd">500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtNy0xLTEtMA_c3eace47-0908-4bcc-95bf-fff0d9224df7"
      unitRef="usd">15800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjYtOS0xLTEtMA_7032cd54-8b51-4ee6-89ad-ed11f6c86229"
      unitRef="usd">21800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctMS0xLTEtMA_cf5b2f53-94ba-4dc3-93db-f1b56645815a"
      unitRef="usd">810600000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctMy0xLTEtMA_2df4eaf7-7210-4b8b-a7f4-1b8005f373e3"
      unitRef="usd">460800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctNS0xLTEtMA_0b76fa36-e319-4e50-a9cf-29dbe371d79b"
      unitRef="usd">46400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctNy0xLTEtOTMwNQ_1df9dcc9-b480-477a-83c2-20ec2258323d"
      unitRef="usd">5300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjctNy0xLTEtMA_fb7c9492-80dc-45e0-af4e-95a1e6e31f4e"
      unitRef="usd">141300000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0751b88dbe5040df8488a2954a9a72ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtMS0xLTEtMA_40608b5e-93a8-45b9-8e3f-afaf0ac7b1d1"
      unitRef="usd">213200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i55e51e14ed66462ebf0425885b125f0e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtMy0xLTEtMA_9865a073-4140-4810-9336-12be0b859e79"
      unitRef="usd">132100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i739da0e2a9b448f2b2ef8cf2325af74b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtNS0xLTEtMA_3fe6b376-c9fb-4bc8-9a32-94648f2008e6"
      unitRef="usd">3500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9760404300fe42ccafac45094346c6e0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtNy0xLTEtOTMwNQ_e2ab5a6f-a44b-4b6e-89cd-1e4c3450e9d2"
      unitRef="usd">-3800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i147869c8a406420b87176150165db51c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMjgtNy0xLTEtMA_70ee041a-3167-44dc-9310-fc1e4a844064"
      unitRef="usd">-141300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItMS0xLTEtMA_7434320f-ef34-4157-a3f5-83ea73168a41"
      unitRef="usd">919800000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItMy0xLTEtMA_23ce2ee7-9c58-420c-9cd7-4e87678fea6b"
      unitRef="usd">546200000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItNS0xLTEtMA_3190f3ee-7087-4444-bcd3-d69dbad1292a"
      unitRef="usd">54800000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItNy0xLTEtOTMwNw_30cf431d-e94f-4d02-9dbf-1f5ae6e8854e"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItNy0xLTEtMA_dc83f70c-8eb8-4cf9-9784-da82e3cbab68"
      unitRef="usd">0</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzItOS0xLTEtMA_8d1548ad-1e66-413f-a126-4544e8bdcaad"
      unitRef="usd">1520800000</us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtMS0xLTEtMA_8d5af6f2-a89d-455d-aef1-bfa5150577f0"
      unitRef="usd">17700000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtMy0xLTEtMA_bd64a939-d677-46f2-bf66-4bf67dcfe5fc"
      unitRef="usd">8900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtNS0xLTEtMA_be3f42e3-4144-4695-ac78-8744810904c7"
      unitRef="usd">1000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtNy0xLTEtOTMwNw_04cc6f6a-3639-4712-83d2-758969f4b7da"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtNy0xLTEtMA_51634986-e5a8-4e29-8844-9f1d4ac3cdec"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzMtOS0xLTEtMA_443a78da-b343-446a-bb40-5f40f4d2b690"
      unitRef="usd">27600000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtMS0xLTEtMA_dcfb9777-4d38-4474-977e-8b141e19c3f1"
      unitRef="usd">543800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtMy0xLTEtMA_37f843d8-7e70-4b63-b444-03e7254236fe"
      unitRef="usd">293100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtNS0xLTEtMA_c628e41c-4e8f-4198-ac82-625667c1cebb"
      unitRef="usd">41700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtNy0xLTEtOTMwNw_1a96fc49-4027-452f-816b-dcbd653aabfe"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtNy0xLTEtMA_4aa1846e-f3cd-4f55-b844-5d65bf68866e"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzQtOS0xLTEtMA_a76612c4-ceba-48c4-bfdc-6ea002e9a327"
      unitRef="usd">878600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtMS0xLTEtMA_d42c136a-8e4c-49d2-a8a5-6cb7cd710ff9"
      unitRef="usd">226700000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtMy0xLTEtMA_ec0b9ea4-fd90-41b2-8d91-dee4960724ae"
      unitRef="usd">127400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtNS0xLTEtMA_f71e743b-4eb8-466d-99cd-14fe9e9fb3ea"
      unitRef="usd">9500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtNy0xLTEtOTMwNw_62938abe-4179-45da-8b24-45f08ea2a56c"
      unitRef="usd">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtNy0xLTEtMA_159a7427-a836-4833-9ffb-81d0019b24fa"
      unitRef="usd">129200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzUtOS0xLTEtMA_7fb8cc25-93c9-4d4d-9003-a56b48b262e8"
      unitRef="usd">492800000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtMS0xLTEtMA_2543de86-af7b-4de4-b592-fc8d4a7e770a"
      unitRef="usd">2900000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtMy0xLTEtMA_4c7c9c46-324f-4f32-81f1-768221fecc56"
      unitRef="usd">1700000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtNS0xLTEtMA_812a37b2-03c0-44ae-83df-be44a69a9616"
      unitRef="usd">100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtNy0xLTEtOTMwNw_9c22a2a3-ad3c-496a-899c-e4b7af1fda51"
      unitRef="usd">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzYtNy0xLTEtMA_e0499fc5-9e15-4146-9125-2a26bfb65c31"
      unitRef="usd">15200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:CostsAndExpenses
      contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctMS0xLTEtMA_35b3d517-3b1a-458f-8a13-b6d0fff87476"
      unitRef="usd">773400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctMy0xLTEtMA_57566fdc-32c0-4e61-834b-54e227896d3b"
      unitRef="usd">422200000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctNS0xLTEtMA_5d9fd114-14af-44e6-8120-02cdeb98db35"
      unitRef="usd">51300000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctNy0xLTEtOTMwNw_df0d7861-52fc-4175-9f2a-39465855a4f6"
      unitRef="usd">0</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctNy0xLTEtMA_4e0cc100-f80d-4773-8bd5-e6126c8bbc68"
      unitRef="usd">144400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzctOS0xLTEtMA_bb32e717-1aa4-433c-99f3-0887befbddad"
      unitRef="usd">1391300000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i62f5c0928ec647b498c5601a298e0d0c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtMS0xLTEtMA_f484f903-f811-486c-927f-40788cdd4cd8"
      unitRef="usd">164100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibcec2a9be50f45f489c0ac428148c9e7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtMy0xLTEtMA_88940d56-69c9-483e-a847-dd95b13b44eb"
      unitRef="usd">132900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5fb5dca6e2c44ec4bc9b3c85377ab443_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtNS0xLTEtMA_ed8cdce2-09b6-4784-8bf8-037ff7dd56d1"
      unitRef="usd">4500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i031c2e8c5eff42d8979351b87abd8d43_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtNy0xLTEtOTMwNw_be34f313-7ff9-4a62-ae0c-d3645fd8d672"
      unitRef="usd">0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id31ba04e44fb4d02a10d1fb42667e16d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtNy0xLTEtMA_99be5e12-35df-483d-87b4-02a73a735e80"
      unitRef="usd">-144400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic8648b7c9d86473b886e64e1e98333fd_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183MC9mcmFnOjEyNDFjYWFlMjc4YjRlYTM4M2ZhYzMxMTA2NTg5MDVmL3RhYmxlOjVkNTQ4ZWQ3MGJmNjQ0N2ZhNjRjZTZiYWJjZjBkMGQ0L3RhYmxlcmFuZ2U6NWQ1NDhlZDcwYmY2NDQ3ZmE2NGNlNmJhYmNmMGQwZDRfMzgtOS0xLTEtMA_a80ea3d5-dd37-45dd-a2b9-b6b1b5870cec"
      unitRef="usd">157100000</us-gaap:OperatingIncomeLoss>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTY0OTI2NzQ0MzQ0Nw_5a3d9aa9-1a51-4b00-bde1-b1a5686a728f">CAPITAL STOCK AND SHARE-BASED COMPENSATION&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. In connection with the exercise, Mr. Kusserow surrendered 231,683 shares of common stock to us to satisfy tax withholding and strike price obligations and elected to hold the net 268,317 shares issued to him. The surrendered shares are classified as treasury shares. This transaction resulted in a cash outflow of $40.4&#160;million, reflected within financing activities in our condensed consolidated statement of cashflows, related to the remittance of tax withholding obligations on Mr. Kusserow's behalf. In addition, Mr. Kusserow's stock option exercise resulted in a $24.0&#160;million income tax benefit that was recorded in our condensed consolidated statement of operations during the three-month period ended September 30, 2020. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation: Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for GAAP purposes. If the tax deduction exceeds the cumulative GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations.&lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i01d5e8892fb243b4b865bd7b871d16be_D20200810-20200810"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTUwMw_fbf69654-df16-4992-8eaf-b5eae0bd5198"
      unitRef="shares">500000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <amed:SurrenderedSharesInShares
      contextRef="i01d5e8892fb243b4b865bd7b871d16be_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTUxMg_5b02246a-c557-4e87-ade5-0d57da6cb409"
      unitRef="shares">231683</amed:SurrenderedSharesInShares>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i01d5e8892fb243b4b865bd7b871d16be_D20200810-20200810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTUyMQ_61f90103-6ab0-43ff-a30a-29174cd46f03"
      unitRef="shares">268317</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib1427f68924a44119e86ad505b770163_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTUzMA_ccc67fa0-a09b-4847-9778-6fb5438616e5"
      unitRef="usd">40400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ib1427f68924a44119e86ad505b770163_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184OC9mcmFnOmE3NGQ2ZjJmOTRiNTQwNjI5NmIwZGEzMGVjZjM0MjQ4L3RleHRyZWdpb246YTc0ZDZmMmY5NGI1NDA2Mjk2YjBkYTMwZWNmMzQyNDhfMTA5OTUxMTYyOTU0NQ_b24218a9-b235-43c0-8cb4-4cdca64cfb10"
      unitRef="usd">24000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:TreasuryStockTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTU5OQ_f439f90e-f26c-4c18-8c73-db153b0e3acd">SHARE REPURCHASES &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021 (the "Existing Share Repurchase Program").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Existing Share Repurchase program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to this program, we repurchased 54,609 shares of our common stock at a weighted average price of $197.84 per share and a total cost of approximately $11&#160;million during the three-month period ended September 30, 2021 and 351,714 shares of our common stock at a weighted average price of $241.30 per share and a total cost of approximately $85&#160;million during the nine-month period ended September 30, 2021. The repurchased shares are classified as treasury shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022, to commence upon the completion of the Company's Existing Share Repurchase Program (the "New Share Repurchase Program"). &lt;/span&gt;&lt;/div&gt;Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i3f23866255254c1e86623c880ffabe48_I20201223"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTk1_4621315d-e9e8-4d21-8e63-7431cc094e9a"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i2381e983ae6a4cb799879628f17fd769_D20201223-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMjM4_201dcf19-4a4d-4751-9851-87b377a2e17d">2021-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i85212f2db10a46fd81194263d32551bd_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfODU2_9bba8471-014b-4eb1-ad66-a25ecc23f36a"
      unitRef="shares">54609</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i85212f2db10a46fd81194263d32551bd_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfOTE3_e94e46af-79a1-41d7-8361-c0eba348d319"
      unitRef="usdPerShare">197.84</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i85212f2db10a46fd81194263d32551bd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfOTY0_62e28308-3239-4123-8ddc-b6c2d6034ac5"
      unitRef="usd">11000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="icea953f101c64f9ea9eb5be5f0f999ff_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTAyMQ_d7c56823-279c-478b-ab59-960fd9968f87"
      unitRef="shares">351714</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="icea953f101c64f9ea9eb5be5f0f999ff_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTA4Mg_67a391fc-db15-4d84-bcaf-0593597e8483"
      unitRef="usdPerShare">241.30</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icea953f101c64f9ea9eb5be5f0f999ff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTEyOQ_daef9df5-757d-42fa-9a71-4c3315e643e1"
      unitRef="usd">85000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if904a87006f24f8cbd91c764ae5909fc_I20210802"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTA5OTUxMTYyOTg3OA_1579b931-8081-4164-bc9f-b0f944f54ba8"
      unitRef="usd">100000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramExpirationDate
      contextRef="i878d81e55fc54bb5a76221d8c7ce04e9_D20210802-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183Ni9mcmFnOmVkZjk3OGYwOTJhNzQ4MzI5M2I0ZGNjODg1MzczNGNhL3RleHRyZWdpb246ZWRmOTc4ZjA5MmE3NDgzMjkzYjRkY2M4ODUzNzM0Y2FfMTA5OTUxMTYyOTkyMg_559b9368-f3c9-404b-8afa-8ca4d2c38a35">2022-12-31</us-gaap:StockRepurchaseProgramExpirationDate>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfNTQ0_cb4029e5-19b7-43c6-bc92-1ae80c0501f4">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $1.4 million and $4.1&#160;million during the three and nine-month periods ended September&#160;30, 2021, respectively, and approximately $1.1&#160;million and $2.2&#160;million during the three and nine-month periods ended September 30, 2020, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i12c67fa7efe64016ba829366460e9a3f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfMjA2_63b6a308-ed14-49ea-9fe4-e9f10529bdc9"
      unitRef="usd">1400000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="ib5985078fbcb439bbdcb8ec2bcdb0330_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfMjEz_5b3e11dc-1744-42b1-a9ad-4d56704da951"
      unitRef="usd">4100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i28c5a54e2c3f42ef8543c32325f45fa2_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfMjk3_255604e1-5841-4ac2-b239-22ab7667aed1"
      unitRef="usd">1100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="i7137075508bc4a80bdbc1291c467c563_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY183OS9mcmFnOmUzM2U3NGQ4NGQ5NzQ2MWY4ZWNmNzA3YzdjNTdiZWNiL3RleHRyZWdpb246ZTMzZTc0ZDg0ZDk3NDYxZjhlY2Y3MDdjN2M1N2JlY2JfMzA0_701b860a-6b46-45ca-bcd9-646df51b5ebf"
      unitRef="usd">2200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184NS9mcmFnOmFmZTk5ZjEwYWU5MTQ0M2RhMDA4MWYzMjVhZDIzMGE0L3RleHRyZWdpb246YWZlOTlmMTBhZTkxNDQzZGEwMDgxZjMyNWFkMjMwYTRfNDMzNA_09c3f5e6-dc28-4f95-bd64-9567afdf7d34">SUBSEQUENT EVENTSOn October 18, 2021, we acquired the regulatory assets of a home health provider in North Carolina for a purchase price of $4.5&#160;million.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6c26203c52124e6db31cba165f90a5ba_D20211018-20211018"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2MGJmMzgzOWI5MTRkMjc5YzQxOGU3MWI5OGM1NTBjL3NlYzpkNjBiZjM4MzliOTE0ZDI3OWM0MThlNzFiOThjNTUwY184NS9mcmFnOmFmZTk5ZjEwYWU5MTQ0M2RhMDA4MWYzMjVhZDIzMGE0L3RleHRyZWdpb246YWZlOTlmMTBhZTkxNDQzZGEwMDgxZjMyNWFkMjMwYTRfMTA5OTUxMTYzNjgyNg_9e7b13f3-627a-4a28-8492-617ea58fb537"
      unitRef="usd">4500000</us-gaap:PaymentsToAcquireBusinessesGross>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789204155480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-24260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMEDISYS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3131700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street Name</a></td>
<td class="text">3854 American Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Suite</a></td>
<td class="text">Suite A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Baton Rouge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State</a></td>
<td class="text">LA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">70816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMED<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,602,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000896262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789208837384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 124,458<span></span>
</td>
<td class="nump">$ 81,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">274,570<span></span>
</td>
<td class="nump">255,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">16,080<span></span>
</td>
<td class="nump">10,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">14,024<span></span>
</td>
<td class="nump">13,265<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">432,882<span></span>
</td>
<td class="nump">361,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation of $100,407 and $95,024</a></td>
<td class="nump">20,381<span></span>
</td>
<td class="nump">23,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">100,028<span></span>
</td>
<td class="nump">93,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,188,054<span></span>
</td>
<td class="nump">932,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization of $20,309 and $22,973</a></td>
<td class="nump">118,084<span></span>
</td>
<td class="nump">74,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">10,111<span></span>
</td>
<td class="nump">47,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">68,105<span></span>
</td>
<td class="nump">33,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,937,645<span></span>
</td>
<td class="nump">1,567,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">41,649<span></span>
</td>
<td class="nump">42,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">155,123<span></span>
</td>
<td class="nump">146,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">154,264<span></span>
</td>
<td class="nump">166,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="nump">58,535<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">13,225<span></span>
</td>
<td class="nump">10,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">31,553<span></span>
</td>
<td class="nump">30,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">454,349<span></span>
</td>
<td class="nump">456,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">434,781<span></span>
</td>
<td class="nump">204,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">67,723<span></span>
</td>
<td class="nump">61,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">31,991<span></span>
</td>
<td class="nump">33,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">988,844<span></span>
</td>
<td class="nump">756,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies&#8212;Note 6</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 60,000,000 shares authorized; 37,659,284 and 37,470,212 shares issued; and 32,590,775 and 32,814,278 shares outstanding</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">720,875<span></span>
</td>
<td class="nump">698,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost 5,068,509 and 4,655,934 shares of common stock</a></td>
<td class="num">(420,665)<span></span>
</td>
<td class="num">(319,092)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">605,016<span></span>
</td>
<td class="nump">429,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Amedisys, Inc. stockholders&#8217; equity</a></td>
<td class="nump">905,264<span></span>
</td>
<td class="nump">809,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">43,537<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">948,801<span></span>
</td>
<td class="nump">810,741<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 1,937,645<span></span>
</td>
<td class="nump">$ 1,567,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable related to funds received from the government related to COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789279625784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Property and equipment, accumulated depreciation</a></td>
<td class="nump">$ 100,407<span></span>
</td>
<td class="nump">$ 95,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="nump">$ 20,309<span></span>
</td>
<td class="nump">$ 22,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (shares)</a></td>
<td class="nump">37,659,284<span></span>
</td>
<td class="nump">37,470,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (shares)</a></td>
<td class="nump">32,590,775<span></span>
</td>
<td class="nump">32,814,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost (shares)</a></td>
<td class="nump">5,068,509<span></span>
</td>
<td class="nump">4,655,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789279128216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 553,485<span></span>
</td>
<td class="nump">$ 544,070<span></span>
</td>
<td class="nump">$ 1,654,795<span></span>
</td>
<td class="nump">$ 1,520,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">4,812<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">27,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">310,294<span></span>
</td>
<td class="nump">297,668<span></span>
</td>
<td class="nump">916,188<span></span>
</td>
<td class="nump">878,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">119,373<span></span>
</td>
<td class="nump">123,146<span></span>
</td>
<td class="nump">349,533<span></span>
</td>
<td class="nump">330,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">4,397<span></span>
</td>
<td class="nump">7,124<span></span>
</td>
<td class="nump">17,860<span></span>
</td>
<td class="nump">19,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other</a></td>
<td class="nump">55,158<span></span>
</td>
<td class="nump">49,348<span></span>
</td>
<td class="nump">158,995<span></span>
</td>
<td class="nump">142,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,487<span></span>
</td>
<td class="nump">8,283<span></span>
</td>
<td class="nump">21,763<span></span>
</td>
<td class="nump">19,955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">496,709<span></span>
</td>
<td class="nump">485,569<span></span>
</td>
<td class="nump">1,464,339<span></span>
</td>
<td class="nump">1,391,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">56,772<span></span>
</td>
<td class="nump">63,313<span></span>
</td>
<td class="nump">203,756<span></span>
</td>
<td class="nump">157,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,730)<span></span>
</td>
<td class="num">(2,692)<span></span>
</td>
<td class="num">(6,734)<span></span>
</td>
<td class="num">(8,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,092<span></span>
</td>
<td class="num">(2,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Miscellaneous, net</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">1,253<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(796)<span></span>
</td>
<td class="num">(1,104)<span></span>
</td>
<td class="nump">29,592<span></span>
</td>
<td class="num">(8,336)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">55,976<span></span>
</td>
<td class="nump">62,209<span></span>
</td>
<td class="nump">233,348<span></span>
</td>
<td class="nump">148,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(10,731)<span></span>
</td>
<td class="nump">10,202<span></span>
</td>
<td class="num">(57,192)<span></span>
</td>
<td class="num">(9,175)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">45,245<span></span>
</td>
<td class="nump">72,411<span></span>
</td>
<td class="nump">176,156<span></span>
</td>
<td class="nump">139,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(239)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
<td class="num">(1,131)<span></span>
</td>
<td class="num">(1,147)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Amedisys, Inc.</a></td>
<td class="nump">$ 45,006<span></span>
</td>
<td class="nump">$ 71,981<span></span>
</td>
<td class="nump">$ 175,025<span></span>
</td>
<td class="nump">$ 138,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)</a></td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="nump">$ 5.36<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (shares)</a></td>
<td class="nump">32,607<span></span>
</td>
<td class="nump">32,662<span></span>
</td>
<td class="nump">32,658<span></span>
</td>
<td class="nump">32,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="nump">$ 5.30<span></span>
</td>
<td class="nump">$ 4.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (shares)</a></td>
<td class="nump">32,899<span></span>
</td>
<td class="nump">33,260<span></span>
</td>
<td class="nump">33,021<span></span>
</td>
<td class="nump">33,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789201605672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2019</a></td>
<td class="nump">$ 641,513<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 645,256<span></span>
</td>
<td class="num">$ (251,241)<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 246,383<span></span>
</td>
<td class="nump">$ 1,063<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,638,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan</a></td>
<td class="nump">3,057<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch', window );">Issuance of stock - 401(k) plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">6,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">19,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(54,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,358<span></span>
</td>
<td class="num">(67,530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">139,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,457<span></span>
</td>
<td class="nump">1,147<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Sep. 30, 2020</a></td>
<td class="nump">757,743<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">690,099<span></span>
</td>
<td class="num">(318,771)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">384,840<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,457,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2020</a></td>
<td class="nump">722,259<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">665,580<span></span>
</td>
<td class="num">(257,625)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">312,859<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,831,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">7,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(47,788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,358<span></span>
</td>
<td class="num">(61,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">72,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,981<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Sep. 30, 2020</a></td>
<td class="nump">757,743<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">690,099<span></span>
</td>
<td class="num">(318,771)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">384,840<span></span>
</td>
<td class="nump">1,538<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,457,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Dec. 31, 2020</a></td>
<td class="nump">810,741<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">698,287<span></span>
</td>
<td class="num">(319,092)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">429,991<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,470,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">3,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">17,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(16,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,694)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(84,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,879)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(1,253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquired noncontrolling interest</a></td>
<td class="nump">42,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">176,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,025<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Sep. 30, 2021</a></td>
<td class="nump">948,801<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">720,875<span></span>
</td>
<td class="num">(420,665)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">605,016<span></span>
</td>
<td class="nump">43,537<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,659,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Jun. 30, 2021</a></td>
<td class="nump">875,887<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">714,334<span></span>
</td>
<td class="num">(400,110)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">560,010<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,553,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of stock - employee stock purchase plan</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of stock - employee stock purchase plan (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Non-cash compensation</a></td>
<td class="nump">4,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedShares', window );">Surrendered Shares</a></td>
<td class="num">(9,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Shares repurchased</a></td>
<td class="num">(10,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distribution</a></td>
<td class="num">(459)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquired noncontrolling interest</a></td>
<td class="nump">42,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">45,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,006<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Stockholders Equity at Sep. 30, 2021</a></td>
<td class="nump">$ 948,801<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 720,875<span></span>
</td>
<td class="num">$ (420,665)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 605,016<span></span>
</td>
<td class="nump">$ 43,537<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,659,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Impact of Write Off of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789204530200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 176,156<span></span>
</td>
<td class="nump">$ 139,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">21,763<span></span>
</td>
<td class="nump">19,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash compensation</a></td>
<td class="nump">17,860<span></span>
</td>
<td class="nump">19,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset', window );">Amortization and impairment of operating lease right of use assets</a></td>
<td class="nump">30,181<span></span>
</td>
<td class="nump">29,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="num">(31,092)<span></span>
</td>
<td class="nump">2,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WriteOffOfOtherComprehensiveIncome', window );">Write-off of other comprehensive income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">34,729<span></span>
</td>
<td class="num">(2,762)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in earnings from equity method investments</a></td>
<td class="num">(3,932)<span></span>
</td>
<td class="num">(2,399)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred debt issuance costs/debt discount</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Return on equity method investments</a></td>
<td class="nump">4,268<span></span>
</td>
<td class="nump">3,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of impact of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Patient accounts receivable</a></td>
<td class="num">(17,638)<span></span>
</td>
<td class="nump">6,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets</a></td>
<td class="num">(6,219)<span></span>
</td>
<td class="num">(28,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(938)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,192)<span></span>
</td>
<td class="num">(1,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(9,363)<span></span>
</td>
<td class="nump">25,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term obligations</a></td>
<td class="num">(1,785)<span></span>
</td>
<td class="nump">38,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(27,372)<span></span>
</td>
<td class="num">(25,576)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="num">(2,304)<span></span>
</td>
<td class="num">(2,775)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">183,727<span></span>
</td>
<td class="nump">223,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from sale of deferred compensation plan assets</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(5,187)<span></span>
</td>
<td class="num">(2,995)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToDevelopSoftware', window );">Investments in technology assets</a></td>
<td class="num">(147)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investments in equity method investees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(264,872)<span></span>
</td>
<td class="num">(299,723)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(269,940)<span></span>
</td>
<td class="num">(285,543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of stock upon exercise of stock options</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">6,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of stock to employee stock purchase plan</a></td>
<td class="nump">3,022<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld to pay taxes on non-cash compensation</a></td>
<td class="num">(16,694)<span></span>
</td>
<td class="num">(54,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashDistributionToNoncontrollingInterest', window );">Noncontrolling interest distribution</a></td>
<td class="num">(1,253)<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings under term loan</a></td>
<td class="nump">290,312<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from borrowings under revolving line of credit</a></td>
<td class="nump">500,700<span></span>
</td>
<td class="nump">432,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of borrowings under revolving line of credit</a></td>
<td class="num">(551,700)<span></span>
</td>
<td class="num">(357,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments of long-term obligations</a></td>
<td class="num">(5,893)<span></span>
</td>
<td class="num">(7,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(2,792)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="num">(84,879)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundsReceivedFromProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="num">(1,465)<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">131,064<span></span>
</td>
<td class="nump">81,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">44,851<span></span>
</td>
<td class="nump">18,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">83,357<span></span>
</td>
<td class="nump">96,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">128,208<span></span>
</td>
<td class="nump">115,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,479<span></span>
</td>
<td class="nump">4,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes, net of refunds received</a></td>
<td class="nump">25,482<span></span>
</td>
<td class="nump">30,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashPaidForOperatingLeaseLiabilities', window );">Cash paid for operating lease liabilities</a></td>
<td class="nump">29,676<span></span>
</td>
<td class="nump">28,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashPaidForFinanceLeaseLiabilities', window );">Cash paid for finance lease liabilities</a></td>
<td class="nump">1,509<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures of Non-Cash Activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">34,881<span></span>
</td>
<td class="nump">29,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right of use assets obtained in exchange for finance lease liabilities</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations', window );">Reductions to right of use assets resulting from reductions to operating lease liabilities</a></td>
<td class="nump">$ 1,183<span></span>
</td>
<td class="nump">$ 767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of dividends or other distributions to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for finance lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashPaidForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashPaidForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundsReceivedFromProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundsReceivedFromProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) In Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WriteOffOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write off of Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WriteOffOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToDevelopSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToDevelopSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789279397960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</a></td>
<td class="text">NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amedisys, Inc., a Delaware corporation (together with its consolidated subsidiaries, referred to herein as &#8220;Amedisys,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a multi-state provider of home health, hospice, personal care and high acuity care services with approximately 75% of our net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2021 and approximately 76% and 75% of our net service revenue derived from Medicare for the three and nine-month periods ended September 30, 2020, respectively. As of September&#160;30, 2021, we owned and operated 328 Medicare-certified home health care centers, 177 Medicare-certified hospice care centers, 14 personal-care care centers and 8 high acuity care joint ventures in 38 states within the United States and the District of Columbia. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 25, 2021 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from the interim financial information presented, as allowed by SEC rules and regulations. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $48.3 million and $14.2 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of September 30, 2021, we are proportionately consolidating seven of our eight joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. We account for one of our joint ventures with a health system partner under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheet are as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789201295928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of our net service revenue for the three and nine-month periods ended September 30, 2021 and approximately 76% and 75% of our net service revenue for the three and nine-month periods ended September 30, 2020, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 20% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and nine-month periods ended September&#160;30, 2021 and September 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of September&#160;30, 2021, we have recorded $8.6 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $2.5&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to patients who are discharged early from a health system facility to complete their inpatient stay at home. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our health insurance plan contracts provide for fixed payment rates for a 30-day or 60-day episode of care indexed to assigned patient diagnoses in return for our obligation to assume risk for the coordination and payment of required medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, is provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the service provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our contracts with health system partners provide for reimbursement on a per diem basis at the contracted rate for each day during the remainder of an inpatient acute stay serviced at the patient&#8217;s home. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of September 30, 2021 includes $58.5&#160;million associated with unutilized CARES Act Provider Relief Fund ("PRF") funds, which were repaid to the U.S. Department of Health and Human Services ("HHS") in October 2021. Restricted cash includes cash that is not available for ordinary business use. As of September 30, 2021, we had $3.8&#160;million of restricted cash that was placed into escrow accounts related to the indemnity and closing payment adjustment provisions within the purchase agreements for various acquisitions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of September&#160;30, 2021, there is no single payor, other than Medicare, that accounts for 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent 65% and 64% of our patient accounts receivable at September&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value. </span></div><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Shares Outstanding</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period. The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-<br/>Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789199333448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19"<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_COVID19TextBlock', window );">COVID-19</a></td>
<td class="text">NOVEL CORONAVIRUS PANDEMIC ("COVID-19")<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared COVID-19 a pandemic. As a healthcare at home company, we have been and will continue to be impacted by the effects of COVID-19; however, we remain committed to carrying out our mission of caring for our patients. We will continue to closely monitor the impact of COVID-19 on all aspects of our business, including the impacts to our employees, patients and suppliers; however, at this time, we are unable to estimate the ultimate impact the pandemic will have on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the CARES Act was signed into legislation. The CARES Act provided for $175&#160;billion to healthcare providers, including hospitals on the front lines of the COVID-19 pandemic. Of this total allocated amount, $30&#160;billion was distributed immediately to providers based on their proportionate share of Medicare fee-for-service reimbursements in 2019. Healthcare providers were required to sign an attestation confirming receipt of the Provider Relief Fund ("PRF") funds and agree to the terms and conditions of payment. Our home health and hospice segments received approximately $100&#160;million from the first $30&#160;billion of funds distributed to healthcare providers in April 2020, which is inclusive of $2&#160;million related to our joint venture care centers (equity method investments). We also acquired approximately $6&#160;million of PRF funds in connection with the acquisition of AseraCare. Under the terms and conditions for receipt of the payment, we were allowed to use the funds to cover lost revenues and health care costs related to COVID-19 through June 30, 2021, and we were required to properly and fully document the use of these funds in reports to the U.S. Department of Health and Human Services ("HHS"). All required reporting was completed during the three-month period ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our wholly-owned subsidiaries, we utilized PRF funds to the extent we had qualifying COVID-19 expenses; we did not use PRF funds to cover lost revenues resulting from COVID-19. The grant income associated with the COVID-19 expenses incurred through June 30, 2021 is reflected in other operating income within our condensed consolidated statements of operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not fully utilize the PRF funds received; therefore, we have recorded a liability for the amount to be repaid which totaled $59&#160;million (including interest) at September 30, 2021 and $60&#160;million at December 31, 2020 (see the Provider Relief Fund Advance account in current liabilities within our condensed consolidated balance sheets). All unutilized funds were repaid in October 2021. In summary, the total funds that we received from the CARES Act PRF have been accounted for as follows as of September 30, 2021 (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:76.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by consolidated entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds to be repaid to the government by consolidated entities (excludes $0.2&#160;million of interest to be repaid)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds to be repaid to the government by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CARES Act also provided for the temporary suspension of the automatic 2% reduction of Medicare claim reimbursements ("sequestration") for the period May 1, 2020 through December 31, 2020. In December 2020, Congress passed additional COVID-19 relief legislation as part of the Consolidated Appropriations Act, 2021. This legislation extended the suspension of sequestration through March 31, 2021. In April 2021, Congress passed H.R. 1868, which among other items, provided for an additional extension of the temporary suspension of sequestration through December 31, 2021. We estimate that the suspension of sequestration will increase our 2021 net service revenue by approximately $36&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the CARES Act provided for the deferral of the employer share of social security tax (6.2%), effective for payments due after the enactment date through December 31, 2020. Fifty percent of the deferred payroll taxes are due on December 31, 2021 with the remaining amounts due on December 31, 2022. During 2020, we deferred approximately $55&#160;million of social security tax; approximately $28&#160;million is reflected in each of payroll and employee benefits and other long-term obligations within our condensed consolidated balance sheets.</span></div>Our personal care segment did not receive funds under the CARES Act; however, it did receive funds totaling $1&#160;million from the Mass Home Care ASAP COVID-19 Provider Sustainability Program, which were used during 2020 to cover costs related to COVID-19.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_COVID19TextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Novel Coronavirus Pandemic "COVID-19"</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_COVID19TextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789200826728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITIONS</a></td>
<td class="text">ACQUISITIONS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We complete acquisitions from time to time in order to pursue our strategy of increasing our market presence by expanding our service base and enhancing our position in certain geographic areas as a leading provider of home health, hospice, personal care and high acuity care services. The purchase price paid for acquisitions is negotiated through arm&#8217;s length transactions, with consideration based on our analysis of, among other things, comparable acquisitions and expected cash flows. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets because of the expected contributions of the acquisitions to our overall corporate strategy. We typically engage outside appraisal firms to assist in the fair value determination of identifiable intangible assets for significant acquisitions. The preliminary purchase price allocation is adjusted, as necessary, up to one year after the acquisition closing date if management obtains more information regarding asset valuations and liabilities assumed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2021, we acquired the regulatory assets of a home health provider in Randolph County, North Carolina for a purchase price of $2.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $2.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, we acquired Visiting Nurse Association ("VNA"), a home health and hospice provider with locations in Nebraska and Iowa for a purchase price of $20.1&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $19.4&#160;million and other intangibles (licenses) of $0.7&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 12, 2021, we acquired the regulatory assets of a home health provider in New York for a purchase price of $1.5&#160;million. The purchase price was paid with cash on hand on the date of the transaction. Based on the Company's preliminary valuation, we recorded goodwill of $1.4&#160;million and other intangibles (certificate of need) of $0.1&#160;million in connection with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2021, we acquired Contessa, a leader in hospital-at-home and skilled nursing facility ("SNF") at-home services for an estimated purchase price of $240.7&#160;million, net of cash acquired. With the addition of Contessa&#8217;s risk-based model and claims analytics capabilities, we will be able to bring the essential elements of inpatient hospital and SNF care to patients&#8217; homes, allowing us to become a risk-bearing, home-based care delivery organization, expanding well beyond traditional home health and hospice. Contessa operates as a wholly-owned division of Amedisys and is reported as a separate operating segment. Under the purchase agreement, the purchase price is subject to a net working capital adjustment, whereby the purchase price will be adjusted to the extent the actual net working capital of Contessa as of the closing differs from the required net working capital under the purchase agreement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of reviewing the fair value of the assets acquired and liabilities assumed. Based on the Company's preliminary valuation, the total estimated consideration of $240.7&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include acquired names ($28.6&#160;million), technology ($19.9&#160;million) and non-compete agreements ($6.7&#160;million). The non-compete agreements will be amortized over a weighted-average period of 2.0 years and the technology will be amortized over a weighted-average period of 7.0 years. The preliminary fair value of noncontrolling interest was determined using a discounted cash flow analysis and an income approach.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contessa contributed $1.5&#160;million in net service revenue and an operating loss of $3.8&#160;million (inclusive of technology intangibles amortization totaling $0.5&#160;million) during the three-month period ended September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Acquisitions</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2020, we acquired Homecare Preferred Choice, Inc., doing business as AseraCare Hospice ("AseraCare"), a national hospice care provider with 44 locations, for an estimated purchase price of $230.4&#160;million, net of cash acquired and inclusive of a $32&#160;million tax asset. The closing payment for the purchase price included estimates for cash, working capital and various other items. Under the purchase agreement, the purchase price was subject to a closing payment adjustment for any differences between estimated amounts included in the closing payment and actual amounts at close, not to exceed $1.0&#160;million. The closing payment adjustment, which was finalized in October 2020, reduced the purchase price by $0.8&#160;million, from $230.4&#160;million&#160;to $229.6&#160;million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company finalized its valuation of the assets acquired and liabilities assumed during the three-month period ended June 30, 2021. The total consideration of $229.6 million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired include licenses ($8.7&#160;million), certificates of need ($0.7&#160;million), acquired names ($5.7&#160;million) and non-compete agreements ($9.2&#160;million). The acquired names will be amortized over a weighted-average period of 2.0 years, and the non-compete agreements will be amortized over a weighted-average period of 1.7 years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the entire amount of goodwill recorded for this acquisition to be deductible for income tax purposes over approximately 15 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789200910040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM OBLIGATIONS</a></td>
<td class="text">LONG-TERM OBLIGATIONS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:66.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.6% at September 30, 2021); due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">First Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 4, 2019, we entered into the First Amendment to our Credit Agreement (as amended by the First Amendment, the "Amended Credit Agreement"). The Amended Credit Agreement provided for a senior secured credit facility in an initial aggregate principal amount of up to $725.0 million, which included a $550.0 million Revolving Credit Facility and a term loan facility with a principal amount of up to $175.0 million (the "Term Loan Facility" and collectively with the Revolving Credit Facility, the "Credit Facility"), which was added by the First Amendment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Second Amendment to Amended and Restated Credit Agreement</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 30, 2021, we entered into the Second Amendment to our Credit Agreement (as amended by the Second Amendment, the "Second Amended Credit Agreement"). The Second Amended Credit Agreement provides for a senior secured credit facility in an initial aggregate principal amount of up to $1.0&#160;billion, which includes a $550.0&#160;million Revolving Credit Facility and a term loan facility with a principal amount of up to $450.0&#160;million (the "Amended Term Loan Facility" and collectively with the Revolving Credit Facility, the "Amended Credit Facility").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net proceeds from the $450.0&#160;million Amended Term Loan Facility were used to fund 100% of the Contessa acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The loans issued under the Amended Credit Facility bear interest on a per annum basis, at our election, at either: (i) the Base Rate plus the Applicable Rate or (ii) the Eurodollar Rate plus the Applicable Rate. The &#8220;Base Rate&#8221; means a fluctuating rate per annum equal to the highest of (a) the federal funds rate plus 0.50% per annum, (b) the prime rate of interest established by the Administrative Agent, and (c) the Eurodollar Rate plus 1% per annum. The &#8220;Eurodollar Rate&#8221; means the quoted rate per annum equal to the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or a comparable successor rate approved by the Administrative Agent for an interest period of one, three or six months (as selected by us). The &#8220;Applicable Rate&#8221; is based on the consolidated leverage ratio and is presented in the table below. As of September&#160;30, 2021, the Applicable Rate is 0.50% per annum for Base Rate loans and 1.50% per annum for Eurodollar Rate loans. We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"/><td style="width:10.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3.00 to 1.0 but &gt; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final maturity date of the Amended Credit Facility is July 30, 2026. The Revolving Credit Facility will terminate and be due and payable as of the final maturity date. The Amended Term Loan Facility, however, is subject to quarterly amortization </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of principal in the amount of (i) 0.625% for the period commencing on July 30, 2021 and ending on September 30, 2023, and (ii) 1.250% for the period commencing on October 1, 2023 and ending on July 30, 2026. The remaining balance of the Amended Term Loan Facility must be paid upon the final maturity date. In addition to the scheduled amortization of the Amended Term Loan Facility, and subject to customary exceptions and reinvestment rights, we are required to prepay the Amended Term Loan Facility first and the Revolving Credit Facility second with 100% of all net cash proceeds received by any loan party or any subsidiary thereof in connection with (a) any asset sale or disposition where such loan party receives net cash proceeds in excess of $5&#160;million or (b) any debt issuance that is not permitted under the Second Amended Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Second Amended Credit Agreement requires maintenance of two financial covenants: (i) a consolidated leverage ratio of funded indebtedness to Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA"), as defined in the Second Amended Credit Agreement, and (ii) a consolidated interest coverage ratio of EBITDA to cash interest charges, as defined in the Second Amended Credit Agreement. Each of these covenants is calculated over rolling four-quarter periods and also is subject to certain exceptions and baskets. The Second Amended Credit Agreement also contains customary covenants, including, but not limited to, restrictions on: incurrence of liens, incurrence of additional debt, sales of assets and other fundamental corporate changes, investments and declarations of dividends. These covenants contain customary exclusions and baskets as detailed in the Second Amended Credit Agreement. In connection with our entry into the Second Amended Credit Agreement, we recorded $2.8&#160;million in deferred debt issuance costs as long-term obligations, less current portion within our condensed consolidated balance sheet during the three-month period ended September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Facility is guaranteed by substantially all of our wholly-owned direct and indirect subsidiaries. The Second Amended Credit Agreement requires at all times that we (i) provide guarantees from wholly-owned subsidiaries that in the aggregate represent not less than 95% of our consolidated net revenues and adjusted EBITDA from all wholly-owned subsidiaries and (ii) provide guarantees from subsidiaries that in the aggregate represent not less than 70% of consolidated adjusted EBITDA, subject to certain exceptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted average interest rate for borrowings under our $550.0 million Revolving Credit Facility was 2.9% and 1.9% for the three and nine-month periods ended September&#160;30, 2021, respectively, and 1.8% and 2.2% for the three and nine-month periods ended September 30, 2020, respectively. Our weighted average interest rate for borrowings under our $450.0&#160;million Amended Term Loan Facility was 1.6% and 1.5% for the three and nine-month periods ended September 30, 2021, respectively, and 1.7% and 2.3% for the three and nine-month periods ended September 30, 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, our consolidated leverage ratio was 1.2, our consolidated interest coverage ratio was 27.5 and we are in compliance with our covenants under the Second Amended Credit Agreement. In the event we are not in compliance with our debt covenants in the future, we would pursue various alternatives in an attempt to successfully resolve the non-compliance, which might include, among other things, seeking debt covenant waivers or amendments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, our availability under our $550.0 million Revolving Credit Facility was $519.9 million as we have no outstanding borrowings and $30.1 million outstanding in letters of credit.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joinder Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Compassionate Care Hospice ("CCH") acquisition, we entered into a Joinder Agreement, dated as of February 4, 2019 (the &#8220;CCH Joinder&#8221;), pursuant to which CCH and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Security Agreement&#8221;), and the Amended and Restated Pledge Agreement, dated as of June 29, 2018 (the &#8220;Amended and Restated Pledge Agreement&#8221;). In connection with the AseraCare acquisition, we entered into a Joinder Agreement, dated as of June 12, 2020, pursuant to which the AseraCare entities were made parties to, and became subject to the terms and conditions of, the Amended Credit Agreement (now the Second Amended Credit Agreement), the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;AseraCare Joinder"). In connection with the Contessa acquisition and the Second Amendment, we entered into a Joinder Agreement, dated as of September 3, 2021, pursuant to which Contessa and its subsidiaries and Asana Hospice, which we acquired on January 1, 2020, and its subsidiaries were made parties to, and became subject to the terms and conditions of, the Second Amended Credit Agreement, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement (the &#8220;Contessa and Asana Joinder,&#8221; and together with the CCH Joinder and the AseraCare Joinder, the &#8220;Joinders&#8221;). </span></div>Pursuant to the Joinders, the Amended and Restated Security Agreement and the Amended and Restated Pledge Agreement, CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana Hospice and its subsidiaries granted in favor of the Administrative Agent a first lien security interest in substantially all of their personal property assets and pledged to the Administrative Agent each of their respective subsidiaries' issued and outstanding equity interests. CCH and its subsidiaries, the AseraCare entities, Contessa and its subsidiaries and Asana Hospice and its subsidiaries also guaranteed our obligations, whether now existing or arising after the respective effective dates of the Joinders, under the Second Amended Credit Agreement pursuant to the terms of the Joinders and the Second Amended Credit Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789199370312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the normal course of business, some of which seek monetary damages, including claims for punitive damages. Based on information available to us as of the date of this filing, we do not believe that these normal course actions, when finally concluded and determined, will have a material impact on our consolidated financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees related to all legal matters are expensed as incurred.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings - Completed</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subpoena Duces Tecum and Civil Investigative Demands Issued by the U.S. Department of Justice</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2021, the U.S. Department of Justice notified the Company that they were closing their investigation into the below-referenced Subpoena Duces Tecum ("Subpoena") and civil investigative demands ("CIDs"). As of March 31, 2021, we had recorded a total of $6.5 million to accrued expenses in our condensed consolidated balance sheets related to these matters. During the three-month period ended June 30, 2021, we reversed our accrual related to these matters.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;21, 2015, we received a Subpoena issued by the U.S. Department of Justice. The Subpoena requested the delivery of information regarding 53 identified hospice patients to the United States Attorney&#8217;s Office for the District of Massachusetts. It also requested the delivery of documents relating to our hospice clinical and business operations and related compliance activities. The Subpoena generally covered the period from January&#160;1, 2011 through May&#160;21, 2015.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;3, 2015, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Morgantown, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Northern District of West Virginia regarding 66 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Morgantown area. The CID generally covered the period from January&#160;1, 2009 through August 31, 2015.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;27, 2016, we received a CID issued by the U.S. Department of Justice pursuant to the federal False Claims Act relating to claims submitted to Medicare and/or Medicaid for hospice services provided through designated facilities in the Parkersburg, West Virginia area. The CID requested the delivery of information to the United States Attorney&#8217;s Office for the Southern District of West Virginia regarding 68 identified hospice patients, as well as documents relating to our hospice clinical and business operations in the Parkersburg area. The CID generally covered the period from January&#160;1, 2011 through June&#160;20, 2016. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third Party Audits - Ongoing</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, in the ordinary course of business, we are subject to audits under various governmental programs in which third party firms engaged by CMS, including Recovery Audit Contractors (&#8220;RACs&#8221;), Zone Program Integrity Contractors (&#8220;ZPICs&#8221;), Uniform Program Integrity Contractors (&#8220;UPICs&#8221;), Program Safeguard Contractors (&#8220;PSCs&#8221;), Medicaid Integrity Contractors (&#8220;MICs&#8221;), Supplemental Medical Review Contractors (&#8220;SMRCs&#8221;) and the Office of Inspector General (&#8220;OIG&#8221;), conduct extensive reviews of claims data to identify potential improper payments. We cannot predict the ultimate outcome of any regulatory reviews or other governmental audits and investigations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2010, our subsidiary that provides hospice services in Florence, South Carolina received from a ZPIC a request for records regarding a sample of 30 beneficiaries who received services from the subsidiary during the period of January&#160;1, 2008 through March&#160;31, 2010 (the &#8220;Review Period&#8221;) to determine whether the underlying services met pertinent Medicare payment requirements.&#160;We acquired the hospice operations subject to this review on August&#160;1, 2009; the Review Period covers time periods both before and after our ownership of these hospice operations.&#160;Based on the ZPIC&#8217;s findings for 16 beneficiaries, which were extrapolated to all claims for hospice services provided by the Florence subsidiary billed during the Review Period, on June&#160;6, 2011, the Medicare Administrative Contractor (&#8220;MAC&#8221;) for the subsidiary issued a notice of overpayment seeking recovery from our subsidiary of an alleged overpayment. We dispute these findings, and our Florence subsidiary has filed appeals through the Original Medicare Standard Appeals Process, in which we are seeking to have those findings overturned. An administrative law judge ("ALJ") hearing was held in early January 2015. On January&#160;18, 2016, we received a letter dated January&#160;6, 2016 referencing the ALJ hearing decision for the overpayment issued on June&#160;6, 2011. The decision was partially favorable with a new overpayment amount of $3.7 million with a balance owed of $5.6 million, including interest, based on 9 disputed claims (originally 16). We filed an appeal to the Medicare Appeals Council on the remaining 9 disputed claims and also argued that the statistical method used to select the sample was not valid.&#160;No assurances can be given as to the timing or outcome of the Medicare Appeals Council decision. As of September&#160;30, 2021, Medicare has withheld payments of $5.7 million (including additional interest) as part of their standard procedures once this level of the appeal process has been reached. In the event we are not able to recoup this alleged overpayment, we are entitled to be indemnified by the prior owners of the hospice operations for amounts relating to the period prior to August&#160;1, 2009. On January 10, 2019, an arbitration panel from the American Health Lawyers Association determined that the prior owners' liability for their indemnification obligation was $2.8 million. This amount is recorded as an indemnity receivable within other assets in our condensed consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company received a request for medical records from SafeGuard Services, L.L.C (&#8220;SafeGuard&#8221;), a ZPIC, related to services provided by some of the care centers that the Company acquired from Infinity Home Care, L.L.C. The review period covers time periods both before and after our ownership of the care centers, which were acquired on December&#160;31, 2015. In August 2017, the Company received Requests for Repayment from Palmetto GBA, LLC ("Palmetto") regarding Infinity Home Care of Lakeland, LLC ("Lakeland Care Centers") and Infinity Home Care of Pinellas, LLC ("Clearwater Care Center"). The Palmetto letters are based on a statistical extrapolation performed by SafeGuard which alleged an overpayment of $34.0 million for the Lakeland Care Centers on a universe of 72 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate and an overpayment of $4.8 million for the Clearwater Care Center on a universe of 70 Medicare claims totaling $0.2 million in actual claims payments using a 100% error rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lakeland Request for Repayment covers claims between January 2, 2014 and September 13, 2016. The Clearwater Request for Repayment covers claims between January 2, 2015 and December 9, 2016. As a result of partially successful Level I and Level II Administrative Appeals, the alleged overpayment for the Lakeland Care Centers has been reduced to $26.0 million and the alleged overpayment for the Clearwater Care Center has been reduced to $3.3 million. The Company has now filed Level III Administrative Appeals, and will continue to vigorously pursue its appeal rights, which include contesting the methodology used by the ZPIC contractor to perform statistical extrapolation. The Company is contractually entitled to indemnification by the prior owners for all claims prior to December 31, 2015, for up to $12.6 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this stage of the review, based on the information currently available to the Company, the Company cannot predict the timing or outcome of this review. The Company estimates a low-end potential range of loss related to this review of $6.5 million (assuming the Company is successful in seeking indemnity from the prior owners and unsuccessful in demonstrating that the extrapolation method used by SafeGuard was erroneous). The Company has reduced its high-end potential range of loss from $38.8 million (the maximum amount Palmetto claims has been overpaid for both the Lakeland Care Centers and the Clearwater Care Center, of which amount $12.6 million is subject to indemnification by the prior owners) to $29.3 million based on the partial success achieved by the Company in prosecuting its Level I and II Administrative Appeals.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021, we have an accrued liability of approximately $17.4 million related to this matter. We expect to be indemnified by the prior owners for approximately $10.9 million of the total $12.6 million available indemnification related to this matter and have recorded this amount within other assets in our condensed consolidated balance sheets. The net of these two amounts, $6.5 million, was recorded as a reduction in net service revenue in our condensed consolidated statements of operations during 2017. As of September&#160;30, 2021, $1.5 million of receivables have been impacted by this payment suspension.</span></div><div style="margin-top:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated for certain costs associated with our insurance programs, including employee health, workers&#8217; compensation and professional liability. While we maintain various insurance programs to cover these risks, we are self-insured for a substantial portion of our potential claims. We recognize our obligations associated with these costs, up to specified deductible limits in the period in which a claim is incurred, including with respect to both reported claims and claims incurred but not reported. These costs have generally been estimated based on historical data of our claims experience. Such estimates, and the resulting reserves, are reviewed and updated by us on a quarterly basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health insurance has an exposure limit of $1.3 million for any individual covered life. Our workers&#8217; compensation insurance has a retention limit of $1.0 million per incident and our professional liability insurance has a retention limit of $0.3 million per incident.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789200815704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve servicing patients through our four reportable business segments: home health, hospice, personal care and high acuity care. Our home health segment delivers a wide range of services in the homes of individuals who may be recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. Our hospice segment provides palliative care and comfort to terminally ill patients and their families. Our personal care segment provides patients with assistance with the essential activities of daily living. Our high acuity care segment, which was established with the acquisition of Contessa during the three-month period ended September 30, 2021, delivers the essential elements of inpatient hospital and skilled nursing facility ("SNF") care to patients in their homes. The &#8220;other&#8221; column in the following tables consists of costs relating to executive management and administrative support functions, primarily information services, accounting, finance, billing and collections, legal, compliance, risk management, procurement, marketing, clinical administration, training, human resources and administration.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management evaluates performance and allocates resources based on the operating income of the reportable segments, which includes an allocation of corporate expenses directly attributable to the specific segment and includes revenues and all other costs directly attributable to the specific segment. Segment assets are not reviewed by the company&#8217;s chief operating decision maker and therefore are not disclosed below (amounts in millions).</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:45.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Period Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Period Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789199191576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">CAPITAL STOCK AND SHARE-BASED COMPENSATION</a></td>
<td class="text">CAPITAL STOCK AND SHARE-BASED COMPENSATION<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, Paul B. Kusserow, President, Chief Executive Officer and Chairman of the Board of Amedisys, exercised 500,000 stock options previously awarded to him under our 2008 Omnibus Incentive Compensation Plan. In connection with the exercise, Mr. Kusserow surrendered 231,683 shares of common stock to us to satisfy tax withholding and strike price obligations and elected to hold the net 268,317 shares issued to him. The surrendered shares are classified as treasury shares. This transaction resulted in a cash outflow of $40.4&#160;million, reflected within financing activities in our condensed consolidated statement of cashflows, related to the remittance of tax withholding obligations on Mr. Kusserow's behalf. In addition, Mr. Kusserow's stock option exercise resulted in a $24.0&#160;million income tax benefit that was recorded in our condensed consolidated statement of operations during the three-month period ended September 30, 2020. We recognize compensation expense for stock option awards on a straight-line basis over the requisite service period for each separately vesting portion of the award in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation: Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; however, the income tax deduction related to stock options is not recognized until the stock option exercise date. As a result, for awards that are expected to result in a tax deduction, a deferred tax asset is created as the entity recognizes compensation expense for GAAP purposes. If the tax deduction exceeds the cumulative GAAP compensation expense for the award, the tax benefit associated with any excess deduction is recognized as an income tax benefit in the statement of operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789200823592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE SHARE REPURCHASE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">SHARE REPURCHASE</a></td>
<td class="text">SHARE REPURCHASES <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2020, we announced that our Board of Directors authorized a stock repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2021 (the "Existing Share Repurchase Program").</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Existing Share Repurchase program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this program, we repurchased 54,609 shares of our common stock at a weighted average price of $197.84 per share and a total cost of approximately $11&#160;million during the three-month period ended September 30, 2021 and 351,714 shares of our common stock at a weighted average price of $241.30 per share and a total cost of approximately $85&#160;million during the nine-month period ended September 30, 2021. The repurchased shares are classified as treasury shares. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 2, 2021, our Board of Directors authorized a share repurchase program, under which we may repurchase up to $100&#160;million of our outstanding common stock through December 31, 2022, to commence upon the completion of the Company's Existing Share Repurchase Program (the "New Share Repurchase Program"). </span></div>Under the terms of the New Share Repurchase Program, we are allowed to repurchase shares from time to time through open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a trading plan in compliance with Exchange Act Rule 10b5-1. The timing and the amount of the repurchases will be determined by management based on a number of factors, including but not limited to share price, trading volume and general market conditions, as well as on working capital requirements, general business conditions and other factors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789199268904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONSWe have an investment in Medalogix, a healthcare predictive data and analytics company, which is accounted for under the equity method. We incurred costs of approximately $1.4 million and $4.1&#160;million during the three and nine-month periods ended September&#160;30, 2021, respectively, and approximately $1.1&#160;million and $2.2&#160;million during the three and nine-month periods ended September 30, 2020, respectively, in connection with our usage of Medalogix's analytics platforms. We believe that the terms of these transactions are consistent with those negotiated at arm's length.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789290645624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENTSOn October 18, 2021, we acquired the regulatory assets of a home health provider in North Carolina for a purchase price of $4.5&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789199557992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly our financial position, our results of operations and our cash flows in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) for interim financial reporting. Our results of operations for the interim periods presented are not necessarily indicative of the results of our operations for the entire year and have not been audited by our independent auditors.</span></div>This report should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, as filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on February 25, 2021 (the &#8220;Form 10-K&#8221;), which includes information and disclosures not included herein.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, the Company adopted Accounting Standards Update ("ASU") 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which included minor technical corrections and clarifications to improve consistency and clarify the application of various provisions of the codification by amending the codification to include all disclosure guidance in the appropriate disclosure sections and by amending and adding new headings, cross referencing to other guidance and refining or correcting terminology. Our adoption of this standard did not have a material effect on our condensed consolidated financial statements.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference the London Inter-Bank Offered Rate ("LIBOR") or another reference rate expected to be discontinued, subject to meeting certain criteria. In January 2021, the FASB issued ASU 2021-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848)</span>, which adds implementation guidance to ASU 2020-04 to clarify certain optional expedients in Topic 848. The guidance in ASU 2020-04 and ASU 2021-01 was effective upon issuance and may generally be applied prospectively through December 31, 2022. This standard will not have an effect on our condensed consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Amedisys, Inc. and our wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated and business combinations accounted for as purchases have been included from their respective dates of acquisition. In addition to our wholly owned subsidiaries, we also have certain equity investments that are accounted for as set forth below.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate investments when the entity is a variable interest entity ("VIE") and we are the primary beneficiary or if we have controlling interests in the entity, which is generally ownership in excess of 50%. Third-party equity interests in our consolidated joint ventures are reflected as noncontrolling interests in our condensed consolidated financial statements. We account for investments in entities in which we have the ability to exercise significant influence under the equity method if we hold 50% or less of the voting stock and the entity is not a VIE in which we are the primary beneficiary. The book value of investments that we account for under the equity method of accounting was $48.3 million and $14.2 million as of September&#160;30, 2021 and December&#160;31, 2020, respectively, and is reflected in other assets within our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Contessa Health ("Contessa") on August 1, 2021, we obtained interests in several joint ventures with health system partners and a professional corporation that employs clinicians. Each of these entities meets the criteria to be classified as a VIE. As of September 30, 2021, we are proportionately consolidating seven of our eight joint ventures with health system partners as well as the professional corporation as we have concluded that we are the primary beneficiary of these VIEs. We have management agreements in place with each of these entities whereby we manage the entities and run the day-to-day operations. As such, we possess the power to direct the activities that most significantly impact the economic performance of the VIEs. The significant activities include, but are not limited to, negotiating provider and payor contracts, establishing patient care policies and protocols, making employment and compensation decisions, developing the operating and capital budgets, performing marketing activities and providing accounting support. We also have the obligation to absorb any expected losses and the right to receive benefits. We account for one of our joint ventures with a health system partner under the equity method of accounting as we are not considered to be the primary beneficiary of this VIE. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreements with each VIE prohibit us from using the assets of the VIE to satisfy the obligations of other entities. The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheet are as follows (amounts in millions):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>During the three-month period ended June 30, 2021, a third-party acquired a majority of the issued and outstanding membership interests of one of our equity method investments, Medalogix, for cash, with the remaining membership interests rolling over into a newly formed entity that includes Medalogix as well as another healthcare predictive data and analytics company. We rolled over 100% of our ownership interest in Medalogix to the newly formed entity, and in connection with this transaction, we recognized a $31.1&#160;million gain based on the purchase price of Medalogix which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. During the three-month period ended June 30, 2020, we sold our investment in the Heritage Healthcare Innovation Fund, LP via a secondary transaction for $17.9&#160;million which resulted in a $3.0 million loss which is reflected in gain (loss) on equity method investments within our condensed consolidated statements of operations. The Company's original investment was made in 2010 and no longer fit within our strategic areas of focus. Proceeds from the sale were used to pay down debt and fund capital needs.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue from contracts with customers in accordance with Accounting Standards Codification ("ASC") 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize revenue in the period in which we satisfy our performance obligations under our contracts by transferring our promised services to our customers in amounts that reflect the consideration to which we expect to be entitled in exchange for providing patient care, which are the transaction prices allocated to the distinct services. The Company's cost of obtaining contracts is not material. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are recognized as performance obligations are satisfied, which varies based on the nature of the services provided. Our performance obligation is the delivery of patient care services in accordance with the nature and frequency of services outlined in physicians' orders, which are determined by a physician based on a patient's specific goals. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's performance obligations relate to contracts with a duration of less than one year; therefore, the Company has elected to apply the optional exemption provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the transaction price based on gross charges for services provided, reduced by estimates for contractual and non-contractual revenue adjustments. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third-party payors and others for services provided. Non-contractual revenue adjustments include discounts provided to self-pay, uninsured patients or other payors, adjustments resulting from payment reviews and adjustments arising from our inability to obtain appropriate billing documentation, authorizations or face-to-face documentation. Subsequent changes to the estimate of the transaction price are recorded as adjustments to net service revenue in the period of change. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-contractual revenue adjustments are recorded for self-pay, uninsured patients and other payors by major payor class based on our historical collection experience, aged accounts receivable by payor and current economic conditions. The non-contractual revenue adjustments represent the difference between amounts billed and amounts we expect to collect based on our collection history with similar payors. The Company assesses its ability to collect for the healthcare services provided at the time of patient admission based on the Company's verification of the patient's insurance coverage under Medicare, Medicaid, and other commercial or managed care insurance programs. Medicare represents approximately 75% of our net service revenue for the three and nine-month periods ended September 30, 2021 and approximately 76% and 75% of our net service revenue for the three and nine-month periods ended September 30, 2020, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our estimates for non-contractual revenue adjustments related to our inability to obtain appropriate billing documentation, authorizations, or face-to-face documentation based on our historical experience which primarily includes a historical collection rate of over 99% on Medicare claims. Revenue is recorded at amounts we estimate to be realizable for services provided.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Home Health Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2020, the Centers for Medicare and Medicaid Services ("CMS") implemented a revised case-mix adjustment methodology, the Patient-Driven Groupings Model ("PDGM"), to better align payment with patient care needs and ensure that clinically complex and ill beneficiaries have adequate access to home health care. PDGM uses 30-day periods of care rather than 60-day episodes of care as the unit of payment, eliminates the use of the number of therapy visits provided in determining payment and relies more heavily on clinical characteristics and other patient information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net service revenue is recorded based on the established Federal Medicare home health payment rate for a 30-day period of care. ASC 606 notes that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity&#8217;s performance completed to date, the entity may recognize revenue in the amount to which the entity has a right to invoice. We have elected to apply the "right to invoice" practical expedient and therefore, our revenue recognition is based on the reimbursement we are entitled to for each 30-day payment period. We utilize our historical average length of stay for each 30-day period of care as the measure of progress towards the satisfaction of our performance obligation.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGM uses timing, admission source, functional impairment levels and principal and other diagnoses to case-mix adjust payments. The case-mix adjusted payment for a 30-day period of care is subject to additional adjustments based on certain variables, including, but not limited to (a) an outlier payment if our patient's care was unusually costly (capped at 10% of total reimbursement per provider number); (b)&#160;a low utilization payment adjustment (&#8220;LUPA&#8221;) if the number of visits provided was less than the established threshold, which ranges from two to six visits and varies for every case-mix group under PDGM; (c)&#160;a partial payment if a patient is transferred to another provider or from another provider before completing the 30-day period of care; and (d) the applicable geographic wage index. Payments for routine and non-routine supplies are included in the 30-day payment rate.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare can also make various adjustments to payments received if we are unable to produce appropriate billing documentation or acceptable authorizations. We estimate the impact of such adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record this estimate during the period in which services are rendered to revenue with a corresponding reduction to patient accounts receivable.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from Medicare include variable consideration for retroactive revenue adjustments due to settlements of audits and payment reviews. We determine our estimates for non-contractual revenue adjustments related to audits and payment reviews based on our historical experience and success rates in the claim appeals and adjudication process.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare contracts are required to have a signed plan of care which represents a single performance obligation, comprised of the delivery of a series of distinct services that are substantially similar and have a similar pattern of transfer to the customer. Accordingly, the Company accounts for the series of services ("episode") as a single performance obligation satisfied over time, as the customer simultaneously receives and consumes the benefits of the goods and services provided. An episode starts the first day a billable visit is performed and ends 60 days later or upon discharge, if earlier, with multiple continuous episodes allowed. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare home health benefit requires that beneficiaries be homebound (meaning that the beneficiary is unable to leave his/her home without a considerable and taxing effort), require intermittent skilled nursing, physical therapy or speech therapy services, and receive treatment under a plan of care established and periodically reviewed by a physician. In order to provide greater flexibility during the novel coronavirus pandemic ("COVID-19"), CMS relaxed the definition of homebound status through the duration of the public health emergency. During the pandemic, a beneficiary is considered homebound if they have been instructed by a physician not to leave their home because of a confirmed or suspected COVID-19 diagnosis or if the patient has a condition that makes them more susceptible to contracting COVID-19. Therefore, if a beneficiary is homebound due to COVID-19 and requires skilled services, the services will be covered under the Medicare home health benefit. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 20% of reimbursement from each Medicare episode, referred to as a request for anticipated payment ("RAP"), was billed near the start of each 30-day period of care, and cash was typically received before all services were rendered. Any cash received from Medicare for a RAP for a 30-day period of care that exceeded the associated revenue earned was recorded to accrued expenses within our condensed consolidated balance sheets. CMS fully eliminated all upfront payments associated with RAPs effective January 1, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Episodic-based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognize revenue in a similar manner as we recognize Medicare revenue for amounts that are paid by other insurance carriers, including Medicare Advantage programs; however, these amounts can vary based upon the negotiated terms, the majority of which range from 95% to 100% of Medicare rates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-episodic based Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established or estimated per-visit rates. Contractual revenue adjustments are recorded for the difference between our standard rates and the contracted rates to be realized from patients, third parties and others for services provided and are deducted from gross revenue to determine net service revenue. We also make non-contractual revenue adjustments to non-episodic revenue based on our historical experience to reflect the estimated transaction price. We receive a minimal amount of our net service revenue from patients who are either self-insured or are obligated for an insurance co-payment.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Medicare Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to the estimated payment rates. The estimated payment rates are predetermined daily or hourly rates for each of the four levels of care we deliver. The four levels of care are routine care, general inpatient care, continuous home care and respite care. Routine care accounted for 97% of our total Medicare hospice service revenue for the three and nine-month periods ended September&#160;30, 2021 and September 30, 2020. There are two separate payment rates for routine care: payments for the first 60 days of care and care beyond 60 days. In addition to the two routine rates, we may also receive a service intensity add-on (&#8220;SIA&#8221;). The SIA is based on visits made in the last seven days of life by a registered nurse or medical social worker for patients in a routine level of care.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation is the delivery of hospice services to the patient, as determined by a physician, each day the patient is on hospice care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make adjustments to Medicare revenue for non-contractual revenue adjustments, which include our inability to obtain appropriate billing documentation or acceptable authorizations and other reasons unrelated to credit risk. We estimate the impact of these non-contractual revenue adjustments based on our historical experience, which primarily includes a historical collection rate of over 99% on Medicare claims, and record it during the period services are rendered.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our hospice service revenue is subject to certain limitations on payments from Medicare which are considered variable consideration. We are subject to an inpatient cap limit and an overall Medicare payment cap for each provider number. We monitor these caps on a provider-by-provider basis and estimate amounts due back to Medicare if we estimate a cap has been exceeded.&#160;We record these adjustments as a reduction to revenue and an increase in accrued expenses within our condensed consolidated balance sheets. Providers are required to self-report and pay their estimated cap liability by February 28</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the following year. As of September&#160;30, 2021, we have recorded $8.6 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2016 through September 30, 2021; $2.5&#160;million of this balance was acquired with the AseraCare acquisition. As of December&#160;31, 2020, we had recorded $9.3 million for estimated amounts due back to Medicare in accrued expenses for the Federal cap years ended October&#160;31, 2014 through September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hospice Non-Medicare Revenue</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross revenue is recorded on an accrual basis based upon the date of service at amounts equal to our established rates or estimated per day rates, as applicable. Contractual revenue adjustments are recorded for the difference between our standard rates and the contractual rates to be realized from patients, third-party payors and others for services provided and are deducted from gross revenue to determine our net service revenue. We also make non-contractual adjustments to non-Medicare revenue based on our historical experience to reflect the estimated transaction price.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Personal Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Personal Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate net service revenues by providing our services directly to patients based on authorized hours, visits or units determined by the relevant agency, at a rate that is either contractual or fixed by legislation. Net service revenue is recognized at the time services are rendered based on gross charges for the services provided, reduced by estimates for contractual and non-contractual revenue adjustments. We receive payment for providing such services from payors, including state and local governmental agencies, managed care organizations, commercial insurers and private consumers. Payors include the following elder service agencies: Aging Services Access Points ("ASAPs"), Senior Care Options ("SCOs"), Program of All-Inclusive Care for the Elderly ("PACE") and the Veterans Administration ("VA"). </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Acuity Care Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">High Acuity Care Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are derived from contracts with (1) health insurance plans for the coordination and provision of home recovery care services to patients who are enrolled members in those insurance plans and (2) health system partners for the coordination and provision of home recovery care services to patients who are discharged early from a health system facility to complete their inpatient stay at home. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our health insurance plan contracts provide for fixed payment rates for a 30-day or 60-day episode of care indexed to assigned patient diagnoses in return for our obligation to assume risk for the coordination and payment of required medical services necessary to treat the medical condition for which the patient was diagnosed in a home-based setting. Our performance obligation is the coordination and provision of patient care in accordance with physicians&#8217; orders over either a 30-day or 60-day episode of care. The majority of our care coordination services and direct patient care is provided in the first five to seven days of the episode period (the "acute phase"). Monitoring services and follow-up direct patient care, as deemed necessary by the treating physician, is provided throughout the remainder of the episode. Since the majority of our services are provided during the acute phase, we recognize net service revenues over the acute phase based on gross charges for the service provided per the applicable managed care contract rates, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our contracts with health system partners provide for reimbursement on a per diem basis at the contracted rate for each day during the remainder of an inpatient acute stay serviced at the patient&#8217;s home. The performance obligation is the coordination and provision of required medical services, as determined by the treating physician, for each day the patient receives inpatient-equivalent care at home. As such, revenues are recognized as services are administered and as our performance obligations are satisfied on a per diem basis, reduced by estimates for revenue adjustments.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recognize adjustments to revenue during the period in which changes to estimates of assigned patient diagnoses or episode terminations become known, in accordance with the applicable managed care contracts. For certain health insurance plans, revenue is reduced by amounts owed by enrollees to healthcare providers under deductible, coinsurance or copay provisions of health insurance plan policies, since those amounts are repaid to the health insurance plans by us as part of a retrospective reconciliation process.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of specific guidance to account for government grants under U.S. GAAP, we have decided to account for government grants in accordance with International Accounting Standard ("IAS") 20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Government Grants and Disclosure of Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and as such, we recognize grant income on a systematic basis in line with the recognition of expenses or the loss of revenues for which the grants are intended to compensate. We recognize grants once both of the following conditions are met: (1) we are able to comply with the relevant conditions of the grant and (2) the grant will be </span></div>received. See Note 3 - Novel Coronavirus Pandemic ("COVID-19") for additional information on our accounting for government funds received under the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") and the Mass Home Care ASAP COVID-19 Provider Sustainability Program.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include certificates of deposit and all highly liquid debt instruments with maturities of three months or less when purchased. Our cash balance as of September 30, 2021 includes $58.5&#160;million associated with unutilized CARES Act Provider Relief Fund ("PRF") funds, which were repaid to the U.S. Department of Health and Human Services ("HHS") in October 2021. Restricted cash includes cash that is not available for ordinary business use. As of September 30, 2021, we had $3.8&#160;million of restricted cash that was placed into escrow accounts related to the indemnity and closing payment adjustment provisions within the purchase agreements for various acquisitions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Patient Accounts Receivable</a></td>
<td class="text"><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Accounts Receivable </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price, which includes contractual and non-contractual revenue adjustments based on the amounts expected to be due from payors. Our patient accounts receivable are uncollateralized and consist of amounts due from Medicare, Medicaid, other third-party payors and patients. The Company's non-Medicare third-party payor base is comprised of a diverse group of payors that are geographically dispersed across the country. As of September&#160;30, 2021, there is no single payor, other than Medicare, that accounts for 10% of our total outstanding patient receivables. Thus, we believe there are no other significant concentrations of receivables that would subject us to any significant credit risk in the collection of our patient accounts receivable. We write off accounts on a monthly basis once we have exhausted our collection efforts and deem an account to be uncollectible. We believe the collectability risk associated with our Medicare accounts, which represent 65% and 64% of our patient accounts receivable at September&#160;30, 2021 and December&#160;31, 2020, respectively, is limited due to our historical collection rate of over 99% from Medicare and the fact that Medicare is a U.S. government payor. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe there are any significant concentrations of revenues from any payor that would subject us to any significant credit risk in the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Home Health</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home health patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. Prior to January 1, 2021, we submitted a RAP for 20% of our estimated payment for each 30-day period of care. The RAP received was then deducted from our final payment. Effective January 1, 2021, CMS eliminated all upfront payments associated with RAPs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Hospice</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our hospice patients, our pre-billing process includes verifying that we are eligible for payment from Medicare for the services that we provide to our patients. Our Medicare billing begins with a process to ensure that our billings are accurate through the utilization of an electronic Medicare claim review. We bill Medicare on a monthly basis for the services provided to the patient.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Medicare Home Health, Hospice, Personal Care and High Acuity Care</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our non-Medicare patients, our pre-billing process primarily begins with verifying a patient&#8217;s eligibility for services with the applicable payor. Once the patient has been confirmed for eligibility, we will provide services to the patient and bill the applicable payor. Our review and evaluation of non-Medicare accounts receivable includes a detailed review of outstanding balances and special consideration to concentrations of receivables from particular payors or groups of payors with similar characteristics that would subject us to any significant credit risk.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:16pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for acquisitions using the acquisition method of accounting in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Acquisitions are accounted for as purchases and are included in our condensed consolidated financial statements from their respective acquisition dates. Assets acquired and liabilities assumed, if any, are measured at fair value on the acquisition date using the appropriate valuation method. Goodwill generated from acquisitions is recognized for the excess of the purchase price over tangible and identifiable intangible assets. In determining the fair value of identifiable intangible assets, we use various valuation techniques including discounted cash flow analysis, the income approach, the cost approach and the market approach. These valuation methods require us to make estimates and assumptions surrounding projected revenues and costs, growth rates and discount rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. The three levels of inputs are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1 &#8211; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2 &#8211; Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities.</span></div>Our deferred compensation plan assets are recorded at fair value and are considered a level 2 measurement. For our other financial instruments, including our cash and cash equivalents, patient accounts receivable, accounts payable, payroll and employee benefits and accrued expenses, we estimate the carrying amounts approximate fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Weighted-Average Shares Outstanding</a></td>
<td class="text">Weighted-Average Shares OutstandingNet income per share attributable to Amedisys, Inc. common stockholders, calculated on the treasury stock method, is based on the weighted average number of shares outstanding during the period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policy disclosure text block for government grants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789199426168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text">The carrying amount of the VIEs&#8217; assets and liabilities included in our condensed consolidated balance sheet are as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Payroll and employee benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789203970392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock', window );">Schedule of Revenue by Payor Class</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by payor class as a percentage of total net service revenue is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Periods Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Periods <br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Home Health:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Episodic-based</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare - Non-episodic based</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Hospice:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Non-Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Personal Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock', window );">Schedule of Cash Cash Equivalents and Restricted Cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.738%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FinancialInstrumentDetailsTableTextBlock', window );">Schedule of Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"/><td style="width:24.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.821%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Financial Instrument</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value as of September 30, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices&#160;in&#160;Active<br/>Markets for Identical<br/>Items<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Weighted-Average Shares Outstanding</a></td>
<td class="text">The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-<br/>Month Periods<br/>Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-<br/>Month Periods<br/>Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested stock and stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,260&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,021&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FinancialInstrumentDetailsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instrument details, table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FinancialInstrumentDetailsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789200786072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock', window );">Schedule of Cares Act Provider Relief Funds</a></td>
<td class="text">In summary, the total funds that we received from the CARES Act PRF have been accounted for as follows as of September 30, 2021 (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:76.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by consolidated entities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds to be repaid to the government by consolidated entities (excludes $0.2&#160;million of interest to be repaid)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds utilized through June 30, 2021 by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funds to be repaid to the government by unconsolidated joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cares Act Provider Relief Funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789199399128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock', window );">Schedule of Business Acquisitions, Contessa</a></td>
<td class="text">Based on the Company's preliminary valuation, the total estimated consideration of $240.7&#160;million has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock', window );">Schedule of Business Acquisitions, AseraCare Hospice</a></td>
<td class="text">The total consideration of $229.6 million&#160;has been allocated to assets acquired and liabilities assumed as of the acquisition date as follows (amounts in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"/><td style="width:74.037%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.763%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets acquired</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities assumed</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net identifiable assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule reflecting the material business combination for Contessa, completed during the period, including background, timing, and recognized assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789200903096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consists of the following for the periods indicated (amounts in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"/><td style="width:66.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$450.0 million Term Loan; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate (1.6% at September 30, 2021); due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550.0 million Revolving Credit Facility; interest only payments; interest rate at Base Rate plus Applicable Rate or Eurodollar Rate plus Applicable Rate; due July&#160;30, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Promissory notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount of long-term obligations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Commitment Fee Under Credit Facilities</a></td>
<td class="text">We are also subject to a commitment fee and letter of credit fee under the terms of the Second Amended Credit Agreement, as presented in the table below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"/><td style="width:10.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pricing Tier</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Leverage Ratio</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Commitment Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Letter of Credit Fee</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eurodollar Rate Loans and Daily Floating LIBOR Rate Loans</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Base Rate Loans</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&gt; 3.00 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 3.00 to 1.0 but &gt; 2.00 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">III</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 2.00 to 1.0 but &gt; 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&lt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> 0.75 to 1.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.25%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789199310728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Operating Income of Reportable Segments</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:45.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three-Month Period Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Period Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,464.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine-Month Period Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Home<br/>Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hospice</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Personal<br/>Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">High Acuity Care</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net service revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789207658424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>state </div>
<div>numberOfJointVentures </div>
<div>care_center</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>state </div>
<div>numberOfJointVentures </div>
<div>care_center</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states with facilities | state</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MinimumPercentOwnershipForControllingInterestPercent', window );">Minimum ownership percentage for controlling interest (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_MaximumPercentOwnershipForEquityMethodPercent', window );">Maximum ownership percentage for equity method investment (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment, aggregate cost</a></td>
<td class="nump">$ 48,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on equity method investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,092<span></span>
</td>
<td class="num">$ (2,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities', window );">Number of Consolidated Entities Classified as Variable Interest Entities | numberOfJointVentures</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 124,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">274,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">14,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">432,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">20,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,937,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,937,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,567,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">155,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">154,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">13,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">454,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">31,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">988,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 756,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeofEquityMethodInvestmentAxis=amed_HeritageHealthcareInnovationFundLPMember', window );">Heritage Healthcare Innovation Fund, LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TypeofEquityMethodInvestmentAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_OperatingCareCenters', window );">Number of owned and operated care centers | care_center</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfJointVentures', window );">Number of Joint Ventures | numberOfJointVentures</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer [Member] | Product Concentration Risk | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MaximumPercentOwnershipForEquityMethodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MaximumPercentOwnershipForEquityMethodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_MinimumPercentOwnershipForControllingInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_MinimumPercentOwnershipForControllingInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Consolidated Entities Classified as Variable Interest Entities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of joint ventures owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_OperatingCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of care centers owned by the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_OperatingCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeofEquityMethodInvestmentAxis=amed_HeritageHealthcareInnovationFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeofEquityMethodInvestmentAxis=amed_HeritageHealthcareInnovationFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TypeofEquityMethodInvestmentAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TypeofEquityMethodInvestmentAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789201529400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>visit</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net service revenue period of care payment rate (days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfTotalReimbursementOfOutlierPayment', window );">Percentage of total reimbursement of outlier payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare', window );">Hospice Medicare revenue rate accounted for routine care</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare', window );">Rate of request for anticipated payment submitted for the initial episode of care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | visit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits', window );">Low utilization payment adjustment, maximum number of visits | visit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonMedicareRevenueTermRates', window );">Non-Medicare revenue term rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenueEpisodePaymentRateDuration', window );">Net service revenue episode payment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember', window );">Cap Year 2014 Through 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember', window );">Cap Year 2016 Through 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenue from Contract with Customer [Member] | Medicare Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of net services revenue</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member] | Cap Year 2016 Through 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities', window );">Estimated amounts due back to Medicare</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HospiceMedicareRevenueRateAccountedForRoutineCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HospiceMedicareRevenueRateAccountedForRoutineCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LowUtilizationPaymentAdjustmentNumberOfVisits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the visit threshold for a low utilization payment adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LowUtilizationPaymentAdjustmentNumberOfVisits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenueEpisodePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenueEpisodePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonMedicareRevenueTermRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonMedicareRevenueTermRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfTotalReimbursementOfOutlierPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage at which total reimbursement is capped if cost of care is unusually costly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfTotalReimbursementOfOutlierPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CapYearAxis=amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=amed_MedicareRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=amed_MedicareRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789204029528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember', window );">Home Health Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember', window );">Home Health Non-Medicare - Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember', window );">Home Health Non-Medicare - Non-Episodic Based [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceMedicareMember', window );">Hospice Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember', window );">Hospice Non-Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PayorClassAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition, Multiple-deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue', window );">Revenue by payor class as a percentage of total net service revenue</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue by payor class as a percentage of total net service revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HomeHealthNonMedicareNonEpisodicBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_HospiceNonMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_HospiceNonMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PayorClassAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PayorClassAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789279092600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 124,458<span></span>
</td>
<td class="nump">$ 81,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">128,208<span></span>
</td>
<td class="nump">$ 83,357<span></span>
</td>
<td class="nump">$ 115,453<span></span>
</td>
<td class="nump">$ 96,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CashBalanceAssociatedWithProviderReliefFund', window );">Cash Balance Associated with Provider Relief Fund</a></td>
<td class="nump">58,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember', window );">Various acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CashBalanceAssociatedWithProviderReliefFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Balance Associated with the CARES Act Provider Relief Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CashBalanceAssociatedWithProviderReliefFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_VariousAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789279624088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_AccountsReceivablePortionDerivedFromMedicare', window );">Accounts receivable derived from Medicare</a></td>
<td class="nump">65.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration', window );">Net service revenue period of care payment rate (days)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfPatientReceivablesOutstanding', window );">Percentage of patient receivables outstanding</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HistoricalCollectionRateFromMedicare', window );">Historical collection rate from Medicare</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare', window );">Rate of request for anticipated payment submitted for the initial episode of care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_AccountsReceivablePortionDerivedFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Portion Derived From Medicare</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_AccountsReceivablePortionDerivedFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HistoricalCollectionRateFromMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Historical collection rate from Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HistoricalCollectionRateFromMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NetServiceRevenuePeriodOfCarePaymentRateDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NetServiceRevenuePeriodOfCarePaymentRateDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfPatientReceivablesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of patient receivables outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfPatientReceivablesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789279407384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases', window );">Debt Instrument Carrying Amount Excluding Finance Leases</a></td>
<td class="nump">$ 450,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">468,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term Debt, Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentCarryingAmountExcludingFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Carrying Amount Excluding Finance Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentCarryingAmountExcludingFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789302534248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic (shares)</a></td>
<td class="nump">32,607<span></span>
</td>
<td class="nump">32,662<span></span>
</td>
<td class="nump">32,658<span></span>
</td>
<td class="nump">32,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options (shares)</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NonVestedStockAndStockUnits', window );">Non-vested stock and stock units (shares)</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (shares)</a></td>
<td class="nump">32,899<span></span>
</td>
<td class="nump">33,260<span></span>
</td>
<td class="nump">33,021<span></span>
</td>
<td class="nump">33,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (shares)</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NonVestedStockAndStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non vested stock and stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NonVestedStockAndStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789201554424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingForHealthcareProvidersIncludingHospitals', window );">Funding for Healthcare Providers, Including Hospitals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements', window );">Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProviderReliefFundAdvance', window );">Provider relief fund advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsUtilized', window );">CARES Act Provider Relief Funds Utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures', window );">CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid', window );">Estimated CARES Act Provider Relief Fund Amounts to be Repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures', window );">Estimated CARES Act Provider Relief Fund Amounts to be Repaid By Unconsolidated Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalCARESActProviderReliefFundsReceived', window );">Total CARES Act Provider Relief Funds Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActInterestToBeRepaidToGovernment', window );">CARES Act Interest To Be Repaid to Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact', window );">Extension of Temporary Suspension of Sequestration, Revenue Impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityMember', window );">COVID-19 Deferral of Social Security</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax', window );">CARES Act Deferral of Employer Share Social Security Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram', window );">Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember', window );">AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity Method Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>NOVEL CORONAVIRUS PANDEMIC "COVID-19" [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FundingReceivedFromCARESAct', window );">Funding Received From CARES Act</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActDeferralOfEmployerShareSocialSecurityTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The deferral of the employer's share social security tax provided by the CARES Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActDeferralOfEmployerShareSocialSecurityTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActInterestToBeRepaidToGovernment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Interest To Be Repaid to Government</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActInterestToBeRepaidToGovernment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Utilized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated CARES Act Provider Relief Fund Amounts to be Repaid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated CARES Act Provider Relief Fund Amounts to be Repaid By Unconsolidated Joint Ventures</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavrius pandemic ("COVID-19").</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingForHealthcareProvidersIncludingHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingForHealthcareProvidersIncludingHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProviderReliefFundAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable related to funds received from the government related to COVID-19</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProviderReliefFundAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalCARESActProviderReliefFundsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total CARES Act Provider Relief Funds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalCARESActProviderReliefFundsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=amed_COVID19DeferralOfSocialSecurityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789190844472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 12, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 01, 2020 </div>
<div>USD ($) </div>
<div>care_center</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553,485<span></span>
</td>
<td class="nump">$ 544,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,654,795<span></span>
</td>
<td class="nump">$ 1,520,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,772<span></span>
</td>
<td class="nump">63,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,756<span></span>
</td>
<td class="nump">157,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500<span></span>
</td>
<td class="nump">199,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586,900<span></span>
</td>
<td class="nump">546,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,700<span></span>
</td>
<td class="nump">48,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,100<span></span>
</td>
<td class="nump">132,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Acquisition, number of care centers acquired | care_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PaymentsRelatedToTaxAsset', window );">Payments related to tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod', window );">GoodwillDeductibleForIncomeTaxPurposesPeriod</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member] | AseraCare Hospice [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessAcquisitionClosingPaymentAdjustment', window );">Business Acquisition Closing Payment Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,600<span></span>
</td>
<td class="nump">326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,500<span></span>
</td>
<td class="nump">919,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">68,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,200<span></span>
</td>
<td class="nump">164,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember', window );">Home Health and Hospice [Member] | Visiting Nurse Association</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,800)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,800)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care | Contessa Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 240,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DepreciationAndAmortizationForContinuingOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NC', window );">NORTH CAROLINA | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">NEW YORK | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill recorded during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete Agreements [Member] | High Acuity Care | Contessa Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember', window );">Acquired Names [Member] | Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember', window );">Acquired Names [Member] | High Acuity Care | Contessa Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicareLicenseMember', window );">Medicare licenses [Member] | Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicareLicenseMember', window );">Medicare licenses [Member] | Home Health and Hospice [Member] | Visiting Nurse Association</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember', window );">Certificates Of Need | Hospice [Member] | AseraCare Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember', window );">Certificate of Need [Member] | NORTH CAROLINA | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember', window );">Certificate of Need [Member] | NEW YORK | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets | High Acuity Care | Contessa Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average amortization period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Acquisition, other intangibles recorded</a></td>
<td class="nump">$ 19,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessAcquisitionClosingPaymentAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Closing Payment Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessAcquisitionClosingPaymentAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity assumed at the acquisition date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total liabilities and equity assumed at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DepreciationAndAmortizationForContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation And Amortization For Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DepreciationAndAmortizationForContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_GoodwillDeductibleForIncomeTaxPurposesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time that goodwill is deductible for income tax purposes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_GoodwillDeductibleForIncomeTaxPurposesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PaymentsRelatedToTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments related to tax asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PaymentsRelatedToTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_AseraCareHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthAndHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_VisitingNurseAssociationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_VisitingNurseAssociationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_ContessaHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_AcquiredNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicareLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_MedicareLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificatesOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=amed_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789203148856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 452.8<span></span>
</td>
<td class="nump">$ 217.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred debt issuance costs</a></td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term obligations, including current portion</a></td>
<td class="nump">448.0<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term obligations</a></td>
<td class="num">(13.2)<span></span>
</td>
<td class="num">(10.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">434.8<span></span>
</td>
<td class="nump">204.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">450.0<span></span>
</td>
<td class="nump">164.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">51.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember', window );">Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember', window );">Finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_PromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CapitalLeaseObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789208843048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Jul. 30,  2026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">Jul. 30,  2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789201576536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember', window );">Consolidated Leverage Ratio: Greater Than 3.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember', window );">Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember', window );">Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_LetterOfCreditFee', window );">Letter Of Credit Fee</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Eurodollar [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember', window );">Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0 | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Greater Than 3.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedLeverageRatio', window );">Consolidated Leverage Ratio</a></td>
<td class="nump">0.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_LetterOfCreditFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the letters of credit, for the letters of credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_LetterOfCreditFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789197507528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM OBLIGATIONS - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">26 Months Ended</th>
<th class="th" colspan="1">34 Months Ended</th>
<th class="th" colspan="1">60 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th"><div>Jul. 30, 2026</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 04, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_TotalLeverageRatio', window );">Consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ConsolidatedInterestCoverageRatio', window );">Consolidated interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,792<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime', window );">Weighted average interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 519,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Outstanding letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 725,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | One Hundred Seventy Five Million Term Loan Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember', window );">Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate', window );">Additional interest rate above Federal Fund rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate', window );">Additional interest rate above Eurodollar rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries', window );">Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries', window );">Percentage of adjusted EBITDA that guarantor subsidiaries represent</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Five Hundred Fifty Million Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember', window );">Second Amended Credit Agreement | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Fluctuating rate per annum equal to the highest of (a)&#160;the federal funds rate plus 0.50% per annum, (b)&#160;the prime rate of interest established by the Administrative Agent, and (c)&#160;the Eurodollar Rate for an interest period of one month plus 1% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember', window );">Base Rate [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Description of variable rate basis</a></td>
<td class="text">Rate at which Eurodollar deposits in the London interbank market for an interest period of one, two, three or six months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Term Loan [Member] | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentInterestRateatPeriodEnd', window );">Debt Instrument Interest Rate at Period End</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary', window );">Proceeds Received From Loan Party Of Subsidiary</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Second Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Second Amended Credit Agreement | Four Hundred Fifty Million Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_DebtInstrumentPeriodicPaymentPercentage', window );">Debt Instrument Periodic Payment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.625%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ConsolidatedInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ConsolidatedInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Eurodollar Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Additional Interest Above Federal Fund Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentInterestRateatPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Interest Rate at Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentInterestRateatPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_DebtInstrumentPeriodicPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the Term Loan that is required as periodic payments including both interest and principal payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_DebtInstrumentPeriodicPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of adjusted EBITDA that guarantor subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProceedsReceivedFromLoanPartyOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds Received From Loan Party Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProceedsReceivedFromLoanPartyOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_TotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of debt to earnings before interest, taxes, depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_TotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtWeightedAverageInterestRateOverTime">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated over time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtWeightedAverageInterestRateOverTime</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FourHundredFiftyMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_OneHundredSeventyFiveMillionTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=amed_SecondAmendmentToAmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=amed_SecondAmendmentToAmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=amed_SecondAmendmentToAmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789196858104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">27 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 27, 2016 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jan. 18, 2016 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Nov. 03, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>May 21, 2015 </div>
<div>patient</div>
</th>
<th class="th">
<div>Jun. 06, 2011 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>beneficiary</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 255,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_HealthInsuranceRetentionLimit', window );">Health insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_WorkersCompensationInsuranceRetentionLimit', window );">Workers compensation insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ProfessionalLiabilityInsuranceRetentionLimit', window );">Professional liability insurance retention limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Extrapolated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfBeneficiaries', window );">Number of beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_SC', window );">South Carolina | Hospice [Member] | Unfavorable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest', window );">Recovery amount of overpayment made to subsidiary including interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld', window );">Recovery amount of over payment made to subsidiary including interest withheld</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ReversalOfLossContingencyAccrual', window );">Reversal of Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Massachusetts | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Morgantown, West Virginia | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember', window );">US Department of Justice | Parkersburg, West Virginia | Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_Numberofpatients', window );">Number of patients | patient</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableNoncurrent', window );">Indemnity receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Infinity HomeCare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_IndemnificationAmount', window );">Indemnification amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_FloridaZpicRevenueReduction', window );">Florida ZPIC revenue reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,800<span></span>
</td>
<td class="nump">29,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Florida | Home Health [Member] | Infinity HomeCare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Lakeland, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember', window );">Safeguard Zone Program Integrity Contractor | Clearwater, Florida | Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary', window );">Recovery amount of overpayment made to subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_NumberOfClaimsSubmittedBySubsidiary', window );">Number of claims submitted by subsidiary | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ActualClaimsPayment', window );">Actual claims payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ErrorRatePercentage', window );">Error rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ActualClaimsPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Actual Claims Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ActualClaimsPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ErrorRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Error Rate Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ErrorRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_FloridaZpicRevenueReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in revenue as a result of the Florida ZPIC audit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_FloridaZpicRevenueReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_HealthInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_HealthInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_IndemnificationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount to be reimbursed if and when certain assumed liabilities are paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_IndemnificationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of beneficiaries who received services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_NumberOfClaimsSubmittedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims submitted by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_NumberOfClaimsSubmittedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Numberofpatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Numberofpatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ProfessionalLiabilityInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ProfessionalLiabilityInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of the overpayment made to the subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of overpayment made to subsidiary including interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recovery amount of over payment made to subsidiary including interest withheld</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ReversalOfLossContingencyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal of Loss Contingency Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ReversalOfLossContingencyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_WorkersCompensationInsuranceRetentionLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_WorkersCompensationInsuranceRetentionLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12053-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_SC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_SC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_ExtrapolatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=amed_UnfavorableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_UsDepartmentOfJusticeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_MorgantownWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ParkersburgWestVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=amed_SafeguardZoneProgramIntegrityContractorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=amed_InfinityHomeCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_LakelandFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_LakelandFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=amed_ClearwaterFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789199513640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>Segments</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable business segments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789190792616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">$ 553,485<span></span>
</td>
<td class="nump">$ 544,070<span></span>
</td>
<td class="nump">$ 1,654,795<span></span>
</td>
<td class="nump">$ 1,520,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">4,812<span></span>
</td>
<td class="nump">13,300<span></span>
</td>
<td class="nump">27,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">310,294<span></span>
</td>
<td class="nump">297,668<span></span>
</td>
<td class="nump">916,188<span></span>
</td>
<td class="nump">878,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">178,900<span></span>
</td>
<td class="nump">179,700<span></span>
</td>
<td class="nump">526,400<span></span>
</td>
<td class="nump">492,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,487<span></span>
</td>
<td class="nump">8,283<span></span>
</td>
<td class="nump">21,763<span></span>
</td>
<td class="nump">19,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">496,709<span></span>
</td>
<td class="nump">485,569<span></span>
</td>
<td class="nump">1,464,339<span></span>
</td>
<td class="nump">1,391,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">56,772<span></span>
</td>
<td class="nump">63,313<span></span>
</td>
<td class="nump">203,756<span></span>
</td>
<td class="nump">157,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember', window );">Home Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">338,600<span></span>
</td>
<td class="nump">326,000<span></span>
</td>
<td class="nump">1,016,500<span></span>
</td>
<td class="nump">919,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">17,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">190,100<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">563,500<span></span>
</td>
<td class="nump">543,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">82,400<span></span>
</td>
<td class="nump">78,800<span></span>
</td>
<td class="nump">243,800<span></span>
</td>
<td class="nump">226,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">273,600<span></span>
</td>
<td class="nump">259,800<span></span>
</td>
<td class="nump">810,600<span></span>
</td>
<td class="nump">773,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">68,800<span></span>
</td>
<td class="nump">213,200<span></span>
</td>
<td class="nump">164,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember', window );">Hospice [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">197,500<span></span>
</td>
<td class="nump">199,700<span></span>
</td>
<td class="nump">586,900<span></span>
</td>
<td class="nump">546,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">107,600<span></span>
</td>
<td class="nump">104,100<span></span>
</td>
<td class="nump">314,400<span></span>
</td>
<td class="nump">293,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">49,500<span></span>
</td>
<td class="nump">47,800<span></span>
</td>
<td class="nump">144,400<span></span>
</td>
<td class="nump">127,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">157,800<span></span>
</td>
<td class="nump">152,500<span></span>
</td>
<td class="nump">460,800<span></span>
</td>
<td class="nump">422,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">39,700<span></span>
</td>
<td class="nump">48,900<span></span>
</td>
<td class="nump">132,100<span></span>
</td>
<td class="nump">132,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember', window );">Personal Care [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">15,900<span></span>
</td>
<td class="nump">18,400<span></span>
</td>
<td class="nump">49,900<span></span>
</td>
<td class="nump">54,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">11,700<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="nump">37,400<span></span>
</td>
<td class="nump">41,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">14,400<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
<td class="nump">46,400<span></span>
</td>
<td class="nump">51,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember', window );">High Acuity Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(3,800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions', window );">Net service revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other operating income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of service, excluding depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">40,500<span></span>
</td>
<td class="nump">49,900<span></span>
</td>
<td class="nump">125,500<span></span>
</td>
<td class="nump">129,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">15,800<span></span>
</td>
<td class="nump">15,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">45,600<span></span>
</td>
<td class="nump">56,600<span></span>
</td>
<td class="nump">141,300<span></span>
</td>
<td class="nump">144,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">$ (45,600)<span></span>
</td>
<td class="num">$ (56,600)<span></span>
</td>
<td class="num">$ (141,300)<span></span>
</td>
<td class="num">$ (144,400)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_PersonalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HighAcuityCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789279556952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL STOCK AND SHARE-BASED COMPENSATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment, Tax Withholding, Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,694<span></span>
</td>
<td class="nump">$ 54,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember', window );">Executive Stock Option Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance/(cancellation) of non-vested stock (shares)</a></td>
<td class="nump">268,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_SurrenderedSharesInShares', window );">Surrendered Shares (in shares)</a></td>
<td class="nump">231,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment, Tax Withholding, Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_SurrenderedSharesInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Surrendered Shares (in shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_SurrenderedSharesInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=amed_ExecutiveStockOptionExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789279128824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE REPURCHASE Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,879<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_ExistingShareRepurchaseProgramMember', window );">Existing Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (shares)</a></td>
<td class="nump">54,609<span></span>
</td>
<td class="nump">351,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of company stock</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury Stock Acquired, Average Cost Per Share</a></td>
<td class="nump">$ 197.84<span></span>
</td>
<td class="nump">$ 241.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_ExistingShareRepurchaseProgramMember', window );">Existing Share Repurchase Program | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember', window );">New Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember', window );">New Share Repurchase Program | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_amed_ShareRepurchaseLineItems', window );"><strong>Share Repurchase [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramExpirationDate', window );">Stock Repurchase Program Expiration Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_amed_ShareRepurchaseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Share Repurchase [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">amed_ShareRepurchaseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>amed_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_ExistingShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_ExistingShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=amed_NewShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789201432600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember', window );">Medalogix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related Party Transaction, Amounts of Transaction</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amed_MedalogixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139789203732792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT - Narrative (Details) - NORTH CAROLINA - Home Health [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 18, 2021</div></th>
<th class="th"><div>May 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=amed_HomeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MD,7ABV_J:6/:+Y97%UOQ)!^D^7-[7\'5\CC+2A6RK)4N4277EXMK\OZ&\79
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MF8V29^*6YY<Z? (H)-5;5Q,?JML(5)I&W9KF]LK45*Z0,*RYN2L(AN-(@TT
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M46JL^T ?@2&$,=)KPM^/!R!<R%CZSA/ 86&[S\>5D^"O[L>#)<&!?GS(N33
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MEE'YAV2.S=V*Q_$.M;&ET#_4(O,P0AV<4[\V.LZEI?P&1"8]F33AY3(F$V<
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M6>T1JNX$?C0\OF=-/XJ'4#(XX:G=K5W]72^P[T@\]G_)^[T? I3*K?CG#CS
MF3K\)B ]3;^HF(8?$G3+P\\Q/DNWTE"A4$ML'0U?'0T"!;1?:EOQSPH6MJYM
MR1_I9D\Y6H#W=!/=?J$#TN],WO\;4$L#!!0    ( #9 8U-7VF&5FR   +1J
M   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL[5U9<QM'DOXK'5Q[1XH
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M+5.>Q#^GRHY/:KW<-"1)"/=_26@FHH7X8#)+R%KQ6"(L$T:'W1H''*&_(7(
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MC-#=KP>-K'-6Y3[! [<];ZV&UC]$DSD/2<_P^3.?UY<(760;R$']\14&NQ4
M:A%)9>L=G'MB;!QI_R#BT!-@?!$TFH-*?"/G\'B,EEIS,;,;TJ7N>S:M7?34
MD0C6=XOPLER(C- ^LW[@,X<8N!)DNI(.H*D.4?FL<<F;2Q^6E,.F#WJ!=@TB
MKDSFLP2%:<"G2*"Y'13YW(JM6]L%B0HVYN"J6"XIX?,BRZ;B"@AT2, MJ.K
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M-;A6'.Y\"@-Y="CD8#?]C-YZ<]U_Z(O1\=%Q.Q@A9?@JY:NR"K?=E0#R<+E
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M/QWVA F?#<.#T[7_5#?5#G72_\0@CAF -V ]T]JU#ZR@^W9[]C]02P,$%
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M8+.MZ8/4YO?!%Z.?(?V[ MX<.';J%RA*+%CIAO@%KS]3P34_;[-\>C4W5#[
M1DPS-=4B/!7/=2=?($GIJ9@^/+SY\"#>QQ*-,PJ3?Y4_<HT?"6H1[Y'%U 6(
MI5-_$\/!N7C'2)S4UO+FH#=![GM+V0VPX_$(RE7,/'E/F_8 4(36TM4*&4*C
M0"OB2MSM4.O)9#".1\8GYY#W@7V^[;,C<4E:?WLWO;G[%A/XFP<QO?]2O,%
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M7'RPN#JLJ:1ZKG*G32ZLFKSJG0^?7QS3>E[PNU9+M_);T$G&QGRFBZOT56]
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MEB$#.WDH'D,/3Z9/0-%513*2]8K"DOZBO=BW(F3*8, 1>):R GB48"X?P2!
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MC\EIP=%B?O+_#[U+:3^#4Y>=7?_/L'>%>NSKL??L?X"]@99^&_@&O!> -@M
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M$38JE:4!^'UEX&+Q"VV0W[U^]6]02P,$%     @ -D!C4VF?W :/!P  \!,
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MSR<1V.;FU"R\J<)M96,\W7W":T&73;1L0-^WQOC#@@-TU]?Y7U!+ P04
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MV-(0S\2P9/VR[KP#GZ^,H9WA$W1_:^.?4$L#!!0    ( #9 8U.MIL1P10(
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MC_/<X9-Y/B'S 4$_R-"$F#I**Y;HM!,*4DIQBV8E0Z1T*FBE/[_0BI+3#H&
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M9@$V!IFR7CHK0[S"ZF/._QEHO0._SXRAO>$3M/]"HW\!4$L#!!0    ( #9
M8U-(5T9<4P0  #H+   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;-56
M;8_B-A#^*Z-HI2[27H! V!<!$K#;'M+=WO;@6E55/YAD .L<.V<[R_+O.W9"
M-ML#>E(_]<L2VS///#.>9];#G=)?S1;1PDLFI!D%6VOSNW;;)%O,F E5CI).
MUDIGS-)2;]HFU\A2[Y2)=M3I#-H9XS(8#_W>DQX/56$%E_BDP119QO1^BD+M
M1D$W.&Q\YINM=1OM\3!G&UR@_9(_:5JU:Y249R@-5Q(TKD?!I'LWC9V]-_B-
MX\XTOL%ELE+JJUO,TU'0<8108&(= J.?9YRA$ Z(:'RK,(,ZI'-L?A_0?_:Y
M4RXK9G"FQ.\\M=M1<!- BFM6"/M9[=YCE8\GF"AA_%_8E;9Q+X"D,%9EE3,Q
MR+@L?]E+58>&PTWGA$-4.42>=QG(L[QGEHV'6NU .VM"<Q\^5>]-Y+ATE[*P
MFDXY^=GQ9/;KE_EBOIQ_>ES Y9*M!)K6L&T)VAFTDPIF6L)$)V!NX:.2=FO@
M0::8OO5O$Z6:5W3@-8W. BXP#Z'7N8*H$W7/X/7J/'L>KW<";UH8VC$&9BI;
M<<E<2QCX<[(R5E-G_'4F1+\.T?<A^J<HDV#20B"H-=3A)LFW@AONPUU1<&EI
MEQTK\%EPI\T[D[,$1P&)SZ!^QF \I79,@7K;;M$EEC.Y_\D &0A.O4(B@V<F
M"I_LE3>RRC(!:"RGAB;?A&CQ%+4W<<0OHGXGO*9.$\+M;)F!%2*I1PB5>!>K
M@!F#UI"B*#=-6TRF(#A;<4&)HG'G1>;VC8-T<=EK&2 E&'>T5H2Y,W#),E5(
MPN/R$->T[F#B=V&R6#PL%_!$#)&6+$E*8XT)\F?7KW !W3"&)XTYXRG@"PTL
M0RPZ80\^47!-.M+:.Y>\.V&7K&FN:;OWW)'(Y9FS\#ZYKX?<@$ J,&@G;)=(
M8? 5X@;FTC*YX8Y!M1O'852%K'9ZA+?T-?]GS2Y@X%A_F$^F\P^DOX<%3![O
MX8'DN/R#VJ9*,V?[*L=+HMVB.NPUU:VDG>5"[1'IAB2N.5F3S:#EG'6!C4I<
M]L)^Z[N\FC=&CC<MN,<U:D>.RT1EU"WLI?2FP+.JAKG2AUX12F[>6=09J)7@
MFTI3!'7;JJIPTB)J564YUC:7MR[@HR(2TKIL'6=.RJ'&=TGV(W=>^KNK<[=X
M<&V>O<&NKKEA2R6-NX[)(_WO(Q%(R]><-:ZS<5==UQB_*)7NJ$$AZG7"?A7D
MK8(NH-3/F7$2U^,D_J_C9$)S@,V81GBO3,X3/#97SD8Y/E>6]:0X,A^BVW#P
MOYL/,5W?D0%Q?7H.#'YH#L3A[9$Y$/7KT=,8.:?F0'] (&_FP!'Q#\+>OXH_
M=L+[7OS=KA?D.?7';CZ<%B3%IUN/?TPIUR2-5Z5T(QJ))Y3B.^F84MJ-]TR&
M>N-?;09\5<JG3;U;/PPGY7OHU;Q\57YD>L-IY@A<DRO=.,E!ER^U<F%5[E]'
M*V7IK>4_M_2X1>T,Z'RME#TL7(#ZN3S^&U!+ P04    "  V0&-3XFMX"5P$
M   ""@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RU5FUSXC80_BL[
M;G(#,W=^ R<T 68@+U<ZY)(AW-V'3C\(>P'U9,N5Y'#Y]UW)X)"4,/W2+[*T
MWGWVV=6NI/Y&JA]ZC6C@9RX*/?#6QI070:#3->9,^[+$@OXLI<J9H:5:!;I4
MR#)GE(L@#L.S(&>\\(9])WM0P[ZLC. %/BC059XS]3Q&(3<#+_)V@AE?K8T5
M!,-^R5;XB.9K^:!H%30H&<^QT%P6H' Y\$;1Q3BQ^D[A&\>-WIN#C60AY0^[
MF&0#+[2$4&!J+ *CSQ->H1 6B&C\O<7T&I?6<'^^0[]UL5,L"Z;Q2HKO/#/K
M@=?S(,,EJX29R<UON(W'$4RET&Z$3:V;=#Q(*VUDOC4F!CDOZB_[N<W#GD$O
M?,<@WAK$CG?MR+&\9H8-^TIN0%EM0K,3%ZJS)G*\L)OR:!3]Y61GAM/[+Y\_
MS6]F=W _GDX^C^:3^R^/<%C:FK.%0-WN!X8\6_L@W7H9UU[B=[S\"G>R,&L-
M-T6&V6O[@!@WM.,=[7%\%/ 12Q\ZX4>(PS@Z@M=ITM!Q>)UW\*YQ8>":ZU1(
M72F$/T8+;125S)]'P+L->->!=]\C2YV450)!+F$JB]6G.:H<K,M#F3R*97OT
M0I<LQ8%'3:A1/:$W=*#&@F8VCE12SVBCK3^S1EA*0;W'BQ7-E).4J+C,-/ B
MXRDSF$&+Y;(JC!51F0E!':/;%T!Y-I@O4#7))M[I5A(Y20@GW23TPYT9N.BF
MDA67!$:L4!M0Y 28@3$U$,SLHA25AE%9"B) 554+B=Y-I61&A)DZHM>*_+-3
MB_=O?NU+R"J$WROQO).=04TP.NOZ$9PDK]C.\$F*)YN<*X49-W#+4BZX>=YC
M+PL"*]DS'49&_V]1'2+^X9=>',67D$1$^4')G&LMU3,4TJ"&T.\U&K>\8$6*
M()#(:(A)/_;/R(87*2^9@'J#;4V(IESD0O 5L\>CIAS%!!='Y_XY[?$2%:6C
MKB?R63GL5-JJ:G7]7AM:L7_>AFZW9QU%"8U7%9F0AU(J=^"^ZZD5=?R8$*+0
M3]HPEX;8G4"W0[CTC<.NG\"1MDN:MDO^<]M=R3SGQNX?W"+"5SJ&U)L-YZ@/
MM>-Q']]I_^FX8$)+NM<6?]%= T8"HU0U#I?DD!49[8RA5%@V:>W8_J@<$]N3
M-DU-RSXB-7$&(P*@ W/'=+12B!;S(S -KO\+V[S4LP[!E=+"7K2^W?C45O6<
MVT@I[5+PS+7Z%)]0T85KBX[+MZF9-BQWZ2'AV_*UW:U=4->,4[W>"DE8Y&TZ
M&=_/]G5>6J->3^##REQ"QP]#FRA;UJ'?"4]I=IZ<VK)U<SM.2%>\T5U4I@:(
M7P'$B35*&IC0C9,=0GP(P>KL(3C;%YS0C9-O-<!KW2C94:PMG/]#!1OLW<LY
MJI5[?6BJ#6K$^HINI,T#9U3?ZR_J]>OHCJD5I_P)7)*IY>.!JE\<]<+(TMWR
M"VGHS>"F:WJDH;(*]'\IZ<C8+JR#YMDW_ =02P,$%     @ -D!C4[:>J<7/
M!   D0T  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULO5=9;^,V$/XK
MA+HHO( KB92H([4-)-DC><B!)&T?BC[($FT+*XDJ2<?9_?6=H6S%26QO-ECT
M13PT\\W!;T;4:"75%[T0PI"'NFKTV%D8TQYYGLX7HLZT*UO1P)N95'5F8*GF
MGFZ5R JK5%<>\_W(J[.R<28CNW>M)B.Y-%79B&M%]+*N,_7U1%1R-7:HL]FX
M*><+@QO>9-1F<W$KS!_MM8*5UZ,492T:7<J&*#$;.\?TZ"1$>2OP9RE6>FM.
M,)*IE%]P<5Z,'1\=$I7(#2)D,-R+4U%5" 1N_+O&='J3J+@]WZ!_LK%#+--,
MBU-9_5469C%V$H<48I8M*W,C5V=B'0]'O%Q6VC[)JI/ES"'Y4AM9KY7!@[IL
MNC%[6.=A2R'Q]RBPM0*S?G>&K)<?,I--1DJNB$)I0,.)#=5J@W-E@X=R:Q2\
M+4'/3&X_?K[X>'E'SB\_7=U<'-^=7UV2P5TVK81^/_(,6$ Y+U^CG71H; ]:
M2BYD8Q::?&P*43S5]\"SWCVV<>^$'02\%:U+ G](F,_H ;R@#S>P>,%>O#DP
MRI ;T4IERF9._CZ>:J. '/\<@ ][^-#"A_O@H6:*926(G)&K5JC,FCAO<EG;
MO<XL9I>L/=&[DGS0");ID6ZS7(P=J$,MU+UP)@0X2LQ"D+N%$N(W>PSD6JA2
M%MUA@,'6B'HJ5)]/<H9NG4G=EKE 82V;K")G0&1RG"]+\Y6<9DJ0*\!5Y$X:
M>'D)?0)-HH82]Z)9"O*.!$'B1C#2-'8YCMQ-<;"+7W])&&6_PXSS '8Z.-FG
MI^S2LQ%[[7@JM<&<KKT9$O&05\L"$0L!B<G+K*O[IB!9C:?]K=N@J>]20OT8
M7*;4C8D/SFY0 ^J[ ?DL&O"NZG0+*+L2.8+] ZQ /]1"DX2Y(0E3"(@!4  8
MH0\+&B<P_7#8 [#O6\,X<L)AQ,0]4J:WPN( W>2QFQ :@D4.[H4<]L(T HBK
MYVD<5%+K]Y#LB+L^'DT*4INC& 1N@N\&B( 3'@'NCU/'_XG489'UDZ9K1Q,(
M<ILT6_0)0TC4'OK@(72'R5]0)80@WTZ7Q <'J8^V:; #G:7(I-=0!JB1D!"/
M,G#9HW<I$(;&&/[W:.-#>-$+!Y '"=!B%WUXBL3A#)F)<AL=.'B@4()$.D A
M]/<=B-EJ9N#S]G$,$,.*!6!\0Z)+Z%;_=_NA0Q^"0X+S)+*^VIR^;$!T&'$D
MPQX.Q1 'LG%?RZ$8Z)N)Q"-D3V"K.(CAL=UW4@B O8I$+ QL+T"8Q%()V,,X
MMA$HI? [',((F.41LZ4"G3HAC&).7K(GH4BW,/*1MM&Z^="0XG,81NC!?O(P
M&EC"T(!!Y4"A/^U %L;*^0'P\H?I\Q-;4$I3RW,>1M9C2Y'=+8@..?/W$XC&
MMA136ZHO^@2VB;>SQQX[2P-(9DBW*GDS)G'RRC;$&'8"RI"#Z59#HRR%^,.4
M@:'#+&(VQ.X#UFMS4*98=SN8%,-G#+Z6#'L(1_[T6I;'=!BD]$D'>\XF&H66
M1<@F6^#/*GM@@:PD?"LIV769\[:NR;50<_LSH$DNEXWI;LS];O^_<=Q=LQ_%
MNY^5BTS-RT:32LQ %;[EW"&J^P'H%D:V]M(]E0:N\':Z@'\FH5  WL^D-)L%
M&NC_PB;_ 5!+ P04    "  V0&-3](S5A<H(  "]+0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6S-6FUOH[@6_BM6M%>:E3H3L TAH[92FZ:EJVD;
MM9W9#ZO5E4N<! W!64SZLMH??X^!QB$&A^Z,KOJE#?#8G.-S?)X'VX=/(OLN
M%YSGZ'F9I/*HM\CSU>=^7T8+OF3RDUCQ%)[,1+9D.5QF\[Y<99Q-BT;+I(\=
MQ^\O69SVC@^+>Y/L^%"L\R1.^21#<KU<LNSEE"?BZ:CG]EYOW,;S1:YN](\/
M5VS.[WC^=37)X*J_Z64:+WDJ8Y&BC,^.>B?NY] +5(,"\2WF3W+K-U*N/ CQ
M75U<3H]ZCK*()SS*51<,_CWR$4\2U1/8\5?5:6_S3M5P^_=K[^>%\^#, Y-\
M))+?XVF^..H%/33E,[9.\EOQ%/+*(4_U%XE$%G_14X5U>BA:RUPLJ\9@P3).
MR__LN1J(K0;@:',#7#7 .PVPV]* 5 U(UP:T:D"[-O"J!EY7'_RJ@=_U#8.J
MP:!K@Z!J4*1+OPQ'$<LSEK/CPTP\H4RAH3?UHTB(HC6$,$Y5[M[E&3R-H5U^
M?'UR__5VC&[.T<UD?'MR?WES?7> 1O#WYLOE67&-3J[/T.1V?#>^OB]O /K\
M\OKD>G1Y\@7=P<WQ%3R[0Q_1-<LRIK(1?3CC.8L3^2OZ!<4INE^(M63I5![V
M<S!;O;P?52:>EB;B%A,)NA)IOI!HG$[YM*']N;W]T-*^#\.U&3/\.F:GV-KA
M'5]]0L0Y0-C![M>[,_3AEU]ESG*>KI<//+N9_2;B-/_&TWR=<1FQC/\W@@N>
M-=@^LK_JMW5JO*JAE[/N!COMO8R[VV+IY?S_-W@7/\7MT-[+&8^@%]?22RV)
MR&;BD:);TM+M339G:?PW4Q4<)IQ(I4CB*2L+>CI%$_ >_"YOB!DZCU.61C%+
MT)T:+:"/7*(_OD"OZ!(NY9\6F^C&)EK81-N*01$"];8B(A)J4;Y ,Q;%29S'
M</U/^:!I#I<]>T7/BC ?CTEPV'_<3@PKI&:PMS'8LQI\%:?Q<KU$XBGEF5S$
M*[3BF4H7H%T$Q(XBF/F92*#='*H09!&7.?I0@9J2X=3^0L_YY#C_:<KZM[>K
M>>QO//;M'K-GN\?\KW6<OZ ESQ=B"CX_@L<J6>Q>VU_:[O7;V]6\'FR\'E@[
M&K<X=8#8?)[Q.>0DA%KF3:Z5/?M;64<#XC@[N=D)%9HHE^(M5,VY8.-<8'5N
MDHF(\ZE$LTPLD60)5S.P+8Y-40B,B;5C^$5@&CX(!GZSX<.-X4.KX1<@C=&'
M1$@@>2A2;18W4O[0,&C'Y+.]B',305QGB'=<-U$?\3!HB9GK:-WD=*R5NG;S
M*6B,O"R5HX1)&<]BN,<D^L:RF#U 9"]?B] &^ ]J9+Y&G>08@1[LC(D54G=U
M2R*Z5E='3"X*3HK4#Q7F1TC2EL!6?=52#5/J[9)!1UQ8X;8="MS :2$.%VNG
ML'W6 ;.JLLBB2*P5EV8\XN 8!*G1+6R8@0?4&^SF9$=<V(3S/)=Z+7YI6>$2
MJU\W^0+2,EIG6>&=E+PE3L0PP*4.IKO^=(*%33""_39OM"!Q[8KD7N2@>#IX
M8VH+2G 0X%UWNN'"!ASQW6% 6QS2@L6U"P$H]L##4";5?%)3:=52U$^KCFH9
MXI# W?6H$RQL@I&!.VSQ1\L1UT[Q98 L@?'-Q!B2@;^5Z)4?'8%A$]#SP96V
MDJ!%AFM7&1/VHK1B&9KE*A$OG*,'GO)9W.+<H,$4S\5DU[=NN+ )1_TA;HN2
M5ABN76*<1%&V!B;BSRN>RA9R,56$ZU'L&Q6A&RYLPODPAW"+,UIUN';9,:JJ
MP4IDKQ]'B4CG'X%801<_)/&\^&AJ=G+85*>PD8R=8&$3S*'#%EF%M;; =FU1
MKWH)*(?J ZS))6PR/O4HH<,=GSKBPD:<3TB+C,!:1F"[C"B9J7.HL$G\Q!T.
M=^M?-UC8!",^;DE&K&4$MLN(,E3[0F22_3 ( KH[M3KBP@JWK9T&'E3*MA!I
M\8#MXJ%%IKX<H$D6J[5M=%J4PRB&W[:5-$WPF+Z;91"L61K;6?I-BA>;U$H&
MQ@?F/E3=4LV_V,Z_;Y2QV"1/[)FV[D'5;=7\BNW\VE6:X@8:-&VT@^HF:J+$
M=J+LJC>Q26Z^N:BP#U4W4A,@MA-@=PV)FPC*L-(.JJ]N:@XC73BL?02)23,^
M-6S;AZH;IZF(V*GHS4J/--"'::P=5+=5,PRQ,TP7[49,XB -]NU!U0W<6LBV
MD\:/Z#%B?C<&IMUV4-ULS3SD+9^6>QB<-'PW-F3K'E3=4LU&Q,Y&;Q1.Q&0:
M<]+O =4MU6Q$NGP-[AM+WUQK-3EH'ZINH>8@8N>@D&=QL58><I;D"[6_!&(G
M%8^EPCA?I],#]&6"_KCB:E'.)B>(9A42O!N10S2-D+TT\F/KSF-BKJVZ@V%;
MD*CF#FKGCA]86!Y77?OU(MQFDF8,:F>,*SYEB9C'SUTR@^KB3O&[R0RJ*SJU
M5_0?&/]1U75]5;ZUM-"MK4E[N0[%\G72=@J!KJ[4>S\AT)64VBNIWEY0.WW3
MPA*E^HI-AJ)JE;OB:O_ ODE^2DTU3["Q-VL'U;W0U9;NJ;9"KN*(=PJ8KJ;T
M_513JJLIM5?3GQFP!D$^V-WHV0.J;Z?KRNO9*^\$#!0I#-5(6=PA;)ZNH)[[
M;L+FZ0+LV=7U3PR;9\IK=W>%QXZI^Z#+M6<OUV$\7Z"3J"C2*FZV@='UUGL_
M"S/>UGD/NQ36X2HV2]'K;NE;=E$]4_KN5D,KI&ZZKNB>O:+?\D>>KGFIMD;J
M7 J+\O*$S:@XYP=^O4XX< ?4V70- $"JE,O*@;Z-Y7=X"&HD+I+SM=,N,U57
M;6_P?D*OR[ZWYYA$>7Q%O3#E.9(\>P1J40M>Q1 T1MK>X\!K.=9RMJ^AWWH*
MZ%^^\>)?-"S'L;]U]A-2:%Z< Y:H6 TL3Z-M[F[.&I\4)VQW[I^ZG\=NP_US
M]_-%>9)8=U\>;+YBV3Q.)4KX#%[E?!K ?,G*L\+E12Y6Q<G3!Y%#?A<_%YQ-
M>:8 \'PF1/YZH5ZP.;%]_#]02P,$%     @ -D!C4U-P,CSR!0  DQT  !D
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M)1$5>@#<O^=<%2=Z@O5WV//_ 5!+ P04    "  V0&-32%_Q@]P#  !4%0
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M45;.;N5&T(,>3K94R%%'+U,Y[B*F /)^1ZDX;U2 >H">_0)02P,$%     @
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MW?7L[D7Q37([N.!*\3!Y7"/5J]8,T+\O.5=/+\9!=DG>_0=02P,$%     @
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M'DN'4)T/.S*/)9T0^2E)M;0^01$B)Q^*.U <I((4*$T&D&5 J$Z!-;3"V9R
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MYE6&L>9>*G/;E>N'IJ ZQ]U%ETU2]<XN2P#67HIXV]?TAQ9?W3,X+S0(U9W
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M@.=K"<6<+>P!.O]@&OX'4$L#!!0    ( #9 8U.B M,M' ,  &L)   9
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M";<ICR7&T*$3_;Z*!*SM.V1,&=7O)2*JA8BJ$U'9(L)EI,N5EJFI%0W//6,
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M/FFS_3U@9.^G?X!N?1T:[H2N8&.60,;5<S47HD 3N<AU/6&@V=K,MSBO9QG
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MI%T-LR.:5P2@GW5J= 6@R-[N:*5??3)Y:M=[XLI!:O5P6C&ZHV^).WANP";
M4:+@#-(:.XKL'3W9OU)U3IQZRZMK ARE"(Z^Y^VQ&^]T*NR4GE\,TB$[2@R<
M=SVT.7&:'BIH5E\1O:/GX1.<$'0GF;W4<_WU1L!1M.T,TN4ZBC"=KBXW\3E=
M9^]9 .5L@ SQ(B2YC"UP0AL?,W<8G8>I+U(L9/UGAM:$@[S$T%^0/U-02\&
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M>;7HY<XGJ29'+3-AE0-V!PP4(?JS+:4^NGB2G"Q80B2=--EJT  3^@?:;-"
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M5_VTJIOE\*!T@K1%J!1:5STXD9X?#&<RQ&"!-X1%$":9*\"Z@# 1,/\$ULN
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MA=H]RSSUIHB_\#A2!1&<#) )1TP-=4"\&,%Y'A>CM(UGH7--R[1^0Q/1E&M
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MX4M=[-I7 &Z+NBZV[<>-2M:J; #Z][NBJ+]_:3HXOJ=R\5]02P,$%     @
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ -D!C4T#Z1T'^ P  XQT
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M]8[I6H7X['FL\?GOI#K=[@W/Q]^7CY.=M_>.LX-_48M?4$L#!!0    ( #9
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M5W_]=Z5=XUJ5S=&?=;^PYI]02P$"% ,4    "  V0&-3!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M #9 8U/V_+['[0   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( #9 8U.97)PC$ 8  )PG   3
M  "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ -D!C4S*V
M-#<T!0  X!4  !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( #9 8U-%[AF_40<  (L<   8
M  " @78-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  V
M0&-3N7X178,#  "S"P  &               @(']%   >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ -D!C4Y*<_[Q8!P  6!\  !@
M         ("!MA@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( #9 8U.3EN08<0D  /8V   8              " @40@  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  V0&-3(!TK-M@)  #6*P
M&               @('K*0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ -D!C4_MX[M\=#0  <R(  !@              ("!^3,  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #9 8U-7VF&5FR
M +1J   8              " @4Q!  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    "  V0&-3*KZ![. (  #'%0  &               @($=
M8@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ -D!C4[;-
M_[$2"P  %B   !D              ("!,VL  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    "  V0&-3"ASKI9<,  #7*   &0
M    @(%\=@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M #9 8U/U@^U"M \  (<M   9              " @4J#  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ -D!C4VF?W :/!P  \!,  !D
M             ("!-9,  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    "  V0&-3;'A%"/,$   R"P  &0              @('[F@  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #9 8U.*\^($?@0
M ,H*   9              " @26@  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ -D!C4[S8-?83 P  X@8  !D              ("!
MVJ0  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  V0&-3
MK:;$<$4"  #;!   &0              @($DJ   >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( #9 8U.\C<G>MR8  /N!   9
M      " @:"J  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ -D!C4RE,(XIT P  (@<  !D              ("!CM$  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  V0&-3)=OG:VT%  !)#0
M&0              @($YU0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( #9 8U-V%FV"$ ,  )$&   9              " @=W:  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ -D!C4TA71EQ3
M!   .@L  !D              ("!)-X  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    "  V0&-3XFMX"5P$   ""@  &0
M@(&NX@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #9
M8U.VGJG%SP0  )$-   9              " @4'G  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ -D!C4_2,U87*"   O2T  !D
M         ("!1^P  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    "  V0&-34W R//(%  "3'0  &0              @(%(]0  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #9 8U-(7_&#W ,  %05
M   9              " @7'[  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ -D!C4TX&HD0  P  '@D  !D              ("!A/\
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  V0&-3P:V2
MN!(#  !="   &0              @(&[ @$ >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( #9 8U/:+0!.U (   $)   9
M  " @00& 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M-D!C4THWD>!U P  3 L  !D              ("!#PD! 'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    "  V0&-3JRC9%\,%   P%P  &0
M            @(&[# $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( #9 8U-OQVZ9(@P  $Y3   9              " @;42 0!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ -D!C4R$KT>:U P
M/ T  !D              ("!#A\! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    "  V0&-3H@+3+1P#  !K"0  &0              @('Z
M(@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #9 8U,5
M9%]GX 0  )$B   9              " @4TF 0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ -D!C4\Y9,_2["   HB\  !D
M     ("!9"L! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #9 8U.B G!_ 00  /,/   9              "
M@8!* 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ -D!C
M4^5] ?"2 @  $0<  !D              ("!N$X! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    "  V0&-3*WUI<U "  "K!0  &0
M        @(&!40$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( #9 8U, =$*&)@,   P3   -              "  0A4 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ -D!C4Y>*NQS     $P(   L
M ( !65<! %]R96QS+RYR96QS4$L! A0#%     @ -D!C4T#Z1T'^ P  XQT
M  \              ( !0E@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M #9 8U-''&"YI $  )L:   :              "  6U< 0!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #9 8U,NTOC K@$  ,H:   3
M              "  4E> 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     T
- #0 (PX  "A@ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>264</ContextCount>
  <ElementCount>377</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2113103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19"</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC "COVID-19"</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - ACQUISITIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONS</Role>
      <ShortName>ACQUISITIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - LONG-TERM OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONS</Role>
      <ShortName>LONG-TERM OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2126106 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128107 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE</Role>
      <ShortName>SHARE REPURCHASE SHARE REPURCHASE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENT</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2306302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - ACQUISITIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSTables</Role>
      <ShortName>ACQUISITIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/ACQUISITIONS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2321305 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables</Role>
      <ShortName>LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails</Role>
      <ShortName>NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details</Role>
      <ShortName>NOVEL CORONAVIRUS PANDEMIC "COVID-19" (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - ACQUISITIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails</Role>
      <ShortName>ACQUISITIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails</Role>
      <ShortName>LONG-TERM OBLIGATIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2431417 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails</Role>
      <ShortName>CAPITAL STOCK AND SHARE-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - SHARE REPURCHASE Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails</Role>
      <ShortName>SHARE REPURCHASE Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="amed-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="amed-20210930.htm">amed-20210930.htm</File>
    <File>amed-20210930.xsd</File>
    <File>amed-20210930_cal.xml</File>
    <File>amed-20210930_def.xml</File>
    <File>amed-20210930_lab.xml</File>
    <File>amed-20210930_pre.xml</File>
    <File>amed-20213009xex32.htm</File>
    <File>amed-20213009xexx311.htm</File>
    <File>amed-20213009xexx312.htm</File>
    <File>amed-20213009xexx321.htm</File>
    <File>amed-20213009xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>amed-20210930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "amed-20210930.htm": {
   "axisCustom": 3,
   "axisStandard": 22,
   "contextCount": 264,
   "dts": {
    "calculationLink": {
     "local": [
      "amed-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "amed-20210930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "amed-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "amed-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amed-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "amed-20210930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 600,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 10,
    "http://xbrl.sec.gov/dei/2020-01-31": 6,
    "total": 16
   },
   "keyCustom": 90,
   "keyStandard": 287,
   "memberCustom": 46,
   "memberStandard": 30,
   "nsprefix": "amed",
   "nsuri": "http://www.amedisys.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.amedisys.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - ACQUISITIONS",
     "role": "http://www.amedisys.com/role/ACQUISITIONS",
     "shortName": "ACQUISITIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - LONG-TERM OBLIGATIONS",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONS",
     "shortName": "LONG-TERM OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126106 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128107 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - SHARE REPURCHASE SHARE REPURCHASE",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE",
     "shortName": "SHARE REPURCHASE SHARE REPURCHASE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - SUBSEQUENT EVENT",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENT",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EquityMethodInvestmentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EquityMethodInvestmentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Tables)",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfCaresActProviderReliefFundsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsContessaTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - ACQUISITIONS (Tables)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSTables",
     "shortName": "ACQUISITIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:ScheduleOfBusinessAcquisitionsContessaTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321305 - Disclosure - LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables",
     "shortName": "LONG-TERM OBLIGATIONS LONG-TERM OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EquityMethodInvestmentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i84de3e983eb740b1bb3c8f25d7622369_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentAggregateCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:NetServiceRevenuePeriodOfCarePaymentRateDuration",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "amed:PercentageOfTotalReimbursementOfOutlierPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i4041053d2da749d8975f3208c6832b54_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue by Payor Class (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i4041053d2da749d8975f3208c6832b54_D20210701-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:Revenuebypayorclassasapercentageoftotalnetservicerevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:CashBalanceAssociatedWithProviderReliefFund",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:AccountsReceivablePortionDerivedFromMedicare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Accounts Receivable Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "amed:AccountsReceivablePortionDerivedFromMedicare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "amed:FinancialInstrumentDetailsTableTextBlock",
       "us-gaap:FairValueOfFinancialInstrumentsPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "amed:DebtInstrumentCarryingAmountExcludingFinanceLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i4041053d2da749d8975f3208c6832b54_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Weighted-Average Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i4041053d2da749d8975f3208c6832b54_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i79965b0e5aa8415ab632c4462ea0fe64_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Details)",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i79965b0e5aa8415ab632c4462ea0fe64_I20200327",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "amed:FundingForHealthcareProvidersIncludingHospitals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i4041053d2da749d8975f3208c6832b54_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - ACQUISITIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
     "shortName": "ACQUISITIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i7503aa98535244ecb469dabeaf84b37d_D20200601-20200601",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "id2212b3038014b39b18d85e2bb708130_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Schedule of Long-Term Debt Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "id2629c6a87704cab9b7d7cc4fcb7d9d7_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Fees and Rates Under Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "id2629c6a87704cab9b7d7cc4fcb7d9d7_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityCommitmentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "amed:TotalLeverageRatio",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - LONG-TERM OBLIGATIONS - Narrative (Details)",
     "role": "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
     "shortName": "LONG-TERM OBLIGATIONS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i257940b085494340a54f2596ffb71f9c_D20210701-20210930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtWeightedAverageInterestRateOverTime",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ibf6f0e31c86e4f05adc0d00f2f4885e8_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "amed:HealthInsuranceRetentionLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segments",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i4041053d2da749d8975f3208c6832b54_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i4041053d2da749d8975f3208c6832b54_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i4041053d2da749d8975f3208c6832b54_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431417 - Disclosure - SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "role": "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
     "shortName": "SEGMENT INFORMATION - Operating Income of Reportable Segments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i4041053d2da749d8975f3208c6832b54_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - CAPITAL STOCK AND SHARE-BASED COMPENSATION (Details)",
     "role": "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails",
     "shortName": "CAPITAL STOCK AND SHARE-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i01d5e8892fb243b4b865bd7b871d16be_D20200810-20200810",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - SHARE REPURCHASE Narrative (Details)",
     "role": "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
     "shortName": "SHARE REPURCHASE Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i3f23866255254c1e86623c880ffabe48_I20201223",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i12c67fa7efe64016ba829366460e9a3f_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - RELATED PARTY TRANSACTIONS Narrative (Details)",
     "role": "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "shortName": "RELATED PARTY TRANSACTIONS Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i12c67fa7efe64016ba829366460e9a3f_D20210701-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "icb4c638a3b064fa5b06f2b26f52f4a80_D20210501-20210501",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - SUBSEQUENT EVENT - Narrative (Details)",
     "role": "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
     "shortName": "SUBSEQUENT EVENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i6c26203c52124e6db31cba165f90a5ba_D20211018-20211018",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ic8a2e6cc1034448789c21e45ddc2a62a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "ic8a2e6cc1034448789c21e45ddc2a62a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "role": "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS",
     "shortName": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113103 - Disclosure - NOVEL CORONAVIRUS PANDEMIC \"COVID-19\"",
     "role": "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19",
     "shortName": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\"",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "amed-20210930.htm",
      "contextRef": "i46ac4ce128604091a4bb7a9e32ade24c_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "amed:COVID19TextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "amed_A2019ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Share Repurchase Program",
        "label": "2019 Share Repurchase Program [Member]",
        "terseLabel": "2019 Share Repurchase Program"
       }
      }
     },
     "localname": "A2019ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_A2021ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Share Repurchase Program",
        "label": "2021 Share Repurchase Program [Member]",
        "terseLabel": "2021 Share Repurchase Program"
       }
      }
     },
     "localname": "A2021ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AccountsReceivablePortionDerivedFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Portion Derived From Medicare",
        "label": "Accounts Receivable, Portion Derived From Medicare",
        "terseLabel": "Accounts receivable derived from Medicare"
       }
      }
     },
     "localname": "AccountsReceivablePortionDerivedFromMedicare",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_AcquiredNamesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Names",
        "label": "Acquired Names [Member]",
        "terseLabel": "Acquired Names [Member]"
       }
      }
     },
     "localname": "AcquiredNamesMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ActualClaimsPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Actual Claims Payment",
        "label": "Actual Claims Payment",
        "terseLabel": "Actual claims payment"
       }
      }
     },
     "localname": "ActualClaimsPayment",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AdditionalFundingDistributedToHealthcareProviders": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional funding distributed to healthcare providers provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Additional Funding Distributed to Healthcare Providers",
        "terseLabel": "Additional Funding Distributed to Healthcare Providers"
       }
      }
     },
     "localname": "AdditionalFundingDistributedToHealthcareProviders",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AmedisysCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amedisys CIA [Member]",
        "label": "Amedisys CIA [Member]",
        "terseLabel": "Amedisys CIA"
       }
      }
     },
     "localname": "AmedisysCIAMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement [Member]"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Four",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Four [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 0.75 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheFourMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche One",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche One [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Greater Than 3.00 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheOneMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Three",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Three [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 2.00 to 1.0 but Greater Than 0.75 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheThreeMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmendedDebtInstrumentByLeverageRatioTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Debt Instrument, By Leverage Ratio, Tranche Two",
        "label": "Amended Debt Instrument, By Leverage Ratio, Tranche Two [Member]",
        "terseLabel": "Consolidated Leverage Ratio: Less Than Equal To 3.00 to 1.0 but Greater Than 2.00 to 1.0"
       }
      }
     },
     "localname": "AmendedDebtInstrumentByLeverageRatioTrancheTwoMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AmortizationandImpairmentofOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "label": "Amortization and Impairment of Operating Lease Right Of Use Asset",
        "terseLabel": "Amortization and impairment of operating lease right of use assets"
       }
      }
     },
     "localname": "AmortizationandImpairmentofOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_AsanaHospiceAquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice Aquisition",
        "label": "Asana Hospice Aquisition [Member]",
        "terseLabel": "Asana Hospice Aquisition [Member]"
       }
      }
     },
     "localname": "AsanaHospiceAquisitionMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AsanaHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asana Hospice",
        "label": "Asana Hospice [Member]",
        "terseLabel": "Asana Hospice [Member]"
       }
      }
     },
     "localname": "AsanaHospiceMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_AseraCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AseraCare Hospice",
        "label": "AseraCare Hospice [Member]",
        "terseLabel": "AseraCare Hospice [Member]"
       }
      }
     },
     "localname": "AseraCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_BusinessAcquisitionClosingPaymentAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Closing Payment Adjustment",
        "label": "Business Acquisition Closing Payment Adjustment",
        "terseLabel": "Business Acquisition Closing Payment Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionClosingPaymentAdjustment",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessAcquisitionWorkingCapitalAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Working Capital Adjustment",
        "label": "Business Acquisition Working Capital Adjustment",
        "terseLabel": "Business Acquisition Working Capital Adjustment"
       }
      }
     },
     "localname": "BusinessAcquisitionWorkingCapitalAdjustment",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity assumed at the acquisition date",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquity",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total liabilities and equity assumed at acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities and Equity"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAndEquity",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset",
        "terseLabel": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Current Asset"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAsset",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentAssetsPrepaidExpense",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Payroll and Employee Benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesPayrollandEmployeeBenefits",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating lease right of use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOperatingleaserightofuseassets",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Businessacquisitionproformaoperatingincomeloss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma operating income (loss) for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business acquisition pro forma operating income loss",
        "terseLabel": "Operating income"
       }
      }
     },
     "localname": "Businessacquisitionproformaoperatingincomeloss",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActDeferralOfEmployerShareSocialSecurityTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The deferral of the employer's share social security tax provided by the CARES Act",
        "label": "CARES Act Deferral of Employer Share Social Security Tax",
        "terseLabel": "CARES Act Deferral of Employer Share Social Security Tax"
       }
      }
     },
     "localname": "CARESActDeferralOfEmployerShareSocialSecurityTax",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActInterestToBeRepaidToGovernment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Interest To Be Repaid to Government",
        "label": "CARES Act Interest To Be Repaid to Government",
        "terseLabel": "CARES Act Interest To Be Repaid to Government"
       }
      }
     },
     "localname": "CARESActInterestToBeRepaidToGovernment",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Utilized",
        "label": "CARES Act Provider Relief Funds Utilized",
        "terseLabel": "CARES Act Provider Relief Funds Utilized"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsUtilized",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures",
        "label": "CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures",
        "terseLabel": "CARES Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures"
       }
      }
     },
     "localname": "CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19DeferralOfSocialSecurityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Deferral of Social Security",
        "label": "COVID-19 Deferral of Social Security [Member]",
        "terseLabel": "COVID-19 Deferral of Social Security"
       }
      }
     },
     "localname": "COVID19DeferralOfSocialSecurityMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_COVID19ExpensesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses incurred as a result of the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "COVID-19 Expenses Incurred",
        "terseLabel": "COVID-19 Expenses Incurred"
       }
      }
     },
     "localname": "COVID19ExpensesIncurred",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_COVID19PPEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 PPE",
        "label": "COVID-19 PPE [Member]",
        "terseLabel": "COVID-19 PPE [Member]"
       }
      }
     },
     "localname": "COVID19PPEMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_COVID19TextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "COVID-19 [Text Block]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19TextBlock",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_CapYearAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Axis]",
        "label": "Cap Year [Axis]",
        "terseLabel": "Cap Year [Axis]"
       }
      }
     },
     "localname": "CapYearAxis",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_CapYearDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year [Domain]",
        "label": "Cap Year [Domain]",
        "terseLabel": "Cap Year [Domain]"
       }
      }
     },
     "localname": "CapYearDomain",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Fourteen Through Two Thousand Twenty One[Member]",
        "label": "Cap Year Two Thousand Fourteen Through Two Thousand Twenty One [Member]",
        "terseLabel": "Cap Year 2014 Through 2021"
       }
      }
     },
     "localname": "CapYearTwoThousandFourteenThroughTwoThousandTwentyOneMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty One",
        "label": "Cap Year Two Thousand Sixteen Through Two Thousand Twenty One [Member]",
        "terseLabel": "Cap Year 2016 Through 2021"
       }
      }
     },
     "localname": "CapYearTwoThousandSixteenThroughTwoThousandTwentyOneMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CashBalanceAssociatedWithProviderReliefFund": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Balance Associated with the CARES Act Provider Relief Fund",
        "label": "Cash Balance Associated with Provider Relief Fund",
        "terseLabel": "Cash Balance Associated with Provider Relief Fund"
       }
      }
     },
     "localname": "CashBalanceAssociatedWithProviderReliefFund",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashDistributionToNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of dividends or other distributions to noncontrolling interest holders.",
        "label": "Cash Distribution To Noncontrolling Interest",
        "negatedLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "CashDistributionToNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForFinanceLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for finance lease liabilities",
        "label": "Cash paid for finance lease liabilities",
        "terseLabel": "Cash paid for finance lease liabilities"
       }
      }
     },
     "localname": "CashPaidForFinanceLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CashPaidForOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for operating lease liabilities",
        "label": "Cash paid for operating lease liabilities",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "CashPaidForOperatingLeaseLiabilities",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_CertificateOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificate of Need",
        "label": "Certificate of Need [Member]",
        "terseLabel": "Certificate of Need [Member]"
       }
      }
     },
     "localname": "CertificateOfNeedMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CertificatesOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates Of Need",
        "label": "Certificates Of Need [Member]",
        "terseLabel": "Certificates Of Need"
       }
      }
     },
     "localname": "CertificatesOfNeedMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ClearwaterFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clearwater, Florida [Member]",
        "label": "Clearwater, Florida [Member]",
        "terseLabel": "Clearwater, Florida"
       }
      }
     },
     "localname": "ClearwaterFloridaMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompanysinsurancecarriersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company's insurance carriers [Member]",
        "label": "Company's insurance carriers [Member]",
        "terseLabel": "Company's insurance carriers [Member]"
       }
      }
     },
     "localname": "CompanysinsurancecarriersMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceCIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice CIA [Member]",
        "label": "Compassionate Care Hospice CIA [Member]",
        "terseLabel": "Compassionate Care Hospice CIA"
       }
      }
     },
     "localname": "CompassionateCareHospiceCIAMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CompassionateCareHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compassionate Care Hospice [Member]",
        "label": "Compassionate Care Hospice [Member]",
        "terseLabel": "Compassionate Care Hospice [Member]"
       }
      }
     },
     "localname": "CompassionateCareHospiceMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ConsolidatedInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of adjusted earnings before interest, taxes, depreciation and amortization to cash interest charges",
        "label": "Consolidated Interest Coverage Ratio",
        "terseLabel": "Consolidated interest coverage ratio"
       }
      }
     },
     "localname": "ConsolidatedInterestCoverageRatio",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ConsolidatedLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Leverage Ratio",
        "label": "Consolidated Leverage Ratio",
        "terseLabel": "Consolidated Leverage Ratio"
       }
      }
     },
     "localname": "ConsolidatedLeverageRatio",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_ContessaHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contessa Health",
        "label": "Contessa Health [Member]",
        "terseLabel": "Contessa Health"
       }
      }
     },
     "localname": "ContessaHealthMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_CorporateIntegrityAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Integrity Agreement Term",
        "label": "Corporate Integrity Agreement Term",
        "terseLabel": "Corporate integrity agreement term (years)"
       }
      }
     },
     "localname": "CorporateIntegrityAgreementTerm",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility, Maximum Allowable Consolidated Leverage Ratio Multiple",
        "label": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple",
        "terseLabel": "Credit Facility Maximum Allowable Consolidated Leverage Ratio Multiple"
       }
      }
     },
     "localname": "CreditFacilityMaximumAllowableConsolidatedLeverageRatioMultiple",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_Creditfacilitymaximumallowableconsolidatedleverageratio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit facility maximum allowable consolidated leverage ratio as defined in the Company's Credit Agreement",
        "label": "Credit facility maximum allowable consolidated leverage ratio",
        "terseLabel": "Credit facility, maximum allowable consolidated leverage ratio"
       }
      }
     },
     "localname": "Creditfacilitymaximumallowableconsolidatedleverageratio",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_DebtInstrumentCarryingAmountExcludingFinanceLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "label": "Debt Instrument Carrying Amount Excluding Finance Leases",
        "terseLabel": "Debt Instrument Carrying Amount Excluding Finance Leases"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmountExcludingFinanceLeases",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveEurodollarRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "label": "Debt Instrument Interest Additional Interest Above Eurodollar Rate",
        "terseLabel": "Additional interest rate above Eurodollar rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveEurodollarRate",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestAdditionalInterestAboveFederalFundRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "label": "Debt Instrument Interest Additional Interest Above Federal Fund Rate",
        "terseLabel": "Additional interest rate above Federal Fund rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestAdditionalInterestAboveFederalFundRate",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentInterestRateatPeriodEnd": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Interest Rate at Period End",
        "label": "Debt Instrument Interest Rate at Period End",
        "terseLabel": "Debt Instrument Interest Rate at Period End"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateatPeriodEnd",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DebtInstrumentPeriodicPaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of the Term Loan that is required as periodic payments including both interest and principal payments",
        "label": "Debt Instrument Periodic Payment Percentage",
        "terseLabel": "Debt Instrument Periodic Payment Percentage"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPercentage",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_DepreciationAndAmortizationForContinuingOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation And Amortization For Continuing Operations",
        "label": "Depreciation And Amortization For Continuing Operations",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortizationForContinuingOperations",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Discountedclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discounted closing stock price",
        "label": "Discounted closing stock price",
        "terseLabel": "Discounted closing stock price"
       }
      }
     },
     "localname": "Discountedclosingstockprice",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "amed_EpisodeOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health episode of care.",
        "label": "Episode Of Care As Episodic Based Revenue Duration",
        "terseLabel": "Episode of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "EpisodeOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_EquityImpactOfWriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact of Write Off of Other Comprehensive Income",
        "label": "Equity Impact of Write Off of Other Comprehensive Income",
        "negatedLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "EquityImpactOfWriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EquityImpactofRepurchaseofNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Impact of Repurchase of Noncontrolling Interest",
        "label": "Equity Impact of Repurchase of Noncontrolling Interest",
        "negatedLabel": "Repurchase of noncontrolling interest"
       }
      }
     },
     "localname": "EquityImpactofRepurchaseofNoncontrollingInterest",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ErrorRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Error Rate Percentage",
        "label": "Error Rate Percentage",
        "terseLabel": "Error rate (percent)"
       }
      }
     },
     "localname": "ErrorRatePercentage",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of obligations due Medicare upon demand due to overages for the inpatient cap and/or overall payment cap.",
        "label": "Estimated Amount Due Back To Medicare In Other Accrued Liabilities",
        "terseLabel": "Estimated amounts due back to Medicare"
       }
      }
     },
     "localname": "EstimatedAmountDueBackToMedicareInOtherAccruedLiabilities",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid",
        "label": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid",
        "terseLabel": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundAmountsToBeRepaid",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid By Unconsolidated Joint Ventures",
        "label": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid By Unconsolidated Joint Ventures",
        "terseLabel": "Estimated CARES Act Provider Relief Fund Amounts to be Repaid By Unconsolidated Joint Ventures"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundAmountsToBeRepaidByUnconsolidatedJointVentures",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedCARESActProviderReliefFundsExpectedToBeUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated CARES Act Provider Relief Funds Expected to be Utilized",
        "label": "Estimated CARES Act Provider Relief Funds Expected to be Utilized",
        "terseLabel": "Estimated CARES Act Provider Relief Funds Expected to be Utilized"
       }
      }
     },
     "localname": "EstimatedCARESActProviderReliefFundsExpectedToBeUtilized",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_EstimatedFutureCOVID19RelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated expenses as a result of the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "Estimated Future COVID-19 related expenses",
        "terseLabel": "Estimated Future COVID-19 related expenses"
       }
      }
     },
     "localname": "EstimatedFutureCOVID19RelatedExpenses",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ExecutiveStockOptionExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Stock Option Exercise",
        "label": "Executive Stock Option Exercise [Member]",
        "terseLabel": "Executive Stock Option Exercise [Member]"
       }
      }
     },
     "localname": "ExecutiveStockOptionExerciseMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ExistingShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Existing Share Repurchase Program",
        "label": "Existing Share Repurchase Program [Member]",
        "terseLabel": "Existing Share Repurchase Program"
       }
      }
     },
     "localname": "ExistingShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The impact on revenue due to the extension of the temporary suspension of sequestration as a result of the novel coronavrius pandemic (\"COVID-19\").",
        "label": "Extension of Temporary Suspension of Sequestration, Revenue Impact",
        "terseLabel": "Extension of Temporary Suspension of Sequestration, Revenue Impact"
       }
      }
     },
     "localname": "ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ExtrapolatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extrapolated [Member]",
        "label": "Extrapolated [Member]",
        "terseLabel": "Extrapolated [Member]"
       }
      }
     },
     "localname": "ExtrapolatedMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FinancialInstrumentDetailsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument details, table.",
        "label": "Financial Instrument Details [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentDetailsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_FirstThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the first threshold of therapy services required.",
        "label": "First Threshold Of Therapy Services Required",
        "terseLabel": "First threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "FirstThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_FiveHundredFiftyMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "label": "Five Hundred Fifty Million Revolving Credit Facility [Member]",
        "terseLabel": "Five Hundred Fifty Million Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "FiveHundredFiftyMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FloridaZpicRevenueReduction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in revenue as a result of the Florida ZPIC audit",
        "label": "Florida Zpic Revenue Reduction",
        "terseLabel": "Florida ZPIC revenue reduction"
       }
      }
     },
     "localname": "FloridaZpicRevenueReduction",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FourHundredFiftyMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four Hundred Fifty Million Term Loan Facility",
        "label": "Four Hundred Fifty Million Term Loan Facility [Member]",
        "terseLabel": "Four Hundred Fifty Million Term Loan Facility"
       }
      }
     },
     "localname": "FourHundredFiftyMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_FundingForHealthcareProvidersIncludingHospitals": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding for healthcare providers, including hospitals provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding for Healthcare Providers, Including Hospitals",
        "terseLabel": "Funding for Healthcare Providers, Including Hospitals"
       }
      }
     },
     "localname": "FundingForHealthcareProvidersIncludingHospitals",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding immediately distributed to healthcare providers based on their 2019 Medicare Fee-For-Service reimbursements provided by the Coronavirus Aid, Relief and Economic Security (CARES) Act",
        "label": "Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements",
        "terseLabel": "Funding Immediately Distributed to Healthcare Providers Based on Their 2019 Medicare Fee-For-Service Reimbursements"
       }
      }
     },
     "localname": "FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromCARESAct": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding received by the Company from the Coronavirus Aid Relief and Economic Security (CARES) Act",
        "label": "Funding Received From CARES Act",
        "terseLabel": "Funding Received From CARES Act"
       }
      }
     },
     "localname": "FundingReceivedFromCARESAct",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program",
        "label": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program",
        "terseLabel": "Funding Received From Mass Home Care ASAP COVID-19 Provider Sustainability Program"
       }
      }
     },
     "localname": "FundingReceivedFromMassHomeCareASAPCOVID19ProviderSustainabilityProgram",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_FundsReceivedFromProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from funds received by the government related to the Novel Coronavirus Pandemic \"COVID-19\"",
        "label": "Funds received from Provider relief fund advance",
        "terseLabel": "Provider relief fund advance"
       }
      }
     },
     "localname": "FundsReceivedFromProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_GoodwillDeductibleForIncomeTaxPurposesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time that goodwill is deductible for income tax purposes",
        "label": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
        "terseLabel": "GoodwillDeductibleForIncomeTaxPurposesPeriod"
       }
      }
     },
     "localname": "GoodwillDeductibleForIncomeTaxPurposesPeriod",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_GovernmentGrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy disclosure text block for government grants",
        "label": "Government Grants [Policy Text Block]",
        "terseLabel": "Government Grants"
       }
      }
     },
     "localname": "GovernmentGrantsPolicyTextBlock",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_HealthInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Health Insurance Claim.",
        "label": "Health Insurance Retention Limit",
        "terseLabel": "Health insurance retention limit"
       }
      }
     },
     "localname": "HealthInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_HeritageHealthcareInnovationFundLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heritage Healthcare Innovation Fund, LP",
        "label": "Heritage Healthcare Innovation Fund, LP [Member]",
        "terseLabel": "Heritage Healthcare Innovation Fund, LP [Member]"
       }
      }
     },
     "localname": "HeritageHealthcareInnovationFundLPMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HighAcuityCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "High Acuity Care",
        "label": "High Acuity Care [Member]",
        "terseLabel": "High Acuity Care"
       }
      }
     },
     "localname": "HighAcuityCareMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HistoricalCollectionRateFromMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Historical collection rate from Medicare.",
        "label": "Historical Collection Rate From Medicare",
        "terseLabel": "Historical collection rate from Medicare"
       }
      }
     },
     "localname": "HistoricalCollectionRateFromMedicare",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HomeHealthAndHospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health and Hospice",
        "label": "Home Health and Hospice [Member]",
        "terseLabel": "Home Health and Hospice [Member]"
       }
      }
     },
     "localname": "HomeHealthAndHospiceMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Medicare [Member]",
        "label": "Home Health Medicare [Member]",
        "terseLabel": "Home Health Medicare [Member]"
       }
      }
     },
     "localname": "HomeHealthMedicareMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health [Member]",
        "label": "Home Health [Member]",
        "terseLabel": "Home Health [Member]"
       }
      }
     },
     "localname": "HomeHealthMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HomeHealthNonMedicareNonEpisodicBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "label": "Home Health Non-Medicare - Non-Episodic Based [Member]",
        "terseLabel": "Home Health Non-Medicare - Non-Episodic Based [Member]"
       }
      }
     },
     "localname": "HomeHealthNonMedicareNonEpisodicBasedMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Medicare [Member]",
        "label": "Hospice Medicare [Member]",
        "terseLabel": "Hospice Medicare [Member]"
       }
      }
     },
     "localname": "HospiceMedicareMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceMedicareRevenueRateAccountedForRoutineCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of the entity's Hospice net Medicare service revenue that is derived from routine care.",
        "label": "Hospice Medicare Revenue Rate Accounted For Routine Care",
        "terseLabel": "Hospice Medicare revenue rate accounted for routine care"
       }
      }
     },
     "localname": "HospiceMedicareRevenueRateAccountedForRoutineCare",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_HospiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice [Member]",
        "label": "Hospice [Member]",
        "terseLabel": "Hospice [Member]"
       }
      }
     },
     "localname": "HospiceMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_HospiceNonMedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hospice Non-Medicare [Member]",
        "label": "Hospice Non-Medicare [Member]",
        "terseLabel": "Hospice Non-Medicare [Member]"
       }
      }
     },
     "localname": "HospiceNonMedicareMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating lease liabilities",
        "label": "Increase (Decrease) In Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) In Operating Lease Right Of Use Asset",
        "label": "Increase (Decrease) In Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IncreaseInEstimatedFutureCOVID19RelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in Estimated Future COVID-19 Related Expenses",
        "label": "Increase in Estimated Future COVID-19 Related Expenses",
        "terseLabel": "Increase in Estimated Future COVID-19 Related Expenses"
       }
      }
     },
     "localname": "IncreaseInEstimatedFutureCOVID19RelatedExpenses",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_IndemnificationAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount to be reimbursed if and when certain assumed liabilities are paid",
        "label": "Indemnification Amount",
        "terseLabel": "Indemnification amount"
       }
      }
     },
     "localname": "IndemnificationAmount",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_InfinityHomeCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infinity HomeCare [Member]",
        "label": "Infinity HomeCare [Member]",
        "terseLabel": "Infinity HomeCare"
       }
      }
     },
     "localname": "InfinityHomeCareMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_InternalAuditComplianceReviewMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal Audit Compliance Review [Member]",
        "label": "Internal Audit Compliance Review [Member]",
        "terseLabel": "Internal Audit Compliance Review [Member]"
       }
      }
     },
     "localname": "InternalAuditComplianceReviewMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LakelandFloridaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lakeland, Florida [Member]",
        "label": "Lakeland, Florida [Member]",
        "terseLabel": "Lakeland, Florida"
       }
      }
     },
     "localname": "LakelandFloridaMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "label": "Lessee, Operating lease, Reductions to ROU assets resulting from reductions to lease obligations",
        "terseLabel": "Reductions to right of use assets resulting from reductions to operating lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LetterOfCreditFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the letters of credit, for the letters of credit",
        "label": "Letter Of Credit Fee",
        "terseLabel": "Letter Of Credit Fee"
       }
      }
     },
     "localname": "LetterOfCreditFee",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Additional Borrowing Capacity",
        "label": "Line Of Credit Facility Additional Borrowing Capacity",
        "terseLabel": "Credit facility, maximum additional borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "label": "Loss Contingency, Receivable, Noncurrent, Related To Amounts Withheld Prior To August 2009",
        "terseLabel": "Indemnity receivable related to amounts withheld prior to August 2009"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrentRelatedToAmountsWithheldPriorToAugust2009",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_LowUtilizationPaymentAdjustmentNumberOfVisits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the visit threshold for a low utilization payment adjustment.",
        "label": "Low Utilization Payment Adjustment Number Of Visits",
        "terseLabel": "Low utilization payment adjustment, maximum number of visits"
       }
      }
     },
     "localname": "LowUtilizationPaymentAdjustmentNumberOfVisits",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MajorSinglePayorCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major Single Payor Customer [Member]",
        "label": "Major Single Payor Customer [Member]",
        "terseLabel": "Single Payor"
       }
      }
     },
     "localname": "MajorSinglePayorCustomerMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Date Request For Anticipated Payment Was Paid",
        "terseLabel": "Maximum days to submit final bill from the date the request for anticipated payment was paid"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromDateRequestForAnticipatedPaymentWasPaid",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the start of the period of care in which the final bill must be submitted to Medicare.",
        "label": "Maximum Days To Submit Final Bill From Start Of Period of Care",
        "terseLabel": "Maximum days to submit final bill from the start of episode"
       }
      }
     },
     "localname": "MaximumDaysToSubmitFinalBillFromStartOfPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_MaximumPercentOwnershipForCostMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the cost method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Cost Method Percent",
        "terseLabel": "Maximum ownership percentage for cost method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForCostMethodPercent",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MaximumPercentOwnershipForEquityMethodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for an investment to be treated under the equity method of accounting in the entity's financial statements.",
        "label": "Maximum Percent Ownership For Equity Method Percent",
        "terseLabel": "Maximum ownership percentage for equity method investment (percent)"
       }
      }
     },
     "localname": "MaximumPercentOwnershipForEquityMethodPercent",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MedalogixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medalogix [Member]",
        "label": "Medalogix [Member]",
        "terseLabel": "Medalogix [Member]"
       }
      }
     },
     "localname": "MedalogixMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare license",
        "label": "Medicare license [Member]",
        "terseLabel": "Medicare licenses [Member]"
       }
      }
     },
     "localname": "MedicareLicenseMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MedicareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Revenue [Member]",
        "label": "Medicare Revenue [Member]",
        "terseLabel": "Medicare Revenue [Member]"
       }
      }
     },
     "localname": "MedicareRevenueMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_MinimumPercentOwnershipForControllingInterestPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage ownership required in order for a variable interest entity (VIE) to be consolidated in the entity's financial statements.",
        "label": "Minimum Percent Ownership For Controlling Interest Percent",
        "terseLabel": "Minimum ownership percentage for controlling interest (percent)"
       }
      }
     },
     "localname": "MinimumPercentOwnershipForControllingInterestPercent",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_MorgantownWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Morgantown, West Virginia [Member]",
        "label": "Morgantown, West Virginia [Member]",
        "terseLabel": "Morgantown, West Virginia"
       }
      }
     },
     "localname": "MorgantownWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NetServiceRevenueEpisodePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Episode Payment Rate Duration",
        "terseLabel": "Net service revenue episode payment rate"
       }
      }
     },
     "localname": "NetServiceRevenueEpisodePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NetServiceRevenuePeriodOfCarePaymentRateDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days from the date the request for anticipated payment was received in which the final bill must be submitted to Medicare.",
        "label": "Net Service Revenue, Period of Care Payment Rate Duration",
        "terseLabel": "Net service revenue period of care payment rate (days)"
       }
      }
     },
     "localname": "NetServiceRevenuePeriodOfCarePaymentRateDuration",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_NewShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Share Repurchase Program",
        "label": "New Share Repurchase Program [Member]",
        "terseLabel": "New Share Repurchase Program"
       }
      }
     },
     "localname": "NewShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_NonMedicareRevenueTermRates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Medicare Revenue Term Rates as a percentage of Medicare Term Rates",
        "label": "Non-Medicare Revenue Term Rates",
        "terseLabel": "Non-Medicare revenue term rates"
       }
      }
     },
     "localname": "NonMedicareRevenueTermRates",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_NonVestedStockAndStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non vested stock and stock units.",
        "label": "Non Vested Stock And Stock Units",
        "terseLabel": "Non-vested stock and stock units (shares)"
       }
      }
     },
     "localname": "NonVestedStockAndStockUnits",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_NumberOfBeneficiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of beneficiaries who received services",
        "label": "Number of beneficiaries",
        "terseLabel": "Number of beneficiaries"
       }
      }
     },
     "localname": "NumberOfBeneficiaries",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfClaimsSubmittedBySubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims submitted by subsidiary.",
        "label": "Number Of Claims Submitted By Subsidiary",
        "terseLabel": "Number of claims submitted by subsidiary"
       }
      }
     },
     "localname": "NumberOfClaimsSubmittedBySubsidiary",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Consolidated Entities Classified as Variable Interest Entities",
        "label": "Number of Consolidated Entities Classified as Variable Interest Entities",
        "terseLabel": "Number of Consolidated Entities Classified as Variable Interest Entities"
       }
      }
     },
     "localname": "NumberOfConsolidatedEntitiesClassifiedAsVariableInterestEntities",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_NumberOfJointVentures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of joint ventures owned by the entity as of the balance sheet date.",
        "label": "Number of Joint Ventures",
        "terseLabel": "Number of Joint Ventures"
       }
      }
     },
     "localname": "NumberOfJointVentures",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_Numberofpatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients",
        "label": "Number of patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "Numberofpatients",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_OneHundredMillionTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "100 Million Term Loan [Member]",
        "label": "One Hundred Million Term Loan [Member]",
        "terseLabel": "100 Million Term Loan"
       }
      }
     },
     "localname": "OneHundredMillionTermLoanMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OneHundredSeventyFiveMillionTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "label": "One Hundred Seventy Five Million Term Loan Facility [Member]",
        "terseLabel": "One Hundred Seventy Five Million Term Loan Facility [Member]"
       }
      }
     },
     "localname": "OneHundredSeventyFiveMillionTermLoanFacilityMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_OperatingCareCenters": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of care centers owned by the entity as of the balance sheet date.",
        "label": "Operating Care Centers",
        "terseLabel": "Number of owned and operated care centers"
       }
      }
     },
     "localname": "OperatingCareCenters",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_ParkersburgWestVirginiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Parkersburg, West Virginia [Member]",
        "label": "Parkersburg, West Virginia [Member]",
        "terseLabel": "Parkersburg, West Virginia"
       }
      }
     },
     "localname": "ParkersburgWestVirginiaMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PaymentsRelatedToTaxAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments related to tax asset",
        "label": "Payments related to tax asset",
        "terseLabel": "Payments related to tax asset"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxAsset",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PayorClassAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor Class [Axis]",
        "label": "Payor Class [Axis]",
        "terseLabel": "Payor Class [Axis]"
       }
      }
     },
     "localname": "PayorClassAxis",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorClassDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payor Class [Axis]",
        "label": "Payor Class [Domain]",
        "terseLabel": "Payor Class [Domain]"
       }
      }
     },
     "localname": "PayorClassDomain",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PayorsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payors [Axis]",
        "label": "Payors [Axis]",
        "terseLabel": "Payors [Axis]"
       }
      }
     },
     "localname": "PayorsAxis",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_PayorsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Payors [Axis]",
        "label": "Payors [Domain]",
        "terseLabel": "Payors [Domain]"
       }
      }
     },
     "localname": "PayorsDomain",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of adjusted EBITDA that guarantor subsidiaries represent",
        "label": "Percentage Of Earnings Before Interest Taxes Depreciation And Amortization From Subsidiaries",
        "terseLabel": "Percentage of adjusted EBITDA that guarantor subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromSubsidiaries",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfPatientReceivablesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of patient receivables outstanding.",
        "label": "Percentage Of Patient Receivables Outstanding",
        "terseLabel": "Percentage of patient receivables outstanding"
       }
      }
     },
     "localname": "PercentageOfPatientReceivablesOutstanding",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of consolidated net revenues and adjusted EBITDA that guarantor wholly-owned subsidiaries represent",
        "label": "Percentage Of Revenue And Of Earnings Before Interest Taxes Depreciation And Amortization From Wholly Owned Subsidiaries",
        "terseLabel": "Percentage of consolidated revenue and adjusted EBITDA that guarantor wholly-owned subsidiaries represent"
       }
      }
     },
     "localname": "PercentageOfRevenueAndOfEarningsBeforeInterestTaxesDepreciationAndAmortizationFromWhollyOwnedSubsidiaries",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageOfTotalReimbursementOfOutlierPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage at which total reimbursement is capped if cost of care is unusually costly.",
        "label": "Percentage Of Total Reimbursement Of Outlier Payment",
        "terseLabel": "Percentage of total reimbursement of outlier payment"
       }
      }
     },
     "localname": "PercentageOfTotalReimbursementOfOutlierPayment",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PercentageofSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Shares Outstanding",
        "label": "Percentage of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "localname": "PercentageofSharesOutstanding",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_Percentageofclosingstockprice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of closing stock price",
        "label": "Percentage of closing stock price",
        "terseLabel": "Percentage of closing stock price"
       }
      }
     },
     "localname": "Percentageofclosingstockprice",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_PeriodOfCareAsEpisodicBasedRevenueDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of days in a home health period of care using PDGM",
        "label": "Period of Care As Episodic Based Revenue Duration",
        "terseLabel": "Period of care as episodic-based revenue (days)"
       }
      }
     },
     "localname": "PeriodOfCareAsEpisodicBasedRevenueDuration",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "amed_PersonalCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Personal Care [Member]",
        "label": "Personal Care [Member]",
        "terseLabel": "Personal Care [Member]"
       }
      }
     },
     "localname": "PersonalCareMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_PriorCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prior Credit Agreement [Member]",
        "label": "Prior Credit Agreement [Member]",
        "terseLabel": "Prior Credit Agreement [Member]"
       }
      }
     },
     "localname": "PriorCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProceedsReceivedFromLoanPartyOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds Received From Loan Party Of Subsidiary",
        "label": "Proceeds Received From Loan Party Of Subsidiary",
        "terseLabel": "Proceeds Received From Loan Party Of Subsidiary"
       }
      }
     },
     "localname": "ProceedsReceivedFromLoanPartyOfSubsidiary",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ProfessionalLiabilityInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Professional Liability Claim.",
        "label": "Professional Liability Insurance Retention Limit",
        "terseLabel": "Professional liability insurance retention limit"
       }
      }
     },
     "localname": "ProfessionalLiabilityInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_PromissoryNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory Notes [Member]",
        "label": "Promissory Notes [Member]",
        "terseLabel": "Promissory Notes [Member]"
       }
      }
     },
     "localname": "PromissoryNotesMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ProviderReliefFundAdvance": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable related to funds received from the government related to COVID-19",
        "label": "Provider relief fund advance",
        "terseLabel": "Provider relief fund advance"
       }
      }
     },
     "localname": "ProviderReliefFundAdvance",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for an initial period of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Initial Period Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for the initial episode of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForInitialPeriodOfCare",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the percentage of estimated payment that is requested at the start of care for any subsequent episodes of care.",
        "label": "Rate Of Request For Anticipated Payment Submitted For Subsequent Episodes Of Care",
        "terseLabel": "Rate of request for anticipated payment submitted for subsequent episodes of care"
       }
      }
     },
     "localname": "RateOfRequestForAnticipatedPaymentSubmittedForSubsequentEpisodesOfCare",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of the overpayment made to the subsidiary.",
        "label": "Recovery Amount Of Overpayment Made To Subsidiary",
        "terseLabel": "Recovery amount of overpayment made to subsidiary"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiary",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of overpayment made to subsidiary including interest",
        "label": "Recovery Amount of Overpayment Made To Subsidiary Including Interest",
        "terseLabel": "Recovery amount of overpayment made to subsidiary including interest"
       }
      }
     },
     "localname": "RecoveryAmountOfOverpaymentMadeToSubsidiaryIncludingInterest",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recovery amount of over payment made to subsidiary including interest withheld",
        "label": "Recovery Amount Of Over Payment Made To Subsidiary Including Interest Withheld",
        "terseLabel": "Recovery amount of over payment made to subsidiary including interest withheld"
       }
      }
     },
     "localname": "Recoveryamountofoverpaymentmadetosubsidiaryincludinginterestwithheld",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevenueAdjustmentToMedicareRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the provisions that reduce the amount of Medicare revenue recognized by the entity.",
        "label": "Revenue Adjustment To Medicare Revenue",
        "terseLabel": "Revenue adjustment to Medicare revenue"
       }
      }
     },
     "localname": "RevenueAdjustmentToMedicareRevenue",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_Revenuebypayorclassasapercentageoftotalnetservicerevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue by payor class as a percentage of total net service revenue",
        "label": "Revenue by payor class as a percentage of total net service revenue",
        "terseLabel": "Revenue by payor class as a percentage of total net service revenue"
       }
      }
     },
     "localname": "Revenuebypayorclassasapercentageoftotalnetservicerevenue",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "amed_ReversalOfLossContingencyAccrual": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reversal of Loss Contingency Accrual",
        "label": "Reversal of Loss Contingency Accrual",
        "terseLabel": "Reversal of Loss Contingency Accrual"
       }
      }
     },
     "localname": "ReversalOfLossContingencyAccrual",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_RevolvingCreditFacilityTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility Total",
        "terseLabel": "Revolving Credit Facility Total"
       }
      }
     },
     "localname": "RevolvingCreditFacilityTotal",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SafeguardZoneProgramIntegrityContractorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Safeguard Zone Program Integrity Contractor [Member]",
        "label": "Safeguard Zone Program Integrity Contractor [Member]",
        "terseLabel": "Safeguard Zone Program Integrity Contractor"
       }
      }
     },
     "localname": "SafeguardZoneProgramIntegrityContractorMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of AseraCare business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, AseraCare Hospice [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, AseraCare Hospice"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsAseraCareHospiceTableTextBlock",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfBusinessAcquisitionsContessaTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting the material business combination for Contessa, completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, Contessa [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, Contessa"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsContessaTableTextBlock",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCaresActProviderReliefFundsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cares Act Provider Relief Funds",
        "label": "Schedule of Cares Act Provider Relief Funds [Table Text Block]",
        "terseLabel": "Schedule of Cares Act Provider Relief Funds"
       }
      }
     },
     "localname": "ScheduleOfCaresActProviderReliefFundsTableTextBlock",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Cash, Cash Equivalents and Restricted Cash Table Text Block",
        "label": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock [Table Text Block]",
        "terseLabel": "Schedule of Cash Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlockTableTextBlock",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "amed_SecondAmendmentToAmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amendment to Amended Credit Agreement",
        "label": "Second Amendment to Amended Credit Agreement [Member]",
        "terseLabel": "Second Amended Credit Agreement"
       }
      }
     },
     "localname": "SecondAmendmentToAmendedCreditAgreementMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecondThresholdOfServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the second threshold of therapy services required.",
        "label": "Second Threshold Of Services Required",
        "terseLabel": "Second threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "SecondThresholdOfServicesRequired",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_SecuritiesClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Class Action Lawsuit [Member]",
        "label": "Securities Class Action Lawsuit [Member]",
        "terseLabel": "Securities Class Action Lawsuit [Member]"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_SecuritiesClassActionLawsuitsettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charge related to Securities Class Action Lawsuit settlement",
        "label": "Securities Class Action Lawsuit settlement",
        "terseLabel": "Securities Class Action Lawsuit settlement, net"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitsettlement",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_ShareRepurchaseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Share Repurchase [Table]",
        "label": "Share Repurchase [Line Items]",
        "terseLabel": "Share Repurchase [Line Items]"
       }
      }
     },
     "localname": "ShareRepurchaseLineItems",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program",
        "label": "Share Repurchase Program [Member]",
        "terseLabel": "Share Repurchase Program"
       }
      }
     },
     "localname": "ShareRepurchaseProgramMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ShareRepurchaseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase [Table]",
        "label": "Share Repurchase [Table]",
        "terseLabel": "Share Repurchase [Table]"
       }
      }
     },
     "localname": "ShareRepurchaseTable",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Shares Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period to employees as employer's matching contribution to the company's 401(K) plan",
        "label": "Stock Issued During Period Value Four Zero One K Employer Match",
        "terseLabel": "Issuance of stock - 401(k) plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueFourZeroOneKEmployerMatch",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SurrenderedShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of common stock surrendered by certain employees to satisfy obligations in connection with the vesting of stock. Shares held in Treasury Stock at cost.",
        "label": "Surrendered Shares",
        "negatedLabel": "Surrendered Shares"
       }
      }
     },
     "localname": "SurrenderedShares",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_SurrenderedSharesInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surrendered Shares (in shares)",
        "label": "Surrendered Shares (in shares)",
        "terseLabel": "Surrendered Shares (in shares)"
       }
      }
     },
     "localname": "SurrenderedSharesInShares",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "amed_SwingLineLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swing Line Loan [Member]",
        "label": "Swing Line Loan [Member]",
        "terseLabel": "Swing Line Loan [Member]"
       }
      }
     },
     "localname": "SwingLineLoanMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_ThirdThresholdOfTherapyServicesRequired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description containing the number of visits related to the third threshold of therapy services required.",
        "label": "Third Threshold Of Therapy Services Required",
        "terseLabel": "Third threshold of therapy services required (visits)"
       }
      }
     },
     "localname": "ThirdThresholdOfTherapyServicesRequired",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "amed_TotalCARESActProviderReliefFundsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total CARES Act Provider Relief Funds Received",
        "label": "Total CARES Act Provider Relief Funds Received",
        "terseLabel": "Total CARES Act Provider Relief Funds Received"
       }
      }
     },
     "localname": "TotalCARESActProviderReliefFundsReceived",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_TotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio of debt to earnings before interest, taxes, depreciation and amortization.",
        "label": "Total Leverage Ratio",
        "terseLabel": "Consolidated leverage ratio"
       }
      }
     },
     "localname": "TotalLeverageRatio",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "amed_TwoHundredMillionRevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Hundred Million Revolving Credit Facility [Member]",
        "label": "Two Hundred Million Revolving Credit Facility [Member]",
        "terseLabel": "200 Million Revolving Credit Facility"
       }
      }
     },
     "localname": "TwoHundredMillionRevolvingCreditFacilityMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeOfEquityMethodInvestmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Equity Method Investment [Domain]",
        "label": "Type of Equity Method Investment [Domain]",
        "terseLabel": "Type of Equity Method Investment [Domain]"
       }
      }
     },
     "localname": "TypeOfEquityMethodInvestmentDomain",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_TypeofEquityMethodInvestmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of Equity Method Investment [Axis]",
        "label": "Type of Equity Method Investment [Axis]",
        "terseLabel": "Type of Equity Method Investment [Axis]"
       }
      }
     },
     "localname": "TypeofEquityMethodInvestmentAxis",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "amed_UnfavorableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unfavorable [Member]",
        "terseLabel": "Unfavorable [Member]"
       }
      }
     },
     "localname": "UnfavorableMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_UsDepartmentOfJusticeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Department of Justice",
        "label": "US Department of Justice [Member]",
        "terseLabel": "US Department of Justice"
       }
      }
     },
     "localname": "UsDepartmentOfJusticeMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_VariousAcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various acquisitions",
        "label": "Various acquisitions [Member]",
        "terseLabel": "Various acquisitions"
       }
      }
     },
     "localname": "VariousAcquisitionsMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_VisitingNurseAssociationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Visiting Nurse Association",
        "label": "Visiting Nurse Association [Member]",
        "terseLabel": "Visiting Nurse Association"
       }
      }
     },
     "localname": "VisitingNurseAssociationMember",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "amed_WorkersCompensationInsuranceRetentionLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments the entity could be required to make related to a specific Workers' Compensation Insurance Claim.",
        "label": "Workers Compensation Insurance Retention Limit",
        "terseLabel": "Workers compensation insurance retention limit"
       }
      }
     },
     "localname": "WorkersCompensationInsuranceRetentionLimit",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "amed_WriteOffOfOtherComprehensiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of Other Comprehensive Income",
        "label": "Write off of Other Comprehensive Income",
        "negatedLabel": "Write-off of other comprehensive income"
       }
      }
     },
     "localname": "WriteOffOfOtherComprehensiveIncome",
     "nsuri": "http://www.amedisys.com/20210930",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Street Name"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Suite"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r323",
      "r324",
      "r331",
      "r332",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r323",
      "r324",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r184",
      "r256",
      "r259",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r271",
      "r273",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r446",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r271",
      "r273",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r446",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r184",
      "r256",
      "r259",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r180",
      "r256",
      "r257",
      "r395",
      "r445",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r180",
      "r256",
      "r257",
      "r395",
      "r445",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r260",
      "r271",
      "r273",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r446",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r260",
      "r271",
      "r273",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r446",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r256",
      "r258",
      "r448",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r256",
      "r258",
      "r448",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_FL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA",
        "terseLabel": "Florida"
       }
      }
     },
     "localname": "FL",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_KY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KENTUCKY",
        "terseLabel": "KENTUCKY"
       }
      }
     },
     "localname": "KY",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NORTH CAROLINA",
        "terseLabel": "NORTH CAROLINA"
       }
      }
     },
     "localname": "NC",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "terseLabel": "NEW YORK"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_SC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOUTH CAROLINA",
        "terseLabel": "South Carolina"
       }
      }
     },
     "localname": "SC",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TENNESSEE",
        "terseLabel": "Tennessee [Member]"
       }
      }
     },
     "localname": "TN",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "terseLabel": "WASHINGTON"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r18",
      "r186",
      "r187"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r223"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r100",
      "r101",
      "r102",
      "r330",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Non-Cash Activity:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r286",
      "r287",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r297",
      "r298",
      "r299",
      "r300",
      "r397",
      "r398",
      "r399",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r274",
      "r276",
      "r290",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r149",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r85",
      "r365"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of deferred debt issuance costs/debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r44",
      "r45",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "AOCI Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "AociAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r162",
      "r169",
      "r176",
      "r199",
      "r323",
      "r331",
      "r353",
      "r416",
      "r431"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r43",
      "r95",
      "r199",
      "r323",
      "r331",
      "r353"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "terseLabel": "Total current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r277",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r270",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r270",
      "r272",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionNameOfAcquiredEntity": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the acquired entity.",
        "label": "Business Acquisition, Name of Acquired Entity",
        "terseLabel": "Business Acquisition, Name of Acquired Entity"
       }
      }
     },
     "localname": "BusinessAcquisitionNameOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "negatedTerseLabel": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITIONS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Business Combination, Integration Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Acquisition, other intangibles recorded"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r312",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r91",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalLeaseObligationsMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.",
        "label": "Capital Lease Obligations [Member]",
        "terseLabel": "Finance leases [Member]"
       }
      }
     },
     "localname": "CapitalLeaseObligationsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash Acquired from Acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r24",
      "r87"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r88",
      "r91",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r80",
      "r87",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r80",
      "r354"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r117",
      "r121",
      "r122",
      "r124",
      "r126",
      "r133",
      "r134",
      "r135",
      "r199",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r232",
      "r421",
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies\u2014Note 6"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 60,000,000 shares authorized; 37,659,284 and 37,470,212 shares issued; and 32,590,775 and 32,814,278 shares outstanding"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r350",
      "r351",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r350",
      "r351",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]",
        "verboseLabel": "Organization, Consolidation and Presentation of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of net services revenue",
        "verboseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r140",
      "r143",
      "r144",
      "r145",
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r184",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r58",
      "r395"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of service, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r141",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPatientAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "LONG-TERM OBLIGATIONS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r417",
      "r418",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r243",
      "r418",
      "r430"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "terseLabel": "Description of variable rate basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r364",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r35",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r36",
      "r98",
      "r247",
      "r248",
      "r249",
      "r250",
      "r363",
      "r364",
      "r366",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross",
        "terseLabel": "Deferred debt issuance cost"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r28",
      "r365"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r96",
      "r296",
      "r302",
      "r303",
      "r304"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r85",
      "r222"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r157"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "CAPITAL STOCK AND SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r53",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r115",
      "r117",
      "r124",
      "r125",
      "r126",
      "r130",
      "r131",
      "r426",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r53",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r117",
      "r124",
      "r125",
      "r126",
      "r130",
      "r131",
      "r426",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r127",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r112",
      "r114",
      "r132",
      "r203",
      "r246",
      "r251",
      "r286",
      "r287",
      "r288",
      "r299",
      "r300",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Equity method investment, aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r51",
      "r79",
      "r85",
      "r439"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Return on equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r25",
      "r163",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.",
        "label": "Equity Method Investments [Member]",
        "terseLabel": "Equity Method Investments [Member]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r25",
      "r79",
      "r91",
      "r198",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar [Member]"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r342",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r343",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r261",
      "r262",
      "r267",
      "r269",
      "r343",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r261",
      "r262",
      "r267",
      "r269",
      "r343",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r343",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r91",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r213",
      "r216",
      "r219",
      "r221",
      "r396",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r213",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r61",
      "r85",
      "r195"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Gain (loss) on equity method investments"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedLabel": "(Gain) loss on equity method investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOnSaleOfInvestments": {
     "auth_ref": [
      "r55",
      "r56",
      "r85",
      "r423",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.",
        "label": "Gain on Sale of Investments",
        "terseLabel": "Gain on Sale of Investments"
       }
      }
     },
     "localname": "GainOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Abstract]",
        "terseLabel": "General and administrative expenses:"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r208",
      "r209",
      "r415"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill recorded during period"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of patient service revenue recognized, net of contractual allowances and discounts, less the provision for bad debts related to patient service revenue plus all other revenue.",
        "label": "Health Care Organization, Revenue Net of Patient Service Revenue Provisions",
        "terseLabel": "Net service revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r50",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r413",
      "r424",
      "r428",
      "r443"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r51",
      "r85",
      "r159",
      "r197",
      "r422",
      "r439"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in earnings from equity method investments",
        "terseLabel": "Equity in earnings from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r113",
      "r114",
      "r160",
      "r295",
      "r301",
      "r305",
      "r444"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes, net of refunds received"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of impact of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r126"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock options (shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r212",
      "r217"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net of accumulated amortization of $20,309 and $22,973"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r49",
      "r156",
      "r362",
      "r365",
      "r427"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r77",
      "r81",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest and Dividend",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Outstanding letters of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r95",
      "r170",
      "r199",
      "r324",
      "r331",
      "r332",
      "r353"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r95",
      "r199",
      "r353",
      "r420",
      "r436"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r95",
      "r199",
      "r324",
      "r331",
      "r332",
      "r353"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Total current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r30",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability under revolving credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r30",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r244",
      "r418",
      "r432"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term obligations, including current portion"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long-term Debt, Fair Value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESFairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time.",
        "label": "Long-term Debt, Weighted Average Interest Rate, over Time",
        "terseLabel": "Weighted average interest rate (percent)"
       }
      }
     },
     "localname": "LongTermDebtWeightedAverageInterestRateOverTime",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r36",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in loss contingency liability.",
        "label": "Loss Contingency Accrual, Period Increase (Decrease)",
        "terseLabel": "Loss contingency accrual, period increase (decrease)"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyReceivableCurrent": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected within one year or the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Current",
        "terseLabel": "Settlement amount to be paid by company's insurance carriers"
       }
      }
     },
     "localname": "LossContingencyReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyReceivableNoncurrent": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivable related to a loss contingency accrual that is expected to be collected after one year or beyond the normal operating cycle, if longer. For example, an insurance recovery receivable.",
        "label": "Loss Contingency, Receivable, Noncurrent",
        "terseLabel": "Indemnity receivable"
       }
      }
     },
     "localname": "LossContingencyReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r41",
      "r95",
      "r199",
      "r353",
      "r419",
      "r435"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Noncontrolling interest distribution"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r80",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r48",
      "r52",
      "r86",
      "r95",
      "r103",
      "r107",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r123",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r199",
      "r353",
      "r425",
      "r440"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Amedisys, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r48",
      "r113",
      "r114",
      "r327",
      "r339"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete Agreements [Member]"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r252",
      "r314",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Acquired noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r251",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of businesses acquired by the entity during the period.",
        "label": "Number of Businesses Acquired",
        "terseLabel": "Acquisition, number of care centers acquired"
       }
      }
     },
     "localname": "NumberOfBusinessesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states with facilities"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OffMarketFavorableLeaseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifiable intangible asset established upon acquisition based on a favorable difference between the terms of an acquired lease and the current market terms for that lease.",
        "label": "Off-Market Favorable Lease [Member]",
        "terseLabel": "Favorable Lease Contract [Member]"
       }
      }
     },
     "localname": "OffMarketFavorableLeaseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OffMarketLeaseUnfavorable": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents a liability associated with the acquisition of an off-market lease when the terms of the lease are unfavorable to the market terms for the lease at the date of acquisition.",
        "label": "Off-market Lease, Unfavorable",
        "terseLabel": "Off-market Lease, Unfavorable"
       }
      }
     },
     "localname": "OffMarketLeaseUnfavorable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r162",
      "r168",
      "r172",
      "r175",
      "r178"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income",
        "verboseLabel": "Operating Income (Loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r371"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r370"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS, CONSOLIDATION AND PRESENTATION OF FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term obligations"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Miscellaneous, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other operating income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchase of company stock",
        "terseLabel": "Purchase of company stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedTerseLabel": "Debt issuance costs",
        "terseLabel": "Payments of Debt Issuance Costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Shares withheld to pay taxes on non-cash compensation",
        "terseLabel": "Payment, Tax Withholding, Share-based Payment Arrangement"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r68",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedTerseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToDevelopSoftware": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments to Develop Software",
        "negatedTerseLabel": "Investments in technology assets"
       }
      }
     },
     "localname": "PaymentsToDevelopSoftware",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r206",
      "r207"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from borrowings under term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from sale of deferred compensation plan assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from borrowings under revolving line of credit"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r281"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of stock to employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r47",
      "r48",
      "r78",
      "r95",
      "r103",
      "r113",
      "r114",
      "r162",
      "r168",
      "r172",
      "r175",
      "r178",
      "r199",
      "r322",
      "r326",
      "r328",
      "r339",
      "r340",
      "r353",
      "r428"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r224",
      "r437"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation of $100,407 and $95,024",
        "verboseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r268",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r376",
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related Party Transaction, Amounts of Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r268",
      "r376",
      "r377",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r268",
      "r376",
      "r379",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r374",
      "r375",
      "r377",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSRELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayments of borrowings under revolving line of credit"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r90",
      "r414",
      "r433"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r251",
      "r289",
      "r434",
      "r457",
      "r462"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r104",
      "r112",
      "r114",
      "r203",
      "r286",
      "r287",
      "r288",
      "r299",
      "r300",
      "r453",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r143",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]",
        "terseLabel": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for finance lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r36",
      "r98",
      "r247",
      "r248",
      "r249",
      "r250",
      "r363",
      "r364",
      "r366",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r30",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Commitment Fee Under Credit Facilities"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSLONGTERMOBLIGATIONSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r97",
      "r378",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r9",
      "r90",
      "r414",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table]",
        "terseLabel": "Schedule of Revenue Sources, Health Care Organization [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuebyPayorClassDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.",
        "label": "Schedule of Revenue Sources, Health Care Organization [Table Text Block]",
        "terseLabel": "Schedule of Revenue by Payor Class"
       }
      }
     },
     "localname": "ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r162",
      "r165",
      "r171",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r162",
      "r165",
      "r171",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Operating Income of Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r277",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r149",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r184",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r151",
      "r152",
      "r162",
      "r166",
      "r172",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r183",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r275",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r149",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r184",
      "r211",
      "r226",
      "r227",
      "r228",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails",
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails",
      "http://www.amedisys.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SEGMENTINFORMATIONOperatingIncomeofReportableSegmentsDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r94",
      "r95",
      "r117",
      "r121",
      "r122",
      "r124",
      "r126",
      "r133",
      "r134",
      "r135",
      "r199",
      "r246",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSProFormaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r40",
      "r100",
      "r101",
      "r102",
      "r104",
      "r112",
      "r114",
      "r132",
      "r203",
      "r246",
      "r251",
      "r286",
      "r287",
      "r288",
      "r299",
      "r300",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r453",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r132",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of stock - employee stock purchase plan (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r251",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CAPITALSTOCKANDSHAREBASEDCOMPENSATIONDetails",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r16",
      "r17",
      "r246",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of stock - employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r246",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance/(cancellation) of non-vested stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r246",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date for the purchase of an entity's own shares under a stock repurchase plan, in the CCYY-MM-DD format.",
        "label": "Stock Repurchase Program Expiration Date",
        "terseLabel": "Stock Repurchase Program Expiration Date"
       }
      }
     },
     "localname": "StockRepurchaseProgramExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r95",
      "r193",
      "r199",
      "r353"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Amedisys, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r95",
      "r100",
      "r101",
      "r102",
      "r104",
      "r112",
      "r199",
      "r203",
      "r251",
      "r286",
      "r287",
      "r288",
      "r299",
      "r300",
      "r320",
      "r321",
      "r338",
      "r353",
      "r355",
      "r356",
      "r360",
      "r454",
      "r455"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, Stockholders Equity",
        "periodStartLabel": "Balance, Stockholders Equity",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r361",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r361",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r361",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r361",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details",
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTNarrativeDetails",
      "http://www.amedisys.com/role/SUBSEQUENTEVENTTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r382",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUBSEQUENTEVENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures of Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology-Based Intangible Assets"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Patient Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/ACQUISITIONSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury Stock Acquired, Average Cost Per Share"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r39",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r39",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock at cost (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r17",
      "r246",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Shares repurchased (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "SHARE REPURCHASE"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SHAREREPURCHASESHAREREPURCHASE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r39",
      "r253",
      "r254"
     ],
     "calculation": {
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost 5,068,509 and 4,655,934 shares of common stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r246",
      "r251",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r297",
      "r298",
      "r299",
      "r300",
      "r397",
      "r398",
      "r399",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "NOVEL CORONAVIRUS PANDEMIC \"COVID-19\" [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NOVELCORONAVIRUSPANDEMICCOVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r146",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r323",
      "r324",
      "r331",
      "r332",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/NATUREOFOPERATIONSCONSOLIDATIONANDPRESENTATIONOFFINANCIALSTATEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSFeesandRatesUnderCreditFacilitiesDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSNarrativeDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtAdditionalInformationDetails",
      "http://www.amedisys.com/role/LONGTERMOBLIGATIONSScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r116",
      "r126"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, diluted (shares)",
        "totalLabel": "Weighted average number of shares outstanding - diluted (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r126"
     ],
     "calculation": {
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, basic (shares)",
        "verboseLabel": "Weighted average number of shares outstanding - basic (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amedisys.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.amedisys.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESWeightedAverageSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27405-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=75018788&loc=d3e30768-111565"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208821"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5227-128473"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121616839&loc=d3e45280-112737"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r475": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r476": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r477": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r478": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r479": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r480": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0000896262-21-000110-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000896262-21-000110-xbrl.zip
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M7HEYJP)1QAD/@1.P? K39>=9X$U_'B\5U%!I%%<Y5.%6$\$=Y30YQ:60;/$
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M N<A<(R3O?>@ W%$V:A9M)(%Y1*?_6TNESQZHGTU#4_<"C# ?820O.$V,4-
MA"2E)7KV7=ZW(=F-G]J-3_76T3HRI-X;-Q^^SDN,,N[AY<]59U8<$UAFDH^"
M4V,AG[%J&0705@<%TGDZ1XYIR9K9=%4$)"-12NDC X;"AX)(7N-O1*/ BMEW
M54MF3<QY4:_0$%E"A58 /.\U+(UV)FBM@8DPK\YKL+%PI]VL=[OMSF6EW7OZ
M59]C<A':2\>3H53%+#5131#J:3ZH%GSP4<]K_YTX)./K)5HZH8,S+%(!*4H=
M@F): DV> R%Q7GO)Z.JZ/:WW;&,GVFZLND;]R,[3F7,QS^R()%)C(ECEK(0
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M998+3#V$MG>*_AAMKY6%BZV8\ ELY_)^=7&CP \K#&(M5Y(#"M=\#!/1E@$
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MYK>C<UM5F+;M^MAL_'O4C3?;1W<(?EV7VEUW&Y-[1[O7OG37W?I]C\I=QH5
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M_H.( JT1Z#50S[P7P20NHU:<"S5+66%<L'H:L5:G$5]VKI6W.L4-&D:,UYR
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M@]Y@.&HFDD]!VL50%!J^'@U/=^?P&M\UEOR?T[GF5;,MI-G"?-C)@Y2&ZT#
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M_A%0)A#/E2<8DDB@?!3&;FTK56,E&VRY*T\\K9;[6)9[I3B2=5I)1"(I1P+
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MZQBEVO9CV?9<?;=@PAF0Q"IT!+2.Q#3CC905&E(2(%DSDMW<THZF1CV>>)Y
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M)I\LH5L7I_?;PE65W!<C]VN](15G3J=2BP<ZD[N#+$PCD\1GS%!S*3.P9:3
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M9>W\K/3H&Y)+GSJ]@@8N#MZ<Y'&2!2Q/":=8(5\%"<EXHDF@_"P6(&4$"="
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M% O;Q6$6$BJSG&1:@"#"M \;F4C-PAY!?I\DQ<N"U5ZKLAJ/V,#;Z<-WKFA
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M &JB ;4)*Z<%8&&'<[)6+P=( K2IM *=P8K=(Z>YUT )K[,ZQ^(%;@3M6E%
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M\"R37,4@UTF=T2QC81Y3A@DVC-\HY.6O9G0[S>#07O(*SDR]?[^Q+/=)!(<
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M&\7M3SA&?GI/AHJ-K"+ IAT.B3=?(#]KU>&!0DD!Y,#_H&W#O!69U7@V-;J
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M3F(45A.= V:;4=G>:X:#D7PFFK".F]BR0M?[VM)>NV6[9G@;)]3)+FL0T"X
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M$B_>D._VA[%[VCCL ]2HB"3*.YR]H<PB9C,MZ_!H?*\%V=)H".L]/,<'.[W
M,%\_OVU,Y#JE@RVI7#-W<+<3!\.9YX4U/=[OP$=!!HJG+ZB>>F/&IG-$KZ-N
M]4MUPP7[5+5;Y9,6N]$?,T[UBG.-@CQM2FL+?PX%$^MK6.@A7+)\NJ,X*$1B
M6!)E#_<;J=L_N8+(^JG*_^9$_M7K&1UXV_RTOM5HPJJ=V&'!R5QP<\$2=^->
M9]@M'GZUL7WNK4>#_O=.)A+)LO5_+P6KHV&80ZK*&"D<C@("(TZ$=9)1S[FD
MT>($F'5WHP"HC*IS -7\U %EX:#>C8I3QW?]P5\3!?VGO-W!<&,LG7_UAT>9
MJ7):SFU>FB<[VQ"[RDL><#+(1*<1A X0N J G"89I3R)+O&8>Q(OFW3@0+?R
MCH.TS)C#H_%RSYJ#_?&*CXD(TP $HY'E=#@F?IM8F:FIW4R5&>C#9[/IZ1=4
M<A6E\^NG*7P;AYE/#NZS>[K6&9;-_3%L]Q=(9-'HO]D#]>H,*":F%3-9WB"^
MBQ%$>"L.OG=\_!0[AVXT&,[- 'AI(KL)L=DN)E*K*!QBR>=#<:J0(82"!-/D
M,8U,FYS%O:R0;BRQV=B%Z=Z YYAL69;FB0B?(\_L#/(+F>8>+I']3<G?"=([
MWK9&BA&!M&0CG7<.7,GLUF7RP+S+JXV_%J@+>+F"M_T_H\Z@].[9'#<RK3NX
M^V%%D@@BG3J#PZQ3!87ZT?%8?<9"U?@4P9NF1I9&P(K_?'JW\ELCP2\5<?K>
M(!8^M& -C8/#\L\3_U>HXU$Y>P(4$#QF 6Y*!2_>6NBRSZ?;>^5CE5SN62VG
M#.NPD,LH)X[)16Q<H,QQ$A)$71EE*VQ\P#KZ*H?!QSD,/I?#D$MKZ:?JIHMT
M1G9MX-DFNB5?F&ZUMC=^M)N[04M0(\>0,#[S4>235R\4LA F8*NTA+ !' *^
M3+T.*_4"XWY86OG.8'A<6^F7)4EGK;U=P;AGE J4B,KS5J1!%D>#O/0L*,8M
M->$G[#28HM)RS1KK2^!&MJ[-HT&G6\';DB*V,RQ1R##7X\#EEI%%$B0.@(VB
MY;GR(!@?DXV!1,!% 7ZLC=(]BU+K1_MD5P8;B4T"R1B+=D&+- D$<6/!+)B0
MI,T]OM>8I$$LZ;*K6/2@#T%.XSNHZ@ADJ!"DDE1LV'B5/?#Q:46A#=*3Q](4
M2OU;$3O#WO8;UE=N^N8N+Z5DO5)2<&>Y#<9BZT@"1)X8_ _C6KKN6;H^GH*A
M,M:9X#E(%]4 *+7VR*;$$+6*89Z-5: K;RZK"CB<VBG 696M*I(TO5XL)>"D
M [ I^\)"9(:=,=5U$S"B?0N"M]KXW,NP[5(\EJ/L.:Q7X;,B,U+ QAP:G93B
M/1J6:9'R9G)NI_\=+M_M@R<>1!#Y42R_HH)TI?##J\-9)9D$8\?[@_YH;[_Q
M]Z@7,U]HMJ[D=9G6BA<Q:T;(<0"JD-^01EWX*?3]*-]MF:P9QNHAAG&Z7H.8
M8?5P#$L_KVZM-M;BD1T4BI<_\-<4?_XU.@107+E=T->5O_[:6@'=;':[TULI
MKYAA<L;Z.377C?G19BCMCPMNV<-^)DDMV<H;\2(_:O&\SR_?\ZY*^YWL]V$/
M4/\D)W:&(S?L .@9='(2#K9O=-SIPD7#C/166P#/D5>^2&6&QG]&\$RIR#1.
M!"/^.(J]81S^D=\4.J'1ZQ\7VWON6HN$KTRP%<G)#!3'5RS33'L#VYLRM0^'
M?=\I9'*B1Q=N(+]Y-"CD;Y&L9@@PB*D;BVQKYIV'JPS&J3VXB>J[\A=,6.E!
M#GHY\CN7+<PQ6!7)G<L-KC;.B\>5)U75+O%,MG[4+^W![X7B@6F><JS_U_FT
M>G4ZAZ<?L0YN#/#0I1^YP)?Y2))(Q-SJS/R[/YBRK.Y%Y ;1?@/["S?[N^V>
MV-/ARO^<US90M>KB.I_B+_OLEYW^/=J2+3[*:[;6US:V=K9>-S;:;\&PM=<:
M6Y__W-I8VVA^VEC?>O+WWP9GO]78WFQL_[4.^MI>6V]OK:_EG[8V/VRL-;?A
MEW<;[6;[[4;S0V-K&_[06F]O/_T'>_6Y9T?@EV/X;>E[O:'L+?K8%:=[UY[6
MS9WN1>XI5DY;# "*J.04)<%[16)P!!#I\SC=^S+U0"7FJ!Q;F1B;^*-QHNJ/
M_'?P"?U!G)[6P8NYT $@?:/;L1"!YB @56=A9<*Y.KH#;&'AV\H LTA-PZ>6
M@?XNR80C(U[+R!,6-G@<,$XT 0 541=)CHO5?TL@_G'NHLP%9OS?#-]MS\>7
MB_</=D3KXVZ$> I[;)%5+D>3 J))#3#0"J4(9L&2/-U97#:E80SX7TV/-CI9
M62%$_"T?6EZ$C@5D748X- ^1Y=JMZ!3'CCC'O$Y4@ )3RJ0I,V"$,E(+Q]T)
MA__1_K@;@B065AXQFX=W&!^0L5PCX9+7)!(>/ C'I6WZ8^$ .5@#2U.* 2F/
M6QNOAC%>GJ>O-@""1%\8FAQ#9DQ;G)&5Q@@P^T]@5&>[Q86&^S$6&8L<%8UZ
M$Z!?&L(J;"O,&%QOTQ_W\\T6H4[C/@N(MOQ^#*-NW$QOB]G7_OBB, ZWBU'8
M+[G&*%<6!Y>T)"@00C*U!$<Z!(<2!1%UF(!S5O.^/!F'N24,"_@OL\3AP&04
M\-]$*<9^OL9H _STZ!!\^FE9#%">LE:AV[X]+JM.JK.=24Y_6@>0'>M,H4LI
MNE59@,UYBYR4&.8?(5Q:8!E?E5ZUR !4NC/\[?>K2YI^"HQ, -1"B'3M,KWY
MWZ(4<1I[%?6/@&6Z]F@8?Q__\$?H#(^Z]O3W3J] ),6'_JCNJ@K8<I0WWYR:
M[[-\N8I?M%I5Q.00IFJ-K;ZXBFY6B^AFKIRS?$W)5<K8I2_C57+I:U==%JP
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M(I:*14K3RALN5^^*5>/G=.&)#Z>8?.D,E*DN@?+[?R?T 7H(KC+KY[(<U7G
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M!\ ,Q,*?>]ECG;O\)"/W>M'7YC!X.'('T1\#N@:AG;]=&S(>F-RY[9U"C)S
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M%X7G2W77S?*F/P]C&G4_=%)\<:*SA_/0>\&UY_D4520*L1>'V L+BS A6LE
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MIQ09-&=O,RQ:(>%9X3ECR6]ZB>HW7+2#V?'FV37!1VP/!+OA[+ S?)WGFF?
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MRFBE*[6TTX.XJIF#?RHQ*)T7G$;,A8@FTFA@CRP'8^&Y6 %8Z.U1+CP:C""
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MMC[7.^M51QYFIEU0[%>4'KO7ZMB[U^A2N[<5TIL_=ESJRDIU>++O)M-EGYD
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MZV5"&J9A#*MHR_C#DID^--['K!VUC8' LABNUK,P8JL& ZM-+M TMR_*S<#
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M[T(IX88=ST.5%S]4ZKL1]?W^$:B/1:DTIQ0IS!W8E9R 29D<DC@I$"TI2>>
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M^\;#>"MC#R2YPLJ;(!VWWAC)75):":5LM"ST%_:M&N GZ.#C 08-T#FNL!%
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MZR^ZZJ?_)KBLSUJ?]:D_*[G95?^[L$'#", Y69K]?SML9Z7^A9P7\3=Z]GY
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M\^'\PZ N^[TM^Q$(U6E=ZWM9ZS>3.?#*G=22AY9E>1AAQYJQ@(-I?!?'YU>
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M#OB2]5>*4_FR\F7ER_L;9EOY\LY\V0D$Q@!:I(\48>,DXDISI%W2"#.5D@K
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M[=?!:-_$#L;XHG7]\3?M[W]^'=]\^6R#XS"]_N=2OQY?3O_^>/'CZN,?X"S
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M'J&I/0AF!UI+!QUN-.L]<"GJH+\-B.X,:P &]V>MW5AT=W-R$I^T0J8=B 4
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MP-%32?+ [VU06Z'G@\**PI'G"_4EK8//0=4:(_!%E8GO#7TVKLD<WW1D@RL
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M33!329PS'ZPD'2\S4BV<.*D6;01K4!O]Y2H5673IZX6J>"1":#Z@:T''1H8
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MJ-)Y=(VYY^)5)IO%($\^+GY@@!<HN'#LT3<AS$\9<,>;-I1;Q.QEB,GH65;
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MP/>BX4CY-0)CWVI2/*0VE _P,W+-=.0YSJSN33'J"Z)!8)LV\VT.]GK*I=_
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M6H<I&Z;S (%''<#]%0N#!,M&G;2"0J=X/EF1()I,'!'?XG! G"T+V=H!C>K
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M!PJ9DP^5!HOLH85?#WTV3G50+>;.^*T4Y'3?$;<&:$+O;::$W.%"_S249<3
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M0#CWB/>\,*SY<'1I*%K#[2:.>36(9<EUI8"/PE(@@-K0'L[FY8<J%-2:U*#
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MQS9418*1X&XTFIV:'0?(UIPUZT<VG^+8._)?8N*$ONU8",7O^#8RN'BT1CA
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M=VTQ $;W1 @BMGIE5$[75H!$4#3T(_:Q;6255NC\7DH/NC$+I**:**K"2>*
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M6&O%6O@,U6ZNYA>P0""M2V+8@7 =<2_PGP_  [*R0QAC<0:R&3(%GSA@N?Z
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MX(0_I9$W=&,KBM66<KS9L\!0'A@N/HRP>!"0R(!V?![)DX3\8:+*.@!6=N0
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MZ!8%#CI!:6": FKR&%'Q[Y2YSD^T("CL,/=!;;7)+AW<+D..EC(N<*G!S+K
M,Q_EKX+D.9M7K97EY:OM62BV3RZT],TQ"O"<3/6#0EX*%^\<"LQ.*'0;X>=X
MO@>] 'LR$01T/([18OAS&/#8QIA"PJ#A-(3-4<.-"SR-FV8$IC(=QZ7>$458
M)O(TL\8L6)G$6?(]=YH3\#6:8V)PU'+RGB8L3[WS_=)QPO&7,.]-)8>48Q')
MXTTY#O+!YCYG8TP-",30E405=/"7=A8(M8%#H*=%?8=1@&'QL)8&HP; N$-'
M18<22E.[ _D%S!/%2V)YJ9B?$U"6![@OW^( ^ZK!^S(0H]25DVP8-[=A\.:3
MZ\Y-(R3RSUJMZ5#RY$XH.T]8=*ZR,)<=TR!IY9$;:,TE67%Y2&#*$#N/9D8#
MK<3*-7,\#%]9,CF&&H#],,18?BTG[26?"3LY8E@P97FR( ^C8:.3?TB=)X<9
M1)?$+SL:<W7^Z^$2#'GLJNM:] V9?K;_X$G2R-GD2!\Z>&:2S1YH$_&?PLBB
M'O@9^9>XP$X /B;NF^RFG./1+=B8CDHD8X2^='M#.FF!]_ F5QPF'L:#3SWY
M>  N_ EN!+QS,G.TCILWH#TSS&^$\ F/>].$N_-L (:./)P'2J%OA:)7'?+D
MCX& 1?Q8;@525L[(]\F &L81"AD2$1GWH]B19 8&G&,J'(@:%O$.^$%X;XM8
M.(V%X,91=S#O?""J<G20JR9^!'VAH%)]9R?U!D:=_I)^:IA,NIC_E828\^#H
MXA<UFL0B<*/G8JQX'H#!?I28Z/?7<GN;3Y%?<$5!E-K@^6- -<=!.0,FEUR@
MQ"KTIEQI%?.P!5[QD$.>3=J8.7_,C&1Y!+&$,;W9"%4ME]PQ[R*K\'FQ"[R,
M\IM]YSEO8M\<B2R\6^1)OG>/OKO8HU_^J #F]V&W<8#=.(K?^]>W[/P<Y,7M
M[V?7[/SRV]7UG_W;\ZO+=0]=S'KSA5.7W9U69(<NIL$NSG[K7\B#EK/3\\O?
M2G/2LCA3AJYI==B1#'9'67H+VAT@E(5'ND"=&*]Z72L?'D=A"IY!XIBXX@X1
M#^6M:KP9M_:9G%GO5.%0SNP;E+W OO5/;J^NE^6-\CB:!4&3))Z0-S[(8*:\
M!IG-B,: %3B#[.1H<>I+>G=X*G@2!TEO)B4(**]@E%X5&*5AL!^7UV>_G=_<
MGEV?G;*;_L79#;OZQL[^^>/\]C_LYNSDQ_7Y[?F9/-?]<7.&#Y74*;G(0:=A
MZ..Y%AE\9!6E(!S2B\DD!IFCZCHX69)I1O 8#& T@&+IYBR^#Z&B:P*,S,2,
MHNL*X6KW,&8ML\]/:%P&U"Q)S-3Z(F0Q]/?X)!2?DW]\ 2-VXO+I9\>C]NBC
M+XHUE,F&UL8\SB'*(/DX,T2,NC1&%,RBZED]-NC1'%*:?-9L&+U.:^'CNF$N
M?/9<LR8\;*[7['//&D;[^'CS@VT9[59SXX.M&^WFXD[U8%_#!JUF9ZDO7X >
M71%A=#O0A]V75)*L$DFR< DTT6?F)!VYMYG5/(A?\:P.^*$4G(2Y+?]Y2;=&
MR)?RA_(GNK@3RG\?^$H#_/"<*#RD][XG%]E>1Y^W6_,7(0[K!1"'^[+F [7F
M?7DC4O[Q'6_]R,7DCBU_FR3*GM8_77YZ"U=_&7#=%;!:JT5%:]'.D?_VAT0F
MN7,84(T5[1?Y+E=;"R]-S'S]/1ZXCN5.T4N0V /R9Y?+:*:Z/Q>^YW6PU3K\
MR1^=<3Q^NA()Q_:S]%EV2IG>]/._N!N+0XH]IFN5<GAXR&XQD/XGG[+_B(A]
M%;/KQ]+;CIM=F+V'[":D1(5+(9<I\N5_)8:B65/^'SQ?JS+S1NJQE ^ N7E<
M:Q[O6<&H*I0VV#+%]ZV^PYY5 VITZD9WU>JT)=]U&P"^WQNIJDN7:6&U/\*J
M7>O!_XX;[3WFY[TO@J8P<_)V<&(G)W@ZKS>2JULM?CV)O<&"\=OENQ+:NIJA
M2LE0:YEQU5TFB5NG5ZG<JV2:[9K9J-?:]55#%;M?JE*=1163]Z Q&WG?^VAA
M!J&80-F"%?045_$U@<(*[K)7>:TZWK<M&T@SU*XC'7J9]#+M?IG6-X)VOU3O
MP0C:H(F^2G'3O0B8KW4,N7%B:<_@R:9X6O!ZQ[Q;.LMNW2+UFR!0N3?U6J><
M5=_46NR_4?1M;SA$"U0M4-\H#+H?>X8L\T]TNZ9DUX1>J%IO&NUD[^DB]45%
MZL^3RLW9K;.9&V<APCIY$GP%H=A#PMU0D!=B/'']J9 7:D,>.>%PRB+^2%?=
M1KYKJX(86%XCC +G9UJ[)U<ZT2G&2[P7LO8*#,CSO2/\,ZWB@1=ZQ:,(+$>A
MC="OO@+?0 @>QX]#=\KX P]L51D# 02S 6=U,AOU>E=6>ZV;778U]IP!S!+H
M@K@9]Q*!5WBAO,-'Z<&+(0E*S7R-\C*?A&Q&+- Q\!4N>[8^(JG"@Q6!4KCD
MQ<6%"&/Y7B)*+"A3Y.<*!)K'\AKN\J7U)&X+PM=DU3MGQJ;05Y@'E%LTSB6'
M.5MW::EZ0TE-=H*+6:;@T8M3-MB_GQ1I4N(BCZCY4K&D^?I,+*UJB/3,6GIN
M>@L;::Q_C=IL5.$:==-@IV??^C\N;F_8C^]7E^SF[/+\ZCIW?;K<5Z4O?:\(
MS7?9-6I788U:!OOS_/*,W?2_G=W^)U_UH>QK$R5%/L#">\4J=:NP2NVEL%S*
MM3Z%>T>-XEUB&O4V@FG4,'>,:92T!G2PCH"V ;>BSQ(,?CJ'8] LP=;I&.SL
M?WX__WI^^Z)$>\-1+\;F$(\C9X#H>%2@)@>,;@5^"#[/=#SP779 ^/RM+X<$
M]B8+ "3 E(4M\,2)E\TDW\\V$P>>+(:@.G7"#-O=8'W$VELT.AXB#DWX,QW@
M_Y%MYH ,";)- B,21HAT4?Q@2M4+0PF;&R"*C8(OHEE-<L5EJ:Q7IVX># X/
MS/KA@>,X=(?R6MS%JF#<S=$?6?&^R@!R](Q&J[<%> >0)!N'=V@UC69G/=2(
M%[ H&MV-#[;1!,IN'I)D.X/M&LWC=D7&>FRTZ\N-=7_0.,ZD\"/EJ/ J]O$*
M_'+$./6MF,3Z*8&+369*C[X_<B10:E@C[LY!M&BICA(TOG=,&G#WV3?0Y4Q!
M'.0)I/?2O& !#KI"@&5%JB'B8ENB*.EHSIF29NN"HY-%)S8OGTBO1?VE3HAT
MEV_1Y?KJMWB?["X?OVDLSK7?M(Q8?!/AN4/$X7!KTY>#L[$0&PG.SQ1\QK=@
M3+S0)U>^VI>=#Y"- C$$.15%D\^?/CT\/!@P3./.O__4#ZP1XHQ_$O8=#S[9
M/.*?NKU.H]/X!*,US5[3;+3KQV:G<UQO?K+%8],T1A%(:3SAP@@0G:6=X#H-
MJ;P;_GGNP1@F?C!3R"LI2DE%!4()0TYH\U0(3SJ<2:#^'[&G<*?,%D;JZ\=_
M_\3GPR&[X,"=YA7<9E1,JV\\6PTNA9*=K:J345?>H*D?O]FN+DP]V)U JQ\U
M6HU.?1/3;Q1.?_D$KYU*]6?35-;+)Y'S6=-:VH[JUJ_NN7VB8JE-HZ'-E J;
M*6 0V$=XQM^LUWN/8'(T"DR.K].C"_X0KF-=7%F1CUD C?3^Z'9MB\J^J@5W
MJ5_='\%MUK5G66F1O:YGV3 ;S4ZCV_EDF[U.JWD,#J995Q[FC<!2*ZR?"' \
M?^RKHNEXTGHM5/FRDT#83L3Z6,U+UG^4)5ED:2D)+)H6E!K(@G1\['MWV)SM
MA-.PABZK00^2G]CO,A6UQBZ,"^/$H(+25'70#P+_002A+$[U&[A6W*/4.RSN
M-I6UV2)?/KV@--@GC[YR[R>.#3H+@ MK[-+HRQ[Z]MCQ5' 6E%C_CN9S@Z4B
MD-ZJ01KIQ:<3=HYU_X*L)**/7>2>S/7,#L[':;V2T!H).ZWHGIXK9\5-_+$3
M18L.@/GA0;OPZ#?GI3*.2Z)JOM')-E8=G[BT2E2!%<M"3J9)';FDPV1D&,Q7
MXTJJ[_PP;HPEBM7+U$6L#0],8AP^U?#/9EH\GX:Q._FTXZ##WT)V0IG=T7RP
MH8ME:RA9($L_;;T SJ%#"_L\_2<:7=N2I7YU?VS)) A@:I.RTB;E?!3@L6DF
M1P_I:8,Z7OC.8Y=]-=@?<0B#\1]J[&3DB"$8!DG%TRM5S?3@F7*HA[492^=&
M7BY* N6-)-)PPX,!]T1X=/7HBBF5N(<GC7J]H>,(.HY0Q5?W4?;K"/">R?[&
M ME_8_E1Q'XSV&^.Y]5R(O]?>&?T>R!"!V]1RGJNI!6^I95:"[3"DP+86BMH
MK? N7]T[K9 HAX9V#/9,.33>U#$PNQ2%/#%FE8'9;-<IA,MM?S(?-IUYLU?O
M:+6AU<9^OKK':D/[%'NF-DKB4YA=55E7:Y5=BZTYK=+16J4<K^Z=5L$LA_/+
MFQ)HE%T0X9PN>K/_^7I]P<Z],.*(-G1$J0-.\J>=7&^T?>C8DV@C@@>(_85"
M[AS7%10-RN53'G%YPVT@+!Z'T$P4RN8C?A?2/7A$_K%M=6,^;2,;1]*?L9TU
MJ>RKVMXN]:M[*1EO3G[7DI'=\D??\\=3,$ CX5%:TXTU$F/.DJO?6E1I456=
M5_=25)WT+[2H*A)5)]RUDL30"\?[.4!$1BVXM."JWJM[*;A.S[YIP54DN$[%
MT/&<&;FEQ9465]5Y=2_%U47_JQ971>+J@@^$&VH32\NL*K^ZES+K^_69EEE%
M,@N/4/$*H'8.M>2J^JO[([G,>NN=BJL3'X;"OO.[1<>*!T,_&/-(W2K/2S?,
M 4%<;0Z_V'@VJ: D&2B )T4Y*\/46]PJ3RJ"S0FV-RE)4 B=7Y8Z!>WZ7(K.
MFG4*6A]^+46=@K>G:W%)@IOSWR[[M\M65L'*<CMB@.^Y'"],4T < R=0H/R8
MGS:;(88P"6;[P#Y,\[\R?(04&T$E@9F]9DOFDTDD#0E3D0 "0Y<C>&8C9 ;E
M4=BR!D$@K_O#< :"A;"0\J8_)ED,Q(B[0X35P(8HZTZ^4).@$[$'7U&#/(Y&
M?@!DL)^6)2E#5<"WK570[!D]L[%.J0*S9[3DEX6/U\63[QB-1F?S*/7PL+/<
M8(OM7+-=#D.WT,SKK6OJI#BB6^#]Y4R>_E;J^BU7KOS/L]/SF__<;&4$2TZ_
MQLYW2(#+DUW.??OB=[EQ'&1JY[ @*7D;\J"S+5^N=&#!7Z>?5_ ^JC"C8I#:
M3;C<.YW6I_ 3NSFYNKVE"P?GEY<S,UR2(S?OC%=CJ5<IA%T:/EA0I&/FTHEF
M@NKO]^)U_I[>"WIZ:8A[ME[X?5WX4W2"^ZD3G"SZTP5?&"$K1W3BE$?B,[OT
M[ZF6LD+"F /[T^5&/_S:-A>'\3X-?'L*_QE%8_?7_P]02P,$%     @ -D!C
M4PV/^ M&&@  M!D! !$   !A;65D+3(P,C$P.3,P+GAS9.T]77?B.++O\RM\
M\W+GGK-T0D)_I,_T['$(=+-#@ 72O3,O<X0M!V\;BY7L).ROWRK9!A.P+//1
M]EZR9\YV %6II"J5JDJETB]_?9YYQB/EPF7^I[/ZFXLS@_H6LUW_X=/9_;A=
M^W#VUU]_^NF7_ZG5_G$S[!JWS IGU ^,)J<DH+;QY 93XYM-Q7?#X6QF?&/\
MN_M(:K5?)5"3S1?<?9@&QN7%9?WEK_SC-;F\I.3B;<V^)DZM0=]?U^"/28U0
MZYWS]CVY=BCYR\-'Y\-E_?K#%:E=3]Z16L.Y@!;O2:-&ZI/+]Y-K"]!8$NFS
M^"BL*9T1 P;FBX_/XM/9- CF'\_/GYZ>WCQ=O6'\X?SRXJ)^_H^[[D@V/8O;
M>J[_?:WU\X1[2?NK<_QY0@1-FI,9M=>:XQ>N6(@W%IN=XW OKJ\NDM:(RU5@
M=WT1$-]:8O>9[X>S[0!VP,^#Q9R>0Z,:M*+<M99P^4#K -C #I8P::K>GD<_
MGADD"+@["0/:9GQV2QT2>@ 2^O\*B><Z+K5!;#R*@K'6(/5S0/@##7HP1V).
M+*HQ<;_^9!C(3W<V9SPP_ U0AXB))%7P ,$N:A?UVE7]S(@DH,LL$DBQ3@]M
M ^B<>H' 3[45BC?/PCX[UR<@%+4'0N;%B4@#1H3$WQ0G)B7>]>OKZ_-GE-=,
M,C8%4+:OX9^U^F6Q;K,D6;]O^%1+X Y!PVJM%J,A@=N3ANT+5(>4-&0O D1:
MKI&6^KO]:-F-CEV)V*Y(--F1 &"W;XMT**CUYH$]GMO4S5V-(@L(_RB^ -=0
MB6#. 5?]0R$"EE#RK]H*?IT$XOLLD'CPF_B[^=SU'19] 5^A)'],Q'E(G43;
M;VQR6W2&_.<CX19G7HZ".9]S-J<\<*E(;Y 2P913Y],9*O=:HM3_],CD#5"2
M--GH8'U-XL_G $*][FHD"2R*YZ<S ?SP:#0W51[XG-.B P<0 3NJ9/1__?@M
MXA4=/X!8H??_8_@V=8H.'T!<W]UA] @]AM\-%^S3)@/K_LS [^Z'G6RS2W89
M-4ZP)?A6A/QZ 88S_&?45HY S9!0OYR_;/L"2RBHW?=_E7^_E.P8.&ZB 'PA
M$MIPZW.Y%2S^,ID\U93V>Z-^MW-KCENW-V;7[#5;HR^MUGBD/<V9"!137Y=3
M?PGS/8*)H\G<IU 9,2XC0O;*D?%H0#B,:DH#%^C<FSWKV-2\PG6LSROCYS7<
M_W>BO!N-X?_O6KWQJ-_N#UI#<]R!7W?A6P8F-<^N+BX:*IZMD!K]MK%"^\JM
M]FC<;_[VI=^];0U'K;_?=\:_+V=Q7_:I4*OYV0#G09^?Z7[^UXAZ6L&^\KC=
M-$=?VMW^M[T7Y J1FG]O+R[>Z?,/L1H2[0GQJF>.[X>MM(Y;S1!\,GNW@V%K
M!%,D/_;;[0Y\U^R8W=7<Z7+S$%TI^ V&<KT>F9:NL#PF0D[A0]3KNK[]B['6
MLP%=&^F^L?6R]Y24O,I%$6:-R<2CX@=*1]RA2D:N+N"_H\H(H/LY(N24C+ #
M<*]'.(=1/-);&A#7^Y&"L]&U2H0:%U>-HXO0DB+CYYBF4Y*FT?W=G3G\'4RW
MSN=>I]UIFC!CS6;_OC?N]#X/8$:;G9;VOJ.)3;VU-.K2=5[C>8Q8VGXKU,8*
MMY$@?^7=B]D>,,^U7/W=H2!6%2\O+]Y>;JY??5Z"JQUW\[HD7S*@V)9?"*=Z
M5W]WM<_R/,4=6V_RA_21^B$=4HL]1%WONDT?K#_UWOR^L9<@U(R8 B-%PNMN
MK,^YR6) %HPW/2+$,25D6S]JR?C0D '5_25CLC!DWX;L_%4D,EG5)&)*?!O_
M:?TK=!^)!R,^CE2HNU(+QG5#1FUW%PSLU8#>HS]2_;_*1K:I!E3"&$W+8B',
M%&A;"K,&F_!Q]Q?];I4R _Z C SO+C,Q(49"B;$BY76[T6!DF[C\*_%"RIRV
MZQ/?<HG7\47 Y:'R<92,9I]JR:DW9$QZ=\E!*@Q)AL$<8TF(D:+D56XR>?B-
M8C(QM<U'RLD#'4T)#+H?!I@ZB$G+1Q$<W4[5DH/6[5Z2DY!1B^DP(D*,%"4G
M*3F]_M=6M]D?]GOFU\[P?C0P>[>MNP[,X=?.;?U:.Q"9@T898*I?U3?-4XG1
M2*$T$IS&F<1: [2OC$IFN."!@Q8R9=BAWKC:D6FG&''(F?"B87\];&J5^A;<
MPAWY=X)ZTFS^_;XSZA3*J5F#46O =_5-/RP-?J(S74RK;8%4J[#W5^I9/T5-
ME1[_KOZH$H=:*WUH7%PK67+JYX/IR1APAE?&R![L>8E"S9UK\/YSN ,(#8GQ
M)+G3[?<^CUO#N_Y-M_.Y6 ;F-E#EIG%Y4=\,Q""6&J(Q4GA.FP%;OBJVKQ3"
MJ=QQ+NM7FBS+^/8$-Z0M4XU7C^W0H\SI,O]A3/'6["0HJ 4+XU6JQDL,;^EQ
MMF8D_6 0"WNJ85<&]O6J-#4X\6?]6#P&S*]<+IO+IFW+/C' [* E@1^.M;B5
MG:EEX:I1WSANWT$65A08*1)>122:NS:E@OCVD 14W/LVY4T.O [:Q'(]%V\0
M[B\8VEVHQ:'1J&_$P[+$ ;N4IZ:R4T/V:D3=&JM^7V7 W,L-U4&EYNG;1GTC
M0)#%T]-V2YO]N[O.6*;PFKW;9E\>P+1Z17)552C4CM"[^N:Y8@J;3#Y>P_?*
M&)R%7==5$93J]?6^4=]PAY2,._EU-FI]QJGI]-K]X9W4/=K'M9N0ZE7UH;[E
MS#5"8J2PG/3D%TSZS8)7!PVNK[:D36PRXA2# YLSNG,.53XFI2Z[NFC4M;CT
MJL%>3G1_3G$^_(>.#^P !VU(L4P0"O.(/NR4T[1/'VHVUQMU':T(WRZ[-*(^
MT?=;]6HDW9ZD$#3-06>,U]#ZS=]@DQ]],8>M&W/4 FOB;M#JC0KM;'K(E)O=
MU65]\S0\QAM=;I>VB$1=D[B--/)3XAR;S:DO)!5#ZF$=RR83@9#Y5#<$L [(
M0@IVL;VQ,%[EG@G_VS1>TET8<1^&[.0O43J8(?LQDHY.<4/56DM%_84B.-7:
MM]&H[[%,3U+5RLD8M@;WP^87F)$7'[5W5#46M7)]6]\\U)<8C!6*C2].ET4[
MF[ Y:-1+ZUVCGL^DTS9=AZTNUDX9F,/Q[^.A"5JE*:-_6=_K,JXP7O5R>U_?
MS-*(41D2EY%&IOCIE;4[Q\BT\:D7Y8?&91%6GO;R'-W?8)$K\,1:7^'_].\Q
MK(.I%]=U??,$>(7!D"A.=\Z+7H+?!JPT[!L75YN.VLOY/T7#_<5<[GZ54(U&
MJ:X:]<9E[N(XI0#8+^?KU:6CSVL5J+'^=%S^7_(16?+G%S:C7RCQ@JGIVU^8
MF+L6O:.S"5:C)1,1<&(%G\X"'M(S64S[TYD*PG<]#]=# B&?4_@XI]QE]EC6
MPK5#+@DZ,T0(Z-T@Q$^?.0OGG\ZBYFY 9V=&5#HW>E_AH\UFQ/4[\ -B6978
MWAB.:04A\9H><6<B=J[3XW"()Y8#V=HV?P11 ?P@^6E"/"R'#R.C$S?0'%;T
MS8SY()-\H3&N._+LSL+9@'(+ON\_^92+J3MO,XY1A3L:3)D=_Y@YWD(X"LR#
M'B.!B_,(N<9PY<U_83Z[(DL*TRT.('5V\-%V@09\8*6SP2@@ ..Y&G1#EW%2
MA_G J?Q5O9I4$*6OI@%G,U<(QA<]%E"1-Y*MC4L?Q!A4H->ET67,(?:4N4*V
M-3WT0HCA8<?2H+WOTR^A;X-XW $9@!:3N;J,^&I6Y(*5SI18S\ T]QTYZT/J
MSB8A%[)=W^F'@>=2GJ?"BZ(Y_+@+J;7/6(+=Q^\^<Y 8(4M<+<;T.;CQF/4]
M<YBY<,?B9Y!TH3$X3#%<W8[O^ $%VVDMZS'^9@*C:5,;%IG7#J-LN,R1[X>T
M9':O+*4>@Z5GNQ;A%/YLS5W!X),\ ] UMC10E+ZJE^>03:"R29$W(I.UVQL?
M1]VZ@/V!<HTA).FS?0?+S+RH= ,&[Y"B,6#AF1'\)IV_Y3I<_Y0Y\$-V486%
MWS2'K1$8T\E:'+,;.J1SXMICMM)<F=.A"UY1RSRRW9PHE78QBVQLXGGL"8FU
MF"] 6=MX .C%A@57VB [XRO54#$%\8F6^[BM9>F*:[4D;T+A^E0(TX(U*>0N
M(YH,1%,(4GA]%T%6B95,YK]3PF_EM&4Q\$6CTGF7JE"GI'NS7>FDMSW&82W_
M 6MA69+1#JVHQPSI4L(4&=&/5));S9A]S:!JVD#@!C^Z8(<.*7@>#MJBIOT8
M/;28Y<1D0^R^YUER&SD6/Z6OE6S<F_3'%=_P05&5IZV%H*+;_A;5+E_-17-V
M[L+@3/N?H0B4ED\A''LL[>/* I9P!4-D06988H\Y^&$>.=PS8M. 8;>N[0(V
MU[>\$ M@N;&MA\\23ZF7+2>'05Y1&;IS_<R K!]PYGDRBS0:36YT=R=DY89Y
M30'&*[I_FI;C]M:EJWPYJSXL5Q"_ %/_/!>E![9GESZIQZ0%6OH 3?AH4WL]
M&'.S6(N4CCD0/J5]/X^+.^$J?0H&A'^'%34)^<,W6$!?70YZQB4Y(7$U4.F#
M^DJ@JW#-/5$/2 %0^F"6)<D<RCGQ^LZ(8<7.$;5"#IZT>F":P*4/,C$90%5,
M7#].898EU/]-[8X-;5W'10I-(6@0,0IV?^+;7?@ZONT+O\&JLYLAQ\<,TS]8
M%@S+;CUC\C+-#MW]8"JJ:@6#(T(\]N ^JV5KHUGI4K0Z-F$.ID^ 92 "9GV?
M<U?EIZBA2@ZV=]G3?0 2]&_917SBLS*@>R'.?=_YBGHK6[(+8CGXF(N&JYOX
MN+$#[G! 1=_IT3Q'.KM]Z4*95 3-C:]M-JQ"[&Q'G6ANTXGI;WP;3P>"Q:&5
M<8&.JZI_[WV'/#*.I*FE?DO#TL7=Q$?'Y5V@(9V'W)H200></7 RRS&@\P%+
M'UR\1 >#EI;9E6I7.NGITSF.QLBV\-0.)WW:N*J@S!(ET8-/.2[!UJ:E<S$^
MI!@_L?$4'!:P/-LLY &E_G@*?3Q,4[^,GP!TD>NX[H6R] D!XM93@H;TD7F/
M&&M,UR#*<9.*8BE]V'B"?NOB>?I$(AZS'O.MS8!8MK&AC:"R =IFZLQ8+P].
M 7$DBU?SF#E-6#+S359T2!F0I1Z@[V()5-T(8+,Y$9A1"Y.>BMLV.V:.ILT'
M+'UP4?ZQQHES=4Z;\>>^$QGU4;9WQW^DD6.K'H@.9.G#RY*:W62M,H*FSB9Y
M>29RD!25/*15L% [/FR:H/1N:?1OQU_F$W;Q<^+)9OO-!3!4-:TBP_J2A^N*
M(U454%5]_?CRRBU9B#$;A9,94.[ZQ+L!>MN<P0\!;(7_"D$KM1DW_<"UW#EN
M]G$,[QL1 ^)F'S0?#'_I(<$D/2;.#LJ-36]K7+K60[/[)I(L4P@\BX&I_N8&
MTTT'6FFZ:^.H:(I DB*S.IAJS>8>6U NC;_U4ZHQ><[-LM5'5%5-L,H%T\T9
MJXQ4W](YIRB'@-3T;7/&>! ?-<1Y&JX?@F:.-R+8BA47(XJCJNHV-L*T9ELF
M!N /8Q;G"!2Z2%<02>FRH$A^BTZ@J'VSN/?3"=]_8[ +? 4LX%)F2\;^B*LJ
M)RW .9/ENC*':,H\,;&Z0[#;'!ZAIXIN,&G%07R[ ]Z0R[$)<];-X2&^:MEW
M[D5TCI1]JWIGA%45.S,N79 ;M]C2L'0ULW1G(SLO;\O<VKC\08"HF!9&'YKY
M8]C:MO0A#&17T4&0*=92UV/;^W9)0';^A3:*(WDA"5#IF4K@=6$ 'EK'9BR]
MH3YU5*D=Y1%454LZEII5>LN8O? '54&$7-"JZO,HCHD;DQ7(ZKQQ_)PY!<^&
MBB.JZI3@M0/*1;IL:<<7(8]RD0-<&UB09N9F3T81%%6=AEAT)XLY1NXMO"M&
M!)FG\MX"C)(!/D'Y(^R47&^9[("PY&RZY-Y%9.7VG?[JWL4=L:D,D<7W+G+O
M;FCAJ*AY_,(B2F[<@7UO6A8.B]K@;@\9=.O+XX/,V=@!4\DRD!<2'<$< EO3
M9LG.X=6MN$H/I79\F\[\*%\2XRQ2D!4'"EM;5U2R1YBZVP%SAMI@-L(N%<V]
MC 8*S&SY@W+6]^EO29SPC@36-/M$:4=T1^*QD/UJ!IHQ< ]K;_OQCZL*M6@!
M5S8Q1&8Q \D]+)B3A,A=EE-<* ^J=%=KRY%F,TI7W\CG+G(U,QM'91G<=A^3
M0E!MUPD6^Z1^[8:K=&%XD2,CC[(U\VGBMH>I+C==X,8;3F0NT([5Y=HN%\%X
M"HIMRCS8)<=3T#GSQ2@R'04>3Z+'FETZ0!>^](TW?7:C%[C*:E^Z &9774SG
MT^Q>NW$KEG*O]8ZG+K?WD%-M^-+E-%U_KD6XCU>B;JC#.%U6,R+/^*QG]F$=
M&K^)'Z2R-8[15<D.QDA&T6P@/K83LZW+S995C2&D;\E%M/;# -<:EB;0NENW
M!:KL0G:N"!@'O>HUF>=166P&/5>4J$3A9CN^6L!ECU"O\G&U4@.3VXA1I-G*
M42 9K4O7H1F>XU?BA?1@?F@>MLJ:\"D7$P,FT.,NWFDF:&7'O2IA.\)(6;!
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MZNV0Z$)M*@U#.W]# [+T4\>("2Z^()>P*WX@6+.$BCZ"*I1+&1&'/H2$VW^
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M+8U6\&2Y-^0K]5CJ4NC62;4^G"%7&=]>,,V^!A_H"S@=)G+1*[H!?0M+8%X
M*D-^=C15<7L+5@JOLK(Y:>Q!CLLPUDEAMF/!"EO=3NNE-#DF[GW A,1#4O'O
M<'Z^.*^80^X$&*1UJ6PU1!8LZ?@42N&$-G:QE[>!6H8*\ME1H9D8FA'C_12/
MPC!O?SG"\0R_KC&I9+/34 H9=Q52 F<*Q8Y>.U:0Y\RZ,.):-,M003T[*JR^
M\<TXL#L_P.GEE3D59$+OR,5SOB94R(<G2+0R;Y0/SMG4Q2_Z'LHRTM?/3OHK
M;GDST;\=AC@<#>=#_(K#<\^=EQ)\T)EP^ R!0C?(-FA5;+8JEAZB_QY**Z/W
M/IQ457N^0"$M+<]:R)%6J01!"9D7P. \J5KF8PD]S=UE..OD^:[(AINLW0K[
MWXSHVX='H\D)X@<<U;ST-2M-'IGTMH"QA(W6F"!PQ8&G&*R523+;)3ZZ$]DZ
M><6-&=)6*BV]Y>GQM7"8E%@<+9&G0)J:6P<Q90]9N.!RX=DYUDEW7(]HG?SD
M]NJC@116)D4]5R!O;?)I2)M)1!UB>7,\SIOY4SVT&7##$_GM# I&"N<<.>RD
MQ32DD&(N.>1<[CP&N?T1Z^3_-A)QPSUMYPI-QA_W<7KX&N-\D;0Y&L[#Z"V&
M&>[&T?#C8GN^KCIF+7/R!HJO)XY>T_H1 Y#O+E@6WBKFNWA)]T&Y3KYS8^70
M3UKMPJHCG!*,\<<%JO/UGYQCLE;[' D)RD*K#YZ!3YX$;I*7A6Q<+%W.M6Z'
MM0QES/.D3$-Y](B_!DX;@49%$(D3 !,]!*DL(*-'>_*#3)2= Z\.X206:YV/
M-8XUY,!)^A%Y*5 "!LG)MW.2/T4XN3:1UKWD_IT:7&W#']EX#C)SJ<CD('$A
MZ_FP@*"C IXCTM?:^&#ZY!:6@K>F@=9J!&DOF-X&LAX]GSOZ3'/M0B1$.54N
M9_"<,5+W,?-"NQ)*%^5Q)[(U#;M6HDI;<;3-3E]8XP4\WI3 &%-@6:(X@0<)
M42E10>54>-%"=\GDW0QI36.UU7C11@"-*S@&4F/(CD5 E$1&731XSQ!XLH4Y
M[4EK=;$EIX]O6X8B M;<10&AD8.R]+?@$D(.1:&.7/#4)1:X]TG+X]9@W$O&
MWZ6/'KS##0]7)Z13YR?O1V%<K6\M CFJY='OD&+2(K-&1]Z9MF1R=5+@3$#
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M1 2W+-397P&\(A\&N4@E6IF4Z^(C7$+1,,?/T4@NO852"QL420IJ3SFPI'S
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M-Y(F_+U_A<?S=5#&OM3IZCFR,K-*TYFI[)3LFGJ_\& )2.RB>%5<TL[Y]6^
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M3\VH\.%H,AGUPW3BPP#.FX\-FA'#">H>GWAQ,IS ",:3GN"&&\,585HKE(H
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MM[LP.EP ;N5G[.$H=VM9KHH>_&$>;?_G.&C&D/[RXV0TA6\_1);#[Y.W@]F
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MGQKI -R4[B7:=67.>=#*:G +;K>!M]IQ>43QCX^Y7_>D@I;NZ[^"B+O>:EO
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M6(@N"A]"T.VN8U<__R66Q-Y("TVW(JQ@/YQ-_&1V3+6<^=G\L&INR./NZ$Q
MN\::<F]CG"76A4@4BYP;'SF(*E;$HZ@.SI;H3@<=IE#>@)MC6;:8:0&FIO5P
M!\WS6 H=:NL^#W86=07;X"XHPWE.-#"2+2V%M73IX1<#R2HZZD#JE*H<G.Q!
M[T_L^?M2^R82[GJ7+[%C\_S<HV&ZNTT)3A6ZR908XTM'2#UK$JH)9Q9-'N,
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M0#KZ B/<#W\90YX.WO<S])0+QJ242Y5PQ$Z])C;J1+Q.X)S@ /?KLG;#F5U
M'Q"K]J:[K@N^+_?.11&3\^;<_S[#V]/> B_^GO,JH3F%*V4(-!/N+2*4#&C+
M:LYKAS@ _7<HPPK'HLOI'C=7H3]<U)&(S<6P% (X28BYG_O^AJ%+$M]MVHR_
MF^(L%S5MYI^<E]DJ?SGN,6\T,\F2J Q:X=PKXJ.+)%K('O?8R'W5W)J:DSL
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MI&(L9-HQHWOW(N<AV%HL;A'OX+K=BQ 6=N"M8SW-U]<;S.5@O$(O0^.A(*,
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MEZ0,+\><&E^TE[W53/[U*A8\B9#[L]-7YQ=A\V@&=-\+[]TC<Z)_XMV5!".
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MPL>_NEO^$F6Z*'65/%.0%+@<IM;)KS'CGK\*R*O9>?^T#3&-3YK=6?P\4#4
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M#]14![4Y4DH$*3AR&;P:2\48#44_5#1=3#ZL76?\UIZN H,;.L+@IEA^N90
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M<<9=]FAR1:T/QMOV,63:'DJ<W%I S%E^.%+-2*#YR4=_;5@.]0HAJ^NHDC\
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MS,^< N UW]ZC_LH([,VL+.T=O?.F=CQYE_-RW3B2> 26CX_Z#8Z&@W:4;>'
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M7G[^Y?WGB\OW-W8&G.4XF!ETXZ$[]G[1L^" K#C8$1T\RP[^&.4>@!MN0YJ
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M[X-1@F!(1""CF'EA'%IM\O;U-K?5H)/-Z;RI'U?#'=NAT!I[C]80*/N=5Q,
M!MUK[>UPVMU5$]U?[*<:O>3&%!](5OQ.EFMQN7I<5^5'14/+L-T&C#D*=:Y4
MZ/-0V8^IET!,.($"(T^F+,0D, IP-.AK;BRA106UK&>@D?8,U/*"T/+RG@G0
M9L0Q$'PCT\9)R%ESB0$F0S))7W>3\HB!WOLL8O**@S_Z2:E 5E7^Y^JOHJQ^
MSXH[99)V<7,"A4(2(: O ZQ3*W.(:1I +'G,F/)#H]3H+.9H3W/CCV=9SX"6
M%G3B6K@_O<@:^)-#X34R81R$RN66="]F%D[B4-A-Y!:>@*&=DV>"2Z];U]O
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MH."/3M0!_21;= 9-R6W:][1YN2T1>9&<V_9]5VI:B2MY40B>59V=@$GHTT1
MF2"DF$@B7=8F4'9"(*2'0S^55AE.7W8Q.[I1$M9'3+6,CALPKR!IRBRGX#,Z
MA]A!X\ <A[0?EB->]#(Q&QS2\N6\/_BDXUG-/2E$?09TD3_H\/7:5SPO"FW>
MU+N^3\^/M*F4S_\D!=>27%;BH5P$7B0$#P*%KD[,3_T$II1',(P15O^?A!Z+
MK0YT3A9I;@Q2B]L>]V_K!+:4 O0);#_799.O-0-_U#.M5L[VT.CT 38\69IT
MV,9VE:89,?O3J\% 'O2(ZW2IICT'&PS%%X=EP[7LQN>?LE5>* .PBWGHLI)^
M4""\4\Y_D=%U'>AUF^LZ+OFJ4L MZQ0FS0N_-F;D0GA1G 0X@#Q-*$1AA"&A
M/(!Q(!6K)XPD@;2[F#R4:$8T,>GUXUUQ0=:%$O$MK>Q8>[!A-./N28=FHHHM
MNV/2":JO\+89ENLR(3O:Z8(>!]X#K8;#4?G0F ])Z(/)-BFM#XWH/KD/WKX;
MQ;^2<+K-1]66Y=H.#4@\DB8^Y1![2:#<=4X@52Z\-LZY1X6(A&<5CV;3^=S,
M\":OVC)?W4'5W0/(Z3*[<RE48C4"9@P\%JXCL^QKU0.R%=ADL&N%'R=4P@6S
M(5G2JO])F= %F7VV<VK#X0K'^V_Z3&IU5]O%U^)1?9KWJKLO17Y7D(=VKRS
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MS"13!FW*!?8P3RU.X YV,S<S9EM0T$D*:E%M"KL>1-7 1!@$JY&7];%ALJF
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M!,R9)#[C,(ZPKQR8 $-,0@F)3!'VPY"CV"J:K*>ON7'=EJC--L&VL/_G/^/
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MYJ2Q(C.N3% 41I ' @F9$!D$5D4/CW4X-P+[?/7[^X_@XNKZZO/Y[Y?7O]V
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MI"=E2!")>&!5VV!8\>:VC#8:_<7.?1MXQ,S\M.\W#B,OD]N*_0MH5#L#&^5
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M]?[6S%?_VI_U_1U,L_J;Z+BQ"8P>=BSBLZ:E^/M:-?S^:WW&OBE-'L=1)&7
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MFJ0)C2+H)9&R?2*)("589^<-O,CWE*\NK/)2&/<\-YK:.73,'Y1)6J_M'X0
MO]4W?'>+=EF7 S$?$D,K:0R@)SQF_[A;4_A9<)L#=GM#RA:U0:TJX\ZG-;%L
M,7EA;UDWX,9J#3UNK+N/>K05@S9WBY77QC!+H$[7!5$B0TBI,KRDQSP9^IAZ
MH=49<$]?<V.NU@!X]D<Z89URY_2!;,9, T$W,A<YHV;-.09X#,DR?=U-RBL&
M>N\SB<DKSI6$U**>KVXJQ4,W]_J>RM6Z*BNRXMGJ;A&EJ4@#&L(0*9<-L2"!
MF/L!#&04)V&:,C\T\M;,NIL;@[QO*^G4(H-:YC/02 VVQ+8N.=2'>#^7#(_C
MR'1R*H0NM8D,D#F]4%%?)U-7+3)0^)421B9O.9R-]B8(\A*B+(Z40II0?9]%
M<HC]%,,X31,O")61$AB%.AWM:6Y4,F1.IE-S7?T726TU&606)X[_Q9)4N4-H
M=^QW<B*JF>2=LDXS-4)6J;K=7_*<_YDME^^4 \DJG<7P0UXT5N M^?9E73SF
MI2B;@\ %%4'L>7ZD[+-0UXI+&20>]F#(1$QB+TD\L]J/UCW/C61M9+<@#ZO!
M,.#?L2 >F8_G@*X%58^%\I051C8W.ZI,^>35/:G 7:L6R$K -ZK5&7/:XB,5
M^08>6_4&XG<7+'OYWJK!Z?C?1<^=]<"I@4%W_=H(!HRI+T4B(",Z/S]1UC9.
M4 "].$Y(X$<D#(;8]YMG+$C/'I93<$@_U"?M_LTN>.0$[(;: 1PONJ2_PSGL
M O9'GYB]Y,8GMX4@Y;IXJG<$ZH-89=2>?Q4%N1,7>:DO3M?[! O?#Z30F4I\
MG;<?A=2#A#$&N>]%?DRQ]+@5M9AV/#>6Z>1N=K5 )_D9:&4'6GA]=[;9[[*C
M'./1,&.?,3 >F8B&@M>:E6RQ&I*@C/N>E*ML$=FG+>OW'3SF)CGKY8/ZFJHK
M^=<BJ\25E%?RJKH7Q47^\%B(>[$JLZ^B(=&%(%R&-(Q@'/( (I^GD,J(04PP
M(B)*TY1M*A@9^,VV_1O-M-V"1B/S62TSS*74#D>NQ:XK#V[DMB_5:3TF!L[S
M*#A/FN>YD5V#7$L/KAK$:P7 C@;M';8Q$;=PJ,=$?B*G>O 1L'.C71'L=:6M
M&YW.G7;5=\>E=F[$81&Y%FI1*LGR2NK+AA?Y2E?O%"OV=,Y8L2;+!:<LCKF(
M( ^(LGUYF$ <80*Q9$$<Q$)&TLCV->IM;@9O)V]]34U)#+9$!JW,%EQU%&R#
MU6!("$=F_ZG1LV#V(5&<B,E/0M..M4W1Z67IHXU,Q\JF^NRPL/%+;IL/GT6E
M0U+:_#C\[=-OI2[AI:/?5DSU=,ZJ[&M]:7(3-!6%D9=X.(2<, :1C A,D7*J
M)$IPQ+$78A_9;$/8BS W?MX*MJHC13>B@V?9_V*W#>$P+F8;$N.B/3*5Z_"2
M&NQ.?%TR\(W60/E(/[Z*^RCA;^X@#KEGX2#%I+L7[BCM[V.<T)*#,:K,6;UO
MHLS:]V65/>@=@ _K:EV(BZO?+]_Y:5O[^?VW1V7^BG+AZ\++OB=@'/BAWI?U
M(24RA)&,(RR3@"F.-+9-+3N?&Q5VXNMH^(T"H-$ U"I /P5=G?-."POSRW9P
M#&S9$2$?_\QH7FA;V+XCHCZ1*3PP^G;&L2-\O;:R;9O3F<Z.VNY8TJYMG)1M
M^+4 R_-2%$3GD/@U+Q\S)O;2JTKNIR%#$8PP]91]K2_MXD1 Y$M"DC#%49(Z
MI!VVEV1N:\MVM-YK@<CE&=@H!%J-G%+A.@R:P3(SU5",O.:XC,)0.8H=!L8I
M6?&X S35139"UTM2 )Z5;)F7>E%20_8\-K0;/)8_4&5)MWF0'AZ70J]7?%UT
MV9":ZW!G^AQJN=9A"H 2]K>[(E^OU&\5EZI?G0&RXJ 0++];9?]0[Y.FIKO^
M[3(CM V]_ G<WF<EJ.K/@>?*/UOE5=NP $O1G$TJOV[]E*^K<JCT2$,,K6%B
M98<.OD>&97<<#J1:/J%!MZVKCR]C>Y_J#A8\Y1X-!8)(9^]'021A2I5K1G@H
M" J4AX:L:H(=[&EN*^3'5V/8GUKZM;Q\=QA?LYVF05 ;>3%S!<QZQ^@H&$-N
M#!WN;-+]GZ,Z[V_S''_!C2GJ$\OS>CWZK$1?%X5:?1<<1W$4!PAZH9= ) B'
M6(0(1C'E<2H%2JE1]$9O+W-CB.:HO5F;[>C@=1#-J.!D:$:F@0:51L S\"SB
M</._%X$AY_[K'4TZ[WMUW9_S_0\[^-Z='7+Q;-5>;ZS22ZY:SV2F2:7IM+L5
MI^S4C\]FJOJ;,M'Y12-.\^270CR2K-L?6&#?\Q+A4<AT33&4T$@'?\4P%2E"
M5#"4)D:)BJ84>FYLM/$?M_0^ \^:@VW5V_FYN9!:NQ9;ZH-6_S/0(K"9T"T(
MW1:<A>LYU<=DL'TPPT]D9%;^WU]'^W58[&',\"N9+.0Z7S>Y3VOK!A3MOGN5
MZ^3.I:[^TVQQU(.=K0#A7XE:S^H(/I:7ZMNIX_P>FT-&H%!;Y0\9 U2LA,S4
MG]4[LMG<;S9$U+=#-E];5>^4D&?G%W#5_5#[%Q,/:^]6QU2R3+<K,C&Z.QLH
M4_=]4GVK:_&8%_H"TKO-GN+S3JOP$$XX%3"E7@A1&DM(!!90AHGO^Z&@,;;+
MW'B\S[G9,S?O?_FDRZQ>?OYP=?WI_/;RZK-3-:Q>G,U<KH'1&_M0H9$6;,0%
MS_*.58O5'* 1ZFSU=OL]JF^9X'"@)I?1JPZ>W&?Q9QV=I-I7W]D]*<670M>*
M?FC3QR01I<Q7$'/J"44X--'4XT&=E8,$*"!1BHT]L".=S8UIE+A-^!UX%ABT
M$EM8L,<@-O!+!@1N9)+IP\PEM]$Q\"S,]@%!G,C<=OH [8Q>0U!ZC=5C;4QG
M9!IJLV,<FK[C6H-$$?2E,AT%?U<?]C;I,9JD=->BK(J,*0^J"1[]DQ3\LZBN
MY(>\D"+3;E"YD)QY09"FD! _A2B)8YC*A$ I<8B],"%1:&?RG2K1W&A:ZZ*=
MS)_?,/V?Y;*>E3]J+W65K^!7I9)R'LLZT/I-6:MY.&7^2(-H:$]..31C6YLU
MWHTRH-&F+;75I<C4VTR=2ET<O%;JK*YPH$9O2[$AJZH,A/&PI5=.%6KB^BP#
M8?BRB,M0#;NQ]876?U4UFUC76?FWYBP^B!B)?,YAZB<)1#BB$#.40DQXK/Z/
M4XI\&PI^O9NY\>J.E$"+Z7;'X0"H9I1X.E0C\YP#2M:<U0_"D$1TH*=)V:5?
MVWW*./*T&P_\0K*5#@6\6MT0?>_J<J6MB+KN^((2&;,P3*%@F$ 4<.41BT!"
M1)#T"&,X9HE9:@V#WHP^]$D3:;S1TOX(ECHL57WPHDDZ\""J^USO^&\DM^.(
M/L#-B.)4$"=*,ZFD;*LV:?2TJ-K2N33 S9HU#! 9DCKZNIN4/PSTWB<1DU?<
MF*0Y)UAP[ L<DP#B* H@DLIXH$&,( DP%P()]?=X4>4569I11M.LE<6P:7R\
MK_M6]^%T\:F%*?9C1(DVKW0*-J08%E(IU3\#B:)4I#**C'8;3X!IBMQJI\)D
MQHCVRH],?N?]&EL3W*Z"0W)9V_*DM+6KS3Y#[?W5C8S:Z*LOI*B>;@NR*@FK
MKY"_=@(6I*F'DS"&"9/ZDC?R(<:$08[2($'ZZC>S\GDL^I[;?+U^__'\]OT[
M\.7\^O8_P.WU^>>;\PM][GAC-WMMX#>;XB.!.C(/=-&:M=A@6^[Q3R0=$!N2
M6&RZGY1]''#9IRB7)MQ+L+P3M+I<E551'\2\??K8AC5=:T=0=\_NQ:T:.M$=
M9"I+R\,I@3ZF'"+%8I#P $..]19.BCV/F!]DNLDP-UY3KG.9+S->3\9.=E +
M_Q?U;^7@W=Z3%7C_][4R5VYS$/SD>?JJE_^3!^BZ K\40KU:-$]Y/R51^T?[
MTB6V@VEP9#K^$(UM+;7E3;0&X%F%,_#V:6^PSD"K"*@U.:&$C.TXV!>7&7$\
M)BX[8STNPY:C<032I%"-;=.3E[!QU/VUXC:N33F&4[Z:7NR"%,63^M7O9+D6
MS8E'ET?AG6C^NR R)JDG8F5_)VKYHIA"2J@R,4+"PC 4/ F,$A:<+,G<%K$Z
M/Q[;RH]'&E7.N@(C69=!Y UO5; \_74?-#,C?I*A&'FQ.I2E\*P]\P6;/"YO
MWAT=!?O SU,1'#0PU%F8:0-'3\7L16#IR0VZ;FI\%:NU^* TU-WKQ&1_S:K[
MBW59Y0^B:"T5A&,/A;'>@-5EQ#P40)HFB<ZOB!B*=,2Z46U&JU[GQI6MT$T"
MQ4YL\*>2&W2"6QJ/=H-@NJDQ,+2C;V<<1_6MFA+W#Z3XVX#%"9WP&G8SPZ3C
MB;<Q++!XN8%A\_)T8;/GK\6A;/]FQ9L\X@M$TM1'.( Q800B$OB01"2$(DTP
M%BP0B3 OECBVM'-CQY%"(;=_J1]JE!\_ M+\JS'839G3MS RG?__]C,8/P)V
ME,]AJDQ?]:'M<F\4V^LOI%%%1ZC.+#K5&O(QPE+-A9A]/*HUGD,$HMIW:F><
M<)$M;@1;%ZH)/Z"W6;44"Y&H.4%9#-,@4!X3#F)($REAFD@:!#0.D#"*.WBM
M\;DM_;50^B*6(.P>L*6:SV;,_"IR_>OIJ7B,O/QMH/"#-_1'T$EZ.HOUZ?WL
ME92=6U(*]M-=_O5G]5KCD:@?]AV15YN<A$+ZE.EF?.\S#M[#W@:+(@Z1?=5D
M\9S3ISV"O<V;1 VE=E_NQ9)_*;*\4+]=WRE?1M\8701<$!FE BJ.UP7B$(58
M^A*&' 5QA#!AL7D"W"$EFQLU7*ZX>%CI1;[8J+6=]X(T^M3^OE8(/&J-]%\:
MG8!6RL+,&W24#2S[[S5V$V](UQ9\J]EV]K&S3>[P6S5B[5AV"H):P_HOWW\L
M+<SS[S6F$YGBWV%L[6SU,?#OM<L'[7 Z&WP,G';L[5$Z<%BZVR(J9/E\U/Q.
M5"1;EGN9M(,8!2AE'A0XH1 E7!G='N>0T1C'7H!]GPKC9=FTU[DMN=O9SS^0
MK #UX5']KTZCK8L7-J4VC,?!8.$< ]V1%\77X .MT*>ECS<&UF(5&P/@B5:H
M9Z"S9Z!Y(_Q9DYA]J'TA6Y1ZUQ'CQJ9;(VSUV^%_ZY<=DSRL:2G^OE:MO_^J
M_N=6M7+^+2L7*&0>PE$ $Q%PB @7D/A<0IR&$>4T$4EBE?WX0#^SX^^-F*"6
M$VA!P1]:5,MCY4/ FATD#P#7R(3LA)1]RH-^' 9-9'"@JVG3$_3K^R+IP)''
MW4HMY\NORNK<R[.NSQ 6*8TC&A(!?67K*1O/#V#J4099& >2DIAC853;\VA/
M<^.%C:PO2@'4XMK5!SZ,KX'M-A1JX]\L<0+,N@3P43".E?\]W,"DI7^/ZK%?
M]O?X"PZS_VHE?EVON&KT4[9<*D/S5A0/'W.R:J]!A6$<4Q82B#VIG#P?8T@Q
M%C!6/EZ*$\RD1?&Q(YW-C0-\SP.MH$!+"K2H%C/_&+8&DW] Q$:>_TI2T(KZ
M$C27,(]CZ%EX9P.B.)%3]NJG-^!]/!M8>OGT6!O34:JA-CNL:OJ. [%>B$(?
MD*L!$%?RLU ]-)^MI((&?DQ@*",=VX<13)'/8<(\WQ>,>:%O?NWM0"=S(](M
M,?7.F!;4A1$.06K HP, -3)_CHR1!5L.@-5$+/D*9@-1XQ$,>BGQT+O34>$1
MZ7<H\-BS@U>[U6<<ZE=D;[,5>TQB/_6@K&.><<AA*H,$AIX?REAB&?KFIPDN
M$LR-- WJJG:*#%8[]<#8&!#LV(B/O;EE#O:8M6L/X#]8S=K3QV$B9M^,AR+:
MI6!55WE65^DN]%G%J\5J=>663L6S\4O73E*+MG_(3JA!>Z#AN=2>[=?;HN;L
MD88<UK=ZT^7B_/K]S3FKOC3E@8IKL<R$_* ^H[(YNE</>D+B2)><C7DD(8H8
M@T2A!*7G!3S!:>R9!4);]3JW=:RYC%X+KABU IWHH)$=U,*#3GH+*C4>!H/E
M:PQP1UZROC^N%LO2&/A.&DQQ,LYV:X(M7KWK@'%CTW&_K7X[?&_]LMM)^:5:
M-]2'5'55]X($I=3W*)0\B?0U9*(+B'LP2CGSPS1DPK-,IKO7@]''/VD"W4Y
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MXN.R*'-!NX*B*=,;>9;"E!*NZ5%1B"EC,,014C+&L>9+^P(:I[J8&PMV0MZ
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M9GUE,T:AWFMB#G&H;1L4&G8)4,TNBF)$190RM_PKQUW,C42,A/O%<'V*5)X
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MA\AP(L)(:+*RMD(O]S<WAC(2F^G4R-P>48.=U."?C=PNF1PM4+<P/X?%<NP
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M,Q*J$,$T3!!$.# Y-2-MRTO.$*<I(CAR";"R[WIN9KV1'.S)"!JYO3+P.@R
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M454!?GB'QFV'<'D$['8&@^(Z\N)VE+GK9I>ZJRG]//1E&&MLAMP+7.YTTCV
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MNK.7^U5W,TD&25+?',E21;0%%)JJ%)KS!$U1A)(486EU_'FM('.C1:T*,+J
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M<;@X#Y"-QVM,V,?V=LT/<1?WUIC(3^7:VHV :D= '([ XVX$GCM%NK\)P%[
M^E'JS4ZIV_B1EQN]9\F%V? L<ZF:$K::;HNGG(-ODF]*L[[]='?[]<.WG_7^
M9;#;A;Y#T>\><VYU0M>8K\:';C'O5CS6I\_%ZE<I<M/>5_E#KC;RNRR?S FR
MGG9)H->;$$/)5*!7HB2&6#$,PS1281A'<8:M\C9<ZFAN:X[)W-#)"LI&6%"G
M72J-N Y4UX>NQ3(R$&8C+Q@'<+5R B-H'><Q%%P.:\! L$W$]A?@ U3_S\05
M<"/*@S0UW[>/6Z#LQMD6T/6R<]_[T_&PA18'C&OSO!NW5NOG<O%?_UCP)$XB
M0<T6BU&(&$:099Q!DA(2")'@4,4V%-JV-S>F_*\/G[__=O=?_[";XQTH_<SG
MH>K(!'=12^LY=J1;3]BH>5)K&.+Z;]#\;6^GWK4SR90Z$KJ;.<<_]O,#ODK1
M>928\_1/VV-OAK!D,J!0"(0ARI( TBA,8$+UQ)()QX%;8JEKA)G;U-PF]SW.
MZ.N96?.J@;)S&$X%_\AT<07RSL["(2 ;TG5XE3R3.A*'0.[8K3A(F[X)A>FJ
M.YII)UTD(T235,&TOKF82@X)"U*8X"232J2"V>78.M_%W#BO-H?KVUQ^H?8G
M0+1CKNN@&9F/:N&ZX^@1PN[/*S]LJN!7O4R<)OB<EJ]3!)]]TC]9^/<VY_!"
M)6& * M@$FM+!\41@501!B7B 1)($1XZE1W:;]QI/D]0N6*7[[I@R_RAWHA7
M-Z:815MU@+<1&,]-91GW7.%;6&WGN1]8H\_P_;S@PR8"/U9WZ/3?V_8G3_I]
MK-FI5-^OGO')-4!?BK*Z_3.O%BR+..7&HYK*3"_)BD)*PQ *B5B(L>(46;D#
MCMJ=VSK<2 ;^:61S"7[>0\K".^JG_\A3<0#572[C>T$PU6U[*R@<[]*_4KC_
MLOSN\0EOP[^2\?"Z^^M?^V2C+*7(UXIR$YWU\D3_S)\V3W2Y+/XP9@??NS"R
M;,.I2S/<"XQCJJU_33DHJ@.I&*0X%C -D8AB3=,)=<A$Z2?$W.BJ40-T>MR
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M2"$+18@)%EEF%R3JV?_<F./]]8DM?$?"PDD\+KZC'Q+O0:NE!_OB RT_V"D
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M7A;\RUV3S"&-$$J$GT*NIU^(<@2)\I5@ZOLIDTD24A89[WR9MCHUUZC%#=;
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M!L1OSX4@_';Q&RDRO?.DCV'[,Q9Z*,"80^J14 U,20"I) %,)*7,(T1KH\W
M9-KPU,:DVO$K*Z@@7X#7!FR5!L).THRY-U.S(1@=6,@T9+#&7$M5";ZMV&V!
M5^D>W$F8+54NU<NX[5&%RY:17<VROK]GK- ++>N\Y=>OU?GC-J:?,\SC""'H
MAR&#2*J_$88#*$/*&>6)4B>KF.9C#4U-CM8X00VT][&)H]2:J8\+P@96FUY<
MV4?:G"#":13-L;;&C9 Y8?%>],NIZ^VTH2R6L]L_%^IC>\R>J]/5$?)#DC(?
M,D:5&*3::R%!"#T>4JFFT&D@D(D8[#UY:E__"IS5$?5]PKH_\;-H&/B;-F;
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M'_VC=:9M2BDCA,;01X&O-"=,(:$X@*F(4AD% >8TL=$<R_:G)D&K0P8;^"^
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MAS4. YPP(F&$\Q1BY2K#C"(*0Y%&"+%8Q':7=[W>U:EQ<B<>6&XE_J\=L8[
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M)"^,-()M:=-P.*#NDC%,WZ=ZR#E R U Y"3&TCM@\0DB(.K#!#[ \KHPRH8
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MFJ,B[2"=-(JPU:RM-!(&HF/ ,-8J27N1$\HG".*HI8Z;K+T^&KK6) U]Y#(
MLO;01:.HNEVI0:6BJ^$EU B%["1#?,B: #59@5/HHAZAU&N_0>\5CU8&P->^
M6FD 9+=*+';N]S99%]'!)&F5/I(A$^N4PS_ ,4M1E+S*S:0.M U]QE(9;'UK
MIRW /=CV<Z0I<^J(\+S<0DZLM,X31-BLK0F.YUBE-=,C- U]['$\@!VDC1:!
MM=GUJ: ^RM7)BL9=WWA% @4,FPV&*9:FF%UMZ_5L]ZOW>>7# 6H/+;0(IMM;
M?-1&^R -R8S;<@DK$9>#*]4XX*6(B?LZ<_T>(:I;3K?W:>?#X6I?A30 KCM5
MAVMN1E[2Q*S/1%DJB=2H?9\E>I$R118$TRI7Z?BUA99N4'JYYP.'BO\EC,3^
M?(9__O;FP]GGT[>G']]\.CE[AS\]]'1TQU-[/QGM0GU/IZ+KKN\WF+L!F' B
M2>X4,=8S!(2C)&@5"-6:QFBS%;1*.YD=]!QJ<GX%/UE>O$*LG\[/_71SAO )
MOL+TJLPK/,T?\3OXPL\P_SJ.L/G)JAO:8M5O [+0+$9!HA2Z=)[RQ#+T!EEF
M21CF$JO37^=@RH<][>P#7_<-V'&5V<"&N>J><-.C8RW2S<#$,J9!JJ <15F"
MBY24)I^X_:> <0MS'#<#X*S*<(S'R1KVQ+(&[GI40P.@>C5;X$HILV)655/K
MI;+X/)ND$1,9951.'MCJ#P/$0F $G4R6>%8^Y"K'XKM)&O;@L0:8>A)_ T#Z
M"TQQ24Q*64FZ'$_'13C+\=?KI?&C^S^/'N6ERPTV7!^ GI8-"0A-(43@& C7
M*1OJ2-^P)XXU(%9#,0W@#1\RFR-3FS[8&VY&QJ<8$UA"5R.#N0[$L3*!Q @/
MWO' 79UI"5O)&=;KJJ+Y^U6WAZNA 3"MXM]?_ +2J]EEX6!=7.1I3$Y&(,EQ
M=!"#!.(TPU4H6(J:XL]2E9'?V\D9UI4Z!IAZ4$,#8%HYB$^(:P1>Q ""$94U
M+A#G+;'2:.*%<@9 :0M52HR[$#>LFW4,H/6NH@9@=[O*]UYQ[XCIXDMJ0;@I
MLD+*22@-LY.-7"&+O-)LLT=H&K8 IX:CU9<"&L!2"4M*0+)9"@M<"T: 1,-K
M>#E>A]45'=S/;8S&&0<HKBI5-O<)&;:LIE8$N+>H&[@2=R\3\GZV6(PBI<F[
MA-H4JMR==IZX8#@)W!OP/"H=ZZ2B'M(R;&E,E?S3@0)O #,?9M/9U@3:C8!R
MCD I"\3RB"Z?=9Q8&S@Q,F9GM,5O5-FPGJ1LV$J8&GCJ5QD-;%[OIE]AL6KN
MN6;GYM[S-+T>E[$VTS1"N8 -S!#K+0HL"$F\]Y28Z( QSU6F56ZA=Z!MV)Q!
MSVAX,*^\7]4T@;8U"]=10XB6"U^:QC&52GEU($'@5UQ8P0H#WE>Y 7Z/CF&3
M!;51M+_(FVA6]6/G?HNB6U]/_PV6%[/T8X$L1HXQ[7VDA*6$FSK-BOBHRMSU
MF+*6EN9090_L1-VP.8+:^.I;/0W8J;_X\;2P=#J]S81R43.!=M9;@V*2( E&
M&($()Y,%P66EJZ];J1GV[*4NI@X7?P,86J7-=LIIY)15U,I F"S=.YR.)+CH
MB!(F&J--YK)>3G,G6<,FFNJBJD>%- "OW8P8E1BNDU*3* +*2&7BT \D-F0=
M#7<FN"K(.@Q4U?)0=4'5CQH:2#/<W<?74QZND*E-!F4V7?P">3:']>?._#=8
MO/F&\D/UC:=^_OT=1MF+'8VKF Y>&Y[07FM6>F<YXLM5-\>EUH#_J5SE:+ B
M3\/>R:B1VF@% ,VL!61QLY9_@2GD\7(4F!*.)D-HTF@HN,<M@DE%+ U4^<"5
MJ%/DM8.>@2]PU /A89)O(FK].)\AW:M\<PY9& B>:)ETN12'9&>6T<\(+#++
MP=<IC/A!PL#7,VH 94_Y-F!</L#RAZGMU/?1.1K1-_7$:W1/I2F-=;5#'Y4'
MJP3C(H4J#2&>36DWG+VH N:ZVCK45)WU%T[<YG.$E$(VUA(G9&EC5D['A.9$
M*^JR13%F4Z7N] X5W=#THBJ8]Y=R X;KNL_\=1N!7_QB''^(!6)@243"K"[)
M94J)<UZ0H)R((E%A;)4;KH]2U0U"+ZI"N3\M-)#$V,K,R$H,$V00!"1'\=@2
M*&0C2::) H;0EMHJ"8RMU Q[PMBCMKO@Z%FB;P _?X/Q^47I<O@58]1S^'!U
M&6!^FA]<]]XP%[P''Q+Q:&LQ"DU 0D[H*"J9&$^&^3KW$9]%Y;!GD?7P5D]5
M#>#POMA>CR=7A==KP46=(*LRL\"5,:E)B[7@T-R')(%QW B.8='NT=7-MKVH
MNM(^-=$NL$; DU=46R*\1!%Q28D509/D438I0 )=I4/-#GK:VB0/TGDW/#U+
M 0W@:(?UW7"SI3U*5#Q'ZPCG9:HHH/!<P!7)C++1R>A"4$?<*G?1V=9FV2?N
M:BKLI74C^7QV^NK??SU]__K-I\]O_L_O[\[^XV;/N,O28>U)'GM-U7XEG?GK
M?ZS#(^-%7 (J$L=0 +=<(C$"(-8K1!3G@@9M W.59@]UH.[P^4R;EYR57-XH
MTL@<#V5N/1-$TH!K5IE(C%=94W#9\2H9UKMD-#-DH2=4/!R#M+?0&]A";ZA?
M2Z1<NIQ-2V'2R;?Q8D2-R]HX( J41?OKBOU-M#0X9SD+8QBMLF$^2E4C@-I#
MW;N0<[#L&P#2/1Y>SR[]>#IB ,&75 N-2F-LS26Q3&4"SJL@(8@DJEP#VDI-
M(\ Y7-OWO?F#1=\ ?F[U-?P-BELXLEIJRT"28*3"@-EPXB*&)=9 SMP#R% E
ML?6 DH'CP,.UN[N%Y!ZB;@ K.Z:D;YB14=JD*2>0,3:1,2GB2Q_#;)US3*I@
M=)6+JH]2-7!,USN&^E-! WBZTPASPX(VF7DC'$D2;;$TSA(O%1#@R08G):Z8
M*I=XMM R[$6+_K%SJ+@;0,RM652K NPBGCE<P'0Q_KJI)=PP!@%T-,R2E"B@
MH"(0+[PB7(7 4[)"JRHGR)TI'/;*107+5$4U#6#N$RQ1-I"N$W0;+FBBSGOC
MB+>LS#1-N'?;!+B!)\^"LM9#%1=[.SG#7K7H'TT]"+T!Z&POZKK>K'D"*I,D
MA@(Z?R9 *>V2)&K#<"EX#;)*2NPQHH:]7-$_C'I30 -@.IG%<9>:P0UWR@7)
M(TV$!896-GE<*E($PB$S"4+[R*LX4L\C<]@F(15VP7I*:@""-[F4]VB;5U<T
M1DQ1JJTN%:F>$AFB)]XP35!2U**HK(IU&O4](*61":T]YB?WDW(3.+F?\D<'
M<')5SA8_EM9<J)(NQ<^"&VX,5X1IC0::"]SHI8_EVH9-W%M$1I59K/V0WTC:
M<T\0/<#DT36Z-XZ_P'P\2RB ^;*_%J5WSL>-5!C!8,AB@O&XNA,E5C-*8E8*
MDO,Y5)I2WU;)0M\8.TC.[<"E+)7UU*G75_.R0%8O6 W->W/Y93+[#K">J'<U
MCQ=^ 67P^XAZK:F7B5 12]O>4K[/+.X?4F80W@BFZT!J'VH;&4/=HVFKJJ]6
M=N2'3*Z7W$XN%R.1$Q3;3"PUK/20=L0&$X@!H804G$6H<DEU3WH;F5I=%9B]
MZFQ :):2ID<7W]O9U?S_P7QV.H5_W[ [_\TOXP5*-;"DT;OVL@SS\Z5T'$-V
MHEQDN&=$:?2]U,G#PJW]7]_( .O#0'8DZ3>*K_4:VLVB-@#,4T%81'<#37H@
M7K%,LK;*&!M\%.D0@#WQ_D9&6-=#6)_R;W=W7:VC3QCWS,=QN1G8??*'GZ?5
MC*RWLWF&\?*JC/\SG@;/$B->H[66#+U=KS(GD0<IP6J=8Y6&<X<2WLCXZ_J.
M8.]:;!>UZ[79B6'.L^84D$UP"7<"E+8SW!$!@)M P,5:I^/FP90W,E7["'YB
M[WIL%[BKA;KZV>F758NA-]]@'L<+W(:B!2YS6MW_0I<%713B@D"7.)8I)M&#
MM\<,8W93VLAT[OH&]7 ]M0O$]<K;SB&5-(-BR%(9IB.%"J5?/!!KE'>)BH@>
M]-%-YOY0/,)$[R,8R<-5U0 83])_7FVZFY[-=M0)KM@-]\<\?8+_NAHOQDO8
M3$%<B^83Q-GY=/64U8H=I<QD\LP1EHL.G"QC$6TD-D=PE@(-ILJ]EMJ,M3)O
MO!^@-P6#P</_*WSC%!5X?<MQ1"E5((PAC E1&BIEXBR3Z.H$YAC+48E[4PIW
M1?;W'SUPOZI>H_:#Q-9$R[P[Q:XKX)Y$A/>\0+Z47Y2>XB.M$^>22Z++L+&"
MZA*P)6*9\,XCH)FMTIFJ"W$#-ZSJV2KUKHXF0/;;>#J;K\["U^?;KR$6/J'T
M/'U=IMJ5 _'B5.PZ$/]U?:(^XB)D;F#5AQ)=C1)[X>JB))>*(T6]-K%*!X:^
M&!BX-5;/8!U$K4T >CL[[Z8_^/_E:H$R7BS0<0CCZ69*J#4QE2F02:_8=)X@
M>YDHHX+5D2N;:HV,>CZU [>IZ1FJ]14VM NWJ3:Z_.+C<I8_P9?-6><L[Z@Q
MLC2M5AUQJDPQDH821Y,G,6>>I++ &._DX3WWS=V0]2*.;:H*?5!+]X"]T_PW
MM/5PFO-IWG5Q9213#)1G0:!4(TDI,@G.0KF!$(PQWCIAGXVI+F_NAJG63UCJ
M"[V)W?-V&VD>$T,K6MKSI"*J3*RE$F-F%E0&$[*NDG!^;IONEW+&L:=H&TC+
M]50YF[7R,0HHI3R:R&@-L9)E$IW@*D:TOE#OJ.U(M= OZESCN"H]L+KUS;0?
M"_>P1%<*93!H=X2S@!M_1#G:PHF@N#!5]!Y4E6X1>Y9"OYCCBH,$W2M:CM27
M[=7)YU_?OC_]V^>[3!S6A>W'0ZOV7-M!>_\=UE[YQ<7;R>R/Q4T++<ZS 6,"
M&I$RAA.=<.)R5,2ZZ QU+-A<M]G8%J)Z&!]0GHE[?AE,FW[Y_OL"TKOIS?CM
MD[@<?QTOQ_!##%Y$)DK=@N4\E+$=&>,/RTD6.B9!$RA5Y:K0\TEMY%K0H5C:
M,HR@ILX:<.1NN: 6MV854B39%/.>5[-'DR*1)X=6W>L@JK2Z>:YW7PM%M96]
MV_E_CN0;P,R=P]ARDCJ-XPG<&=QQ-GNN*"4W .6^,)/%KQ Z$&>Y(EPFQIP'
M+7F54ZL:S P\+/NX.!X<#0VLB-> ;X[CE8KQZPFL=#U-)Y<E<OKO=7[:>)^M
M<IK0U4;DH=S YT"2RM9*G]!UKA)4="%N6,L[/(1FE?79 $:OAU7<+8\9Q9R,
MSS&5VZB92!8$L:5I.Q/2, -6I%2GA_%6<H:UG,WAL >=#7W2=7O)8-!?,N7C
M>1'Q+-]([7TYUOM4NKF?9A3HR6(!RY&-3&<I19EJ4F[56W2**..$4B.!:Y%E
MNE=3NN-T8E\*AKT/W P6CZ?%!HSD7_QX6D1[.OWL)W":4;C(WO)[N8.ZZK7[
MI3 ] I<B-PE-OR\+4$E#?+EI$(VBRI>F#U#%:'8C;]C[PLT MZ).FSB8N\_7
MN^E7V A^5&:K,%D:@,72 =HZ2ZR(Z-7K$+-F7.+CC@'06S0->\&X>53NJ[WA
MZPXZ''J7:3_HG"0B-2LC$3PRQ!PG48%R/K+([X<^._;RGFH+JI6K- .S&III
MPNJ]WKQXUQCT[ RCTD8B \6HS**P/#>4:.EL5MPSHZI<17J"KF'O%#<#RQI:
M;,!M_"'&4IRX/CU?EW_?-NN".Y:-"X3*,O9:%J:2+7V"@P/*LM2F2OE,)^J&
MO3S<'$#[UV@3UO-V''>:WXXQF(LHO')=87$R3:_'BSB[*IQ9)G.R7N*RX[@O
M2!8Q;G.&:&&II<I$;ZO4[G<E<-@KQ<W!M8I>&S"LVQ?>ZW$1ZC0M3N=W;BZ,
MC#/&.F5(2@D=YZ =L2E'0M'+,:"25KKBA*"N9 Y\![DY\%94<@,0OKZV<'W?
MYI8<-Q=7?TR.4\:8C$O2!5TJ@CV04&:G\N@8Y0%\B%5\U^XD#GRKN#GH5E)N
MD[ ]B>L]!.4.XZ^KAM LH9O#M2),4%UR9AYWDY!(9@HC]^P<,U7RH%V(&_9(
MLQ8PGL3?@5IJPDM]R-7'.7SQXW0=-FZB1?1L5HF-U5'#8I182$&C;\,YLV7T
M@2'.HS?N GKB H#J7*5<;C]RASWJ' R?O6NR4<2NV/FQ[:SY<EP%&7Q:%1\2
MR4N3264T4<P8,!'=FE0K ]"!O&$// =#Y,&::A2!USO!1_]]M0VHF+S2#$._
M+"21D-!OYED2C0Z.XY*65,9Q-^L-9<.>5PZ^4^^CGU8=Q/D5TC'V83Q9^=@C
M*Z3+5# 2.7K4TG&&W)4K(Y8*<#2:H(^'N7O$#7L@.23L#M%2D\A;F?!R(6W5
MXF=YFS<J!#H261 .RI=3KD@\U9H(2B/&>LPE4Z6N^#E$#GMF.>S&>[C6AJYP
M>T1^JY*H:[Z^CP+/F5%%47(FELD?B7B1+;'9!$N3%9;=2ZKO. ;O_,IACQTK
M(ZNB]%O'U/TRNV!B-)I:$K)#\2DP*#X3B,8_5 P0J(^](&N?&LEJIX8MX.L0
M332PEW:_+#*B@,88C$7? -F36D42%*!-%F6VK;060I6A>-U)'#: /?*]FTJ:
MVQ^3,UQO-3&Y/AK:+L@ N*0U1,*@5,QI28EEF1%KC/6: MKW*E[>\TEM9+C9
MD6[*]J6S!BPELA8!TJH>9%VR^:,+_>V:D,P=QN\F$UR[NE349>)=-@1,DEP%
MP/5>)0O=D;XF[]CV!I.'=VQ[UUF34+Q3TWXR33_*VI5+2I?XB=F(K/'D2 ",
M\IWF(8K$7$A'@N-.&IN\+GL\2/:CNQ9@Z;]?=^A>M\'=S9FU2CG&-(DL8D!&
M!6XZ4B2B0_9"9JEMG:Q,=Q*;]"6K@;*.YIHX&/G!VVOX"I/9E\^SO/P#M3!B
M6@8'& ER_*U22,2(9T80FHRBP!*3K$[#BUT4#7L0,ACF#M'+H1 [JV?];CL8
M-@L.40/!<&\U=0.]:N44R3$EFQDSKL[9VV-$#7O^,;2%VU<[#0'N@2>QJTQ=
MVY!5YH886FRV*1UMM4_$:PG.^\A"G8EFG2D<]@!D< ^P#[VUZ/]==^F&Q6HX
M6Q'R]8"$D8_.^!0LR8$G(ID6Q!=SSP.2QB-C25;>?)\F<MC3DZ$M9%_::\(+
M["[,D>,L&O"4I"Q9F1N(0I2AI/&%,D9G!W6N:74G<=A3ER/CLI+FVLUSW]S>
MV2)(:G(0"?<!ZH-#3\5S8K72*,BD&3!F&52QFL\G==CX^=AY[KYTUL(N?ML]
MV3I",/AHM)*9H*5?S;&6)"BF21 H/LJD"76ZGSQ)69.Y[=Z@\9@;>;">6@1>
M23Z5&XM &8>,IMPB%RI$#,Z0*26E$9KEH$V58^?MY#29JSX:Q)ZOD19PM7%L
M/\%D%8#/SORWOXV7%Z77/<KL[6R^H\V:]8('BOY#5!Q*#;C$?0+EEQU70G/#
M5*Z#O#T);C)E70V;Q]#J\,UUBDAO7W_=.7=!!NHD=6C=HP]$6B-(T(X3H-89
M(35S_M[5YQT58%W?V&2RNF^TU=-!$U'Q;0-?QDBC[. TOY]-S\]@?OD:PG*4
MG$G>8, F?"Y=3JDH59.,&"M2@)!-JM85_ G2FLQ?'V,K[D%3+6S+MYV+B]E\
M><.(EL)Q3A6!)%T9N^:(BX:AF48!RD2I=G4.2W91U&1Z^BA.W]YZ:0!@G^#+
MQD<XS7<98<!]CMIBQ%\JP<$:XD'B/TT,SD>:A:AR'K*3HB83S;4 UH]>FM@_
M;[-RQQ8+*I.SWA.ALR(R*$H"TX$P<$"C<5KQ*B9L%T%-9HR/ ;"]M=($OC[>
M\%'HO][W5UV=1L(SS:(01#A:^N0)=#M-"LB;SUI2E26O<ZB[FZ9AFW(-%( >
MJIN&"@HV'&'L_&,X[FG&Z/ER-EWE?T8JH:0T%R2!P. YTH06FI<!N2JZ3$LG
MT3K5I$^2-G!3K8' UY.JAL]SO+V:IDW/&DC%]=Q($MF;C"&7'Y^DKV6%C2C3
M)J*D")B,BTOQ2(+#*)N5J0A)6*MBM['%W=\Y<-NK8R8[*BFB@7B@NQ1'HG2?
M-=P@*R%AI ,6[;=F)$3CN5'41%&ECV!W$KLA\A_E(**2ZAJH 2ALE?]+"=A7
M/UEGM*^OJ*Q*;J;I[C=N??+C:K#I_1NJ;[YMQO;B%Q=^>@Z?T$2_R1E0"3E[
MH.CLDJ3*.(ZL'/'!>**S$UDK1I.LXC0>E\UA4]/5:@\:QLI+7TDC],Y5\#X0
M[TN//,,""2H)XEC4"5 4E1K5'$3UL!GP-G'^+$T>.%(:)3!?-@!>FK6VE$EB
MN,,]#^5.++4H[.@Y9.4-L"H'U?7!6RVIWBAXGZ/)7N>A'S!7\.K+E\E*E'YR
M+<IWTSR;7ZZ5>2U482CW1DL24KG5(Z,FSI11[]$&JV@P053I*-^1OF%3\-7@
M6$,[#<1RUT?N'_TX87" ZX9[R[DG7*=8QLQ)XG')$,:5#\DP5^E^U3TZ!AZ#
M7D/7#[IX[2_X)G"SF3<#BVL.7$Q1*B>($E2543.XNFRV1)L438X\:56K1>$]
M4@9N#7(4]!PD_J&[<JUR$$CWV]E\>Y.QDH#0,@I=$A"4.T=D3)J4.5H$*!-H
MMEGRZEZ(_4@AUE-O&[C*OB)DZ@B\(02MDU?P@!V.\;4%HXAV15C"6N*TT433
MC!QY)FCNUB3PZ7<-G"<Y(GKZ$'8#V]=)2N/5"-X;@;U92[ ,^>DJ3R:"Y"9*
MDGQI=A-U*=\N_^1&)&D2VMTJ&UX?Q ];QU#-2S^Z7AO \KW&B:=AZ<?3DM6_
M3D7N-/K?1RJSR"5W! 3:?9DE$)>T(\F%&('Q5*E]S $T#QL:'!]@]VMRCJ3M
M%P+L;?O1]U% .R&LB80SW-%E-AX%[!V)3C$0680(>2A8;Z5XV(CE18#Z<$T/
M[;.^+ST X&9Q3E9=;R%=Q=5UP^7LT^GO?C4T ]5_-2D?*:J:W_K$ZE=F83(^
M]^L1;C*Y;#WZ<%QD6<Z"(W&141(L!6F%#HRF3CYN_[0-&U$-!ND6--T;T/_E
MYP?*>X_?6/UH]9/R6Y\@_U3^_OW3NSO/+Y(8+[XO_AQGE^O'?S@Y^_W3F].W
MIQ_??#HY>W?ZX?,K_/_T_;O7JW^=?'C]\=.;SV\^G*W^>?KV[3O\WJMW)^\_
MXW?>_(8_^'R7Q<7X$A7Y%,#[>.W//WB^+XW-VQ_ ]PC\P[<E3!.D/QVVT9[.
MS_UT,_3T%8)M-AFG]4J8IH^WN+T9B.HG-Q[\K=X4S-F@M4&?0B)"#07B&=<D
M4!%\HD8%+VMLNKU0?ZBO<A 19:KL9+:XFL,9:O272:DZI)Q'[GTB29<6'*6Z
MVBF%<K7!@1':VU#EE*=O1H9UUX^/[/NNS:# ^ ?>",[*J*?%0-O!YN6M; K;
M9-'4UI"UBXYI32"Y,AG6<!*<",0$+H+(H)RMDBEK8FOX'"_0L2OMZ?[JY^.B
MJNNSOS?3Y2I[^F-Q>Z&4LLP10Z4H5T^+S2F=GKQR(AE;&L96.=OO3N,_@D%_
M#AX?% )44N<_L*W^X.<E$/H*KP$#^\E05OL!&:W8[\?ETY0E%X)2#M*3M.K,
MX&.Y6:H8T670F#4V9_C'M>3XXHC/FZ_>]&F\^/O9>MXDM\DP'=$IE(9(0(\L
M.$F)LMZ B@Z]QBI&>SLY_PCV^3DH>U W>+B2&LA]GZ3_O-ITKWT[FW^ /S9#
M3L?3\X_SV12_C!N9?1LO1OC[D9FH<0,KNXL!3JP)B)D<@!LNN=15@L5G43DL
M,/N Q8/#QEHZ:@" 9_BYTWR29JMF>+_!98#Y*$:KK.6>>)-\:?F4B.40"60E
M()AL)*_2PV8;,4.? U;3_:QG130 IA_"06,_37Z>%K]_P7T!.&6:\@U3U @=
MLO7$.16)S" (6GI)M/%0!JQ%>O\^:D]6K MUP\+M<!#<MUV]:Z0!F#VP\;]\
M_P6F\>+2S_^^6H<A&JE!"^*@7&G1!D@(@)B('KT*)HP25<Z%GR)LV./?"EMC
MKYIH$EG7W+R>7?KQ= 0BN9101)R:TC%;*.)8#B0*"C)8H3/GQT'67<(:<[H.
M@L&3&#M )PU@[!-\A>D5E%8!KTI/1 R$2A_.5^AGS"YAOC')F5H0+EMBM/"E
M-:(C0?-,4H9D*)7BP8E_7PV1.E#7&MH. <2#7DA]:Z<!R&U9G\736"U-W/:S
M5[Q,<2S5X$D4GU6@BZ&,5L8(*^K44#U"T[ E)<?9)O>2?XM0*HQLUAV+3'.9
M&4D8!A%)K21!1D.2 \L@!9&@2GKB$9I:LU1[ZOW)W-=^2ABZ4NXW2..(DMP8
MW>MH)%N=J,O$68'1"(J#!)J Z#+&TW.&4?2]<0D[BMVV/KXQ1.RKN5FO8FS
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M/=)))5$^E+Q7="2 P=#56ANS\4A]G4DGJ]=W \I+RUSO(=H&K,R;RR^3V7>
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M/N)C9E,_N=4S2B:NC9:*4%4J225+Q&=IT&<R)@>'+CGM&&T^>/8P1;P]Z_U
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M.-N@9U-)=B>G7@M,7MS>F_'%%?W9HSW>Y97>LC9@()_1&XBU![^BNP'H[K"
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M?@L75SARM$7A50%,SH*2TD(4AH'(3AJGF308#G0"]MM),^S_+9[>#RCR_J^
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M:=J0R$"!=9.&@:L#YUCP9/9ET-'7UYZD(?B"P,A"U%Y9)C='?W4'L0>4#<.
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M<WGVWW^>?;PZ^Q_\..24=?L1P[0RVD?70&>F6V4(#R=:)A 5/5404BPG6I2
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MB8QD'XF,N4HRX4N$-75\<J#Z=W0Q&T07]6\:-W\H']XMTW_^V_\!4$L#!!0
M   ( #9 8U,Y;!1GZ%   (DT @ 6    86UE9"TR,#(Q,S P.7AE>#,R+FAT
M;>U]:W/;QI;M]_LK,#XU9Z0J6+%LQW:<W%0ILGRB,XGML91DYM,MD 1%V"#
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M6:';/L$E/22<@>0E,:8[LZD:_M+R*KN-@CB]PZ10W<0)DD1Q;EP3HIM,0)
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M8B&W8XME$.X0"?4AY43GQN8Z4GZNC =M,EJ=T>_')FHZH$M@%CU5,NA_L 3
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M0$>PD/CW(LR9VE?.,(V$^1$\RE72)@$UO\:\I:"7S3>4"IT3I!9W6Z-E^FP
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M#,<J-B"J8T&7*VN_<QR4RB$VU$O:TI2X1@DHO.2B2E:+:&^ZS[L#5 @''8?
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M K(HWE^*1_DT-:* Y^$&+M_MO#T\T*O41,7I1'0,::7K=9&*L7WYS3#GU'Y
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M.3EF81X6>]XZ]NM/QS#=%KXD)_)&JC@, H8+[P*FFP5,-]['VQ8R7>O !1$
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M,?-)5W _K4+T\,&S+7]-NW3P2&EE.)HF99;1,L4BOV0M!Q26$HDN1>UV)9E
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MC\*7KQEMW-:N,M#C;6_%PL=(P\H^SO+8;>>C5[_UWW 1[:_$3_\"4$L#!!0
M   ( #9 8U.1[#ZHS <  &P?   8    86UE9"TR,#(Q,S P.7AE>'@S,3(N
M:'1MU5EM<]LV$OY^OP)5YE)G1J)$O<2V['C&M9V>9WI)ZJC-W*<;D  EC$&"
M!4#)NE]_#P!2DBVY4=+D?.Y,'9'87>SKLPOB](?+]Q>3?WVX(C.;2_+AMY]^
MN;X@K4ZW^VEPT>U>3B[)/R;__(4,HUY,)IH61EBA"BJ[W:MW+=*:65N.N]W%
M8A$M!I'2T^[DINM$#;M2*<,C9EGK[-2]P5].V=G?3G_H=,BE2JN<%Y:DFE/+
M&:F,**;D$^/FEG0Z-=6%*I=:3&>6]'O]F'Q2^E;,:5BWPDI^UL@Y[8;GTZ[?
MY#11;'EVRL2<"/:F)>)>TD_[@\/C?C(:'B;)T2 >)'C1CU\/:3J*_QU#R2[(
M X^Q2\G?M')1=&;<[3\>]J/#46E/%H+9V3CN]?[>\J1GIYDJ+/;3X \_@Y@M
M89;?V0Z58EJ,O4FMP-HLITHJ/7[1\_^=N)5.1G,AE^,?)R+GAKSC"W*C<EK\
MV#8(0\=P+;) :,1_.'2">OYQ$50^A!PI"MZ8$/>=TE=W,Y$(2P9QU+^O\:;A
M5$]ANU7EN#^$V W=4SB;ZR=2_N+J9G+]]OKB?'+]_MT^VL?]\OL[>KA3U^LV
M^9@J:\G/$?E9%$6;I%Q;D2V)G5'[\L7HZ&0?"UYCLY(RANKH2)[9<;\?C9[,
MJ#@BUV1&YYQH/A=\@<*U,V'(KQ752 NY)#>\5-H259"W2N<D[G5^)9G2(./D
MCT!%>,' ^)&7EN<)UR]?Q*][)X->VU=YFZB,G.><";,T;7)=I!&<=?P,G=6/
MR$_4P%(X(U^2VT(M)&=3W@X^T\%33&''0@$)(9"*@M!B2:K"ZHI#86"CATGX
MA)(<3UI023*:XI4F*D<E6Q7HM@@*GG)CJ%XZDIS><A^$E4R#=PS*8$OI,19[
M.()4:& JR JP0Q.&B"UF(IT14[D_:_X%U[P6X@S(A9$ 7X?C"V%G,-"4//4*
M.KDE5%,,9L[!QDBRW'3#,PWQX$]"S$DF"CC1Q6/MM#;B"W(LZXUU4:!&$#VT
M5OQ.9>4*!('9\% ;016NPDKXU:6$2Q4IUS&OW6T>;(VT8KYGMQU%)4& 0"M$
MPV]GO#XI-3.22;4P319H/A7&HN%;0MW+H#>T;&\$TS3*;&G[3.,YC,CDGO$O
M7QSUX\,34T>LAG"7XBK+!!Z]6ZX)U=P'  X5B>0>\CBBGDAA9H[<D>4H;U?B
M[AGPEDIE*O"YPM=*ADB46J6<X;4A!W \XXAD\.[573JCQ923<]34325!$0]H
M)QX=\%>>-1ZQ\!0>A6O41<@ )Y^XPMM(C! HI\O>&V7W-LJP40/MF^D""M<B
MOK[%#8^?, 5H1"ZYP:@#9WC ^WRDV@Z+4UJ9_5D<*"8<7J]W"C"K*@T!J*VY
M,+YB0<4++\<-#>M:W\0+S27U8:QQ=AV*=HTE;E&@[J&+45(P/W";*C&"":J%
M,T"$;N 1K'"2*N,0VF>]\7#NZQL3/13"J.V92K1SD5:2.EB"65Z)-=*#(_2-
MS7:'7PEWA$ .\'/V]4CQI&F2/$R3O<MM*UOV+]2]DP:)-A?,Y0(U.*TY1*(&
M>>1ZNDL0JED3+*2/H(F0PBX=]N_:UJ6NCZL/6<BZ>Z0;,X$'OKO:H++2)5+&
M^%Z5IDHSKX"?#J:\0 N2R!RLN%&0>1),/B$[D+JB!/8\T_Q((W(UI[+RM>:<
MQ[,,W5G,8;;9T657C68/[ B/NQNO3P<PHNY-:.^)JNSC&NR#;G1%S=WLDGU^
MG"-),Q7Y#.?!$]#'1]-M\/PBRE#QP5G;3G<S>]TT_<K.R'Y!G3NP5VE::>?:
M#63=(357QN*].Y=#EDDAJ#EG'3S"DB%'4($/J&O%,0IR?]QP)Y&B6NGU*F@U
MHV;5AESM^ISBS(.:]T<-.$L<*FZYK,\>#^C;?]E%?RV/GG3&''WMC.G/W:Q)
MP?:ZQES);Z;!NMQ<(+^@,6U-$"O5**8(J[19]0+_ B)S'$$MYW\":(E"MW'K
M3$ _+^0 R0+\, Z?\*^;99H,YW]4 NK[;*Z*U!]17CW?4?(<)S37K04"Z89C
M-V:G@L/S-8ZO1KH%I[<.F$.W]-#L^[P_YS>GM2^*9SU]A:/)CK*D#(R&KZKR
MT=C7TP%8$$ T\7;H#@:MP50YW ^?>&-J--QYKGW&R(]9[QP GVDD?1M>Y;Y.
M$1?_U:,.8#O@HRCF2LZY \F"3NN/-[HN;9Z74BTY5A<S%>J9WDL/A/.;=)#H
M__SCZ"6<YHN:O(,)&Q\!PS= LJ7^MU:SOY>:0:E&&>OGZ%J%!'7 =0>:2%H:
M/FY^G "@2TF78U%X>9[II/9ZHJQ5^=A=),P=RJ/]UI_5_1?VL%S?,?1'42]<
M,UB-_UFS<7T#$?FEKF7;:\='T7'O\>5>%*_6NEZV;@@:XT.I63?=25/2XDUK
MT&IHZK(<]TCLJ3;E?(ZG7]XYKLW[!%?=#YT1_-#Z+H'_;'[V0N"'AZNX?U,%
MCO;:_^-WV?M+C+]_>?'@;FN/D-?UX7&FA GNNP-I=/_:?/@?WSF%4-SS0Z+/
MKNYX6KEC%/D=PQGY@",2CMKUAZ^+F> 9>;M"Y/=A@EOY[SL6RU,XY^!#.*?#
MTBV;7VT;W?5HN/_EZ(Y[U0VF!U>SI0IWT^/P06S.MRYKU[GI8;BW9J$)$K2R
MC[,\=@/ZZ,UO_3?<0_L;\;/_ E!+ P04    "  V0&-3-'V]&LX$   =$
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M+3(P,C$P.3,P7VQA8BYX;6Q02P$"% ,4    "  V0&-3N:' %-^O   FE@<
M%0              @ %SL 0 86UE9"TR,#(Q,#DS,%]P<F4N>&UL4$L! A0#
M%     @ -D!C4SEL%&?H4   B30" !8              ( !A6 % &%M960M
M,C R,3,P,#EX97@S,BYH=&U02P$"% ,4    "  V0&-3DQ]GWLT'  !M'P
M&               @ &AL04 86UE9"TR,#(Q,S P.7AE>'@S,3$N:'1M4$L!
M A0#%     @ -D!C4Y'L/JC,!P  ;!\  !@              ( !I+D% &%M
M960M,C R,3,P,#EX97AX,S$R+FAT;5!+ 0(4 Q0    ( #9 8U,T?;T:S@0
M !T0   8              "  :;!!0!A;65D+3(P,C$S,# Y>&5X>#,R,2YH
M=&U02P$"% ,4    "  V0&-3366WO-4$  !.$   &               @ &J
MQ@4 86UE9"TR,#(Q,S P.7AE>'@S,C(N:'1M4$L%!@     ,  P * ,  +7+
$!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
